Word	Tag	Begin-End
Identification	O	0-14
of	O	15-17
blood	O	18-23
microRNAs	O	24-33
associated	O	34-44
to	O	45-47
Parkinson	O	48-58
'	O	58-59
s	O	59-60
disease	O	61-68
.  	O	68-71

While	O	0-5
miR	B	6-9
-	I	9-10
1	I	10-11
,	O	11-12
miR	B	13-16
-	I	16-17
22	I	17-19
*	O	19-20
and	O	21-24
miR	B	25-28
-	I	28-29
29	I	29-31
expression	O	32-42
levels	O	43-49
allowed	O	50-57
to	O	58-60
distinguish	O	61-72
non	O	73-76
-	O	76-77
treated	O	77-84
PD	O	85-87
from	O	88-92
healthy	O	93-100
subjects	O	101-109
,	O	109-110
miR	B	111-114
-	I	114-115
16	I	115-117
-	I	117-118
2	I	118-119
*	O	119-120
,	O	120-121
miR	B	122-125
-	I	125-126
26a2	I	126-130
*	O	130-131
and	O	132-135
miR30a	B	136-142
differentiated	O	143-157
treated	O	158-165
from	O	166-170
untreated	O	171-180
patients	O	181-189
. 	O	189-191

They	O	0-4
form	O	5-9
two	O	10-13
groups	O	14-20
according	O	21-30
to	O	31-33
their	O	34-39
expression	O	40-50
profile	O	51-58
in	O	59-61
control	O	62-69
,	O	69-70
non	O	71-74
-	O	74-75
treated	O	75-82
,	O	82-83
early	O	84-89
-	O	89-90
onset	O	90-95
and	O	96-99
treated	O	100-107
Parkinson	O	108-117
'	O	117-118
s	O	118-119
disease	O	120-127
subjects	O	128-136
. 	O	136-138

A	O	0-1
set	O	2-5
of	O	6-8
six	O	9-12
differentially	O	13-27
expressed	O	28-37
microRNAs	O	38-47
were	O	48-52
identified	O	53-63
. 	O	63-65

The	O	0-3
present	O	4-11
study	O	12-17
demonstrates	O	18-30
that	O	31-35
blood	O	36-41
samples	O	42-49
can	O	50-53
be	O	54-56
used	O	57-61
as	O	62-64
a	O	65-66
source	O	67-73
of	O	74-76
miRNA	O	77-82
identification	O	83-97
associated	O	98-108
to	O	109-111
Parkinson	O	112-121
'	O	121-122
s	O	122-123
disease	O	124-131
(	O	132-133
PD	O	133-135
)	O	135-136
. 	O	136-138

This	O	0-4
study	O	5-10
is	O	11-13
innovative	O	14-24
in	O	25-27
contributing	O	28-40
to	O	41-43
the	O	44-47
development	O	48-59
of	O	60-62
effective	O	63-72
PD	O	73-75
biomarkers	O	76-86
.   	O	86-90

This	O	0-4
reveals	O	5-12
a	O	13-14
previously	O	15-25
unrecognized	O	26-38
signaling	O	39-48
cascade	O	49-56
involved	O	57-65
in	O	66-68
meningioma	O	69-79
tumor	O	80-85
development	O	86-97
and	O	98-101
highlights	O	102-112
a	O	113-114
novel	O	115-120
molecular	O	121-130
interaction	O	131-142
between	O	143-150
miR	B	151-154
-	I	154-155
200a	I	155-159
and	O	160-163
Wnt	O	164-167
signaling	O	168-177
,	O	177-178
thereby	O	179-186
providing	O	187-196
insights	O	197-205
into	O	206-210
novel	O	211-216
therapies	O	217-226
for	O	227-230
meningiomas	O	231-242
.   	O	242-246

A	O	0-1
direct	O	2-8
correlation	O	9-20
was	O	21-24
found	O	25-30
between	O	31-38
the	O	39-42
downregulation	O	43-57
of	O	58-60
miR	B	61-64
-	I	64-65
200a	I	65-69
and	O	70-73
the	O	74-77
upregulation	O	78-90
of	O	91-93
beta	O	94-98
-	O	98-99
catenin	O	99-106
in	O	107-109
human	O	110-115
meningioma	O	116-126
samples	O	127-134
. 	O	134-136

Thus	O	0-4
,	O	4-5
miR	B	6-9
-	I	9-10
200a	I	10-14
appears	O	15-22
to	O	23-25
act	O	26-29
as	O	30-32
a	O	33-34
multifunctional	O	35-50
tumor	O	51-56
suppressor	O	57-67
miRNA	O	68-73
in	O	74-76
meningiomas	O	77-88
through	O	89-96
effects	O	97-104
on	O	105-107
the	O	108-111
E	O	112-113
-	O	113-114
cadherin	O	114-122
and	O	123-126
Wnt	O	127-130
/	O	130-131
beta	O	131-135
-	O	135-136
catenin	O	136-143
signaling	O	144-153
pathways	O	154-162
. 	O	162-164

miR	B	0-3
-	I	3-4
200a	I	4-8
was	O	9-12
found	O	13-18
to	O	19-21
directly	O	22-30
target	O	31-37
beta	O	38-42
-	O	42-43
catenin	O	43-50
mRNA	O	51-55
,	O	55-56
thereby	O	57-64
inhibiting	O	65-75
its	O	76-79
translation	O	80-91
and	O	92-95
blocking	O	96-104
Wnt	O	105-108
/	O	108-109
beta	O	109-113
-	O	113-114
catenin	O	114-121
signaling	O	122-131
,	O	131-132
which	O	133-138
is	O	139-141
frequently	O	142-152
involved	O	153-161
in	O	162-164
cancer	O	165-171
. 	O	171-173

Downregulation	O	0-14
of	O	15-17
miR	B	18-21
-	I	21-22
200a	I	22-26
in	O	27-29
meningiomas	O	30-41
and	O	42-45
arachnoidal	O	46-57
cells	O	58-63
resulted	O	64-72
in	O	73-75
increased	O	76-85
expression	O	86-96
of	O	97-99
beta	O	100-104
-	O	104-105
catenin	O	105-112
and	O	113-116
cyclin	O	117-123
D1	O	124-126
involved	O	127-135
in	O	136-138
cell	O	139-143
proliferation	O	144-157
. 	O	157-159

Upregulation	O	0-12
of	O	13-15
miR	B	16-19
-	I	19-20
200a	I	20-24
decreased	O	25-34
the	O	35-38
expression	O	39-49
of	O	50-52
transcription	O	53-66
factors	O	67-74
ZEB1	O	75-79
and	O	80-83
SIP1	O	84-88
,	O	88-89
with	O	90-94
consequent	O	95-105
increased	O	106-115
expression	O	116-126
of	O	127-129
E	O	130-131
-	O	131-132
cadherin	O	132-140
,	O	140-141
an	O	142-144
adhesion	O	145-153
protein	O	154-161
associated	O	162-172
with	O	173-177
cell	O	178-182
differentiation	O	183-198
. 	O	198-200

Elevated	O	0-8
levels	O	9-15
of	O	16-18
miR	B	19-22
-	I	22-23
200a	I	23-27
inhibited	O	28-37
meningioma	O	38-48
cell	O	49-53
growth	O	54-60
in	O	61-63
culture	O	64-71
and	O	72-75
in	O	76-78
a	O	79-80
tumor	O	81-86
model	O	87-92
in	O	93-95
vivo	O	96-100
. 	O	100-102

Meningiomas	O	0-11
,	O	11-12
one	O	13-16
of	O	17-19
the	O	20-23
most	O	24-28
common	O	29-35
human	O	36-41
brain	O	42-47
tumors	O	48-54
,	O	54-55
are	O	56-59
derived	O	60-67
from	O	68-72
arachnoidal	O	73-84
cells	O	85-90
associated	O	91-101
with	O	102-106
brain	O	107-112
meninges	O	113-121
,	O	121-122
are	O	123-126
usually	O	127-134
benign	O	135-141
,	O	141-142
and	O	143-146
are	O	147-150
frequently	O	151-161
associated	O	162-172
with	O	173-177
neurofibromatosis	O	178-195
type	O	196-200
2	O	201-202
.	O	202-203
Here	O	204-208
,	O	208-209
we	O	210-212
define	O	213-219
a	O	220-221
typical	O	222-229
human	O	230-235
meningioma	O	236-246
microRNA	O	247-255
(	O	256-257
miRNA	O	257-262
)	O	262-263
profile	O	264-271
and	O	272-275
characterize	O	276-288
the	O	289-292
effects	O	293-300
of	O	301-303
one	O	304-307
downregulated	O	308-321
miRNA	O	322-327
,	O	327-328
miR	B	329-332
-	I	332-333
200a	I	333-337
,	O	337-338
on	O	339-341
tumor	O	342-347
growth	O	348-354
. 	O	354-356

Downregulated	O	0-13
microRNA	B	14-22
-	I	22-23
200a	I	23-27
in	O	28-30
meningiomas	O	31-42
promotes	O	43-51
tumor	O	52-57
growth	O	58-64
by	O	65-67
reducing	O	68-76
E	O	77-78
-	O	78-79
cadherin	O	79-87
and	O	88-91
activating	O	92-102
the	O	103-106
Wnt	O	107-110
/	O	110-111
beta	O	111-115
-	O	115-116
catenin	O	116-123
signaling	O	124-133
pathway	O	134-141
.  	O	141-144

These	O	0-5
data	O	6-10
support	O	11-18
the	O	19-22
hypothesis	O	23-33
that	O	34-38
patterns	O	39-47
of	O	48-50
miRNA	O	51-56
expression	O	57-67
in	O	68-70
cortical	O	71-79
GM	O	80-82
may	O	83-86
contribute	O	87-97
to	O	98-100
AD	O	101-103
pathogenetically	O	104-120
,	O	120-121
because	O	122-129
the	O	130-133
aggregate	O	134-143
change	O	144-150
in	O	151-153
miRNA	O	154-159
expression	O	160-170
observed	O	171-179
early	O	180-185
in	O	186-188
the	O	189-192
disease	O	193-200
would	O	201-206
be	O	207-209
predicted	O	210-219
to	O	220-222
cause	O	223-228
profound	O	229-237
changes	O	238-245
in	O	246-248
gene	O	249-253
expression	O	254-264
.   	O	264-268

Patterns	O	0-8
of	O	9-11
microRNA	O	12-20
expression	O	21-31
in	O	32-34
normal	O	35-41
and	O	42-45
early	O	46-51
Alzheimer	O	52-61
'	O	61-62
s	O	62-63
disease	O	64-71
human	O	72-77
temporal	O	78-86
cortex	O	87-93
:	O	93-94
white	O	95-100
matter	O	101-107
versus	O	108-114
gray	O	115-119
matter	O	120-126
.  	O	126-129

MicroRNA	O	0-8
(	O	9-10
miRNA	O	10-15
)	O	15-16
expression	O	17-27
was	O	28-31
assessed	O	32-40
in	O	41-43
human	O	44-49
cerebral	O	50-58
cortical	O	59-67
gray	O	68-72
matter	O	73-79
(	O	80-81
GM	O	81-83
)	O	83-84
and	O	85-88
white	O	89-94
matter	O	95-101
(	O	102-103
WM	O	103-105
)	O	105-106
in	O	107-109
order	O	110-115
to	O	116-118
provide	O	119-126
the	O	127-130
first	O	131-136
insights	O	137-145
into	O	146-150
the	O	151-154
difference	O	155-165
between	O	166-173
GM	O	174-176
and	O	177-180
WM	O	181-183
miRNA	O	184-189
repertoires	O	190-201
across	O	202-208
a	O	209-210
range	O	211-216
of	O	217-219
Alzheimer	O	220-229
'	O	229-230
s	O	230-231
disease	O	232-239
(	O	240-241
AD	O	241-243
)	O	243-244
pathology	O	245-254
. 	O	254-256

RNA	O	0-3
was	O	4-7
isolated	O	8-16
separately	O	17-27
from	O	28-32
GM	O	33-35
and	O	36-39
WM	O	40-42
portions	O	43-51
of	O	52-54
superior	O	55-63
and	O	64-67
middle	O	68-74
temporal	O	75-83
cerebral	O	84-92
cortex	O	93-99
(	O	100-101
N	O	101-102
=	O	103-104
10	O	105-107
elderly	O	108-115
females	O	116-123
,	O	123-124
postmortem	O	125-135
interval	O	136-144
<	O	145-146
4	O	147-148
h	O	149-150
)	O	150-151
. 	O	151-153

miRNA	O	0-5
profiling	O	6-15
experiments	O	16-27
were	O	28-32
performed	O	33-42
using	O	43-48
state	O	49-54
-	O	54-55
of	O	55-57
-	O	57-58
the	O	58-61
-	O	61-62
art	O	62-65
Exiqon	O	66-72
(	O	72-73
©	O	73-74
)	O	74-75
LNA	O	76-79
-	O	79-80
microarrays	O	80-91
. 	O	91-93

A	O	0-1
subset	O	2-8
of	O	9-11
miRNAs	O	12-18
that	O	19-23
appeared	O	24-32
to	O	33-35
be	O	36-38
strongly	O	39-47
expressed	O	48-57
according	O	58-67
to	O	68-70
the	O	71-74
microarrays	O	75-86
did	O	87-90
not	O	91-94
appear	O	95-101
to	O	102-104
be	O	105-107
conventional	O	108-120
miRNAs	O	121-127
according	O	128-137
to	O	138-140
Northern	O	141-149
blot	O	150-154
analyses	O	155-163
. 	O	163-165

Some	O	0-4
well	O	5-9
-	O	9-10
characterized	O	10-23
miRNAs	O	24-30
were	O	31-35
substantially	O	36-49
enriched	O	50-58
in	O	59-61
WM	O	62-64
as	O	65-67
expected	O	68-76
. 	O	76-78

However	O	0-7
,	O	7-8
most	O	9-13
of	O	14-16
the	O	17-20
miRNA	O	21-26
expression	O	27-37
variability	O	38-49
that	O	50-54
correlated	O	55-65
with	O	66-70
the	O	71-74
presence	O	75-83
of	O	84-86
early	O	87-92
AD	O	93-95
-	O	95-96
related	O	96-103
pathology	O	104-113
was	O	114-117
seen	O	118-122
in	O	123-125
GM	O	126-128
. 	O	128-130

We	O	0-2
confirm	O	3-10
that	O	11-15
downregulation	O	16-30
of	O	31-33
a	O	34-35
set	O	36-39
of	O	40-42
miRNAs	O	43-49
in	O	50-52
GM	O	53-55
(	O	56-57
including	O	57-66
several	O	67-74
miR	B	75-78
-	I	78-79
15	I	79-81
/	I	81-82
107	I	82-85
genes	O	86-91
and	O	92-95
miR	B	96-99
-	I	99-100
29	I	100-102
paralogs	O	103-111
)	O	111-112
correlated	O	113-123
strongly	O	124-132
with	O	133-137
the	O	138-141
density	O	142-149
of	O	150-152
diffuse	O	153-160
amyloid	O	161-168
plaques	O	169-176
detected	O	177-185
in	O	186-188
adjacent	O	189-197
tissue	O	198-204
. 	O	204-206

A	O	0-1
few	O	2-5
miRNAs	O	6-12
were	O	13-17
differentially	O	18-32
expressed	O	33-42
in	O	43-45
WM	O	46-48
,	O	48-49
including	O	50-59
miR	B	60-63
-	I	63-64
212	I	64-67
that	O	68-72
is	O	73-75
downregulated	O	76-89
in	O	90-92
AD	O	93-95
and	O	96-99
miR	B	100-103
-	I	103-104
424	I	104-107
which	O	108-113
is	O	114-116
upregulated	O	117-128
in	O	129-131
AD	O	132-134
. 	O	134-136

The	O	0-3
expression	O	4-14
of	O	15-17
certain	O	18-25
miRNAs	O	26-32
correlates	O	33-43
with	O	44-48
other	O	49-54
miRNAs	O	55-61
across	O	62-68
different	O	69-78
cases	O	79-84
,	O	84-85
and	O	86-89
particular	O	90-100
subsets	O	101-108
of	O	109-111
miRNAs	O	112-118
are	O	119-122
coordinately	O	123-135
expressed	O	136-145
in	O	146-148
relation	O	149-157
to	O	158-160
AD	O	161-163
-	O	163-164
related	O	164-171
pathology	O	172-181
. 	O	181-183

Remarks	O	0-7
are	O	8-11
also	O	12-16
provided	O	17-25
to	O	26-28
point	O	29-34
out	O	35-38
the	O	39-42
unanswered	O	43-53
questions	O	54-63
and	O	64-67
to	O	68-70
outline	O	71-78
the	O	79-82
new	O	83-86
directions	O	87-97
for	O	98-101
the	O	102-105
future	O	106-112
research	O	113-121
of	O	122-124
the	O	125-128
field	O	129-134
.   	O	134-138

Speculations	O	0-12
on	O	13-15
the	O	16-19
development	O	20-31
of	O	32-34
miRNAs	O	35-41
as	O	42-44
potential	O	45-54
therapeutic	O	55-66
targets	O	67-74
are	O	75-78
also	O	79-83
presented	O	84-93
. 	O	93-95

These	O	0-5
small	O	6-11
molecules	O	12-21
act	O	22-25
by	O	26-28
repressing	O	29-39
the	O	40-43
expression	O	44-54
of	O	55-57
either	O	58-64
the	O	65-68
proapoptotic	O	69-81
or	O	82-84
antiapoptotic	O	85-98
genes	O	99-104
to	O	105-107
produce	O	108-115
antiapoptotic	O	116-129
or	O	130-132
proapoptotic	O	133-145
effects	O	146-153
. 	O	153-155

Appealing	O	0-9
evidence	O	10-18
has	O	19-22
been	O	23-27
accumulating	O	28-40
for	O	41-44
the	O	45-48
involvement	O	49-60
of	O	61-63
miRNAs	O	64-70
in	O	71-73
human	O	74-79
diseases	O	80-88
associated	O	89-99
with	O	100-104
apoptotic	O	105-114
cell	O	115-119
death	O	120-125
and	O	126-129
the	O	130-133
potential	O	134-143
of	O	144-146
miRNAs	O	147-153
as	O	154-156
novel	O	157-162
therapeutic	O	163-174
targets	O	175-182
for	O	183-186
the	O	187-190
treatment	O	191-200
of	O	201-203
the	O	204-207
diseases	O	208-216
. 	O	216-218

The	O	0-3
importance	O	4-14
of	O	15-17
miRNAs	O	18-24
has	O	25-28
steadily	O	29-37
gained	O	38-44
appreciation	O	45-57
and	O	58-61
miRNA	O	62-67
biology	O	68-75
has	O	76-79
exploded	O	80-88
into	O	89-93
a	O	94-95
massive	O	96-103
swell	O	104-109
of	O	110-112
interest	O	113-121
with	O	122-126
enormous	O	127-135
range	O	136-141
and	O	142-145
potential	O	146-155
in	O	156-158
almost	O	159-165
every	O	166-171
biological	O	172-182
discipline	O	183-193
because	O	194-201
of	O	202-204
their	O	205-210
widespread	O	211-221
expression	O	222-232
and	O	233-236
diverse	O	237-244
functions	O	245-254
in	O	255-257
both	O	258-262
animals	O	263-270
and	O	271-274
humans	O	275-281
. 	O	281-283

It	O	0-2
has	O	3-6
been	O	7-11
established	O	12-23
that	O	24-28
miRNAs	O	29-35
are	O	36-39
critical	O	40-48
regulators	O	49-59
of	O	60-62
apoptosis	O	63-72
of	O	73-75
various	O	76-83
cell	O	84-88
types	O	89-94
. 	O	94-96

Tremendous	O	0-10
efforts	O	11-18
have	O	19-23
been	O	24-28
made	O	29-33
to	O	34-36
improve	O	37-44
our	O	45-48
understanding	O	49-62
of	O	63-65
the	O	66-69
molecular	O	70-79
mechanisms	O	80-90
and	O	91-94
signaling	O	95-104
pathways	O	105-113
involved	O	114-122
in	O	123-125
apoptosistic	O	126-138
cell	O	139-143
death	O	144-149
. 	O	149-151

Once	O	0-4
ignored	O	5-12
completely	O	13-23
or	O	24-26
overlooked	O	27-37
as	O	38-40
cellular	O	41-49
detritus	O	50-58
,	O	58-59
microRNAs	O	60-69
(	O	70-71
miRNAs	O	71-77
)	O	77-78
that	O	79-83
were	O	84-88
discovered	O	89-99
only	O	100-104
a	O	105-106
decade	O	107-113
ago	O	114-117
,	O	117-118
have	O	119-123
recently	O	124-132
taken	O	133-138
many	O	139-143
by	O	144-146
surprise	O	147-155
. 	O	155-157

MicroRNA	O	0-8
:	O	8-9
A	O	10-11
matter	O	12-18
of	O	19-21
life	O	22-26
or	O	27-29
death	O	30-35
.  	O	35-38

Progressive	O	0-11
cell	O	12-16
loss	O	17-21
due	O	22-25
to	O	26-28
apoptosis	O	29-38
is	O	39-41
a	O	42-43
pathological	O	44-56
hallmark	O	57-65
implicated	O	66-76
in	O	77-79
a	O	80-81
wide	O	82-86
spectrum	O	87-95
of	O	96-98
degenerative	O	99-111
diseases	O	112-120
such	O	121-125
as	O	126-128
heart	O	129-134
disease	O	135-142
,	O	142-143
atherosclerotic	O	144-159
arteries	O	160-168
and	O	169-172
hypertensive	O	173-185
vessels	O	186-193
,	O	193-194
Alzheimer	O	195-204
'	O	204-205
s	O	205-206
disease	O	207-214
and	O	215-218
other	O	219-224
neurodegenerative	O	225-242
disorders	O	243-252
. 	O	252-254

This	O	0-4
editorial	O	5-14
aims	O	15-19
to	O	20-22
convey	O	23-29
this	O	30-34
message	O	35-42
and	O	43-46
to	O	47-49
boost	O	50-55
up	O	56-58
the	O	59-62
research	O	63-71
interest	O	72-80
by	O	81-83
providing	O	84-93
a	O	94-95
timely	O	96-102
,	O	102-103
comprehensive	O	104-117
overview	O	118-126
on	O	127-129
regulation	O	130-140
of	O	141-143
apoptosis	O	144-153
by	O	154-156
miRNAs	O	157-163
and	O	164-167
a	O	168-169
synopsis	O	170-178
on	O	179-181
the	O	182-185
pathophysiologic	O	186-202
implications	O	203-215
of	O	216-218
this	O	219-223
novel	O	224-229
regulatory	O	230-240
network	O	241-248
based	O	249-254
on	O	255-257
the	O	258-261
currently	O	262-271
available	O	272-281
data	O	282-286
in	O	287-289
the	O	290-293
literature	O	294-304
. 	O	304-306

It	O	0-2
begins	O	3-9
with	O	10-14
a	O	15-16
brief	O	17-22
introduction	O	23-35
to	O	36-38
apoptosis	O	39-48
and	O	49-52
miRNAs	O	53-59
,	O	59-60
followed	O	61-69
by	O	70-72
the	O	73-76
description	O	77-88
of	O	89-91
the	O	92-95
fundamental	O	96-107
aspects	O	108-115
of	O	116-118
miRNA	O	119-124
biogenesis	O	125-135
and	O	136-139
action	O	140-146
,	O	146-147
and	O	148-151
the	O	152-155
role	O	156-160
of	O	161-163
miRNAs	O	164-170
in	O	171-173
regulating	O	174-184
apoptosis	O	185-194
of	O	195-197
cancer	O	198-204
cells	O	205-210
and	O	211-214
cardiovascular	O	215-229
cells	O	230-235
. 	O	235-237

METHODS	O	0-7
:	O	7-8
We	O	9-11
prospectively	O	12-25
collected	O	26-35
surgical	O	36-44
outcome	O	45-52
data	O	53-57
for	O	58-61
2	O	62-63
to	O	64-66
11	O	67-69
years	O	70-75
for	O	76-79
134	O	80-83
consecutive	O	84-95
patients	O	96-104
who	O	105-108
specifically	O	109-121
had	O	122-125
MTLE	O	126-130
and	O	131-134
unilateral	O	135-145
HS	O	146-148
,	O	148-149
according	O	150-159
to	O	160-162
magnetic	O	163-171
resonance	O	172-181
imaging	O	182-189
(	O	190-191
MRI	O	191-194
)	O	194-195
and	O	196-199
confirmed	O	200-209
by	O	210-212
histopathology	O	213-227
. 	O	227-229

PURPOSE	O	0-7
:	O	7-8
Surgical	O	9-17
results	O	18-25
in	O	26-28
patients	O	29-37
with	O	38-42
mesial	O	43-49
temporal	O	50-58
lobe	O	59-63
epilepsy	O	64-72
due	O	73-76
to	O	77-79
hippocampal	O	80-91
sclerosis	O	92-101
(	O	102-103
MTLE	O	103-107
/	O	107-108
HS	O	108-110
)	O	110-111
are	O	112-115
often	O	116-121
reported	O	122-130
in	O	131-133
conjunction	O	134-145
with	O	146-150
other	O	151-156
etiologies	O	157-167
of	O	168-170
TLE	O	171-174
. 	O	174-176

Survival	O	0-8
analysis	O	9-17
of	O	18-20
the	O	21-24
surgical	O	25-33
outcome	O	34-41
of	O	42-44
temporal	O	45-53
lobe	O	54-58
epilepsy	O	59-67
due	O	68-71
to	O	72-74
hippocampal	O	75-86
sclerosis	O	87-96
.  	O	96-99

Of	O	0-2
the	O	3-6
patients	O	7-15
tested	O	16-22
,	O	22-23
26	O	24-26
%	O	26-27
of	O	28-30
those	O	31-36
operated	O	37-45
on	O	46-48
the	O	49-52
left	O	53-57
side	O	58-62
and	O	63-66
22	O	67-69
%	O	69-70
of	O	71-73
those	O	74-79
operated	O	80-88
on	O	89-91
the	O	92-95
right	O	96-101
had	O	102-105
postoperative	O	106-119
decline	O	120-127
of	O	128-130
>	O	131-132
1	O	132-133
SD	O	134-136
in	O	137-139
verbal	O	140-146
or	O	147-149
visual	O	150-156
memory	O	157-163
,	O	163-164
respectively	O	165-177
. 	O	177-179

CONCLUSIONS	O	0-11
:	O	11-12
High	O	13-17
rates	O	18-23
of	O	24-26
seizure	O	27-34
freedom	O	35-42
can	O	43-46
be	O	47-49
obtained	O	50-58
and	O	59-62
remain	O	63-69
stable	O	70-76
over	O	77-81
the	O	82-85
years	O	86-91
in	O	92-94
patients	O	95-103
operated	O	104-112
on	O	113-115
for	O	116-119
unilateral	O	120-130
MTLE	O	131-135
/	O	135-136
HS	O	136-138
,	O	138-139
even	O	140-144
in	O	145-147
countries	O	148-157
with	O	158-162
limited	O	163-170
resources	O	171-180
.   	O	180-184

RESULTS	O	0-7
:	O	7-8
Kaplan	O	9-15
-	O	15-16
Meier	O	16-21
estimates	O	22-31
of	O	32-34
complete	O	35-43
seizure	O	44-51
freedom	O	52-59
(	O	60-61
Engel	O	61-66
'	O	66-67
s	O	67-68
class	O	69-74
IA	O	75-77
)	O	77-78
for	O	79-82
years	O	83-88
1	O	89-90
,	O	90-91
2	O	92-93
,	O	93-94
5	O	95-96
,	O	96-97
and	O	98-101
10	O	102-104
were	O	105-109
85	O	110-112
%	O	112-113
,	O	113-114
77	O	115-117
%	O	117-118
,	O	118-119
74	O	120-122
%	O	122-123
,	O	123-124
and	O	125-128
66	O	129-131
%	O	131-132
,	O	132-133
and	O	134-137
of	O	138-140
Engel	O	141-146
'	O	146-147
s	O	147-148
class	O	149-154
I	O	155-156
were	O	157-161
89	O	162-164
%	O	164-165
,	O	165-166
86	O	167-169
%	O	169-170
,	O	170-171
83	O	172-174
%	O	174-175
,	O	175-176
and	O	177-180
81	O	181-183
%	O	183-184
. 	O	184-186

Only	O	0-4
nine	O	5-9
(	O	10-11
6	O	11-12
.	O	12-13
7	O	13-14
%	O	14-15
)	O	15-16
patients	O	17-25
had	O	26-29
outcome	O	30-37
classes	O	38-45
III	O	46-49
or	O	50-52
IV	O	53-55
at	O	56-58
any	O	59-62
point	O	63-68
during	O	69-75
follow	O	76-82
-	O	82-83
up	O	83-85
. 	O	85-87

Sixty	O	0-5
-	O	5-6
five	O	6-10
had	O	11-14
postoperative	O	15-28
neuropsychological	O	29-47
testing	O	48-55
. 	O	55-57

Outcome	O	0-7
was	O	8-11
analyzed	O	12-20
by	O	21-23
using	O	24-29
Engel	O	30-35
'	O	35-36
s	O	36-37
classification	O	38-52
(	O	53-54
a	O	54-55
)	O	55-56
through	O	57-64
Kaplan	O	65-71
-	O	71-72
Meier	O	72-77
estimated	O	78-87
survival	O	88-96
curves	O	97-103
(	O	104-105
as	O	105-107
a	O	108-109
function	O	110-118
of	O	119-121
the	O	122-125
time	O	126-130
to	O	131-133
seizure	O	134-141
recurrence	O	142-152
)	O	152-153
,	O	153-154
(	O	155-156
b	O	156-157
)	O	157-158
as	O	159-161
percentage	O	162-172
of	O	173-175
patients	O	176-184
in	O	185-187
each	O	188-192
outcome	O	193-200
class	O	201-206
on	O	207-209
a	O	210-211
yearly	O	212-218
basis	O	219-224
,	O	224-225
and	O	226-229
(	O	230-231
c	O	231-232
)	O	232-233
at	O	234-236
the	O	237-240
last	O	241-245
updated	O	246-253
follow	O	254-260
-	O	260-261
up	O	261-263
. 	O	263-265

Western	O	0-7
blot	O	8-12
analysis	O	13-21
of	O	22-24
human	O	25-30
glioblastoma	O	31-43
specimens	O	44-53
showed	O	54-60
high	O	61-65
levels	O	66-72
of	O	73-75
PKM2	O	76-80
protein	O	81-88
,	O	88-89
but	O	90-93
none	O	94-98
was	O	99-102
observed	O	103-111
in	O	112-114
normal	O	115-121
brain	O	122-127
samples	O	128-135
. 	O	135-137

Our	O	0-3
data	O	4-8
suggest	O	9-16
PKM2	O	17-21
inhibition	O	22-32
as	O	33-35
a	O	36-37
therapy	O	38-45
for	O	46-49
glioblastoma	O	50-62
,	O	62-63
with	O	64-68
the	O	69-72
potential	O	73-82
for	O	83-86
minimal	O	87-94
toxicity	O	95-103
to	O	104-106
the	O	107-110
brain	O	111-116
.   	O	116-120

Strikingly	O	0-10
,	O	10-11
cells	O	12-17
with	O	18-22
high	O	23-27
levels	O	28-34
of	O	35-37
PKM2	O	38-42
expressed	O	43-52
lower	O	53-58
levels	O	59-65
of	O	66-68
miR	B	69-72
-	I	72-73
326	I	73-76
,	O	76-77
suggestive	O	78-88
of	O	89-91
endogenous	O	92-102
regulation	O	103-113
of	O	114-116
PKM2	O	117-121
by	O	122-124
miR	B	125-128
-	I	128-129
326	I	129-132
. 	O	132-134

Emerging	O	0-8
studies	O	9-16
have	O	17-21
identified	O	22-32
microRNAs	O	33-42
(	O	43-44
miRNAs	O	44-50
)	O	50-51
as	O	52-54
possible	O	55-63
therapeutic	O	64-75
tools	O	76-81
for	O	82-85
the	O	86-89
treatment	O	90-99
of	O	100-102
glioma	O	103-109
,	O	109-110
the	O	111-114
most	O	115-119
aggressive	O	120-130
brain	O	131-136
tumor	O	137-142
. 	O	142-144

Pyruvate	O	0-8
kinase	O	9-15
M2	O	16-18
is	O	19-21
a	O	22-23
target	O	24-30
of	O	31-33
the	O	34-37
tumor	O	38-43
-	O	43-44
suppressive	O	44-55
microRNA	B	56-64
-	I	64-65
326	I	65-68
and	O	69-72
regulates	O	73-82
the	O	83-86
survival	O	87-95
of	O	96-98
glioma	O	99-105
cells	O	106-111
.  	O	111-114

Their	O	0-5
important	O	6-15
targets	O	16-23
in	O	24-26
this	O	27-31
tumor	O	32-37
are	O	38-41
not	O	42-45
well	O	46-50
understood	O	51-61
. 	O	61-63

We	O	0-2
recently	O	3-11
found	O	12-17
that	O	18-22
the	O	23-26
Notch	O	27-32
pathway	O	33-40
is	O	41-43
a	O	44-45
target	O	46-52
of	O	53-55
miRNA	B	56-61
-	I	61-62
326	I	62-65
. 	O	65-67

Ectopic	O	0-7
expression	O	8-18
of	O	19-21
miRNA	B	22-27
-	I	27-28
326	I	28-31
in	O	32-34
glioma	O	35-41
and	O	42-45
glioma	O	46-52
stem	O	53-57
cells	O	58-63
induced	O	64-71
their	O	72-77
apoptosis	O	78-87
and	O	88-91
reduced	O	92-99
their	O	100-105
metabolic	O	106-115
activity	O	116-124
. 	O	124-126

Computational	O	0-13
target	O	14-20
gene	O	21-25
prediction	O	26-36
revealed	O	37-45
pyruvate	O	46-54
kinase	O	55-61
type	O	62-66
M2	O	67-69
(	O	70-71
PKM2	O	71-75
)	O	75-76
as	O	77-79
another	O	80-87
target	O	88-94
of	O	95-97
miRNA	B	98-103
-	I	103-104
326	I	104-107
. 	O	107-109

PKM2	O	0-4
has	O	5-8
recently	O	9-17
been	O	18-22
shown	O	23-28
to	O	29-31
play	O	32-36
a	O	37-38
key	O	39-42
role	O	43-47
in	O	48-50
cancer	O	51-57
cell	O	58-62
metabolism	O	63-73
. 	O	73-75

To	O	0-2
investigate	O	3-14
whether	O	15-22
it	O	23-25
might	O	26-31
be	O	32-34
a	O	35-36
functionally	O	37-49
important	O	50-59
target	O	60-66
of	O	67-69
miR	B	70-73
-	I	73-74
326	I	74-77
,	O	77-78
we	O	79-81
used	O	82-86
RNA	O	87-90
interference	O	91-103
to	O	104-106
knockdown	O	107-116
PKM2	O	117-121
expression	O	122-132
in	O	133-135
glioma	O	136-142
cells	O	143-148
. 	O	148-150

Transfection	O	0-12
of	O	13-15
the	O	16-19
established	O	20-31
glioma	O	32-38
and	O	39-42
glioma	O	43-49
stem	O	50-54
cells	O	55-60
with	O	61-65
PKM2	O	66-70
siRNA	O	71-76
reduced	O	77-84
their	O	85-90
growth	O	91-97
,	O	97-98
cellular	O	99-107
invasion	O	108-116
,	O	116-117
metabolic	O	118-127
activity	O	128-136
,	O	136-137
ATP	O	138-141
and	O	142-145
glutathione	O	146-157
levels	O	158-164
,	O	164-165
and	O	166-169
activated	O	170-179
AMP	O	180-183
-	O	183-184
activated	O	184-193
protein	O	194-201
kinase	O	202-208
. 	O	208-210

The	O	0-3
cytotoxic	O	4-13
effects	O	14-21
exhibited	O	22-31
by	O	32-34
PKM2	O	35-39
knockdown	O	40-49
in	O	50-52
glioma	O	53-59
and	O	60-63
glioma	O	64-70
stem	O	71-75
cells	O	76-81
were	O	82-86
not	O	87-90
observed	O	91-99
in	O	100-102
transformed	O	103-114
human	O	115-120
astrocytes	O	121-131
. 	O	131-133

Membership	O	0-10
in	O	11-13
this	O	14-18
group	O	19-24
is	O	25-27
defined	O	28-35
based	O	36-41
on	O	42-44
sequence	O	45-53
similarity	O	54-64
near	O	65-69
the	O	70-73
mature	O	74-80
miRNAs	O	81-87
'	O	87-88
5	O	89-90
'	O	90-91
end	O	92-95
:	O	95-96
all	O	97-100
include	O	101-108
the	O	109-112
sequence	O	113-121
AGCAGC	O	122-128
. 	O	128-130

Here	O	0-4
we	O	5-7
provide	O	8-15
an	O	16-18
overview	O	19-27
of	O	28-30
the	O	31-34
following	O	35-44
:	O	44-45
(	O	46-47
1	O	47-48
)	O	48-49
the	O	50-53
evolution	O	54-63
of	O	64-66
miR	B	67-70
-	I	70-71
15	I	71-73
/	I	73-74
107	I	74-77
group	O	78-83
member	O	84-90
genes	O	91-96
;	O	96-97
(	O	98-99
2	O	99-100
)	O	100-101
the	O	102-105
expression	O	106-116
levels	O	117-123
of	O	124-126
miRNAs	O	127-133
in	O	134-136
mammalian	O	137-146
tissues	O	147-154
;	O	154-155
(	O	156-157
3	O	157-158
)	O	158-159
evidence	O	160-168
for	O	169-172
overlapping	O	173-184
gene	O	185-189
-	O	189-190
regulatory	O	190-200
functions	O	201-210
by	O	211-213
different	O	214-223
miRNAs	O	224-230
;	O	230-231
(	O	232-233
4	O	233-234
)	O	234-235
the	O	236-239
normal	O	240-246
biochemical	O	247-258
pathways	O	259-267
regulated	O	268-277
by	O	278-280
miR	B	281-284
-	I	284-285
15	I	285-287
/	I	287-288
107	I	288-291
group	O	292-297
miRNAs	O	298-304
;	O	304-305
and	O	306-309
(	O	310-311
5	O	311-312
)	O	312-313
the	O	314-317
roles	O	318-323
played	O	324-330
by	O	331-333
these	O	334-339
miRNAs	O	340-346
in	O	347-349
human	O	350-355
diseases	O	356-364
. 	O	364-366

While	O	0-5
all	O	6-9
vertebrates	O	10-21
studied	O	22-29
to	O	30-32
date	O	33-37
express	O	38-45
miR	B	46-49
-	I	49-50
15a	I	50-53
,	O	53-54
miR	B	55-58
-	I	58-59
15b	I	59-62
,	O	62-63
miR	B	64-67
-	I	67-68
16	I	68-70
,	O	70-71
miR	B	72-75
-	I	75-76
103	I	76-79
,	O	79-80
and	O	81-84
miR	B	85-88
-	I	88-89
107	I	89-92
,	O	92-93
mammals	O	94-101
alone	O	102-107
are	O	108-111
known	O	112-117
to	O	118-120
express	O	121-128
miR	B	129-132
-	I	132-133
195	I	133-136
,	O	136-137
miR	B	138-141
-	I	141-142
424	I	142-145
,	O	145-146
miR	B	147-150
-	I	150-151
497	I	151-154
,	O	154-155
miR	B	156-159
-	I	159-160
503	I	160-163
,	O	163-164
and	O	165-168
miR	B	169-172
-	I	172-173
646	I	173-176
. 	O	176-178

Phylogeny	O	0-9
of	O	10-12
this	O	13-17
group	O	18-23
of	O	24-26
miRNAs	O	27-33
is	O	34-36
incomplete	O	37-47
;	O	47-48
thus	O	49-53
,	O	53-54
a	O	55-56
definitive	O	57-67
taxonomic	O	68-77
classification	O	78-92
(	O	93-94
e	O	94-95
.	O	95-96
g	O	96-97
.	O	97-98
,	O	98-99
designation	O	100-111
as	O	112-114
a	O	115-116
"	O	117-118
superfamily	O	118-129
"	O	129-130
)	O	130-131
is	O	132-134
currently	O	135-144
not	O	145-148
possible	O	149-157
. 	O	157-159

We	O	0-2
present	O	3-10
data	O	11-15
on	O	16-18
the	O	19-22
expression	O	23-33
of	O	34-36
all	O	37-40
known	O	41-46
miR	B	47-50
-	I	50-51
15	I	51-53
/	I	53-54
107	I	54-57
group	O	58-63
members	O	64-71
in	O	72-74
human	O	75-80
cerebral	O	81-89
cortical	O	90-98
gray	O	99-103
matter	O	104-110
and	O	111-114
white	O	115-120
matter	O	121-127
using	O	128-133
new	O	134-137
miRNA	O	138-143
profiling	O	144-153
microarrays	O	154-165
. 	O	165-167

Multiple	O	0-8
different	O	9-18
miRNAs	O	19-25
in	O	26-28
the	O	29-32
miR	B	33-36
-	I	36-37
15	I	37-39
/	I	39-40
107	I	40-43
group	O	44-49
are	O	50-53
expressed	O	54-63
at	O	64-66
moderate	O	67-75
to	O	76-78
high	O	79-83
levels	O	84-90
in	O	91-93
human	O	94-99
tissues	O	100-107
. 	O	107-109

The	O	0-3
miR	B	4-7
-	I	7-8
15	I	8-10
/	I	10-11
107	I	11-14
group	O	15-20
of	O	21-23
microRNA	O	24-32
genes	O	33-38
:	O	38-39
evolutionary	O	40-52
biology	O	53-60
,	O	60-61
cellular	O	62-70
functions	O	71-80
,	O	80-81
and	O	82-85
roles	O	86-91
in	O	92-94
human	O	95-100
diseases	O	101-109
.  	O	109-112

The	O	0-3
miR	B	4-7
-	I	7-8
15	I	8-10
/	I	10-11
107	I	11-14
group	O	15-20
of	O	21-23
microRNA	O	24-32
(	O	33-34
miRNA	O	34-39
)	O	39-40
gene	O	41-45
is	O	46-48
increasingly	O	49-61
appreciated	O	62-73
to	O	74-76
serve	O	77-82
key	O	83-86
functions	O	87-96
in	O	97-99
humans	O	100-106
. 	O	106-108

These	O	0-5
miRNAs	O	6-12
regulate	O	13-21
gene	O	22-26
expression	O	27-37
involved	O	38-46
in	O	47-49
cell	O	50-54
division	O	55-63
,	O	63-64
metabolism	O	65-75
,	O	75-76
stress	O	77-83
response	O	84-92
,	O	92-93
and	O	94-97
angiogenesis	O	98-110
in	O	111-113
vertebrate	O	114-124
species	O	125-132
. 	O	132-134

The	O	0-3
miR	B	4-7
-	I	7-8
15	I	8-10
/	I	10-11
107	I	11-14
group	O	15-20
has	O	21-24
also	O	25-29
been	O	30-34
implicated	O	35-45
in	O	46-48
human	O	49-54
cancers	O	55-62
,	O	62-63
cardiovascular	O	64-78
disease	O	79-86
and	O	87-90
neurodegenerative	O	91-108
disease	O	109-116
,	O	116-117
including	O	118-127
Alzheimer	O	128-137
'	O	137-138
s	O	138-139
disease	O	140-147
. 	O	147-149

In	O	0-2
conclusion	O	3-13
,	O	13-14
the	O	15-18
miR	B	19-22
-	I	22-23
15	I	23-25
/	I	25-26
107	I	26-29
group	O	30-35
of	O	36-38
miRNA	O	39-44
genes	O	45-50
is	O	51-53
a	O	54-55
fascinating	O	56-67
topic	O	68-73
of	O	74-76
study	O	77-82
for	O	83-86
evolutionary	O	87-99
biologists	O	100-110
,	O	110-111
miRNA	O	112-117
biochemists	O	118-129
,	O	129-130
and	O	131-134
clinically	O	135-145
oriented	O	146-154
translational	O	155-168
researchers	O	169-180
alike	O	181-186
.   	O	186-190

We	O	0-2
show	O	3-7
new	O	8-11
data	O	12-16
from	O	17-21
cultured	O	22-30
H4	O	31-33
cancer	O	34-40
cells	O	41-46
that	O	47-51
demonstrate	O	52-63
similarities	O	64-76
in	O	77-79
mRNAs	O	80-85
targeted	O	86-94
by	O	95-97
miR	B	98-101
-	I	101-102
16	I	102-104
and	O	105-108
miR	B	109-112
-	I	112-113
103	I	113-116
and	O	117-120
also	O	121-125
support	O	126-133
the	O	134-137
importance	O	138-148
of	O	149-151
the	O	152-155
mature	O	156-162
miRNAs	O	163-169
'	O	169-170
5	O	171-172
'	O	172-173
seed	O	174-178
region	O	179-185
in	O	186-188
mRNA	O	189-193
target	O	194-200
recognition	O	201-212
. 	O	212-214

There	O	0-5
is	O	6-8
extensive	O	9-18
overlap	O	19-26
in	O	27-29
the	O	30-33
mRNAs	O	34-39
targeted	O	40-48
by	O	49-51
miR	B	52-55
-	I	55-56
15	I	56-58
/	I	58-59
107	I	59-62
group	O	63-68
members	O	69-76
. 	O	76-78

Knockdown	O	0-9
of	O	10-12
GAD67	O	13-18
protein	O	19-26
levels	O	27-33
normalizes	O	34-44
neuronal	O	45-53
activity	O	54-62
in	O	63-65
a	O	66-67
rat	O	68-71
model	O	72-77
of	O	78-80
Parkinson	O	81-90
'	O	90-91
s	O	91-92
disease	O	93-100
.  	O	100-103

METHODS	O	0-7
:	O	7-8
To	O	9-11
normalize	O	12-21
the	O	22-25
GAD67	O	26-31
expression	O	32-42
in	O	43-45
the	O	46-49
striatum	O	50-58
after	O	59-64
dopamine	O	65-73
depletion	O	74-83
,	O	83-84
we	O	85-87
developed	O	88-97
several	O	98-105
lentiviral	O	106-116
vectors	O	117-124
that	O	125-129
express	O	130-137
RNA	O	138-141
interference	O	142-154
(	O	155-156
RNAi	O	156-160
)	O	160-161
directed	O	162-170
against	O	171-178
GAD67	O	179-184
mitochondrial	O	185-198
RNA	O	199-202
. 	O	202-204

The	O	0-3
vectors	O	4-11
were	O	12-16
injected	O	17-25
into	O	26-30
the	O	31-34
striatum	O	35-43
of	O	44-46
hemiparkinsonian	O	47-63
rats	O	64-68
and	O	69-72
the	O	73-76
level	O	77-82
of	O	83-85
GAD67	O	86-91
protein	O	92-99
as	O	100-102
well	O	103-107
as	O	108-110
a	O	111-112
marker	O	113-119
of	O	120-122
neuronal	O	123-131
activity	O	132-140
,	O	140-141
mtCO1	O	142-147
,	O	147-148
was	O	149-152
analyzed	O	153-161
using	O	162-167
western	O	168-175
blots	O	176-181
. 	O	181-183

BACKGROUND	O	0-10
:	O	10-11
Dopamine	O	12-20
depletion	O	21-30
of	O	31-33
the	O	34-37
striatum	O	38-46
is	O	47-49
one	O	50-53
of	O	54-56
the	O	57-60
hallmarks	O	61-70
of	O	71-73
Parkinson	O	74-83
'	O	83-84
s	O	84-85
disease	O	86-93
. 	O	93-95

The	O	0-3
loss	O	4-8
of	O	9-11
dopamine	O	12-20
upregulates	O	21-32
GAD67	O	33-38
expression	O	39-49
in	O	50-52
the	O	53-56
striatal	O	57-65
projection	O	66-76
neurons	O	77-84
and	O	85-88
causes	O	89-95
other	O	96-101
changes	O	102-109
in	O	110-112
the	O	113-116
activity	O	117-125
of	O	126-128
the	O	129-132
basal	O	133-138
ganglia	O	139-146
circuit	O	147-154
. 	O	154-156

Using	O	0-5
a	O	6-7
lentiviral	O	8-18
vectors	O	19-26
with	O	27-31
a	O	32-33
synthetic	O	34-43
miRNA	O	44-49
scaffold	O	50-58
to	O	59-61
deliver	O	62-69
RNAi	O	70-74
,	O	74-75
we	O	76-78
were	O	79-83
able	O	84-88
to	O	89-91
normalize	O	92-101
the	O	102-105
GAD67	O	106-111
protein	O	112-119
levels	O	120-126
in	O	127-129
the	O	130-133
parkinsonian	O	134-146
rat	O	147-150
striatum	O	151-159
. 	O	159-161

In	O	0-2
addition	O	3-11
,	O	11-12
we	O	13-15
were	O	16-20
able	O	21-25
to	O	26-28
normalize	O	29-38
the	O	39-42
increased	O	43-52
neural	O	53-59
activity	O	60-68
,	O	68-69
which	O	70-75
resulted	O	76-84
from	O	85-89
the	O	90-93
loss	O	94-98
of	O	99-101
dopamine	O	102-110
as	O	111-113
measured	O	114-122
by	O	123-125
the	O	126-129
marker	O	130-136
mtCO1	O	137-142
. 	O	142-144

RESULTS	O	0-7
:	O	7-8
Unilateral	O	9-19
lesions	O	20-27
of	O	28-30
the	O	31-34
dopamine	O	35-43
neurons	O	44-51
in	O	52-54
substantia	O	55-65
nigra	O	66-71
resulted	O	72-80
in	O	81-83
an	O	84-86
increased	O	87-96
level	O	97-102
of	O	103-105
GAD67	O	106-111
protein	O	112-119
in	O	120-122
the	O	123-126
ipsilateral	O	127-138
striatum	O	139-147
. 	O	147-149

Furthermore	O	0-11
,	O	11-12
we	O	13-15
detected	O	16-24
significantly	O	25-38
higher	O	39-45
levels	O	46-52
of	O	53-55
mtCO1	O	56-61
,	O	61-62
after	O	63-68
dopamine	O	69-77
depletion	O	78-87
in	O	88-90
the	O	91-94
striatum	O	95-103
. 	O	103-105

CONCLUSIONS	O	0-11
:	O	11-12
We	O	13-15
conclude	O	16-24
that	O	25-29
RNAi	O	30-34
directed	O	35-43
against	O	44-51
GAD67	O	52-57
may	O	58-61
be	O	62-64
a	O	65-66
valid	O	67-72
approach	O	73-81
to	O	82-84
correct	O	85-92
the	O	93-96
dysregulation	O	97-110
of	O	111-113
the	O	114-117
basal	O	118-123
ganglia	O	124-131
circuit	O	132-139
in	O	140-142
a	O	143-144
rat	O	145-148
model	O	149-154
of	O	155-157
Parkinson	O	158-167
'	O	167-168
s	O	168-169
disease	O	170-177
. 	O	177-179

The	O	0-3
possibility	O	4-15
to	O	16-18
correct	O	19-26
for	O	27-30
a	O	31-32
loss	O	33-37
of	O	38-40
dopamine	O	41-49
using	O	50-55
nondopamimetic	O	56-70
tools	O	71-76
is	O	77-79
interesting	O	80-91
because	O	92-99
it	O	100-102
may	O	103-106
be	O	107-109
more	O	110-114
directed	O	115-123
towards	O	124-131
the	O	132-135
casual	O	136-142
mechanisms	O	143-153
of	O	154-156
the	O	157-160
motor	O	161-166
symptoms	O	167-175
. 	O	175-177

Copyright	O	0-9
©	O	10-11
2011	O	12-16
John	O	17-21
Wiley	O	22-27
&	O	28-29
Sons	O	30-34
,	O	34-35
Ltd	O	36-39
.   	O	39-43

Out	O	0-3
of	O	4-6
the	O	7-10
5	O	11-12
positive	O	13-21
samples	O	22-29
,	O	29-30
one	O	31-34
was	O	35-38
an	O	39-41
HTLV	O	42-46
,	O	46-47
three	O	48-53
HTLV	O	54-58
-	O	58-59
1	O	59-60
and	O	61-64
one	O	65-68
HTLV	O	69-73
-	O	73-74
2	O	74-75
. 	O	75-77

These	O	0-5
blood	O	6-11
donors	O	12-18
were	O	19-23
residents	O	24-33
of	O	34-36
Posadas	O	37-44
,	O	44-45
Eldorado	O	46-54
and	O	55-58
Oberá	O	59-64
,	O	64-65
with	O	66-70
no	O	71-73
risk	O	74-78
antecedents	O	79-90
. 	O	90-92

This	O	0-4
study	O	5-10
demonstrates	O	11-23
the	O	24-27
presence	O	28-36
of	O	37-39
HTLV	O	40-44
-	O	44-45
1	O	45-46
/	O	46-47
2	O	47-48
in	O	49-51
a	O	52-53
population	O	54-64
of	O	65-67
Misiones	O	68-76
with	O	77-81
a	O	82-83
prevalence	O	84-94
rate	O	95-99
similar	O	100-107
to	O	108-110
those	O	111-116
reported	O	117-125
among	O	126-131
blood	O	132-137
donors	O	138-144
from	O	145-149
non	O	150-153
-	O	153-154
endemic	O	154-161
areas	O	162-167
.   	O	167-171

[	O	0-1
Seroprevalence	O	1-15
of	O	16-18
HTLV	O	19-23
-	O	23-24
1	O	24-25
/	O	25-26
2	O	26-27
in	O	28-30
blood	O	31-36
donors	O	37-43
from	O	44-48
Misiones	O	49-57
Province	O	58-66
]	O	66-67
.  	O	67-70

The	O	0-3
aim	O	4-7
of	O	8-10
this	O	11-15
study	O	16-21
was	O	22-25
to	O	26-28
estimate	O	29-37
the	O	38-41
seroprevalence	O	42-56
of	O	57-59
HTLV	O	60-64
-	O	64-65
1	O	65-66
/	O	66-67
2	O	67-68
in	O	69-71
a	O	72-73
blood	O	74-79
donor	O	80-85
population	O	86-96
from	O	97-101
Misiones	O	102-110
province	O	111-119
. 	O	119-121

They	O	0-4
are	O	5-8
transmitted	O	9-20
through	O	21-28
sex	O	29-32
contact	O	33-40
,	O	40-41
parenterally	O	42-54
and	O	55-58
from	O	59-63
mother	O	64-70
to	O	71-73
child	O	74-79
. 	O	79-81

HTLV	O	0-4
-	O	4-5
1	O	5-6
/	O	6-7
2	O	7-8
screening	O	9-18
was	O	19-22
performed	O	23-32
with	O	33-37
ELISA	O	38-43
and	O	44-47
particle	O	48-56
agglutination	O	57-70
,	O	70-71
and	O	72-75
reactive	O	76-84
samples	O	85-92
were	O	93-97
confirmed	O	98-107
by	O	108-110
Western	O	111-118
Blot	O	119-123
. 	O	123-125

A	O	0-1
total	O	2-7
of	O	8-10
6912	O	11-15
accepted	O	16-24
blood	O	25-30
donations	O	31-40
in	O	41-43
2008	O	44-48
were	O	49-53
analyzed	O	54-62
. 	O	62-64

It	O	0-2
is	O	3-5
endemic	O	6-13
worldwide	O	14-23
,	O	23-24
including	O	25-34
the	O	35-38
North	O	39-44
of	O	45-47
Argentina	O	48-57
where	O	58-63
both	O	64-68
associated	O	69-79
diseases	O	80-88
have	O	89-93
also	O	94-98
been	O	99-103
detected	O	104-112
. 	O	112-114

Human	O	0-5
T	O	6-7
-	O	7-8
cell	O	8-12
Lymphotropic	O	13-25
viruses	O	26-33
type	O	34-38
1	O	39-40
(	O	41-42
HTLV	O	42-46
-	O	46-47
1	O	47-48
)	O	48-49
,	O	49-50
the	O	51-54
first	O	55-60
human	O	61-66
oncoretrovirus	O	67-81
to	O	82-84
be	O	85-87
discovered	O	88-98
,	O	98-99
is	O	100-102
the	O	103-106
etiologic	O	107-116
agent	O	117-122
of	O	123-125
Adult	O	126-131
T	O	132-133
-	O	133-134
cell	O	134-138
Leukemia	O	139-147
(	O	148-149
ATL	O	149-152
)	O	152-153
and	O	154-157
HTLV	O	158-162
-	O	162-163
1	O	163-164
Associated	O	165-175
Mielopathy	O	176-186
or	O	187-189
Tropical	O	190-198
Spastic	O	199-206
Paraparesis	O	207-218
(	O	219-220
HAM	O	220-223
/	O	223-224
TSP	O	224-227
)	O	227-228
. 	O	228-230

Both	O	0-4
retroviruses	O	5-17
are	O	18-21
endemic	O	22-29
in	O	30-32
native	O	33-39
populations	O	40-51
of	O	52-54
The	O	55-58
Americas	O	59-67
,	O	67-68
Africa	O	69-75
and	O	76-79
at	O	80-82
-	O	82-83
risk	O	83-87
populations	O	88-99
. 	O	99-101

No	O	0-2
etiologic	O	3-12
role	O	13-17
has	O	18-21
been	O	22-26
described	O	27-36
for	O	37-40
HTLV	O	41-45
-	O	45-46
2	O	46-47
,	O	47-48
although	O	49-57
it	O	58-60
has	O	61-64
been	O	65-69
associated	O	70-80
with	O	81-85
HAM	O	86-89
/	O	89-90
TSP	O	90-93
-	O	93-94
like	O	94-98
neurologic	O	99-109
syndromes	O	110-119
. 	O	119-121

From	O	0-4
the	O	5-8
total	O	9-14
,	O	14-15
5	O	16-17
samples	O	18-25
resulted	O	26-34
seropositive	O	35-47
with	O	48-52
a	O	53-54
final	O	55-60
prevalence	O	61-71
of	O	72-74
0	O	75-76
.	O	76-77
00072	O	77-82
. 	O	82-84

The	O	0-3
results	O	4-11
suggest	O	12-19
(	O	20-21
a	O	21-22
)	O	22-23
that	O	24-28
unless	O	29-35
specifically	O	36-48
stabilized	O	49-59
,	O	59-60
certain	O	61-68
brain	O	69-74
-	O	74-75
enriched	O	75-83
miRNAs	O	84-90
represent	O	91-100
a	O	101-102
rapidly	O	103-110
executed	O	111-119
signaling	O	120-129
system	O	130-136
employing	O	137-146
highly	O	147-153
transient	O	154-163
effectors	O	164-173
of	O	174-176
CNS	O	177-180
gene	O	181-185
expression	O	186-196
,	O	196-197
and	O	198-201
(	O	202-203
b	O	203-204
)	O	204-205
that	O	206-210
in	O	211-213
AD	O	214-216
temporal	O	217-225
lobe	O	226-230
neocortex	O	231-240
specific	O	241-249
brain	O	250-255
miRNAs	O	256-262
are	O	263-266
significantly	O	267-280
up	O	281-283
-	O	283-284
regulated	O	284-293
in	O	294-296
abundance	O	297-306
and	O	307-310
strongly	O	311-319
correlate	O	320-329
with	O	330-334
the	O	335-338
presence	O	339-347
of	O	348-350
AD	O	351-353
-	O	353-354
type	O	354-358
neuropatholgical	O	359-375
change	O	376-382
.   	O	382-386

In	O	0-2
short	O	3-8
PMI	O	9-12
Alzheimer	O	13-22
'	O	22-23
s	O	23-24
disease	O	25-32
(	O	33-34
AD	O	34-36
)	O	36-37
-	O	37-38
affected	O	38-46
temporal	O	47-55
lobe	O	56-60
neocortex	O	61-70
,	O	70-71
miRNA	B	72-77
-	I	77-78
9	I	78-79
,	O	79-80
miRNA	B	81-86
-	I	86-87
125b	I	87-91
and	O	92-95
miRNA	B	96-101
-	I	101-102
146a	I	102-106
were	O	107-111
found	O	112-117
to	O	118-120
be	O	121-123
significantly	O	124-137
up	O	138-140
-	O	140-141
regulated	O	141-150
,	O	150-151
an	O	152-154
effect	O	155-161
that	O	162-166
was	O	167-170
not	O	171-174
seen	O	175-179
in	O	180-182
several	O	183-190
related	O	191-198
neurological	O	199-211
disorders	O	212-221
. 	O	221-223

In	O	0-2
these	O	3-8
studies	O	9-16
,	O	16-17
miRNA	O	18-23
array	O	24-29
and	O	30-33
Northern	O	34-42
blot	O	43-47
based	O	48-53
tracking	O	54-62
of	O	63-65
specific	O	66-74
miRNA	O	75-80
abundances	O	81-91
and	O	92-95
decay	O	96-101
kinetics	O	102-110
in	O	111-113
human	O	114-119
neural	O	120-126
(	O	127-128
HN	O	128-130
)	O	130-131
cells	O	132-137
in	O	138-140
primary	O	141-148
culture	O	149-156
and	O	157-160
in	O	161-163
short	O	164-169
post	O	170-174
-	O	174-175
mortem	O	175-181
interval	O	182-190
(	O	191-192
PMI	O	192-195
,	O	195-196
approximately	O	197-210
1h	O	211-213
)	O	213-214
human	O	215-220
brain	O	221-226
tissues	O	227-234
showed	O	235-241
a	O	242-243
limited	O	244-251
stability	O	252-261
and	O	262-265
relatively	O	266-276
short	O	277-282
half	O	283-287
-	O	287-288
life	O	288-292
(	O	293-294
approximately	O	295-308
1	O	309-310
-	O	310-311
3	O	311-312
.	O	312-313
5h	O	313-315
)	O	315-316
for	O	317-320
specific	O	321-329
brain	O	330-335
-	O	335-336
enriched	O	336-344
miRNAs	O	345-351
. 	O	351-353

Micro	O	0-5
-	O	5-6
RNA	O	6-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
mediated	O	18-26
regulation	O	27-37
of	O	38-40
messenger	O	41-50
RNA	O	51-54
(	O	55-56
mRNA	O	56-60
)	O	60-61
complexity	O	62-72
in	O	73-75
the	O	76-79
central	O	80-87
nervous	O	88-95
system	O	96-102
(	O	103-104
CNS	O	104-107
)	O	107-108
is	O	109-111
emerging	O	112-120
as	O	121-123
a	O	124-125
critical	O	126-134
factor	O	135-141
in	O	142-144
the	O	145-148
control	O	149-156
of	O	157-159
CNS	O	160-163
-	O	163-164
specific	O	164-172
gene	O	173-177
expression	O	178-188
during	O	189-195
development	O	196-207
,	O	207-208
plasticity	O	209-219
,	O	219-220
aging	O	221-226
and	O	227-230
disease	O	231-238
. 	O	238-240

Micro	O	0-5
-	O	5-6
RNA	O	6-9
abundance	O	10-19
and	O	20-23
stability	O	24-33
in	O	34-36
human	O	37-42
brain	O	43-48
:	O	48-49
specific	O	50-58
alterations	O	59-70
in	O	71-73
Alzheimer	O	74-83
'	O	83-84
s	O	84-85
disease	O	86-93
temporal	O	94-102
lobe	O	103-107
neocortex	O	108-117
.  	O	117-120

While	O	0-5
confirmation	O	6-18
is	O	19-21
required	O	22-30
,	O	30-31
this	O	32-36
study	O	37-42
suggests	O	43-51
that	O	52-56
microRNA	O	57-65
mutations	O	66-75
can	O	76-79
contribute	O	80-90
to	O	91-93
schizophrenia	O	94-107
.   	O	107-111

One	O	0-3
ultra	O	4-9
-	O	9-10
rare	O	10-14
variant	O	15-22
was	O	23-26
identified	O	27-37
in	O	38-40
a	O	41-42
control	O	43-50
sample	O	51-57
(	O	58-59
with	O	59-63
a	O	64-65
history	O	66-73
of	O	74-76
depression	O	77-87
)	O	87-88
(	O	89-90
8	O	90-91
/	O	91-92
193	O	92-95
versus	O	96-102
1	O	103-104
/	O	104-105
191	O	105-108
,	O	108-109
p	O	110-111
=	O	112-113
0	O	114-115
.	O	115-116
02	O	116-118
by	O	119-121
one	O	122-125
-	O	125-126
sided	O	126-131
Fisher	O	132-138
'	O	138-139
s	O	139-140
exact	O	141-146
test	O	147-151
,	O	151-152
odds	O	153-157
ratio	O	158-163
=	O	164-165
8	O	166-167
.	O	167-168
2	O	168-169
)	O	169-170
. 	O	170-172

These	O	0-5
variants	O	6-14
were	O	15-19
not	O	20-23
found	O	24-29
in	O	30-32
an	O	33-35
additional	O	36-46
7	O	47-48
,	O	48-49
197	O	49-52
control	O	53-60
X	O	61-62
-	O	62-63
chromosomes	O	63-74
. 	O	74-76

CONCLUSIONS	O	0-11
:	O	11-12
Functional	O	13-23
analyses	O	24-32
of	O	33-35
ectopically	O	36-47
expressed	O	48-57
copies	O	58-64
of	O	65-67
the	O	68-71
variant	O	72-79
miRNA	O	80-85
precursors	O	86-96
demonstrate	O	97-108
loss	O	109-113
of	O	114-116
function	O	117-125
,	O	125-126
gain	O	127-131
of	O	132-134
function	O	135-143
or	O	144-146
altered	O	147-154
expression	O	155-165
levels	O	166-172
. 	O	172-174

In	O	0-2
addition	O	3-11
,	O	11-12
components	O	13-23
required	O	24-32
for	O	33-36
miRNA	O	37-42
processing	O	43-53
and	O	54-57
/	O	57-58
or	O	58-60
function	O	61-69
have	O	70-74
also	O	75-79
been	O	80-84
implicated	O	85-95
in	O	96-98
X	O	99-100
-	O	100-101
linked	O	101-107
mental	O	108-114
retardation	O	115-126
,	O	126-127
neurological	O	128-140
and	O	141-144
neoplastic	O	145-155
diseases	O	156-164
,	O	164-165
pointing	O	166-174
to	O	175-177
the	O	178-181
wide	O	182-186
ranging	O	187-194
involvement	O	195-206
of	O	207-209
miRNAs	O	210-216
in	O	217-219
disease	O	220-227
. 	O	227-229

METHODS	O	0-7
AND	O	8-11
FINDINGS	O	12-20
:	O	20-21
To	O	22-24
explore	O	25-32
the	O	33-36
role	O	37-41
of	O	42-44
miRNAs	O	45-51
in	O	52-54
schizophrenia	O	55-68
,	O	68-69
59	O	70-72
microRNA	O	73-81
genes	O	82-87
on	O	88-90
the	O	91-94
X	O	95-96
-	O	96-97
chromosome	O	97-107
were	O	108-112
amplified	O	113-122
and	O	123-126
sequenced	O	127-136
in	O	137-139
males	O	140-145
with	O	146-150
(	O	151-152
193	O	152-155
)	O	155-156
and	O	157-160
without	O	161-168
(	O	169-170
191	O	170-173
)	O	173-174
schizophrenia	O	175-188
spectrum	O	189-197
disorders	O	198-207
to	O	208-210
test	O	211-215
the	O	216-219
hypothesis	O	220-230
that	O	231-235
ultra	O	236-241
-	O	241-242
rare	O	242-246
mutations	O	247-256
in	O	257-259
microRNA	O	260-268
collectively	O	269-281
contribute	O	282-292
to	O	293-295
the	O	296-299
risk	O	300-304
of	O	305-307
schizophrenia	O	308-321
. 	O	321-323

Here	O	0-4
we	O	5-7
provide	O	8-15
the	O	16-19
first	O	20-25
association	O	26-37
of	O	38-40
microRNA	O	41-49
gene	O	50-54
dysfunction	O	55-66
with	O	67-71
schizophrenia	O	72-85
. 	O	85-87

Eight	O	0-5
ultra	O	6-11
-	O	11-12
rare	O	12-16
variants	O	17-25
in	O	26-28
the	O	29-32
precursor	O	33-42
or	O	43-45
mature	O	46-52
miRNA	O	53-58
were	O	59-63
identified	O	64-74
in	O	75-77
eight	O	78-83
distinct	O	84-92
miRNA	O	93-98
genes	O	99-104
in	O	105-107
4	O	108-109
%	O	109-110
of	O	111-113
analyzed	O	114-122
males	O	123-128
with	O	129-133
schizophrenia	O	134-147
. 	O	147-149

Evidence	O	0-8
for	O	9-12
X	O	13-14
-	O	14-15
chromosomal	O	15-26
schizophrenia	O	27-40
associated	O	41-51
with	O	52-56
microRNA	O	57-65
alterations	O	66-77
.  	O	77-80

BACKGROUND	O	0-10
:	O	10-11
Schizophrenia	O	12-25
is	O	26-28
a	O	29-30
severe	O	31-37
disabling	O	38-47
brain	O	48-53
disease	O	54-61
affecting	O	62-71
about	O	72-77
1	O	78-79
%	O	79-80
of	O	81-83
the	O	84-87
population	O	88-98
. 	O	98-100

Individual	O	0-10
microRNAs	O	11-20
(	O	21-22
miRNAs	O	22-28
)	O	28-29
affect	O	30-36
moderate	O	37-45
downregulation	O	46-60
of	O	61-63
gene	O	64-68
expression	O	69-79
. 	O	79-81

We	O	0-2
will	O	3-7
describe	O	8-16
the	O	17-20
evidence	O	21-29
that	O	30-34
disruption	O	35-45
to	O	46-48
the	O	49-52
REST	O	53-57
regulon	O	58-65
brought	O	66-73
about	O	74-79
by	O	80-82
a	O	83-84
loss	O	85-89
of	O	90-92
interaction	O	93-104
between	O	105-112
REST	O	113-117
and	O	118-121
mutHtt	O	122-128
may	O	129-132
be	O	133-135
a	O	136-137
key	O	138-141
contributory	O	142-154
factor	O	155-161
in	O	162-164
the	O	165-168
widespread	O	169-179
dysregulation	O	180-193
of	O	194-196
gene	O	197-201
expression	O	202-212
in	O	213-215
HD	O	216-218
.   	O	218-222

Transcriptional	O	0-15
dysregulation	O	16-29
of	O	30-32
coding	O	33-39
and	O	40-43
non	O	44-47
-	O	47-48
coding	O	48-54
genes	O	55-60
in	O	61-63
cellular	O	64-72
models	O	73-79
of	O	80-82
Huntington	O	83-93
'	O	93-94
s	O	94-95
disease	O	96-103
.  	O	103-106

HD	O	0-2
(	O	3-4
Huntington	O	4-14
'	O	14-15
s	O	15-16
disease	O	17-24
)	O	24-25
is	O	26-28
a	O	29-30
late	O	31-35
onset	O	36-41
heritable	O	42-51
neurodegenerative	O	52-69
disorder	O	70-78
that	O	79-83
is	O	84-86
characterized	O	87-100
by	O	101-103
neuronal	O	104-112
dysfunction	O	113-124
and	O	125-128
death	O	129-134
,	O	134-135
particularly	O	136-148
in	O	149-151
the	O	152-155
cerebral	O	156-164
cortex	O	165-171
and	O	172-175
medium	O	176-182
spiny	O	183-188
neurons	O	189-196
of	O	197-199
the	O	200-203
striatum	O	204-212
. 	O	212-214

This	O	0-4
is	O	5-7
followed	O	8-16
by	O	17-19
progressive	O	20-31
chorea	O	32-38
,	O	38-39
dementia	O	40-48
and	O	49-52
emotional	O	53-62
dysfunction	O	63-74
,	O	74-75
eventually	O	76-86
resulting	O	87-96
in	O	97-99
death	O	100-105
. 	O	105-107

HD	O	0-2
is	O	3-5
caused	O	6-12
by	O	13-15
an	O	16-18
expanded	O	19-27
CAG	O	28-31
repeat	O	32-38
in	O	39-41
the	O	42-45
first	O	46-51
exon	O	52-56
of	O	57-59
the	O	60-63
HD	O	64-66
gene	O	67-71
that	O	72-76
results	O	77-84
in	O	85-87
an	O	88-90
abnormally	O	91-101
elongated	O	102-111
polyQ	O	112-117
(	O	118-119
polyglutamine	O	119-132
)	O	132-133
tract	O	134-139
in	O	140-142
its	O	143-146
protein	O	147-154
product	O	155-162
,	O	162-163
Htt	O	164-167
(	O	168-169
Huntingtin	O	169-179
)	O	179-180
. 	O	180-182

Wild	O	0-4
-	O	4-5
type	O	5-9
Htt	O	10-13
is	O	14-16
largely	O	17-24
cytoplasmic	O	25-36
;	O	36-37
however	O	38-45
,	O	45-46
in	O	47-49
HD	O	50-52
,	O	52-53
proteolytic	O	54-65
N	O	66-67
-	O	67-68
terminal	O	68-76
fragments	O	77-86
of	O	87-89
Htt	O	90-93
form	O	94-98
insoluble	O	99-108
deposits	O	109-117
in	O	118-120
both	O	121-125
the	O	126-129
cytoplasm	O	130-139
and	O	140-143
nucleus	O	144-151
,	O	151-152
provoking	O	153-162
the	O	163-166
idea	O	167-171
that	O	172-176
mutHtt	O	177-183
(	O	184-185
mutant	O	185-191
Htt	O	192-195
)	O	195-196
causes	O	197-203
transcriptional	O	204-219
dysfunction	O	220-231
. 	O	231-233

While	O	0-5
a	O	6-7
number	O	8-14
of	O	15-17
specific	O	18-26
transcription	O	27-40
factors	O	41-48
and	O	49-52
co	O	53-55
-	O	55-56
factors	O	56-63
have	O	64-68
been	O	69-73
proposed	O	74-82
as	O	83-85
mediators	O	86-95
of	O	96-98
mutHtt	O	99-105
toxicity	O	106-114
,	O	114-115
the	O	116-119
causal	O	120-126
relationship	O	127-139
between	O	140-147
these	O	148-153
Htt	O	154-157
/	O	157-158
transcription	O	158-171
factor	O	172-178
interactions	O	179-191
and	O	192-195
HD	O	196-198
pathology	O	199-208
remains	O	209-216
unknown	O	217-224
. 	O	224-226

Previous	O	0-8
work	O	9-13
has	O	14-17
highlighted	O	18-29
REST	O	30-34
[	O	35-36
RE1	O	36-39
(	O	40-41
repressor	O	41-50
element	O	51-58
1	O	59-60
)	O	60-61
-	O	61-62
silencing	O	62-71
transcription	O	72-85
factor	O	86-92
]	O	92-93
as	O	94-96
one	O	97-100
such	O	101-105
transcription	O	106-119
factor	O	120-126
. 	O	126-128

Recent	O	0-6
evidence	O	7-15
has	O	16-19
also	O	20-24
shown	O	25-30
that	O	31-35
REST	O	36-40
regulates	O	41-50
transcription	O	51-64
of	O	65-67
regulatory	O	68-78
miRNAs	O	79-85
(	O	86-87
microRNAs	O	87-96
)	O	96-97
,	O	97-98
many	O	99-103
of	O	104-106
which	O	107-112
are	O	113-116
known	O	117-122
to	O	123-125
regulate	O	126-134
neuronal	O	135-143
gene	O	144-148
expression	O	149-159
and	O	160-163
are	O	164-167
dysregulated	O	168-180
in	O	181-183
HD	O	184-186
.	O	186-187
Thus	O	188-192
repression	O	193-203
of	O	204-206
miRNAs	O	207-213
constitutes	O	214-225
a	O	226-227
second	O	228-234
,	O	234-235
indirect	O	236-244
mechanism	O	245-254
by	O	255-257
which	O	258-263
REST	O	264-268
can	O	269-272
alter	O	273-278
the	O	279-282
neuronal	O	283-291
transcriptome	O	292-305
in	O	306-308
HD	O	309-311
. 	O	311-313

Many	O	0-4
of	O	5-7
its	O	8-11
direct	O	12-18
target	O	19-25
genes	O	26-31
are	O	32-35
known	O	36-41
or	O	42-44
suspected	O	45-54
to	O	55-57
have	O	58-62
a	O	63-64
role	O	65-69
in	O	70-72
HD	O	73-75
pathogenesis	O	76-88
,	O	88-89
including	O	90-99
BDNF	O	100-104
(	O	105-106
brain	O	106-111
-	O	111-112
derived	O	112-119
neurotrophic	O	120-132
factor	O	133-139
)	O	139-140
. 	O	140-142

REST	O	0-4
is	O	5-7
a	O	8-9
master	O	10-16
regulator	O	17-26
of	O	27-29
neuronal	O	30-38
genes	O	39-44
,	O	44-45
repressing	O	46-56
their	O	57-62
expression	O	63-73
. 	O	73-75

BACKGROUND	O	0-10
:	O	10-11
The	O	12-15
aberrant	O	16-24
expression	O	25-35
of	O	36-38
microRNAs	O	39-48
(	O	49-50
miRNAs	O	50-56
)	O	56-57
is	O	58-60
associated	O	61-71
with	O	72-76
a	O	77-78
variety	O	79-86
of	O	87-89
diseases	O	90-98
including	O	99-108
cancers	O	109-116
. 	O	116-118

In	O	0-2
the	O	3-6
present	O	7-14
study	O	15-20
,	O	20-21
the	O	22-25
miRNA	O	26-31
expression	O	32-42
profile	O	43-50
was	O	51-54
examined	O	55-63
in	O	64-66
astrocytoma	O	67-78
,	O	78-79
a	O	80-81
malignant	O	82-91
and	O	92-95
prevalent	O	96-105
intracranial	O	106-118
tumour	O	119-125
in	O	126-128
adults	O	129-135
. 	O	135-137

METHODS	O	0-7
:	O	7-8
We	O	9-11
screened	O	12-20
the	O	21-24
expression	O	25-35
profile	O	36-43
of	O	44-46
200	O	47-50
miRNAs	O	51-57
in	O	58-60
a	O	61-62
training	O	63-71
sample	O	72-78
set	O	79-82
consisting	O	83-93
of	O	94-96
84	O	97-99
astrocytoma	O	100-111
samples	O	112-119
and	O	120-123
20	O	124-126
normal	O	127-133
adjacent	O	134-142
tissue	O	143-149
(	O	150-151
NAT	O	151-154
)	O	154-155
samples	O	156-163
using	O	164-169
the	O	170-173
method	O	174-180
of	O	181-183
stem	O	184-188
-	O	188-189
loop	O	189-193
quantitative	O	194-206
RT	O	207-209
-	O	209-210
PCR	O	210-213
. 	O	213-215

The	O	0-3
significantly	O	4-17
altered	O	18-25
miRNAs	O	26-32
were	O	33-37
validated	O	38-47
in	O	48-50
another	O	51-58
independent	O	59-70
sample	O	71-77
set	O	78-81
consisting	O	82-92
of	O	93-95
40	O	96-98
astrocytoma	O	99-110
samples	O	111-118
and	O	119-122
40	O	123-125
NAT	O	126-129
samples	O	130-137
. 	O	137-139

The	O	0-3
correlation	O	4-15
of	O	16-18
the	O	19-22
miRNA	O	23-28
levels	O	29-35
with	O	36-40
survival	O	41-49
in	O	50-52
astrocytoma	O	53-64
samples	O	65-72
was	O	73-76
estimated	O	77-86
by	O	87-89
performing	O	90-100
Kaplan	O	101-107
-	O	107-108
Meier	O	108-113
survival	O	114-122
analysis	O	123-131
and	O	132-135
univariate	O	136-146
/	O	146-147
multivariate	O	147-159
Cox	O	160-163
proportional	O	164-176
hazard	O	177-183
regression	O	184-194
analysis	O	195-203
. 	O	203-205

RESULTS	O	0-7
:	O	7-8
After	O	9-14
a	O	15-16
two	O	17-20
-	O	20-21
phase	O	21-26
selection	O	27-36
and	O	37-40
validation	O	41-51
process	O	52-59
,	O	59-60
seven	O	61-66
miRNAs	O	67-73
were	O	74-78
found	O	79-84
to	O	85-87
have	O	88-92
a	O	93-94
significantly	O	95-108
different	O	109-118
expression	O	119-129
profile	O	130-137
in	O	138-140
astrocytoma	O	141-152
samples	O	153-160
upon	O	161-165
comparison	O	166-176
to	O	177-179
the	O	180-183
NAT	O	184-187
samples	O	188-195
. 	O	195-197

Unsupervised	O	0-12
clustering	O	13-23
analysis	O	24-32
further	O	33-40
revealed	O	41-49
the	O	50-53
great	O	54-59
potential	O	60-69
of	O	70-72
the	O	73-76
7	O	77-78
-	O	78-79
miRNA	O	79-84
profile	O	85-92
to	O	93-95
differentiate	O	96-109
between	O	110-117
tumours	O	118-125
and	O	126-129
normal	O	130-136
brain	O	137-142
tissues	O	143-150
. 	O	150-152

The	O	0-3
down	O	4-8
-	O	8-9
regulation	O	9-19
of	O	20-22
hsa	B	23-26
-	I	26-27
miR	I	27-30
-	I	30-31
137	I	31-34
in	O	35-37
astrocytomas	O	38-50
was	O	51-54
shown	O	55-60
to	O	61-63
be	O	64-66
associated	O	67-77
with	O	78-82
advanced	O	83-91
clinical	O	92-100
stages	O	101-107
of	O	108-110
this	O	111-115
disease	O	116-123
. 	O	123-125

The	O	0-3
use	O	4-7
of	O	8-10
hsa	B	11-14
-	I	14-15
miR	I	15-18
-	I	18-19
21	I	19-21
,	O	21-22
hsa	B	23-26
-	I	26-27
miR	I	27-30
-	I	30-31
181b	I	31-35
and	O	36-39
hsa	B	40-43
-	I	43-44
miR	I	44-47
-	I	47-48
106a	I	48-52
as	O	53-55
prognostic	O	56-66
indicators	O	67-77
of	O	78-80
astrocytoma	O	81-92
.  	O	92-95

Using	O	0-5
Kaplan	O	6-12
-	O	12-13
Meier	O	13-18
survival	O	19-27
analysis	O	28-36
we	O	37-39
showed	O	40-46
that	O	47-51
low	O	52-55
expression	O	56-66
of	O	67-69
hsa	B	70-73
-	I	73-74
miR	I	74-77
-	I	77-78
181b	I	78-82
or	O	83-85
hsa	B	86-89
-	I	89-90
miR	I	90-93
-	I	93-94
106a	I	94-98
,	O	98-99
or	O	100-102
high	O	103-107
expression	O	108-118
of	O	119-121
hsa	B	122-125
-	I	125-126
miR	I	126-129
-	I	129-130
21	I	130-132
was	O	133-136
significantly	O	137-150
associated	O	151-161
with	O	162-166
poor	O	167-171
patient	O	172-179
survival	O	180-188
. 	O	188-190

CONCLUSIONS	O	0-11
:	O	11-12
Our	O	13-16
results	O	17-24
suggest	O	25-32
a	O	33-34
great	O	35-40
potential	O	41-50
for	O	51-54
the	O	55-58
use	O	59-62
of	O	63-65
miRNA	O	66-71
profiling	O	72-81
as	O	82-84
a	O	85-86
powerful	O	87-95
diagnostic	O	96-106
and	O	107-110
prognostic	O	111-121
marker	O	122-128
in	O	129-131
defining	O	132-140
the	O	141-144
signature	O	145-154
of	O	155-157
astrocytomas	O	158-170
and	O	171-174
in	O	175-177
predicting	O	178-188
the	O	189-192
post	O	193-197
-	O	197-198
surgical	O	198-206
outcome	O	207-214
.   	O	214-218

Moreover	O	0-8
,	O	8-9
Cox	O	10-13
proportional	O	14-26
hazard	O	27-33
regression	O	34-44
analysis	O	45-53
revealed	O	54-62
that	O	63-67
this	O	68-72
prognostic	O	73-83
impact	O	84-90
was	O	91-94
independent	O	95-106
of	O	107-109
other	O	110-115
clinicopathological	O	116-135
factors	O	136-143
. 	O	143-145

Expression	O	0-10
profiling	O	11-20
showed	O	21-27
strong	O	28-34
miRNA	O	35-40
and	O	41-44
isomiR	O	45-51
expression	O	52-62
deregulation	O	63-75
in	O	76-78
HD	O	79-81
,	O	81-82
most	O	83-87
being	O	88-93
common	O	94-100
to	O	101-103
both	O	104-108
FC	O	109-111
and	O	112-115
ST	O	116-118
. 	O	118-120

Around	O	0-6
80	O	7-9
-	O	9-10
90	O	10-12
%	O	12-13
of	O	14-16
the	O	17-20
miRNAs	O	21-27
presented	O	28-37
modifications	O	38-51
in	O	52-54
the	O	55-58
3	O	59-60
'	O	60-61
-	O	61-62
terminus	O	62-70
mainly	O	71-77
in	O	78-80
the	O	81-84
form	O	85-89
of	O	90-92
trimming	O	93-101
and	O	102-105
/	O	105-106
or	O	106-108
as	O	109-111
nucleotide	O	112-122
addition	O	123-131
variants	O	132-140
,	O	140-141
while	O	142-147
the	O	148-151
5	O	152-153
'	O	153-154
-	O	154-155
terminus	O	155-163
of	O	164-166
the	O	167-170
miRNAs	O	171-177
was	O	178-181
specially	O	182-191
protected	O	192-201
from	O	202-206
changes	O	207-214
. 	O	214-216

Deep	O	0-4
sequencing	O	5-15
revealed	O	16-24
length	O	25-31
and	O	32-35
sequence	O	36-44
heterogeneity	O	45-58
(	O	59-60
IsomiRs	O	60-67
)	O	67-68
for	O	69-72
the	O	73-76
vast	O	77-81
majority	O	82-90
of	O	91-93
miRNAs	O	94-100
. 	O	100-102

More	O	0-4
than	O	5-9
80	O	10-12
%	O	12-13
of	O	14-16
the	O	17-20
small	O	21-26
-	O	26-27
RNAs	O	27-31
were	O	32-36
annotated	O	37-46
as	O	47-49
microRNAs	O	50-59
(	O	60-61
miRNAs	O	61-67
)	O	67-68
in	O	69-71
all	O	72-75
samples	O	76-83
. 	O	83-85

We	O	0-2
have	O	3-7
applied	O	8-15
the	O	16-19
Illumina	O	20-28
massively	O	29-38
parallel	O	39-47
sequencing	O	48-58
to	O	59-61
deeply	O	62-68
analyze	O	69-76
the	O	77-80
small	O	81-86
RNA	O	87-90
populations	O	91-102
of	O	103-105
two	O	106-109
different	O	110-119
forebrain	O	120-129
areas	O	130-135
,	O	135-136
the	O	137-140
frontal	O	141-148
cortex	O	149-155
(	O	156-157
FC	O	157-159
)	O	159-160
and	O	161-164
the	O	165-168
striatum	O	169-177
(	O	178-179
ST	O	179-181
)	O	181-182
of	O	183-185
healthy	O	186-193
individuals	O	194-205
and	O	206-209
individuals	O	210-221
with	O	222-226
HD	O	227-229
. 	O	229-231

Huntington	O	0-10
disease	O	11-18
(	O	19-20
HD	O	20-22
)	O	22-23
is	O	24-26
a	O	27-28
neurodegenerative	O	29-46
disorder	O	47-55
that	O	56-60
predominantly	O	61-74
affects	O	75-82
neurons	O	83-90
of	O	91-93
the	O	94-97
forebrain	O	98-107
. 	O	107-109

A	O	0-1
myriad	O	2-8
of	O	9-11
miRNA	O	12-17
variants	O	18-26
in	O	27-29
control	O	30-37
and	O	38-41
Huntington	O	42-52
'	O	52-53
s	O	53-54
disease	O	55-62
brain	O	63-68
regions	O	69-76
detected	O	77-85
by	O	86-88
massively	O	89-98
parallel	O	99-107
sequencing	O	108-118
.  	O	118-121

Our	O	0-3
results	O	4-11
show	O	12-16
that	O	17-21
miRNA	O	22-27
variability	O	28-39
is	O	40-42
a	O	43-44
ubiquitous	O	45-55
phenomenon	O	56-66
in	O	67-69
the	O	70-73
adult	O	74-79
human	O	80-85
brain	O	86-91
,	O	91-92
which	O	93-98
may	O	99-102
influence	O	103-112
gene	O	113-117
expression	O	118-128
in	O	129-131
physiological	O	132-145
and	O	146-149
pathological	O	150-162
conditions	O	163-173
.   	O	173-177

The	O	0-3
putative	O	4-12
targets	O	13-20
of	O	21-23
deregulated	O	24-35
miRNAs	O	36-42
and	O	43-46
seed	O	47-51
-	O	51-52
region	O	52-58
IsomiRs	O	59-66
strongly	O	67-75
suggest	O	76-83
that	O	84-88
their	O	89-94
altered	O	95-102
expression	O	103-113
contributes	O	114-125
to	O	126-128
the	O	129-132
aberrant	O	133-141
gene	O	142-146
expression	O	147-157
in	O	158-160
HD	O	161-163
. 	O	163-165

The	O	0-3
analysis	O	4-12
of	O	13-15
the	O	16-19
upstream	O	20-28
regulatory	O	29-39
regions	O	40-47
in	O	48-50
co	O	51-53
-	O	53-54
regulated	O	54-63
miRNAs	O	64-70
suggests	O	71-79
a	O	80-81
role	O	82-86
for	O	87-90
RE1	O	91-94
-	O	94-95
Silencing	O	95-104
Transcription	O	105-118
Factor	O	119-125
(	O	126-127
REST	O	127-131
)	O	131-132
and	O	133-136
P53	O	137-140
in	O	141-143
miRNAs	O	144-150
downregulation	O	151-165
in	O	166-168
HD	O	169-171
. 	O	171-173

To	O	0-2
determine	O	3-12
the	O	13-16
role	O	17-21
of	O	22-24
possible	O	25-33
pathogenic	O	34-44
cofactors	O	45-54
such	O	55-59
as	O	60-62
geographic	O	63-73
,	O	73-74
ethnic	O	75-81
,	O	81-82
genetic	O	83-90
,	O	90-91
and	O	92-95
cultural	O	96-104
features	O	105-113
,	O	113-114
further	O	115-122
pertinent	O	123-132
surveys	O	133-140
are	O	141-144
required	O	145-153
in	O	154-156
subtropical	O	157-168
northwestern	O	169-181
Argentina	O	182-191
.   	O	191-195

Considering	O	0-11
the	O	12-15
HAM	O	16-19
/	O	19-20
TSP	O	20-23
cluster	O	24-31
described	O	32-41
here	O	42-46
plus	O	47-51
previously	O	52-62
reported	O	63-71
isolated	O	72-80
cases	O	81-86
in	O	87-89
neighboring	O	90-101
Salta	O	102-107
Province	O	108-116
,	O	116-117
we	O	118-120
speculate	O	121-130
that	O	131-135
the	O	136-139
Puna	O	140-144
Jujeña	O	145-151
region	O	152-158
and	O	159-162
regions	O	163-170
in	O	171-173
that	O	174-178
vicinity	O	179-187
would	O	188-193
be	O	194-196
a	O	197-198
microepidemic	O	199-212
focus	O	213-218
of	O	219-221
disease	O	222-229
. 	O	229-231

Therefore	O	0-9
,	O	9-10
the	O	11-14
long	O	15-19
-	O	19-20
term	O	20-24
presence	O	25-33
of	O	34-36
virus	O	37-42
in	O	43-45
Jujuy	O	46-51
natives	O	52-59
may	O	60-63
be	O	64-66
taken	O	67-72
for	O	73-76
granted	O	77-84
. 	O	84-86

In	O	0-2
contrast	O	3-11
to	O	12-14
the	O	15-18
Andean	O	19-25
region	O	26-32
of	O	33-35
Bolivia	O	36-43
,	O	43-44
where	O	45-50
high	O	51-55
HTLV	O	56-60
-	O	60-61
I	O	61-62
seroprevalence	O	63-77
is	O	78-80
in	O	81-83
part	O	84-88
attributable	O	89-101
to	O	102-104
Japanese	O	105-113
immigrants	O	114-124
,	O	124-125
the	O	126-129
Jujuy	O	130-135
population	O	136-146
mainly	O	147-153
consists	O	154-162
of	O	163-165
aborigines	O	166-176
,	O	176-177
mestizos	O	178-186
,	O	186-187
and	O	188-191
European	O	192-200
descendants	O	201-212
. 	O	212-214

No	O	0-2
history	O	3-10
of	O	11-13
risk	O	14-18
factors	O	19-26
was	O	27-30
disclosed	O	31-40
,	O	40-41
except	O	42-48
for	O	49-52
a	O	53-54
single	O	55-61
transfusion	O	62-73
in	O	74-76
1	O	77-78
patient	O	79-86
. 	O	86-88

Most	O	0-4
patients	O	5-13
(	O	14-15
9	O	15-16
/	O	16-17
11	O	17-19
)	O	19-20
were	O	21-25
born	O	26-30
in	O	31-33
Cochinoca	O	34-43
Department	O	44-54
,	O	54-55
located	O	56-63
in	O	64-66
an	O	67-69
Andes	O	70-75
highland	O	76-84
area	O	85-89
called	O	90-96
Puna	O	97-101
Jujeña	O	102-108
,	O	108-109
situated	O	110-118
at	O	119-121
more	O	122-126
that	O	127-131
3400	O	132-136
m	O	137-138
above	O	139-144
sea	O	145-148
level	O	149-154
. 	O	154-156

Accordingly	O	0-11
,	O	11-12
a	O	13-14
clinically	O	15-25
diagnosed	O	26-35
and	O	36-39
serologically	O	40-53
confirmed	O	54-63
cluster	O	64-71
of	O	72-74
cases	O	75-80
in	O	81-83
1	O	84-85
man	O	86-89
and	O	90-93
10	O	94-96
women	O	97-102
,	O	102-103
including	O	104-113
2	O	114-115
sisters	O	116-123
,	O	123-124
is	O	125-127
described	O	128-137
here	O	138-142
. 	O	142-144

Compared	O	0-8
with	O	9-13
other	O	14-19
regions	O	20-27
in	O	28-30
Argentina	O	31-40
,	O	40-41
greater	O	42-49
human	O	50-55
T	O	56-57
-	O	57-58
cell	O	58-62
lymphotropic	O	63-75
virus	O	76-81
type	O	82-86
I	O	87-88
(	O	89-90
HTLV	O	90-94
-	O	94-95
I	O	95-96
)	O	96-97
seroprevalence	O	98-112
has	O	113-116
been	O	117-121
reported	O	122-130
in	O	131-133
Jujuy	O	134-139
Province	O	140-148
,	O	148-149
where	O	150-155
it	O	156-158
reaches	O	159-166
2	O	167-168
.	O	168-169
32	O	169-171
%	O	171-172
in	O	173-175
the	O	176-179
general	O	180-187
population	O	188-198
,	O	198-199
so	O	200-202
that	O	203-207
a	O	208-209
search	O	210-216
for	O	217-220
HTLV	O	221-225
-	O	225-226
I	O	226-227
-	O	227-228
associated	O	228-238
myelopathy	O	239-249
/	O	249-250
tropical	O	250-258
spastic	O	259-266
paraparesis	O	267-278
(	O	279-280
HAM	O	280-283
/	O	283-284
TSP	O	284-287
)	O	287-288
cases	O	289-294
deserved	O	295-303
to	O	304-306
be	O	307-309
carried	O	310-317
out	O	318-321
. 	O	321-323

A	O	0-1
cluster	O	2-9
of	O	10-12
human	O	13-18
T	O	19-20
-	O	20-21
cell	O	21-25
lymphotropic	O	26-38
virus	O	39-44
type	O	45-49
I	O	50-51
-	O	51-52
associated	O	52-62
myelopathy	O	63-73
/	O	73-74
tropical	O	74-82
spastic	O	83-90
paraparesis	O	91-102
in	O	103-105
Jujuy	O	106-111
,	O	111-112
Argentina	O	113-122
.  	O	122-125

DESIGN	O	0-6
:	O	6-7
:	O	8-9
Cross	O	10-15
-	O	15-16
sectional	O	16-25
study	O	26-31
. 	O	31-33

OBJECTIVE	O	0-9
:	O	9-10
:	O	11-12
To	O	13-15
compare	O	16-23
presentation	O	24-36
of	O	37-39
Alzheimer	O	40-49
disease	O	50-57
(	O	58-59
AD	O	59-61
)	O	61-62
at	O	63-65
the	O	66-69
time	O	70-74
of	O	75-77
initial	O	78-85
evaluation	O	86-96
at	O	97-99
a	O	100-101
university	O	102-112
specialty	O	113-122
clinic	O	123-129
across	O	130-136
three	O	137-142
ethnoracial	O	143-154
groups	O	155-161
in	O	162-164
order	O	165-170
to	O	171-173
understand	O	174-184
similarities	O	185-197
and	O	198-201
differences	O	202-213
in	O	214-216
the	O	217-220
demographic	O	221-232
,	O	232-233
clinical	O	234-242
,	O	242-243
cognitive	O	244-253
,	O	253-254
psychiatric	O	255-266
,	O	266-267
and	O	268-271
biologic	O	272-280
features	O	281-289
. 	O	289-291

Ethnoracial	O	0-11
differences	O	12-23
in	O	24-26
the	O	27-30
clinical	O	31-39
characteristics	O	40-55
of	O	56-58
Alzheimer	O	59-68
'	O	68-69
s	O	69-70
disease	O	71-78
at	O	79-81
initial	O	82-89
presentation	O	90-102
at	O	103-105
an	O	106-108
urban	O	109-114
Alzheimer	O	115-124
'	O	124-125
s	O	125-126
disease	O	127-134
center	O	135-141
.  	O	141-144

The	O	0-3
apolipoprotein	O	4-18
E	O	19-20
-	O	20-21
4	O	21-22
genotype	O	23-31
was	O	32-35
not	O	36-39
associated	O	40-50
with	O	51-55
AD	O	56-58
in	O	59-61
the	O	62-65
Latino	O	66-72
cohort	O	73-79
. 	O	79-81

Greater	O	0-7
severity	O	8-16
of	O	17-19
symptoms	O	20-28
was	O	29-32
not	O	33-36
accounted	O	37-46
for	O	47-50
by	O	51-53
a	O	54-55
difference	O	56-66
in	O	67-69
lag	O	70-73
time	O	74-78
between	O	79-86
onset	O	87-92
of	O	93-95
symptoms	O	96-104
and	O	105-108
initial	O	109-116
evaluation	O	117-127
. 	O	127-129

There	O	0-5
was	O	6-9
more	O	10-14
depression	O	15-25
in	O	26-28
the	O	29-32
Latinos	O	33-40
compared	O	41-49
with	O	50-54
African	O	55-62
Americans	O	63-72
and	O	73-76
WNHs	O	77-81
. 	O	81-83

In	O	0-2
particular	O	3-13
,	O	13-14
the	O	15-18
largely	O	19-26
immigrant	O	27-36
Puerto	O	37-43
Rican	O	44-49
Latino	O	50-56
group	O	57-62
had	O	63-66
an	O	67-69
earlier	O	70-77
age	O	78-81
of	O	82-84
onset	O	85-90
of	O	91-93
AD	O	94-96
,	O	96-97
more	O	98-102
cognitive	O	103-112
impairment	O	113-123
,	O	123-124
and	O	125-128
greater	O	129-136
severity	O	137-145
of	O	146-148
cognitive	O	149-158
impairment	O	159-169
at	O	170-172
the	O	173-176
time	O	177-181
of	O	182-184
initial	O	185-192
evaluation	O	193-203
in	O	204-206
the	O	207-210
setting	O	211-218
of	O	219-221
low	O	222-225
average	O	226-233
education	O	234-243
and	O	244-247
socioeconomic	O	248-261
status	O	262-268
. 	O	268-270

RESULTS	O	0-7
:	O	7-8
:	O	9-10
Differences	O	11-22
among	O	23-28
ethnoracial	O	29-40
groups	O	41-47
were	O	48-52
found	O	53-58
for	O	59-62
nearly	O	63-69
all	O	70-73
variables	O	74-83
of	O	84-86
interest	O	87-95
. 	O	95-97

MEASUREMENTS	O	0-12
:	O	12-13
:	O	14-15
Demographic	O	16-27
variables	O	28-37
and	O	38-41
age	O	42-45
of	O	46-48
onset	O	49-54
of	O	55-57
AD	O	58-60
,	O	60-61
as	O	62-64
well	O	65-69
as	O	70-72
cognitive	O	73-82
,	O	82-83
functional	O	84-94
,	O	94-95
and	O	96-99
mood	O	100-104
impairments	O	105-116
at	O	117-119
the	O	120-123
time	O	124-128
of	O	129-131
initial	O	132-139
presentation	O	140-152
and	O	153-156
frequencies	O	157-168
of	O	169-171
apolipoprotein	O	172-186
E	O	187-188
genotypes	O	189-198
,	O	198-199
were	O	200-204
compared	O	205-213
across	O	214-220
groups	O	221-227
. 	O	227-229

PARTICIPANTS	O	0-12
:	O	12-13
:	O	14-15
A	O	16-17
total	O	18-23
of	O	24-26
1	O	27-28
,	O	28-29
341	O	29-32
self	O	33-37
-	O	37-38
identified	O	38-48
African	O	49-56
American	O	57-65
,	O	65-66
Latino	O	67-73
(	O	74-75
primarily	O	75-84
of	O	85-87
Caribbean	O	88-97
origin	O	98-104
)	O	104-105
,	O	105-106
and	O	107-110
white	O	111-116
non	O	117-120
-	O	120-121
Hispanic	O	121-129
(	O	130-131
"	O	131-132
WNH	O	132-135
"	O	135-136
)	O	136-137
subjects	O	138-146
were	O	147-151
recruited	O	152-161
from	O	162-166
primary	O	167-174
care	O	175-179
sites	O	180-185
or	O	186-188
by	O	189-191
referral	O	192-200
by	O	201-203
primary	O	204-211
care	O	212-216
physicians	O	217-227
. 	O	227-229

Important	O	0-9
potential	O	10-19
confounds	O	20-29
need	O	30-34
to	O	35-37
be	O	38-40
considered	O	41-51
and	O	52-55
future	O	56-62
research	O	63-71
comparing	O	72-81
immigrant	O	82-91
and	O	92-95
nonimmigrant	O	96-108
Latino	O	109-115
groups	O	116-122
will	O	123-127
be	O	128-130
necessary	O	131-140
to	O	141-143
elucidate	O	144-153
the	O	154-157
highly	O	158-164
significant	O	165-176
differences	O	177-188
reported	O	189-197
.   	O	197-201

CONCLUSIONS	O	0-11
:	O	11-12
:	O	13-14
Minority	O	15-23
groups	O	24-30
in	O	31-33
Philadelphia	O	34-46
,	O	46-47
especially	O	48-58
Latinos	O	59-66
,	O	66-67
exhibit	O	68-75
a	O	76-77
more	O	78-82
severe	O	83-89
profile	O	90-97
of	O	98-100
AD	O	101-103
at	O	104-106
the	O	107-110
time	O	111-115
of	O	116-118
presentation	O	119-131
than	O	132-136
WNHs	O	137-141
. 	O	141-143

Furthermore	O	0-11
,	O	11-12
methods	O	13-20
to	O	21-23
profile	O	24-31
miRNAs	O	32-38
from	O	39-43
formalin	O	44-52
-	O	52-53
fixed	O	53-58
,	O	58-59
paraffin	O	60-68
-	O	68-69
embedded	O	69-77
(	O	78-79
FFPE	O	79-83
)	O	83-84
archival	O	85-93
tissues	O	94-101
or	O	102-104
to	O	105-107
study	O	108-113
their	O	114-119
cellular	O	120-128
and	O	129-132
subcellular	O	133-144
localization	O	145-157
in	O	158-160
FFPE	O	161-165
tissues	O	166-173
have	O	174-178
been	O	179-183
lacking	O	184-191
. 	O	191-193

Here	O	0-4
we	O	5-7
report	O	8-14
the	O	15-18
coordinated	O	19-30
miRNA	O	31-36
expression	O	37-47
analysis	O	48-56
from	O	57-61
the	O	62-65
tissue	O	66-72
level	O	73-78
to	O	79-81
the	O	82-85
subcellular	O	86-97
level	O	98-103
,	O	103-104
using	O	105-110
the	O	111-114
RAKE	O	115-119
(	O	120-121
RNA	O	121-124
-	O	124-125
primed	O	125-131
,	O	131-132
array	O	133-138
-	O	138-139
based	O	139-144
,	O	144-145
Klenow	O	146-152
Enzyme	O	153-159
)	O	159-160
miRNA	O	161-166
microarray	O	167-177
platform	O	178-186
in	O	187-189
conjunction	O	190-201
with	O	202-206
Locked	O	207-213
Nucleic	O	214-221
Acid	O	222-226
(	O	227-228
LNA	O	228-231
)	O	231-232
-	O	232-233
based	O	233-238
in	O	239-241
situ	O	242-246
hybridization	O	247-260
(	O	261-262
LNA	O	262-265
-	O	265-266
ISH	O	266-269
)	O	269-270
on	O	271-273
archival	O	274-282
FFPE	O	283-287
human	O	288-293
brains	O	294-300
and	O	301-304
oligodendroglial	O	305-321
tumors	O	322-328
. 	O	328-330

The	O	0-3
ability	O	4-11
to	O	12-14
profile	O	15-22
miRNAs	O	23-29
from	O	30-34
archival	O	35-43
tissues	O	44-51
at	O	52-54
the	O	55-58
tissue	O	59-65
level	O	66-71
,	O	71-72
by	O	73-75
RAKE	O	76-80
microarrays	O	81-92
,	O	92-93
and	O	94-97
at	O	98-100
the	O	101-104
cellular	O	105-113
level	O	114-119
by	O	120-122
LNA	O	123-126
-	O	126-127
ISH	O	127-130
,	O	130-131
will	O	132-136
accelerate	O	137-147
studies	O	148-155
of	O	156-158
miRNAs	O	159-165
in	O	166-168
human	O	169-174
diseases	O	175-183
.   	O	183-187

RAKE	O	0-4
and	O	5-8
LNA	O	9-12
-	O	12-13
ISH	O	13-16
reveal	O	17-23
microRNA	O	24-32
expression	O	33-43
and	O	44-47
localization	O	48-60
in	O	61-63
archival	O	64-72
human	O	73-78
brain	O	79-84
.  	O	84-87

microRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
(	O	29-30
approximately	O	30-43
22	O	44-46
nucleotide	O	47-57
)	O	57-58
regulatory	O	59-69
RNAs	O	70-74
which	O	75-80
play	O	81-85
fundamental	O	86-97
roles	O	98-103
in	O	104-106
many	O	107-111
biological	O	112-122
processes	O	123-132
. 	O	132-134

Recent	O	0-6
studies	O	7-14
have	O	15-19
shown	O	20-25
that	O	26-30
the	O	31-34
expression	O	35-45
of	O	46-48
many	O	49-53
miRNAs	O	54-60
is	O	61-63
altered	O	64-71
in	O	72-74
various	O	75-82
human	O	83-88
tumors	O	89-95
and	O	96-99
some	O	100-104
miRNAs	O	105-111
may	O	112-115
function	O	116-124
as	O	125-127
oncogenes	O	128-137
or	O	138-140
tumor	O	141-146
suppressor	O	147-157
genes	O	158-163
. 	O	163-165

However	O	0-7
,	O	7-8
with	O	9-13
the	O	14-17
exception	O	18-27
of	O	28-30
glioblastoma	O	31-43
multiforme	O	44-54
,	O	54-55
the	O	56-59
expression	O	60-70
of	O	71-73
miRNAs	O	74-80
in	O	81-83
brain	O	84-89
tumors	O	90-96
is	O	97-99
unknown	O	100-107
. 	O	107-109

Plasma	O	0-6
concentrations	O	7-21
of	O	22-24
miR	B	25-28
-	I	28-29
124	I	29-32
were	O	33-37
significantly	O	38-51
elevated	O	52-60
at	O	61-63
6	O	64-65
h	O	66-67
,	O	67-68
and	O	69-72
remained	O	73-81
elevated	O	82-90
at	O	91-93
48	O	94-96
h	O	97-98
after	O	99-104
MCAO	O	105-109
introduction	O	110-122
. 	O	122-124

Thus	O	0-4
,	O	4-5
plasma	O	6-12
concentration	O	13-26
of	O	27-29
miR	B	30-33
-	I	33-34
124	I	34-37
provides	O	38-46
a	O	47-48
promising	O	49-58
candidate	O	59-68
biomarker	O	69-78
for	O	79-82
early	O	83-88
detection	O	89-98
of	O	99-101
cerebral	O	102-110
infarction	O	111-121
.   	O	121-125

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
miRNA	O	15-20
array	O	21-26
analysis	O	27-35
in	O	36-38
various	O	39-46
tissues	O	47-54
showed	O	55-61
that	O	62-66
miR	B	67-70
-	I	70-71
124	I	71-74
is	O	75-77
almost	O	78-84
exclusively	O	85-96
expressed	O	97-106
in	O	107-109
the	O	110-113
central	O	114-121
nervous	O	122-129
system	O	130-136
and	O	137-140
neuronal	O	141-149
cells	O	150-155
,	O	155-156
suggesting	O	157-167
that	O	168-172
it	O	173-175
might	O	176-181
be	O	182-184
useful	O	185-191
as	O	192-194
a	O	195-196
potential	O	197-206
biomarker	O	207-216
for	O	217-220
neurological	O	221-233
diseases	O	234-242
. 	O	242-244

We	O	0-2
examined	O	3-11
whether	O	12-19
plasma	O	20-26
concentrations	O	27-41
of	O	42-44
brain	O	45-50
-	O	50-51
specific	O	51-59
miRNA	O	60-65
can	O	66-69
serve	O	70-75
as	O	76-78
a	O	79-80
biomarker	O	81-90
for	O	91-94
cerebral	O	95-103
infarction	O	104-114
,	O	114-115
where	O	116-121
the	O	122-125
cerebral	O	126-134
infarction	O	135-145
was	O	146-149
modeled	O	150-157
by	O	158-160
middle	O	161-167
cerebral	O	168-176
artery	O	177-183
occlusion	O	184-193
(	O	194-195
MCAO	O	195-199
)	O	199-200
in	O	201-203
the	O	204-207
rat	O	208-211
. 	O	211-213

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
endogenous	O	23-33
small	O	34-39
RNAs	O	40-44
that	O	45-49
play	O	50-54
an	O	55-57
important	O	58-67
role	O	68-72
in	O	73-75
various	O	76-83
physiological	O	84-97
processes	O	98-107
by	O	108-110
downregulating	O	111-125
target	O	126-132
genes	O	133-138
. 	O	138-140

Recently	O	0-8
,	O	8-9
plasma	O	10-16
miRNAs	O	17-23
have	O	24-28
been	O	29-33
investigated	O	34-46
as	O	47-49
biomarkers	O	50-60
for	O	61-64
various	O	65-72
diseases	O	73-81
. 	O	81-83

Plasma	O	0-6
miR	B	7-10
-	I	10-11
124	I	11-14
as	O	15-17
a	O	18-19
biomarker	O	20-29
for	O	30-33
cerebral	O	34-42
infarction	O	43-53
.  	O	53-56

The	O	0-3
basis	O	4-9
for	O	10-13
the	O	14-17
younger	O	18-25
age	O	26-29
at	O	30-32
symptom	O	33-40
onset	O	41-46
remains	O	47-54
obscure	O	55-62
.   	O	62-66

CONCLUSIONS	O	0-11
:	O	11-12
An	O	13-15
earlier	O	16-23
age	O	24-27
at	O	28-30
symptom	O	31-38
onset	O	39-44
suggests	O	45-53
that	O	54-58
US	O	59-61
mainland	O	62-70
Latino	O	71-77
individuals	O	78-89
may	O	90-93
experience	O	94-104
an	O	105-107
increased	O	108-117
burden	O	118-124
of	O	125-127
AD	O	128-130
compared	O	131-139
with	O	140-144
Anglo	O	145-150
individuals	O	151-162
. 	O	162-164

OBJECTIVE	O	0-9
:	O	9-10
To	O	11-13
compare	O	14-21
the	O	22-25
age	O	26-29
at	O	30-32
AD	O	33-35
symptom	O	36-43
onset	O	44-49
in	O	50-52
Latino	O	53-59
and	O	60-63
Anglo	O	64-69
individuals	O	70-81
. 	O	81-83

BACKGROUND	O	0-10
:	O	10-11
Latino	O	12-18
individuals	O	19-30
are	O	31-34
the	O	35-38
largest	O	39-46
minority	O	47-55
group	O	56-61
and	O	62-65
the	O	66-69
fastest	O	70-77
growing	O	78-85
population	O	86-96
group	O	97-102
in	O	103-105
the	O	106-109
United	O	110-116
States	O	117-123
,	O	123-124
yet	O	125-128
there	O	129-134
are	O	135-138
few	O	139-142
studies	O	143-150
comparing	O	151-160
the	O	161-164
clinical	O	165-173
features	O	174-182
of	O	183-185
Alzheimer	O	186-195
disease	O	196-203
(	O	204-205
AD	O	205-207
)	O	207-208
in	O	209-211
this	O	212-216
population	O	217-227
with	O	228-232
those	O	233-238
found	O	239-244
in	O	245-247
Anglo	O	248-253
(	O	254-255
white	O	255-260
non	O	261-264
-	O	264-265
Latino	O	265-271
)	O	271-272
patients	O	273-281
. 	O	281-283

Earlier	O	0-7
onset	O	8-13
of	O	14-16
Alzheimer	O	17-26
disease	O	27-34
symptoms	O	35-43
in	O	44-46
latino	O	47-53
individuals	O	54-65
compared	O	66-74
with	O	75-79
anglo	O	80-85
individuals	O	86-97
.  	O	97-100

RESULTS	O	0-7
:	O	7-8
After	O	9-14
adjusting	O	15-24
for	O	25-28
center	O	29-35
,	O	35-36
sex	O	37-40
,	O	40-41
and	O	42-45
years	O	46-51
of	O	52-54
education	O	55-64
,	O	64-65
Latino	O	66-72
patients	O	73-81
had	O	82-85
a	O	86-87
mean	O	88-92
age	O	93-96
at	O	97-99
symptom	O	100-107
onset	O	108-113
6	O	114-115
.	O	115-116
8	O	116-117
years	O	118-123
earlier	O	124-131
(	O	132-133
95	O	133-135
%	O	135-136
confidence	O	137-147
interval	O	148-156
,	O	156-157
3	O	158-159
.	O	159-160
5	O	160-161
-	O	161-162
10	O	162-164
.	O	164-165
3	O	165-166
years	O	167-172
earlier	O	173-180
)	O	180-181
than	O	182-186
Anglo	O	187-192
patients	O	193-201
. 	O	201-203

PATIENTS	O	0-8
:	O	8-9
We	O	10-12
evaluated	O	13-22
119	O	23-26
Latino	O	27-33
and	O	34-37
55	O	38-40
Anglo	O	41-46
patients	O	47-55
who	O	56-59
had	O	60-63
a	O	64-65
diagnosis	O	66-75
of	O	76-78
AD	O	79-81
.	O	81-82
MAIN	O	83-87
OUTCOME	O	88-95
MEASURE	O	96-103
:	O	103-104
Age	O	105-108
at	O	109-111
symptom	O	112-119
onset	O	120-125
. 	O	125-127

SETTING	O	0-7
:	O	7-8
Five	O	9-13
National	O	14-22
Institute	O	23-32
on	O	33-35
Aging	O	36-41
-	O	41-42
sponsored	O	42-51
Alzheimer	O	52-61
'	O	61-62
s	O	62-63
Disease	O	64-71
Centers	O	72-79
with	O	80-84
experience	O	85-95
evaluating	O	96-106
Spanish	O	107-114
-	O	114-115
speaking	O	115-123
individuals	O	124-135
. 	O	135-137

DESIGN	O	0-6
:	O	6-7
Cross	O	8-13
-	O	13-14
sectional	O	14-23
assessment	O	24-34
using	O	35-40
standardized	O	41-53
methods	O	54-61
to	O	62-64
collect	O	65-72
and	O	73-76
compare	O	77-84
age	O	85-88
at	O	89-91
AD	O	92-94
symptom	O	95-102
onset	O	103-108
,	O	108-109
demographic	O	110-121
variables	O	122-131
,	O	131-132
and	O	133-136
medical	O	137-144
variables	O	145-154
. 	O	154-156

We	O	0-2
conclude	O	3-11
that	O	12-16
miR	B	17-20
-	I	20-21
17	I	21-23
/	I	23-24
92	I	24-26
is	O	27-29
a	O	30-31
positive	O	32-40
effector	O	41-49
of	O	50-52
Shh	O	53-56
-	O	56-57
mediated	O	57-65
proliferation	O	66-79
and	O	80-83
that	O	84-88
aberrant	O	89-97
expression	O	98-108
/	O	108-109
amplification	O	109-122
of	O	123-125
this	O	126-130
miR	O	131-134
confers	O	135-142
a	O	143-144
growth	O	145-151
advantage	O	152-161
to	O	162-164
medulloblastomas	O	165-181
.   	O	181-185

Ectopic	O	0-7
miR	B	8-11
-	I	11-12
17	I	12-14
/	I	14-15
92	I	15-17
expression	O	18-28
in	O	29-31
CGNPs	O	32-37
synergized	O	38-48
with	O	49-53
exogenous	O	54-63
Shh	O	64-67
to	O	68-70
increase	O	71-79
proliferation	O	80-93
and	O	94-97
also	O	98-102
enabled	O	103-110
them	O	111-115
to	O	116-118
proliferate	O	119-130
in	O	131-133
the	O	134-137
absence	O	138-145
of	O	146-148
Shh	O	149-152
. 	O	152-154

In	O	0-2
CGNPs	O	3-8
,	O	8-9
the	O	10-13
Shh	O	14-17
effector	O	18-26
N	O	27-28
-	O	28-29
myc	O	29-32
,	O	32-33
but	O	34-37
not	O	38-41
Gli1	O	42-46
,	O	46-47
induced	O	48-55
miR	B	56-59
-	I	59-60
17	I	60-62
/	I	62-63
92	I	63-65
expression	O	66-76
. 	O	76-78

Consistent	O	0-10
with	O	11-15
its	O	16-19
regulation	O	20-30
by	O	31-33
Shh	O	34-37
,	O	37-38
we	O	39-41
observed	O	42-50
that	O	51-55
Shh	O	56-59
treatment	O	60-69
of	O	70-72
primary	O	73-80
cerebellar	O	81-91
granule	O	92-99
neuron	O	100-106
precursors	O	107-117
(	O	118-119
CGNP	O	119-123
)	O	123-124
,	O	124-125
proposed	O	126-134
cells	O	135-140
of	O	141-143
origin	O	144-150
for	O	151-154
the	O	155-158
Shh	O	159-162
-	O	162-163
associated	O	163-173
medulloblastomas	O	174-190
,	O	190-191
resulted	O	192-200
in	O	201-203
increased	O	204-213
miR	B	214-217
-	I	217-218
17	I	218-220
/	I	220-221
92	I	221-223
expression	O	224-234
. 	O	234-236

Medulloblastomas	O	0-16
in	O	17-19
which	O	20-25
miR	B	26-29
-	I	29-30
17	I	30-32
/	I	32-33
92	I	33-35
was	O	36-39
up	O	40-42
-	O	42-43
regulated	O	43-52
also	O	53-57
had	O	58-61
elevated	O	62-70
levels	O	71-77
of	O	78-80
MYC	O	81-84
/	O	84-85
MYCN	O	85-89
expression	O	90-100
. 	O	100-102

Expression	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
17	I	18-20
/	I	20-21
92	I	21-23
was	O	24-27
highest	O	28-35
in	O	36-38
the	O	39-42
subgroup	O	43-51
of	O	52-54
medulloblastomas	O	55-71
associated	O	72-82
with	O	83-87
activation	O	88-98
of	O	99-101
the	O	102-105
sonic	O	106-111
hedgehog	O	112-120
(	O	121-122
Shh	O	122-125
)	O	125-126
signaling	O	127-136
pathway	O	137-144
compared	O	145-153
with	O	154-158
other	O	159-164
subgroups	O	165-174
of	O	175-177
medulloblastoma	O	178-193
. 	O	193-195

Profiling	O	0-9
the	O	10-13
expression	O	14-24
of	O	25-27
427	O	28-31
mature	O	32-38
microRNAs	O	39-48
(	O	49-50
miRNA	O	50-55
)	O	55-56
in	O	57-59
a	O	60-61
series	O	62-68
of	O	69-71
90	O	72-74
primary	O	75-82
human	O	83-88
medulloblastomas	O	89-105
revealed	O	106-114
that	O	115-119
components	O	120-130
of	O	131-133
the	O	134-137
miR	B	138-141
-	I	141-142
17	I	142-144
/	I	144-145
92	I	145-147
polycistron	O	148-159
are	O	160-163
the	O	164-167
most	O	168-172
highly	O	173-179
up	O	180-182
-	O	182-183
regulated	O	183-192
miRNAs	O	193-199
in	O	200-202
medulloblastoma	O	203-218
. 	O	218-220

We	O	0-2
identified	O	3-13
recurrent	O	14-23
amplification	O	24-37
of	O	38-40
the	O	41-44
miR	B	45-48
-	I	48-49
17	I	49-51
/	I	51-52
92	I	52-54
polycistron	O	55-66
proto	O	67-72
-	O	72-73
oncogene	O	73-81
in	O	82-84
6	O	85-86
%	O	86-87
of	O	88-90
pediatric	O	91-100
medulloblastomas	O	101-117
by	O	118-120
high	O	121-125
-	O	125-126
resolution	O	126-136
single	O	137-143
-	O	143-144
nucleotide	O	144-154
polymorphism	O	155-167
genotyping	O	168-178
arrays	O	179-185
and	O	186-189
subsequent	O	190-200
interphase	O	201-211
fluorescence	O	212-224
in	O	225-227
situ	O	228-232
hybridization	O	233-246
on	O	247-249
a	O	250-251
human	O	252-257
medulloblastoma	O	258-273
tissue	O	274-280
microarray	O	281-291
. 	O	291-293

Medulloblastoma	O	0-15
is	O	16-18
the	O	19-22
most	O	23-27
common	O	28-34
malignant	O	35-44
pediatric	O	45-54
brain	O	55-60
tumor	O	61-66
,	O	66-67
and	O	68-71
mechanisms	O	72-82
underlying	O	83-93
its	O	94-97
development	O	98-109
are	O	110-113
poorly	O	114-120
understood	O	121-131
. 	O	131-133

The	O	0-3
miR	B	4-7
-	I	7-8
17	I	8-10
/	I	10-11
92	I	11-13
polycistron	O	14-25
is	O	26-28
up	O	29-31
-	O	31-32
regulated	O	32-41
in	O	42-44
sonic	O	45-50
hedgehog	O	51-59
-	O	59-60
driven	O	60-66
medulloblastomas	O	67-83
and	O	84-87
induced	O	88-95
by	O	96-98
N	O	99-100
-	O	100-101
myc	O	101-104
in	O	105-107
sonic	O	108-113
hedgehog	O	114-122
-	O	122-123
treated	O	123-130
cerebellar	O	131-141
neural	O	142-148
precursors	O	149-159
.  	O	159-162

MicroRNA	O	0-8
regulation	O	9-19
of	O	20-22
IFN	O	23-26
-	O	26-27
beta	O	27-31
protein	O	32-39
expression	O	40-50
:	O	50-51
rapid	O	52-57
and	O	58-61
sensitive	O	62-71
modulation	O	72-82
of	O	83-85
the	O	86-89
innate	O	90-96
immune	O	97-103
response	O	104-112
.  	O	112-115

In	O	0-2
primary	O	3-10
primate	O	11-18
macrophages	O	19-30
,	O	30-31
the	O	32-35
main	O	36-40
cell	O	41-45
type	O	46-50
implicated	O	51-61
in	O	62-64
HIV	O	65-68
and	O	69-72
SIV	O	73-76
infection	O	77-86
in	O	87-89
the	O	90-93
CNS	O	94-97
,	O	97-98
specific	O	99-107
miRNAs	O	108-114
reduce	O	115-121
,	O	121-122
whereas	O	123-130
miRNA	O	131-136
inhibitors	O	137-147
enhance	O	148-155
,	O	155-156
IFN	O	157-160
-	O	160-161
beta	O	161-165
protein	O	166-173
production	O	174-184
. 	O	184-186

The	O	0-3
potential	O	4-13
biologic	O	14-22
significance	O	23-35
of	O	36-38
this	O	39-43
regulation	O	44-54
is	O	55-57
supported	O	58-67
by	O	68-70
evidence	O	71-79
of	O	80-82
an	O	83-85
apparent	O	86-94
negative	O	95-103
feedback	O	104-112
loop	O	113-117
,	O	117-118
with	O	119-123
increased	O	124-133
expression	O	134-144
of	O	145-147
three	O	148-153
IFN	O	154-157
-	O	157-158
beta	O	158-162
-	O	162-163
regulating	O	163-173
miRNAs	O	174-180
by	O	181-183
primate	O	184-191
macrophages	O	192-203
exposed	O	204-211
to	O	212-214
recombinant	O	215-226
IFN	O	227-230
-	O	230-231
beta	O	231-235
or	O	236-238
stimulated	O	239-249
to	O	250-252
produce	O	253-260
IFN	O	261-264
-	O	264-265
beta	O	265-269
. 	O	269-271

Thus	O	0-4
,	O	4-5
miRNAs	O	6-12
may	O	13-16
contribute	O	17-27
significantly	O	28-41
to	O	42-44
the	O	45-48
regulation	O	49-59
of	O	60-62
IFN	O	63-66
-	O	66-67
beta	O	67-71
in	O	72-74
innate	O	75-81
immune	O	82-88
responses	O	89-98
.   	O	98-102

IFN	O	0-3
-	O	3-4
beta	O	4-8
production	O	9-19
is	O	20-22
an	O	23-25
inaugural	O	26-35
event	O	36-41
in	O	42-44
the	O	45-48
innate	O	49-55
immune	O	56-62
response	O	63-71
to	O	72-74
viral	O	75-80
infections	O	81-91
,	O	91-92
with	O	93-97
relatively	O	98-108
small	O	109-114
fold	O	115-119
changes	O	120-127
in	O	128-130
IFN	O	131-134
-	O	134-135
beta	O	135-139
expression	O	140-150
resulting	O	151-160
in	O	161-163
the	O	164-167
activation	O	168-178
of	O	179-181
important	O	182-191
antiviral	O	192-201
signaling	O	202-211
cascades	O	212-220
. 	O	220-222

In	O	0-2
our	O	3-6
rapid	O	7-12
SIV	O	13-16
/	O	16-17
macaque	O	17-24
model	O	25-30
of	O	31-33
HIV	O	34-37
encephalitis	O	38-50
,	O	50-51
the	O	52-55
virus	O	56-61
enters	O	62-68
the	O	69-72
CNS	O	73-76
within	O	77-83
4	O	84-85
d	O	86-87
of	O	88-90
infection	O	91-100
,	O	100-101
accompanied	O	102-113
by	O	114-116
a	O	117-118
marked	O	119-125
IFN	O	126-129
-	O	129-130
beta	O	130-134
response	O	135-143
that	O	144-148
wanes	O	149-154
as	O	155-157
SIV	O	158-161
replication	O	162-173
is	O	174-176
controlled	O	177-187
. 	O	187-189

The	O	0-3
centrality	O	4-14
of	O	15-17
IFN	O	18-21
-	O	21-22
beta	O	22-26
to	O	27-29
the	O	30-33
innate	O	34-40
antiviral	O	41-50
response	O	51-59
in	O	60-62
the	O	63-66
CNS	O	67-70
combines	O	71-79
with	O	80-84
the	O	85-88
potential	O	89-98
inflammatory	O	99-111
damage	O	112-118
associated	O	119-129
with	O	130-134
long	O	135-139
-	O	139-140
term	O	140-144
activation	O	145-155
of	O	156-158
this	O	159-163
pathway	O	164-171
to	O	172-174
suggest	O	175-182
that	O	183-187
IFN	O	188-191
-	O	191-192
beta	O	192-196
may	O	197-200
be	O	201-203
subject	O	204-211
to	O	212-214
regulatory	O	215-225
fine	O	226-230
-	O	230-231
tuning	O	231-237
in	O	238-240
addition	O	241-249
to	O	250-252
well	O	253-257
-	O	257-258
established	O	258-269
transcriptional	O	270-285
and	O	286-289
message	O	290-297
stability	O	298-307
mechanisms	O	308-318
of	O	319-321
regulation	O	322-332
. 	O	332-334

In	O	0-2
this	O	3-7
paper	O	8-13
,	O	13-14
we	O	15-17
present	O	18-25
for	O	26-29
the	O	30-33
first	O	34-39
time	O	40-44
evidence	O	45-53
that	O	54-58
microRNAs	O	59-68
(	O	69-70
miRNAs	O	70-76
)	O	76-77
,	O	77-78
including	O	79-88
miR	B	89-92
-	I	92-93
26a	I	93-96
,	I	96-97
-	I	98-99
34a	I	99-102
,	I	102-103
-	I	104-105
145	I	105-108
,	O	108-109
and	O	110-113
let	B	114-117
-	I	117-118
7b	I	118-120
,	O	120-121
may	O	122-125
directly	O	126-134
regulate	O	135-143
IFN	O	144-147
-	O	147-148
beta	O	148-152
in	O	153-155
human	O	156-161
and	O	162-165
macaque	O	166-173
cells	O	174-179
. 	O	179-181

Identification	O	0-14
of	O	15-17
miRNA	O	18-23
changes	O	24-31
in	O	32-34
Alzheimer	O	35-44
'	O	44-45
s	O	45-46
disease	O	47-54
brain	O	55-60
and	O	61-64
CSF	O	65-68
yields	O	69-75
putative	O	76-84
biomarkers	O	85-95
and	O	96-99
insights	O	100-108
into	O	109-113
disease	O	114-121
pathways	O	122-130
.  	O	130-133

MicroRNAs	O	0-9
have	O	10-14
essential	O	15-24
functional	O	25-35
roles	O	36-41
in	O	42-44
brain	O	45-50
development	O	51-62
and	O	63-66
neuronal	O	67-75
specification	O	76-89
but	O	90-93
their	O	94-99
roles	O	100-105
in	O	106-108
neurodegenerative	O	109-126
diseases	O	127-135
such	O	136-140
as	O	141-143
Alzheimer	O	144-153
'	O	153-154
s	O	154-155
disease	O	156-163
(	O	164-165
AD	O	165-167
)	O	167-168
is	O	169-171
unknown	O	172-179
. 	O	179-181

Using	O	0-5
a	O	6-7
sensitive	O	8-17
qRT	O	18-21
-	O	21-22
PCR	O	22-25
platform	O	26-34
we	O	35-37
identified	O	38-48
regional	O	49-57
and	O	58-61
stage	O	62-67
-	O	67-68
specific	O	68-76
deregulation	O	77-89
of	O	90-92
miRNA	O	93-98
expression	O	99-109
in	O	110-112
AD	O	113-115
patient	O	116-123
brains	O	124-130
. 	O	130-132

We	O	0-2
used	O	3-7
experimental	O	8-20
validation	O	21-31
in	O	32-34
addition	O	35-43
to	O	44-46
literature	O	47-57
to	O	58-60
reveal	O	61-67
how	O	68-71
the	O	72-75
deregulated	O	76-87
brain	O	88-93
microRNAs	O	94-103
are	O	104-107
biomarkers	O	108-118
for	O	119-122
known	O	123-128
and	O	129-132
novel	O	133-138
pathways	O	139-147
in	O	148-150
AD	O	151-153
pathogenesis	O	154-166
related	O	167-174
to	O	175-177
amyloid	O	178-185
processing	O	186-196
,	O	196-197
neurogenesis	O	198-210
,	O	210-211
insulin	O	212-219
resistance	O	220-230
,	O	230-231
and	O	232-235
innate	O	236-242
immunity	O	243-251
. 	O	251-253

We	O	0-2
additionally	O	3-15
recovered	O	16-25
miRNAs	O	26-32
from	O	33-37
cerebrospinal	O	38-51
fluid	O	52-57
and	O	58-61
discovered	O	62-72
AD	O	73-75
-	O	75-76
specific	O	76-84
miRNA	O	85-90
changes	O	91-98
consistent	O	99-109
with	O	110-114
their	O	115-120
role	O	121-125
as	O	126-128
potential	O	129-138
biomarkers	O	139-149
of	O	150-152
disease	O	153-160
.   	O	160-164

In	O	0-2
sum	O	3-6
,	O	6-7
our	O	8-11
results	O	12-19
suggest	O	20-27
that	O	28-32
specific	O	33-41
miRNAs	O	42-48
are	O	49-52
involved	O	53-61
in	O	62-64
the	O	65-68
fine	O	69-73
-	O	73-74
tuning	O	74-80
of	O	81-83
APP	O	84-87
alternative	O	88-99
splicing	O	100-108
in	O	109-111
neurons	O	112-119
. 	O	119-121

Finally	O	0-7
,	O	7-8
we	O	9-11
show	O	12-16
that	O	17-21
miR	B	22-25
-	I	25-26
124	I	26-29
is	O	30-32
down	O	33-37
-	O	37-38
regulated	O	38-47
in	O	48-50
AD	O	51-53
brain	O	54-59
. 	O	59-61

Furthermore	O	0-11
,	O	11-12
PTBP1	O	13-18
levels	O	19-25
correlate	O	26-35
with	O	36-40
the	O	41-44
presence	O	45-53
of	O	54-56
APP	O	57-60
exons	O	61-66
7	O	67-68
and	O	69-72
8	O	73-74
,	O	74-75
while	O	76-81
PTBP2	O	82-87
levels	O	88-94
correlate	O	95-104
with	O	105-109
the	O	110-113
skipping	O	114-122
of	O	123-125
these	O	126-131
exons	O	132-137
during	O	138-144
neuronal	O	145-153
differentiation	O	154-169
. 	O	169-171

Similar	O	0-7
results	O	8-15
were	O	16-20
obtained	O	21-29
by	O	30-32
depletion	O	33-42
of	O	43-45
endogenous	O	46-56
polypyrimidine	O	57-71
tract	O	72-77
binding	O	78-85
protein	O	86-93
1	O	94-95
(	O	96-97
PTBP1	O	97-102
)	O	102-103
in	O	104-106
cells	O	107-112
,	O	112-113
a	O	114-115
recognized	O	116-126
miR	B	127-130
-	I	130-131
124	I	131-134
target	O	135-141
gene	O	142-146
. 	O	146-148

In	O	0-2
vivo	O	3-7
regulation	O	8-18
of	O	19-21
amyloid	O	22-29
precursor	O	30-39
protein	O	40-47
neuronal	O	48-56
splicing	O	57-65
by	O	66-68
microRNAs	O	69-78
.  	O	78-81

The	O	0-3
β	O	4-5
-	O	5-6
amyloid	O	6-13
peptide	O	14-21
that	O	22-26
accumulate	O	27-37
in	O	38-40
Alzheimer	O	41-50
'	O	50-51
s	O	51-52
disease	O	53-60
(	O	61-62
AD	O	62-64
)	O	64-65
brain	O	66-71
derive	O	72-78
from	O	79-83
proteolytic	O	84-95
processing	O	96-106
of	O	107-109
the	O	110-113
amyloid	O	114-121
precursor	O	122-131
protein	O	132-139
(	O	140-141
APP	O	141-144
)	O	144-145
. 	O	145-147

Here	O	0-4
,	O	4-5
we	O	6-8
present	O	9-16
evidence	O	17-25
that	O	26-30
,	O	30-31
besides	O	32-39
APP	O	40-43
expression	O	44-54
regulation	O	55-65
,	O	65-66
miRNAs	O	67-73
are	O	74-77
equally	O	78-85
involved	O	86-94
in	O	95-97
the	O	98-101
regulation	O	102-112
of	O	113-115
neuronal	O	116-124
APP	O	125-128
mRNA	O	129-133
alternative	O	134-145
splicing	O	146-154
. 	O	154-156

Lack	O	0-4
of	O	5-7
miRNAs	O	8-14
in	O	15-17
post	O	18-22
-	O	22-23
mitotic	O	23-30
neurons	O	31-38
in	O	39-41
vivo	O	42-46
is	O	47-49
associated	O	50-60
with	O	61-65
APP	O	66-69
exons	O	70-75
7	O	76-77
and	O	78-81
8	O	82-83
inclusion	O	84-93
,	O	93-94
while	O	95-100
ectopic	O	101-108
expression	O	109-119
of	O	120-122
miR	B	123-126
-	I	126-127
124	I	127-130
,	O	130-131
an	O	132-134
abundant	O	135-143
neuronal	O	144-152
-	O	152-153
specific	O	153-161
miRNA	O	162-167
,	O	167-168
reversed	O	169-177
these	O	178-183
effects	O	184-191
in	O	192-194
cultured	O	195-203
neurons	O	204-211
. 	O	211-213

Recent	O	0-6
evidence	O	7-15
suggest	O	16-23
that	O	24-28
microRNAs	O	29-38
(	O	39-40
miRNAs	O	40-46
)	O	46-47
participate	O	48-59
in	O	60-62
the	O	63-66
post	O	67-71
-	O	71-72
transcriptional	O	72-87
regulation	O	88-98
of	O	99-101
APP	O	102-105
expression	O	106-116
. 	O	116-118

Because	O	0-7
gene	O	8-12
dosage	O	13-19
effects	O	20-27
of	O	28-30
the	O	31-34
APP	O	35-38
gene	O	39-43
can	O	44-47
cause	O	48-53
genetic	O	54-61
AD	O	62-64
,	O	64-65
dysregulation	O	66-79
of	O	80-82
the	O	83-86
miRNA	O	87-92
network	O	93-100
could	O	101-106
contribute	O	107-117
significantly	O	118-131
to	O	132-134
disease	O	135-142
. 	O	142-144

Since	O	0-5
abnormal	O	6-14
neuronal	O	15-23
splicing	O	24-32
of	O	33-35
APP	O	36-39
affects	O	40-47
β	O	48-49
-	O	49-50
amyloid	O	50-57
peptide	O	58-65
production	O	66-76
,	O	76-77
these	O	78-83
results	O	84-91
could	O	92-97
contribute	O	98-108
to	O	109-111
the	O	112-115
understanding	O	116-129
of	O	130-132
the	O	133-136
implication	O	137-148
of	O	149-151
miRNAs	O	152-158
in	O	159-161
brain	O	162-167
health	O	168-174
and	O	175-178
disease	O	179-186
.   	O	186-190

A	O	0-1
greater	O	2-9
understanding	O	10-23
of	O	24-26
aberrant	O	27-35
miRNA	O	36-41
expression	O	42-52
in	O	53-55
pediatric	O	56-65
brain	O	66-71
tumors	O	72-78
may	O	79-82
aid	O	83-86
in	O	87-89
the	O	90-93
development	O	94-105
of	O	106-108
novel	O	109-114
therapies	O	115-124
. 	O	124-126

The	O	0-3
characterization	O	4-20
of	O	21-23
tumor	O	24-29
-	O	29-30
specific	O	30-38
miRNA	O	39-44
signatures	O	45-55
may	O	56-59
aid	O	60-63
in	O	64-66
the	O	67-70
discovery	O	71-80
of	O	81-83
biomarkers	O	84-94
with	O	95-99
diagnostic	O	100-110
or	O	111-113
prognostic	O	114-124
utility	O	125-132
.   	O	132-136

The	O	0-3
present	O	4-11
study	O	12-17
provides	O	18-26
an	O	27-29
initial	O	30-37
survey	O	38-44
of	O	45-47
miRNA	O	48-53
expression	O	54-64
in	O	65-67
pediatric	O	68-77
central	O	78-85
nervous	O	86-93
system	O	94-100
(	O	101-102
CNS	O	102-105
)	O	105-106
malignancies	O	107-119
including	O	120-129
atypical	O	130-138
teratoid	O	139-147
/	O	147-148
rhabdoid	O	148-156
tumor	O	157-162
,	O	162-163
ependymoma	O	164-174
,	O	174-175
glioblastoma	O	176-188
,	O	188-189
medulloblastoma	O	190-205
,	O	205-206
and	O	207-210
pilocytic	O	211-220
astrocytoma	O	221-232
. 	O	232-234

PROCEDURE	O	0-9
:	O	9-10
MicroRNA	O	11-19
expression	O	20-30
in	O	31-33
pediatric	O	34-43
brain	O	44-49
tumors	O	50-56
and	O	57-60
normal	O	61-67
tissue	O	68-74
controls	O	75-83
was	O	84-87
examined	O	88-96
by	O	97-99
microarray	O	100-110
. 	O	110-112

BACKGROUND	O	0-10
:	O	10-11
A	O	12-13
better	O	14-20
understanding	O	21-34
of	O	35-37
pediatric	O	38-47
brain	O	48-53
tumor	O	54-59
biology	O	60-67
is	O	68-70
needed	O	71-77
to	O	78-80
assist	O	81-87
in	O	88-90
the	O	91-94
development	O	95-106
of	O	107-109
less	O	110-114
toxic	O	115-120
therapies	O	121-130
and	O	131-134
to	O	135-137
provide	O	138-145
better	O	146-152
markers	O	153-160
for	O	161-164
disease	O	165-172
stratification	O	173-187
. 	O	187-189

MicroRNAs	O	0-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
may	O	18-21
play	O	22-26
a	O	27-28
significant	O	29-40
role	O	41-45
in	O	46-48
brain	O	49-54
tumor	O	55-60
biology	O	61-68
. 	O	68-70

When	O	0-4
further	O	5-12
examined	O	13-21
by	O	22-24
qRT	O	25-28
-	O	28-29
PCR	O	29-32
,	O	32-33
these	O	34-39
miRNAs	O	40-46
demonstrated	O	47-59
differential	O	60-72
expression	O	73-83
that	O	84-88
significantly	O	89-102
correlated	O	103-113
with	O	114-118
the	O	119-122
microarray	O	123-133
findings	O	134-142
. 	O	142-144

Distinctive	O	0-11
miRNA	O	12-17
expression	O	18-28
profiles	O	29-37
were	O	38-42
also	O	43-47
observed	O	48-56
in	O	57-59
the	O	60-63
different	O	64-73
pediatric	O	74-83
brain	O	84-89
tumor	O	90-95
types	O	96-101
. 	O	101-103

Three	O	0-5
aberrantly	O	6-16
expressed	O	17-26
miRNAs	O	27-33
were	O	34-38
further	O	39-46
studied	O	47-54
in	O	55-57
a	O	58-59
larger	O	60-66
cohort	O	67-73
by	O	74-76
quantitative	O	77-89
real	O	90-94
-	O	94-95
time	O	95-99
PCR	O	100-103
(	O	104-105
qRT	O	105-108
-	O	108-109
PCR	O	109-112
)	O	112-113
. 	O	113-115

RESULTS	O	0-7
:	O	7-8
MicroRNA	B	9-17
-	I	17-18
129	I	18-21
,	O	21-22
miR	B	23-26
-	I	26-27
142	I	27-30
-	I	30-31
5p	I	31-33
,	O	33-34
and	O	35-38
miR	B	39-42
-	I	42-43
25	I	43-45
were	O	46-50
differentially	O	51-65
expressed	O	66-75
in	O	76-78
every	O	79-84
pediatric	O	85-94
brain	O	95-100
tumor	O	101-106
type	O	107-111
compared	O	112-120
to	O	121-123
normal	O	124-130
tissue	O	131-137
controls	O	138-146
as	O	147-149
measured	O	150-158
by	O	159-161
microarray	O	162-172
. 	O	172-174

CONCLUSIONS	O	0-11
:	O	11-12
MicroRNAs	O	13-22
are	O	23-26
differentially	O	27-41
expressed	O	42-51
between	O	52-59
pediatric	O	60-69
CNS	O	70-73
neoplasms	O	74-83
and	O	84-87
normal	O	88-94
tissue	O	95-101
suggesting	O	102-112
that	O	113-117
they	O	118-122
may	O	123-126
play	O	127-131
a	O	132-133
significant	O	134-145
role	O	146-150
in	O	151-153
oncogenesis	O	154-165
. 	O	165-167

Survey	O	0-6
of	O	7-9
MicroRNA	O	10-18
expression	O	19-29
in	O	30-32
pediatric	O	33-42
brain	O	43-48
tumors	O	49-55
.  	O	55-58

The	O	0-3
authors	O	4-11
reviewed	O	12-20
the	O	21-24
records	O	25-32
of	O	33-35
nineteen	O	36-44
consecutive	O	45-56
children	O	57-65
with	O	66-70
newly	O	71-76
diagnosed	O	77-86
IIH	O	87-90
in	O	91-93
order	O	94-99
to	O	100-102
compare	O	103-110
demographic	O	111-122
characteristics	O	123-138
,	O	138-139
clinical	O	140-148
pictures	O	149-157
and	O	158-161
ophthalmologic	O	162-176
aspects	O	177-184
as	O	185-187
optic	O	188-193
disc	O	194-198
evaluation	O	199-209
and	O	210-213
visual	O	214-220
field	O	221-226
evaluation	O	227-237
,	O	237-238
as	O	239-241
well	O	242-246
as	O	247-249
treatment	O	250-259
modalities	O	260-270
and	O	271-274
follow	O	275-281
up	O	282-284
. 	O	284-286

Beside	O	0-6
obesity	O	7-14
and	O	15-18
female	O	19-25
gender	O	26-32
,	O	32-33
potential	O	34-43
alternative	O	44-55
risk	O	56-60
factors	O	61-68
remains	O	69-76
to	O	77-79
be	O	80-82
investigated	O	83-95
,	O	95-96
which	O	97-102
need	O	103-107
a	O	108-109
good	O	110-114
collaboration	O	115-128
between	O	129-136
neuro	O	137-142
-	O	142-143
ophthalmologists	O	143-159
and	O	160-163
pediatric	O	164-173
neurologists	O	174-186
.   	O	186-190

Idiopathic	O	0-10
intracranial	O	11-23
hypertension	O	24-36
(	O	37-38
IIH	O	38-41
)	O	41-42
is	O	43-45
a	O	46-47
clinical	O	48-56
condition	O	57-66
characterized	O	67-80
by	O	81-83
elevated	O	84-92
intracranial	O	93-105
pressure	O	106-114
and	O	115-118
absence	O	119-126
of	O	127-129
clinical	O	130-138
,	O	138-139
laboratory	O	140-150
or	O	151-153
radiographic	O	154-166
evidence	O	167-175
of	O	176-178
central	O	179-186
nervous	O	187-194
system	O	195-201
infection	O	202-211
,	O	211-212
vascular	O	213-221
malformation	O	222-234
,	O	234-235
intracranial	O	236-248
space	O	249-254
occupying	O	255-264
lesion	O	265-271
or	O	272-274
hydrocephalus	O	275-288
. 	O	288-290

In	O	0-2
the	O	3-6
last	O	7-11
years	O	12-17
the	O	18-21
raising	O	22-29
understanding	O	30-43
of	O	44-46
pediatric	O	47-56
IIH	O	57-60
,	O	60-61
especially	O	62-72
concerning	O	73-83
its	O	84-87
demographics	O	88-100
and	O	101-104
epidemiology	O	105-117
,	O	117-118
has	O	119-122
brought	O	123-130
up	O	131-133
to	O	134-136
a	O	137-138
redefinition	O	139-151
of	O	152-154
diagnostic	O	155-165
criteria	O	166-174
and	O	175-178
reevaluation	O	179-191
of	O	192-194
pathogenesis	O	195-207
and	O	208-211
treatment	O	212-221
. 	O	221-223

Pediatric	O	0-9
idiopathic	O	10-20
intracranial	O	21-33
hypertension	O	34-46
:	O	46-47
clinical	O	48-56
and	O	57-60
demographic	O	61-72
features	O	73-81
.  	O	81-84

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
summarise	O	19-28
the	O	29-32
current	O	33-40
knowledge	O	41-50
of	O	51-53
miR	B	54-57
-	I	57-58
21	I	58-60
functions	O	61-70
in	O	71-73
human	O	74-79
disease	O	80-87
,	O	87-88
with	O	89-93
an	O	94-96
emphasis	O	97-105
on	O	106-108
its	O	109-112
regulation	O	113-123
,	O	123-124
oncogenic	O	125-134
role	O	135-139
,	O	139-140
targets	O	141-148
in	O	149-151
human	O	152-157
cancers	O	158-165
,	O	165-166
potential	O	167-176
as	O	177-179
a	O	180-181
disease	O	182-189
biomarker	O	190-199
and	O	200-203
novel	O	204-209
therapeutic	O	210-221
target	O	222-228
in	O	229-231
oncology	O	232-240
.   	O	240-244

However	O	0-7
,	O	7-8
an	O	9-11
miR	B	12-15
-	I	15-16
21	I	16-18
knockout	O	19-27
mouse	O	28-33
has	O	34-37
not	O	38-41
yet	O	42-45
been	O	46-50
generated	O	51-60
,	O	60-61
and	O	62-65
the	O	66-69
data	O	70-74
about	O	75-80
miR	B	81-84
-	I	84-85
21	I	85-87
functions	O	88-97
in	O	98-100
normal	O	101-107
cells	O	108-113
are	O	114-117
still	O	118-123
very	O	124-128
limited	O	129-136
. 	O	136-138

Since	O	0-5
its	O	6-9
identification	O	10-24
3	O	25-26
years	O	27-32
ago	O	33-36
as	O	37-39
the	O	40-43
miRNA	O	44-49
most	O	50-54
commonly	O	55-63
and	O	64-67
strongly	O	68-76
up	O	77-79
-	O	79-80
regulated	O	80-89
in	O	90-92
human	O	93-98
brain	O	99-104
tumour	O	105-111
glioblastoma	O	112-124
[	O	125-126
1	O	126-127
]	O	127-128
,	O	128-129
miR	B	130-133
-	I	133-134
21	I	134-136
has	O	137-140
attracted	O	141-150
the	O	151-154
attention	O	155-164
of	O	165-167
researchers	O	168-179
in	O	180-182
various	O	183-190
fields	O	191-197
,	O	197-198
such	O	199-203
as	O	204-206
development	O	207-218
,	O	218-219
oncology	O	220-228
,	O	228-229
stem	O	230-234
cell	O	235-239
biology	O	240-247
and	O	248-251
aging	O	252-257
,	O	257-258
becoming	O	259-267
one	O	268-271
of	O	272-274
the	O	275-278
most	O	279-283
studied	O	284-291
miRNAs	O	292-298
,	O	298-299
along	O	300-305
with	O	306-310
let	B	311-314
-	I	314-315
7	I	315-316
,	O	316-317
miR	B	318-321
-	I	321-322
17	I	322-324
-	I	324-325
92	I	325-327
cluster	O	328-335
(	O	336-337
'	O	337-338
oncomir	B	338-345
-	I	345-346
1	I	346-347
'	O	347-348
)	O	348-349
,	O	349-350
miR	B	351-354
-	I	354-355
155	I	355-358
and	O	359-362
a	O	363-364
few	O	365-368
others	O	369-375
. 	O	375-377

Particular	O	0-10
miRNAs	O	11-17
emerge	O	18-24
as	O	25-27
principal	O	28-37
regulators	O	38-48
that	O	49-53
control	O	54-61
major	O	62-67
cell	O	68-72
functions	O	73-82
in	O	83-85
various	O	86-93
physiological	O	94-107
and	O	108-111
pathophysiological	O	112-130
settings	O	131-139
. 	O	139-141

miR	B	0-3
-	I	3-4
21	I	4-6
:	O	6-7
a	O	8-9
small	O	10-15
multi	O	16-21
-	O	21-22
faceted	O	22-29
RNA	O	30-33
.  	O	33-36

More	O	0-4
than	O	5-9
1000	O	10-14
microRNAs	O	15-24
(	O	25-26
miRNAs	O	26-32
)	O	32-33
are	O	34-37
expressed	O	38-47
in	O	48-50
human	O	51-56
cells	O	57-62
,	O	62-63
some	O	64-68
tissue	O	69-75
or	O	76-78
cell	O	79-83
type	O	84-88
specific	O	89-97
,	O	97-98
others	O	99-105
considered	O	106-116
as	O	117-119
house	O	120-125
-	O	125-126
keeping	O	126-133
molecules	O	134-143
. 	O	143-145

Functions	O	0-9
and	O	10-13
direct	O	14-20
mRNA	O	21-25
targets	O	26-33
for	O	34-37
some	O	38-42
miRNAs	O	43-49
have	O	50-54
been	O	55-59
relatively	O	60-70
well	O	71-75
studied	O	76-83
over	O	84-88
the	O	89-92
last	O	93-97
years	O	98-103
. 	O	103-105

Every	O	0-5
miRNA	O	6-11
potentially	O	12-23
regulates	O	24-33
the	O	34-37
expression	O	38-48
of	O	49-51
numerous	O	52-60
protein	O	61-68
-	O	68-69
coding	O	69-75
genes	O	76-81
(	O	82-83
tens	O	83-87
to	O	88-90
hundreds	O	91-99
)	O	99-100
,	O	100-101
but	O	102-105
it	O	106-108
has	O	109-112
become	O	113-119
increasingly	O	120-132
clear	O	133-138
that	O	139-143
not	O	144-147
all	O	148-151
miRNAs	O	152-158
are	O	159-162
equally	O	163-170
important	O	171-180
;	O	180-181
diverse	O	182-189
high	O	190-194
-	O	194-195
throughput	O	195-205
screenings	O	206-216
of	O	217-219
various	O	220-227
systems	O	228-235
have	O	236-240
identified	O	241-251
a	O	252-253
limited	O	254-261
number	O	262-268
of	O	269-271
key	O	272-275
functional	O	276-286
miRNAs	O	287-293
over	O	294-298
and	O	299-302
over	O	303-307
again	O	308-313
. 	O	313-315

Expression	O	0-10
levels	O	11-17
of	O	18-20
select	O	21-27
protein	O	28-35
-	O	35-36
coding	O	36-42
genes	O	43-48
and	O	49-52
miRNAs	O	53-59
could	O	60-65
classify	O	66-74
an	O	75-77
independent	O	78-89
set	O	90-93
of	O	94-96
medulloblastomas	O	97-113
. 	O	113-115

Twelve	O	0-6
of	O	7-9
31	O	10-12
medulloblastomas	O	13-29
were	O	30-34
found	O	35-40
to	O	41-43
overexpress	O	44-55
genes	O	56-61
belonging	O	62-71
to	O	72-74
the	O	75-78
canonical	O	79-88
WNT	O	89-92
signaling	O	93-102
pathway	O	103-110
and	O	111-114
carry	O	115-120
a	O	121-122
mutation	O	123-131
in	O	132-134
CTNNB1	O	135-141
gene	O	142-146
. 	O	146-148

In	O	0-2
order	O	3-8
to	O	9-11
get	O	12-15
a	O	16-17
better	O	18-24
understanding	O	25-38
of	O	39-41
medulloblastoma	O	42-57
biology	O	58-65
,	O	65-66
miRNA	O	67-72
profiling	O	73-82
of	O	83-85
medulloblastomas	O	86-102
was	O	103-106
carried	O	107-114
out	O	115-118
in	O	119-121
parallel	O	122-130
with	O	131-135
expression	O	136-146
profiling	O	147-156
of	O	157-159
protein	O	160-167
-	O	167-168
coding	O	168-174
genes	O	175-180
. 	O	180-182

MATERIALS	O	0-9
AND	O	10-13
METHODS	O	14-21
:	O	21-22
miRNA	O	23-28
profiling	O	29-38
of	O	39-41
medulloblastomas	O	42-58
was	O	59-62
carried	O	63-70
out	O	71-74
using	O	75-80
Taqman	O	81-87
Low	O	88-91
Density	O	92-99
Array	O	100-105
v	O	106-107
1	O	108-109
.	O	109-110
0	O	110-111
having	O	112-118
365	O	119-122
human	O	123-128
microRNAs	O	129-138
. 	O	138-140

In	O	0-2
parallel	O	3-11
,	O	11-12
genome	O	13-19
-	O	19-20
wide	O	20-24
expression	O	25-35
profiling	O	36-45
of	O	46-48
protein	O	49-56
-	O	56-57
coding	O	57-63
genes	O	64-69
was	O	70-73
carried	O	74-81
out	O	82-85
using	O	86-91
Affymetrix	O	92-102
gene	O	103-107
1	O	108-109
.	O	109-110
0	O	110-111
ST	O	112-114
arrays	O	115-121
. 	O	121-123

RESULTS	O	0-7
:	O	7-8
Both	O	9-13
the	O	14-17
profiling	O	18-27
studies	O	28-35
identified	O	36-46
four	O	47-51
molecular	O	52-61
subtypes	O	62-70
of	O	71-73
medulloblastomas	O	74-90
. 	O	90-92

Distinctive	O	0-11
microRNA	O	12-20
signature	O	21-30
of	O	31-33
medulloblastomas	O	34-50
associated	O	51-61
with	O	62-66
the	O	67-70
WNT	O	71-74
signaling	O	75-84
pathway	O	85-92
.  	O	92-95

AIM	O	0-3
:	O	3-4
Medulloblastoma	O	5-20
is	O	21-23
a	O	24-25
malignant	O	26-35
brain	O	36-41
tumor	O	42-47
that	O	48-52
occurs	O	53-59
predominantly	O	60-73
in	O	74-76
children	O	77-85
. 	O	85-87

Current	O	0-7
risk	O	8-12
stratification	O	13-27
based	O	28-33
on	O	34-36
clinical	O	37-45
parameters	O	46-56
is	O	57-59
inadequate	O	60-70
for	O	71-74
accurate	O	75-83
prognostication	O	84-99
. 	O	99-101

MicroRNA	O	0-8
expression	O	9-19
is	O	20-22
known	O	23-28
to	O	29-31
be	O	32-34
deregulated	O	35-46
in	O	47-49
various	O	50-57
cancers	O	58-65
and	O	66-69
has	O	70-73
been	O	74-78
found	O	79-84
to	O	85-87
be	O	88-90
useful	O	91-97
in	O	98-100
predicting	O	101-111
tumor	O	112-117
behavior	O	118-126
. 	O	126-128

A	O	0-1
number	O	2-8
of	O	9-11
miRNAs	O	12-18
like	O	19-23
miR	B	24-27
-	I	27-28
193a	I	28-32
,	O	32-33
miR	B	34-37
-	I	37-38
224	I	38-41
/	O	41-42
miR	B	42-45
-	I	45-46
452	I	46-49
cluster	O	50-57
,	O	57-58
miR	B	59-62
-	I	62-63
182	I	63-66
/	O	66-67
miR	B	67-70
-	I	70-71
183	I	71-74
/	O	74-75
miR	B	75-78
-	I	78-79
96	I	79-81
cluster	O	82-89
,	O	89-90
and	O	91-94
miR	B	95-98
-	I	98-99
148a	I	99-103
having	O	104-110
potential	O	111-120
tumor	O	121-126
/	O	126-127
metastasis	O	127-137
suppressive	O	138-149
activity	O	150-158
were	O	159-163
found	O	164-169
to	O	170-172
be	O	173-175
overexpressed	O	176-189
in	O	190-192
the	O	193-196
WNT	O	197-200
signaling	O	201-210
associated	O	211-221
medulloblastomas	O	222-238
. 	O	238-240

CONCLUSION	O	0-10
:	O	10-11
Expression	O	12-22
level	O	23-28
of	O	29-31
tumor	O	32-37
/	O	37-38
metastasis	O	38-48
suppressive	O	49-60
miRNAs	O	61-67
in	O	68-70
the	O	71-74
WNT	O	75-78
signaling	O	79-88
associated	O	89-99
medulloblastomas	O	100-116
is	O	117-119
likely	O	120-126
to	O	127-129
determine	O	130-139
their	O	140-145
response	O	146-154
to	O	155-157
treatment	O	158-167
,	O	167-168
and	O	169-172
thus	O	173-177
,	O	177-178
these	O	179-184
miRNAs	O	185-191
would	O	192-197
be	O	198-200
important	O	201-210
biomarkers	O	211-221
for	O	222-225
risk	O	226-230
stratification	O	231-245
within	O	246-252
the	O	253-256
WNT	O	257-260
signaling	O	261-270
associated	O	271-281
medulloblastomas	O	282-298
.   	O	298-302

Exogenous	O	0-9
expression	O	10-20
of	O	21-23
miR	B	24-27
-	I	27-28
193a	I	28-32
and	O	33-36
miR	B	37-40
-	I	40-41
224	I	41-44
,	O	44-45
two	O	46-49
miRNAs	O	50-56
that	O	57-61
have	O	62-66
the	O	67-70
highest	O	71-78
WNT	O	79-82
pathway	O	83-90
specific	O	91-99
upregulation	O	100-112
,	O	112-113
was	O	114-117
found	O	118-123
to	O	124-126
inhibit	O	127-134
proliferation	O	135-148
,	O	148-149
increase	O	150-158
radiation	O	159-168
sensitivity	O	169-180
and	O	181-184
reduce	O	185-191
anchorage	O	192-201
-	O	201-202
independent	O	202-213
growth	O	214-220
of	O	221-223
medulloblastoma	O	224-239
cells	O	240-245
. 	O	245-247

We	O	0-2
now	O	3-6
report	O	7-13
clinical	O	14-22
and	O	23-26
genetic	O	27-34
findings	O	35-43
in	O	44-46
nine	O	47-51
additional	O	52-62
European	O	63-71
families	O	72-80
with	O	81-85
myoclonus	O	86-95
-	O	95-96
dystonia	O	96-104
syndrome	O	105-113
. 	O	113-115

Mutations	O	0-9
in	O	10-12
the	O	13-16
gene	O	17-21
for	O	22-25
epsilon	O	26-33
-	O	33-34
sarcoglycan	O	34-45
(	O	46-47
SGCE	O	47-51
)	O	51-52
have	O	53-57
been	O	58-62
found	O	63-68
to	O	69-71
cause	O	72-77
myoclonus	O	78-87
-	O	87-88
dystonia	O	88-96
syndrome	O	97-105
. 	O	105-107

Six	O	0-3
novel	O	4-9
and	O	10-13
one	O	14-17
previously	O	18-28
known	O	29-34
heterozygous	O	35-47
SGCE	O	48-52
mutations	O	53-62
were	O	63-67
identified	O	68-78
. 	O	78-80

The	O	0-3
clinical	O	4-12
presentation	O	13-25
in	O	26-28
24	O	29-31
affecteds	O	32-41
was	O	42-45
homogeneous	O	46-57
with	O	58-62
myoclonus	O	63-72
predominantly	O	73-86
of	O	87-89
neck	O	90-94
and	O	95-98
upper	O	99-104
limbs	O	105-110
in	O	111-113
23	O	114-116
of	O	117-119
them	O	120-124
and	O	125-128
dystonia	O	129-137
,	O	137-138
presenting	O	139-149
as	O	150-152
cervical	O	153-161
dystonia	O	162-170
and	O	171-174
/	O	174-175
or	O	175-177
writer	O	178-184
'	O	184-185
s	O	185-186
cramp	O	187-192
,	O	192-193
in	O	194-196
13	O	197-199
cases	O	200-205
. 	O	205-207

SGCE	O	0-4
deficiency	O	5-15
seems	O	16-21
to	O	22-24
be	O	25-27
the	O	28-31
common	O	32-38
pathogenetic	O	39-51
mechanism	O	52-61
in	O	62-64
myoclonus	O	65-74
-	O	74-75
dystonia	O	75-83
syndrome	O	84-92
.   	O	92-96

Myoclonus	O	0-9
-	O	9-10
dystonia	O	10-18
syndrome	O	19-27
:	O	27-28
epsilon	O	29-36
-	O	36-37
sarcoglycan	O	37-48
mutations	O	49-58
and	O	59-62
phenotype	O	63-72
.  	O	72-75

This	O	0-4
review	O	5-11
summarizes	O	12-22
recent	O	23-29
findings	O	30-38
of	O	39-41
miRNA	O	42-47
study	O	48-53
in	O	54-56
brain	O	57-62
tumors	O	63-69
.   	O	69-73

Several	O	0-7
deregulated	O	8-19
miRNAs	O	20-26
uncovered	O	27-36
in	O	37-39
glioblastomas	O	40-53
and	O	54-57
medulloblastomas	O	58-74
have	O	75-79
their	O	80-85
gene	O	86-90
targets	O	91-98
and	O	99-102
the	O	103-106
associated	O	107-117
genetic	O	118-125
pathways	O	126-134
identified	O	135-145
. 	O	145-147

Moreover	O	0-8
,	O	8-9
specific	O	10-18
miRNA	O	19-24
subsets	O	25-32
may	O	33-36
have	O	37-41
potential	O	42-51
diagnostic	O	52-62
and	O	63-66
prognostic	O	67-77
values	O	78-84
in	O	85-87
some	O	88-92
brain	O	93-98
tumors	O	99-105
. 	O	105-107

Expression	O	0-10
profiling	O	11-20
has	O	21-24
unveiled	O	25-33
miRNA	O	34-39
signatures	O	40-50
that	O	51-55
not	O	56-59
only	O	60-64
distinguish	O	65-76
brain	O	77-82
tumors	O	83-89
from	O	90-94
normal	O	95-101
tissues	O	102-109
,	O	109-110
but	O	111-114
can	O	115-118
also	O	119-123
differentiate	O	124-137
histotypes	O	138-148
or	O	149-151
molecular	O	152-161
subtypes	O	162-170
with	O	171-175
altered	O	176-183
genetic	O	184-191
pathways	O	192-200
. 	O	200-202

Recent	O	0-6
years	O	7-12
have	O	13-17
seen	O	18-22
considerable	O	23-35
progress	O	36-44
in	O	45-47
miRNA	O	48-53
research	O	54-62
in	O	63-65
brain	O	66-71
tumors	O	72-78
,	O	78-79
particularly	O	80-92
in	O	93-95
glioblastomas	O	96-109
and	O	110-113
medulloblastomas	O	114-130
,	O	130-131
providing	O	132-141
novel	O	142-147
insights	O	148-156
into	O	157-161
the	O	162-165
pathogenesis	O	166-178
of	O	179-181
these	O	182-187
malignant	O	188-197
lesions	O	198-205
. 	O	205-207

Emerging	O	0-8
evidence	O	9-17
indicates	O	18-27
that	O	28-32
miRNAs	O	33-39
play	O	40-44
an	O	45-47
important	O	48-57
role	O	58-62
in	O	63-65
the	O	66-69
development	O	70-81
of	O	82-84
human	O	85-90
cancers	O	91-98
,	O	98-99
with	O	100-104
their	O	105-110
deregulation	O	111-123
resulting	O	124-133
in	O	134-136
altered	O	137-144
activity	O	145-153
of	O	154-156
downstream	O	157-167
tumor	O	168-173
suppressors	O	174-185
,	O	185-186
oncogenes	O	187-196
and	O	197-200
other	O	201-206
signaling	O	207-216
molecules	O	217-226
. 	O	226-228

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
short	O	23-28
non	O	29-32
-	O	32-33
protein	O	33-40
-	O	40-41
coding	O	41-47
RNAs	O	48-52
that	O	53-57
function	O	58-66
as	O	67-69
key	O	70-73
regulators	O	74-84
of	O	85-87
diverse	O	88-95
biological	O	96-106
processes	O	107-116
through	O	117-124
negative	O	125-133
control	O	134-141
on	O	142-144
gene	O	145-149
expression	O	150-160
at	O	161-163
the	O	164-167
post	O	168-172
-	O	172-173
transcriptional	O	173-188
level	O	189-194
. 	O	194-196

Oncogenic	O	0-9
role	O	10-14
of	O	15-17
microRNAs	O	18-27
in	O	28-30
brain	O	31-36
tumors	O	37-43
.  	O	43-46

Additionally	O	0-12
,	O	12-13
a	O	14-15
control	O	16-23
shRNA	O	24-29
containing	O	30-40
mismatches	O	41-51
also	O	52-56
induced	O	57-64
toxicity	O	65-73
,	O	73-74
although	O	75-83
it	O	84-86
did	O	87-90
not	O	91-94
reduce	O	95-101
HDh	O	102-105
mRNA	O	106-110
expression	O	111-121
. 	O	121-123

Interestingly	O	0-13
,	O	13-14
the	O	15-18
toxic	O	19-24
shRNAs	O	25-31
generated	O	32-41
higher	O	42-48
antisense	O	49-58
RNA	O	59-62
levels	O	63-69
,	O	69-70
compared	O	71-79
with	O	80-84
the	O	85-88
nontoxic	O	89-97
shRNA	O	98-103
. 	O	103-105

These	O	0-5
results	O	6-13
demonstrate	O	14-25
that	O	26-30
the	O	31-34
robust	O	35-41
levels	O	42-48
of	O	49-51
antisense	O	52-61
RNAs	O	62-66
emerging	O	67-75
from	O	76-80
shRNA	O	81-86
expression	O	87-97
systems	O	98-105
can	O	106-109
be	O	110-112
problematic	O	113-124
in	O	125-127
the	O	128-131
mouse	O	132-137
brain	O	138-143
. 	O	143-145

Importantly	O	0-11
,	O	11-12
when	O	13-17
sequences	O	18-27
that	O	28-32
were	O	33-37
toxic	O	38-43
in	O	44-46
the	O	47-50
context	O	51-58
of	O	59-61
shRNAs	O	62-68
were	O	69-73
placed	O	74-80
into	O	81-85
artificial	O	86-96
microRNA	O	97-105
(	O	106-107
miRNA	O	107-112
)	O	112-113
expression	O	114-124
systems	O	125-132
,	O	132-133
molecular	O	134-143
and	O	144-147
neuropathological	O	148-165
readouts	O	166-174
of	O	175-177
neurotoxicity	O	178-191
were	O	192-196
significantly	O	197-210
attenuated	O	211-221
without	O	222-229
compromising	O	230-242
mouse	O	243-248
HDh	O	249-252
silencing	O	253-262
efficacy	O	263-271
. 	O	271-273

Artificial	O	0-10
miRNAs	O	11-17
mitigate	O	18-26
shRNA	O	27-32
-	O	32-33
mediated	O	33-41
toxicity	O	42-50
in	O	51-53
the	O	54-57
brain	O	58-63
:	O	63-64
implications	O	65-77
for	O	78-81
the	O	82-85
therapeutic	O	86-97
development	O	98-109
of	O	110-112
RNAi	O	113-117
.  	O	117-120

Huntington	O	0-10
'	O	10-11
s	O	11-12
disease	O	13-20
(	O	21-22
HD	O	22-24
)	O	24-25
is	O	26-28
a	O	29-30
fatal	O	31-36
,	O	36-37
dominant	O	38-46
neurodegenerative	O	47-64
disease	O	65-72
caused	O	73-79
by	O	80-82
a	O	83-84
polyglutamine	O	85-98
repeat	O	99-105
expansion	O	106-115
in	O	116-118
exon	O	119-123
1	O	124-125
of	O	126-128
the	O	129-132
HD	O	133-135
gene	O	136-140
,	O	140-141
which	O	142-147
encodes	O	148-155
the	O	156-159
huntingtin	O	160-170
protein	O	171-178
. 	O	178-180

We	O	0-2
and	O	3-6
others	O	7-13
have	O	14-18
shown	O	19-24
that	O	25-29
RNAi	O	30-34
is	O	35-37
a	O	38-39
candidate	O	40-49
therapy	O	50-57
for	O	58-61
HD	O	62-64
because	O	65-72
expression	O	73-83
of	O	84-86
inhibitory	O	87-97
RNAs	O	98-102
targeting	O	103-112
mutant	O	113-119
human	O	120-125
HD	O	126-128
transgenes	O	129-139
improved	O	140-148
neuropathology	O	149-163
and	O	164-167
behavioral	O	168-178
deficits	O	179-187
in	O	188-190
HD	O	191-193
mouse	O	194-199
models	O	200-206
. 	O	206-208

Here	O	0-4
,	O	4-5
we	O	6-8
developed	O	9-18
shRNAs	O	19-25
targeting	O	26-35
conserved	O	36-45
sequences	O	46-55
in	O	56-58
human	O	59-64
HD	O	65-67
and	O	68-71
mouse	O	72-77
HD	O	78-80
homolog	O	81-88
(	O	89-90
HDh	O	90-93
)	O	93-94
mRNAs	O	95-100
to	O	101-103
initiate	O	104-112
preclinical	O	113-124
testing	O	125-132
in	O	133-135
a	O	136-137
knockin	O	138-145
mouse	O	146-151
model	O	152-157
of	O	158-160
HD	O	161-163
. 	O	163-165

We	O	0-2
screened	O	3-11
35	O	12-14
shRNAs	O	15-21
in	O	22-24
vitro	O	25-30
and	O	31-34
subsequently	O	35-47
narrowed	O	48-56
our	O	57-60
focus	O	61-66
to	O	67-69
three	O	70-75
candidates	O	76-86
for	O	87-90
in	O	91-93
vivo	O	94-98
testing	O	99-106
. 	O	106-108

Unexpectedly	O	0-12
,	O	12-13
two	O	14-17
active	O	18-24
shRNAs	O	25-31
induced	O	32-39
significant	O	40-51
neurotoxicity	O	52-65
in	O	66-68
mouse	O	69-74
striatum	O	75-83
,	O	83-84
although	O	85-93
HDh	O	94-97
mRNA	O	98-102
expression	O	103-113
was	O	114-117
reduced	O	118-125
to	O	126-128
similar	O	129-136
levels	O	137-143
by	O	144-146
all	O	147-150
three	O	151-156
. 	O	156-158

Thus	O	0-4
,	O	4-5
miRNA	O	6-11
-	O	11-12
based	O	12-17
approaches	O	18-28
may	O	29-32
provide	O	33-40
more	O	41-45
appropriate	O	46-57
biological	O	58-68
tools	O	69-74
for	O	75-78
expressing	O	79-89
inhibitory	O	90-100
RNAs	O	101-105
in	O	106-108
the	O	109-112
brain	O	113-118
,	O	118-119
the	O	120-123
implications	O	124-136
of	O	137-139
which	O	140-145
are	O	146-149
crucial	O	150-157
to	O	158-160
the	O	161-164
development	O	165-176
of	O	177-179
RNAi	O	180-184
for	O	185-188
both	O	189-193
basic	O	194-199
biological	O	200-210
and	O	211-214
therapeutic	O	215-226
applications	O	227-239
.   	O	239-243

These	O	0-5
results	O	6-13
are	O	14-17
the	O	18-21
first	O	22-27
to	O	28-30
demonstrate	O	31-42
that	O	43-47
levels	O	48-54
of	O	55-57
human	O	58-63
APP	O	64-67
can	O	68-71
be	O	72-74
regulated	O	75-84
by	O	85-87
miRNAs	O	88-94
.   	O	94-98

Over	O	0-4
-	O	4-5
expression	O	5-15
of	O	16-18
these	O	19-24
miRNAs	O	25-31
,	O	31-32
but	O	33-36
not	O	37-40
control	O	41-48
miRNAs	O	49-55
,	O	55-56
results	O	57-64
in	O	65-67
translational	O	68-81
repression	O	82-92
of	O	93-95
APP	O	96-99
mRNA	O	100-104
and	O	105-108
significantly	O	109-122
reduces	O	123-130
APP	O	131-134
protein	O	135-142
levels	O	143-149
. 	O	149-151

Here	O	0-4
we	O	5-7
test	O	8-12
the	O	13-16
hypothesis	O	17-27
that	O	28-32
APP	O	33-36
protein	O	37-44
levels	O	45-51
can	O	52-55
be	O	56-58
regulated	O	59-68
by	O	69-71
miRNAs	O	72-78
,	O	78-79
evolutionarily	O	80-94
conserved	O	95-104
small	O	105-110
noncoding	O	111-120
RNA	O	121-124
molecules	O	125-134
that	O	135-139
play	O	140-144
an	O	145-147
important	O	148-157
role	O	158-162
in	O	163-165
regulating	O	166-176
gene	O	177-181
expression	O	182-192
. 	O	192-194

Utilizing	O	0-9
human	O	10-15
cell	O	16-20
lines	O	21-26
,	O	26-27
we	O	28-30
demonstrate	O	31-42
that	O	43-47
miRNAs	O	48-54
hsa	B	55-58
-	I	58-59
mir	I	59-62
-	I	62-63
106a	I	63-67
and	O	68-71
hsa	B	72-75
-	I	75-76
mir	I	76-79
-	I	79-80
520c	I	80-84
bind	O	85-89
to	O	90-92
their	O	93-98
predicted	O	99-108
target	O	109-115
sequences	O	116-125
in	O	126-128
the	O	129-132
APP	O	133-136
3	O	137-138
'	O	138-139
UTR	O	139-142
and	O	143-146
negatively	O	147-157
regulate	O	158-166
reporter	O	167-175
gene	O	176-180
expression	O	181-191
. 	O	191-193

ABSTRACT	O	0-8
:	O	8-9
A	O	10-11
number	O	12-18
of	O	19-21
studies	O	22-29
have	O	30-34
shown	O	35-40
that	O	41-45
increased	O	46-55
APP	O	56-59
levels	O	60-66
,	O	66-67
resulting	O	68-77
from	O	78-82
either	O	83-89
a	O	90-91
genomic	O	92-99
locus	O	100-105
duplication	O	106-117
or	O	118-120
alteration	O	121-131
in	O	132-134
APP	O	135-138
regulatory	O	139-149
sequences	O	150-159
,	O	159-160
can	O	161-164
lead	O	165-169
to	O	170-172
development	O	173-184
of	O	185-187
early	O	188-193
-	O	193-194
onset	O	194-199
dementias	O	200-209
,	O	209-210
including	O	211-220
Alzheimer	O	221-230
'	O	230-231
s	O	231-232
disease	O	233-240
(	O	241-242
AD	O	242-244
)	O	244-245
. 	O	245-247

Therefore	O	0-9
,	O	9-10
understanding	O	11-24
how	O	25-28
APP	O	29-32
levels	O	33-39
are	O	40-43
regulated	O	44-53
could	O	54-59
provide	O	60-67
valuable	O	68-76
insight	O	77-84
into	O	85-89
the	O	90-93
genetic	O	94-101
basis	O	102-107
of	O	108-110
AD	O	111-113
and	O	114-117
illuminate	O	118-128
novel	O	129-134
therapeutic	O	135-146
avenues	O	147-154
for	O	155-158
AD	O	159-161
. 	O	161-163

MicroRNAs	O	0-9
can	O	10-13
regulate	O	14-22
human	O	23-28
APP	O	29-32
levels	O	33-39
.  	O	39-42

Predictive	O	0-10
miRNAs	O	11-17
could	O	18-23
be	O	24-26
potentially	O	27-38
useful	O	39-45
diagnostic	O	46-56
markers	O	57-64
,	O	64-65
improving	O	66-75
the	O	76-79
classification	O	80-94
of	O	95-97
pituitary	O	98-107
adenomas	O	108-116
.   	O	116-120

Several	O	0-7
of	O	8-10
the	O	11-14
identified	O	15-25
miRNAs	O	26-32
are	O	33-36
involved	O	37-45
in	O	46-48
cell	O	49-53
proliferation	O	54-67
and	O	68-71
apoptosis	O	72-81
,	O	81-82
suggesting	O	83-93
that	O	94-98
their	O	99-104
deregulated	O	105-116
expression	O	117-127
may	O	128-131
be	O	132-134
involved	O	135-143
in	O	144-146
pituitary	O	147-156
tumorigenesis	O	157-170
. 	O	170-172

Identification	O	0-14
of	O	15-17
differentially	O	18-32
expressed	O	33-42
microRNAs	O	43-52
by	O	53-55
microarray	O	56-66
:	O	66-67
a	O	68-69
possible	O	70-78
role	O	79-83
for	O	84-87
microRNA	O	88-96
genes	O	97-102
in	O	103-105
pituitary	O	106-115
adenomas	O	116-124
.  	O	124-127

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
non	O	29-32
-	O	32-33
coding	O	33-39
RNAs	O	40-44
that	O	45-49
control	O	50-57
gene	O	58-62
expression	O	63-73
by	O	74-76
targeting	O	77-86
mRNA	O	87-91
. 	O	91-93

It	O	0-2
has	O	3-6
been	O	7-11
demonstrated	O	12-24
that	O	25-29
miRNA	O	30-35
expression	O	36-46
is	O	47-49
altered	O	50-57
in	O	58-60
many	O	61-65
human	O	66-71
cancers	O	72-79
,	O	79-80
suggesting	O	81-91
that	O	92-96
they	O	97-101
may	O	102-105
play	O	106-110
a	O	111-112
role	O	113-117
in	O	118-120
human	O	121-126
neoplasia	O	127-136
. 	O	136-138

To	O	0-2
determine	O	3-12
whether	O	13-20
miRNA	O	21-26
expression	O	27-37
is	O	38-40
altered	O	41-48
in	O	49-51
pituitary	O	52-61
adenomas	O	62-70
,	O	70-71
we	O	72-74
analyzed	O	75-83
the	O	84-87
entire	O	88-94
miRNAome	O	95-103
in	O	104-106
32	O	107-109
pituitary	O	110-119
adenomas	O	120-128
and	O	129-132
in	O	133-135
6	O	136-137
normal	O	138-144
pituitary	O	145-154
samples	O	155-162
by	O	163-165
microarray	O	166-176
and	O	177-180
by	O	181-183
Real	O	184-188
-	O	188-189
Time	O	189-193
PCR	O	194-197
. 	O	197-199

Here	O	0-4
,	O	4-5
we	O	6-8
show	O	9-13
that	O	14-18
30	O	19-21
miRNAs	O	22-28
are	O	29-32
differentially	O	33-47
expressed	O	48-57
between	O	58-65
normal	O	66-72
pituitary	O	73-82
and	O	83-86
pituitary	O	87-96
adenomas	O	97-105
. 	O	105-107

Moreover	O	0-8
,	O	8-9
24	O	10-12
miRNAs	O	13-19
were	O	20-24
identified	O	25-35
as	O	36-38
a	O	39-40
predictive	O	41-51
signature	O	52-61
of	O	62-64
pituitary	O	65-74
adenoma	O	75-82
and	O	83-86
29	O	87-89
miRNAs	O	90-96
were	O	97-101
able	O	102-106
to	O	107-109
predict	O	110-117
pituitary	O	118-127
adenoma	O	128-135
histotype	O	136-145
. 	O	145-147

miRNA	O	0-5
expression	O	6-16
could	O	17-22
differentiate	O	23-36
micro	O	37-42
-	O	42-43
from	O	44-48
macro	O	49-54
-	O	54-55
adenomas	O	55-63
and	O	64-67
treated	O	68-75
from	O	76-80
non	O	81-84
-	O	84-85
treated	O	85-92
patient	O	93-100
samples	O	101-108
. 	O	108-110

Comparison	O	0-10
of	O	11-13
mouse	O	14-19
cerebellar	O	20-30
development	O	31-42
and	O	43-46
medulloblastoma	O	47-62
demonstrates	O	63-75
a	O	76-77
shared	O	78-84
miRNA	O	85-90
-	O	90-91
mRNA	O	91-95
co	O	96-98
-	O	98-99
expression	O	99-109
program	O	110-117
for	O	118-121
brain	O	122-127
-	O	127-128
specific	O	128-136
neurologic	O	137-147
processes	O	148-157
such	O	158-162
as	O	163-165
synaptic	O	166-174
transmission	O	175-187
and	O	188-191
exocytosis	O	192-202
,	O	202-203
in	O	204-206
which	O	207-212
miRNA	O	213-218
target	O	219-225
expression	O	226-236
increases	O	237-246
with	O	247-251
the	O	252-255
accumulation	O	256-268
of	O	269-271
multiple	O	272-280
miRNAs	O	281-287
in	O	288-290
developing	O	291-301
cerebellum	O	302-312
and	O	313-316
decreases	O	317-326
with	O	327-331
the	O	332-335
loss	O	336-340
of	O	341-343
these	O	344-349
miRNAs	O	350-356
in	O	357-359
brain	O	360-365
tumors	O	366-372
. 	O	372-374

These	O	0-5
findings	O	6-14
demonstrate	O	15-26
the	O	27-30
context	O	31-38
-	O	38-39
dependence	O	39-49
of	O	50-52
miRNA	O	53-58
-	O	58-59
mRNA	O	59-63
co	O	64-66
-	O	66-67
expression	O	67-77
.   	O	77-81

Although	O	0-8
miRNAs	O	9-15
in	O	16-18
general	O	19-26
suppress	O	27-35
target	O	36-42
mRNA	O	43-47
messages	O	48-56
,	O	56-57
many	O	58-62
predicted	O	63-72
miRNA	O	73-78
targets	O	79-86
demonstrate	O	87-98
a	O	99-100
significantly	O	101-114
higher	O	115-121
level	O	122-127
of	O	128-130
co	O	131-133
-	O	133-134
expression	O	134-144
than	O	145-149
non	O	150-153
-	O	153-154
target	O	154-160
genes	O	161-166
in	O	167-169
developing	O	170-180
cerebellum	O	181-191
. 	O	191-193

This	O	0-4
phenomenon	O	5-15
is	O	16-18
tissue	O	19-25
specific	O	26-34
since	O	35-40
it	O	41-43
is	O	44-46
not	O	47-50
observed	O	51-59
in	O	60-62
developing	O	63-73
lungs	O	74-79
. 	O	79-81

Towards	O	0-7
that	O	8-12
goal	O	13-17
,	O	17-18
we	O	19-21
examined	O	22-30
miRNA	O	31-36
-	O	36-37
mRNA	O	37-41
interactions	O	42-54
by	O	55-57
measuring	O	58-67
miRNA	O	68-73
and	O	74-77
mRNA	O	78-82
in	O	83-85
the	O	86-89
same	O	90-94
tissue	O	95-101
during	O	102-108
development	O	109-120
and	O	121-124
also	O	125-129
in	O	130-132
malignant	O	133-142
conditions	O	143-153
. 	O	153-155

We	O	0-2
identified	O	3-13
significant	O	14-25
miRNA	O	26-31
-	O	31-32
mediated	O	32-40
biological	O	41-51
process	O	52-59
categories	O	60-70
in	O	71-73
developing	O	74-84
mouse	O	85-90
cerebellum	O	91-101
and	O	102-105
lung	O	106-110
using	O	111-116
non	O	117-120
-	O	120-121
targeted	O	121-129
mRNA	O	130-134
expression	O	135-145
as	O	146-148
the	O	149-152
negative	O	153-161
control	O	162-169
. 	O	169-171

Tissue	O	0-6
and	O	7-10
process	O	11-18
specific	O	19-27
microRNA	O	28-36
-	O	36-37
mRNA	O	37-41
co	O	42-44
-	O	44-45
expression	O	45-55
in	O	56-58
mammalian	O	59-68
development	O	69-80
and	O	81-84
malignancy	O	85-95
.  	O	95-98

An	O	0-2
association	O	3-14
between	O	15-22
enrichment	O	23-33
and	O	34-37
depletion	O	38-47
of	O	48-50
microRNA	O	51-59
(	O	60-61
miRNA	O	61-66
)	O	66-67
binding	O	68-75
sites	O	76-81
,	O	81-82
3	O	83-84
'	O	84-85
UTR	O	86-89
length	O	90-96
,	O	96-97
and	O	98-101
mRNA	O	102-106
expression	O	107-117
has	O	118-121
been	O	122-126
demonstrated	O	127-139
in	O	140-142
various	O	143-150
developing	O	151-161
tissues	O	162-169
and	O	170-173
tissues	O	174-181
from	O	182-186
different	O	187-196
mature	O	197-203
organs	O	204-210
;	O	210-211
but	O	212-215
functional	O	216-226
,	O	226-227
context	O	228-235
-	O	235-236
dependent	O	236-245
miRNA	O	246-251
regulations	O	252-263
have	O	264-268
yet	O	269-272
to	O	273-275
be	O	276-278
elucidated	O	279-289
. 	O	289-291

The	O	0-3
transcription	O	4-17
factor	O	18-24
REST	O	25-29
silences	O	30-38
neuronal	O	39-47
gene	O	48-52
expression	O	53-63
in	O	64-66
non	O	67-70
-	O	70-71
neuronal	O	71-79
cells	O	80-85
. 	O	85-87

The	O	0-3
bifunctional	O	4-16
microRNA	O	17-25
miR	B	26-29
-	I	29-30
9	I	30-31
/	O	31-32
miR	B	32-35
-	I	35-36
9	I	36-37
*	O	37-38
regulates	O	39-48
REST	O	49-53
and	O	54-57
CoREST	O	58-64
and	O	65-68
is	O	69-71
downregulated	O	72-85
in	O	86-88
Huntington	O	89-99
'	O	99-100
s	O	100-101
disease	O	102-109
.  	O	109-112

Polyglutamine	O	0-13
expansions	O	14-24
in	O	25-27
huntingtin	O	28-38
,	O	38-39
which	O	40-45
causes	O	46-52
Huntington	O	53-63
'	O	63-64
s	O	64-65
disease	O	66-73
(	O	74-75
HD	O	75-77
)	O	77-78
,	O	78-79
abrogates	O	80-89
REST	O	90-94
-	O	94-95
huntingtin	O	95-105
binding	O	106-113
. 	O	113-115

In	O	0-2
neurons	O	3-10
,	O	10-11
the	O	12-15
protein	O	16-23
is	O	24-26
sequestered	O	27-38
in	O	39-41
the	O	42-45
cytoplasm	O	46-55
in	O	56-58
part	O	59-63
through	O	64-71
binding	O	72-79
to	O	80-82
huntingtin	O	83-93
. 	O	93-95

In	O	0-2
this	O	3-7
work	O	8-12
,	O	12-13
we	O	14-16
found	O	17-22
that	O	23-27
levels	O	28-34
of	O	35-37
several	O	38-45
microRNAs	O	46-55
(	O	56-57
miRNAs	O	57-63
)	O	63-64
with	O	65-69
upstream	O	70-78
RE1	O	79-82
sites	O	83-88
are	O	89-92
decreased	O	93-102
in	O	103-105
HD	O	106-108
patient	O	109-116
cortices	O	117-125
relative	O	126-134
to	O	135-137
healthy	O	138-145
controls	O	146-154
. 	O	154-156

Consequently	O	0-12
,	O	12-13
REST	O	14-18
translocates	O	19-31
to	O	32-34
the	O	35-38
nucleus	O	39-46
,	O	46-47
occupies	O	48-56
RE1	O	57-60
repressor	O	61-70
sequences	O	71-80
and	O	81-84
decreases	O	85-94
neuronal	O	95-103
gene	O	104-108
expression	O	109-119
. 	O	119-121

Interestingly	O	0-13
,	O	13-14
one	O	15-18
of	O	19-21
these	O	22-27
,	O	27-28
the	O	29-32
bifunctional	O	33-45
brain	O	46-51
enriched	O	52-60
miR	B	61-64
-	I	64-65
9	I	65-66
/	O	66-67
miR	B	67-70
-	I	70-71
9	I	71-72
*	O	72-73
,	O	73-74
targets	O	75-82
two	O	83-86
components	O	87-97
of	O	98-100
the	O	101-104
REST	O	105-109
complex	O	110-117
:	O	117-118
miR	B	119-122
-	I	122-123
9	I	123-124
targets	O	125-132
REST	O	133-137
and	O	138-141
miR	B	142-145
-	I	145-146
9	I	146-147
*	O	147-148
targets	O	149-156
CoREST	O	157-163
. 	O	163-165

These	O	0-5
data	O	6-10
provide	O	11-18
evidence	O	19-27
for	O	28-31
a	O	32-33
double	O	34-40
negative	O	41-49
feedback	O	50-58
loop	O	59-63
between	O	64-71
the	O	72-75
REST	O	76-80
silencing	O	81-90
complex	O	91-98
and	O	99-102
the	O	103-106
miRNAs	O	107-113
it	O	114-116
regulates	O	117-126
.   	O	126-130

MiRNAs	O	0-6
may	O	7-10
be	O	11-13
a	O	14-15
new	O	16-19
therapeutic	O	20-31
target	O	32-38
for	O	39-42
proliferative	O	43-56
vascular	O	57-65
diseases	O	66-74
such	O	75-79
as	O	80-82
atherosclerosis	O	83-98
,	O	98-99
postangioplasty	O	100-115
restenosis	O	116-126
,	O	126-127
transplantation	O	128-143
arteriopathy	O	144-156
,	O	156-157
and	O	158-161
stroke	O	162-168
.   	O	168-172

The	O	0-3
results	O	4-11
suggest	O	12-19
that	O	20-24
miRNAs	O	25-31
are	O	32-35
novel	O	36-41
regulatory	O	42-52
RNAs	O	53-57
for	O	58-61
neointimal	O	62-72
lesion	O	73-79
formation	O	80-89
. 	O	89-91

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
a	O	23-24
recently	O	25-33
discovered	O	34-44
class	O	45-50
of	O	51-53
endogenous	O	54-64
,	O	64-65
small	O	66-71
,	O	71-72
noncoding	O	73-82
RNAs	O	83-87
that	O	88-92
regulate	O	93-101
about	O	102-107
30	O	108-110
%	O	110-111
of	O	112-114
the	O	115-118
encoding	O	119-127
genes	O	128-133
of	O	134-136
the	O	137-140
human	O	141-146
genome	O	147-153
. 	O	153-155

MicroRNA	O	0-8
expression	O	9-19
signature	O	20-29
and	O	30-33
antisense	O	34-43
-	O	43-44
mediated	O	44-52
depletion	O	53-62
reveal	O	63-69
an	O	70-72
essential	O	73-82
role	O	83-87
of	O	88-90
MicroRNA	O	91-99
in	O	100-102
vascular	O	103-111
neointimal	O	112-122
lesion	O	123-129
formation	O	130-139
.  	O	139-142

Western	O	0-7
blot	O	8-12
analysis	O	13-21
demonstrated	O	22-34
that	O	35-39
PTEN	O	40-44
and	O	45-48
Bcl	O	49-52
-	O	52-53
2	O	53-54
were	O	55-59
involved	O	60-68
in	O	69-71
miR	B	72-75
-	I	75-76
21	I	76-78
-	O	78-79
mediated	O	79-87
cellular	O	88-96
effects	O	97-104
. 	O	104-106

MiR	B	0-3
-	I	3-4
21	I	4-6
-	O	6-7
mediated	O	7-15
cellular	O	16-24
effects	O	25-32
were	O	33-37
further	O	38-45
confirmed	O	46-55
in	O	56-58
vivo	O	59-63
in	O	64-66
balloon	O	67-74
-	O	74-75
injured	O	75-82
rat	O	83-86
carotid	O	87-94
arteries	O	95-103
. 	O	103-105

Depletion	O	0-9
of	O	10-12
miR	B	13-16
-	I	16-17
21	I	17-19
resulted	O	20-28
in	O	29-31
decreased	O	32-41
cell	O	42-46
proliferation	O	47-60
and	O	61-64
increased	O	65-74
cell	O	75-79
apoptosis	O	80-89
in	O	90-92
a	O	93-94
dose	O	95-99
-	O	99-100
dependent	O	100-109
manner	O	110-116
. 	O	116-118

In	O	0-2
vitro	O	3-8
,	O	8-9
the	O	10-13
expression	O	14-24
level	O	25-30
of	O	31-33
miR	B	34-37
-	I	37-38
21	I	38-40
in	O	41-43
dedifferentiated	O	44-60
vascular	O	61-69
smooth	O	70-76
muscle	O	77-83
cells	O	84-89
was	O	90-93
significantly	O	94-107
higher	O	108-114
than	O	115-119
that	O	120-124
in	O	125-127
fresh	O	128-133
isolated	O	134-142
differentiated	O	143-157
cells	O	158-163
. 	O	163-165

Modulating	O	0-10
an	O	11-13
aberrantly	O	14-24
overexpressed	O	25-38
miRNA	O	39-44
,	O	44-45
miR	B	46-49
-	I	49-50
21	I	50-52
,	O	52-53
via	O	54-57
antisense	O	58-67
-	O	67-68
mediated	O	68-76
depletion	O	77-86
(	O	87-88
knock	O	88-93
-	O	93-94
down	O	94-98
)	O	98-99
had	O	100-103
a	O	104-105
significant	O	106-117
negative	O	118-126
effect	O	127-133
on	O	134-136
neointimal	O	137-147
lesion	O	148-154
formation	O	155-164
. 	O	164-166

The	O	0-3
aberrantly	O	4-14
expressed	O	15-24
miRNAs	O	25-31
were	O	32-36
further	O	37-44
confirmed	O	45-54
by	O	55-57
Northern	O	58-66
blot	O	67-71
and	O	72-75
quantitative	O	76-88
real	O	89-93
-	O	93-94
time	O	94-98
polymerase	O	99-109
chain	O	110-115
reaction	O	116-124
. 	O	124-126

Using	O	0-5
microarray	O	6-16
analysis	O	17-25
,	O	25-26
we	O	27-29
demonstrated	O	30-42
for	O	43-46
the	O	47-50
first	O	51-56
time	O	57-61
that	O	62-66
miRNAs	O	67-73
are	O	74-77
aberrantly	O	78-88
expressed	O	89-98
in	O	99-101
the	O	102-105
vascular	O	106-114
walls	O	115-120
after	O	121-126
balloon	O	127-134
injury	O	135-141
. 	O	141-143

However	O	0-7
,	O	7-8
the	O	9-12
role	O	13-17
of	O	18-20
miRNAs	O	21-27
in	O	28-30
vascular	O	31-39
disease	O	40-47
is	O	48-50
currently	O	51-60
completely	O	61-71
unknown	O	72-79
. 	O	79-81

Point	O	0-5
mutations	O	6-15
in	O	16-18
exon	O	19-23
1	O	24-25
of	O	26-28
the	O	29-32
NR4A2	O	33-38
gene	O	39-43
are	O	44-47
not	O	48-51
a	O	52-53
major	O	54-59
cause	O	60-65
of	O	66-68
familial	O	69-77
Parkinson	O	78-87
'	O	87-88
s	O	88-89
disease	O	90-97
.     	O	97-103

In	O	0-2
a	O	3-4
pilot	O	5-10
study	O	11-16
we	O	17-19
could	O	20-25
show	O	26-30
that	O	31-35
hsa	B	36-39
-	I	39-40
miR	I	40-43
-	I	43-44
342	I	44-47
-	I	47-48
3p	I	48-50
was	O	51-54
also	O	55-59
upregulated	O	60-71
in	O	72-74
brain	O	75-80
samples	O	81-88
of	O	89-91
human	O	92-97
type	O	98-102
1	O	103-104
and	O	105-108
type	O	109-113
2	O	114-115
sporadic	O	116-124
CJD	O	125-128
. 	O	128-130

Our	O	0-3
study	O	4-9
revealed	O	10-18
significant	O	19-30
upregulation	O	31-43
of	O	44-46
hsa	B	47-50
-	I	50-51
miR	I	51-54
-	I	54-55
342	I	55-58
-	I	58-59
3p	I	59-61
and	O	62-65
hsa	B	66-69
-	I	69-70
miR	I	70-73
-	I	73-74
494	I	74-77
in	O	78-80
the	O	81-84
brains	O	85-91
of	O	92-94
BSE	O	95-98
-	O	98-99
infected	O	99-107
macaques	O	108-116
compared	O	117-125
to	O	126-128
non	O	129-132
-	O	132-133
infected	O	133-141
animals	O	142-149
. 	O	149-151

Shock	O	0-5
-	O	5-6
frozen	O	6-12
brain	O	13-18
sections	O	19-27
of	O	28-30
six	O	31-34
BSE	O	35-38
-	O	38-39
infected	O	39-47
and	O	48-51
five	O	52-56
non	O	57-60
-	O	60-61
infected	O	61-69
macaques	O	70-78
were	O	79-83
used	O	84-88
to	O	89-91
validate	O	92-100
regulated	O	101-110
miRNA	O	111-116
candidates	O	117-127
by	O	128-130
two	O	131-134
independent	O	135-146
qRT	O	147-150
-	O	150-151
PCR	O	151-154
-	O	154-155
based	O	155-160
methods	O	161-168
. 	O	168-170

We	O	0-2
have	O	3-7
applied	O	8-15
miRNA	O	16-21
-	O	21-22
microarrays	O	22-33
to	O	34-36
identify	O	37-45
deregulated	O	46-57
miRNA	O	58-63
candidates	O	64-74
in	O	75-77
brains	O	78-84
of	O	85-87
BSE	O	88-91
-	O	91-92
infected	O	92-100
macaques	O	101-109
. 	O	109-111

Therefore	O	0-9
,	O	9-10
we	O	11-13
hypothesized	O	14-26
that	O	27-31
miRNAs	O	32-38
are	O	39-42
also	O	43-47
regulated	O	48-57
in	O	58-60
response	O	61-69
to	O	70-72
human	O	73-78
prion	O	79-84
disease	O	85-92
. 	O	92-94

Among	O	0-5
other	O	6-11
functions	O	12-21
they	O	22-26
contribute	O	27-37
to	O	38-40
neuronal	O	41-49
development	O	50-61
and	O	62-65
survival	O	66-74
. 	O	74-76

Recently	O	0-8
,	O	8-9
the	O	10-13
lack	O	14-18
of	O	19-21
miRNA	O	22-27
processing	O	28-38
has	O	39-42
been	O	43-47
shown	O	48-53
to	O	54-56
promote	O	57-64
neurodegeneration	O	65-82
and	O	83-86
deregulation	O	87-99
of	O	100-102
several	O	103-110
miRNAs	O	111-117
has	O	118-121
been	O	122-126
reported	O	127-135
to	O	136-138
be	O	139-141
associated	O	142-152
with	O	153-157
Scrapie	O	158-165
in	O	166-168
mice	O	169-173
. 	O	173-175

ABSTRACT	O	0-8
:	O	8-9
The	O	10-13
aim	O	14-17
of	O	18-20
our	O	21-24
study	O	25-30
was	O	31-34
to	O	35-37
analyze	O	38-45
the	O	46-49
differential	O	50-62
expression	O	63-73
of	O	74-76
miRNAs	O	77-83
in	O	84-86
the	O	87-90
brains	O	91-97
of	O	98-100
BSE	O	101-104
-	O	104-105
infected	O	105-113
cynomolgus	O	114-124
macaques	O	125-133
as	O	134-136
a	O	137-138
model	O	139-144
for	O	145-148
Creutzfeldt	O	149-160
-	O	160-161
Jakob	O	161-166
disease	O	167-174
(	O	175-176
CJD	O	176-179
)	O	179-180
. 	O	180-182

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNAs	O	39-43
regulating	O	44-54
gene	O	55-59
expression	O	60-70
by	O	71-73
mRNA	O	74-78
targeting	O	79-88
. 	O	88-90

Upregulation	O	0-12
of	O	13-15
miRNA	O	16-21
hsa	B	22-25
-	I	25-26
miR	I	26-29
-	I	29-30
342	I	30-33
-	I	33-34
3p	I	34-36
in	O	37-39
experimental	O	40-52
and	O	53-56
idiopathic	O	57-67
prion	O	68-73
disease	O	74-81
.  	O	81-84

With	O	0-4
respect	O	5-12
to	O	13-15
the	O	16-19
reported	O	20-28
regulation	O	29-39
of	O	40-42
this	O	43-47
miRNA	O	48-53
in	O	54-56
Scrapie	O	57-64
-	O	64-65
infected	O	65-73
mice	O	74-78
,	O	78-79
we	O	80-82
propose	O	83-90
that	O	91-95
upregulation	O	96-108
of	O	109-111
hsa	B	112-115
-	I	115-116
miR	I	116-119
-	I	119-120
342	I	120-123
-	I	123-124
3p	I	124-126
may	O	127-130
be	O	131-133
a	O	134-135
general	O	136-143
phenomenon	O	144-154
in	O	155-157
late	O	158-162
stage	O	163-168
prion	O	169-174
disease	O	175-182
and	O	183-186
might	O	187-192
be	O	193-195
used	O	196-200
as	O	201-203
a	O	204-205
novel	O	206-211
marker	O	212-218
for	O	219-222
animal	O	223-229
and	O	230-233
human	O	234-239
TSEs	O	240-244
.   	O	244-248

Altered	O	0-7
microRNAs	O	8-17
in	O	18-20
STHdh	O	21-26
(	O	26-27
Q111	O	27-31
)	O	31-32
/	O	32-33
Hdh	O	33-36
(	O	36-37
Q111	O	37-41
)	O	41-42
cells	O	43-48
:	O	48-49
miR	B	50-53
-	I	53-54
146a	I	54-58
targets	O	59-66
TBP	O	67-70
.  	O	70-73

We	O	0-2
studied	O	3-10
expression	O	11-21
of	O	22-24
90	O	25-27
miRNAs	O	28-34
in	O	35-37
STHdh	O	38-43
(	O	43-44
Q111	O	44-48
)	O	48-49
/	O	49-50
Hdh	O	50-53
(	O	53-54
Q111	O	54-58
)	O	58-59
cells	O	60-65
,	O	65-66
a	O	67-68
model	O	69-74
for	O	75-78
Huntington	O	79-89
'	O	89-90
s	O	90-91
disease	O	92-99
and	O	100-103
compared	O	104-112
with	O	113-117
that	O	118-122
obtained	O	123-131
in	O	132-134
STHdh	O	135-140
(	O	140-141
Q7	O	141-143
)	O	143-144
/	O	144-145
Hdh	O	145-148
(	O	148-149
Q7	O	149-151
)	O	151-152
cells	O	153-158
. 	O	158-160

Fifteen	O	0-7
miRNAs	O	8-14
were	O	15-19
down	O	20-24
regulated	O	25-34
and	O	35-38
12	O	39-41
miRNAs	O	42-48
were	O	49-53
up	O	54-56
regulated	O	57-66
more	O	67-71
than	O	72-76
2	O	77-78
-	O	78-79
fold	O	79-83
. 	O	83-85

Such	O	0-4
changes	O	5-12
were	O	13-17
statistically	O	18-31
significant	O	32-43
. 	O	43-45

One	O	0-3
hundred	O	4-11
and	O	12-15
forty	O	16-21
-	O	21-22
two	O	22-25
genes	O	26-31
are	O	32-35
experimentally	O	36-50
known	O	51-56
targets	O	57-64
of	O	65-67
these	O	68-73
altered	O	74-81
miRNAs	O	82-88
. 	O	88-90

Using	O	0-5
luciferase	O	6-16
reporter	O	17-25
assays	O	26-32
with	O	33-37
3	O	38-39
'	O	39-40
-	O	40-41
UTRs	O	41-45
of	O	46-48
TBP	O	49-52
,	O	52-53
over	O	54-58
-	O	58-59
expression	O	59-69
and	O	70-73
inhibition	O	74-84
of	O	85-87
miR	B	88-91
-	I	91-92
146a	I	92-96
,	O	96-97
we	O	98-100
showed	O	101-107
that	O	108-112
miR	B	113-116
-	I	116-117
146a	I	117-121
targets	O	122-129
TBP	O	130-133
. 	O	133-135

It	O	0-2
has	O	3-6
been	O	7-11
predicted	O	12-21
that	O	22-26
miR	B	27-30
-	I	30-31
146a	I	31-35
may	O	36-39
target	O	40-46
Tata	O	47-51
Binding	O	52-59
Protein	O	60-67
(	O	68-69
TBP	O	69-72
)	O	72-73
. 	O	73-75

Regulation	O	0-10
of	O	11-13
TBP	O	14-17
by	O	18-20
miR	B	21-24
-	I	24-25
146a	I	25-29
may	O	30-33
contribute	O	34-44
to	O	45-47
HD	O	48-50
pathogenesis	O	51-63
.   	O	63-67

This	O	0-4
is	O	5-7
,	O	7-8
to	O	9-11
our	O	12-15
knowledge	O	16-25
,	O	25-26
the	O	27-30
first	O	31-36
case	O	37-41
of	O	42-44
this	O	45-49
kind	O	50-54
found	O	55-60
in	O	61-63
Argentina	O	64-73
and	O	74-77
is	O	78-80
additional	O	81-91
evidence	O	92-100
that	O	101-105
HAM	O	106-109
/	O	109-110
TSP	O	110-113
solely	O	114-120
related	O	121-128
to	O	129-131
HTLV	O	132-136
-	O	136-137
II	O	137-139
infection	O	140-149
occurs	O	150-156
in	O	157-159
HTLV	O	160-164
-	O	164-165
I	O	165-166
-	O	166-167
negative	O	167-175
subjects	O	176-184
.   	O	184-188

A	O	0-1
case	O	2-6
of	O	7-9
neurological	O	10-22
disease	O	23-30
featuring	O	31-40
human	O	41-46
T	O	47-48
lymphocyte	O	49-59
virus	O	60-65
-	O	65-66
associated	O	66-76
myelopathy	O	77-87
/	O	87-88
tropical	O	88-96
spastic	O	97-104
paraparesis	O	105-116
(	O	117-118
HAM	O	118-121
/	O	121-122
TSP	O	122-125
)	O	125-126
was	O	127-130
diagnosed	O	131-140
by	O	141-143
serological	O	144-155
(	O	156-157
Western	O	157-164
blot	O	165-169
)	O	169-170
and	O	171-174
molecular	O	175-184
(	O	185-186
polymerase	O	186-196
chain	O	197-202
reaction	O	203-211
)	O	211-212
criteria	O	213-221
as	O	222-224
related	O	225-232
to	O	233-235
human	O	236-241
T	O	242-243
lymphocyte	O	244-254
virus	O	255-260
(	O	261-262
HTLV	O	262-266
)	O	266-267
-	O	267-268
II	O	268-270
infection	O	271-280
. 	O	280-282

A	O	0-1
possible	O	2-10
case	O	11-15
of	O	16-18
myelopathy	O	19-29
/	O	29-30
tropical	O	30-38
spastic	O	39-46
paraparesis	O	47-58
in	O	59-61
an	O	62-64
Argentinian	O	65-76
woman	O	77-82
with	O	83-87
human	O	88-93
T	O	94-95
lymphocyte	O	96-106
virus	O	107-112
type	O	113-117
II	O	118-120
.  	O	120-123

Knockdown	O	0-9
of	O	10-12
miR	B	13-16
-	I	16-17
21	I	17-19
in	O	20-22
cultured	O	23-31
glioblastoma	O	32-44
cells	O	45-50
triggers	O	51-59
activation	O	60-70
of	O	71-73
caspases	O	74-82
and	O	83-86
leads	O	87-92
to	O	93-95
increased	O	96-105
apoptotic	O	106-115
cell	O	116-120
death	O	121-126
. 	O	126-128

Our	O	0-3
studies	O	4-11
show	O	12-16
markedly	O	17-25
elevated	O	26-34
miR	B	35-38
-	I	38-39
21	I	39-41
levels	O	42-48
in	O	49-51
human	O	52-57
glioblastoma	O	58-70
tumor	O	71-76
tissues	O	77-84
,	O	84-85
early	O	86-91
-	O	91-92
passage	O	92-99
glioblastoma	O	100-112
cultures	O	113-121
,	O	121-122
and	O	123-126
in	O	127-129
six	O	130-133
established	O	134-145
glioblastoma	O	146-158
cell	O	159-163
lines	O	164-169
(	O	170-171
A172	O	171-175
,	O	175-176
U87	O	177-180
,	O	180-181
U373	O	182-186
,	O	186-187
LN229	O	188-193
,	O	193-194
LN428	O	195-200
,	O	200-201
and	O	202-205
LN308	O	206-211
)	O	211-212
compared	O	213-221
with	O	222-226
nonneoplastic	O	227-240
fetal	O	241-246
and	O	247-250
adult	O	251-256
brain	O	257-262
tissues	O	263-270
and	O	271-274
compared	O	275-283
with	O	284-288
cultured	O	289-297
nonneoplastic	O	298-311
glial	O	312-317
cells	O	318-323
. 	O	323-325

Our	O	0-3
data	O	4-8
suggest	O	9-16
that	O	17-21
aberrantly	O	22-32
expressed	O	33-42
miR	B	43-46
-	I	46-47
21	I	47-49
may	O	50-53
contribute	O	54-64
to	O	65-67
the	O	68-71
malignant	O	72-81
phenotype	O	82-91
by	O	92-94
blocking	O	95-103
expression	O	104-114
of	O	115-117
critical	O	118-126
apoptosis	O	127-136
-	O	136-137
related	O	137-144
genes	O	145-150
.   	O	150-154

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNA	O	39-42
molecules	O	43-52
that	O	53-57
regulate	O	58-66
protein	O	67-74
expression	O	75-85
by	O	86-88
targeting	O	89-98
the	O	99-102
mRNA	O	103-107
of	O	108-110
protein	O	111-118
-	O	118-119
coding	O	119-125
genes	O	126-131
for	O	132-135
either	O	136-142
cleavage	O	143-151
or	O	152-154
repression	O	155-165
of	O	166-168
translation	O	169-180
. 	O	180-182

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
is	O	12-14
an	O	15-17
antiapoptotic	O	18-31
factor	O	32-38
in	O	39-41
human	O	42-47
glioblastoma	O	48-60
cells	O	61-66
.  	O	66-69

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
the	O	18-21
highly	O	22-28
malignant	O	29-38
human	O	39-44
brain	O	45-50
tumor	O	51-56
,	O	56-57
glioblastoma	O	58-70
,	O	70-71
strongly	O	72-80
over	O	81-85
-	O	85-86
expresses	O	86-95
a	O	96-97
specific	O	98-106
miRNA	O	107-112
,	O	112-113
miR	B	114-117
-	I	117-118
21	I	118-120
. 	O	120-122

The	O	0-3
roles	O	4-9
of	O	10-12
miRNAs	O	13-19
in	O	20-22
lineage	O	23-30
determination	O	31-44
and	O	45-48
proliferation	O	49-62
as	O	63-65
well	O	66-70
as	O	71-73
the	O	74-77
location	O	78-86
of	O	87-89
several	O	90-97
miRNA	O	98-103
genes	O	104-109
at	O	110-112
sites	O	113-118
of	O	119-121
translocation	O	122-135
breakpoints	O	136-147
or	O	148-150
deletions	O	151-160
has	O	161-164
led	O	165-168
to	O	169-171
the	O	172-175
speculation	O	176-187
that	O	188-192
miRNAs	O	193-199
could	O	200-205
be	O	206-208
important	O	209-218
factors	O	219-226
in	O	227-229
the	O	230-233
development	O	234-245
or	O	246-248
maintenance	O	249-260
of	O	261-263
the	O	264-267
neoplastic	O	268-278
state	O	279-284
. 	O	284-286

Key	O	0-3
microRNAs	O	4-13
have	O	14-18
been	O	19-23
identified	O	24-34
as	O	35-37
essential	O	38-47
for	O	48-51
a	O	52-53
variety	O	54-61
of	O	62-64
cellular	O	65-73
events	O	74-80
including	O	81-90
cell	O	91-95
lineage	O	96-103
determination	O	104-117
,	O	117-118
proliferation	O	119-132
,	O	132-133
apoptosis	O	134-143
,	O	143-144
DNA	O	145-148
repair	O	149-155
,	O	155-156
and	O	157-160
cytoskeletal	O	161-173
organization	O	174-186
;	O	186-187
most	O	188-192
,	O	192-193
if	O	194-196
not	O	197-200
all	O	201-204
,	O	204-205
acting	O	206-212
to	O	213-215
fine	O	216-220
-	O	220-221
tune	O	221-225
gene	O	226-230
expression	O	231-241
at	O	242-244
the	O	245-248
post	O	249-253
-	O	253-254
transcriptional	O	254-269
level	O	270-275
in	O	276-278
a	O	279-280
host	O	281-285
of	O	286-288
cellular	O	289-297
signaling	O	298-307
networks	O	308-316
. 	O	316-318

Their	O	0-5
discovery	O	6-15
has	O	16-19
evoked	O	20-26
great	O	27-32
excitement	O	33-43
in	O	44-46
biomedical	O	47-57
research	O	58-66
for	O	67-70
their	O	71-76
promise	O	77-84
as	O	85-87
potential	O	88-97
disease	O	98-105
biomarkers	O	106-116
and	O	117-120
therapeutic	O	121-132
targets	O	133-140
. 	O	140-142

MicroRNAs	O	0-9
are	O	10-13
one	O	14-17
of	O	18-20
the	O	21-24
major	O	25-30
noncoding	O	31-40
RNAs	O	41-45
that	O	46-50
function	O	51-59
as	O	60-62
negative	O	63-71
regulators	O	72-82
to	O	83-85
silence	O	86-93
or	O	94-96
suppress	O	97-105
gene	O	106-110
expression	O	111-121
via	O	122-125
translational	O	126-139
inhibition	O	140-150
or	O	151-153
message	O	154-161
degradation	O	162-173
. 	O	173-175

Unlike	O	0-6
the	O	7-10
familial	O	11-19
forms	O	20-25
of	O	26-28
AD	O	29-31
,	O	31-32
the	O	33-36
genetic	O	37-44
and	O	45-48
environmental	O	49-62
risks	O	63-68
factors	O	69-76
identified	O	77-87
for	O	88-91
sporadic	O	92-100
AD	O	101-103
are	O	104-107
extensive	O	108-117
. 	O	117-119

Understanding	O	0-13
complex	O	14-21
diseases	O	22-30
such	O	31-35
as	O	36-38
sporadic	O	39-47
Alzheimer	O	48-57
disease	O	58-65
(	O	66-67
AD	O	67-69
)	O	69-70
has	O	71-74
been	O	75-79
a	O	80-81
major	O	82-87
challenge	O	88-97
. 	O	97-99

MicroRNA	O	0-8
:	O	8-9
Implications	O	10-22
for	O	23-26
Alzheimer	O	27-36
Disease	O	37-44
and	O	45-48
other	O	49-54
Human	O	55-60
CNS	O	61-64
Disorders	O	65-74
.  	O	74-77

Here	O	0-4
,	O	4-5
the	O	6-9
current	O	10-17
understanding	O	18-31
of	O	32-34
the	O	35-38
role	O	39-43
of	O	44-46
miRNAs	O	47-53
in	O	54-56
the	O	57-60
central	O	61-68
nervous	O	69-76
system	O	77-83
is	O	84-86
reviewed	O	87-95
with	O	96-100
emphasis	O	101-109
on	O	110-112
their	O	113-118
impact	O	119-125
on	O	126-128
the	O	129-132
etiopathogenesis	O	133-149
of	O	150-152
sporadic	O	153-161
AD	O	162-164
.   	O	164-168

Dysfunctional	O	0-13
microRNA	O	14-22
-	O	22-23
mediated	O	23-31
regulation	O	32-42
has	O	43-46
been	O	47-51
implicated	O	52-62
in	O	63-65
the	O	66-69
pathogenesis	O	70-82
of	O	83-85
many	O	86-90
disease	O	91-98
states	O	99-105
. 	O	105-107

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
in	O	19-21
neurodegenerative	O	22-39
diseases	O	40-48
.  	O	48-51

Prior	O	0-5
studies	O	6-13
have	O	14-18
shown	O	19-24
that	O	25-29
RNAs	O	30-34
are	O	35-38
pathologically	O	39-53
altered	O	54-61
during	O	62-68
the	O	69-72
inexorable	O	73-83
course	O	84-90
of	O	91-93
some	O	94-98
NDs	O	99-102
. 	O	102-104

Aging	O	0-5
-	O	5-6
related	O	6-13
neurodegenerative	O	14-31
diseases	O	32-40
(	O	41-42
NDs	O	42-45
)	O	45-46
are	O	47-50
the	O	51-54
culmination	O	55-66
of	O	67-69
many	O	70-74
different	O	75-84
genetic	O	85-92
and	O	93-96
environmental	O	97-110
influences	O	111-121
. 	O	121-123

miRNAs	O	0-6
are	O	7-10
brain	O	11-16
-	O	16-17
enriched	O	17-25
,	O	25-26
small	O	27-32
(	O	33-34
approximately	O	35-48
22	O	49-51
nucleotides	O	52-63
)	O	63-64
non	O	65-68
-	O	68-69
coding	O	69-75
RNAs	O	76-80
that	O	81-85
participate	O	86-97
in	O	98-100
mRNA	O	101-105
translational	O	106-119
regulation	O	120-130
. 	O	130-132

Recent	O	0-6
evidence	O	7-15
suggests	O	16-24
that	O	25-29
microRNAs	O	30-39
(	O	40-41
miRNAs	O	41-47
)	O	47-48
may	O	49-52
be	O	53-55
a	O	56-57
contributing	O	58-70
factor	O	71-77
in	O	78-80
neurodegeneration	O	81-98
. 	O	98-100

Research	O	0-8
about	O	9-14
miRNAs	O	15-21
in	O	22-24
the	O	25-28
context	O	29-36
of	O	37-39
neurodegeneration	O	40-57
is	O	58-60
accumulating	O	61-73
rapidly	O	74-81
,	O	81-82
and	O	83-86
the	O	87-90
goal	O	91-95
of	O	96-98
this	O	99-103
review	O	104-110
is	O	111-113
to	O	114-116
provide	O	117-124
perspective	O	125-136
for	O	137-140
these	O	141-146
new	O	147-150
data	O	151-155
that	O	156-160
may	O	161-164
be	O	165-167
helpful	O	168-175
to	O	176-178
specialists	O	179-190
in	O	191-193
either	O	194-200
field	O	201-206
. 	O	206-208

Although	O	0-8
discovered	O	9-19
in	O	20-22
the	O	23-26
framework	O	27-36
of	O	37-39
worm	O	40-44
development	O	45-56
,	O	56-57
miRNAs	O	58-64
are	O	65-68
now	O	69-72
appreciated	O	73-84
to	O	85-87
play	O	88-92
a	O	93-94
dynamic	O	95-102
role	O	103-107
in	O	108-110
many	O	111-115
mammalian	O	116-125
brain	O	126-131
-	O	131-132
related	O	132-139
biochemical	O	140-151
pathways	O	152-160
,	O	160-161
including	O	162-171
neuroplasticity	O	172-187
and	O	188-191
stress	O	192-198
responses	O	199-208
. 	O	208-210

Recently	O	0-8
published	O	9-18
studies	O	19-26
pertaining	O	27-37
to	O	38-40
the	O	41-44
roles	O	45-50
of	O	51-53
miRNAs	O	54-60
in	O	61-63
NDs	O	64-67
-	O	67-68
-	O	68-69
including	O	69-78
Alzheimer	O	79-88
'	O	88-89
s	O	89-90
disease	O	91-98
,	O	98-99
Parkinson	O	100-109
'	O	109-110
s	O	110-111
disease	O	112-119
and	O	120-123
triplet	O	124-131
repeat	O	132-138
disorders	O	139-148
-	O	148-149
are	O	149-152
described	O	153-162
. 	O	162-164

An	O	0-2
overview	O	3-11
is	O	12-14
provided	O	15-23
about	O	24-29
the	O	30-33
normal	O	34-40
functions	O	41-50
for	O	51-54
miRNAs	O	55-61
,	O	61-62
including	O	63-72
some	O	73-77
of	O	78-80
the	O	81-84
newer	O	85-90
concepts	O	91-99
related	O	100-107
to	O	108-110
the	O	111-114
human	O	115-120
brain	O	121-126
. 	O	126-128

Finally	O	0-7
,	O	7-8
a	O	9-10
discussion	O	11-21
is	O	22-24
included	O	25-33
with	O	34-38
theoretical	O	39-50
syntheses	O	51-60
and	O	61-64
possible	O	65-73
future	O	74-80
directions	O	81-91
in	O	92-94
exploring	O	95-104
the	O	105-108
nexus	O	109-114
between	O	115-122
miRNA	O	123-128
and	O	129-132
ND	O	133-135
research	O	136-144
.   	O	144-148

Traumatic	O	0-9
brain	O	10-15
injury	O	16-22
(	O	23-24
TBI	O	24-27
)	O	27-28
initiates	O	29-38
many	O	39-43
different	O	44-53
signaling	O	54-63
cascades	O	64-72
throughout	O	73-83
the	O	84-87
brain	O	88-93
that	O	94-98
impact	O	99-105
both	O	106-110
pathophysiological	O	111-129
and	O	130-133
neuroprotective	O	134-149
processes	O	150-159
. 	O	159-161

Altered	O	0-7
expression	O	8-18
of	O	19-21
miRNA	B	22-27
-	I	27-28
21	I	28-30
and	O	31-34
its	O	35-38
targets	O	39-46
in	O	47-49
the	O	50-53
hippocampus	O	54-65
after	O	66-71
traumatic	O	72-81
brain	O	82-87
injury	O	88-94
.  	O	94-97

In	O	0-2
situ	O	3-7
localization	O	8-20
of	O	21-23
miR	B	24-27
-	I	27-28
21	I	28-30
transcripts	O	31-42
indicates	O	43-52
widespread	O	53-63
expression	O	64-74
in	O	75-77
normal	O	78-84
brain	O	85-90
,	O	90-91
with	O	92-96
a	O	97-98
pronounced	O	99-109
increase	O	110-118
in	O	119-121
expression	O	122-132
after	O	133-138
TBI	O	139-142
evident	O	143-150
throughout	O	151-161
the	O	162-165
cortex	O	166-172
and	O	173-176
hippocampus	O	177-188
,	O	188-189
including	O	190-199
the	O	200-203
dentate	O	204-211
gyrus	O	212-217
and	O	218-221
CA3	O	222-225
cell	O	226-230
layer	O	231-236
. 	O	236-238

We	O	0-2
report	O	3-9
that	O	10-14
miR	B	15-18
-	I	18-19
21	I	19-21
expression	O	22-32
is	O	33-35
significantly	O	36-49
up	O	50-52
-	O	52-53
regulated	O	53-62
in	O	63-65
the	O	66-69
hippocampus	O	70-81
after	O	82-87
rodent	O	88-94
TBI	O	95-98
,	O	98-99
with	O	100-104
expression	O	105-115
levels	O	116-122
peaking	O	123-130
by	O	131-133
3	O	134-135
days	O	136-140
postinjury	O	141-151
and	O	152-155
returning	O	156-165
to	O	166-168
near	O	169-173
sham	O	174-178
levels	O	179-185
by	O	186-188
15	O	189-191
days	O	192-196
postinjury	O	197-207
. 	O	207-209

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
an	O	23-25
important	O	26-35
class	O	36-41
of	O	42-44
noncoding	O	45-54
regulatory	O	55-65
RNAs	O	66-70
providing	O	71-80
an	O	81-83
epigenetic	O	84-94
mechanism	O	95-104
for	O	105-108
the	O	109-112
regulation	O	113-123
of	O	124-126
protein	O	127-134
expression	O	135-145
levels	O	146-152
of	O	153-155
target	O	156-162
genes	O	163-168
. 	O	168-170

Cellular	O	0-8
mechanisms	O	9-19
that	O	20-24
can	O	25-28
modulate	O	29-37
these	O	38-43
processes	O	44-53
may	O	54-57
play	O	58-62
an	O	63-65
important	O	66-75
role	O	76-80
in	O	81-83
determining	O	84-95
the	O	96-99
nature	O	100-106
and	O	107-110
extent	O	111-117
of	O	118-120
the	O	121-124
damage	O	125-131
suffered	O	132-140
after	O	141-146
TBI	O	147-150
and	O	151-154
therefore	O	155-164
influence	O	165-174
overall	O	175-182
outcome	O	183-190
after	O	191-196
injury	O	197-203
. 	O	203-205

These	O	0-5
results	O	6-13
suggest	O	14-21
that	O	22-26
increased	O	27-36
miR	B	37-40
-	I	40-41
21	I	41-43
expression	O	44-54
in	O	55-57
the	O	58-61
hippocampus	O	62-73
may	O	74-77
influence	O	78-87
multiple	O	88-96
components	O	97-107
of	O	108-110
TBI	O	111-114
pathophysiology	O	115-130
.   	O	130-134

Analysis	O	0-8
of	O	9-11
these	O	12-17
genes	O	18-23
'	O	23-24
annotated	O	25-34
Gene	O	35-39
Ontology	O	40-48
molecular	O	49-58
function	O	59-67
and	O	68-71
biological	O	72-82
process	O	83-90
terms	O	91-96
revealed	O	97-105
an	O	106-108
overrepresentation	O	109-127
of	O	128-130
genes	O	131-136
involved	O	137-145
in	O	146-148
enzyme	O	149-155
-	O	155-156
linked	O	156-162
receptor	O	163-171
signaling	O	172-181
,	O	181-182
transcriptional	O	183-198
regulation	O	199-209
,	O	209-210
and	O	211-214
developmental	O	215-228
processes	O	229-238
. 	O	238-240

We	O	0-2
used	O	3-7
a	O	8-9
combination	O	10-21
of	O	22-24
the	O	25-28
miRanda	O	29-36
,	O	36-37
TargetScan	O	38-48
,	O	48-49
and	O	50-53
PicTar	O	54-60
prediction	O	61-71
algorithms	O	72-82
to	O	83-85
identify	O	86-94
99	O	95-97
potential	O	98-107
target	O	108-114
genes	O	115-120
that	O	121-125
possess	O	126-133
miR	B	134-137
-	I	137-138
21	I	138-140
binding	O	141-148
sites	O	149-154
within	O	155-161
their	O	162-167
3	O	168-169
'	O	169-170
untranslated	O	171-183
regions	O	184-191
. 	O	191-193

MiRNA	O	0-5
expression	O	6-16
profiling	O	17-26
of	O	27-29
human	O	30-35
tumors	O	36-42
has	O	43-46
led	O	47-50
to	O	51-53
the	O	54-57
identification	O	58-72
of	O	73-75
signatures	O	76-86
correlated	O	87-97
with	O	98-102
the	O	103-106
tumor	O	107-112
diagnosis	O	113-122
,	O	122-123
staging	O	124-131
,	O	131-132
progression	O	133-144
,	O	144-145
prognosis	O	146-155
and	O	156-159
response	O	160-168
to	O	169-171
treatment	O	172-181
. 	O	181-183

MiRNA	O	0-5
fingerprinting	O	6-20
can	O	21-24
therefore	O	25-34
be	O	35-37
added	O	38-43
to	O	44-46
the	O	47-50
diagnostic	O	51-61
and	O	62-65
prognostic	O	66-76
tools	O	77-82
used	O	83-87
by	O	88-90
medical	O	91-98
oncologists	O	99-110
. 	O	110-112

Furthermore	O	0-11
,	O	11-12
new	O	13-16
therapeutic	O	17-28
strategies	O	29-39
involving	O	40-49
miRNA	O	50-55
silencing	O	56-65
or	O	66-68
miRNA	O	69-74
mimics	O	75-81
could	O	82-87
be	O	88-90
proposed	O	91-99
based	O	100-105
on	O	106-108
the	O	109-112
roles	O	113-118
of	O	119-121
these	O	122-127
small	O	128-133
non	O	134-137
-	O	137-138
coding	O	138-144
RNAs	O	145-149
as	O	150-152
oncogenes	O	153-162
and	O	163-166
tumor	O	167-172
suppressors	O	173-184
in	O	185-187
brain	O	188-193
tumors	O	194-200
.   	O	200-204

MicroRNA	O	0-8
involvement	O	9-20
in	O	21-23
brain	O	24-29
tumors	O	30-36
:	O	36-37
from	O	38-42
bench	O	43-48
to	O	49-51
bedside	O	52-59
.  	O	59-62

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
,	O	18-19
a	O	20-21
novel	O	22-27
class	O	28-33
of	O	34-36
small	O	37-42
non	O	43-46
-	O	46-47
coding	O	47-53
RNAs	O	54-58
,	O	58-59
are	O	60-63
effective	O	64-73
post	O	74-78
-	O	78-79
transcriptional	O	79-94
regulators	O	95-105
of	O	106-108
gene	O	109-113
expression	O	114-124
,	O	124-125
exhibiting	O	126-136
,	O	136-137
when	O	138-142
altered	O	143-150
in	O	151-153
human	O	154-159
tumors	O	160-166
,	O	166-167
both	O	168-172
oncogenic	O	173-182
and	O	183-186
tumor	O	187-192
suppressive	O	193-204
potential	O	205-214
. 	O	214-216

Recently	O	0-8
,	O	8-9
miRNA	O	10-15
involvement	O	16-27
in	O	28-30
the	O	31-34
pathophysiology	O	35-50
of	O	51-53
brain	O	54-59
cancer	O	60-66
has	O	67-70
been	O	71-75
assessed	O	76-84
. 	O	84-86

Aberrant	O	0-8
gene	O	9-13
expression	O	14-24
is	O	25-27
the	O	28-31
main	O	32-36
mechanism	O	37-46
of	O	47-49
miRNAs	O	50-56
dysfunction	O	57-68
in	O	69-71
cancer	O	72-78
,	O	78-79
with	O	80-84
abnormal	O	85-93
expression	O	94-104
levels	O	105-111
of	O	112-114
mature	O	115-121
and	O	122-125
/	O	125-126
or	O	126-128
precursor	O	129-138
miRNA	O	139-144
expression	O	145-155
in	O	156-158
tumor	O	159-164
samples	O	165-172
versus	O	173-179
normal	O	180-186
. 	O	186-188

MiRNA	O	0-5
germline	O	6-14
and	O	15-18
somatic	O	19-26
mutations	O	27-36
or	O	37-39
polymorphisms	O	40-53
in	O	54-56
the	O	57-60
protein	O	61-68
coding	O	69-75
messenger	O	76-85
RNA	O	86-89
targeted	O	90-98
by	O	99-101
miRNAs	O	102-108
may	O	109-112
also	O	113-117
occur	O	118-123
,	O	123-124
contributing	O	125-137
to	O	138-140
cancer	O	141-147
predisposition	O	148-162
,	O	162-163
initiation	O	164-174
and	O	175-178
/	O	178-179
or	O	179-181
progression	O	182-193
. 	O	193-195

If	O	0-2
present	O	3-10
in	O	11-13
somatic	O	14-21
cells	O	22-27
,	O	27-28
miRNA	O	29-34
alterations	O	35-46
may	O	47-50
play	O	51-55
a	O	56-57
role	O	58-62
in	O	63-65
tumor	O	66-71
initiation	O	72-82
,	O	82-83
while	O	84-89
if	O	90-92
present	O	93-100
in	O	101-103
germ	O	104-108
line	O	109-113
cells	O	114-119
they	O	120-124
could	O	125-130
constitute	O	131-141
a	O	142-143
cancer	O	144-150
predisposing	O	151-163
event	O	164-169
. 	O	169-171

RESULTS	O	0-7
:	O	7-8
We	O	9-11
detected	O	12-20
a	O	21-22
total	O	23-28
of	O	29-31
360	O	32-35
miRNAs	O	36-42
. 	O	42-44

Selective	O	0-9
miRNAs	O	10-16
then	O	17-21
were	O	22-26
synthesized	O	27-38
and	O	39-42
transfected	O	43-54
into	O	55-59
Neuro	O	60-65
-	O	65-66
2a	O	66-68
cells	O	69-74
before	O	75-81
oxygen	O	82-88
-	O	88-89
glucose	O	89-96
deprivation	O	97-108
. 	O	108-110

Transfections	O	0-13
of	O	14-16
some	O	17-21
of	O	22-24
these	O	25-30
were	O	31-35
neuroprotective	O	36-51
in	O	52-54
in	O	55-57
vitro	O	58-63
ischemia	O	64-72
. 	O	72-74

Two	O	0-3
miRNA	O	4-9
families	O	10-18
,	O	18-19
miR	B	20-23
-	I	23-24
200	I	24-27
and	O	28-31
miR	B	32-35
-	I	35-36
182	I	36-39
,	O	39-40
were	O	41-45
selectively	O	46-57
upregulated	O	58-69
at	O	70-72
3	O	73-74
hours	O	75-80
after	O	81-86
ischemic	O	87-95
preconditioning	O	96-111
. 	O	111-113

Although	O	0-8
miRNAs	O	9-15
control	O	16-23
a	O	24-25
number	O	26-32
of	O	33-35
conditions	O	36-46
and	O	47-50
diseases	O	51-59
,	O	59-60
few	O	61-64
neuroprotective	O	65-80
miRNAs	O	81-87
have	O	88-92
been	O	93-97
described	O	98-107
. 	O	107-109

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
investigated	O	18-30
neuroprotective	O	31-46
miRNAs	O	47-53
induced	O	54-61
early	O	62-67
in	O	68-70
ischemic	O	71-79
preconditioning	O	80-95
. 	O	95-97

METHODS	O	0-7
:	O	7-8
Ischemic	O	9-17
preconditioning	O	18-33
or	O	34-36
focal	O	37-42
cerebral	O	43-51
ischemia	O	52-60
was	O	61-64
induced	O	65-72
in	O	73-75
mice	O	76-80
by	O	81-83
transient	O	84-93
occlusion	O	94-103
of	O	104-106
the	O	107-110
middle	O	111-117
cerebral	O	118-126
artery	O	127-133
for	O	134-137
15	O	138-140
or	O	141-143
120	O	144-147
minutes	O	148-155
. 	O	155-157

We	O	0-2
prepared	O	3-11
RNA	O	12-15
samples	O	16-23
from	O	24-28
the	O	29-32
ischemic	O	33-41
cortex	O	42-48
at	O	49-51
3	O	52-53
or	O	54-56
24	O	57-59
hours	O	60-65
after	O	66-71
the	O	72-75
onset	O	76-81
of	O	82-84
ischemia	O	85-93
. 	O	93-95

MicroRNAs	O	0-9
induced	O	10-17
during	O	18-24
ischemic	O	25-33
preconditioning	O	34-49
.  	O	49-52

BACKGROUND	O	0-10
AND	O	11-14
PURPOSE	O	15-22
:	O	22-23
MicroRNAs	O	24-33
(	O	34-35
miRNA	O	35-40
)	O	40-41
are	O	42-45
single	O	46-52
-	O	52-53
stranded	O	53-61
short	O	62-67
RNA	O	68-71
molecules	O	72-81
that	O	82-86
regulate	O	87-95
gene	O	96-100
expression	O	101-111
by	O	112-114
either	O	115-121
degradation	O	122-133
or	O	134-136
translational	O	137-150
repression	O	151-161
of	O	162-164
mRNA	O	165-169
. 	O	169-171

Among	O	0-5
them	O	6-10
,	O	10-11
miR	B	12-15
-	I	15-16
200b	I	16-20
,	O	20-21
miR	B	22-25
-	I	25-26
200c	I	26-30
,	O	30-31
and	O	32-35
miR	B	36-39
-	I	39-40
429	I	40-43
targeted	O	44-52
prolyl	O	53-59
hydroxylase	O	60-71
2	O	72-73
and	O	74-77
had	O	78-81
the	O	82-85
best	O	86-90
neuroprotective	O	91-106
effect	O	107-113
. 	O	113-115

CONCLUSIONS	O	0-11
:	O	11-12
Two	O	13-16
miRNA	O	17-22
families	O	23-31
,	O	31-32
miR	B	33-36
-	I	36-37
200	I	37-40
and	O	41-44
miR	B	45-48
-	I	48-49
182	I	49-52
,	O	52-53
were	O	54-58
upregulated	O	59-70
early	O	71-76
after	O	77-82
ischemic	O	83-91
preconditioning	O	92-107
and	O	108-111
the	O	112-115
miR	B	116-119
-	I	119-120
200	I	120-123
family	O	124-130
was	O	131-134
neuroprotective	O	135-150
mainly	O	151-157
by	O	158-160
downregulating	O	161-175
prolyl	O	176-182
hydroxylase	O	183-194
2	O	195-196
levels	O	197-203
. 	O	203-205

These	O	0-5
miRNAs	O	6-12
may	O	13-16
be	O	17-19
useful	O	20-26
in	O	27-29
future	O	30-36
research	O	37-45
and	O	46-49
therapeutic	O	50-61
applications	O	62-74
.   	O	74-78

A	O	0-1
significant	O	2-13
association	O	14-25
with	O	26-30
death	O	31-36
was	O	37-40
found	O	41-46
for	O	47-50
major	O	51-56
adverse	O	57-64
events	O	65-71
,	O	71-72
medical	O	73-80
adverse	O	81-88
events	O	89-95
,	O	95-96
and	O	97-100
nosocomial	O	101-111
infections	O	112-122
,	O	122-123
with	O	124-128
adjusted	O	129-137
odds	O	138-142
ratio	O	143-148
estimates	O	149-158
of	O	159-161
3	O	162-163
.	O	163-164
74	O	164-166
[	O	167-168
95	O	168-170
%	O	170-171
confidence	O	172-182
interval	O	183-191
(	O	192-193
CI	O	193-195
)	O	195-196
1	O	197-198
.	O	198-199
64	O	199-201
-	O	201-202
8	O	202-203
.	O	203-204
54	O	204-206
]	O	206-207
,	O	207-208
3	O	209-210
.	O	210-211
71	O	211-213
(	O	214-215
95	O	215-217
%	O	217-218
CI	O	219-221
1	O	222-223
.	O	223-224
61	O	224-226
-	O	226-227
8	O	227-228
.	O	228-229
53	O	229-231
)	O	231-232
,	O	232-233
and	O	234-237
3	O	238-239
.	O	239-240
22	O	240-242
(	O	243-244
95	O	244-246
%	O	246-247
CI	O	248-250
1	O	251-252
.	O	252-253
21	O	253-255
-	O	255-256
8	O	256-257
.	O	257-258
59	O	258-260
)	O	260-261
,	O	261-262
respectively	O	263-275
. 	O	275-277

CONCLUSION	O	0-10
:	O	10-11
Adverse	O	12-19
events	O	20-26
,	O	26-27
mostly	O	28-34
severe	O	35-41
,	O	41-42
predominated	O	43-55
among	O	56-61
deceased	O	62-70
patients	O	71-79
,	O	79-80
resulting	O	81-90
mainly	O	91-97
from	O	98-102
diagnostic	O	103-113
or	O	114-116
therapeutic	O	117-128
procedures	O	129-139
and	O	140-143
nursing	O	144-151
activities	O	152-162
. 	O	162-164

In	O	0-2
spite	O	3-8
of	O	9-11
limitations	O	12-23
concerning	O	24-34
the	O	35-38
observational	O	39-52
retrospective	O	53-66
nature	O	67-73
of	O	74-76
this	O	77-81
study	O	82-87
,	O	87-88
we	O	89-91
found	O	92-97
that	O	98-102
severe	O	103-109
adverse	O	110-117
events	O	118-124
,	O	124-125
medical	O	126-133
adverse	O	134-141
events	O	142-148
,	O	148-149
and	O	150-153
nosocomial	O	154-164
infections	O	165-175
were	O	176-180
significantly	O	181-194
associated	O	195-205
with	O	206-210
death	O	211-216
in	O	217-219
stroke	O	220-226
patients	O	227-235
.   	O	235-239

OBJECTIVES	O	0-10
:	O	10-11
To	O	12-14
identify	O	15-23
the	O	24-27
occurrence	O	28-38
of	O	39-41
adverse	O	42-49
events	O	50-56
in	O	57-59
stroke	O	60-66
patients	O	67-75
presenting	O	76-86
to	O	87-89
the	O	90-93
emergency	O	94-103
department	O	104-114
of	O	115-117
a	O	118-119
tertiary	O	120-128
university	O	129-139
facility	O	140-148
,	O	148-149
and	O	150-153
to	O	154-156
disclose	O	157-165
the	O	166-169
categories	O	170-180
of	O	181-183
adverse	O	184-191
events	O	192-198
associated	O	199-209
with	O	210-214
death	O	215-220
. 	O	220-222

Adverse	O	0-7
events	O	8-14
and	O	15-18
death	O	19-24
in	O	25-27
stroke	O	28-34
patients	O	35-43
admitted	O	44-52
to	O	53-55
the	O	56-59
emergency	O	60-69
department	O	70-80
of	O	81-83
a	O	84-85
tertiary	O	86-94
university	O	95-105
hospital	O	106-114
.  	O	114-117

Major	O	0-5
adverse	O	6-13
events	O	14-20
equaled	O	21-28
54	O	29-31
.	O	31-32
1	O	32-33
%	O	33-34
of	O	35-37
all	O	38-41
events	O	42-48
(	O	49-50
659	O	50-53
episodes	O	54-62
)	O	62-63
:	O	63-64
538	O	65-68
events	O	69-75
in	O	76-78
143	O	79-82
cases	O	83-88
and	O	89-92
121	O	93-96
in	O	97-99
65	O	100-102
controls	O	103-111
. 	O	111-113

RESULTS	O	0-7
:	O	7-8
Adverse	O	9-16
events	O	17-23
totaled	O	24-31
1218	O	32-36
and	O	37-40
occurred	O	41-49
in	O	50-52
295	O	53-56
patients	O	57-65
:	O	65-66
932	O	67-70
events	O	71-77
(	O	78-79
76	O	79-81
.	O	81-82
5	O	82-83
%	O	83-84
)	O	84-85
in	O	86-88
170	O	89-92
cases	O	93-98
and	O	99-102
286	O	103-106
(	O	107-108
23	O	108-110
.	O	110-111
5	O	111-112
%	O	112-113
)	O	113-114
in	O	115-117
125	O	118-121
controls	O	122-130
. 	O	130-132

Nursing	O	0-7
(	O	8-9
38	O	9-11
.	O	11-12
4	O	12-13
%	O	13-14
)	O	14-15
and	O	16-19
medical	O	20-27
(	O	28-29
31	O	29-31
%	O	31-32
)	O	32-33
adverse	O	34-41
events	O	42-48
represented	O	49-60
the	O	61-64
most	O	65-69
common	O	70-76
related	O	77-84
professional	O	85-97
categories	O	98-108
. 	O	108-110

Diagnostic	O	0-10
or	O	11-13
therapeutic	O	14-25
procedures	O	26-36
and	O	37-40
nursing	O	41-48
activities	O	49-59
accounted	O	60-69
for	O	70-73
55	O	74-76
.	O	76-77
2	O	77-78
%	O	78-79
of	O	80-82
events	O	83-89
. 	O	89-91

The	O	0-3
cases	O	4-9
comprised	O	10-19
234	O	20-23
consecutive	O	24-35
deaths	O	36-42
and	O	43-46
the	O	47-50
controls	O	51-59
234	O	60-63
discharged	O	64-74
patients	O	75-83
,	O	83-84
matched	O	85-92
for	O	93-96
primary	O	97-104
diagnosis	O	105-114
and	O	115-118
admission	O	119-128
period	O	129-135
. 	O	135-137

METHODS	O	0-7
:	O	7-8
This	O	9-13
matched	O	14-21
case	O	22-26
-	O	26-27
control	O	27-34
study	O	35-40
enrolled	O	41-49
468	O	50-53
patients	O	54-62
admitted	O	63-71
with	O	72-76
stroke	O	77-83
to	O	84-86
the	O	87-90
emergency	O	91-100
department	O	101-111
from	O	112-116
March	O	117-122
1996	O	123-127
to	O	128-130
September	O	131-140
1999	O	141-145
. 	O	145-147

The	O	0-3
association	O	4-15
with	O	16-20
death	O	21-26
was	O	27-30
analysed	O	31-39
by	O	40-42
conditional	O	43-54
logistic	O	55-63
regression	O	64-74
. 	O	74-76

Adverse	O	0-7
events	O	8-14
,	O	14-15
detected	O	16-24
by	O	25-27
chart	O	28-33
review	O	34-40
,	O	40-41
were	O	42-46
classified	O	47-57
according	O	58-67
to	O	68-70
the	O	71-74
degree	O	75-81
of	O	82-84
severity	O	85-93
,	O	93-94
immediate	O	95-104
causes	O	105-111
,	O	111-112
and	O	113-116
professional	O	117-129
category	O	130-138
. 	O	138-140

These	O	0-5
findings	O	6-14
reveal	O	15-21
a	O	22-23
novel	O	24-29
mechanism	O	30-39
of	O	40-42
targeted	O	43-51
intercellular	O	52-65
protein	O	66-73
regulation	O	74-84
between	O	85-92
brain	O	93-98
tumor	O	99-104
cells	O	105-110
.   	O	110-114

Here	O	0-4
,	O	4-5
we	O	6-8
transformed	O	9-20
rat	O	21-24
9L	O	25-27
gliosarcoma	O	28-39
cells	O	40-45
to	O	46-48
express	O	49-56
cel	B	57-60
-	I	60-61
miR	I	61-64
-	I	64-65
67	I	65-67
,	O	67-68
a	O	69-70
miRNA	O	71-76
that	O	77-81
lacks	O	82-87
homology	O	88-96
in	O	97-99
rat	O	100-103
. 	O	103-105

Coculture	O	0-9
of	O	10-12
these	O	13-18
cells	O	19-24
with	O	25-29
cells	O	30-35
that	O	36-40
expressed	O	41-50
a	O	51-52
luciferase	O	53-63
reporter	O	64-72
that	O	73-77
contained	O	78-87
a	O	88-89
complementary	O	90-103
sequence	O	104-112
to	O	113-115
cel	B	116-119
-	I	119-120
miR	I	120-123
-	I	123-124
67	I	124-126
resulted	O	127-135
in	O	136-138
significant	O	139-150
suppression	O	151-162
of	O	163-165
luciferase	O	166-176
expression	O	177-187
. 	O	187-189

Functional	O	0-10
microRNA	O	11-19
is	O	20-22
transferred	O	23-34
between	O	35-42
glioma	O	43-49
cells	O	50-55
.  	O	55-58

MicroRNAs	O	0-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
are	O	18-21
single	O	22-28
-	O	28-29
stranded	O	29-37
17	O	38-40
-	O	40-41
to	O	42-44
27	O	45-47
-	O	47-48
nucleotide	O	48-58
RNA	O	59-62
molecules	O	63-72
that	O	73-77
regulate	O	78-86
gene	O	87-91
expression	O	92-102
by	O	103-105
posttranscriptional	O	106-125
silencing	O	126-135
of	O	136-138
target	O	139-145
mRNAs	O	146-151
. 	O	151-153

Finally	O	0-7
,	O	7-8
in	O	9-11
situ	O	12-16
hybridization	O	17-30
revealed	O	31-39
the	O	40-43
presence	O	44-52
of	O	53-55
cel	B	56-59
-	I	59-60
miR	I	60-63
-	I	63-64
67	I	64-66
in	O	67-69
cel	B	70-73
-	I	73-74
miR	I	74-77
-	I	77-78
67	I	78-80
-	O	80-81
null	O	81-85
9L	O	86-88
cells	O	89-94
after	O	95-100
coculture	O	101-110
with	O	111-115
cel	B	116-119
-	I	119-120
miR	I	120-123
-	I	123-124
67	I	124-126
-	O	126-127
expressing	O	127-137
cells	O	138-143
. 	O	143-145

Our	O	0-3
data	O	4-8
show	O	9-13
that	O	14-18
miRNA	O	19-24
transcribed	O	25-36
in	O	37-39
glioma	O	40-46
cells	O	47-52
can	O	53-56
be	O	57-59
transferred	O	60-71
to	O	72-74
adjacent	O	75-83
cells	O	84-89
and	O	90-93
induces	O	94-101
targeted	O	102-110
inhibition	O	111-121
of	O	122-124
protein	O	125-132
expression	O	133-143
in	O	144-146
the	O	147-150
acceptor	O	151-159
cells	O	160-165
. 	O	165-167

This	O	0-4
effect	O	5-11
was	O	12-15
also	O	16-20
observed	O	21-29
in	O	30-32
the	O	33-36
U87	O	37-40
-	O	40-41
MG	O	41-43
human	O	44-49
glioma	O	50-56
cell	O	57-61
line	O	62-66
. 	O	66-68

Moreover	O	0-8
,	O	8-9
luciferase	O	10-20
suppression	O	21-32
was	O	33-36
inhibited	O	37-46
by	O	47-49
the	O	50-53
addition	O	54-62
of	O	63-65
carbenoxolone	O	66-79
to	O	80-82
cocultures	O	83-93
,	O	93-94
suggesting	O	95-105
that	O	106-110
gap	O	111-114
junction	O	115-123
communication	O	124-137
regulates	O	138-147
intercellular	O	148-161
transfer	O	162-170
of	O	171-173
miRNA	O	174-179
. 	O	179-181

Moreover	O	0-8
,	O	8-9
bioinformatics	O	10-24
analyses	O	25-33
revealed	O	34-42
a	O	43-44
theoretical	O	45-56
basis	O	57-62
for	O	63-66
many	O	67-71
other	O	72-77
potential	O	78-87
interactions	O	88-100
between	O	101-108
natural	O	109-116
antisense	O	117-126
transcripts	O	127-138
and	O	139-142
miRNAs	O	143-149
at	O	150-152
the	O	153-156
binding	O	157-164
sites	O	165-170
of	O	171-173
the	O	174-177
latter	O	178-184
.   	O	184-188

In	O	0-2
addition	O	3-11
,	O	11-12
mammalian	O	13-22
genomes	O	23-30
contain	O	31-38
numerous	O	39-47
natural	O	48-55
antisense	O	56-65
transcripts	O	66-77
,	O	77-78
most	O	79-83
of	O	84-86
which	O	87-92
appear	O	93-99
to	O	100-102
be	O	103-105
non	O	106-109
-	O	109-110
protein	O	110-117
-	O	117-118
coding	O	118-124
RNAs	O	125-129
(	O	130-131
ncRNAs	O	131-137
)	O	137-138
. 	O	138-140

BACKGROUND	O	0-10
:	O	10-11
MicroRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
have	O	31-35
the	O	36-39
potential	O	40-49
to	O	50-52
regulate	O	53-61
diverse	O	62-69
sets	O	70-74
of	O	75-77
mRNA	O	78-82
targets	O	83-90
. 	O	90-92

Evidence	O	0-8
for	O	9-12
natural	O	13-20
antisense	O	21-30
transcript	O	31-41
-	O	41-42
mediated	O	42-50
inhibition	O	51-61
of	O	62-64
microRNA	O	65-73
function	O	74-82
.  	O	82-85

Indeed	O	0-6
,	O	6-7
miR	B	8-11
-	I	11-12
485	I	12-15
-	I	15-16
5p	I	16-18
and	O	19-22
BACE1	O	23-28
-	O	28-29
antisense	O	29-38
compete	O	39-46
for	O	47-50
binding	O	51-58
within	O	59-65
the	O	66-69
same	O	70-74
region	O	75-81
in	O	82-84
the	O	85-88
open	O	89-93
reading	O	94-101
frame	O	102-107
of	O	108-110
the	O	111-114
BACE1	O	115-120
mRNA	O	121-125
. 	O	125-127

RESULTS	O	0-7
:	O	7-8
We	O	9-11
report	O	12-18
here	O	19-23
that	O	24-28
BACE1	O	29-34
-	O	34-35
antisense	O	35-44
prevents	O	45-53
miRNA	O	54-59
-	O	59-60
induced	O	60-67
repression	O	68-78
of	O	79-81
BACE1	O	82-87
mRNA	O	88-92
by	O	93-95
masking	O	96-103
the	O	104-107
binding	O	108-115
site	O	116-120
for	O	121-124
miR	B	125-128
-	I	128-129
485	I	129-132
-	I	132-133
5p	I	133-135
. 	O	135-137

The	O	0-3
BACE1	O	4-9
-	O	9-10
antisense	O	10-19
transcript	O	20-30
is	O	31-33
markedly	O	34-42
up	O	43-45
-	O	45-46
regulated	O	46-55
in	O	56-58
brain	O	59-64
samples	O	65-72
from	O	73-77
Alzheimer	O	78-87
'	O	87-88
s	O	88-89
disease	O	90-97
patients	O	98-106
and	O	107-110
promotes	O	111-119
the	O	120-123
stability	O	124-133
of	O	134-136
the	O	137-140
(	O	141-142
sense	O	142-147
)	O	147-148
BACE1	O	149-154
transcript	O	155-165
. 	O	165-167

We	O	0-2
have	O	3-7
recently	O	8-16
identified	O	17-27
and	O	28-31
characterized	O	32-45
a	O	46-47
highly	O	48-54
conserved	O	55-64
non	O	65-68
-	O	68-69
coding	O	69-75
antisense	O	76-85
transcript	O	86-96
for	O	97-100
beta	O	101-105
-	O	105-106
secretase	O	106-115
-	O	115-116
1	O	116-117
(	O	118-119
BACE1	O	119-124
)	O	124-125
,	O	125-126
a	O	127-128
critical	O	129-137
enzyme	O	138-144
in	O	145-147
Alzheimer	O	148-157
'	O	157-158
s	O	158-159
disease	O	160-167
pathophysiology	O	168-183
. 	O	183-185

We	O	0-2
observed	O	3-11
opposing	O	12-20
effects	O	21-28
of	O	29-31
BACE1	O	32-37
-	O	37-38
antisense	O	38-47
and	O	48-51
miR	B	52-55
-	I	55-56
485	I	56-59
-	I	59-60
5p	I	60-62
on	O	63-65
BACE1	O	66-71
protein	O	72-79
in	O	80-82
vitro	O	83-88
and	O	89-92
showed	O	93-99
that	O	100-104
Locked	O	105-111
Nucleic	O	112-119
Acid	O	120-124
-	O	124-125
antimiR	O	125-132
mediated	O	133-141
knockdown	O	142-151
of	O	152-154
miR	B	155-158
-	I	158-159
485	I	159-162
-	I	162-163
5p	I	163-165
as	O	166-168
well	O	169-173
as	O	174-176
BACE1	O	177-182
-	O	182-183
antisense	O	183-192
over	O	193-197
-	O	197-198
expression	O	198-208
can	O	209-212
prevent	O	213-220
the	O	221-224
miRNA	O	225-230
-	O	230-231
induced	O	231-238
BACE1	O	239-244
suppression	O	245-256
. 	O	256-258

We	O	0-2
found	O	3-8
that	O	9-13
the	O	14-17
expression	O	18-28
of	O	29-31
BACE1	O	32-37
-	O	37-38
antisense	O	38-47
as	O	48-50
well	O	51-55
as	O	56-58
miR	B	59-62
-	I	62-63
485	I	63-66
-	I	66-67
5p	I	67-69
are	O	70-73
dysregulated	O	74-86
in	O	87-89
RNA	O	90-93
samples	O	94-101
from	O	102-106
Alzheimer	O	107-116
'	O	116-117
s	O	117-118
disease	O	119-126
subjects	O	127-135
compared	O	136-144
to	O	145-147
control	O	148-155
individuals	O	156-167
. 	O	167-169

CONCLUSIONS	O	0-11
:	O	11-12
Our	O	13-16
data	O	17-21
demonstrate	O	22-33
an	O	34-36
interface	O	37-46
between	O	47-54
two	O	55-58
distinct	O	59-67
groups	O	68-74
of	O	75-77
regulatory	O	78-88
RNAs	O	89-93
in	O	94-96
the	O	97-100
computation	O	101-112
of	O	113-115
BACE1	O	116-121
gene	O	122-126
expression	O	127-137
. 	O	137-139

The	O	0-3
mRNA	O	4-8
expression	O	9-19
of	O	20-22
the	O	23-26
RNases	O	27-33
Drosha	O	34-40
and	O	41-44
Dicer	O	45-50
,	O	50-51
cofactor	O	52-60
Pasha	O	61-66
,	O	66-67
and	O	68-71
the	O	72-75
pre	O	76-79
-	O	79-80
miRNA	O	80-85
transporter	O	86-97
exportin	O	98-106
-	O	106-107
5	O	107-108
,	O	108-109
which	O	110-115
modulate	O	116-124
miRNA	O	125-130
biogenesis	O	131-141
,	O	141-142
were	O	143-147
not	O	148-151
altered	O	152-159
after	O	160-165
transient	O	166-175
middle	O	176-182
cerebral	O	183-191
artery	O	192-198
occlusion	O	199-208
. 	O	208-210

Thus	O	0-4
,	O	4-5
the	O	6-9
present	O	10-17
studies	O	18-25
indicate	O	26-34
a	O	35-36
critical	O	37-45
role	O	46-50
of	O	51-53
miRNAs	O	54-60
in	O	61-63
controlling	O	64-75
mRNA	O	76-80
transcription	O	81-94
and	O	95-98
translation	O	99-110
in	O	111-113
the	O	114-117
postischemic	O	118-130
brain	O	131-136
.   	O	136-140

Bioinformatics	O	0-14
analysis	O	15-23
indicated	O	24-33
a	O	34-35
correlation	O	36-47
between	O	48-55
miRNAs	O	56-62
altered	O	63-70
to	O	71-73
several	O	74-81
mRNAs	O	82-87
known	O	88-93
to	O	94-96
mediate	O	97-104
inflammation	O	105-117
,	O	117-118
transcription	O	119-132
,	O	132-133
neuroprotection	O	134-149
,	O	149-150
receptors	O	151-160
function	O	161-169
,	O	169-170
and	O	171-174
ionic	O	175-180
homeostasis	O	181-192
. 	O	192-194

Of	O	0-2
those	O	3-8
,	O	8-9
17	O	10-12
showed	O	13-19
>	O	20-21
5	O	21-22
fold	O	23-27
change	O	28-34
. 	O	34-36

In	O	0-2
silico	O	3-9
analysis	O	10-18
showed	O	19-25
sequence	O	26-34
complementarity	O	35-50
of	O	51-53
eight	O	54-59
miRNAs	O	60-66
induced	O	67-74
after	O	75-80
focal	O	81-86
ischemia	O	87-95
to	O	96-98
877	O	99-102
promoters	O	103-112
indicating	O	113-123
the	O	124-127
possibility	O	128-139
of	O	140-142
noncoding	O	143-152
RNA	O	153-156
-	O	156-157
induced	O	157-164
activation	O	165-175
of	O	176-178
gene	O	179-183
expression	O	184-194
. 	O	194-196

Antagomir	O	0-9
-	O	9-10
mediated	O	10-18
prevention	O	19-29
of	O	30-32
mir	B	33-36
-	I	36-37
145	I	37-40
expression	O	41-51
led	O	52-55
to	O	56-58
an	O	59-61
increased	O	62-71
protein	O	72-79
expression	O	80-90
of	O	91-93
its	O	94-97
downstream	O	98-108
target	O	109-115
superoxide	O	116-126
dismutase	O	127-136
-	O	136-137
2	O	137-138
in	O	139-141
the	O	142-145
postischemic	O	146-158
brain	O	159-164
. 	O	164-166

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
approximately	O	23-36
22	O	37-39
nucleotides	O	40-51
long	O	52-56
,	O	56-57
noncoding	O	58-67
RNAs	O	68-72
that	O	73-77
control	O	78-85
cellular	O	86-94
function	O	95-103
by	O	104-106
either	O	107-113
degrading	O	114-123
mRNAs	O	124-129
or	O	130-132
arresting	O	133-142
their	O	143-148
translation	O	149-160
. 	O	160-162

Transient	O	0-9
focal	O	10-15
ischemia	O	16-24
induces	O	25-32
extensive	O	33-42
temporal	O	43-51
changes	O	52-59
in	O	60-62
rat	O	63-66
cerebral	O	67-75
microRNAome	O	76-87
.  	O	87-90

Of	O	0-2
the	O	3-6
238	O	7-10
miRNAs	O	11-17
evaluated	O	18-27
,	O	27-28
8	O	29-30
showed	O	31-37
increased	O	38-47
and	O	48-51
12	O	52-54
showed	O	55-61
decreased	O	62-71
expression	O	72-82
at	O	83-85
least	O	86-91
at	O	92-94
4	O	95-96
out	O	97-100
of	O	101-103
5	O	104-105
reperfusion	O	106-117
time	O	118-122
points	O	123-129
studied	O	130-137
between	O	138-145
3	O	146-147
h	O	148-149
and	O	150-153
3	O	154-155
days	O	156-160
compared	O	161-169
with	O	170-174
sham	O	175-179
. 	O	179-181

To	O	0-2
understand	O	3-13
their	O	14-19
functional	O	20-30
significance	O	31-43
in	O	44-46
ischemic	O	47-55
pathophysiology	O	56-71
,	O	71-72
we	O	73-75
profiled	O	76-84
miRNAs	O	85-91
in	O	92-94
adult	O	95-100
rat	O	101-104
brain	O	105-110
as	O	111-113
a	O	114-115
function	O	116-124
of	O	125-127
reperfusion	O	128-139
time	O	140-144
after	O	145-150
transient	O	151-160
middle	O	161-167
cerebral	O	168-176
artery	O	177-183
occlusion	O	184-193
. 	O	193-195

The	O	0-3
possible	O	4-12
use	O	13-16
of	O	17-19
RNAi	O	20-24
in	O	25-27
the	O	28-31
treatment	O	32-41
of	O	42-44
spinocerebellar	O	45-60
ataxia	O	61-67
or	O	68-70
amyotrophic	O	71-82
lateral	O	83-90
sclerosis	O	91-100
,	O	100-101
with	O	102-106
its	O	107-110
advantages	O	111-121
and	O	122-125
pitfalls	O	126-134
and	O	135-138
possible	O	139-147
extensions	O	148-158
to	O	159-161
other	O	162-167
diseases	O	168-176
are	O	177-180
discussed	O	181-190
.   	O	190-194

RNAi	O	0-4
has	O	5-8
moved	O	9-14
from	O	15-19
a	O	20-21
purely	O	22-28
experimental	O	29-41
technique	O	42-51
to	O	52-54
the	O	55-58
stage	O	59-64
of	O	65-67
potential	O	68-77
clinical	O	78-86
applications	O	87-99
. 	O	99-101

RNAi	O	0-4
utilises	O	5-13
cellular	O	14-22
machinery	O	23-32
associated	O	33-43
with	O	44-48
the	O	49-52
processing	O	53-63
of	O	64-66
naturally	O	67-76
occurring	O	77-86
micro	O	87-92
RNA	O	93-96
(	O	97-98
miRNAs	O	98-104
)	O	104-105
. 	O	105-107

RNAi	O	0-4
has	O	5-8
both	O	9-13
admirers	O	14-22
and	O	23-26
detractors	O	27-37
,	O	37-38
but	O	39-42
is	O	43-45
undeniably	O	46-56
a	O	57-58
technique	O	59-68
with	O	69-73
great	O	74-79
potential	O	80-89
,	O	89-90
which	O	91-96
has	O	97-100
come	O	101-105
a	O	106-107
long	O	108-112
way	O	113-116
in	O	117-119
the	O	120-123
short	O	124-129
time	O	130-134
since	O	135-140
its	O	141-144
discovery	O	145-154
. 	O	154-156

RNA	O	0-3
interference	O	4-16
has	O	17-20
become	O	21-27
the	O	28-31
tool	O	32-36
of	O	37-39
choice	O	40-46
to	O	47-49
analyse	O	50-57
the	O	58-61
loss	O	62-66
-	O	66-67
of	O	67-69
-	O	69-70
function	O	70-78
of	O	79-81
individual	O	82-92
genes	O	93-98
and	O	99-102
has	O	103-106
been	O	107-111
exploited	O	112-121
to	O	122-124
identify	O	125-133
complex	O	134-141
regulatory	O	142-152
pathways	O	153-161
following	O	162-171
genomic	O	172-179
screening	O	180-189
. 	O	189-191

Design	O	0-6
of	O	7-9
shRNAs	O	10-16
for	O	17-20
RNAi	O	21-25
-	O	25-26
A	O	26-27
lesson	O	28-34
from	O	35-39
pre	O	40-43
-	O	43-44
miRNA	O	44-49
processing	O	50-60
:	O	60-61
possible	O	62-70
clinical	O	71-79
applications	O	80-92
.  	O	92-95

The	O	0-3
cellular	O	4-12
processing	O	13-23
of	O	24-26
shRNAs	O	27-33
shares	O	34-40
common	O	41-47
features	O	48-56
with	O	57-61
the	O	62-65
biogenesis	O	66-76
of	O	77-79
naturally	O	80-89
occurring	O	90-99
miRNA	O	100-105
such	O	106-110
as	O	111-113
cleavage	O	114-122
by	O	123-125
nuclear	O	126-133
RNase	O	134-139
Drosha	O	140-146
,	O	146-147
export	O	148-154
from	O	155-159
the	O	160-163
nucleus	O	164-171
,	O	171-172
processing	O	173-183
by	O	184-186
a	O	187-188
cytoplasmic	O	189-200
RNase	O	201-206
Dicer	O	207-212
,	O	212-213
and	O	214-217
incorporation	O	218-231
into	O	232-236
the	O	237-240
RNA	O	241-244
-	O	244-245
induced	O	245-252
silencing	O	253-262
complex	O	263-270
(	O	271-272
RISC	O	272-276
)	O	276-277
. 	O	277-279

Each	O	0-4
step	O	5-9
has	O	10-13
a	O	14-15
crucial	O	16-23
influence	O	24-33
on	O	34-36
the	O	37-40
efficiency	O	41-51
of	O	52-54
RNAi	O	55-59
and	O	60-63
their	O	64-69
consideration	O	70-83
should	O	84-90
be	O	91-93
a	O	94-95
part	O	96-100
of	O	101-103
a	O	104-105
standard	O	106-114
experimental	O	115-127
design	O	128-134
. 	O	134-136

More	O	0-4
recently	O	5-13
an	O	14-16
introduction	O	17-29
of	O	30-32
short	O	33-38
approximately	O	39-52
22	O	53-55
nucleotide	O	56-66
RNA	O	67-70
duplexes	O	71-79
has	O	80-83
become	O	84-90
the	O	91-94
standard	O	95-103
in	O	104-106
short	O	107-112
-	O	112-113
term	O	113-117
experiments	O	118-129
,	O	129-130
but	O	131-134
is	O	135-137
insufficient	O	138-150
for	O	151-154
long	O	155-159
-	O	159-160
term	O	160-164
knock	O	165-170
-	O	170-171
down	O	171-175
assays	O	176-182
. 	O	182-184

Long	O	0-4
-	O	4-5
term	O	5-9
expression	O	10-20
of	O	21-23
siRNAs	O	24-30
has	O	31-34
been	O	35-39
achieved	O	40-48
by	O	49-51
in	O	52-54
vivo	O	55-59
transcription	O	60-73
from	O	74-78
plasmids	O	79-87
coding	O	88-94
for	O	95-98
short	O	99-104
hairpin	O	105-112
RNAs	O	113-117
(	O	118-119
shRNAs	O	119-125
)	O	125-126
. 	O	126-128

Effective	O	0-9
use	O	10-13
of	O	14-16
RNAi	O	17-21
requires	O	22-30
detailed	O	31-39
knowledge	O	40-49
of	O	50-52
the	O	53-56
individual	O	57-67
steps	O	68-73
and	O	74-77
the	O	78-81
proteins	O	82-90
involved	O	91-99
,	O	99-100
as	O	101-103
well	O	104-108
as	O	109-111
the	O	112-115
similarities	O	116-128
and	O	129-132
distinctions	O	133-145
between	O	146-153
miRNA	O	154-159
and	O	160-163
siRNA	O	164-169
pathways	O	170-178
. 	O	178-180

RNAi	O	0-4
was	O	5-8
originally	O	9-19
induced	O	20-27
by	O	28-30
the	O	31-34
introduction	O	35-47
of	O	48-50
long	O	51-55
double	O	56-62
stranded	O	63-71
RNAs	O	72-76
(	O	77-78
dsRNAs	O	78-84
)	O	84-85
into	O	86-90
cells	O	91-96
in	O	97-99
which	O	100-105
the	O	106-109
RNA	O	110-113
was	O	114-117
cleaved	O	118-125
into	O	126-130
short	O	131-136
RNAs	O	137-141
which	O	142-147
effectively	O	148-159
interfered	O	160-170
with	O	171-175
a	O	176-177
transcription	O	178-191
of	O	192-194
cognate	O	195-202
mRNA	O	203-207
. 	O	207-209

Our	O	0-3
microarray	O	4-14
based	O	15-20
analysis	O	21-29
of	O	30-32
microRNA	O	33-41
expression	O	42-52
in	O	53-55
rat	O	56-59
cerebral	O	60-68
cortex	O	69-75
after	O	76-81
traumatic	O	82-91
brain	O	92-97
injury	O	98-104
has	O	105-108
shown	O	109-114
that	O	115-119
some	O	120-124
microRNA	O	125-133
such	O	134-138
as	O	139-141
miR	B	142-145
-	I	145-146
21	I	146-148
could	O	149-154
be	O	155-157
involved	O	158-166
in	O	167-169
the	O	170-173
intricate	O	174-183
process	O	184-191
of	O	192-194
TBI	O	195-198
course	O	199-205
.   	O	205-209

Furthermore	O	0-11
,	O	11-12
we	O	13-15
revealed	O	16-24
global	O	25-31
up	O	32-34
-	O	34-35
regulation	O	35-45
of	O	46-48
miR	B	49-52
-	I	52-53
21	I	53-55
expression	O	56-66
within	O	67-73
all	O	74-77
the	O	78-81
four	O	82-86
time	O	87-91
points	O	92-98
post	O	99-103
injury	O	104-110
. 	O	110-112

Our	O	0-3
research	O	4-12
revealed	O	13-21
that	O	22-26
136	O	27-30
miRNAs	O	31-37
were	O	38-42
expressing	O	43-53
at	O	54-56
6	O	57-58
h	O	59-60
post	O	61-65
injury	O	66-72
,	O	72-73
in	O	74-76
which	O	77-82
13	O	83-85
miRNAs	O	86-92
were	O	93-97
more	O	98-102
than	O	103-107
2	O	108-109
-	O	109-110
fold	O	110-114
up	O	115-117
-	O	117-118
regulated	O	118-127
,	O	127-128
and	O	129-132
14	O	133-135
miRNAs	O	136-142
were	O	143-147
more	O	148-152
than	O	153-157
2	O	158-159
-	O	159-160
fold	O	160-164
down	O	165-169
-	O	169-170
regulated	O	170-179
;	O	179-180
118	O	181-184
miRNAs	O	185-191
were	O	192-196
expressing	O	197-207
at	O	208-210
24	O	211-213
h	O	214-215
post	O	216-220
injury	O	221-227
,	O	227-228
in	O	229-231
which	O	232-237
4	O	238-239
miRNAs	O	240-246
were	O	247-251
more	O	252-256
than	O	257-261
2	O	262-263
-	O	263-264
fold	O	264-268
up	O	269-271
-	O	271-272
regulated	O	272-281
,	O	281-282
and	O	283-286
23	O	287-289
miRNAs	O	290-296
were	O	297-301
more	O	302-306
than	O	307-311
2	O	312-313
-	O	313-314
fold	O	314-318
down	O	319-323
-	O	323-324
regulated	O	324-333
;	O	333-334
149	O	335-338
miRNAs	O	339-345
were	O	346-350
expressing	O	351-361
at	O	362-364
48	O	365-367
h	O	368-369
post	O	370-374
injury	O	375-381
,	O	381-382
in	O	383-385
which	O	386-391
16	O	392-394
miRNAs	O	395-401
were	O	402-406
more	O	407-411
than	O	412-416
2	O	417-418
-	O	418-419
fold	O	419-423
up	O	424-426
-	O	426-427
regulated	O	427-436
,	O	436-437
and	O	438-441
11	O	442-444
miRNAs	O	445-451
were	O	452-456
more	O	457-461
than	O	462-466
2	O	467-468
-	O	468-469
fold	O	469-473
down	O	474-478
-	O	478-479
regulated	O	479-488
;	O	488-489
and	O	490-493
203	O	494-497
miRNAs	O	498-504
were	O	505-509
expressing	O	510-520
at	O	521-523
72	O	524-526
h	O	527-528
post	O	529-533
injury	O	534-540
,	O	540-541
in	O	542-544
which	O	545-550
19	O	551-553
miRNAs	O	554-560
were	O	561-565
more	O	566-570
than	O	571-575
2	O	576-577
-	O	577-578
fold	O	578-582
up	O	583-585
-	O	585-586
regulated	O	586-595
,	O	595-596
and	O	597-600
5	O	601-602
miRNAs	O	603-609
were	O	610-614
more	O	615-619
than	O	620-624
2	O	625-626
-	O	626-627
fold	O	627-631
down	O	632-636
-	O	636-637
regulated	O	637-646
. 	O	646-648

The	O	0-3
qRT	O	4-7
-	O	7-8
PCR	O	8-11
results	O	12-19
indicated	O	20-29
good	O	30-34
consistency	O	35-46
with	O	47-51
the	O	52-55
results	O	56-63
of	O	64-66
the	O	67-70
microarray	O	71-81
method	O	82-88
. 	O	88-90

Finally	O	0-7
,	O	7-8
we	O	9-11
utilized	O	12-20
qRT	O	21-24
-	O	24-25
PCR	O	25-28
methods	O	29-36
to	O	37-39
verify	O	40-46
the	O	47-50
microarray	O	51-61
results	O	62-69
. 	O	69-71

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
very	O	23-27
important	O	28-37
regulators	O	38-48
of	O	49-51
biological	O	52-62
processes	O	63-72
such	O	73-77
as	O	78-80
development	O	81-92
,	O	92-93
cellular	O	94-102
differentiation	O	103-118
,	O	118-119
and	O	120-123
tumor	O	124-129
generation	O	130-140
. 	O	140-142

MiRNA	O	0-5
microarray	O	6-16
has	O	17-20
been	O	21-25
found	O	26-31
to	O	32-34
be	O	35-37
a	O	38-39
high	O	40-44
throughput	O	45-55
global	O	56-62
analysis	O	63-71
tool	O	72-76
for	O	77-80
detecting	O	81-90
miRNA	O	91-96
expression	O	97-107
profiling	O	108-117
,	O	117-118
and	O	119-122
miRNA	O	123-128
expression	O	129-139
profiling	O	140-149
will	O	150-154
facilitate	O	155-165
the	O	166-169
study	O	170-175
of	O	176-178
the	O	179-182
biological	O	183-193
function	O	194-202
of	O	203-205
miRNAs	O	206-212
. 	O	212-214

In	O	0-2
this	O	3-7
report	O	8-14
,	O	14-15
we	O	16-18
describe	O	19-27
the	O	28-31
miRNA	O	32-37
expression	O	38-48
level	O	49-54
in	O	55-57
rat	O	58-61
cerebral	O	62-70
cortex	O	71-77
after	O	78-83
traumatic	O	84-93
brain	O	94-99
injury	O	100-106
using	O	107-112
microarray	O	113-123
method	O	124-130
. 	O	130-132

We	O	0-2
choose	O	3-9
several	O	10-17
time	O	18-22
points	O	23-29
post	O	30-34
brain	O	35-40
injury	O	41-47
:	O	47-48
6	O	49-50
h	O	51-52
,	O	52-53
24	O	54-56
h	O	57-58
,	O	58-59
48	O	60-62
h	O	63-64
and	O	65-68
72	O	69-71
h	O	72-73
,	O	73-74
respectively	O	75-87
,	O	87-88
to	O	89-91
reveal	O	92-98
differential	O	99-111
expression	O	112-122
of	O	123-125
miRNAs	O	126-132
in	O	133-135
rat	O	136-139
brain	O	140-145
cortex	O	146-152
compared	O	153-161
with	O	162-166
control	O	167-174
groups	O	175-181
. 	O	181-183

Microarray	O	0-10
based	O	11-16
analysis	O	17-25
of	O	26-28
microRNA	O	29-37
expression	O	38-48
in	O	49-51
rat	O	52-55
cerebral	O	56-64
cortex	O	65-71
after	O	72-77
traumatic	O	78-87
brain	O	88-93
injury	O	94-100
.  	O	100-103

MiR	B	0-3
-	I	3-4
107	I	4-7
is	O	8-10
reduced	O	11-18
in	O	19-21
Alzheimer	O	22-31
'	O	31-32
s	O	32-33
disease	O	34-41
brain	O	42-47
neocortex	O	48-57
:	O	57-58
validation	O	59-69
study	O	70-75
.  	O	75-78

MiR	B	0-3
-	I	3-4
107	I	4-7
is	O	8-10
a	O	11-12
microRNA	O	13-21
(	O	22-23
miRNA	O	23-28
)	O	28-29
that	O	30-34
we	O	35-37
reported	O	38-46
previously	O	47-57
to	O	58-60
have	O	61-65
decreased	O	66-75
expression	O	76-86
in	O	87-89
the	O	90-93
temporal	O	94-102
cortical	O	103-111
gray	O	112-116
matter	O	117-123
early	O	124-129
in	O	130-132
the	O	133-136
progression	O	137-148
of	O	149-151
Alzheimer	O	152-161
'	O	161-162
s	O	162-163
disease	O	164-171
(	O	172-173
AD	O	173-175
)	O	175-176
. 	O	176-178

Correlation	O	0-11
was	O	12-15
observed	O	16-24
between	O	25-32
decreased	O	33-42
miR	B	43-46
-	I	46-47
107	I	47-50
expression	O	51-61
and	O	62-65
increased	O	66-75
neuritic	O	76-84
plaque	O	85-91
counts	O	92-98
(	O	99-100
P	O	100-101
<	O	101-102
0	O	103-104
.	O	104-105
05	O	105-107
)	O	107-108
and	O	109-112
neurofibrillary	O	113-128
tangle	O	129-135
counts	O	136-142
(	O	143-144
P	O	144-145
<	O	145-146
0	O	147-148
.	O	148-149
02	O	149-151
)	O	151-152
in	O	153-155
adjacent	O	156-164
brain	O	165-170
tissue	O	171-177
. 	O	177-179

Adjusted	O	0-8
miR	B	9-12
-	I	12-13
107	I	13-16
and	O	17-20
BACE1	O	21-26
mRNA	O	27-31
levels	O	32-38
tended	O	39-45
to	O	46-48
correlate	O	49-58
negatively	O	59-69
(	O	70-71
trend	O	71-76
with	O	77-81
regression	O	82-92
P	O	93-94
<	O	94-95
0	O	96-97
.	O	97-98
07	O	98-100
)	O	100-101
. 	O	101-103

Here	O	0-4
we	O	5-7
study	O	8-13
a	O	14-15
new	O	16-19
group	O	20-25
of	O	26-28
well	O	29-33
-	O	33-34
characterized	O	34-47
human	O	48-53
temporal	O	54-62
cortex	O	63-69
samples	O	70-77
(	O	78-79
N	O	79-80
=	O	80-81
19	O	81-83
)	O	83-84
. 	O	84-86

MiR	B	0-3
-	I	3-4
107	I	4-7
expression	O	8-18
was	O	19-22
assessed	O	23-31
,	O	31-32
normalized	O	33-43
to	O	44-46
miR	B	47-50
-	I	50-51
124	I	51-54
and	O	55-58
let	B	59-62
-	I	62-63
7a	I	63-65
. 	O	65-67

In	O	0-2
sum	O	3-6
,	O	6-7
miR	B	8-11
-	I	11-12
107	I	12-15
expression	O	16-26
tends	O	27-32
to	O	33-35
be	O	36-38
lower	O	39-44
relative	O	45-53
to	O	54-56
other	O	57-62
miRNAs	O	63-69
as	O	70-72
AD	O	73-75
progresses	O	76-86
.   	O	86-90

Small	O	0-5
RNAs	O	6-10
are	O	11-14
short	O	15-20
(	O	21-22
approximately	O	22-35
18	O	36-38
to	O	39-41
30	O	42-44
nucleotides	O	45-56
)	O	56-57
,	O	57-58
non	O	59-62
-	O	62-63
coding	O	63-69
RNA	O	70-73
molecules	O	74-83
that	O	84-88
can	O	89-92
regulate	O	93-101
gene	O	102-106
expression	O	107-117
in	O	118-120
both	O	121-125
the	O	126-129
cytoplasm	O	130-139
and	O	140-143
the	O	144-147
nucleus	O	148-155
via	O	156-159
post	O	160-164
-	O	164-165
transcriptional	O	165-180
gene	O	181-185
silencing	O	186-195
(	O	196-197
PTGS	O	197-201
)	O	201-202
,	O	202-203
chromatin	O	204-213
-	O	213-214
dependent	O	214-223
gene	O	224-228
silencing	O	229-238
(	O	239-240
CDGS	O	240-244
)	O	244-245
or	O	246-248
RNA	O	249-252
activation	O	253-263
(	O	264-265
RNAa	O	265-269
)	O	269-270
. 	O	270-272

Novel	O	0-5
functions	O	6-15
for	O	16-19
small	O	20-25
RNA	O	26-29
molecules	O	30-39
.  	O	39-42

Research	O	0-8
has	O	9-12
indicated	O	13-22
that	O	23-27
small	O	28-33
RNAs	O	34-38
play	O	39-43
important	O	44-53
roles	O	54-59
in	O	60-62
cellular	O	63-71
processes	O	72-81
such	O	82-86
as	O	87-89
cell	O	90-94
differentiation	O	95-110
,	O	110-111
growth	O	112-118
/	O	118-119
proliferation	O	119-132
,	O	132-133
migration	O	134-143
,	O	143-144
apoptosis	O	145-154
/	O	154-155
death	O	155-160
,	O	160-161
metabolism	O	162-172
and	O	173-176
defense	O	177-184
. 	O	184-186

Three	O	0-5
classes	O	6-13
of	O	14-16
small	O	17-22
RNAs	O	23-27
have	O	28-32
been	O	33-37
defined	O	38-45
:	O	45-46
microRNAs	O	47-56
(	O	57-58
miRNAs	O	58-64
)	O	64-65
,	O	65-66
siRNAs	O	67-73
and	O	74-77
Piwi	O	78-82
-	O	82-83
interacting	O	83-94
RNAs	O	95-99
(	O	100-101
piRNAs	O	101-107
)	O	107-108
. 	O	108-110

More	O	0-4
interestingly	O	5-18
,	O	18-19
increasing	O	20-30
evidence	O	31-39
indicates	O	40-49
that	O	50-54
small	O	55-60
RNAs	O	61-65
are	O	66-69
involved	O	70-78
in	O	79-81
the	O	82-85
pathogenesis	O	86-98
of	O	99-101
diverse	O	102-109
diseases	O	110-118
including	O	119-128
cancer	O	129-135
,	O	135-136
cardiovascular	O	137-151
disease	O	152-159
,	O	159-160
stroke	O	161-167
,	O	167-168
neurodegenerative	O	169-186
disease	O	187-194
,	O	194-195
diabetes	O	196-204
,	O	204-205
liver	O	206-211
disease	O	212-219
,	O	219-220
kidney	O	221-227
disease	O	228-235
and	O	236-239
infectious	O	240-250
disease	O	251-258
. 	O	258-260

Accordingly	O	0-11
,	O	11-12
small	O	13-18
RNAs	O	19-23
are	O	24-27
critical	O	28-36
regulators	O	37-47
of	O	48-50
normal	O	51-57
development	O	58-69
and	O	70-73
physiology	O	74-84
. 	O	84-86

Additionally	O	0-12
,	O	12-13
small	O	14-19
RNAs	O	20-24
may	O	25-28
serve	O	29-34
as	O	35-37
novel	O	38-43
biomarkers	O	44-54
and	O	55-58
therapeutic	O	59-70
targets	O	71-78
for	O	79-82
the	O	83-86
majority	O	87-95
of	O	96-98
diseases	O	99-107
.   	O	107-111

More	O	0-4
than	O	5-9
20	O	10-12
clinical	O	13-21
trials	O	22-28
are	O	29-32
ongoing	O	33-40
to	O	41-43
evaluate	O	44-52
therapies	O	53-62
based	O	63-68
on	O	69-71
small	O	72-77
RNA	O	78-81
. 	O	81-83

We	O	0-2
studied	O	3-10
the	O	11-14
expression	O	15-25
of	O	26-28
selected	O	29-37
miRNAs	O	38-44
following	O	45-54
infection	O	55-64
of	O	65-67
CBA	O	68-71
mice	O	72-76
with	O	77-81
Plasmodium	O	82-92
berghei	O	93-100
ANKA	O	101-105
(	O	106-107
PbA	O	107-110
)	O	110-111
,	O	111-112
which	O	113-118
causes	O	119-125
cerebral	O	126-134
malaria	O	135-142
(	O	143-144
CM	O	144-146
)	O	146-147
,	O	147-148
or	O	149-151
Plasmodium	O	152-162
berghei	O	163-170
K173	O	171-175
(	O	176-177
PbK	O	177-180
)	O	180-181
,	O	181-182
which	O	183-188
causes	O	189-195
severe	O	196-202
malaria	O	203-210
but	O	211-214
without	O	215-222
cerebral	O	223-231
complications	O	232-245
,	O	245-246
termed	O	247-253
non	O	254-257
-	O	257-258
CM	O	258-260
. 	O	260-262

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
posttranscriptional	O	23-42
regulatory	O	43-53
molecules	O	54-63
that	O	64-68
have	O	69-73
been	O	74-78
implicated	O	79-89
in	O	90-92
the	O	93-96
regulation	O	97-107
of	O	108-110
immune	O	111-117
responses	O	118-127
,	O	127-128
but	O	129-132
their	O	133-138
role	O	139-143
in	O	144-146
the	O	147-150
immune	O	151-157
response	O	158-166
to	O	167-169
Plasmodium	O	170-180
infection	O	181-190
is	O	191-193
unknown	O	194-201
. 	O	201-203

Differential	O	0-12
MicroRNA	O	13-21
Expression	O	22-32
in	O	33-35
Experimental	O	36-48
Cerebral	O	49-57
and	O	58-61
Noncerebral	O	62-73
Malaria	O	74-81
.  	O	81-84

To	O	0-2
investigate	O	3-14
the	O	15-18
involvement	O	19-30
of	O	31-33
let	B	34-37
-	I	37-38
7i	I	38-40
,	O	40-41
miR	B	42-45
-	I	45-46
27a	I	46-49
,	O	49-50
and	O	51-54
miR	B	55-58
-	I	58-59
150	I	59-62
in	O	63-65
CM	O	66-68
-	O	68-69
resistant	O	69-78
mice	O	79-83
,	O	83-84
we	O	85-87
assessed	O	88-96
the	O	97-100
expression	O	101-111
levels	O	112-118
in	O	119-121
gamma	O	122-127
interferon	O	128-138
knockout	O	139-147
(	O	148-149
IFN	O	149-152
-	O	152-153
γ	O	153-154
(	O	154-155
-	O	155-156
/	O	156-157
-	O	157-158
)	O	158-159
)	O	159-160
mice	O	161-165
on	O	166-168
a	O	169-170
C57BL	O	171-176
/	O	176-177
6	O	177-178
genetic	O	179-186
background	O	187-197
. 	O	197-199

In	O	0-2
contrast	O	3-11
,	O	11-12
no	O	13-15
miRNA	O	16-21
changes	O	22-29
were	O	30-34
detected	O	35-43
in	O	44-46
the	O	47-50
heart	O	51-56
,	O	56-57
an	O	58-60
organ	O	61-66
with	O	67-71
no	O	72-74
known	O	75-80
pathology	O	81-90
during	O	91-97
acute	O	98-103
malaria	O	104-111
. 	O	111-113

We	O	0-2
identified	O	3-13
three	O	14-19
miRNAs	O	20-26
that	O	27-31
were	O	32-36
differentially	O	37-51
expressed	O	52-61
in	O	62-64
the	O	65-68
brain	O	69-74
of	O	75-77
PbA	O	78-81
-	O	81-82
infected	O	82-90
CBA	O	91-94
mice	O	95-99
:	O	99-100
let7i	B	101-106
,	O	106-107
miR	B	108-111
-	I	111-112
27a	I	112-115
,	O	115-116
and	O	117-120
miR	B	121-124
-	I	124-125
150	I	125-128
. 	O	128-130

The	O	0-3
differential	O	4-16
expression	O	17-27
profiles	O	28-36
of	O	37-39
selected	O	40-48
miRNAs	O	49-55
(	O	56-57
let	B	57-60
-	I	60-61
7i	I	61-63
,	O	63-64
miR	B	65-68
-	I	68-69
27a	I	69-72
,	O	72-73
miR	B	74-77
-	I	77-78
150	I	78-81
,	O	81-82
miR	B	83-86
-	I	86-87
126	I	87-90
,	O	90-91
miR	B	92-95
-	I	95-96
210	I	96-99
,	O	99-100
and	O	101-104
miR	B	105-108
-	I	108-109
155	I	109-112
)	O	112-113
were	O	114-118
analyzed	O	119-127
in	O	128-130
mouse	O	131-136
brain	O	137-142
and	O	143-146
heart	O	147-152
tissue	O	153-159
by	O	160-162
quantitative	O	163-175
reverse	O	176-183
transcription	O	184-197
-	O	197-198
PCR	O	198-201
(	O	202-203
qRT	O	203-206
-	O	206-207
PCR	O	207-210
)	O	210-211
. 	O	211-213

Our	O	0-3
data	O	4-8
suggest	O	9-16
that	O	17-21
in	O	22-24
the	O	25-28
CBA	O	29-32
mouse	O	33-38
at	O	39-41
least	O	42-47
,	O	47-48
miRNA	O	49-54
may	O	55-58
have	O	59-63
a	O	64-65
regulatory	O	66-76
role	O	77-81
in	O	82-84
the	O	85-88
pathogenesis	O	89-101
of	O	102-104
severe	O	105-111
malaria	O	112-119
.   	O	119-123

Overexpression	O	0-14
of	O	15-17
these	O	18-23
three	O	24-29
miRNAs	O	30-36
during	O	37-43
PbA	O	44-47
,	O	47-48
but	O	49-52
not	O	53-56
PbK	O	57-60
,	O	60-61
infection	O	62-71
in	O	72-74
WT	O	75-77
mice	O	78-82
may	O	83-86
be	O	87-89
critical	O	90-98
for	O	99-102
the	O	103-106
triggering	O	107-117
of	O	118-120
the	O	121-124
neurological	O	125-137
syndrome	O	138-146
via	O	147-150
regulation	O	151-161
of	O	162-164
their	O	165-170
potential	O	171-180
downstream	O	181-191
targets	O	192-199
. 	O	199-201

The	O	0-3
expression	O	4-14
of	O	15-17
let	B	18-21
-	I	21-22
7i	I	22-24
,	O	24-25
miR	B	26-29
-	I	29-30
27a	I	30-33
,	O	33-34
and	O	35-38
miR	B	39-42
-	I	42-43
150	I	43-46
was	O	47-50
unchanged	O	51-60
in	O	61-63
both	O	64-68
wild	O	69-73
-	O	73-74
type	O	74-78
(	O	79-80
WT	O	80-82
)	O	82-83
and	O	84-87
IFN	O	88-91
-	O	91-92
γ	O	92-93
(	O	93-94
-	O	94-95
/	O	95-96
-	O	96-97
)	O	97-98
mice	O	99-103
following	O	104-113
infection	O	114-123
. 	O	123-125

We	O	0-2
also	O	3-7
discuss	O	8-15
the	O	16-19
implications	O	20-32
of	O	33-35
these	O	36-41
findings	O	42-50
with	O	51-55
respect	O	56-63
to	O	64-66
the	O	67-70
involvement	O	71-82
of	O	83-85
miRNAs	O	86-92
in	O	93-95
the	O	96-99
etiopathology	O	100-113
of	O	114-116
brain	O	117-122
disorders	O	123-132
and	O	133-136
pinpoint	O	137-145
the	O	146-149
emerging	O	150-158
therapeutic	O	159-170
potential	O	171-180
of	O	181-183
miRNAs	O	184-190
for	O	191-194
the	O	195-198
treatment	O	199-208
of	O	209-211
human	O	212-217
diseases	O	218-226
.   	O	226-230

They	O	0-4
are	O	5-8
now	O	9-12
thought	O	13-20
to	O	21-23
be	O	24-26
involved	O	27-35
in	O	36-38
the	O	39-42
control	O	43-50
of	O	51-53
about	O	54-59
one	O	60-63
third	O	64-69
of	O	70-72
all	O	73-76
protein	O	77-84
-	O	84-85
coding	O	85-91
genes	O	92-97
and	O	98-101
play	O	102-106
a	O	107-108
role	O	109-113
in	O	114-116
the	O	117-120
majority	O	121-129
of	O	130-132
cellular	O	133-141
processes	O	142-151
that	O	152-156
have	O	157-161
been	O	162-166
studied	O	167-174
. 	O	174-176

We	O	0-2
focus	O	3-8
on	O	9-11
the	O	12-15
role	O	16-20
of	O	21-23
the	O	24-27
miRNA	O	28-33
pathway	O	34-41
in	O	42-44
brain	O	45-50
development	O	51-62
,	O	62-63
function	O	64-72
,	O	72-73
and	O	74-77
disease	O	78-85
by	O	86-88
highlighting	O	89-101
recent	O	102-108
observations	O	109-121
with	O	122-126
respect	O	127-134
to	O	135-137
miRNA	O	138-143
-	O	143-144
mediated	O	144-152
gene	O	153-157
regulation	O	158-168
in	O	169-171
neuronal	O	172-180
differentiation	O	181-196
,	O	196-197
synaptic	O	198-206
plasticity	O	207-217
,	O	217-218
and	O	219-222
the	O	223-226
circadian	O	227-236
clock	O	237-242
. 	O	242-244

MicroRNAs	O	0-9
in	O	10-12
brain	O	13-18
function	O	19-27
and	O	28-31
disease	O	32-39
.  	O	39-42

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
,	O	18-19
a	O	20-21
class	O	22-27
of	O	28-30
small	O	31-36
,	O	36-37
non	O	38-41
-	O	41-42
protein	O	42-49
-	O	49-50
coding	O	50-56
transcripts	O	57-68
about	O	69-74
21	O	75-77
nucleotides	O	78-89
long	O	90-94
,	O	94-95
have	O	96-100
recently	O	101-109
entered	O	110-117
center	O	118-124
stage	O	125-130
in	O	131-133
the	O	134-137
study	O	138-143
of	O	144-146
posttranscriptional	O	147-166
gene	O	167-171
regulation	O	172-182
. 	O	182-184

In	O	0-2
an	O	3-5
effort	O	6-12
to	O	13-15
shed	O	16-20
light	O	21-26
on	O	27-29
consequences	O	30-42
mediated	O	43-51
by	O	52-54
p53	O	55-58
inactivation	O	59-71
in	O	72-74
gliomas	O	75-82
,	O	82-83
we	O	84-86
established	O	87-98
the	O	99-102
Tet	O	103-106
-	O	106-107
On	O	107-109
system	O	110-116
for	O	117-120
p53	O	121-124
in	O	125-127
the	O	128-131
LN	O	132-134
-	O	134-135
Z308	O	135-139
glioblastoma	O	140-152
cell	O	153-157
line	O	158-162
. 	O	162-164

p53	O	0-3
is	O	4-6
activated	O	7-16
upon	O	17-21
various	O	22-29
kinds	O	30-35
of	O	36-38
cellular	O	39-47
stress	O	48-54
leading	O	55-62
to	O	63-65
apoptosis	O	66-75
or	O	76-78
cell	O	79-83
cycle	O	84-89
arrest	O	90-96
,	O	96-97
but	O	98-101
is	O	102-104
also	O	105-109
implicated	O	110-120
in	O	121-123
complex	O	124-131
biological	O	132-142
processes	O	143-152
such	O	153-157
as	O	158-160
inhibition	O	161-171
of	O	172-174
angiogenesis	O	175-187
and	O	188-191
metastasis	O	192-202
. 	O	202-204

Oxygen	O	0-6
deprivation	O	7-18
,	O	18-19
an	O	20-22
important	O	23-32
cellular	O	33-41
stress	O	42-48
,	O	48-49
revealed	O	50-58
MIC	O	59-62
-	O	62-63
1	O	63-64
as	O	65-67
an	O	68-70
anoxia	O	71-77
responsive	O	78-88
gene	O	89-93
in	O	94-96
glioblastoma	O	97-109
cell	O	110-114
lines	O	115-120
. 	O	120-122

The	O	0-3
macrophage	O	4-14
inhibitory	O	15-25
cytokine	O	26-34
-	O	34-35
1	O	35-36
(	O	37-38
MIC	O	38-41
-	O	41-42
1	O	42-43
)	O	43-44
gene	O	45-49
was	O	50-53
identified	O	54-64
as	O	65-67
a	O	68-69
most	O	70-74
prominent	O	75-84
p53	O	85-88
target	O	89-95
gene	O	96-100
upon	O	101-105
gene	O	106-110
expression	O	111-121
profiling	O	122-131
. 	O	131-133

Furthermore	O	0-11
,	O	11-12
ectopic	O	13-20
expression	O	21-31
of	O	32-34
MIC	O	35-38
-	O	38-39
1	O	39-40
in	O	41-43
LN	O	44-46
-	O	46-47
Z308	O	47-51
cell	O	52-56
line	O	57-61
completely	O	62-72
abolished	O	73-82
its	O	83-86
inherent	O	87-95
tumorigenicity	O	96-110
in	O	111-113
nude	O	114-118
mice	O	119-123
,	O	123-124
while	O	125-130
proliferation	O	131-144
in	O	145-147
vitro	O	148-153
was	O	154-157
not	O	158-161
affected	O	162-170
. 	O	170-172

MIC	O	0-3
-	O	3-4
1	O	4-5
up	O	6-8
-	O	8-9
regulation	O	9-19
by	O	20-22
anoxia	O	23-29
is	O	30-32
mediated	O	33-41
through	O	42-49
an	O	50-52
alternative	O	53-64
,	O	64-65
p53	O	66-69
and	O	70-73
hypoxia	O	74-81
inducible	O	82-91
factor	O	92-98
1	O	99-100
(	O	101-102
HIF	O	102-105
-	O	105-106
1	O	106-107
)	O	107-108
independent	O	109-120
pathway	O	121-128
. 	O	128-130

Taken	O	0-5
together	O	6-14
,	O	14-15
these	O	16-21
data	O	22-26
suggest	O	27-34
that	O	35-39
MIC	O	40-43
-	O	43-44
1	O	44-45
is	O	46-48
an	O	49-51
important	O	52-61
downstream	O	62-72
mediator	O	73-81
of	O	82-84
p53	O	85-88
function	O	89-97
,	O	97-98
while	O	99-104
acting	O	105-111
itself	O	112-118
as	O	119-121
an	O	122-124
intercessor	O	125-136
of	O	137-139
cellular	O	140-148
stress	O	149-155
signaling	O	156-165
and	O	166-169
exerting	O	170-178
anti	O	179-183
-	O	183-184
tumorigenic	O	184-195
activities	O	196-206
.   	O	206-210

In	O	0-2
the	O	3-6
present	O	7-14
experimental	O	15-27
model	O	28-33
MIC	O	34-37
-	O	37-38
1	O	38-39
may	O	40-43
exert	O	44-49
its	O	50-53
anti	O	54-58
-	O	58-59
tumorigenic	O	59-70
properties	O	71-81
via	O	82-85
a	O	86-87
paracrine	O	88-97
mechanism	O	98-107
mediated	O	108-116
by	O	117-119
host	O	120-124
cells	O	125-130
in	O	131-133
vivo	O	134-138
. 	O	138-140

Human	O	0-5
astrocytic	O	6-16
brain	O	17-22
tumors	O	23-29
select	O	30-36
for	O	37-40
mutations	O	41-50
in	O	51-53
the	O	54-57
p53	O	58-61
tumor	O	62-67
suppressor	O	68-78
gene	O	79-83
early	O	84-89
in	O	90-92
malignant	O	93-102
progression	O	103-114
. 	O	114-116

Anoxia	O	0-6
induces	O	7-14
macrophage	O	15-25
inhibitory	O	26-36
cytokine	O	37-45
-	O	45-46
1	O	46-47
(	O	48-49
MIC	O	49-52
-	O	52-53
1	O	53-54
)	O	54-55
in	O	56-58
glioblastoma	O	59-71
cells	O	72-77
independently	O	78-91
of	O	92-94
p53	O	95-98
and	O	99-102
HIF	O	103-106
-	O	106-107
1	O	107-108
.  	O	108-111

This	O	0-4
approach	O	5-13
protected	O	14-23
HSCs	O	24-28
from	O	29-33
GALC	O	34-38
toxicity	O	39-47
and	O	48-51
allowed	O	52-59
successful	O	60-70
treatment	O	71-80
of	O	81-83
a	O	84-85
mouse	O	86-91
GLD	O	92-95
model	O	96-101
,	O	101-102
providing	O	103-112
a	O	113-114
rationale	O	115-124
to	O	125-127
explore	O	128-135
HSC	O	136-139
-	O	139-140
based	O	140-145
gene	O	146-150
therapy	O	151-158
for	O	159-162
GLD	O	163-166
.   	O	166-170

Globoid	O	0-7
cell	O	8-12
leukodystrophy	O	13-27
(	O	28-29
GLD	O	29-32
;	O	32-33
also	O	34-38
known	O	39-44
as	O	45-47
Krabbe	O	48-54
disease	O	55-62
)	O	62-63
is	O	64-66
an	O	67-69
invariably	O	70-80
fatal	O	81-86
lysosomal	O	87-96
storage	O	97-104
disorder	O	105-113
caused	O	114-120
by	O	121-123
mutations	O	124-133
in	O	134-136
the	O	137-140
galactocerebrosidase	O	141-161
(	O	162-163
GALC	O	163-167
)	O	167-168
gene	O	169-173
. 	O	173-175

Hematopoietic	O	0-13
stem	O	14-18
cell	O	19-23
(	O	24-25
HSC	O	25-28
)	O	28-29
-	O	29-30
based	O	30-35
gene	O	36-40
therapy	O	41-48
is	O	49-51
being	O	52-57
explored	O	58-66
for	O	67-70
GLD	O	71-74
;	O	74-75
however	O	76-83
,	O	83-84
we	O	85-87
found	O	88-93
that	O	94-98
forced	O	99-105
GALC	O	106-110
expression	O	111-121
was	O	122-125
toxic	O	126-131
to	O	132-134
HSCs	O	135-139
and	O	140-143
early	O	144-149
progenitors	O	150-161
,	O	161-162
highlighting	O	163-175
the	O	176-179
need	O	180-184
for	O	185-188
improved	O	189-197
regulation	O	198-208
of	O	209-211
vector	O	212-218
expression	O	219-229
. 	O	229-231

Identification	O	0-14
of	O	15-17
hematopoietic	O	18-31
stem	O	32-36
cell	O	37-41
-	O	41-42
specific	O	42-50
miRNAs	O	51-57
enables	O	58-65
gene	O	66-70
therapy	O	71-78
of	O	79-81
globoid	O	82-89
cell	O	90-94
leukodystrophy	O	95-109
.  	O	109-112

Moreover	O	0-8
,	O	8-9
repopulating	O	10-22
HSCs	O	23-27
could	O	28-33
be	O	34-36
purified	O	37-45
solely	O	46-52
on	O	53-55
the	O	56-59
basis	O	60-65
of	O	66-68
miRNA	O	69-74
expression	O	75-85
,	O	85-86
providing	O	87-96
a	O	97-98
new	O	99-102
method	O	103-109
relevant	O	110-118
for	O	119-122
human	O	123-128
HSC	O	129-132
isolation	O	133-142
. 	O	142-144

By	O	0-2
incorporating	O	3-16
miR	B	17-20
-	I	20-21
126	I	21-24
target	O	25-31
sequences	O	32-41
into	O	42-46
a	O	47-48
GALC	O	49-53
-	O	53-54
expressing	O	54-64
vector	O	65-71
,	O	71-72
we	O	73-75
suppressed	O	76-86
GALC	O	87-91
expression	O	92-102
in	O	103-105
HSCs	O	106-110
while	O	111-116
maintaining	O	117-128
robust	O	129-135
expression	O	136-146
in	O	147-149
mature	O	150-156
hematopoietic	O	157-170
cells	O	171-176
. 	O	176-178

We	O	0-2
used	O	3-7
a	O	8-9
genetic	O	10-17
reporter	O	18-26
strategy	O	27-35
based	O	36-41
on	O	42-44
lentiviral	O	45-55
vectors	O	56-63
to	O	64-66
detect	O	67-73
microRNA	O	74-82
activity	O	83-91
in	O	92-94
hematopoietic	O	95-108
cells	O	109-114
at	O	115-117
single	O	118-124
-	O	124-125
cell	O	125-129
resolution	O	130-140
. 	O	140-142

We	O	0-2
report	O	3-9
that	O	10-14
miR	B	15-18
-	I	18-19
126	I	19-22
and	O	23-26
miR	B	27-30
-	I	30-31
130a	I	31-35
were	O	36-40
expressed	O	41-50
in	O	51-53
HSCs	O	54-58
and	O	59-62
early	O	63-68
progenitors	O	69-80
from	O	81-85
both	O	86-90
mice	O	91-95
and	O	96-99
humans	O	100-106
,	O	106-107
but	O	108-111
not	O	112-115
in	O	116-118
differentiated	O	119-133
progeny	O	134-141
. 	O	141-143

The	O	0-3
genomic	O	4-11
sequences	O	12-21
predict	O	22-29
that	O	30-34
miRNAs	O	35-41
are	O	42-45
likely	O	46-52
to	O	53-55
be	O	56-58
derived	O	59-66
from	O	67-71
larger	O	72-78
precursors	O	79-89
that	O	90-94
have	O	95-99
the	O	100-103
capacity	O	104-112
to	O	113-115
form	O	116-120
stem	O	121-125
-	O	125-126
loop	O	126-130
structures	O	131-141
.  	O	141-144

Here	O	0-4
we	O	5-7
report	O	8-14
that	O	15-19
Gemin3	O	20-26
and	O	27-30
Gemin4	O	31-37
are	O	38-41
also	O	42-46
in	O	47-49
a	O	50-51
separate	O	52-60
complex	O	61-68
that	O	69-73
contains	O	74-82
eIF2C2	O	83-89
,	O	89-90
a	O	91-92
member	O	93-99
of	O	100-102
the	O	103-106
Argonaute	O	107-116
protein	O	117-124
family	O	125-131
. 	O	131-133

The	O	0-3
SMN	O	4-7
complex	O	8-15
has	O	16-19
critical	O	20-28
functions	O	29-38
in	O	39-41
the	O	42-45
assembly	O	46-54
/	O	54-55
restructuring	O	55-68
of	O	69-71
diverse	O	72-79
ribonucleoprotein	O	80-97
(	O	98-99
RNP	O	99-102
)	O	102-103
complexes	O	104-113
. 	O	113-115

We	O	0-2
describe	O	3-11
40	O	12-14
miRNAs	O	15-21
,	O	21-22
a	O	23-24
few	O	25-28
of	O	29-31
which	O	32-37
are	O	38-41
identical	O	42-51
to	O	52-54
recently	O	55-63
described	O	64-73
human	O	74-79
miRNAs	O	80-86
,	O	86-87
a	O	88-89
class	O	90-95
of	O	96-98
small	O	99-104
endogenous	O	105-115
RNAs	O	116-120
. 	O	120-122

This	O	0-4
novel	O	5-10
complex	O	11-18
is	O	19-21
a	O	22-23
large	O	24-29
approximately	O	30-43
15S	O	44-47
RNP	O	48-51
that	O	52-56
contains	O	57-65
numerous	O	66-74
microRNAs	O	75-84
(	O	85-86
miRNAs	O	86-92
)	O	92-93
. 	O	93-95

miRNPs	O	0-6
:	O	6-7
a	O	8-9
novel	O	10-15
class	O	16-21
of	O	22-24
ribonucleoproteins	O	25-43
containing	O	44-54
numerous	O	55-63
microRNAs	O	64-73
.  	O	73-76

Reduction	O	0-9
in	O	10-12
SMN	O	13-16
protein	O	17-24
results	O	25-32
in	O	33-35
Spinal	O	36-42
muscular	O	43-51
atrophy	O	52-59
(	O	60-61
SMA	O	61-64
)	O	64-65
,	O	65-66
a	O	67-68
common	O	69-75
neurodegenerative	O	76-93
disease	O	94-101
. 	O	101-103

Gemin3	O	0-6
is	O	7-9
a	O	10-11
DEAD	O	12-16
-	O	16-17
box	O	17-20
RNA	O	21-24
helicase	O	25-33
that	O	34-38
binds	O	39-44
to	O	45-47
the	O	48-51
Survival	O	52-60
of	O	61-63
Motor	O	64-69
Neurons	O	70-77
(	O	78-79
SMN	O	79-82
)	O	82-83
protein	O	84-91
and	O	92-95
is	O	96-98
a	O	99-100
component	O	101-110
of	O	111-113
the	O	114-117
SMN	O	118-121
complex	O	122-129
,	O	129-130
which	O	131-136
also	O	137-141
comprises	O	142-151
SMN	O	152-155
,	O	155-156
Gemin2	O	157-163
,	O	163-164
Gemin4	O	165-171
,	O	171-172
Gemin5	O	173-179
,	O	179-180
and	O	181-184
Gemin6	O	185-191
. 	O	191-193

Defective	O	0-9
RNA	O	10-13
metabolism	O	14-24
is	O	25-27
an	O	28-30
emerging	O	31-39
mechanism	O	40-49
involved	O	50-58
in	O	59-61
ALS	O	62-65
pathogenesis	O	66-78
and	O	79-82
possibly	O	83-91
in	O	92-94
other	O	95-100
neurodegenerative	O	101-118
disorders	O	119-128
. 	O	128-130

miRNA	O	0-5
malfunction	O	6-17
causes	O	18-24
spinal	O	25-31
motor	O	32-37
neuron	O	38-44
disease	O	45-52
.  	O	52-55

Thus	O	0-4
,	O	4-5
mice	O	6-10
that	O	11-15
do	O	16-18
not	O	19-22
process	O	23-30
miRNA	O	31-36
in	O	37-39
SMNs	O	40-44
exhibit	O	45-52
hallmarks	O	53-62
of	O	63-65
spinal	O	66-72
muscular	O	73-81
atrophy	O	82-89
(	O	90-91
SMA	O	91-94
)	O	94-95
,	O	95-96
including	O	97-106
sclerosis	O	107-116
of	O	117-119
the	O	120-123
spinal	O	124-130
cord	O	131-135
ventral	O	136-143
horns	O	144-149
,	O	149-150
aberrant	O	151-159
end	O	160-163
plate	O	164-169
architecture	O	170-182
,	O	182-183
and	O	184-187
myofiber	O	188-196
atrophy	O	197-204
with	O	205-209
signs	O	210-215
of	O	216-218
denervation	O	219-230
. 	O	230-232

Here	O	0-4
,	O	4-5
we	O	6-8
show	O	9-13
that	O	14-18
microRNA	O	19-27
(	O	28-29
miRNA	O	29-34
)	O	34-35
activity	O	36-44
is	O	45-47
essential	O	48-57
for	O	58-61
long	O	62-66
-	O	66-67
term	O	67-71
survival	O	72-80
of	O	81-83
postmitotic	O	84-95
spinal	O	96-102
motor	O	103-108
neurons	O	109-116
(	O	117-118
SMNs	O	118-122
)	O	122-123
in	O	124-126
vivo	O	127-131
. 	O	131-133

We	O	0-2
demonstrate	O	3-14
that	O	15-19
the	O	20-23
heavy	O	24-29
neurofilament	O	30-43
subunit	O	44-51
is	O	52-54
a	O	55-56
target	O	57-63
of	O	64-66
miR	B	67-70
-	I	70-71
9	I	71-72
,	O	72-73
a	O	74-75
miRNA	O	76-81
that	O	82-86
is	O	87-89
specifically	O	90-102
down	O	103-107
-	O	107-108
regulated	O	108-117
in	O	118-120
a	O	121-122
genetic	O	123-130
model	O	131-136
of	O	137-139
SMA	O	140-143
. 	O	143-145

Furthermore	O	0-11
,	O	11-12
a	O	13-14
neurofilament	O	15-28
heavy	O	29-34
subunit	O	35-42
previously	O	43-53
implicated	O	54-64
in	O	65-67
motor	O	68-73
neuron	O	74-80
degeneration	O	81-93
is	O	94-96
specifically	O	97-109
up	O	110-112
-	O	112-113
regulated	O	113-122
in	O	123-125
miRNA	O	126-131
-	O	131-132
deficient	O	132-141
SMNs	O	142-146
. 	O	146-148

These	O	0-5
data	O	6-10
provide	O	11-18
evidence	O	19-27
for	O	28-31
miRNA	O	32-37
function	O	38-46
in	O	47-49
SMN	O	50-53
diseases	O	54-62
and	O	63-66
emphasize	O	67-76
the	O	77-80
potential	O	81-90
role	O	91-95
of	O	96-98
miR	B	99-102
-	I	102-103
9	I	103-104
-	O	104-105
based	O	105-110
regulatory	O	111-121
mechanisms	O	122-132
in	O	133-135
adult	O	136-141
neurons	O	142-149
and	O	150-153
neurodegenerative	O	154-171
states	O	172-178
.   	O	178-182

Novel	O	0-5
animal	O	6-12
models	O	13-19
for	O	20-23
studying	O	24-32
complex	O	33-40
brain	O	41-46
disorders	O	47-56
:	O	56-57
BAC	O	58-61
-	O	61-62
driven	O	62-68
miRNA	O	69-74
-	O	74-75
mediated	O	75-83
in	O	84-86
vivo	O	87-91
silencing	O	92-101
of	O	102-104
gene	O	105-109
expression	O	110-120
.  	O	120-123

In	O	0-2
schizophrenia	O	3-16
,	O	16-17
glutamic	O	18-26
acid	O	27-31
decarboxylase	O	32-45
1	O	46-47
(	O	48-49
GAD1	O	49-53
)	O	53-54
disturbances	O	55-67
are	O	68-71
robust	O	72-78
,	O	78-79
consistently	O	80-92
observed	O	93-101
,	O	101-102
cell	O	103-107
-	O	107-108
type	O	108-112
specific	O	113-121
and	O	122-125
represent	O	126-135
a	O	136-137
core	O	138-142
feature	O	143-150
of	O	151-153
the	O	154-157
disease	O	158-165
. 	O	165-167

In	O	0-2
addition	O	3-11
,	O	11-12
neuropeptide	O	13-25
Y	O	26-27
(	O	28-29
NPY	O	29-32
)	O	32-33
,	O	33-34
which	O	35-40
is	O	41-43
a	O	44-45
phenotypic	O	46-56
marker	O	57-63
of	O	64-66
a	O	67-68
sub	O	69-72
-	O	72-73
population	O	73-83
of	O	84-86
GAD1	O	87-91
-	O	91-92
containing	O	92-102
interneurons	O	103-115
,	O	115-116
has	O	117-120
shown	O	121-126
reduced	O	127-134
expression	O	135-145
in	O	146-148
the	O	149-152
prefrontal	O	153-163
cortex	O	164-170
in	O	171-173
subjects	O	174-182
with	O	183-187
schizophrenia	O	188-201
,	O	201-202
suggesting	O	203-213
that	O	214-218
dysfunction	O	219-230
of	O	231-233
the	O	234-237
NPY	O	238-241
+	O	241-242
cortical	O	243-251
interneuronal	O	252-265
sub	O	266-269
-	O	269-270
population	O	270-280
might	O	281-286
be	O	287-289
a	O	290-291
core	O	292-296
feature	O	297-304
of	O	305-307
this	O	308-312
devastating	O	313-324
disorder	O	325-333
. 	O	333-335

However	O	0-7
,	O	7-8
modeling	O	9-17
gene	O	18-22
expression	O	23-33
disturbances	O	34-46
in	O	47-49
schizophrenia	O	50-63
in	O	64-66
a	O	67-68
cell	O	69-73
type	O	74-78
-	O	78-79
specific	O	79-87
manner	O	88-94
has	O	95-98
been	O	99-103
extremely	O	104-113
challenging	O	114-125
. 	O	125-127

To	O	0-2
more	O	3-7
closely	O	8-15
mimic	O	16-21
these	O	22-27
molecular	O	28-37
and	O	38-41
cellular	O	42-50
human	O	51-56
post	O	57-61
-	O	61-62
mortem	O	62-68
findings	O	69-77
,	O	77-78
we	O	79-81
generated	O	82-91
a	O	92-93
transgenic	O	94-104
mouse	O	105-110
in	O	111-113
which	O	114-119
we	O	120-122
downregulated	O	123-136
GAD1	O	137-141
mRNA	O	142-146
expression	O	147-157
specifically	O	158-170
in	O	171-173
NPY	O	174-177
+	O	177-178
neurons	O	179-186
. 	O	186-188

This	O	0-4
novel	O	5-10
,	O	10-11
cell	O	12-16
type	O	17-21
-	O	21-22
specific	O	22-30
in	O	31-33
vivo	O	34-38
system	O	39-45
for	O	46-49
reducing	O	50-58
gene	O	59-63
expression	O	64-74
uses	O	75-79
a	O	80-81
bacterial	O	82-91
artificial	O	92-102
chromosome	O	103-113
(	O	114-115
BAC	O	115-118
)	O	118-119
containing	O	120-130
the	O	131-134
NPY	O	135-138
promoter	O	139-147
-	O	147-148
enhancer	O	148-156
elements	O	157-165
,	O	165-166
the	O	167-170
reporter	O	171-179
molecule	O	180-188
(	O	189-190
eGFP	O	190-194
)	O	194-195
and	O	196-199
a	O	200-201
modified	O	202-210
intron	O	211-217
containing	O	218-228
a	O	229-230
synthetic	O	231-240
microRNA	O	241-249
(	O	250-251
miRNA	O	251-256
)	O	256-257
targeted	O	258-266
to	O	267-269
GAD1	O	270-274
. 	O	274-276

The	O	0-3
animals	O	4-11
of	O	12-14
isogenic	O	15-23
strains	O	24-31
are	O	32-35
generated	O	36-45
rapidly	O	46-53
,	O	53-54
providing	O	55-64
a	O	65-66
new	O	67-70
tool	O	71-75
for	O	76-79
better	O	80-86
understanding	O	87-100
the	O	101-104
molecular	O	105-114
disturbances	O	115-127
in	O	128-130
the	O	131-134
GABAergic	O	135-144
system	O	145-151
observed	O	152-160
in	O	161-163
complex	O	164-171
neuropsychiatric	O	172-188
disorders	O	189-198
such	O	199-203
as	O	204-206
schizophrenia	O	207-220
. 	O	220-222

In	O	0-2
the	O	3-6
future	O	7-13
,	O	13-14
because	O	15-22
of	O	23-25
the	O	26-29
small	O	30-35
size	O	36-40
of	O	41-43
the	O	44-47
silencing	O	48-57
miRNAs	O	58-64
combined	O	65-73
with	O	74-78
our	O	79-82
BAC	O	83-86
strategy	O	87-95
,	O	95-96
this	O	97-101
method	O	102-108
may	O	109-112
be	O	113-115
modified	O	116-124
to	O	125-127
allow	O	128-133
generation	O	134-144
of	O	145-147
mice	O	148-152
with	O	153-157
simultaneous	O	158-170
silencing	O	171-180
of	O	181-183
multiple	O	184-192
genes	O	193-198
in	O	199-201
the	O	202-205
same	O	206-210
cells	O	211-216
with	O	217-221
a	O	222-223
single	O	224-230
construct	O	231-240
,	O	240-241
and	O	242-245
production	O	246-256
of	O	257-259
splice	O	260-266
-	O	266-267
variant	O	267-274
-	O	274-275
specific	O	275-283
knockdown	O	284-293
animals	O	294-301
.   	O	301-305

Through	O	0-7
various	O	8-15
experimental	O	16-28
approaches	O	29-39
,	O	39-40
we	O	41-43
validated	O	44-53
computational	O	54-67
predictions	O	68-79
and	O	80-83
demonstrated	O	84-96
that	O	97-101
miR	B	102-105
-	I	105-106
298	I	106-109
and	O	110-113
miR	B	114-117
-	I	117-118
328	I	118-121
recognize	O	122-131
specific	O	132-140
binding	O	141-148
sites	O	149-154
in	O	155-157
the	O	158-161
3	O	162-163
'	O	163-164
-	O	164-165
UTR	O	165-168
of	O	169-171
BACE1	O	172-177
mRNA	O	178-182
and	O	183-186
exert	O	187-192
regulatory	O	193-203
effects	O	204-211
on	O	212-214
BACE1	O	215-220
protein	O	221-228
expression	O	229-239
in	O	240-242
cultured	O	243-251
neuronal	O	252-260
cells	O	261-266
. 	O	266-268

Here	O	0-4
we	O	5-7
also	O	8-12
observed	O	13-21
a	O	22-23
loss	O	24-28
of	O	29-31
correlation	O	32-43
between	O	44-51
BACE1	O	52-57
mRNA	O	58-62
and	O	63-66
protein	O	67-74
levels	O	75-81
in	O	82-84
the	O	85-88
hippocampus	O	89-100
of	O	101-103
a	O	104-105
mouse	O	106-111
model	O	112-117
of	O	118-120
AD	O	121-123
.	O	123-124
Consistent	O	125-135
with	O	136-140
an	O	141-143
impairment	O	144-154
of	O	155-157
miRNA	O	158-163
-	O	163-164
mediated	O	164-172
regulation	O	173-183
of	O	184-186
BACE1	O	187-192
expression	O	193-203
,	O	203-204
these	O	205-210
findings	O	211-219
prompted	O	220-228
us	O	229-231
to	O	232-234
investigate	O	235-246
the	O	247-250
regulatory	O	251-261
role	O	262-266
of	O	267-269
the	O	270-273
BACE1	O	274-279
3	O	280-281
'	O	281-282
-	O	282-283
UTR	O	283-286
element	O	287-294
and	O	295-298
the	O	299-302
possible	O	303-311
involvement	O	312-323
of	O	324-326
specific	O	327-335
miRNAs	O	336-342
in	O	343-345
cultured	O	346-354
neuronal	O	355-363
(	O	364-365
N2a	O	365-368
)	O	368-369
and	O	370-373
fibroblastic	O	374-386
(	O	387-388
NIH	O	388-391
3T3	O	392-395
)	O	395-396
cells	O	397-402
. 	O	402-404

Our	O	0-3
results	O	4-11
may	O	12-15
provide	O	16-23
the	O	24-27
molecular	O	28-37
basis	O	38-43
underlying	O	44-54
BACE1	O	55-60
deregulation	O	61-73
in	O	74-76
AD	O	77-79
and	O	80-83
offer	O	84-89
new	O	90-93
perspectives	O	94-106
on	O	107-109
the	O	110-113
etiology	O	114-122
of	O	123-125
this	O	126-130
neurological	O	131-143
disorder	O	144-152
.   	O	152-156

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
key	O	23-26
regulatory	O	27-37
RNAs	O	38-42
known	O	43-48
to	O	49-51
repress	O	52-59
mRNA	O	60-64
translation	O	65-76
through	O	77-84
recognition	O	85-96
of	O	97-99
specific	O	100-108
binding	O	109-116
sites	O	117-122
located	O	123-130
mainly	O	131-137
in	O	138-140
their	O	141-146
3	O	147-148
'	O	148-149
-	O	149-150
untranslated	O	150-162
region	O	163-169
(	O	170-171
UTR	O	171-174
)	O	174-175
. 	O	175-177

MicroRNA	B	0-8
-	I	8-9
298	I	9-12
and	O	13-16
microRNA	B	17-25
-	I	25-26
328	I	26-29
regulate	O	30-38
expression	O	39-49
of	O	50-52
mouse	O	53-58
beta	O	59-63
-	O	63-64
amyloid	O	64-71
precursor	O	72-81
protein	O	82-89
-	O	89-90
converting	O	90-100
enzyme	O	101-107
1	O	108-109
.  	O	109-112

Intriguingly	O	0-12
,	O	12-13
previous	O	14-22
post	O	23-27
-	O	27-28
mortem	O	28-34
analyses	O	35-43
showed	O	44-50
higher	O	51-57
beta	O	58-62
-	O	62-63
amyloid	O	63-70
precursor	O	71-80
protein	O	81-88
-	O	88-89
converting	O	89-99
enzyme	O	100-106
(	O	107-108
BACE	O	108-112
)	O	112-113
protein	O	114-121
,	O	121-122
but	O	123-126
not	O	127-130
mRNA	O	131-135
,	O	135-136
levels	O	137-143
in	O	144-146
the	O	147-150
brain	O	151-156
of	O	157-159
patients	O	160-168
that	O	169-173
suffered	O	174-182
from	O	183-187
Alzheimer	O	188-197
disease	O	198-205
(	O	206-207
AD	O	207-209
)	O	209-210
. 	O	210-212

Loss	O	0-4
of	O	5-7
specific	O	8-16
miRNA	O	17-22
control	O	23-30
of	O	31-33
gene	O	34-38
expression	O	39-49
is	O	50-52
thus	O	53-57
expected	O	58-66
to	O	67-69
underlie	O	70-78
serious	O	79-86
genetic	O	87-94
diseases	O	95-103
. 	O	103-105

MiRNAs	O	0-6
microarray	O	7-17
analysis	O	18-26
results	O	27-34
showed	O	35-41
that	O	42-46
125	O	47-50
miRNAs	O	51-57
were	O	58-62
detected	O	63-71
in	O	72-74
the	O	75-78
hippocampus	O	79-90
of	O	91-93
lithium	O	94-101
-	O	101-102
pilocarpine	O	102-113
-	O	113-114
induced	O	114-121
TLE	O	122-125
rats	O	126-130
and	O	131-134
normal	O	135-141
rats	O	142-146
. 	O	146-148

To	O	0-2
understand	O	3-13
the	O	14-17
role	O	18-22
of	O	23-25
miRNAs	O	26-32
in	O	33-35
the	O	36-39
molecular	O	40-49
mechanisms	O	50-60
of	O	61-63
temporal	O	64-72
lobe	O	73-77
epilepsy	O	78-86
(	O	87-88
TLE	O	88-91
)	O	91-92
,	O	92-93
we	O	94-96
investigated	O	97-109
the	O	110-113
changes	O	114-121
in	O	122-124
microRNA	O	125-133
(	O	134-135
miRNA	O	135-140
)	O	140-141
expression	O	142-152
profiles	O	153-161
of	O	162-164
chronic	O	165-172
TLE	O	173-176
rat	O	177-180
models	O	181-187
. 	O	187-189

Temporal	O	0-8
lobe	O	9-13
epilepsy	O	14-22
induces	O	23-30
differential	O	31-43
expression	O	44-54
of	O	55-57
hippocampal	O	58-69
miRNAs	O	70-76
including	O	77-86
let	B	87-90
-	I	90-91
7e	I	91-93
and	O	94-97
miR	B	98-101
-	I	101-102
23a	I	102-105
/	I	105-106
b	I	106-107
.  	O	107-110

let	B	0-3
-	I	3-4
7e	I	4-6
was	O	7-10
detected	O	11-19
down	O	20-24
-	O	24-25
regulated	O	25-34
expression	O	35-45
at	O	46-48
0h	O	49-51
,	O	51-52
1h	O	53-55
,	O	55-56
6h	O	57-59
,	O	59-60
2days	O	61-66
,	O	66-67
7days	O	68-73
,	O	73-74
50days	O	75-81
after	O	82-87
SE	O	88-90
and	O	91-94
up	O	95-97
-	O	97-98
regulated	O	98-107
expression	O	108-118
at	O	119-121
12h	O	122-125
,	O	125-126
24h	O	127-130
,	O	130-131
10days	O	132-138
,	O	138-139
30days	O	140-146
after	O	147-152
SE	O	153-155
,	O	155-156
which	O	157-162
was	O	163-166
significantly	O	167-180
up	O	181-183
-	O	183-184
regulated	O	184-193
expression	O	194-204
at	O	205-207
24h	O	208-211
after	O	212-217
SE	O	218-220
(	O	221-222
10	O	222-224
.	O	224-225
49	O	225-227
folds	O	228-233
,	O	233-234
P	O	235-236
<	O	236-237
0	O	237-238
.	O	238-239
01	O	239-241
)	O	241-242
. 	O	242-244

miR	B	0-3
-	I	3-4
23a	I	4-7
/	I	7-8
b	I	8-9
was	O	10-13
detected	O	14-22
down	O	23-27
-	O	27-28
regulated	O	28-37
at	O	38-40
0h	O	41-43
,	O	43-44
1h	O	45-47
,	O	47-48
6h	O	49-51
,	O	51-52
12h	O	53-56
,	O	56-57
2days	O	58-63
,	O	63-64
7days	O	65-70
,	O	70-71
10days	O	72-78
,	O	78-79
30days	O	80-86
after	O	87-92
SE	O	93-95
and	O	96-99
significantly	O	100-113
up	O	114-116
-	O	116-117
regulated	O	117-126
at	O	127-129
24h	O	130-133
(	O	134-135
4	O	135-136
.	O	136-137
49	O	137-139
folds	O	140-145
P	O	146-147
<	O	147-148
0	O	148-149
.	O	149-150
01	O	150-152
)	O	152-153
,	O	153-154
50d	O	155-158
(	O	159-160
2	O	160-161
.	O	161-162
4	O	162-163
folds	O	164-169
,	O	169-170
P	O	171-172
<	O	172-173
0	O	173-174
.	O	174-175
01	O	175-177
)	O	177-178
after	O	179-184
SE	O	185-187
.	O	187-188
TLE	O	189-192
alters	O	193-199
the	O	200-203
expression	O	204-214
levels	O	215-221
of	O	222-224
a	O	225-226
subset	O	227-233
of	O	234-236
miRNAs	O	237-243
in	O	244-246
the	O	247-250
hippocampus	O	251-262
and	O	263-266
these	O	267-272
deregulated	O	273-284
miRNAs	O	285-291
may	O	292-295
be	O	296-298
involved	O	299-307
in	O	308-310
the	O	311-314
pathogenesis	O	315-327
of	O	328-330
epilepsy	O	331-339
directly	O	340-348
or	O	349-351
indirectly	O	352-362
. 	O	362-364

Compared	O	0-8
with	O	9-13
normal	O	14-20
rats	O	21-25
(	O	26-27
control	O	27-34
group	O	35-40
)	O	40-41
,	O	41-42
23	O	43-45
of	O	46-48
the	O	49-52
125	O	53-56
miRNAs	O	57-63
were	O	64-68
expressed	O	69-78
differentially	O	79-93
in	O	94-96
TLE	O	97-100
rats	O	101-105
including	O	106-115
5	O	116-117
down	O	118-122
-	O	122-123
regulated	O	123-132
miRNAs	O	133-139
(	O	140-141
let	B	141-144
-	I	144-145
7e	I	145-147
included	O	148-156
)	O	156-157
and	O	158-161
18	O	162-164
up	O	165-167
-	O	167-168
regulated	O	168-177
miRNAs	O	178-184
(	O	185-186
miR	B	186-189
-	I	189-190
23a	I	190-193
/	I	193-194
b	I	194-195
included	O	196-204
)	O	204-205
. 	O	205-207

Furthermore	O	0-11
,	O	11-12
let	B	13-16
-	I	16-17
7e	I	17-19
and	O	20-23
miR	B	24-27
-	I	27-28
23a	I	28-31
/	I	31-32
b	I	32-33
analysis	O	34-42
in	O	43-45
rat	O	46-49
hippocampus	O	50-61
were	O	62-66
performed	O	67-76
by	O	77-79
real	O	80-84
-	O	84-85
time	O	85-89
quantitative	O	90-102
polymerase	O	103-113
chain	O	114-119
reaction	O	120-128
at	O	129-131
0h	O	132-134
,	O	134-135
1h	O	136-138
,	O	138-139
6h	O	140-142
,	O	142-143
12h	O	144-147
,	O	147-148
24h	O	149-152
,	O	152-153
2days	O	154-159
,	O	159-160
7days	O	161-166
,	O	166-167
10days	O	167-173
,	O	173-174
30days	O	175-181
,	O	181-182
50days	O	182-188
after	O	189-194
induction	O	195-204
of	O	205-207
status	O	208-214
epilepticus	O	215-226
(	O	227-228
SE	O	228-230
)	O	230-231
. 	O	231-233

Also	O	0-4
the	O	5-8
temporal	O	9-17
change	O	18-24
of	O	25-27
the	O	28-31
let	B	32-35
-	I	35-36
7e	I	36-38
and	O	39-42
miR	B	43-46
-	I	46-47
23a	I	47-50
/	I	50-51
b	I	51-52
expression	O	53-63
in	O	64-66
the	O	67-70
epileptogenesis	O	71-86
indicated	O	87-96
their	O	97-102
underlying	O	103-113
functions	O	114-123
on	O	124-126
TLE	O	127-130
.   	O	130-134

However	O	0-7
,	O	7-8
prior	O	9-14
to	O	15-17
expression	O	18-28
,	O	28-29
it	O	30-32
is	O	33-35
necessary	O	36-45
to	O	46-48
convert	O	49-56
the	O	57-60
single	O	61-67
-	O	67-68
stranded	O	68-76
DNA	O	77-80
genome	O	81-87
into	O	88-92
double	O	93-99
-	O	99-100
stranded	O	100-108
DNA	O	109-112
,	O	112-113
which	O	114-119
hinders	O	120-127
the	O	128-131
efficiency	O	132-142
of	O	143-145
these	O	146-151
vectors	O	152-159
. 	O	159-161

Numerous	O	0-8
studies	O	9-16
and	O	17-20
clinical	O	21-29
trials	O	30-36
have	O	37-41
demonstrated	O	42-54
the	O	55-58
efficacy	O	59-67
of	O	68-70
recombinant	O	71-82
adeno	O	83-88
-	O	88-89
associated	O	89-99
virus	O	100-105
gene	O	106-110
delivery	O	111-119
vectors	O	120-127
. 	O	127-129

[	O	0-1
Trends	O	1-7
in	O	8-10
development	O	11-22
of	O	23-25
self	O	26-30
-	O	30-31
complementary	O	31-44
adeno	O	45-50
-	O	50-51
associated	O	51-61
virus	O	62-67
vector	O	68-74
]	O	74-75
.  	O	75-78

We	O	0-2
can	O	3-6
entirely	O	7-15
circumvent	O	16-26
this	O	27-31
step	O	32-36
through	O	37-44
the	O	45-48
use	O	49-52
of	O	53-55
self	O	56-60
-	O	60-61
complementary	O	61-74
recombinant	O	75-86
adeno	O	87-92
-	O	92-93
associated	O	93-103
virus	O	104-109
vector	O	110-116
(	O	117-118
scrAAV	O	118-124
)	O	124-125
. 	O	125-127

ScrAAV	O	0-6
packages	O	7-15
an	O	16-18
inverted	O	19-27
repeat	O	28-34
genome	O	35-41
that	O	42-46
can	O	47-50
fold	O	51-55
into	O	56-60
double	O	61-67
-	O	67-68
stranded	O	68-76
DNA	O	77-80
without	O	81-88
the	O	89-92
requirement	O	93-104
for	O	105-108
DNA	O	109-112
synthesis	O	113-122
or	O	123-125
base	O	126-130
-	O	130-131
pairing	O	131-138
between	O	139-146
multiple	O	147-155
vector	O	156-162
genomes	O	163-170
. 	O	170-172

By	O	0-2
using	O	3-8
scrAAV	O	9-15
,	O	15-16
we	O	17-19
could	O	20-25
increase	O	26-34
expression	O	35-45
efficiency	O	46-56
and	O	57-60
reduce	O	61-67
immune	O	68-74
response	O	75-83
caused	O	84-90
by	O	91-93
vectors	O	94-101
themselves	O	102-112
. 	O	112-114

Therefore	O	0-9
,	O	9-10
it	O	11-13
is	O	14-16
a	O	17-18
promising	O	19-28
vector	O	29-35
for	O	36-39
gene	O	40-44
therapy	O	45-52
. 	O	52-54

So	O	0-2
far	O	3-6
,	O	6-7
it	O	8-10
has	O	11-14
been	O	15-19
used	O	20-24
in	O	25-27
the	O	28-31
treatment	O	32-41
of	O	42-44
hepatic	O	45-52
diseases	O	53-61
,	O	61-62
central	O	63-70
nervous	O	71-78
system	O	79-85
diseases	O	86-94
,	O	94-95
and	O	96-99
eye	O	100-103
diseases	O	104-112
. 	O	112-114

It	O	0-2
has	O	3-6
also	O	7-11
been	O	12-16
used	O	17-21
in	O	22-24
the	O	25-28
modifications	O	29-42
of	O	43-45
stem	O	46-50
cells	O	51-56
and	O	57-60
as	O	61-63
vectors	O	64-71
for	O	72-75
siRNA	O	76-81
/	O	81-82
miRNA	O	82-87
and	O	88-91
ribozymes	O	92-101
. 	O	101-103

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
focused	O	19-26
on	O	27-29
the	O	30-33
preparation	O	34-45
,	O	45-46
expression	O	47-57
and	O	58-61
location	O	62-70
of	O	71-73
scrAAV	O	74-80
both	O	81-85
in	O	86-88
vitro	O	89-94
and	O	95-98
in	O	99-101
vivo	O	102-106
. 	O	106-108

We	O	0-2
mainly	O	3-9
introduced	O	10-20
the	O	21-24
recent	O	25-31
progress	O	32-40
of	O	41-43
scrAAV	O	44-50
based	O	51-56
therapy	O	57-64
of	O	65-67
Hemophilia	O	68-78
B	O	79-80
,	O	80-81
in	O	82-84
order	O	85-90
to	O	91-93
elucidate	O	94-103
the	O	104-107
potential	O	108-117
and	O	118-121
prospects	O	122-131
of	O	132-134
scrAAV	O	135-141
in	O	142-144
gene	O	145-149
therapy	O	150-157
.   	O	157-161

Learning	O	0-8
,	O	8-9
retention	O	10-19
and	O	20-23
generalization	O	24-38
of	O	39-41
a	O	42-43
mirror	O	44-50
tracing	O	51-58
skill	O	59-64
in	O	65-67
Alzheimer	O	68-77
'	O	77-78
s	O	78-79
disease	O	80-87
.  	O	87-90

The	O	0-3
present	O	4-11
study	O	12-17
examined	O	18-26
the	O	27-30
ability	O	31-38
of	O	39-41
12	O	42-44
patients	O	45-53
with	O	54-58
probable	O	59-67
Alzheimer	O	68-77
'	O	77-78
s	O	78-79
disease	O	80-87
(	O	88-89
AD	O	89-91
)	O	91-92
and	O	93-96
12	O	97-99
age	O	100-103
-	O	103-104
and	O	105-108
education	O	109-118
-	O	118-119
matched	O	119-126
normal	O	127-133
control	O	134-141
(	O	142-143
NC	O	143-145
)	O	145-146
subjects	O	147-155
to	O	156-158
learn	O	159-164
and	O	165-168
retain	O	169-175
the	O	176-179
visuomotor	O	180-190
skills	O	191-197
necessary	O	198-207
to	O	208-210
efficiently	O	211-222
trace	O	223-228
a	O	229-230
pattern	O	231-238
(	O	239-240
e	O	240-241
.	O	241-242
g	O	242-243
.	O	243-244
,	O	244-245
a	O	246-247
4	O	248-249
-	O	249-250
or	O	251-253
6	O	254-255
-	O	255-256
pointed	O	256-263
star	O	264-268
)	O	268-269
seen	O	270-274
only	O	275-279
in	O	280-282
mirror	O	283-289
-	O	289-290
reversed	O	290-298
view	O	299-303
. 	O	303-305

Those	O	0-5
AD	O	6-8
(	O	9-10
N	O	10-11
=	O	11-12
6	O	12-13
)	O	13-14
and	O	15-18
NC	O	19-21
(	O	22-23
N	O	23-24
=	O	24-25
7	O	25-26
)	O	26-27
subjects	O	28-36
who	O	37-40
were	O	41-45
able	O	46-50
to	O	51-53
initially	O	54-63
perform	O	64-71
the	O	72-75
basic	O	76-81
mirror	O	82-88
tracing	O	89-96
task	O	97-101
did	O	102-105
not	O	106-109
differ	O	110-116
significantly	O	117-130
in	O	131-133
initial	O	134-141
level	O	142-147
of	O	148-150
performance	O	151-162
,	O	162-163
learning	O	164-172
over	O	173-177
trials	O	178-184
,	O	184-185
retention	O	186-195
of	O	196-198
the	O	199-202
skill	O	203-208
over	O	209-213
a	O	214-215
30	O	216-218
-	O	218-219
min	O	219-222
delay	O	223-228
interval	O	229-237
,	O	237-238
and	O	239-242
generalization	O	243-257
of	O	258-260
the	O	261-264
skill	O	265-270
to	O	271-273
a	O	274-275
new	O	276-279
figure	O	280-286
or	O	287-289
to	O	290-292
the	O	293-296
opposite	O	297-305
direction	O	306-315
of	O	316-318
tracing	O	319-326
. 	O	326-328

The	O	0-3
AD	O	4-6
patients	O	7-15
who	O	16-19
were	O	20-24
unable	O	25-31
to	O	32-34
initially	O	35-44
perform	O	45-52
the	O	53-56
mirror	O	57-63
tracing	O	64-71
task	O	72-76
were	O	77-81
significantly	O	82-95
worse	O	96-101
than	O	102-106
those	O	107-112
who	O	113-116
could	O	117-122
perform	O	123-130
the	O	131-134
task	O	135-139
on	O	140-142
several	O	143-150
neuropsychological	O	151-169
measures	O	170-178
sensitive	O	179-188
to	O	189-191
deficits	O	192-200
in	O	201-203
problem	O	204-211
solving	O	212-219
and	O	220-223
executive	O	224-233
functions	O	234-243
,	O	243-244
but	O	245-248
not	O	249-252
on	O	253-255
tests	O	256-261
of	O	262-264
global	O	265-271
cognitive	O	272-281
decline	O	282-289
,	O	289-290
memory	O	291-297
,	O	297-298
language	O	299-307
,	O	307-308
or	O	309-311
visuoperceptual	O	312-327
functioning	O	328-339
. 	O	339-341

These	O	0-5
results	O	6-13
indicate	O	14-22
that	O	23-27
acquisition	O	28-39
and	O	40-43
retention	O	44-53
of	O	54-56
a	O	57-58
complex	O	59-66
visuomotor	O	67-77
skill	O	78-83
can	O	84-87
proceed	O	88-95
normally	O	96-104
in	O	105-107
the	O	108-111
early	O	112-117
stages	O	118-124
of	O	125-127
AD	O	128-130
in	O	131-133
those	O	134-139
individuals	O	140-151
who	O	152-155
can	O	156-159
initially	O	160-169
perform	O	170-177
the	O	178-181
basic	O	182-187
task	O	188-192
,	O	192-193
and	O	194-197
that	O	198-202
inability	O	203-212
to	O	213-215
perform	O	216-223
the	O	224-227
basic	O	228-233
task	O	234-238
may	O	239-242
be	O	243-245
related	O	246-253
to	O	254-256
the	O	257-260
frontal	O	261-268
lobe	O	269-273
dysfunction	O	274-285
that	O	286-290
is	O	291-293
often	O	294-299
prominent	O	300-309
in	O	310-312
the	O	313-316
disorder	O	317-325
.   	O	325-329

This	O	0-4
review	O	5-11
reports	O	12-19
the	O	20-23
current	O	24-31
knowledge	O	32-41
of	O	42-44
microRNA	O	45-53
(	O	54-55
miRNA	O	55-60
)	O	60-61
expression	O	62-72
in	O	73-75
pituitary	O	76-85
adenomas	O	86-94
,	O	94-95
focusing	O	96-104
on	O	105-107
recent	O	108-114
microarray	O	115-125
data	O	126-130
. 	O	130-132

Moreover	O	0-8
,	O	8-9
a	O	10-11
discussion	O	12-22
is	O	23-25
provided	O	26-34
concerning	O	35-45
the	O	46-49
possible	O	50-58
role	O	59-63
of	O	64-66
validated	O	67-76
and	O	77-80
putative	O	81-89
targets	O	90-97
of	O	98-100
the	O	101-104
most	O	105-109
dysregulated	O	110-122
miRNA	O	123-128
in	O	129-131
pituitary	O	132-141
adenoma	O	142-149
pathogenesis	O	150-162
.   	O	162-166

MicroRNAs	O	0-9
and	O	10-13
possible	O	14-22
role	O	23-27
in	O	28-30
pituitary	O	31-40
adenoma	O	41-48
.  	O	48-51

Expression	O	0-10
profile	O	11-18
of	O	19-21
MicroRNAs	O	22-31
in	O	32-34
young	O	35-40
stroke	O	41-47
patients	O	48-56
.  	O	56-59

BACKGROUND	O	0-10
:	O	10-11
The	O	12-15
methods	O	16-23
currently	O	24-33
available	O	34-43
for	O	44-47
diagnosis	O	48-57
and	O	58-61
prognosis	O	62-71
of	O	72-74
cerebral	O	75-83
ischaemia	O	84-93
still	O	94-99
require	O	100-107
further	O	108-115
improvements	O	116-128
. 	O	128-130

Blood	O	0-5
samples	O	6-13
from	O	14-18
normal	O	19-25
(	O	26-27
n	O	27-28
=	O	28-29
5	O	29-30
)	O	30-31
individuals	O	32-43
were	O	44-48
used	O	49-53
as	O	54-56
controls	O	57-65
. 	O	65-67

Total	O	0-5
RNA	O	6-9
extracted	O	10-19
from	O	20-24
whole	O	25-30
blood	O	31-36
was	O	37-40
subjected	O	41-50
to	O	51-53
miroRNA	O	54-61
profiling	O	62-71
and	O	72-75
real	O	76-80
-	O	80-81
time	O	81-85
PCR	O	86-89
analysis	O	90-98
. 	O	98-100

miRNAs	O	0-6
that	O	7-11
are	O	12-15
implicated	O	16-26
in	O	27-29
the	O	30-33
endothelial	O	34-45
/	O	45-46
vascular	O	46-54
function	O	55-63
,	O	63-64
erythropoiesis	O	65-79
,	O	79-80
angiogenesis	O	81-93
and	O	94-97
neural	O	98-104
function	O	105-113
showed	O	114-120
differential	O	121-133
expression	O	134-144
profile	O	145-152
as	O	153-155
compared	O	156-164
to	O	165-167
the	O	168-171
normal	O	172-178
control	O	179-186
. 	O	186-188

Interestingly	O	0-13
,	O	13-14
miRNAs	O	15-21
that	O	22-26
are	O	27-30
involved	O	31-39
in	O	40-42
hypoxic	O	43-50
conditions	O	51-61
have	O	62-66
also	O	67-71
been	O	72-76
found	O	77-82
in	O	83-85
our	O	86-89
miRNA	O	90-95
profiles	O	96-104
. 	O	104-106

Micro	O	0-5
-	O	5-6
RNAs	O	6-10
(	O	11-12
small	O	12-17
non	O	18-21
-	O	21-22
coding	O	22-28
RNAs	O	29-33
)	O	33-34
have	O	35-39
been	O	40-44
recently	O	45-53
reported	O	54-62
as	O	63-65
useful	O	66-72
biomarkers	O	73-83
in	O	84-86
diseases	O	87-95
such	O	96-100
as	O	101-103
cancer	O	104-110
and	O	111-114
diabetes	O	115-123
. 	O	123-125

We	O	0-2
therefore	O	3-12
carried	O	13-20
out	O	21-24
microRNA	O	25-33
(	O	34-35
miRNA	O	35-40
)	O	40-41
profiling	O	42-51
from	O	52-56
peripheral	O	57-67
blood	O	68-73
to	O	74-76
detect	O	77-83
and	O	84-87
identify	O	88-96
characteristic	O	97-111
patterns	O	112-120
in	O	121-123
ischaemic	O	124-133
stroke	O	134-140
. 	O	140-142

METHODS	O	0-7
/	O	7-8
PRINCIPAL	O	8-17
FINDINGS	O	18-26
:	O	26-27
The	O	28-31
ischaemic	O	32-41
stroke	O	42-48
patients	O	49-57
aged	O	58-62
between	O	63-70
18	O	71-73
-	O	73-74
49	O	74-76
years	O	77-82
,	O	82-83
characterized	O	84-97
based	O	98-103
on	O	104-106
World	O	107-112
Health	O	113-119
Organization	O	120-132
clinical	O	133-141
criteria	O	142-150
were	O	151-155
further	O	156-163
classified	O	164-174
according	O	175-184
to	O	185-187
TOAST	O	188-193
classification	O	194-208
,	O	208-209
a	O	210-211
)	O	211-212
Large	O	213-218
-	O	218-219
vessel	O	219-225
atherosclerosis	O	226-241
[	O	242-243
n	O	243-244
=	O	244-245
8	O	245-246
]	O	246-247
b	O	248-249
)	O	249-250
Small	O	251-256
-	O	256-257
vessel	O	257-263
disease	O	264-271
[	O	272-273
n	O	273-274
=	O	274-275
3	O	275-276
]	O	276-277
c	O	278-279
)	O	279-280
Cardioembolism	O	281-295
[	O	296-297
n	O	297-298
=	O	298-299
5	O	299-300
]	O	300-301
d	O	302-303
)	O	303-304
Undetermined	O	305-317
cause	O	318-323
[	O	324-325
n	O	325-326
=	O	326-327
3	O	327-328
]	O	328-329
. 	O	329-331

The	O	0-3
patients	O	4-12
'	O	12-13
functional	O	14-24
status	O	25-31
at	O	32-34
the	O	35-38
time	O	39-43
of	O	44-46
blood	O	47-52
sampling	O	53-61
(	O	62-63
at	O	63-65
the	O	66-69
outpatient	O	70-80
clinics	O	81-88
)	O	88-89
was	O	90-93
evaluated	O	94-103
with	O	104-108
the	O	109-112
modified	O	113-121
Rankin	O	122-128
Scale	O	129-134
(	O	135-136
mRS	O	136-139
)	O	139-140
. 	O	140-142

CONCLUSION	O	0-10
:	O	10-11
We	O	12-14
demonstrate	O	15-26
that	O	27-31
the	O	32-35
peripheral	O	36-46
blood	O	47-52
miRNAs	O	53-59
and	O	60-63
their	O	64-69
profiles	O	70-78
can	O	79-82
be	O	83-85
developed	O	86-95
as	O	96-98
biomarkers	O	99-109
in	O	110-112
diagnosis	O	113-122
and	O	123-126
prognosis	O	127-136
of	O	137-139
cerebral	O	140-148
ischaemic	O	149-158
stroke	O	159-165
. 	O	165-167

The	O	0-3
dysregulated	O	4-16
miRNAs	O	17-23
have	O	24-28
been	O	29-33
detectable	O	34-44
even	O	45-49
after	O	50-55
several	O	56-63
months	O	64-70
from	O	71-75
the	O	76-79
onset	O	80-85
of	O	86-88
stroke	O	89-95
in	O	96-98
what	O	99-103
is	O	104-106
usually	O	107-114
regarded	O	115-123
as	O	124-126
neurologically	O	127-141
stable	O	142-148
patients	O	149-157
.   	O	157-161

We	O	0-2
also	O	3-7
indentified	O	8-19
97	O	20-22
differentially	O	23-37
expressed	O	38-47
microRNAs	O	48-57
among	O	58-63
240	O	64-67
tumor	O	68-73
and	O	74-77
10	O	78-80
normal	O	81-87
samples	O	88-95
. 	O	95-97

22	O	0-2
of	O	3-5
which	O	6-11
have	O	12-16
been	O	17-21
reported	O	22-30
to	O	31-33
affect	O	34-40
glioblastoma	O	41-53
and	O	54-57
50	O	58-60
of	O	61-63
which	O	64-69
were	O	70-74
implicated	O	75-85
in	O	86-88
other	O	89-94
cancers	O	95-102
and	O	103-106
brain	O	107-112
diseases	O	113-121
. 	O	121-123

Though	O	0-6
a	O	7-8
lot	O	9-12
of	O	13-15
research	O	16-24
has	O	25-28
been	O	29-33
focused	O	34-41
on	O	42-44
this	O	45-49
disease	O	50-57
,	O	57-58
the	O	59-62
causes	O	63-69
and	O	70-73
pathogenesis	O	74-86
of	O	87-89
glioblastoma	O	90-102
have	O	103-107
not	O	108-111
been	O	112-116
indentified	O	117-128
clearly	O	129-136
. 	O	136-138

RESULTS	O	0-7
:	O	7-8
We	O	9-11
indentified	O	12-23
1	O	24-25
,	O	25-26
236	O	26-29
significantly	O	30-43
differentially	O	44-58
expressed	O	59-68
genes	O	69-74
,	O	74-75
and	O	76-79
30	O	80-82
pathways	O	83-91
enriched	O	92-100
in	O	101-103
the	O	104-107
set	O	108-111
of	O	112-114
differentially	O	115-129
expressed	O	130-139
genes	O	140-145
among	O	146-151
243	O	152-155
tumor	O	156-161
and	O	162-165
11	O	166-168
normal	O	169-175
samples	O	176-183
. 	O	183-185

Investigation	O	0-13
gene	O	14-18
and	O	19-22
microRNA	O	23-31
expression	O	32-42
in	O	43-45
glioblastoma	O	46-58
.  	O	58-61

BACKGROUND	O	0-10
:	O	10-11
Glioblastoma	O	12-24
is	O	25-27
the	O	28-31
most	O	32-36
common	O	37-43
primary	O	44-51
brain	O	52-57
tumor	O	58-63
in	O	64-66
adults	O	67-73
. 	O	73-75

CONCLUSION	O	0-10
:	O	10-11
We	O	12-14
investigated	O	15-27
gene	O	28-32
and	O	33-36
microRNA	O	37-45
Expression	O	46-56
in	O	57-59
Glioblastoma	O	60-72
and	O	73-76
gave	O	77-81
a	O	82-83
comprehensive	O	84-97
function	O	98-106
study	O	107-112
of	O	113-115
differential	O	116-128
expressed	O	129-138
gene	O	139-143
and	O	144-147
microRNA	O	148-156
in	O	157-159
glioblastoma	O	160-172
patients	O	173-181
. 	O	181-183

Further	O	0-7
function	O	8-16
analysis	O	17-25
of	O	26-28
target	O	29-35
genes	O	36-41
suggested	O	42-51
that	O	52-56
microRNAs	O	57-66
most	O	67-71
frequently	O	72-82
targeted	O	83-91
genes	O	92-97
associated	O	98-108
with	O	109-113
Cell	O	114-118
Signalling	O	119-129
and	O	130-133
Nervous	O	134-141
System	O	142-148
. 	O	148-150

We	O	0-2
found	O	3-8
two	O	9-12
experimentally	O	13-27
validated	O	28-37
microRNA	O	38-46
targets	O	47-54
and	O	55-58
1	O	59-60
,	O	60-61
094	O	61-64
miRNA	O	65-70
-	O	70-71
target	O	71-77
gene	O	78-82
pairs	O	83-88
in	O	89-91
our	O	92-95
datasets	O	96-104
which	O	105-110
were	O	111-115
predicted	O	116-125
by	O	126-128
miRanda	O	129-136
algorithm	O	137-146
,	O	146-147
8	O	148-149
of	O	150-152
the	O	153-156
target	O	157-163
genes	O	164-169
were	O	170-174
tumor	O	175-180
suppressor	O	181-191
genes	O	192-197
and	O	198-201
3	O	202-203
were	O	204-208
oncogenes	O	209-218
. 	O	218-220

We	O	0-2
regressed	O	3-12
gene	O	13-17
expression	O	18-28
on	O	29-31
microRNA	O	32-40
expression	O	41-51
in	O	52-54
237	O	55-58
tumor	O	59-64
tissues	O	65-72
and	O	73-76
10	O	77-79
normal	O	80-86
tissues	O	87-94
comprehensively	O	95-110
. 	O	110-112

These	O	0-5
findings	O	6-14
gave	O	15-19
important	O	20-29
clues	O	30-35
to	O	36-38
study	O	39-44
of	O	45-47
the	O	48-51
carcinogenic	O	52-64
process	O	65-72
in	O	73-75
glioblastomas	O	76-89
.   	O	89-93

CONCLUSION	O	0-10
:	O	10-11
Our	O	12-15
results	O	16-23
indicate	O	24-32
a	O	33-34
time	O	35-39
-	O	39-40
dependent	O	40-49
expression	O	50-60
pattern	O	61-68
of	O	69-71
miR	B	72-75
-	I	75-76
223	I	76-79
and	O	80-83
miR	B	84-87
-	I	87-88
124a	I	88-92
in	O	93-95
a	O	96-97
mouse	O	98-103
model	O	104-109
of	O	110-112
SCI	O	113-116
. 	O	116-118

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
the	O	15-18
time	O	19-23
course	O	24-30
of	O	31-33
miRNA	B	34-39
-	I	39-40
223	I	40-43
expression	O	44-54
may	O	55-58
be	O	59-61
related	O	62-69
to	O	70-72
inflammatory	O	73-85
responses	O	86-95
after	O	96-101
SCI	O	102-105
,	O	105-106
and	O	107-110
the	O	111-114
time	O	115-119
course	O	120-126
of	O	127-129
decreased	O	130-139
miR	B	140-143
-	I	143-144
124a	I	144-148
expression	O	149-159
may	O	160-163
reflect	O	164-171
cell	O	172-176
death	O	177-182
.   	O	182-186

However	O	0-7
,	O	7-8
miR	B	9-12
-	I	12-13
124a	I	13-17
,	O	17-18
which	O	19-24
was	O	25-28
present	O	29-36
in	O	37-39
the	O	40-43
normal	O	44-50
spinal	O	51-57
cord	O	58-62
,	O	62-63
was	O	64-67
not	O	68-71
observed	O	72-80
at	O	81-83
the	O	84-87
injured	O	88-95
site	O	96-100
. 	O	100-102

RESULTS	O	0-7
:	O	7-8
Quantitative	O	9-21
PCR	O	22-25
revealed	O	26-34
two	O	35-38
peaks	O	39-44
of	O	45-47
miR	B	48-51
-	I	51-52
223	I	52-55
expression	O	56-66
at	O	67-69
6	O	70-71
and	O	72-75
12	O	76-78
h	O	79-80
and	O	81-84
3	O	85-86
days	O	87-91
after	O	92-97
SCI	O	98-101
.	O	101-102
MiR	B	103-106
-	I	106-107
124a	I	107-111
expression	O	112-122
decreased	O	123-132
significantly	O	133-146
from	O	147-151
1	O	152-153
day	O	154-157
to	O	158-160
7	O	161-162
days	O	163-167
after	O	168-173
SCI	O	174-177
. 	O	177-179

In	O	0-2
situ	O	3-7
hybridization	O	8-21
demonstrated	O	22-34
the	O	35-38
presence	O	39-47
of	O	48-50
miR	B	51-54
-	I	54-55
223	I	55-58
around	O	59-65
the	O	66-69
injured	O	70-77
site	O	78-82
. 	O	82-84

METHODS	O	0-7
:	O	7-8
We	O	9-11
examined	O	12-20
the	O	21-24
expression	O	25-35
of	O	36-38
miRNA	B	39-44
(	I	45-46
miR	I	46-49
)	I	49-50
-	I	50-51
223	I	51-54
and	O	55-58
miR	B	59-62
-	I	62-63
124a	I	63-67
in	O	68-70
a	O	71-72
mouse	O	73-78
model	O	79-84
at	O	85-87
6	O	88-89
h	O	90-91
,	O	91-92
12	O	93-95
h	O	96-97
,	O	97-98
1	O	99-100
day	O	101-104
,	O	104-105
3	O	106-107
days	O	108-112
and	O	113-116
7	O	117-118
days	O	119-123
after	O	124-129
SCI	O	130-133
using	O	134-139
quantitative	O	140-152
PCR	O	153-156
. 	O	156-158

The	O	0-3
miRNA	O	4-9
expression	O	10-20
was	O	21-24
confirmed	O	25-34
by	O	35-37
in	O	38-40
situ	O	41-45
hybridization	O	46-59
. 	O	59-61

MiRNAs	O	0-6
are	O	7-10
short	O	11-16
noncoding	O	17-26
RNAs	O	27-31
that	O	32-36
suppress	O	37-45
the	O	46-49
translation	O	50-61
of	O	62-64
target	O	65-71
genes	O	72-77
by	O	78-80
binding	O	81-88
to	O	89-91
their	O	92-97
mRNAs	O	98-103
,	O	103-104
and	O	105-108
play	O	109-113
a	O	114-115
central	O	116-123
role	O	124-128
in	O	129-131
gene	O	132-136
regulation	O	137-147
in	O	148-150
health	O	151-157
and	O	158-161
disease	O	162-169
. 	O	169-171

The	O	0-3
purpose	O	4-11
of	O	12-14
this	O	15-19
study	O	20-25
was	O	26-29
to	O	30-32
examine	O	33-40
miRNA	O	41-46
expression	O	47-57
after	O	58-63
SCI	O	64-67
.	O	67-68
SETTING	O	69-76
:	O	76-77
Department	O	78-88
of	O	89-91
Orthopaedic	O	92-103
Surgery	O	104-111
,	O	111-112
Graduate	O	113-121
School	O	122-128
of	O	129-131
Biomedical	O	132-142
Sciences	O	143-151
,	O	151-152
Hiroshima	O	153-162
University	O	163-173
. 	O	173-175

STUDY	O	0-5
DESIGN	O	6-12
:	O	12-13
We	O	14-16
investigated	O	17-29
microRNA	O	30-38
(	O	39-40
miRNA	O	40-45
)	O	45-46
expression	O	47-57
after	O	58-63
spinal	O	64-70
cord	O	71-75
injury	O	76-82
(	O	83-84
SCI	O	84-87
)	O	87-88
in	O	89-91
mice	O	92-96
. 	O	96-98

OBJECTIVES	O	0-10
:	O	10-11
The	O	12-15
recent	O	16-22
discovery	O	23-32
of	O	33-35
miRNAs	O	36-42
suggests	O	43-51
a	O	52-53
novel	O	54-59
regulatory	O	60-70
control	O	71-78
over	O	79-83
gene	O	84-88
expression	O	89-99
during	O	100-106
plant	O	107-112
and	O	113-116
animal	O	117-123
development	O	124-135
. 	O	135-137

Responses	O	0-9
of	O	10-12
microRNAs	B	13-22
124a	I	23-27
and	I	28-31
223	I	32-35
following	O	36-45
spinal	O	46-52
cord	O	53-57
injury	O	58-64
in	O	65-67
mice	O	68-72
.  	O	72-75

Aberrant	O	0-8
microRNA	O	9-17
expression	O	18-28
in	O	29-31
the	O	32-35
brains	O	36-42
of	O	43-45
neurodegenerative	O	46-63
diseases	O	64-72
:	O	72-73
miR	B	74-77
-	I	77-78
29a	I	78-81
decreased	O	82-91
in	O	92-94
Alzheimer	O	95-104
disease	O	105-112
brains	O	113-119
targets	O	120-127
neurone	O	128-135
navigator	O	136-145
3	O	146-147
.	O	147-148
AIMS	O	150-154
:	O	154-155
MicroRNAs	O	156-165
(	O	166-167
miRNAs	O	167-173
)	O	173-174
are	O	175-178
small	O	179-184
non	O	185-188
-	O	188-189
coding	O	189-195
RNAs	O	196-200
that	O	201-205
regulate	O	206-214
translational	O	215-228
repression	O	229-239
of	O	240-242
target	O	243-249
mRNAs	O	250-255
.  	O	255-257

MiR	B	0-3
-	I	3-4
29a	I	4-7
-	O	7-8
mediated	O	8-16
down	O	17-21
-	O	21-22
regulation	O	22-32
of	O	33-35
NAV3	O	36-40
was	O	41-44
verified	O	45-53
by	O	54-56
the	O	57-60
luciferase	O	61-71
reporter	O	72-80
assay	O	81-86
. 	O	86-88

However	O	0-7
,	O	7-8
we	O	9-11
found	O	12-17
significant	O	18-29
down	O	30-34
-	O	34-35
regulation	O	35-45
of	O	46-48
miR	B	49-52
-	I	52-53
29a	I	53-56
in	O	57-59
Alzheimer	O	60-69
disease	O	70-77
(	O	78-79
AD	O	79-81
)	O	81-82
brains	O	83-89
. 	O	89-91

The	O	0-3
database	O	4-12
search	O	13-19
on	O	20-22
TargetScan	O	23-33
,	O	33-34
PicTar	O	35-41
and	O	42-45
miRBase	O	46-53
Target	O	54-60
identified	O	61-71
neurone	O	72-79
navigator	O	80-89
3	O	90-91
(	O	92-93
NAV3	O	93-97
)	O	97-98
,	O	98-99
a	O	100-101
regulator	O	102-111
of	O	112-114
axon	O	115-119
guidance	O	120-128
,	O	128-129
as	O	130-132
a	O	133-134
principal	O	135-144
target	O	145-151
of	O	152-154
miR	B	155-158
-	I	158-159
29a	I	159-162
,	O	162-163
and	O	164-167
actually	O	168-176
NAV3	O	177-181
mRNA	O	182-186
levels	O	187-193
were	O	194-198
elevated	O	199-207
in	O	208-210
AD	O	211-213
brains	O	214-220
. 	O	220-222

This	O	0-4
was	O	5-8
followed	O	9-17
by	O	18-20
enlargement	O	21-32
of	O	33-35
study	O	36-41
population	O	42-52
with	O	53-57
quantitative	O	58-70
RT	O	71-73
-	O	73-74
PCR	O	74-77
analysis	O	78-86
(	O	87-88
n	O	88-89
=	O	90-91
21	O	92-94
)	O	94-95
. 	O	95-97

RESULTS	O	0-7
:	O	7-8
By	O	9-11
microarray	O	12-22
analysis	O	23-31
,	O	31-32
we	O	33-35
identified	O	36-46
up	O	47-49
-	O	49-50
regulation	O	50-60
of	O	61-63
miR	B	64-67
-	I	67-68
29a	I	68-71
,	O	71-72
miR	B	73-76
-	I	76-77
29b	I	77-80
and	O	81-84
miR	B	85-88
-	I	88-89
338	I	89-92
-	I	92-93
3p	I	93-95
in	O	96-98
amyotrophic	O	99-110
lateral	O	111-118
sclerosis	O	119-128
brains	O	129-135
,	O	135-136
but	O	137-140
due	O	141-144
to	O	145-147
a	O	148-149
great	O	150-155
interindividual	O	156-171
variation	O	172-181
,	O	181-182
we	O	183-185
could	O	186-191
not	O	192-195
validate	O	196-204
these	O	205-210
results	O	211-218
by	O	219-221
quantitative	O	222-234
RT	O	235-237
-	O	237-238
PCR	O	238-241
. 	O	241-243

To	O	0-2
identify	O	3-11
miRNAs	O	12-18
closely	O	19-26
associated	O	27-37
with	O	38-42
neurodegeneration	O	43-60
,	O	60-61
we	O	62-64
performed	O	65-74
miRNA	O	75-80
expression	O	81-91
profiling	O	92-101
of	O	102-104
brain	O	105-110
tissues	O	111-118
of	O	119-121
various	O	122-129
neurodegenerative	O	130-147
diseases	O	148-156
. 	O	156-158

METHODS	O	0-7
:	O	7-8
We	O	9-11
initially	O	12-21
studied	O	22-29
the	O	30-33
frontal	O	34-41
cortex	O	42-48
derived	O	49-56
from	O	57-61
three	O	62-67
amyotrophic	O	68-79
lateral	O	80-87
sclerosis	O	88-97
patients	O	98-106
by	O	107-109
using	O	110-115
a	O	116-117
microarray	O	118-128
of	O	129-131
723	O	132-135
human	O	136-141
miRNAs	O	142-148
. 	O	148-150

Accumulating	O	0-12
evidence	O	13-21
indicates	O	22-31
that	O	32-36
various	O	37-44
miRNAs	O	45-51
,	O	51-52
expressed	O	53-62
in	O	63-65
a	O	66-67
spatially	O	68-77
and	O	78-81
temporally	O	82-92
controlled	O	93-103
that	O	104-108
manner	O	109-115
in	O	116-118
the	O	119-122
brain	O	123-128
plays	O	129-134
a	O	135-136
key	O	137-140
role	O	141-145
in	O	146-148
neuronal	O	149-157
development	O	158-169
. 	O	169-171

However	O	0-7
,	O	7-8
at	O	9-11
present	O	12-19
,	O	19-20
the	O	21-24
pathological	O	25-37
implication	O	38-49
of	O	50-52
aberrant	O	53-61
miRNA	O	62-67
expression	O	68-78
in	O	79-81
neurodegenerative	O	82-99
events	O	100-106
remains	O	107-114
largely	O	115-122
unknown	O	123-130
. 	O	130-132

By	O	0-2
immunohistochemistry	O	3-23
,	O	23-24
NAV3	O	25-29
expression	O	30-40
was	O	41-44
most	O	45-49
evidently	O	50-59
enhanced	O	60-68
in	O	69-71
degenerating	O	72-84
pyramidal	O	85-94
neurones	O	95-103
in	O	104-106
the	O	107-110
cerebral	O	111-119
cortex	O	120-126
of	O	127-129
AD	O	130-132
.	O	132-133
CONCLUSIONS	O	134-145
:	O	145-146
These	O	147-152
observations	O	153-165
suggest	O	166-173
the	O	174-177
hypothesis	O	178-188
that	O	189-193
underexpression	O	194-209
of	O	210-212
miR	B	213-216
-	I	216-217
29a	I	217-220
affects	O	221-228
neurodegenerative	O	229-246
processes	O	247-256
by	O	257-259
enhancing	O	260-269
neuronal	O	270-278
NAV3	O	279-283
expression	O	284-294
in	O	295-297
AD	O	298-300
brains	O	301-307
.   	O	307-311

Many	O	0-4
miRNA	O	5-10
targets	O	11-18
have	O	19-23
been	O	24-28
computationally	O	29-44
predicted	O	45-54
but	O	55-58
only	O	59-63
a	O	64-65
limited	O	66-73
number	O	74-80
of	O	81-83
these	O	84-89
were	O	90-94
experimentally	O	95-109
validated	O	110-119
. 	O	119-121

However	O	0-7
,	O	7-8
interactions	O	9-21
between	O	22-29
miRNAs	O	30-36
and	O	37-40
their	O	41-46
targets	O	47-54
are	O	55-58
complex	O	59-66
and	O	67-70
very	O	71-75
often	O	76-81
there	O	82-87
are	O	88-91
numerous	O	92-100
putative	O	101-109
miRNA	O	110-115
recognition	O	116-127
sites	O	128-133
in	O	134-136
mRNAs	O	137-142
. 	O	142-144

Therefore	O	0-9
,	O	9-10
it	O	11-13
is	O	14-16
of	O	17-19
particular	O	20-30
interest	O	31-39
to	O	40-42
reliably	O	43-51
predict	O	52-59
potential	O	60-69
miRNA	O	70-75
targets	O	76-83
which	O	84-89
might	O	90-95
be	O	96-98
involved	O	99-107
in	O	108-110
these	O	111-116
diseases	O	117-125
. 	O	125-127

Both	O	0-4
the	O	5-8
deregulation	O	9-21
of	O	22-24
genes	O	25-30
controlled	O	31-41
by	O	42-44
miRNAs	O	45-51
and	O	52-55
the	O	56-59
altered	O	60-67
miRNA	O	68-73
expression	O	74-84
have	O	85-89
been	O	90-94
linked	O	95-101
to	O	102-104
many	O	105-109
disorders	O	110-119
,	O	119-120
including	O	121-130
cancer	O	131-137
,	O	137-138
cardiovascular	O	139-153
,	O	153-154
metabolic	O	155-164
and	O	165-168
neurodegenerative	O	169-186
diseases	O	187-195
. 	O	195-197

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
currently	O	16-25
available	O	26-35
and	O	36-39
frequently	O	40-50
used	O	51-55
computational	O	56-69
tools	O	70-75
for	O	76-79
miRNA	O	80-85
target	O	86-92
prediction	O	93-103
,	O	103-104
i	O	105-106
.	O	106-107
e	O	107-108
.	O	108-109
,	O	109-110
PicTar	O	111-117
,	O	117-118
TargetScan	O	119-129
,	O	129-130
DIANA	O	131-136
-	O	136-137
microT	O	137-143
,	O	143-144
miRanda	O	145-152
,	O	152-153
rna22	O	154-159
and	O	160-163
PITA	O	164-168
are	O	169-172
outlined	O	173-181
and	O	182-185
various	O	186-193
practical	O	194-203
aspects	O	204-211
of	O	212-214
miRNA	O	215-220
target	O	221-227
analysis	O	228-236
are	O	237-240
extensively	O	241-252
discussed	O	253-262
. 	O	262-264

Hence	O	0-5
,	O	5-6
finding	O	7-14
a	O	15-16
functional	O	17-27
miRNA	O	28-33
target	O	34-40
is	O	41-43
still	O	44-49
a	O	50-51
challenging	O	52-63
task	O	64-68
. 	O	68-70

Although	O	0-8
a	O	9-10
variety	O	11-18
of	O	19-21
miRNA	O	22-27
target	O	28-34
prediction	O	35-45
algorithms	O	46-56
are	O	57-60
available	O	61-70
,	O	70-71
results	O	72-79
of	O	80-82
their	O	83-88
application	O	89-100
are	O	101-104
often	O	105-110
inconsistent	O	111-123
. 	O	123-125

microRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
endogenous	O	23-33
non	O	34-37
-	O	37-38
coding	O	38-44
RNAs	O	45-49
that	O	50-54
control	O	55-62
gene	O	63-67
expression	O	68-78
at	O	79-81
the	O	82-85
posttranscriptional	O	86-105
level	O	106-111
. 	O	111-113

These	O	0-5
small	O	6-11
regulatory	O	12-22
molecules	O	23-32
play	O	33-37
a	O	38-39
key	O	40-43
role	O	44-48
in	O	49-51
the	O	52-55
majority	O	56-64
of	O	65-67
biological	O	68-78
processes	O	79-88
and	O	89-92
their	O	93-98
expression	O	99-109
is	O	110-112
also	O	113-117
tightly	O	118-125
regulated	O	126-135
. 	O	135-137

Practical	O	0-9
Aspects	O	10-17
of	O	18-20
microRNA	O	21-29
Target	O	30-36
Prediction	O	37-47
.  	O	47-50

Moreover	O	0-8
,	O	8-9
the	O	10-13
performance	O	14-25
of	O	26-28
three	O	29-34
algorithms	O	35-45
(	O	46-47
PicTar	O	47-53
,	O	53-54
TargetScan	O	55-65
and	O	66-69
DIANA	O	70-75
-	O	75-76
microT	O	76-82
)	O	82-83
is	O	84-86
both	O	87-91
demonstrated	O	92-104
and	O	105-108
evaluated	O	109-118
by	O	119-121
performing	O	122-132
an	O	133-135
in	O	136-138
-	O	138-139
depth	O	139-144
analysis	O	145-153
of	O	154-156
miRNA	O	157-162
interactions	O	163-175
with	O	176-180
mRNAs	O	181-186
derived	O	187-194
from	O	195-199
genes	O	200-205
triggering	O	206-216
hereditary	O	217-227
neurological	O	228-240
disorders	O	241-250
known	O	251-256
as	O	257-259
trinucleotide	O	260-273
repeat	O	274-280
expansion	O	281-290
diseases	O	291-299
(	O	300-301
TREDs	O	301-306
)	O	306-307
,	O	307-308
such	O	309-313
as	O	314-316
Huntington	O	317-327
'	O	327-328
s	O	328-329
disease	O	330-337
(	O	338-339
HD	O	339-341
)	O	341-342
,	O	342-343
a	O	344-345
number	O	346-352
of	O	353-355
spinocerebellar	O	356-371
ataxias	O	372-379
(	O	380-381
SCAs	O	381-385
)	O	385-386
,	O	386-387
and	O	388-391
myotonic	O	392-400
dystrophy	O	401-410
type	O	411-415
1	O	416-417
(	O	418-419
DM1	O	419-422
)	O	422-423
.   	O	423-427

CONCLUSIONS	O	0-11
:	O	11-12
Our	O	13-16
results	O	17-24
indicate	O	25-33
that	O	34-38
altered	O	39-46
miRNAs	O	47-53
expression	O	54-64
is	O	65-67
involved	O	68-76
in	O	77-79
GH	O	80-82
-	O	82-83
secreting	O	83-92
pituitary	O	93-102
adenomas	O	103-111
transformation	O	112-126
,	O	126-127
which	O	128-133
will	O	134-138
shed	O	139-143
light	O	144-149
on	O	150-152
the	O	153-156
mechanisms	O	157-167
for	O	168-171
the	O	172-175
treatment	O	176-185
of	O	186-188
acromegaly	O	189-199
by	O	200-202
SSA	O	203-206
. 	O	206-208

Identification	O	0-14
and	O	15-18
characterization	O	19-35
of	O	36-38
the	O	39-42
targets	O	43-50
of	O	51-53
altered	O	54-61
miRNAs	O	62-68
genes	O	69-74
may	O	75-78
elucidate	O	79-88
molecular	O	89-98
mechanisms	O	99-109
involved	O	110-118
in	O	119-121
the	O	122-125
pathogenesis	O	126-138
of	O	139-141
pituitary	O	142-151
adenoma	O	152-159
.   	O	159-163

Several	O	0-7
identified	O	8-18
miRNAs	O	19-25
may	O	26-29
be	O	30-32
involved	O	33-41
in	O	42-44
cell	O	45-49
proliferation	O	50-63
,	O	63-64
apoptosis	O	65-74
,	O	74-75
cancer	O	76-82
development	O	83-94
and	O	95-98
progression	O	99-110
. 	O	110-112

Seven	O	0-5
miRNAs	O	6-12
were	O	13-17
differentially	O	18-32
expressed	O	33-42
between	O	43-50
SSA	O	51-54
responders	O	55-65
or	O	66-68
GH	O	69-71
nonresponders	O	72-85
. 	O	85-87

RESULTS	O	0-7
:	O	7-8
Fifty	O	9-14
-	O	14-15
two	O	15-18
miRNAs	O	19-25
were	O	26-30
differentially	O	31-45
expressed	O	46-55
between	O	56-63
GH	O	64-66
-	O	66-67
secreting	O	67-76
pituitary	O	77-86
adenomas	O	87-95
and	O	96-99
normal	O	100-106
pituitaries	O	107-118
. 	O	118-120

We	O	0-2
analyzed	O	3-11
the	O	12-15
miRNAs	O	16-22
in	O	23-25
21	O	26-28
GH	O	29-31
-	O	31-32
secreting	O	32-41
pituitary	O	42-51
adenomas	O	52-60
and	O	61-64
6	O	65-66
normal	O	67-73
pituitaries	O	74-85
by	O	86-88
miRCURY™	O	89-97
LNA	O	98-101
array	O	102-107
and	O	108-111
some	O	112-116
differentially	O	117-131
expressed	O	132-141
miRNAs	O	142-148
were	O	149-153
validated	O	154-163
by	O	164-166
quantitative	O	167-179
real	O	180-184
-	O	184-185
time	O	185-189
PCR	O	190-193
. 	O	193-195

Thirteen	O	0-8
miRNAs	O	9-15
were	O	16-20
differentially	O	21-35
expressed	O	36-45
between	O	46-53
tumor	O	54-59
samples	O	60-67
from	O	68-72
lanreotide	O	73-83
-	O	83-84
treated	O	84-91
patients	O	92-100
and	O	101-104
those	O	105-110
from	O	111-115
lanreotide	O	116-126
-	O	126-127
untreated	O	127-136
patients	O	137-145
. 	O	145-147

Differential	O	0-12
expression	O	13-23
of	O	24-26
9	O	27-28
miRNAs	O	29-35
was	O	36-39
observed	O	40-48
between	O	49-56
micro	O	57-62
-	O	62-63
and	O	64-67
macro	O	68-73
-	O	73-74
adenomas	O	74-82
. 	O	82-84

Differential	O	0-12
expression	O	13-23
of	O	24-26
microRNAs	O	27-36
in	O	37-39
GH	O	40-42
-	O	42-43
secreting	O	43-52
pituitary	O	53-62
adenomas	O	63-71
.  	O	71-74

BACKGROUND	O	0-10
:	O	10-11
The	O	12-15
purpose	O	16-23
of	O	24-26
this	O	27-31
study	O	32-37
was	O	38-41
to	O	42-44
(	O	45-46
1	O	46-47
)	O	47-48
identify	O	49-57
specific	O	58-66
miRNAs	O	67-73
in	O	74-76
growth	O	77-83
hormones	O	84-92
(	O	93-94
GH	O	94-96
)	O	96-97
-	O	97-98
secreting	O	98-107
pituitary	O	108-117
adenomas	O	118-126
;	O	126-127
(	O	128-129
2	O	129-130
)	O	130-131
determine	O	132-141
the	O	142-145
relationship	O	146-158
between	O	159-166
the	O	167-170
expression	O	171-181
of	O	182-184
these	O	185-190
miRNAs	O	191-197
and	O	198-201
tumor	O	202-207
size	O	208-212
,	O	212-213
somatostatin	O	214-226
analogs	O	227-234
treatment	O	235-244
,	O	244-245
and	O	246-249
responsiveness	O	250-264
to	O	265-267
somatostatin	O	268-280
analogs	O	281-288
(	O	289-290
SSA	O	290-293
)	O	293-294
. 	O	294-296

METHODS	O	0-7
:	O	7-8
Fifteen	O	9-16
GH	O	17-19
-	O	19-20
secreting	O	20-29
adenomas	O	30-38
patients	O	39-47
were	O	48-52
treated	O	53-60
with	O	61-65
lanreotide	O	66-76
for	O	77-80
4	O	81-82
months	O	83-89
before	O	90-96
surgery	O	97-104
. 	O	104-106

Patients	O	0-8
with	O	9-13
50	O	14-16
%	O	16-17
reduction	O	18-27
of	O	28-30
GH	O	31-33
secretion	O	34-43
by	O	44-46
lanreotide	O	47-57
were	O	58-62
considered	O	63-73
as	O	74-76
SSA	O	77-80
responders	O	81-91
,	O	91-92
while	O	93-98
patients	O	99-107
with	O	108-112
less	O	113-117
than	O	118-122
50	O	123-125
%	O	125-126
of	O	127-129
GH	O	130-132
reduction	O	133-142
were	O	143-147
considered	O	148-158
as	O	159-161
SSA	O	162-165
nonresponders	O	166-179
. 	O	179-181

We	O	0-2
recently	O	3-11
showed	O	12-18
in	O	19-21
HeLa	O	22-26
cells	O	27-32
that	O	33-37
two	O	38-41
components	O	42-52
of	O	53-55
the	O	56-59
SMN	O	60-63
complex	O	64-71
,	O	71-72
Gemin3	O	73-79
and	O	80-83
Gemin4	O	84-90
,	O	90-91
together	O	92-100
with	O	101-105
the	O	106-109
argonaute	O	110-119
protein	O	120-127
eIF2C2	O	128-134
,	O	134-135
also	O	136-140
associate	O	141-150
with	O	151-155
microRNAs	O	156-165
(	O	166-167
miRNAs	O	167-173
)	O	173-174
as	O	175-177
part	O	178-182
of	O	183-185
a	O	186-187
novel	O	188-193
class	O	194-199
of	O	200-202
RNPs	O	203-207
termed	O	208-214
miRNPs	O	215-221
. 	O	221-223

SMN	O	0-3
is	O	4-6
part	O	7-11
of	O	12-14
a	O	15-16
large	O	17-22
complex	O	23-30
that	O	31-35
functions	O	36-45
in	O	46-48
the	O	49-52
assembly	O	53-61
/	O	61-62
restructuring	O	62-75
of	O	76-78
ribonucleoprotein	O	79-96
(	O	97-98
RNP	O	98-101
)	O	101-102
complexes	O	103-112
. 	O	112-114

Spinal	O	0-6
muscular	O	7-15
atrophy	O	16-23
(	O	24-25
SMA	O	25-28
)	O	28-29
is	O	30-32
a	O	33-34
common	O	35-41
neurodegenerative	O	42-59
disease	O	60-67
that	O	68-72
is	O	73-75
caused	O	76-82
by	O	83-85
deletions	O	86-95
or	O	96-98
loss	O	99-103
-	O	103-104
of	O	104-106
-	O	106-107
function	O	107-115
mutations	O	116-125
in	O	126-128
the	O	129-132
Survival	O	133-141
of	O	142-144
Motor	O	145-150
Neuron	O	151-157
(	O	158-159
SMN	O	159-162
)	O	162-163
protein	O	164-171
. 	O	171-173

Numerous	O	0-8
microRNPs	O	9-18
in	O	19-21
neuronal	O	22-30
cells	O	31-36
containing	O	37-47
novel	O	48-53
microRNAs	O	54-63
.  	O	63-66

The	O	0-3
chromosomal	O	4-15
locations	O	16-25
of	O	26-28
most	O	29-33
of	O	34-36
the	O	37-40
novel	O	41-46
miRNAs	O	47-53
were	O	54-58
identified	O	59-69
and	O	70-73
indicate	O	74-82
some	O	83-87
phylogenetic	O	88-100
conservation	O	101-113
of	O	114-116
the	O	117-120
likely	O	121-127
precursor	O	128-137
structures	O	138-148
. 	O	148-150

Interestingly	O	0-13
the	O	14-17
gene	O	18-22
locus	O	23-28
of	O	29-31
one	O	32-35
miRNA	O	36-41
,	O	41-42
miR	B	43-46
-	I	46-47
175	I	47-50
,	O	50-51
is	O	52-54
a	O	55-56
candidate	O	57-66
region	O	67-73
for	O	74-77
two	O	78-81
neurologic	O	82-92
diseases	O	93-101
:	O	101-102
early	O	103-108
-	O	108-109
onset	O	109-114
parkinsonism	O	115-127
(	O	128-129
Waisman	O	129-136
syndrome	O	137-145
)	O	145-146
and	O	147-150
X	O	151-152
-	O	152-153
linked	O	153-159
mental	O	160-166
retardation	O	167-178
(	O	179-180
MRX3	O	180-184
)	O	184-185
. 	O	185-187

Here	O	0-4
we	O	5-7
report	O	8-14
on	O	15-17
miRNPs	O	18-24
isolated	O	25-33
from	O	34-38
neuronal	O	39-47
cell	O	48-52
lines	O	53-58
of	O	59-61
mouse	O	62-67
and	O	68-71
human	O	72-77
,	O	77-78
and	O	79-82
describe	O	83-91
53	O	92-94
novel	O	95-100
miRNAs	O	101-107
. 	O	107-109

Several	O	0-7
of	O	8-10
these	O	11-16
miRNAs	O	17-23
are	O	24-27
conserved	O	28-37
in	O	38-40
divergent	O	41-50
organisms	O	51-60
,	O	60-61
including	O	62-71
rat	O	72-75
,	O	75-76
zebrafish	O	77-86
,	O	86-87
pufferfish	O	88-98
,	O	98-99
and	O	100-103
the	O	104-107
nematode	O	108-116
Caenorhabditis	O	117-131
elegans	O	132-139
. 	O	139-141

Also	O	0-4
,	O	4-5
several	O	6-13
miRNAs	O	14-20
identified	O	21-31
as	O	32-34
part	O	35-39
of	O	40-42
miRNPs	O	43-49
in	O	50-52
these	O	53-58
cells	O	59-64
appear	O	65-71
to	O	72-74
constitute	O	75-85
two	O	86-89
distinct	O	90-98
subfamilies	O	99-110
. 	O	110-112

These	O	0-5
subfamilies	O	6-17
comprise	O	18-26
multiple	O	27-35
copies	O	36-42
of	O	43-45
miRNAs	O	46-52
on	O	53-55
different	O	56-65
chromosomes	O	66-77
,	O	77-78
suggesting	O	79-89
an	O	90-92
important	O	93-102
function	O	103-111
in	O	112-114
the	O	115-118
regulation	O	119-129
of	O	130-132
gene	O	133-137
expression	O	138-148
.   	O	148-152

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
human	O	18-23
platelets	O	24-33
harbor	O	34-40
an	O	41-43
abundant	O	44-52
and	O	53-56
diverse	O	57-64
array	O	65-70
of	O	71-73
microRNAs	O	74-83
(	O	84-85
miRNAs	O	85-91
)	O	91-92
,	O	92-93
which	O	94-99
are	O	100-103
known	O	104-109
as	O	110-112
key	O	113-116
regulators	O	117-127
of	O	128-130
mRNA	O	131-135
translation	O	136-147
in	O	148-150
other	O	151-156
cell	O	157-161
types	O	162-167
. 	O	167-169

Further	O	0-7
analyses	O	8-16
revealed	O	17-25
that	O	26-30
platelets	O	31-40
contain	O	41-48
the	O	49-52
Dicer	O	53-58
and	O	59-62
Argonaute	O	63-72
2	O	73-74
(	O	75-76
Ago2	O	76-80
)	O	80-81
complexes	O	82-91
,	O	91-92
which	O	93-98
function	O	99-107
in	O	108-110
the	O	111-114
processing	O	115-125
of	O	126-128
exogenous	O	129-138
miRNA	O	139-144
precursors	O	145-155
and	O	156-159
the	O	160-163
control	O	164-171
of	O	172-174
specific	O	175-183
reporter	O	184-192
transcripts	O	193-204
,	O	204-205
respectively	O	206-218
. 	O	218-220

Detection	O	0-9
of	O	10-12
the	O	13-16
receptor	O	17-25
P2Y	O	26-29
(	O	29-30
12	O	30-32
)	O	32-33
mRNA	O	34-38
in	O	39-41
Ago2	O	42-46
immunoprecipitates	O	47-65
suggests	O	66-74
that	O	75-79
P2Y	O	80-83
(	O	83-84
12	O	84-86
)	O	86-87
expression	O	88-98
may	O	99-102
be	O	103-105
subjected	O	106-115
to	O	116-118
miRNA	O	119-124
control	O	125-132
in	O	133-135
human	O	136-141
platelets	O	142-151
. 	O	151-153

Our	O	0-3
study	O	4-9
lends	O	10-15
an	O	16-18
additional	O	19-29
level	O	30-35
of	O	36-38
complexity	O	39-49
to	O	50-52
the	O	53-56
control	O	57-64
of	O	65-67
gene	O	68-72
expression	O	73-83
in	O	84-86
these	O	87-92
anucleate	O	93-102
elements	O	103-111
of	O	112-114
the	O	115-118
cardiovascular	O	119-133
system	O	134-140
.   	O	140-144

Existence	O	0-9
of	O	10-12
a	O	13-14
microRNA	O	15-23
pathway	O	24-31
in	O	32-34
anucleate	O	35-44
platelets	O	45-54
.  	O	54-57

Platelets	O	0-9
have	O	10-14
a	O	15-16
crucial	O	17-24
role	O	25-29
in	O	30-32
the	O	33-36
maintenance	O	37-48
of	O	49-51
hemostasis	O	52-62
as	O	63-65
well	O	66-70
as	O	71-73
in	O	74-76
thrombosis	O	77-87
and	O	88-91
vessel	O	92-98
occlusion	O	99-108
,	O	108-109
which	O	110-115
underlie	O	116-124
stroke	O	125-131
and	O	132-135
acute	O	136-141
coronary	O	142-150
syndromes	O	151-160
. 	O	160-162

Anucleate	O	0-9
platelets	O	10-19
contain	O	20-27
mRNAs	O	28-33
and	O	34-37
are	O	38-41
capable	O	42-49
of	O	50-52
protein	O	53-60
synthesis	O	61-70
,	O	70-71
raising	O	72-79
the	O	80-83
issue	O	84-89
of	O	90-92
how	O	93-96
these	O	97-102
mRNAs	O	103-108
are	O	109-112
regulated	O	113-122
. 	O	122-124

miR	B	0-3
-	I	3-4
15a	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
16	I	16-18
-	I	18-19
1	I	19-20
in	O	21-23
cancer	O	24-30
:	O	30-31
discovery	O	32-41
,	O	41-42
function	O	43-51
and	O	52-55
future	O	56-62
perspectives	O	63-75
.  	O	75-78

Expression	O	0-10
of	O	11-13
these	O	14-19
miRNAs	O	20-26
inhibits	O	27-35
cell	O	36-40
proliferation	O	41-54
,	O	54-55
promotes	O	56-64
apoptosis	O	65-74
of	O	75-77
cancer	O	78-84
cells	O	85-90
,	O	90-91
and	O	92-95
suppresses	O	96-106
tumorigenicity	O	107-121
both	O	122-126
in	O	127-129
vitro	O	130-135
and	O	136-139
in	O	140-142
vivo	O	143-147
. 	O	147-149

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
encoded	O	19-26
by	O	27-29
the	O	30-33
miR	B	34-37
-	I	37-38
15	I	38-40
/	I	40-41
16	I	41-43
cluster	O	44-51
are	O	52-55
known	O	56-61
to	O	62-64
act	O	65-68
as	O	69-71
tumor	O	72-77
suppressors	O	78-89
. 	O	89-91

Down	O	0-4
-	O	4-5
regulation	O	5-15
of	O	16-18
these	O	19-24
miRNAs	O	25-31
has	O	32-35
been	O	36-40
reported	O	41-49
in	O	50-52
chronic	O	53-60
lymphocytic	O	61-72
lymphoma	O	73-81
(	O	82-83
CLL	O	83-86
)	O	86-87
,	O	87-88
pituitary	O	89-98
adenomas	O	99-107
,	O	107-108
and	O	109-112
prostate	O	113-121
carcinoma	O	122-131
. 	O	131-133

miR	B	0-3
-	I	3-4
15a	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
16	I	16-18
-	I	18-19
1	I	19-20
function	O	21-29
by	O	30-32
targeting	O	33-42
multiple	O	43-51
oncogenes	O	52-61
,	O	61-62
including	O	63-72
BCL2	O	73-77
,	O	77-78
MCL1	O	79-83
,	O	83-84
CCND1	O	85-90
,	O	90-91
and	O	92-95
WNT3A	O	96-101
. 	O	101-103

This	O	0-4
review	O	5-11
summarizes	O	12-22
the	O	23-26
discovery	O	27-36
,	O	36-37
functions	O	38-47
,	O	47-48
and	O	49-52
clinical	O	53-61
relevance	O	62-71
of	O	72-74
these	O	75-80
miRNAs	O	81-87
in	O	88-90
cancer	O	91-97
,	O	97-98
particularly	O	99-111
CLL	O	112-115
.   	O	115-119

Molecular	O	0-9
and	O	10-13
cellular	O	14-22
neurobiological	O	23-38
studies	O	39-46
of	O	47-49
the	O	50-53
miRNAs	O	54-60
in	O	61-63
neurodegeneration	O	64-81
represent	O	82-91
the	O	92-95
exploration	O	96-107
of	O	108-110
a	O	111-112
new	O	113-116
Frontier	O	117-125
of	O	126-128
miRNAs	O	129-135
biology	O	136-143
and	O	144-147
the	O	148-151
potential	O	152-161
development	O	162-173
of	O	174-176
new	O	177-180
diagnostic	O	181-191
tests	O	192-197
and	O	198-201
genetic	O	202-209
therapies	O	210-219
for	O	220-223
neurodegenerative	O	224-241
diseases	O	242-250
.   	O	250-254

MiRNA	O	0-5
studies	O	6-13
in	O	14-16
neurobiology	O	17-29
showed	O	30-36
their	O	37-42
involvement	O	43-54
in	O	55-57
synaptic	O	58-66
plasticity	O	67-77
and	O	78-81
brain	O	82-87
diseases	O	88-96
. 	O	96-98

In	O	0-2
this	O	3-7
review	O	8-14
,	O	15-16
correlations	O	16-28
between	O	29-36
miRNA	O	37-42
-	O	42-43
mediated	O	43-51
gene	O	52-56
silencing	O	57-66
and	O	67-70
Alzheimer	O	71-80
'	O	80-81
s	O	81-82
,	O	82-83
Parkinson	O	84-93
'	O	93-94
s	O	94-95
,	O	95-96
and	O	97-100
other	O	101-106
neurodegenerative	O	107-124
diseases	O	125-133
will	O	134-138
be	O	139-141
discussed	O	142-151
. 	O	151-153

In	O	0-2
few	O	3-6
years	O	7-12
our	O	13-16
understanding	O	17-30
of	O	31-33
microRNA	O	34-42
(	O	43-44
miRNA	O	44-49
)	O	49-50
biogenesis	O	51-61
,	O	61-62
molecular	O	63-72
mechanisms	O	73-83
by	O	84-86
which	O	87-92
miRNAs	O	93-99
regulate	O	100-108
gene	O	109-113
expression	O	114-124
,	O	124-125
and	O	126-129
the	O	130-133
functional	O	134-144
roles	O	145-150
of	O	151-153
miRNAs	O	154-160
has	O	161-164
been	O	165-169
expanded	O	170-178
. 	O	178-180

Interestingly	O	0-13
,	O	13-14
numerous	O	15-23
miRNAs	O	24-30
are	O	31-34
expressed	O	35-44
in	O	45-47
a	O	48-49
spatially	O	50-59
and	O	60-63
temporally	O	64-74
controlled	O	75-85
manner	O	86-92
in	O	93-95
the	O	96-99
nervous	O	100-107
system	O	108-114
,	O	114-115
suggesting	O	116-126
that	O	127-131
their	O	132-137
posttrascriptional	O	138-156
regulation	O	157-167
may	O	168-171
be	O	172-174
particularly	O	175-187
relevant	O	188-196
in	O	197-199
neural	O	200-206
development	O	207-218
and	O	219-222
function	O	223-231
. 	O	231-233

Searching	O	0-9
for	O	10-13
MIND	O	14-18
:	O	18-19
microRNAs	O	20-29
in	O	30-32
neurodegenerative	O	33-50
diseases	O	51-59
.  	O	59-62

TAKE	O	0-4
HOME	O	5-9
MESSAGE	O	10-17
:	O	17-18
Based	O	19-24
on	O	25-27
current	O	28-35
data	O	36-40
,	O	40-41
although	O	42-50
limited	O	51-58
,	O	58-59
the	O	60-63
mesenchymal	O	64-75
-	O	75-76
epithelial	O	76-86
transition	O	87-97
is	O	98-100
proposed	O	101-109
to	O	110-112
be	O	113-115
one	O	116-119
of	O	120-122
the	O	123-126
important	O	127-136
ways	O	137-141
for	O	142-145
MSCs	O	146-150
to	O	151-153
participate	O	154-165
tissue	O	166-172
repair	O	173-179
.   	O	179-183

AREAS	O	0-5
COVERED	O	6-13
IN	O	14-16
THIS	O	17-21
REVIEW	O	22-28
:	O	28-29
This	O	30-34
review	O	35-41
focuses	O	42-49
on	O	50-52
recent	O	53-59
understanding	O	60-73
on	O	74-76
MSC	O	77-80
'	O	80-81
s	O	81-82
basic	O	83-88
biological	O	89-99
characteristics	O	100-115
and	O	116-119
the	O	120-123
mechanisms	O	124-134
underlying	O	135-145
the	O	146-149
therapeutic	O	150-161
effects	O	162-169
of	O	170-172
MSCs	O	173-177
in	O	178-180
vivo	O	181-185
. 	O	185-187

IMPORTANCE	O	0-10
OF	O	11-13
THE	O	14-17
FIELD	O	18-23
:	O	23-24
The	O	25-28
pan	O	29-32
-	O	32-33
tissue	O	33-39
existence	O	40-49
and	O	50-53
multipotency	O	54-66
of	O	67-69
differentiation	O	70-85
make	O	86-90
mesenchymal	O	91-102
stem	O	103-107
cells	O	108-113
(	O	114-115
MSCs	O	115-119
)	O	119-120
an	O	121-123
attractive	O	124-134
source	O	135-141
of	O	142-144
cells	O	145-150
as	O	151-153
tissue	O	154-160
repair	O	161-167
cells	O	168-173
,	O	173-174
seeds	O	175-180
of	O	181-183
engineered	O	184-194
tissue	O	195-201
,	O	201-202
vehicles	O	203-211
for	O	212-215
gene	O	216-220
therapy	O	221-228
or	O	229-231
in	O	232-234
combination	O	235-246
to	O	247-249
promote	O	250-257
tissue	O	258-264
regeneration	O	265-277
in	O	278-280
wound	O	281-286
healing	O	287-294
and	O	295-298
disease	O	299-306
recovery	O	307-315
. 	O	315-317

More	O	0-4
insight	O	5-12
into	O	13-17
mesenchymal	O	18-29
stem	O	30-34
cells	O	35-40
and	O	41-44
their	O	45-50
effects	O	51-58
inside	O	59-65
the	O	66-69
body	O	70-74
.  	O	74-77

As	O	0-2
examples	O	3-11
,	O	11-12
a	O	13-14
detailed	O	15-23
description	O	24-35
is	O	36-38
given	O	39-44
on	O	45-47
the	O	48-51
regeneration	O	52-64
of	O	65-67
functional	O	68-78
sweat	O	79-84
glands	O	85-91
on	O	92-94
burned	O	95-101
skin	O	102-106
as	O	107-109
well	O	110-114
as	O	115-117
neural	O	118-124
cells	O	125-130
in	O	131-133
middle	O	134-140
cerebral	O	141-149
artery	O	150-156
occlusion	O	157-166
(	O	167-168
MCAO	O	168-172
)	O	172-173
animals	O	174-181
upon	O	182-186
MSC	O	187-190
transplantation	O	191-206
. 	O	206-208

The	O	0-3
mechanisms	O	4-14
of	O	15-17
therapeutic	O	18-29
effects	O	30-37
of	O	38-40
MSCs	O	41-45
are	O	46-49
attributed	O	50-60
to	O	61-63
their	O	64-69
ability	O	70-77
to	O	78-80
migrate	O	81-88
along	O	89-94
chemokine	O	95-104
gradients	O	105-114
,	O	114-115
differentiate	O	116-129
into	O	130-134
tissue	O	135-141
-	O	141-142
specific	O	142-150
cells	O	151-156
,	O	156-157
enhance	O	158-165
angiogenesis	O	166-178
of	O	179-181
wound	O	182-187
tissue	O	188-194
and	O	195-198
regulate	O	199-207
immune	O	208-214
response	O	215-223
. 	O	223-225

Special	O	0-7
attention	O	8-17
is	O	18-20
given	O	21-26
to	O	27-29
miRNA	O	30-35
expression	O	36-46
and	O	47-50
its	O	51-54
relationship	O	55-67
with	O	68-72
the	O	73-76
characteristics	O	77-92
of	O	93-95
MSCs	O	96-100
. 	O	100-102

WHAT	O	0-4
THE	O	5-8
READER	O	9-15
WILL	O	16-20
GAIN	O	21-25
:	O	25-26
The	O	27-30
gene	O	31-35
expression	O	36-46
profiles	O	47-55
for	O	56-59
mRNA	O	60-64
,	O	64-65
protein	O	66-73
,	O	73-74
microRNA	O	75-83
and	O	84-87
cell	O	88-92
surface	O	93-100
marker	O	101-107
of	O	108-110
MSCs	O	111-115
are	O	116-119
summarized	O	120-130
. 	O	130-132

MicroRNA	O	0-8
expression	O	9-19
in	O	20-22
the	O	23-26
blood	O	27-32
and	O	33-36
brain	O	37-42
of	O	43-45
rats	O	46-50
subjected	O	51-60
to	O	61-63
transient	O	64-73
focal	O	74-79
ischemia	O	80-88
by	O	89-91
middle	O	92-98
cerebral	O	99-107
artery	O	108-114
occlusion	O	115-124
.  	O	124-127

BACKGROUND	O	0-10
AND	O	11-14
PURPOSE	O	15-22
:	O	22-23
Several	O	24-31
hundred	O	32-39
small	O	40-45
RNAs	O	46-50
called	O	51-57
microRNAs	O	58-67
(	O	68-69
miRNAs	O	69-75
)	O	75-76
have	O	77-81
been	O	82-86
identified	O	87-97
and	O	98-101
characterized	O	102-115
from	O	116-120
various	O	121-128
organisms	O	129-138
,	O	138-139
including	O	140-149
humans	O	150-156
. 	O	156-158

In	O	0-2
humans	O	3-9
,	O	9-10
some	O	11-15
of	O	16-18
these	O	19-24
miRNAs	O	25-31
have	O	32-36
been	O	37-41
found	O	42-47
to	O	48-50
regulate	O	51-59
(	O	60-61
patho	O	61-66
)	O	66-67
physiologic	O	67-78
conditions	O	79-89
such	O	90-94
as	O	95-97
tumor	O	98-103
progression	O	104-115
/	O	115-116
regression	O	116-126
,	O	126-127
cholesterol	O	128-139
and	O	140-143
glucose	O	144-151
homeostasis	O	152-163
,	O	163-164
etc	O	165-168
. 	O	168-170

In	O	0-2
this	O	3-7
report	O	8-14
,	O	14-15
we	O	16-18
present	O	19-26
data	O	27-31
on	O	32-34
the	O	35-38
miRNAs	O	39-45
expressed	O	46-55
under	O	56-61
ischemic	O	62-70
conditions	O	71-81
in	O	82-84
both	O	85-89
the	O	90-93
brain	O	94-99
and	O	100-103
blood	O	104-109
of	O	110-112
rats	O	113-117
subjected	O	118-127
to	O	128-130
middle	O	131-137
cerebral	O	138-146
artery	O	147-153
occlusion	O	154-163
(	O	164-165
MCAo	O	165-169
)	O	169-170
. 	O	170-172

METHODS	O	0-7
:	O	7-8
Sprague	O	9-16
-	O	16-17
Dawley	O	17-23
rats	O	24-28
subjected	O	29-38
to	O	39-41
MCAo	O	42-46
were	O	47-51
reperfused	O	52-62
for	O	63-66
either	O	67-73
24	O	74-76
or	O	77-79
48	O	80-82
hours	O	83-88
,	O	88-89
and	O	90-93
both	O	94-98
blood	O	99-104
and	O	105-108
brain	O	109-114
samples	O	115-122
were	O	123-127
harvested	O	128-137
. 	O	137-139

miRNA	O	0-5
expression	O	6-16
profiling	O	17-26
and	O	27-30
oligonucleotide	O	31-46
microarray	O	47-57
were	O	58-62
carried	O	63-70
out	O	71-74
,	O	74-75
and	O	76-79
the	O	80-83
data	O	84-88
were	O	89-93
validated	O	94-103
by	O	104-106
quantitative	O	107-119
real	O	120-124
-	O	124-125
time	O	125-129
polymerase	O	130-140
chain	O	141-146
reaction	O	147-155
and	O	156-159
correlated	O	160-170
with	O	171-175
published	O	176-185
data	O	186-190
on	O	191-193
protein	O	194-201
and	O	202-205
gene	O	206-210
expression	O	211-221
in	O	222-224
MCAo	O	225-229
rats	O	230-234
. 	O	234-236

RESULTS	O	0-7
:	O	7-8
We	O	9-11
report	O	12-18
here	O	19-23
for	O	24-27
the	O	28-31
first	O	32-37
time	O	38-42
the	O	43-46
involvement	O	47-58
of	O	59-61
miRNA	O	62-67
regulation	O	68-78
in	O	79-81
brain	O	82-87
pathogenesis	O	88-100
associated	O	101-111
with	O	112-116
MCAo	O	117-121
. 	O	121-123

Comparison	O	0-10
with	O	11-15
the	O	16-19
corresponding	O	20-33
DNA	O	34-37
microarray	O	38-48
data	O	49-53
revealed	O	54-62
that	O	63-67
the	O	68-71
target	O	72-78
mRNA	O	79-83
expression	O	84-94
is	O	95-97
correlated	O	98-108
with	O	109-113
the	O	114-117
regulation	O	118-128
of	O	129-131
miRNA	O	132-137
. 	O	137-139

We	O	0-2
have	O	3-7
also	O	8-12
provided	O	13-21
evidence	O	22-30
that	O	31-35
some	O	36-40
of	O	41-43
the	O	44-47
miRNAs	O	48-54
that	O	55-59
are	O	60-63
highly	O	64-70
expressed	O	71-80
in	O	81-83
the	O	84-87
ischemic	O	88-96
brain	O	97-102
can	O	103-106
be	O	107-109
detected	O	110-118
in	O	119-121
blood	O	122-127
samples	O	128-135
. 	O	135-137

CONCLUSIONS	O	0-11
:	O	11-12
Further	O	13-20
studies	O	21-28
are	O	29-32
needed	O	33-39
to	O	40-42
evaluate	O	43-51
the	O	52-55
possible	O	56-64
use	O	65-68
of	O	69-71
miRNAs	O	72-78
as	O	79-81
biomarkers	O	82-92
in	O	93-95
stroke	O	96-102
and	O	103-106
related	O	107-114
pathologies	O	115-126
.   	O	126-130

[	O	0-1
A	O	1-2
study	O	3-8
on	O	9-11
miRNA	O	12-17
alternation	O	18-29
after	O	30-35
H2O2	O	36-40
-	O	40-41
induced	O	41-48
PC12	O	49-53
cell	O	54-58
apoptosis	O	59-68
using	O	69-74
microarray	O	75-85
technique	O	86-95
]	O	95-96
.  	O	96-99

METHODS	O	0-7
:	O	7-8
PC12	O	9-13
cells	O	14-19
were	O	20-24
treated	O	25-32
with	O	33-37
different	O	38-47
concentrations	O	48-62
of	O	63-65
H2O2	O	66-70
for	O	71-74
12	O	75-77
hours	O	78-83
,	O	83-84
and	O	85-88
then	O	89-93
the	O	94-97
cell	O	98-102
viabilities	O	103-114
were	O	115-119
evaluated	O	120-129
by	O	130-132
MTT	O	133-136
assay	O	137-142
and	O	143-146
cell	O	147-151
apoptosis	O	152-161
rates	O	162-167
were	O	168-172
assessed	O	173-181
by	O	182-184
flow	O	185-189
cytometry	O	190-199
(	O	200-201
FCM	O	201-204
)	O	204-205
. 	O	205-207

OBJECTIVE	O	0-9
:	O	9-10
To	O	11-13
screen	O	14-20
the	O	21-24
differentially	O	25-39
expressed	O	40-49
microRNAs	O	50-59
(	O	59-60
miRNA	O	60-65
)	O	65-66
between	O	67-74
H2O2	O	75-79
-	O	79-80
induced	O	80-87
PC12	O	88-92
cell	O	93-97
apoptosis	O	98-107
and	O	108-111
normal	O	112-118
PC12	O	119-123
cells	O	124-129
with	O	130-134
microarray	O	135-145
chips	O	146-151
. 	O	151-153

Of	O	0-2
the	O	3-6
46	O	7-9
miRNAs	O	10-16
in	O	17-19
the	O	20-23
H2O2	O	24-28
treated	O	29-36
groups	O	37-43
,	O	43-44
39	O	45-47
were	O	48-52
similar	O	53-60
to	O	61-63
that	O	64-68
of	O	69-71
the	O	72-75
control	O	76-83
group	O	84-89
and	O	90-93
6	O	94-95
were	O	96-100
significantly	O	101-114
down	O	115-119
-	O	119-120
regulated	O	120-129
. 	O	129-131

CONCLUSION	O	0-10
:	O	10-11
Our	O	12-15
preliminary	O	16-27
data	O	28-32
may	O	33-36
provide	O	37-44
a	O	45-46
new	O	47-50
potential	O	51-60
foundation	O	61-71
for	O	72-75
further	O	76-83
study	O	84-89
of	O	90-92
pathogenesis	O	93-105
and	O	106-109
its	O	110-113
treatment	O	114-123
of	O	124-126
nerve	O	127-132
cell	O	133-137
apoptosis	O	138-147
caused	O	148-154
by	O	155-157
cerebral	O	158-166
ischemia	O	167-175
reperfusion	O	176-187
.   	O	187-191

The	O	0-3
apoptosis	O	4-13
rates	O	14-19
for	O	20-23
them	O	24-28
were	O	29-33
2	O	34-35
.	O	35-36
6	O	36-37
%	O	37-38
,	O	38-39
5	O	40-41
.	O	41-42
2	O	42-43
%	O	43-44
,	O	44-45
7	O	46-47
.	O	47-48
2	O	48-49
%	O	49-50
,	O	50-51
10	O	52-54
.	O	54-55
4	O	55-56
%	O	56-57
,	O	57-58
16	O	59-61
.	O	61-62
6	O	62-63
%	O	63-64
,	O	64-65
and	O	66-69
72	O	70-72
.	O	72-73
2	O	73-74
%	O	74-75
accordingly	O	76-87
. 	O	87-89

Expression	O	0-10
of	O	11-13
68	O	14-16
miRNAs	O	17-23
and	O	24-27
46	O	28-30
miRNAs	O	31-37
were	O	38-42
detected	O	43-51
in	O	52-54
both	O	55-59
control	O	60-67
group	O	68-73
and	O	74-77
the	O	78-81
H2O2	O	82-86
treated	O	87-94
groups	O	95-101
. 	O	101-103

miRNAs	O	0-6
were	O	7-11
isolated	O	12-20
from	O	21-25
control	O	26-33
(	O	34-35
0	O	35-36
nmol	O	37-41
/	O	41-42
L	O	42-43
H2O2	O	44-48
)	O	48-49
and	O	50-53
H2O2	O	54-58
treated	O	59-66
(	O	67-68
at	O	68-70
concentrations	O	71-85
of	O	86-88
50	O	89-91
,	O	91-92
100	O	93-96
,	O	96-97
200	O	98-101
,	O	101-102
and	O	103-106
400	O	107-110
nmol	O	111-115
/	O	115-116
L	O	116-117
H2O2	O	118-122
,	O	122-123
respectively	O	124-136
)	O	136-137
groups	O	138-144
of	O	145-147
the	O	148-151
PC12	O	152-156
cells	O	157-162
,	O	162-163
respectively	O	164-176
,	O	176-177
and	O	178-181
were	O	182-186
then	O	187-191
detected	O	192-200
and	O	201-204
analyzed	O	205-213
by	O	214-216
microarray	O	217-227
chips	O	228-233
. 	O	233-235

RESULTS	O	0-7
:	O	7-8
The	O	9-12
P12	O	13-16
cell	O	17-21
viabilities	O	22-33
in	O	34-36
control	O	37-44
and	O	45-48
H2O2	O	49-53
treated	O	54-61
group	O	62-67
were	O	68-72
(	O	73-74
92	O	74-76
+	O	77-78
/	O	78-79
-	O	79-80
9	O	81-82
.	O	82-83
8	O	83-84
)	O	84-85
%	O	85-86
,	O	86-87
(	O	88-89
90	O	89-91
+	O	92-93
/	O	93-94
-	O	94-95
14	O	96-98
.	O	98-99
70	O	99-101
)	O	101-102
%	O	102-103
,	O	103-104
(	O	105-106
80	O	106-108
+	O	109-110
/	O	110-111
-	O	111-112
13	O	113-115
.	O	115-116
85	O	116-118
)	O	118-119
%	O	119-120
,	O	120-121
(	O	122-123
54	O	123-125
+	O	126-127
/	O	127-128
-	O	128-129
12	O	130-132
.	O	132-133
23	O	133-135
)	O	135-136
%	O	136-137
,	O	137-138
and	O	139-142
(	O	143-144
22	O	144-146
+	O	147-148
/	O	148-149
-	O	149-150
7	O	151-152
.	O	152-153
35	O	153-155
)	O	155-156
%	O	156-157
,	O	157-158
respectively	O	159-171
. 	O	171-173

CONCLUSIONS	O	0-11
:	O	11-12
The	O	13-16
irregularity	O	17-29
of	O	30-32
prolactin	O	33-42
secretion	O	43-52
in	O	53-55
patients	O	56-64
with	O	65-69
NPG	O	70-73
is	O	74-76
not	O	77-80
dependant	O	81-90
on	O	91-93
the	O	94-97
presence	O	98-106
of	O	107-109
a	O	110-111
pituitary	O	112-121
tumour	O	122-128
which	O	129-134
suggests	O	135-143
that	O	144-148
a	O	149-150
hypothalamic	O	151-163
dysfunction	O	164-175
underlies	O	176-185
this	O	186-190
condition	O	191-200
. 	O	200-202

An	O	0-2
irregular	O	3-12
secretion	O	13-22
and	O	23-26
a	O	27-28
higher	O	29-35
daily	O	36-41
mass	O	42-46
production	O	47-57
of	O	58-60
prolactin	O	61-70
in	O	71-73
patients	O	74-82
with	O	83-87
NPG	O	88-91
could	O	92-97
explain	O	98-105
both	O	106-110
galactorrhea	O	111-123
and	O	124-127
infertility	O	128-139
.   	O	139-143

BACKGROUND	O	0-10
:	O	10-11
Abnormal	O	12-20
frequency	O	21-30
and	O	31-34
pulse	O	35-40
amplitud	O	41-49
of	O	50-52
prolactin	O	53-62
secretion	O	63-72
in	O	73-75
micro	O	76-81
and	O	82-85
macroprolactinomas	O	86-104
has	O	105-108
been	O	109-113
atributed	O	114-123
to	O	124-126
a	O	127-128
dysfunctional	O	129-142
tumoral	O	143-150
lactotrope	O	151-161
. 	O	161-163

[	O	0-1
Irregular	O	1-10
secretion	O	11-20
of	O	21-23
prolactin	O	24-33
in	O	34-36
infertile	O	37-46
women	O	47-52
with	O	53-57
normoprolactinemic	O	58-76
galactorrhea	O	77-89
]	O	89-90
.  	O	90-93

The	O	0-3
regularity	O	4-14
of	O	15-17
prolactin	O	18-27
secretion	O	28-37
has	O	38-41
not	O	42-45
been	O	46-50
studied	O	51-58
with	O	59-63
cuantitative	O	64-76
methods	O	77-84
in	O	85-87
patients	O	88-96
with	O	97-101
normoprolactinemic	O	102-120
galactorrhea	O	121-133
(	O	134-135
NPG	O	135-138
)	O	138-139
which	O	140-145
could	O	146-151
be	O	152-154
considered	O	155-165
an	O	166-168
entity	O	169-175
that	O	176-180
precedes	O	181-189
non	O	190-193
tumoral	O	194-201
and	O	202-205
tumoral	O	206-213
hyperprolactinemia	O	214-232
. 	O	232-234

Previous	O	0-8
evidence	O	9-17
suggests	O	18-26
that	O	27-31
non	O	32-35
tumoral	O	36-43
hyperprolactinemia	O	44-62
is	O	63-65
caused	O	66-72
by	O	73-75
a	O	76-77
hypothalamic	O	78-90
dysfunction	O	91-102
. 	O	102-104

PATIENTS	O	0-8
AND	O	9-12
METHODS	O	13-20
:	O	20-21
A	O	22-23
transversal	O	24-35
-	O	35-36
comparative	O	36-47
study	O	48-53
was	O	54-57
carried	O	58-65
out	O	66-69
in	O	70-72
6	O	73-74
infertile	O	75-84
women	O	85-90
with	O	91-95
normoprolactinemic	O	96-114
galactorrhea	O	115-127
and	O	128-131
4	O	132-133
healthy	O	134-141
women	O	142-147
as	O	148-150
controls	O	151-159
. 	O	159-161

Objective	O	0-9
:	O	9-10
To	O	11-13
analyze	O	14-21
the	O	22-25
24	O	26-28
-	O	28-29
hour	O	29-33
prolactin	O	34-43
secretion	O	44-53
pattern	O	54-61
and	O	62-65
its	O	66-69
secretion	O	70-79
regularity	O	80-90
in	O	91-93
a	O	94-95
group	O	96-101
of	O	102-104
infertile	O	105-114
women	O	115-120
with	O	121-125
normoprolactinemic	O	126-144
galatorea	O	145-154
. 	O	154-156

RESULTS	O	0-7
:	O	7-8
Blunting	O	9-17
of	O	18-20
the	O	21-24
nyctohemeral	O	25-37
rythm	O	38-43
and	O	44-47
nocturn	O	48-55
hyperprolactinaemia	O	56-75
occurred	O	76-84
in	O	85-87
patients	O	88-96
with	O	97-101
normoprolactinemic	O	102-120
galactorrhea	O	121-133
(	O	134-135
NPG	O	135-138
)	O	138-139
. 	O	139-141

The	O	0-3
24	O	4-6
hour	O	7-11
prolactin	O	12-21
profile	O	22-29
,	O	29-30
the	O	31-34
ratio	O	35-40
night	O	41-46
time	O	47-51
mean	O	52-56
concentration	O	57-70
/	O	70-71
daytime	O	71-78
mean	O	79-83
concentrattion	O	84-98
(	O	99-100
NM	O	100-102
/	O	102-103
DM	O	103-105
ratio	O	106-111
)	O	111-112
and	O	113-116
apparent	O	117-125
entropy	O	126-133
(	O	134-135
Ap	O	135-137
En	O	138-140
,	O	140-141
Ap	O	142-144
En	O	145-147
ratio	O	148-153
)	O	153-154
were	O	155-159
compared	O	160-168
in	O	169-171
the	O	172-175
two	O	176-179
groups	O	180-186
. 	O	186-188

Higher	O	0-6
irregularity	O	7-19
of	O	20-22
prolactin	O	23-32
secretion	O	33-42
was	O	43-46
found	O	47-52
in	O	53-55
patients	O	56-64
with	O	65-69
NPG	O	70-73
(	O	74-75
ApEn	O	75-79
:	O	79-80
0	O	81-82
.	O	82-83
853	O	83-86
+	O	87-88
/	O	88-89
-	O	89-90
0	O	91-92
.	O	92-93
158	O	93-96
vs	O	97-99
0	O	100-101
.	O	101-102
608	O	102-105
+	O	106-107
/	O	107-108
-	O	108-109
0	O	110-111
.	O	111-112
171	O	112-115
,	O	115-116
p	O	117-118
=	O	118-119
0	O	119-120
.	O	120-121
04	O	121-123
;	O	123-124
Ap	O	125-127
En	O	128-130
ratio	O	131-136
:	O	136-137
0	O	138-139
.	O	139-140
839	O	140-143
+	O	144-145
/	O	145-146
-	O	146-147
0	O	148-149
.	O	149-150
11	O	150-152
vs	O	153-155
0	O	156-157
.	O	157-158
661	O	158-161
+	O	162-163
/	O	163-164
-	O	164-165
0	O	166-167
.	O	167-168
14	O	168-170
;	O	170-171
p	O	172-173
=	O	173-174
0	O	174-175
.	O	175-176
04	O	176-178
)	O	178-179
. 	O	179-181

NM	O	0-2
/	O	2-3
DM	O	3-5
ratio	O	6-11
was	O	12-15
lower	O	16-21
in	O	22-24
patients	O	25-33
with	O	34-38
NPG	O	39-42
than	O	43-47
in	O	48-50
controls	O	51-59
(	O	60-61
1	O	61-62
.	O	62-63
28	O	63-65
+	O	66-67
/	O	67-68
-	O	68-69
0	O	70-71
.	O	71-72
25	O	72-74
vs	O	75-77
.	O	77-78
1	O	79-80
.	O	80-81
75	O	81-83
+	O	84-85
/	O	85-86
-	O	86-87
0	O	88-89
.	O	89-90
05	O	90-92
;	O	92-93
p	O	94-95
=	O	95-96
0	O	97-98
.	O	98-99
01	O	99-101
)	O	101-102
. 	O	102-104

Alteration	O	0-10
of	O	11-13
miRNA	O	14-19
expression	O	20-30
by	O	31-33
disease	O	34-41
and	O	42-45
insult	O	46-52
also	O	53-57
holds	O	58-63
the	O	64-67
potential	O	68-77
for	O	78-81
improved	O	82-90
diagnostic	O	91-101
tools	O	102-107
. 	O	107-109

Finally	O	0-7
,	O	7-8
miRNAs	O	9-15
have	O	16-20
been	O	21-25
shown	O	26-31
to	O	32-34
control	O	35-42
cellular	O	43-51
proliferation	O	52-65
and	O	66-69
specification	O	70-83
,	O	83-84
suggesting	O	85-95
that	O	96-100
manipulation	O	101-113
of	O	114-116
miRNAs	O	117-123
in	O	124-126
cultured	O	127-135
cells	O	136-141
could	O	142-147
result	O	148-154
in	O	155-157
more	O	158-162
convenient	O	163-173
generation	O	174-184
of	O	185-187
pure	O	188-192
cell	O	193-197
populations	O	198-209
for	O	210-213
transplantation	O	214-229
.   	O	229-233

miRNAs	O	0-6
appear	O	7-13
to	O	14-16
be	O	17-19
dysregulated	O	20-32
in	O	33-35
a	O	36-37
number	O	38-44
of	O	45-47
neurodegenerative	O	48-65
diseases	O	66-74
,	O	74-75
developmental	O	76-89
disorders	O	90-99
,	O	99-100
and	O	101-104
as	O	105-107
a	O	108-109
result	O	110-116
of	O	117-119
stroke	O	120-126
. 	O	126-128

MicroRNAS	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
have	O	19-23
been	O	24-28
suggested	O	29-38
to	O	39-41
play	O	42-46
important	O	47-56
roles	O	57-62
in	O	63-65
the	O	66-69
central	O	70-77
nervous	O	78-85
system	O	86-92
during	O	93-99
development	O	100-111
as	O	112-114
well	O	115-119
as	O	120-122
disease	O	123-130
. 	O	130-132

The	O	0-3
therapeutic	O	4-15
potential	O	16-25
of	O	26-28
microRNAs	O	29-38
in	O	39-41
nervous	O	42-49
system	O	50-56
damage	O	57-63
,	O	63-64
degeneration	O	65-77
,	O	77-78
and	O	79-82
repair	O	83-89
.  	O	89-92

Artificial	O	0-10
miRNAs	O	11-17
have	O	18-22
also	O	23-27
been	O	28-32
generated	O	33-42
for	O	43-46
the	O	47-50
repression	O	51-61
of	O	62-64
specific	O	65-73
transcripts	O	74-85
. 	O	85-87

Both	O	0-4
viral	O	5-10
delivery	O	11-19
and	O	20-23
administration	O	24-38
of	O	39-41
modified	O	42-50
oligonucleotides	O	51-67
mimicking	O	68-77
or	O	78-80
inhibiting	O	81-91
specific	O	92-100
miRNAs	O	101-107
have	O	108-112
been	O	113-117
effective	O	118-127
in	O	128-130
model	O	131-136
systems	O	137-144
. 	O	144-146

Recent	O	0-6
findings	O	7-15
suggest	O	16-23
that	O	24-28
it	O	29-31
may	O	32-35
eventually	O	36-46
be	O	47-49
possible	O	50-58
to	O	59-61
treat	O	62-67
some	O	68-72
neurological	O	73-85
disorders	O	86-95
by	O	96-98
restoring	O	99-108
or	O	109-111
inhibiting	O	112-122
miRNAs	O	123-129
altered	O	130-137
by	O	138-140
disease	O	141-148
pathology	O	149-158
. 	O	158-160

Each	O	0-4
miRNA	O	5-10
has	O	11-14
the	O	15-18
ability	O	19-26
to	O	27-29
regulate	O	30-38
hundreds	O	39-47
of	O	48-50
messenger	O	51-60
RNA	O	61-64
transcripts	O	65-76
,	O	76-77
both	O	78-82
by	O	83-85
causing	O	86-93
degradation	O	94-105
of	O	106-108
the	O	109-112
mRNA	O	113-117
and	O	118-121
by	O	122-124
inhibition	O	125-135
of	O	136-138
protein	O	139-146
translation	O	147-158
. 	O	158-160

CONCLUSIONS	O	0-11
:	O	11-12
The	O	13-16
study	O	17-22
suggests	O	23-31
that	O	32-36
spatial	O	37-44
orientation	O	45-56
memory	O	57-63
relies	O	64-70
on	O	71-73
the	O	74-77
integrity	O	78-87
of	O	88-90
the	O	91-94
right	O	95-100
hippocampus	O	101-112
. 	O	112-114

Nevertheless	O	0-12
,	O	12-13
further	O	14-21
studies	O	22-29
are	O	30-33
necessary	O	34-43
to	O	44-46
confirm	O	47-54
this	O	55-59
hypothesis	O	60-70
.   	O	70-74

The	O	0-3
subjects	O	4-12
were	O	13-17
submitted	O	18-27
to	O	28-30
a	O	31-32
neuropsychologic	O	33-49
evaluation	O	50-60
through	O	61-68
the	O	69-72
Route	O	73-78
Learning	O	79-87
Test	O	88-92
and	O	93-96
the	O	97-100
Childhood	O	101-110
Home	O	111-115
Test	O	116-120
in	O	121-123
the	O	124-127
preoperative	O	128-140
period	O	141-147
. 	O	147-149

The	O	0-3
statistical	O	4-15
analysis	O	16-24
was	O	25-28
performed	O	29-38
using	O	39-44
the	O	45-48
Kruskal	O	49-56
-	O	56-57
Wallis	O	57-63
,	O	63-64
analysis	O	65-73
of	O	74-76
variance	O	77-85
,	O	85-86
χ	O	87-88
,	O	88-89
and	O	90-93
Mann	O	94-98
-	O	98-99
Whitney	O	99-106
U	O	107-108
tests	O	109-114
. 	O	114-116

RESULTS	O	0-7
:	O	7-8
There	O	9-14
was	O	15-18
no	O	19-21
significant	O	22-33
difference	O	34-44
in	O	45-47
performance	O	48-59
in	O	60-62
the	O	63-66
remote	O	67-73
visuospatial	O	74-86
memory	O	87-93
(	O	94-95
as	O	95-97
measured	O	98-106
by	O	107-109
the	O	110-113
Childhood	O	114-123
Home	O	124-128
Test	O	129-133
)	O	133-134
across	O	135-141
the	O	142-145
groups	O	146-152
(	O	153-154
LTLE	O	154-158
,	O	158-159
RTLE	O	160-164
,	O	164-165
and	O	166-169
control	O	170-177
)	O	177-178
. 	O	178-180

Concerning	O	0-10
the	O	11-14
spatial	O	15-22
orientation	O	23-34
memory	O	35-41
,	O	41-42
however	O	43-50
,	O	50-51
there	O	52-57
was	O	58-61
a	O	62-63
significant	O	64-75
difference	O	76-86
between	O	87-94
the	O	95-98
LTLE	O	99-103
and	O	104-107
controls	O	108-116
as	O	117-119
compared	O	120-128
with	O	129-133
the	O	134-137
RTLE	O	138-142
group	O	143-148
(	O	149-150
P	O	150-151
<	O	151-152
0	O	152-153
.	O	153-154
001	O	154-157
)	O	157-158
,	O	158-159
the	O	160-163
latter	O	164-170
showing	O	171-178
a	O	179-180
poorer	O	181-187
performance	O	188-199
. 	O	199-201

However	O	0-7
,	O	7-8
evaluations	O	9-20
of	O	21-23
the	O	24-27
right	O	28-33
hippocampal	O	34-45
functions	O	46-55
have	O	56-60
not	O	61-64
been	O	65-69
consistent	O	70-80
. 	O	80-82

In	O	0-2
ablative	O	3-11
interventions	O	12-25
,	O	25-26
neuropsychologic	O	27-43
testing	O	44-51
of	O	52-54
memory	O	55-61
is	O	62-64
a	O	65-66
crucial	O	67-74
step	O	75-79
. 	O	79-81

METHODS	O	0-7
:	O	7-8
A	O	9-10
controlled	O	11-21
study	O	22-27
of	O	28-30
patients	O	31-39
with	O	40-44
left	O	45-49
(	O	50-51
LTLE	O	51-55
)	O	55-56
or	O	57-59
right	O	60-65
(	O	66-67
RTLE	O	67-71
)	O	71-72
TLE	O	73-76
. 	O	76-78

AIM	O	0-3
:	O	3-4
To	O	5-7
assess	O	8-14
the	O	15-18
hippocampal	O	19-30
function	O	31-39
in	O	40-42
remote	O	43-49
orientation	O	50-61
and	O	62-65
visuospatial	O	66-78
memory	O	79-85
in	O	86-88
patients	O	89-97
with	O	98-102
refractory	O	103-113
temporal	O	114-122
epilepsy	O	123-131
. 	O	131-133

INTRODUCTION	O	0-12
:	O	12-13
In	O	14-16
temporal	O	17-25
lobe	O	26-30
epilepsy	O	31-39
(	O	40-41
TLE	O	41-44
)	O	44-45
,	O	45-46
about	O	47-52
30	O	53-55
%	O	55-56
of	O	57-59
the	O	60-63
patients	O	64-72
do	O	73-75
not	O	76-79
achieve	O	80-87
adequate	O	88-96
pharmacologic	O	97-110
control	O	111-118
of	O	119-121
refractory	O	122-132
crises	O	133-139
,	O	139-140
and	O	141-144
surgery	O	145-152
becomes	O	153-160
an	O	161-163
alternative	O	164-175
. 	O	175-177

Route	O	0-5
Learning	O	6-14
Performance	O	15-26
:	O	26-27
Is	O	28-30
it	O	31-33
a	O	34-35
Hippocampus	O	36-47
Function	O	48-56
?  	O	56-59

Yet	O	0-3
,	O	3-4
genetic	O	5-12
testing	O	13-20
for	O	21-24
CADASIL	O	25-32
is	O	33-35
associated	O	36-46
with	O	47-51
a	O	52-53
nameable	O	54-62
proportion	O	63-73
of	O	74-76
false	O	77-82
-	O	82-83
negative	O	83-91
results	O	92-99
. 	O	99-101

Thus	O	0-4
,	O	4-5
genetic	O	6-13
testing	O	14-21
should	O	22-28
initially	O	29-38
be	O	39-41
focused	O	42-49
on	O	50-52
these	O	53-58
exons	O	59-64
,	O	64-65
with	O	66-70
some	O	71-75
variation	O	76-85
depending	O	86-95
on	O	96-98
the	O	99-102
population	O	103-113
in	O	114-116
whom	O	117-121
it	O	122-124
is	O	125-127
being	O	128-133
performed	O	134-143
. 	O	143-145

CONCLUSIONS	O	0-11
:	O	11-12
Almost	O	13-19
90	O	20-22
%	O	22-23
of	O	24-26
mutations	O	27-36
could	O	37-42
be	O	43-45
detected	O	46-54
within	O	55-61
a	O	62-63
few	O	64-67
exons	O	68-73
(	O	74-75
exons	O	75-80
2	O	81-82
-	O	82-83
6	O	83-84
)	O	84-85
. 	O	85-87

Cases	O	0-5
with	O	6-10
a	O	11-12
high	O	13-17
index	O	18-23
of	O	24-26
clinical	O	27-35
suspicion	O	36-45
should	O	46-52
be	O	53-55
investigated	O	56-68
by	O	69-71
skin	O	72-76
biopsy	O	77-83
if	O	84-86
genetic	O	87-94
testing	O	95-102
is	O	103-105
negative	O	106-114
.   	O	114-118

Of	O	0-2
the	O	3-6
mutations	O	7-16
,	O	16-17
58	O	18-20
.	O	20-21
3	O	21-22
%	O	22-23
were	O	24-28
located	O	29-36
in	O	37-39
exon	O	40-44
4	O	45-46
and	O	47-50
85	O	51-53
.	O	53-54
8	O	54-55
%	O	55-56
in	O	57-59
exons	O	60-65
2	O	66-67
through	O	68-75
6	O	76-77
. 	O	77-79

In	O	0-2
5	O	3-4
patients	O	5-13
(	O	14-15
4	O	15-16
.	O	16-17
0	O	17-18
%	O	18-19
)	O	19-20
,	O	20-21
no	O	22-24
mutation	O	25-33
was	O	34-37
identified	O	38-48
. 	O	48-50

Results	O	0-7
were	O	8-12
compared	O	13-21
with	O	22-26
those	O	27-32
of	O	33-35
previously	O	36-46
published	O	47-56
studies	O	57-64
. 	O	64-66

RESULTS	O	0-7
:	O	7-8
We	O	9-11
detected	O	12-20
54	O	21-23
distinct	O	24-32
mutations	O	33-42
(	O	43-44
117	O	44-47
missense	O	48-56
mutations	O	57-66
and	O	67-70
3	O	71-72
in	O	73-75
-	O	75-76
frame	O	76-81
deletions	O	82-91
)	O	91-92
in	O	93-95
120	O	96-99
(	O	100-101
96	O	101-103
.	O	103-104
0	O	104-105
%	O	105-106
)	O	106-107
of	O	108-110
the	O	111-114
125	O	115-118
patients	O	119-127
. 	O	127-129

BACKGROUND	O	0-10
:	O	10-11
Mutations	O	12-21
in	O	22-24
the	O	25-28
NOTCH3	O	29-35
gene	O	36-40
are	O	41-44
the	O	45-48
cause	O	49-54
of	O	55-57
cerebral	O	58-66
autosomal	O	67-76
dominant	O	77-85
arteriopathy	O	86-98
with	O	99-103
subcortical	O	104-115
infarcts	O	116-124
and	O	125-128
leukoencephalopathy	O	129-148
(	O	149-150
CADASIL	O	150-157
)	O	157-158
,	O	158-159
which	O	160-165
is	O	166-168
an	O	169-171
important	O	172-181
cause	O	182-187
of	O	188-190
stroke	O	191-197
in	O	198-200
young	O	201-206
adults	O	207-213
. 	O	213-215

Spectrum	O	0-8
of	O	9-11
mutations	O	12-21
in	O	22-24
biopsy	O	25-31
-	O	31-32
proven	O	32-38
CADASIL	O	39-46
:	O	46-47
implications	O	48-60
for	O	61-64
diagnostic	O	65-75
strategies	O	76-86
.  	O	86-89

DESIGN	O	0-6
:	O	6-7
Screening	O	8-17
for	O	18-21
NOTCH3	O	22-28
mutations	O	29-38
was	O	39-42
performed	O	43-52
in	O	53-55
125	O	56-59
unrelated	O	60-69
German	O	70-76
CADASIL	O	77-84
patients	O	85-93
with	O	94-98
biopsy	O	99-105
-	O	105-106
proven	O	106-112
disease	O	113-120
by	O	121-123
direct	O	124-130
sequencing	O	131-141
of	O	142-144
exons	O	145-150
coding	O	151-157
for	O	158-161
epidermal	O	162-171
growth	O	172-178
factor	O	179-185
-	O	185-186
like	O	186-190
repeats	O	191-198
. 	O	198-200

OBJECTIVES	O	0-10
:	O	10-11
To	O	12-14
identify	O	15-23
the	O	24-27
spectrum	O	28-36
of	O	37-39
NOTCH3	O	40-46
mutations	O	47-56
in	O	57-59
CADASIL	O	60-67
and	O	68-71
to	O	72-74
discuss	O	75-82
the	O	83-86
implications	O	87-99
for	O	100-103
diagnostic	O	104-114
strategies	O	115-125
. 	O	125-127

Identification	O	0-14
of	O	15-17
the	O	18-21
mutation	O	22-30
is	O	31-33
critical	O	34-42
for	O	43-46
genetic	O	47-54
counseling	O	55-65
and	O	66-69
testing	O	70-77
of	O	78-80
relatives	O	81-90
at	O	91-93
risk	O	94-98
. 	O	98-100

Mutations	O	0-9
are	O	10-13
typically	O	14-23
located	O	24-31
within	O	32-38
epidermal	O	39-48
growth	O	49-55
factor	O	56-62
-	O	62-63
like	O	63-67
repeat	O	68-74
domains	O	75-82
in	O	83-85
the	O	86-89
extracellular	O	90-103
part	O	104-108
of	O	109-111
the	O	112-115
Notch3	O	116-122
receptor	O	123-131
. 	O	131-133

Mutations	O	0-9
in	O	10-12
ABHD12	O	13-19
cause	O	20-25
the	O	26-29
neurodegenerative	O	30-47
disease	O	48-55
PHARC	O	56-61
:	O	61-62
An	O	63-65
inborn	O	66-72
error	O	73-78
of	O	79-81
endocannabinoid	O	82-97
metabolism	O	98-108
.  	O	108-111

Previously	O	0-10
,	O	10-11
we	O	12-14
mapped	O	15-21
this	O	22-26
Refsum	O	27-33
-	O	33-34
like	O	34-38
disorder	O	39-47
to	O	48-50
a	O	51-52
16	O	53-55
Mb	O	56-58
region	O	59-65
on	O	66-68
chromosome	O	69-79
20	O	80-82
. 	O	82-84

Polyneuropathy	O	0-14
,	O	14-15
hearing	O	16-23
loss	O	24-28
,	O	28-29
ataxia	O	30-36
,	O	36-37
retinitis	O	38-47
pigmentosa	O	48-58
,	O	58-59
and	O	60-63
cataract	O	64-72
(	O	73-74
PHARC	O	74-79
)	O	79-80
is	O	81-83
a	O	84-85
neurodegenerative	O	86-103
disease	O	104-111
marked	O	112-118
by	O	119-121
early	O	122-127
-	O	127-128
onset	O	128-133
cataract	O	134-142
and	O	143-146
hearing	O	147-154
loss	O	155-159
,	O	159-160
retinitis	O	161-170
pigmentosa	O	171-181
,	O	181-182
and	O	183-186
involvement	O	187-198
of	O	199-201
both	O	202-206
the	O	207-210
central	O	211-218
and	O	219-222
peripheral	O	223-233
nervous	O	234-241
systems	O	242-249
,	O	249-250
including	O	251-260
demyelinating	O	261-274
sensorimotor	O	275-287
polyneuropathy	O	288-302
and	O	303-306
cerebellar	O	307-317
ataxia	O	318-324
. 	O	324-326

Our	O	0-3
findings	O	4-12
show	O	13-17
that	O	18-22
ABHD12	O	23-29
performs	O	30-38
essential	O	39-48
functions	O	49-58
in	O	59-61
both	O	62-66
the	O	67-70
central	O	71-78
and	O	79-82
peripheral	O	83-93
nervous	O	94-101
systems	O	102-109
and	O	110-113
the	O	114-117
eye	O	118-121
. 	O	121-123

Any	O	0-3
future	O	4-10
drug	O	11-15
-	O	15-16
mediated	O	16-24
interference	O	25-37
with	O	38-42
this	O	43-47
enzyme	O	48-54
should	O	55-61
consider	O	62-70
the	O	71-74
potential	O	75-84
risk	O	85-89
of	O	90-92
long	O	93-97
-	O	97-98
term	O	98-102
adverse	O	103-110
effects	O	111-118
.   	O	118-122

Here	O	0-4
we	O	5-7
report	O	8-14
that	O	15-19
mutations	O	20-29
in	O	30-32
the	O	33-36
ABHD12	O	37-43
gene	O	44-48
cause	O	49-54
PHARC	O	55-60
disease	O	61-68
and	O	69-72
we	O	73-75
describe	O	76-84
the	O	85-88
clinical	O	89-97
manifestations	O	98-112
in	O	113-115
a	O	116-117
total	O	118-123
of	O	124-126
19	O	127-129
patients	O	130-138
from	O	139-143
four	O	144-148
different	O	149-158
countries	O	159-168
. 	O	168-170

The	O	0-3
ABHD12	O	4-10
enzyme	O	11-17
was	O	18-21
recently	O	22-30
shown	O	31-36
to	O	37-39
hydrolyze	O	40-49
2	O	50-51
-	O	51-52
arachidonoyl	O	52-64
glycerol	O	65-73
(	O	74-75
2	O	75-76
-	O	76-77
AG	O	77-79
)	O	79-80
,	O	80-81
the	O	82-85
main	O	86-90
endocannabinoid	O	91-106
lipid	O	107-112
transmitter	O	113-124
that	O	125-129
acts	O	130-134
on	O	135-137
cannabinoid	O	138-149
receptors	O	150-159
CB1	O	160-163
and	O	164-167
CB2	O	168-171
. 	O	171-173

Our	O	0-3
data	O	4-8
therefore	O	9-18
represent	O	19-28
an	O	29-31
example	O	32-39
of	O	40-42
an	O	43-45
inherited	O	46-55
disorder	O	56-64
related	O	65-72
to	O	73-75
endocannabinoid	O	76-91
metabolism	O	92-102
. 	O	102-104

The	O	0-3
endocannabinoid	O	4-19
system	O	20-26
is	O	27-29
involved	O	30-38
in	O	39-41
a	O	42-43
wide	O	44-48
range	O	49-54
of	O	55-57
physiological	O	58-71
processes	O	72-81
including	O	82-91
neurotransmission	O	92-109
,	O	109-110
mood	O	111-115
,	O	115-116
appetite	O	117-125
,	O	125-126
pain	O	127-131
appreciation	O	132-144
,	O	144-145
addiction	O	146-155
behavior	O	156-164
,	O	164-165
and	O	166-169
inflammation	O	170-182
,	O	182-183
and	O	184-187
several	O	188-195
potential	O	196-205
drugs	O	206-211
targeting	O	212-221
these	O	222-227
pathways	O	228-236
are	O	237-240
in	O	241-243
development	O	244-255
for	O	256-259
clinical	O	260-268
applications	O	269-281
. 	O	281-283

HIV	O	0-3
-	O	3-4
1	O	4-5
-	O	5-6
infected	O	6-14
opiate	O	15-21
abusers	O	22-29
often	O	30-35
exhibit	O	36-43
an	O	44-46
accelerated	O	47-58
form	O	59-63
of	O	64-66
HIV	O	67-70
-	O	70-71
1	O	71-72
-	O	72-73
associated	O	73-83
dementia	O	84-92
and	O	93-96
enhanced	O	97-105
neurological	O	106-118
dysfunction	O	119-130
. 	O	130-132

Morphine	O	0-8
treatment	O	9-18
of	O	19-21
human	O	22-27
monocyte	O	28-36
-	O	36-37
derived	O	37-44
macrophages	O	45-56
induces	O	57-64
differential	O	65-77
miRNA	O	78-83
and	O	84-87
protein	O	88-95
expression	O	96-106
:	O	106-107
impact	O	108-114
on	O	115-117
inflammation	O	118-130
and	O	131-134
oxidative	O	135-144
stress	O	145-151
in	O	152-154
the	O	155-158
central	O	159-166
nervous	O	167-174
system	O	175-181
.  	O	181-184

In	O	0-2
order	O	3-8
to	O	9-11
understand	O	12-22
the	O	23-26
role	O	27-31
of	O	32-34
morphine	O	35-43
in	O	44-46
this	O	47-51
process	O	52-59
,	O	59-60
we	O	61-63
performed	O	64-73
a	O	74-75
genome	O	76-82
-	O	82-83
wide	O	83-87
association	O	88-99
study	O	100-105
at	O	106-108
the	O	109-112
micro	O	113-118
RNA	O	119-122
(	O	123-124
miRNA	O	124-129
)	O	129-130
and	O	131-134
protein	O	135-142
levels	O	143-149
in	O	150-152
human	O	153-158
monocyte	O	159-167
-	O	167-168
derived	O	168-175
macrophages	O	176-187
(	O	188-189
h	O	189-190
-	O	190-191
mdms	O	191-195
)	O	195-196
. 	O	196-198

Productive	O	0-10
HIV	O	11-14
-	O	14-15
1	O	15-16
infection	O	17-26
of	O	27-29
microglia	O	30-39
and	O	40-43
perivascular	O	44-56
macrophages	O	57-68
and	O	69-72
the	O	73-76
resultant	O	77-86
secretion	O	87-96
of	O	97-99
neurotoxic	O	100-110
molecules	O	111-120
by	O	121-123
these	O	124-129
cells	O	130-135
contribute	O	136-146
to	O	147-149
this	O	150-154
phenomenon	O	155-165
. 	O	165-167

Computational	O	0-13
analysis	O	14-22
predicted	O	23-32
fibroblast	O	33-43
growth	O	44-50
factor	O	51-57
-	O	57-58
2	O	58-59
(	O	60-61
FGF	O	61-64
-	O	64-65
2	O	65-66
)	O	66-67
as	O	68-70
the	O	71-74
strongest	O	75-84
target	O	85-91
gene	O	92-96
for	O	97-100
hsa	B	101-104
-	I	104-105
miR15b	I	105-111
. 	O	111-113

A	O	0-1
total	O	2-7
of	O	8-10
26	O	11-13
differentially	O	14-28
expressed	O	29-38
miRNA	O	39-44
were	O	45-49
identified	O	50-60
(	O	61-62
P	O	62-63
<	O	64-65
0	O	66-67
.	O	67-68
01	O	68-70
)	O	70-71
,	O	71-72
of	O	73-75
which	O	76-81
hsa	B	82-85
-	I	85-86
miR	I	86-89
-	I	89-90
15b	I	90-93
and	O	94-97
hsa	B	98-101
-	I	101-102
miR	I	102-105
-	I	105-106
181b	I	106-110
had	O	111-114
the	O	115-118
greatest	O	119-127
increase	O	128-136
and	O	137-140
decrease	O	141-149
in	O	150-152
expression	O	153-163
levels	O	164-170
,	O	170-171
respectively	O	172-184
. 	O	184-186

Both	O	0-4
hsa	B	5-8
-	I	8-9
miR	I	9-12
-	I	12-13
15b	I	13-16
and	O	17-20
hsa	B	21-24
-	I	24-25
miR	I	25-28
-	I	28-29
181b	I	29-33
have	O	34-38
several	O	39-46
predicted	O	47-56
gene	O	57-61
targets	O	62-69
involved	O	70-78
in	O	79-81
inflammation	O	82-94
and	O	95-98
T	O	99-100
-	O	100-101
cell	O	101-105
activation	O	106-116
pathways	O	117-125
. 	O	125-127

Of	O	0-2
note	O	3-7
,	O	7-8
we	O	9-11
observed	O	12-20
a	O	21-22
decrease	O	23-31
in	O	32-34
FGF	O	35-38
-	O	38-39
2	O	39-40
protein	O	41-48
expression	O	49-59
in	O	60-62
response	O	63-71
to	O	72-74
morphine	O	75-83
. 	O	83-85

Moreover	O	0-8
,	O	8-9
proteomic	O	10-19
analysis	O	20-28
revealed	O	29-37
the	O	38-41
induction	O	42-51
of	O	52-54
mitochondrial	O	55-68
superoxide	O	69-79
dismutase	O	80-89
in	O	90-92
response	O	93-101
to	O	102-104
morphine	O	105-113
treatment	O	114-123
. 	O	123-125

In	O	0-2
this	O	3-7
context	O	8-15
,	O	15-16
we	O	17-19
observed	O	20-28
induction	O	29-38
of	O	39-41
MCP	O	42-45
-	O	45-46
2	O	46-47
and	O	48-51
IL	O	52-54
-	O	54-55
6	O	55-56
by	O	57-59
morphine	O	60-68
. 	O	68-70

Of	O	0-2
note	O	3-7
,	O	7-8
differentially	O	9-23
expressed	O	24-33
miRNAs	O	34-40
(	O	41-42
hsa	B	42-45
-	I	45-46
miR	I	46-49
-	I	49-50
15b	I	50-53
and	I	54-57
181	I	58-61
-	I	61-62
b	I	62-63
)	O	63-64
may	O	65-68
have	O	69-73
a	O	74-75
potential	O	76-85
role	O	86-90
in	O	91-93
regulating	O	94-104
these	O	105-110
processes	O	111-120
.   	O	120-124

Collectively	O	0-12
,	O	12-13
these	O	14-19
observations	O	20-32
demonstrate	O	33-44
that	O	45-49
morphine	O	50-58
induces	O	59-66
inflammation	O	67-79
and	O	80-83
oxidative	O	84-93
stress	O	94-100
in	O	101-103
h	O	104-105
-	O	105-106
mdms	O	106-110
thereby	O	111-118
contributing	O	119-131
to	O	132-134
expansion	O	135-144
of	O	145-147
HIV	O	148-151
-	O	151-152
1	O	152-153
CNS	O	154-157
reservoir	O	158-167
expansion	O	168-177
and	O	178-181
disease	O	182-189
progression	O	190-201
. 	O	201-203

HIV	O	0-3
-	O	3-4
1	O	4-5
infection	O	6-15
did	O	16-19
not	O	20-23
induce	O	24-30
mitochondrial	O	31-44
superoxide	O	45-55
dismutase	O	56-65
. 	O	65-67

MRI	O	0-3
scan	O	4-8
showed	O	9-15
an	O	16-18
area	O	19-23
of	O	24-26
encephalomalacia	O	27-43
in	O	44-46
the	O	47-50
left	O	51-55
temporal	O	56-64
lobe	O	65-69
,	O	69-70
as	O	71-73
well	O	74-78
as	O	79-81
post	O	82-86
-	O	86-87
surgical	O	87-95
changes	O	96-103
in	O	104-106
the	O	107-110
left	O	111-115
frontal	O	116-123
area	O	124-128
. 	O	128-130

He	O	0-2
presented	O	3-12
with	O	13-17
status	O	18-24
epilepticus	O	25-36
every	O	37-42
two	O	43-46
or	O	47-49
three	O	50-55
months	O	56-62
,	O	62-63
and	O	64-67
required	O	68-76
long	O	77-81
periods	O	82-89
of	O	90-92
hospitalization	O	93-108
on	O	109-111
each	O	112-116
occasion	O	117-125
for	O	126-129
post	O	130-134
-	O	134-135
ictal	O	135-140
confusion	O	141-150
and	O	151-154
aphasia	O	155-162
. 	O	162-164

He	O	0-2
continued	O	3-12
to	O	13-15
have	O	16-20
frequent	O	21-29
seizures	O	30-38
despite	O	39-46
treatment	O	47-56
with	O	57-61
multiple	O	62-70
combinations	O	71-83
of	O	84-86
antiepileptic	O	87-100
medications	O	101-112
. 	O	112-114

EEG	O	0-3
telemetry	O	4-13
recorded	O	14-22
multiple	O	23-31
seizures	O	32-40
,	O	40-41
all	O	42-45
with	O	46-50
a	O	51-52
clear	O	53-58
focus	O	59-64
in	O	65-67
the	O	68-71
left	O	72-76
temporal	O	77-85
area	O	86-90
. 	O	90-92

Scalp	O	0-5
EEG	O	6-9
showed	O	10-16
continuous	O	17-27
spikes	O	28-34
and	O	35-38
polyspikes	O	39-49
and	O	50-53
persistent	O	54-64
slowing	O	65-72
in	O	73-75
the	O	76-79
left	O	80-84
temporal	O	85-93
area	O	94-98
,	O	98-99
as	O	100-102
well	O	103-107
as	O	108-110
spikes	O	111-117
in	O	118-120
the	O	121-124
left	O	125-129
frontal	O	130-137
area	O	138-142
. 	O	142-144

CASE	O	0-4
REPORT	O	5-11
:	O	11-12
We	O	13-15
report	O	16-22
a	O	23-24
case	O	25-29
of	O	30-32
a	O	33-34
75	O	35-37
-	O	37-38
year	O	38-42
-	O	42-43
old	O	43-46
right	O	47-52
-	O	52-53
handed	O	53-59
man	O	60-63
who	O	64-67
underwent	O	68-77
a	O	78-79
left	O	80-84
fronto	O	85-91
-	O	91-92
temporal	O	92-100
craniotomy	O	101-111
for	O	112-115
resection	O	116-125
of	O	126-128
a	O	129-130
suprasellar	O	131-142
meningioma	O	143-153
in	O	154-156
2002	O	157-161
. 	O	161-163

Immediately	O	0-11
following	O	12-21
hospital	O	22-30
discharge	O	31-40
,	O	40-41
he	O	42-44
began	O	45-50
to	O	51-53
experience	O	54-64
complex	O	65-72
partial	O	73-80
seizures	O	81-89
. 	O	89-91

BACKGROUND	O	0-10
:	O	10-11
Epilepsy	O	12-20
surgery	O	21-28
is	O	29-31
increasingly	O	32-44
well	O	45-49
-	O	49-50
supported	O	50-59
as	O	60-62
an	O	63-65
effective	O	66-75
treatment	O	76-85
for	O	86-89
patients	O	90-98
with	O	99-103
intractable	O	104-115
epilepsy	O	116-124
. 	O	124-126

It	O	0-2
is	O	3-5
most	O	6-10
often	O	11-16
performed	O	17-26
on	O	27-29
younger	O	30-37
patients	O	38-46
and	O	47-50
the	O	51-54
safety	O	55-61
and	O	62-65
efficacy	O	66-74
of	O	75-77
epilepsy	O	78-86
surgery	O	87-94
in	O	95-97
elderly	O	98-105
patients	O	106-114
are	O	115-118
not	O	119-122
frequently	O	123-133
described	O	134-143
. 	O	143-145

Epilepsy	O	0-8
surgery	O	9-16
in	O	17-19
the	O	20-23
elderly	O	24-31
:	O	31-32
an	O	33-35
unusual	O	36-43
case	O	44-48
of	O	49-51
a	O	52-53
75	O	54-56
-	O	56-57
year	O	57-61
-	O	61-62
old	O	62-65
man	O	66-69
with	O	70-74
recurrent	O	75-84
status	O	85-91
epilepticus	O	92-103
.  	O	103-106

In	O	0-2
addition	O	3-11
,	O	11-12
few	O	13-16
cases	O	17-22
with	O	23-27
such	O	28-32
a	O	33-34
malignant	O	35-44
evolution	O	45-54
of	O	55-57
temporal	O	58-66
lobe	O	67-71
epilepsy	O	72-80
have	O	81-85
been	O	86-90
described	O	91-100
in	O	101-103
this	O	104-108
age	O	109-112
group	O	113-118
.   	O	118-122

A	O	0-1
left	O	2-6
anteromesial	O	7-19
temporal	O	20-28
lobectomy	O	29-38
was	O	39-42
performed	O	43-52
with	O	53-57
intraoperative	O	58-72
electrocorticography	O	73-93
. 	O	93-95

Neuropsychological	O	0-18
testing	O	19-26
showed	O	27-33
bilateral	O	34-43
memory	O	44-50
impairment	O	51-61
with	O	62-66
no	O	67-69
significant	O	70-81
cognitive	O	82-91
decline	O	92-99
expected	O	100-108
after	O	109-114
unilateral	O	115-125
temporal	O	126-134
lobe	O	135-139
resection	O	140-149
. 	O	149-151

CONCLUSIONS	O	0-11
:	O	11-12
This	O	13-17
is	O	18-20
one	O	21-24
of	O	25-27
the	O	28-31
oldest	O	32-38
patients	O	39-47
reported	O	48-56
in	O	57-59
the	O	60-63
literature	O	64-74
with	O	75-79
epilepsy	O	80-88
surgery	O	89-96
and	O	97-100
supports	O	101-109
the	O	110-113
possibility	O	114-125
of	O	126-128
epilepsy	O	129-137
surgery	O	138-145
in	O	146-148
elderly	O	149-156
patients	O	157-165
for	O	166-169
particular	O	170-180
cases	O	181-186
. 	O	186-188

Since	O	0-5
surgery	O	6-13
,	O	13-14
the	O	15-18
patient	O	19-26
was	O	27-30
not	O	31-34
seizure	O	35-42
-	O	42-43
free	O	43-47
(	O	48-49
Engel	O	49-54
class	O	55-60
II	O	61-63
-	O	63-64
b	O	64-65
)	O	65-66
,	O	66-67
but	O	68-71
had	O	72-75
no	O	76-78
further	O	79-86
episodes	O	87-95
of	O	96-98
status	O	99-105
epilepticus	O	106-117
in	O	118-120
one	O	121-124
year	O	125-129
and	O	130-133
two	O	134-137
months	O	138-144
of	O	145-147
follow	O	148-154
-	O	154-155
up	O	155-157
. 	O	157-159

Aberrant	O	0-8
expression	O	9-19
of	O	20-22
miRNAs	O	23-29
can	O	30-33
lead	O	34-38
to	O	39-41
diseases	O	42-50
,	O	50-51
including	O	52-61
cancer	O	62-68
. 	O	68-70

Expression	O	0-10
of	O	11-13
many	O	14-18
miRNAs	O	19-25
in	O	26-28
the	O	29-32
de	O	33-35
-	O	35-36
differentiated	O	36-50
brain	O	51-56
tumor	O	57-62
cancer	O	63-69
stem	O	70-74
cells	O	75-80
resembles	O	81-90
that	O	91-95
of	O	96-98
neural	O	99-105
stem	O	106-110
cells	O	111-116
. 	O	116-118

MicroRNAs	O	0-9
:	O	9-10
regulators	O	11-21
of	O	22-24
oncogenesis	O	25-36
and	O	37-40
stemness	O	41-49
.  	O	49-52

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
essential	O	23-32
post	O	33-37
-	O	37-38
transcriptional	O	38-53
regulators	O	54-64
that	O	65-69
determine	O	70-79
cell	O	80-84
identity	O	85-93
and	O	94-97
fate	O	98-102
. 	O	102-104

In	O	0-2
this	O	3-7
issue	O	8-13
of	O	14-16
BMC	O	17-20
Medicine	O	21-29
,	O	29-30
Silber	O	31-37
et	O	38-40
al	O	41-43
provide	O	44-51
evidence	O	52-60
of	O	61-63
the	O	64-67
expression	O	68-78
of	O	79-81
such	O	82-86
miRNAs	O	87-93
and	O	94-97
their	O	98-103
potential	O	104-113
to	O	114-116
mediate	O	117-124
differentiation	O	125-140
in	O	141-143
both	O	144-148
stem	O	149-153
cell	O	154-158
populations	O	159-170
. 	O	170-172

In	O	0-2
this	O	3-7
commentary	O	8-18
,	O	18-19
we	O	20-22
discuss	O	23-30
the	O	31-34
known	O	35-40
functions	O	41-50
of	O	51-53
miRNAs	O	54-60
in	O	61-63
cancer	O	64-70
and	O	71-74
stem	O	75-79
cells	O	80-85
,	O	85-86
their	O	87-92
therapeutic	O	93-104
potential	O	105-114
and	O	115-118
how	O	119-122
the	O	123-126
findings	O	127-135
of	O	136-138
Silber	O	139-145
et	O	146-148
al	O	149-151
provide	O	152-159
insight	O	160-167
into	O	168-172
the	O	173-176
role	O	177-181
of	O	182-184
miR	B	185-188
-	I	188-189
124	I	189-192
/	O	192-193
miR	B	193-196
-	I	196-197
137	I	197-200
dysregulation	O	201-214
in	O	215-217
glioblastomas	O	218-231
.   	O	231-235

RESULTS	O	0-7
:	O	7-8
We	O	9-11
hypothesized	O	12-24
that	O	25-29
schizophrenia	O	30-43
might	O	44-49
be	O	50-52
associated	O	53-63
with	O	64-68
altered	O	69-76
miRNA	O	77-82
profiles	O	83-91
. 	O	91-93

To	O	0-2
investigate	O	3-14
this	O	15-19
possibility	O	20-31
we	O	32-34
compared	O	35-43
the	O	44-47
expression	O	48-58
of	O	59-61
264	O	62-65
human	O	66-71
miRNAs	O	72-78
from	O	79-83
postmortem	O	84-94
prefrontal	O	95-105
cortex	O	106-112
tissue	O	113-119
of	O	120-122
individuals	O	123-134
with	O	135-139
schizophrenia	O	140-153
(	O	154-155
n	O	155-156
=	O	157-158
13	O	159-161
)	O	161-162
or	O	163-165
schizoaffective	O	166-181
disorder	O	182-190
(	O	191-192
n	O	192-193
=	O	194-195
2	O	196-197
)	O	197-198
to	O	199-201
tissue	O	202-208
of	O	209-211
21	O	212-214
psychiatrically	O	215-230
unaffected	O	231-241
individuals	O	242-253
using	O	254-259
a	O	260-261
custom	O	262-268
miRNA	O	269-274
microarray	O	275-285
. 	O	285-287

Allowing	O	0-8
a	O	9-10
5	O	11-12
%	O	12-13
false	O	14-19
discovery	O	20-29
rate	O	30-34
,	O	34-35
we	O	36-38
found	O	39-44
that	O	45-49
16	O	50-52
miRNAs	O	53-59
were	O	60-64
differentially	O	65-79
expressed	O	80-89
in	O	90-92
prefrontal	O	93-103
cortex	O	104-110
of	O	111-113
patient	O	114-121
subjects	O	122-130
,	O	130-131
with	O	132-136
15	O	137-139
expressed	O	140-149
at	O	150-152
lower	O	153-158
levels	O	159-165
(	O	166-167
fold	O	167-171
change	O	172-178
0	O	179-180
.	O	180-181
63	O	181-183
to	O	184-186
0	O	187-188
.	O	188-189
89	O	189-191
)	O	191-192
and	O	193-196
1	O	197-198
at	O	199-201
a	O	202-203
higher	O	204-210
level	O	211-216
(	O	217-218
fold	O	218-222
change	O	223-229
1	O	230-231
.	O	231-232
77	O	232-234
)	O	234-235
than	O	236-240
in	O	241-243
the	O	244-247
psychiatrically	O	248-263
unaffected	O	264-274
comparison	O	275-285
subjects	O	286-294
. 	O	294-296

The	O	0-3
expression	O	4-14
levels	O	15-21
of	O	22-24
12	O	25-27
selected	O	28-36
miRNAs	O	37-43
were	O	44-48
also	O	49-53
determined	O	54-64
by	O	65-67
quantitative	O	68-80
RT	O	81-83
-	O	83-84
PCR	O	84-87
in	O	88-90
our	O	91-94
lab	O	95-98
. 	O	98-100

For	O	0-3
the	O	4-7
eight	O	8-13
miRNAs	O	14-20
distinguished	O	21-34
by	O	35-37
being	O	38-43
expressed	O	44-53
at	O	54-56
lower	O	57-62
microarray	O	63-73
levels	O	74-80
in	O	81-83
schizophrenia	O	84-97
samples	O	98-105
versus	O	106-112
comparison	O	113-123
samples	O	124-131
,	O	131-132
seven	O	133-138
were	O	139-143
also	O	144-148
expressed	O	149-158
at	O	159-161
lower	O	162-167
levels	O	168-174
with	O	175-179
quantitative	O	180-192
RT	O	193-195
-	O	195-196
PCR	O	196-199
. 	O	199-201

CONCLUSION	O	0-10
:	O	10-11
This	O	12-16
study	O	17-22
is	O	23-25
the	O	26-29
first	O	30-35
to	O	36-38
find	O	39-43
altered	O	44-51
miRNA	O	52-57
profiles	O	58-66
in	O	67-69
postmortem	O	70-80
prefrontal	O	81-91
cortex	O	92-98
from	O	99-103
schizophrenia	O	104-117
patients	O	118-126
.   	O	126-130

microRNA	O	0-8
expression	O	9-19
in	O	20-22
the	O	23-26
prefrontal	O	27-37
cortex	O	38-44
of	O	45-47
individuals	O	48-59
with	O	60-64
schizophrenia	O	65-78
and	O	79-82
schizoaffective	O	83-98
disorder	O	99-107
.  	O	107-110

BACKGROUND	O	0-10
:	O	10-11
microRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
are	O	31-34
small	O	35-40
,	O	40-41
noncoding	O	42-51
RNA	O	52-55
molecules	O	56-65
that	O	66-70
are	O	71-74
now	O	75-78
thought	O	79-86
to	O	87-89
regulate	O	90-98
the	O	99-102
expression	O	103-113
of	O	114-116
many	O	117-121
mRNAs	O	122-127
. 	O	127-129

They	O	0-4
have	O	5-9
been	O	10-14
implicated	O	15-25
in	O	26-28
the	O	29-32
etiology	O	33-41
of	O	42-44
a	O	45-46
variety	O	47-54
of	O	55-57
complex	O	58-65
diseases	O	66-74
,	O	74-75
including	O	76-85
Tourette	O	86-94
'	O	94-95
s	O	95-96
syndrome	O	97-105
,	O	105-106
Fragile	O	107-114
x	O	115-116
syndrome	O	117-125
,	O	125-126
and	O	127-130
several	O	131-138
types	O	139-144
of	O	145-147
cancer	O	148-154
. 	O	154-156

We	O	0-2
explored	O	3-11
to	O	12-14
what	O	15-19
extent	O	20-26
abnormalities	O	27-40
of	O	41-43
echogenicity	O	44-56
of	O	57-59
the	O	60-63
periventricular	O	64-79
crossroads	O	80-90
correlate	O	91-100
with	O	101-105
changes	O	106-113
in	O	114-116
size	O	117-121
of	O	122-124
the	O	125-128
corpus	O	129-135
callosum	O	136-144
. 	O	144-146

These	O	0-5
lesions	O	6-13
damage	O	14-20
the	O	21-24
periventricular	O	25-40
crossroads	O	41-51
of	O	52-54
commissural	O	55-66
,	O	66-67
projection	O	68-78
and	O	79-82
associative	O	83-94
pathways	O	95-103
,	O	103-104
which	O	105-110
are	O	111-114
in	O	115-117
a	O	118-119
close	O	120-125
topographical	O	126-139
relationship	O	140-152
with	O	153-157
the	O	158-161
lateral	O	162-169
ventricles	O	170-180
. 	O	180-182

Periventricular	O	0-15
areas	O	16-21
,	O	21-22
which	O	23-28
topographically	O	29-44
correspond	O	45-55
to	O	56-58
the	O	59-62
frontal	O	63-70
,	O	70-71
main	O	72-76
and	O	77-80
occipital	O	81-90
crossroad	O	91-100
,	O	100-101
were	O	102-106
readily	O	107-114
visualized	O	115-125
by	O	126-128
cranial	O	129-136
ultrasound	O	137-147
scans	O	148-153
,	O	153-154
performed	O	155-164
during	O	165-171
the	O	172-175
first	O	176-181
two	O	182-185
weeks	O	186-191
after	O	192-197
birth	O	198-203
. 	O	203-205

Our	O	0-3
study	O	4-9
included	O	10-18
nine	O	19-23
infants	O	24-31
(	O	32-33
gestation	O	33-42
from	O	43-47
26	O	48-50
-	O	50-51
41	O	51-53
weeks	O	54-59
;	O	59-60
birth	O	61-66
weight	O	67-73
between	O	74-81
938	O	82-85
-	O	85-86
4450	O	86-90
grams	O	91-96
)	O	96-97
with	O	98-102
perinatal	O	103-112
brain	O	113-118
injury	O	119-125
. 	O	125-127

We	O	0-2
found	O	3-8
a	O	9-10
statistically	O	11-24
significant	O	25-36
correlation	O	37-48
between	O	49-56
the	O	57-60
increased	O	61-70
echogenicity	O	71-83
in	O	84-86
the	O	87-90
crossroad	O	91-100
areas	O	101-106
and	O	107-110
the	O	111-114
decrease	O	115-123
of	O	124-126
the	O	127-130
corpus	O	131-137
callosum	O	138-146
midsagittal	O	147-158
area	O	159-163
(	O	164-165
p	O	165-166
<	O	167-168
0	O	169-170
.	O	170-171
05	O	171-173
)	O	173-174
. 	O	174-176

Corpus	O	0-6
callosum	O	7-15
mediosagittal	O	16-29
area	O	30-34
measurements	O	35-47
were	O	48-52
performed	O	53-62
using	O	63-68
magnetic	O	69-77
resonance	O	78-87
images	O	88-94
,	O	94-95
acquired	O	96-104
between	O	105-112
the	O	113-116
first	O	117-122
and	O	123-126
sixth	O	127-132
postnatal	O	133-142
month	O	143-148
(	O	149-150
postmenstrual	O	150-163
age	O	164-167
40	O	168-170
-	O	170-171
49	O	171-173
weeks	O	174-179
)	O	179-180
. 	O	180-182

This	O	0-4
supports	O	5-13
the	O	14-17
hypothesis	O	18-28
that	O	29-33
callosal	O	34-42
fibers	O	43-49
can	O	50-53
be	O	54-56
damaged	O	57-64
,	O	64-65
during	O	66-72
growth	O	73-79
through	O	80-87
the	O	88-91
periventricular	O	92-107
crossroads	O	108-118
of	O	119-121
pathways	O	122-130
.   	O	130-134

Changes	O	0-7
of	O	8-10
the	O	11-14
corpus	O	15-21
callosum	O	22-30
in	O	31-33
children	O	34-42
who	O	43-46
suffered	O	47-55
perinatal	O	56-65
injury	O	66-72
of	O	73-75
the	O	76-79
periventricular	O	80-95
crossroads	O	96-106
of	O	107-109
pathways	O	110-118
.  	O	118-121

There	O	0-5
is	O	6-8
a	O	9-10
high	O	11-15
incidence	O	16-25
of	O	26-28
periventricular	O	29-44
leukomalacia	O	45-57
,	O	57-58
caused	O	59-65
by	O	66-68
hypoxia	O	69-76
-	O	76-77
ischemia	O	77-85
,	O	85-86
in	O	87-89
preterm	O	90-97
infants	O	98-105
. 	O	105-107

These	O	0-5
results	O	6-13
confirm	O	14-21
those	O	22-27
of	O	28-30
other	O	31-36
studies	O	37-44
with	O	45-49
animals	O	50-57
and	O	58-61
humans	O	62-68
using	O	69-74
novel	O	75-80
imaging	O	81-88
techniques	O	89-99
,	O	99-100
suggesting	O	101-111
that	O	112-116
the	O	117-120
motor	O	121-126
homunculus	O	127-137
may	O	138-141
not	O	142-145
always	O	146-152
be	O	153-155
considered	O	156-166
a	O	167-168
definite	O	169-177
and	O	178-181
absolute	O	182-190
representation	O	191-205
of	O	206-208
M1	O	209-211
.   	O	211-215

The	O	0-3
results	O	4-11
of	O	12-14
this	O	15-19
study	O	20-25
challenge	O	26-35
the	O	36-39
notion	O	40-46
of	O	47-49
orderly	O	50-57
topographic	O	58-69
relationships	O	70-83
between	O	84-91
the	O	92-95
human	O	96-101
sensorimotor	O	102-114
functions	O	115-124
and	O	125-128
their	O	129-134
representation	O	135-149
in	O	150-152
the	O	153-156
primary	O	157-164
motor	O	165-170
cortex	O	171-177
. 	O	177-179

Electrode	O	0-9
position	O	10-18
was	O	19-22
represented	O	23-34
graphically	O	35-46
whenever	O	47-55
a	O	56-57
stimulus	O	58-66
was	O	67-70
delivered	O	71-80
. 	O	80-82

A	O	0-1
total	O	2-7
of	O	8-10
43	O	11-13
maps	O	14-18
from	O	19-23
36	O	24-26
patients	O	27-35
were	O	36-40
analyzed	O	41-49
. 	O	49-51

The	O	0-3
authors	O	4-11
found	O	12-17
variations	O	18-28
in	O	29-31
the	O	32-35
organization	O	36-48
of	O	49-51
M1	O	52-54
(	O	55-56
primary	O	56-63
motor	O	64-69
cortex	O	70-76
)	O	76-77
in	O	78-80
seven	O	81-86
patients	O	87-95
(	O	96-97
19	O	97-99
.	O	99-100
4	O	100-101
%	O	101-102
)	O	102-103
. 	O	103-105

Four	O	0-4
patients	O	5-13
(	O	14-15
11	O	15-17
.	O	17-18
1	O	18-19
%	O	19-20
)	O	20-21
presented	O	22-31
mosaicism	O	32-41
(	O	42-43
overlapping	O	43-54
of	O	55-57
functional	O	58-68
areas	O	69-74
)	O	74-75
,	O	75-76
two	O	77-80
(	O	81-82
5	O	82-83
.	O	83-84
6	O	84-85
%	O	85-86
)	O	86-87
presented	O	88-97
variability	O	98-109
(	O	110-111
inverted	O	111-119
disposition	O	120-131
of	O	132-134
M1	O	135-137
functional	O	138-148
areas	O	149-154
)	O	154-155
,	O	155-156
and	O	157-160
one	O	161-164
(	O	165-166
2	O	166-167
.	O	167-168
8	O	168-169
%	O	169-170
)	O	170-171
had	O	172-175
both	O	176-180
. 	O	180-182

Functional	O	0-10
variability	O	11-22
of	O	23-25
the	O	26-29
human	O	30-35
cortical	O	36-44
motor	O	45-50
map	O	51-54
:	O	54-55
electrical	O	56-66
stimulation	O	67-78
findings	O	79-87
in	O	88-90
perirolandic	O	91-103
epilepsy	O	104-112
surgery	O	113-120
.  	O	120-123

The	O	0-3
purpose	O	4-11
of	O	12-14
this	O	15-19
study	O	20-25
was	O	26-29
to	O	30-32
assess	O	33-39
the	O	40-43
cortical	O	44-52
representation	O	53-67
of	O	68-70
sensorimotor	O	71-83
functions	O	84-93
in	O	94-96
patients	O	97-105
undergoing	O	106-116
perirolandic	O	117-129
epilepsy	O	130-138
surgery	O	139-146
,	O	146-147
focusing	O	148-156
on	O	157-159
somatotopy	O	160-170
,	O	170-171
mosaicism	O	172-181
,	O	181-182
and	O	183-186
variability	O	187-198
of	O	199-201
function	O	202-210
in	O	211-213
relation	O	214-222
to	O	223-225
the	O	226-229
classic	O	230-237
motor	O	238-243
homunculus	O	244-254
. 	O	254-256

The	O	0-3
authors	O	4-11
studied	O	12-19
36	O	20-22
patients	O	23-31
in	O	32-34
whom	O	35-39
intraoperative	O	40-54
or	O	55-57
extraoperative	O	58-72
electrical	O	73-83
cortical	O	84-92
stimulation	O	93-104
to	O	105-107
map	O	108-111
motor	O	112-117
functions	O	118-127
was	O	128-131
performed	O	132-141
. 	O	141-143

A	O	0-1
computer	O	2-10
program	O	11-18
was	O	19-22
devised	O	23-30
to	O	31-33
register	O	34-42
electrode	O	43-52
number	O	53-59
,	O	59-60
stimulation	O	61-72
parameters	O	73-83
,	O	83-84
and	O	85-88
response	O	89-97
to	O	98-100
each	O	101-105
stimulus	O	106-114
. 	O	114-116

These	O	0-5
results	O	6-13
indicate	O	14-22
that	O	23-27
miRNAs	O	28-34
are	O	35-38
differentially	O	39-53
expressed	O	54-63
in	O	64-66
C	O	67-68
.	O	68-69
elegans	O	70-77
PD	O	78-80
models	O	81-87
and	O	88-91
suggest	O	92-99
a	O	100-101
role	O	102-106
for	O	107-110
these	O	111-116
molecules	O	117-126
in	O	127-129
disease	O	130-137
pathogenesis	O	138-150
.   	O	150-154

Here	O	0-4
,	O	4-5
we	O	6-8
show	O	9-13
that	O	14-18
12	O	19-21
specific	O	22-30
miRNAs	O	31-37
are	O	38-41
differentially	O	42-56
regulated	O	57-66
in	O	67-69
the	O	70-73
animals	O	74-81
overexpressing	O	82-96
alpha	O	97-102
-	O	102-103
synuclein	O	103-112
,	O	112-113
five	O	114-118
in	O	119-121
cat	O	122-125
-	O	125-126
1	O	126-127
,	O	127-128
and	O	129-132
three	O	133-138
in	O	139-141
the	O	142-145
pdr	O	146-149
-	O	149-150
1	O	150-151
mutants	O	152-159
. 	O	159-161

The	O	0-3
family	O	4-10
of	O	11-13
miR	B	14-17
-	I	17-18
64	I	18-20
and	O	21-24
miR	B	25-28
-	I	28-29
65	I	29-31
are	O	32-35
co	O	36-38
-	O	38-39
underexpressed	O	39-53
in	O	54-56
the	O	57-60
alpha	O	61-66
-	O	66-67
synuclein	O	67-76
transgenic	O	77-87
and	O	88-91
cat	O	92-95
-	O	95-96
1	O	96-97
strains	O	98-105
,	O	105-106
and	O	107-110
members	O	111-118
of	O	119-121
let	B	122-125
-	I	125-126
7	I	126-127
family	O	128-134
co	O	135-137
-	O	137-138
underexpressed	O	138-152
in	O	153-155
the	O	156-159
alpha	O	160-165
-	O	165-166
synuclein	O	166-175
and	O	176-179
pdr	O	180-183
-	O	183-184
1	O	184-185
strains	O	186-193
;	O	193-194
mdl	O	195-198
-	O	198-199
1	O	199-200
and	O	201-204
ptc	O	205-208
-	O	208-209
1	O	209-210
genes	O	211-216
are	O	217-220
target	O	221-227
candidates	O	228-238
for	O	239-242
miR	B	243-246
-	I	246-247
64	I	247-249
and	O	250-253
miR	B	254-257
-	I	257-258
65	I	258-260
and	O	261-264
are	O	265-268
overexpressed	O	269-282
in	O	283-285
alpha	O	286-291
-	O	291-292
synuclein	O	292-301
transgenic	O	302-312
as	O	313-315
well	O	316-320
as	O	321-323
miR	B	324-327
-	I	327-328
64	I	328-330
/	I	330-331
65	I	331-333
(	O	334-335
tm3711	O	335-341
)	O	341-342
knockout	O	343-351
animals	O	352-359
. 	O	359-361

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
play	O	19-23
an	O	24-26
important	O	27-36
role	O	37-41
in	O	42-44
human	O	45-50
brain	O	51-56
development	O	57-68
and	O	69-72
maintenance	O	73-84
. 	O	84-86

To	O	0-2
search	O	3-9
for	O	10-13
miRNAs	O	14-20
that	O	21-25
may	O	26-29
be	O	30-32
involved	O	33-41
in	O	42-44
the	O	45-48
pathogenesis	O	49-61
of	O	62-64
Parkinsons	O	65-75
disease	O	76-83
(	O	84-85
PD	O	85-87
)	O	87-88
,	O	88-89
we	O	90-92
utilized	O	93-101
miRNA	O	102-107
microarrays	O	108-119
to	O	120-122
identify	O	123-131
potential	O	132-141
gene	O	142-146
expression	O	147-157
changes	O	158-165
in	O	166-168
115	O	169-172
annotated	O	173-182
miRNAs	O	183-189
in	O	190-192
PD	O	193-195
-	O	195-196
associated	O	196-206
Caenorhabditis	O	207-221
elegans	O	222-229
models	O	230-236
that	O	237-241
either	O	242-248
overexpress	O	249-260
human	O	261-266
A53T	O	267-271
alpha	O	272-277
-	O	277-278
synuclein	O	278-287
or	O	288-290
have	O	291-295
mutations	O	296-305
within	O	306-312
the	O	313-316
vesicular	O	317-326
catecholamine	O	327-340
transporter	O	341-352
(	O	353-354
cat	O	354-357
-	O	357-358
1	O	358-359
)	O	359-360
or	O	361-363
parkin	O	364-370
(	O	371-372
pdr	O	372-375
-	O	375-376
1	O	376-377
)	O	377-378
ortholog	O	379-387
. 	O	387-389

Global	O	0-6
microRNA	O	7-15
expression	O	16-26
profiling	O	27-36
of	O	37-39
Caenorhabditis	O	40-54
elegans	O	55-62
Parkinson	O	63-72
'	O	72-73
s	O	73-74
disease	O	75-82
models	O	83-89
.  	O	89-92

Glioma	O	0-6
angiogenesis	O	7-19
:	O	19-20
Towards	O	21-28
novel	O	29-34
RNA	O	35-38
therapeutics	O	39-51
.  	O	51-54

Brain	O	0-5
tumors	O	6-12
exhibit	O	13-20
marked	O	21-27
and	O	28-31
aberrant	O	32-40
blood	O	41-46
vessel	O	47-53
formation	O	54-63
indicating	O	64-74
angiogenic	O	75-85
endothelial	O	86-97
cells	O	98-103
as	O	104-106
a	O	107-108
potential	O	109-118
target	O	119-125
for	O	126-129
brain	O	130-135
tumor	O	136-141
treatment	O	142-151
. 	O	151-153

The	O	0-3
brain	O	4-9
tumor	O	10-15
blood	O	16-21
vessels	O	22-29
are	O	30-33
used	O	34-38
for	O	39-42
nutrient	O	43-51
delivery	O	52-60
,	O	60-61
and	O	62-65
possibly	O	66-74
for	O	75-78
cancer	O	79-85
cell	O	86-90
migration	O	91-100
. 	O	100-102

The	O	0-3
process	O	4-11
of	O	12-14
angiogenesis	O	15-27
is	O	28-30
complex	O	31-38
and	O	39-42
involves	O	43-51
multiple	O	52-60
players	O	61-68
. 	O	68-70

The	O	0-3
current	O	4-11
angiogenesis	O	12-24
inhibitors	O	25-35
used	O	36-40
in	O	41-43
clinical	O	44-52
trials	O	53-59
mostly	O	60-66
target	O	67-73
single	O	74-80
angiogenic	O	81-91
proteins	O	92-100
and	O	101-104
so	O	105-107
far	O	108-111
show	O	112-116
limited	O	117-124
effects	O	125-132
on	O	133-135
tumor	O	136-141
growth	O	142-148
. 	O	148-150

Besides	O	0-7
the	O	8-11
conventional	O	12-24
angiogenesis	O	25-37
inhibitors	O	38-48
,	O	48-49
RNA	O	50-53
-	O	53-54
based	O	54-59
inhibitors	O	60-70
such	O	71-75
as	O	76-78
small	O	79-84
-	O	84-85
interfering	O	85-96
RNAs	O	97-101
(	O	102-103
siRNAs	O	103-109
)	O	109-110
are	O	111-114
being	O	115-120
analyzed	O	121-129
for	O	130-133
their	O	134-139
capacity	O	140-148
to	O	149-151
silence	O	152-159
the	O	160-163
message	O	164-171
of	O	172-174
proteins	O	175-183
involved	O	184-192
in	O	193-195
neovascularization	O	196-214
. 	O	214-216

More	O	0-4
recently	O	5-13
,	O	13-14
a	O	15-16
new	O	17-20
family	O	21-27
of	O	28-30
non	O	31-34
-	O	34-35
coding	O	35-41
RNAs	O	42-46
,	O	46-47
named	O	48-53
angiomirs	O	54-63
[	O	64-65
microRNAs	O	65-74
(	O	75-76
miRNAs	O	76-82
)	O	82-83
involved	O	84-92
in	O	93-95
angiogenesis	O	96-108
]	O	108-109
has	O	110-113
emerged	O	114-121
. 	O	121-123

These	O	0-5
small	O	6-11
RNAs	O	12-16
have	O	17-21
the	O	22-25
advantage	O	26-35
over	O	36-40
siRNAs	O	41-47
in	O	48-50
that	O	51-55
they	O	56-60
have	O	61-65
the	O	66-69
potential	O	70-79
of	O	80-82
silencing	O	83-92
multiple	O	93-101
messages	O	102-110
at	O	111-113
the	O	114-117
same	O	118-122
time	O	123-127
and	O	128-131
therefore	O	132-141
they	O	142-146
might	O	147-152
become	O	153-159
therapeutically	O	160-175
relevant	O	176-184
in	O	185-187
a	O	188-189
"	O	190-191
one	O	191-194
-	O	194-195
hit	O	195-198
multiple	O	199-207
-	O	207-208
target	O	208-214
"	O	214-215
context	O	216-223
against	O	224-231
brain	O	232-237
tumor	O	238-243
angiogenesis	O	244-256
. 	O	256-258

In	O	0-2
this	O	3-7
review	O	8-14
we	O	15-17
will	O	18-22
discuss	O	23-30
the	O	31-34
emerging	O	35-43
technologies	O	44-56
in	O	57-59
anti	O	60-64
-	O	64-65
angiogenesis	O	65-77
emphasizing	O	78-89
on	O	90-92
RNA	O	93-96
-	O	96-97
based	O	97-102
therapeutics	O	103-115
.   	O	115-119

RNA	O	0-3
editing	O	4-11
by	O	12-14
adenosine	O	15-24
deamination	O	25-36
is	O	37-39
a	O	40-41
posttranscriptional	O	42-61
mechanism	O	62-71
for	O	72-75
the	O	76-79
regulation	O	80-90
of	O	91-93
gene	O	94-98
expression	O	99-109
and	O	110-113
is	O	114-116
particularly	O	117-129
widespread	O	130-140
in	O	141-143
mammals	O	144-151
. 	O	151-153

Gene	O	0-4
regulation	O	5-15
through	O	16-23
RNA	O	24-27
editing	O	28-35
.  	O	35-38

Here	O	0-4
,	O	4-5
I	O	6-7
am	O	8-10
reviewing	O	11-20
main	O	21-25
features	O	26-34
of	O	35-37
this	O	38-42
epigenetic	O	43-53
phenomenon	O	54-64
,	O	64-65
its	O	66-69
relevance	O	70-79
for	O	80-83
health	O	84-90
and	O	91-94
disease	O	95-102
,	O	102-103
as	O	104-106
well	O	107-111
as	O	112-114
potential	O	115-124
prospects	O	125-134
for	O	135-138
using	O	139-144
RNA	O	145-148
editing	O	149-156
as	O	157-159
a	O	160-161
therapeutic	O	162-173
tool	O	174-178
.   	O	178-182

Widespread	O	0-10
A	O	11-12
-	O	12-13
to	O	13-15
-	O	15-16
I	O	16-17
modification	O	18-30
of	O	31-33
repeat	O	34-40
sequences	O	41-50
in	O	51-53
the	O	54-57
human	O	58-63
transcriptome	O	64-77
suggests	O	78-86
additional	O	87-97
roles	O	98-103
for	O	104-107
RNA	O	108-111
editing	O	112-119
and	O	120-123
links	O	124-129
it	O	130-132
to	O	133-135
other	O	136-141
processes	O	142-151
of	O	152-154
gene	O	155-159
regulation	O	160-170
,	O	170-171
such	O	172-176
as	O	177-179
RNA	O	180-183
splicing	O	184-192
as	O	193-195
well	O	196-200
as	O	201-203
siRNA	O	204-209
mediated	O	210-218
gene	O	219-223
silencing	O	224-233
and	O	234-237
miRNA	O	238-243
function	O	244-252
. 	O	252-254

The	O	0-3
deficiency	O	4-14
or	O	15-17
misregulation	O	18-31
of	O	32-34
editing	O	35-42
has	O	43-46
been	O	47-51
implicated	O	52-62
in	O	63-65
the	O	66-69
etiology	O	70-78
of	O	79-81
neurological	O	82-94
diseases	O	95-103
,	O	103-104
such	O	105-109
as	O	110-112
epilepsy	O	113-121
,	O	121-122
amyotrophic	O	123-134
lateral	O	135-142
sclerosis	O	143-152
(	O	153-154
ALS	O	154-157
)	O	157-158
,	O	158-159
depression	O	160-170
and	O	171-174
tumor	O	175-180
progression	O	181-192
. 	O	192-194

Also	O	0-4
,	O	4-5
it	O	6-8
regulates	O	9-18
important	O	19-28
functional	O	29-39
properties	O	40-50
of	O	51-53
neurotransmitter	O	54-70
receptor	O	71-79
genes	O	80-85
in	O	86-88
the	O	89-92
central	O	93-100
nervous	O	101-108
system	O	109-115
by	O	116-118
changing	O	119-127
single	O	128-134
codons	O	135-141
in	O	142-144
pre	O	145-148
-	O	148-149
mRNA	O	149-153
. 	O	153-155

A	O	0-1
-	O	1-2
to	O	2-4
-	O	4-5
I	O	5-6
RNA	O	7-10
editing	O	11-18
generates	O	19-28
transcriptome	O	29-42
and	O	43-46
proteome	O	47-55
diversity	O	56-65
allowing	O	66-74
organisms	O	75-84
to	O	85-87
produce	O	88-95
many	O	96-100
more	O	101-105
gene	O	106-110
products	O	111-119
and	O	120-123
functions	O	124-133
than	O	134-138
predicted	O	139-148
based	O	149-154
on	O	155-157
the	O	158-161
number	O	162-168
of	O	169-171
genes	O	172-177
within	O	178-184
their	O	185-190
genome	O	191-197
. 	O	197-199

New	O	0-3
insights	O	4-12
into	O	13-17
the	O	18-21
roles	O	22-27
of	O	28-30
microRNAs	O	31-40
in	O	41-43
drug	O	44-48
addiction	O	49-58
and	O	59-62
neuroplasticity	O	63-78
.  	O	78-81

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
the	O	16-19
aim	O	20-23
is	O	24-26
to	O	27-29
provide	O	30-37
an	O	38-40
overview	O	41-49
of	O	50-52
the	O	53-56
emerging	O	57-65
role	O	66-70
of	O	71-73
miRNAs	O	74-80
in	O	81-83
addiction	O	84-93
.   	O	93-97

miRNAs	O	0-6
are	O	7-10
small	O	11-16
non	O	17-20
-	O	20-21
coding	O	21-27
RNAs	O	28-32
,	O	32-33
particularly	O	34-46
abundant	O	47-55
in	O	56-58
the	O	59-62
nervous	O	63-70
system	O	71-77
,	O	77-78
that	O	79-83
play	O	84-88
key	O	89-92
roles	O	93-98
as	O	99-101
regulatory	O	102-112
molecules	O	113-122
in	O	123-125
processes	O	126-135
such	O	136-140
as	O	141-143
neurogenesis	O	144-156
,	O	156-157
synapse	O	158-165
development	O	166-177
and	O	178-181
plasticity	O	182-192
in	O	193-195
the	O	196-199
brain	O	200-205
. 	O	205-207

They	O	0-4
also	O	5-9
act	O	10-13
as	O	14-16
key	O	17-20
spatiotemporal	O	21-35
regulators	O	36-46
during	O	47-53
dendritic	O	54-63
morphogenesis	O	64-77
,	O	77-78
controlling	O	79-90
the	O	91-94
expression	O	95-105
of	O	106-108
hundreds	O	109-117
of	O	118-120
genes	O	121-126
involved	O	127-135
in	O	136-138
neuroplasticity	O	139-154
and	O	155-158
in	O	159-161
the	O	162-165
function	O	166-174
of	O	175-177
synapses	O	178-186
. 	O	186-188

Recent	O	0-6
studies	O	7-14
have	O	15-19
identified	O	20-30
changes	O	31-38
of	O	39-41
several	O	42-49
specific	O	50-58
miRNA	O	59-64
expression	O	65-75
profiles	O	76-84
and	O	85-88
polymorphisms	O	89-102
affecting	O	103-112
the	O	113-116
interactions	O	117-129
between	O	130-137
miRNAs	O	138-144
and	O	145-148
their	O	149-154
targets	O	155-162
in	O	163-165
various	O	166-173
brain	O	174-179
disorders	O	180-189
,	O	189-190
including	O	191-200
addiction	O	201-210
:	O	210-211
miR	B	212-215
-	I	215-216
16	I	216-218
causes	O	219-225
adaptive	O	226-234
changes	O	235-242
in	O	243-245
production	O	246-256
of	O	257-259
the	O	260-263
serotonin	O	264-273
transporter	O	274-285
;	O	285-286
miR	B	287-290
-	I	290-291
133b	I	291-295
is	O	296-298
specifically	O	299-311
expressed	O	312-321
in	O	322-324
midbrain	O	325-333
dopaminergic	O	334-346
neurons	O	347-354
,	O	354-355
and	O	356-359
regulates	O	360-369
the	O	370-373
production	O	374-384
of	O	385-387
tyrosine	O	388-396
hydroxylase	O	397-408
and	O	409-412
the	O	413-416
dopamine	O	417-425
transporter	O	426-437
;	O	437-438
miR	B	439-442
-	I	442-443
212	I	443-446
affects	O	447-454
production	O	455-465
of	O	466-468
striatal	O	469-477
brain	O	478-483
-	O	483-484
derived	O	484-491
neurotrophic	O	492-504
factor	O	505-511
and	O	512-515
synaptic	O	516-524
plasticity	O	525-535
upon	O	536-540
cocaine	O	541-548
. 	O	548-550

Clearly	O	0-7
,	O	7-8
specific	O	9-17
miRNAs	O	18-24
have	O	25-29
emerged	O	30-37
as	O	38-40
key	O	41-44
regulators	O	45-55
leading	O	56-63
to	O	64-66
addiction	O	67-76
,	O	76-77
and	O	78-81
could	O	82-87
serve	O	88-93
as	O	94-96
valuable	O	97-105
targets	O	106-113
for	O	114-117
more	O	118-122
efficient	O	123-132
therapies	O	133-142
. 	O	142-144

ABSTRACT	O	0-8
:	O	9-10
Drug	O	11-15
addiction	O	16-25
is	O	26-28
a	O	29-30
major	O	31-36
public	O	37-43
health	O	44-50
issue	O	51-56
. 	O	56-58

It	O	0-2
is	O	3-5
typically	O	6-15
a	O	16-17
multigenetic	O	18-30
brain	O	31-36
disorder	O	37-45
,	O	45-46
implying	O	47-55
combined	O	56-64
changes	O	65-72
of	O	73-75
expression	O	76-86
of	O	87-89
several	O	90-97
hundred	O	98-105
genes	O	106-111
. 	O	111-113

Psychostimulants	O	0-16
(	O	17-18
such	O	18-22
as	O	23-25
cocaine	O	26-33
,	O	33-34
heroin	O	35-41
and	O	42-45
amphetamines	O	46-58
)	O	58-59
induce	O	60-66
strong	O	67-73
and	O	74-77
persistent	O	78-88
neuroadaptive	O	89-102
changes	O	103-110
through	O	111-118
a	O	119-120
surfeit	O	121-128
of	O	129-131
gene	O	132-136
regulatory	O	137-147
mechanisms	O	148-158
leading	O	159-166
to	O	167-169
addiction	O	170-179
. 	O	179-181

Activity	O	0-8
-	O	8-9
dependent	O	9-18
synaptic	O	19-27
plasticity	O	28-38
of	O	39-41
the	O	42-45
mesolimbic	O	46-56
dopaminergic	O	57-69
system	O	70-76
,	O	76-77
known	O	78-83
as	O	84-86
the	O	87-90
'	O	91-92
reward	O	92-98
pathway	O	99-106
'	O	106-107
,	O	107-108
plays	O	109-114
a	O	115-116
crucial	O	117-124
role	O	125-129
in	O	130-132
the	O	133-136
development	O	137-148
of	O	149-151
drug	O	152-156
dependence	O	157-167
. 	O	167-169

The	O	0-3
authors	O	4-11
review	O	12-18
the	O	19-22
literature	O	23-33
on	O	34-36
the	O	37-40
role	O	41-45
of	O	46-48
miRNAs	O	49-55
in	O	56-58
the	O	59-62
formation	O	63-72
and	O	73-76
propagation	O	77-88
of	O	89-91
gliomas	O	92-99
and	O	100-103
medulloblastomas	O	104-120
,	O	120-121
highlighting	O	122-134
the	O	135-138
potential	O	139-148
of	O	149-151
these	O	152-157
molecules	O	158-167
and	O	168-171
their	O	172-177
inhibitors	O	178-188
as	O	189-191
therapeutics	O	192-204
.   	O	204-208

In	O	0-2
addition	O	3-11
to	O	12-14
the	O	15-18
established	O	19-30
role	O	31-35
of	O	36-38
miRNAs	O	39-45
as	O	46-48
developmental	O	49-62
regulators	O	63-73
of	O	74-76
normal	O	77-83
cellular	O	84-92
function	O	93-101
,	O	101-102
they	O	103-107
have	O	108-112
recently	O	113-121
been	O	122-126
shown	O	127-132
to	O	133-135
be	O	136-138
important	O	139-148
players	O	149-156
in	O	157-159
pathological	O	160-172
states	O	173-179
such	O	180-184
as	O	185-187
cancer	O	188-194
. 	O	194-196

The	O	0-3
many	O	4-8
roles	O	9-14
of	O	15-17
microRNAs	O	18-27
in	O	28-30
brain	O	31-36
tumor	O	37-42
biology	O	43-50
.  	O	50-53

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
now	O	23-26
recognized	O	27-37
as	O	38-40
the	O	41-44
primary	O	45-52
RNAs	O	53-57
involved	O	58-66
in	O	67-69
the	O	70-73
purposeful	O	74-84
silencing	O	85-94
of	O	95-97
the	O	98-101
cell	O	102-106
'	O	106-107
s	O	107-108
own	O	109-112
message	O	113-120
. 	O	120-122

Micro	O	0-5
RNAs	O	6-10
(	O	11-12
miRNAs	O	12-18
)	O	18-19
are	O	20-23
post	O	24-28
-	O	28-29
transcriptional	O	29-44
modulators	O	45-55
of	O	56-58
gene	O	59-63
expression	O	64-74
that	O	75-79
regulate	O	80-88
the	O	89-92
stability	O	93-102
and	O	103-106
translation	O	107-118
of	O	119-121
their	O	122-127
target	O	128-134
messenger	O	135-144
RNAs	O	145-149
(	O	150-151
mRNAs	O	151-156
)	O	156-157
. 	O	157-159

Micro	B	0-5
RNA	I	6-9
-	I	9-10
125b	I	10-14
(	O	15-16
miRNA	B	16-21
-	I	21-22
125b	I	22-26
)	O	26-27
function	O	28-36
in	O	37-39
astrogliosis	O	40-52
and	O	53-56
glial	O	57-62
cell	O	63-67
proliferation	O	68-81
.  	O	81-84

In	O	0-2
vitro	O	3-8
,	O	8-9
anti	O	10-14
-	O	14-15
miRNA	O	15-20
-	O	20-21
125b	O	21-25
added	O	26-31
exogenously	O	32-43
to	O	44-46
IL	O	47-49
-	O	49-50
6	O	50-51
-	O	51-52
stressed	O	52-60
NHA	O	61-64
cultures	O	65-73
attenuated	O	74-84
both	O	85-89
glial	O	90-95
cell	O	96-100
proliferation	O	101-114
and	O	115-118
increased	O	119-128
the	O	129-132
expression	O	133-143
of	O	144-146
the	O	147-150
cyclin	O	151-157
-	O	157-158
dependent	O	158-167
kinase	O	168-174
inhibitor	O	175-184
2A	O	185-187
(	O	188-189
CDKN2A	O	189-195
)	O	195-196
,	O	196-197
a	O	198-199
miRNA	B	200-205
-	I	205-206
125b	I	206-210
target	O	211-217
and	O	218-221
negative	O	222-230
regulator	O	231-240
of	O	241-243
cell	O	244-248
growth	O	249-255
. 	O	255-257

Here	O	0-4
we	O	5-7
report	O	8-14
that	O	15-19
the	O	20-23
levels	O	24-30
of	O	31-33
a	O	34-35
human	O	36-41
brain	O	42-47
-	O	47-48
enriched	O	48-56
miRNA	B	57-62
-	I	62-63
125b	I	63-67
are	O	68-71
up	O	72-74
-	O	74-75
regulated	O	75-84
in	O	85-87
interleukin	O	88-99
-	O	99-100
6	O	100-101
(	O	102-103
IL	O	103-105
-	O	105-106
6	O	106-107
)	O	107-108
-	O	108-109
stressed	O	109-117
normal	O	118-124
human	O	125-130
astrocytes	O	131-141
(	O	142-143
NHA	O	143-146
)	O	146-147
,	O	147-148
a	O	149-150
treatment	O	151-160
known	O	161-166
to	O	167-169
induce	O	170-176
astrogliosis	O	177-189
. 	O	189-191

The	O	0-3
results	O	4-11
suggest	O	12-19
that	O	20-24
miRNA	B	25-30
-	I	30-31
125b	I	31-35
up	O	36-38
-	O	38-39
regulation	O	39-49
contributes	O	50-61
to	O	62-64
astrogliosis	O	65-77
and	O	78-81
to	O	82-84
defects	O	85-92
in	O	93-95
the	O	96-99
cell	O	100-104
cycle	O	105-110
that	O	111-115
are	O	116-119
characteristic	O	120-134
of	O	135-137
degenerating	O	138-150
brain	O	151-156
tissues	O	157-164
.   	O	164-168

A	O	0-1
strong	O	2-8
positive	O	9-17
correlation	O	18-29
between	O	30-37
miRNA	B	38-43
-	I	43-44
125b	I	44-48
abundance	O	49-58
and	O	59-62
the	O	63-66
glial	O	67-72
cell	O	73-77
markers	O	78-85
glial	O	86-91
fibrillary	O	92-102
acidic	O	103-109
protein	O	110-117
(	O	118-119
GFAP	O	119-123
)	O	123-124
and	O	125-128
vimentin	O	129-137
,	O	137-138
and	O	139-142
CDKN2A	O	143-149
down	O	150-154
-	O	154-155
regulation	O	155-165
was	O	166-169
noted	O	170-175
in	O	176-178
advanced	O	179-187
Alzheimer	O	188-197
'	O	197-198
s	O	198-199
disease	O	200-207
(	O	208-209
AD	O	209-211
)	O	211-212
and	O	213-216
in	O	217-219
Down	O	220-224
'	O	224-225
s	O	225-226
syndrome	O	227-235
(	O	236-237
DS	O	237-239
)	O	239-240
brain	O	241-246
,	O	246-247
chronic	O	248-255
neurological	O	256-268
disorders	O	269-278
associated	O	279-289
with	O	290-294
astrogliosis	O	295-307
. 	O	307-309

PURPOSE	O	0-7
Medulloblastomas	O	8-24
are	O	25-28
heterogeneous	O	29-42
tumors	O	43-49
that	O	50-54
collectively	O	55-67
represent	O	68-77
the	O	78-81
most	O	82-86
common	O	87-93
malignant	O	94-103
brain	O	104-109
tumor	O	110-115
in	O	116-118
children	O	119-127
. 	O	127-129

Integrative	O	0-11
genomic	O	12-19
analysis	O	20-28
of	O	29-31
medulloblastoma	O	32-47
identifies	O	48-58
a	O	59-60
molecular	O	61-70
subgroup	O	71-79
that	O	80-84
drives	O	85-91
poor	O	92-96
clinical	O	97-105
outcome	O	106-113
.  	O	113-116

We	O	0-2
reveal	O	3-9
the	O	10-13
relative	O	14-22
contribution	O	23-35
of	O	36-38
each	O	39-43
subgroup	O	44-52
to	O	53-55
clinical	O	56-64
outcome	O	65-72
as	O	73-75
a	O	76-77
whole	O	78-83
and	O	84-87
show	O	88-92
that	O	93-97
a	O	98-99
previously	O	100-110
unidentified	O	111-123
molecular	O	124-133
subgroup	O	134-142
,	O	142-143
characterized	O	144-157
genetically	O	158-169
by	O	170-172
c	O	173-174
-	O	174-175
MYC	O	175-178
copy	O	179-183
number	O	184-190
gains	O	191-196
and	O	197-200
transcriptionally	O	201-218
by	O	219-221
enrichment	O	222-232
of	O	233-235
photoreceptor	O	236-249
pathways	O	250-258
and	O	259-262
increased	O	263-272
miR	B	273-276
-	I	276-277
183∼96∼182	I	277-287
expression	O	288-298
,	O	298-299
is	O	300-302
associated	O	303-313
with	O	314-318
significantly	O	319-332
lower	O	333-338
rates	O	339-344
of	O	345-347
event	O	348-353
-	O	353-354
free	O	354-358
and	O	359-362
overall	O	363-370
survivals	O	371-380
. 	O	380-382

Results	O	0-7
Identified	O	8-18
are	O	19-22
six	O	23-26
molecular	O	27-36
subgroups	O	37-46
of	O	47-49
medulloblastoma	O	50-65
,	O	65-66
each	O	67-71
with	O	72-76
a	O	77-78
unique	O	79-85
combination	O	86-97
of	O	98-100
numerical	O	101-110
and	O	111-114
structural	O	115-125
chromosomal	O	126-137
aberrations	O	138-149
that	O	150-154
globally	O	155-163
influence	O	164-173
mRNA	O	174-178
and	O	179-182
miRNA	O	183-188
expression	O	189-199
. 	O	199-201

CONCLUSION	O	0-10
Our	O	11-14
results	O	15-22
detail	O	23-29
the	O	30-33
complex	O	34-41
genomic	O	42-49
heterogeneity	O	50-63
of	O	64-66
medulloblastomas	O	67-83
and	O	84-87
identify	O	88-96
a	O	97-98
previously	O	99-109
unrecognized	O	110-122
molecular	O	123-132
subgroup	O	133-141
with	O	142-146
poor	O	147-151
clinical	O	152-160
outcome	O	161-168
for	O	169-172
which	O	173-178
more	O	179-183
effective	O	184-193
therapeutic	O	194-205
strategies	O	206-216
should	O	217-223
be	O	224-226
developed	O	227-236
.   	O	236-240

PATIENTS	O	0-8
AND	O	9-12
METHODS	O	13-20
We	O	21-23
profiled	O	24-32
the	O	33-36
mRNA	O	37-41
transcriptome	O	42-55
of	O	56-58
194	O	59-62
medulloblastomas	O	63-79
and	O	80-83
performed	O	84-93
high	O	94-98
-	O	98-99
density	O	99-106
single	O	107-113
nucleotide	O	114-124
polymorphism	O	125-137
array	O	138-143
and	O	144-147
miRNA	O	148-153
analysis	O	154-162
on	O	163-165
115	O	166-169
and	O	170-173
98	O	174-176
of	O	177-179
these	O	180-185
,	O	185-186
respectively	O	187-199
. 	O	199-201

To	O	0-2
understand	O	3-13
the	O	14-17
molecular	O	18-27
characteristics	O	28-43
underlying	O	44-54
their	O	55-60
heterogeneity	O	61-74
and	O	75-78
to	O	79-81
identify	O	82-90
whether	O	91-98
such	O	99-103
characteristics	O	104-119
represent	O	120-129
risk	O	130-134
factors	O	135-142
for	O	143-146
patients	O	147-155
with	O	156-160
this	O	161-165
disease	O	166-173
,	O	173-174
we	O	175-177
performed	O	178-187
an	O	188-190
integrated	O	191-201
genomic	O	202-209
analysis	O	210-218
of	O	219-221
a	O	222-223
large	O	224-229
series	O	230-236
of	O	237-239
primary	O	240-247
tumors	O	248-254
. 	O	254-256

We	O	0-2
additionally	O	3-15
validated	O	16-25
our	O	26-29
findings	O	30-38
in	O	39-41
three	O	42-47
previously	O	48-58
published	O	59-68
independent	O	69-80
medulloblastoma	O	81-96
data	O	97-101
sets	O	102-106
. 	O	106-108

Non	O	0-3
-	O	3-4
negative	O	4-12
matrix	O	13-19
factorization	O	20-33
-	O	33-34
based	O	34-39
clustering	O	40-50
of	O	51-53
mRNA	O	54-58
expression	O	59-69
data	O	70-74
was	O	75-78
used	O	79-83
to	O	84-86
identify	O	87-95
molecular	O	96-105
subgroups	O	106-115
of	O	116-118
medulloblastoma	O	119-134
;	O	134-135
DNA	O	136-139
copy	O	140-144
number	O	145-151
,	O	151-152
miRNA	O	153-158
profiles	O	159-167
,	O	167-168
and	O	169-172
clinical	O	173-181
outcomes	O	182-190
were	O	191-195
analyzed	O	196-204
for	O	205-208
each	O	209-213
. 	O	213-215

MicroRNAs	O	0-9
and	O	10-13
apoptosis	O	14-23
:	O	23-24
implications	O	25-37
in	O	38-40
the	O	41-44
molecular	O	45-54
therapy	O	55-62
of	O	63-65
human	O	66-71
disease	O	72-79
.  	O	79-82

1	O	0-1
.	O	1-2
MicroRNAs	O	3-12
(	O	13-14
miRNAs	O	14-20
)	O	20-21
,	O	21-22
the	O	23-26
small	O	27-32
non	O	33-36
-	O	36-37
coding	O	37-43
RNAs	O	44-48
of	O	49-51
approximately	O	52-65
22	O	66-68
nucleotides	O	69-80
,	O	80-81
are	O	82-85
now	O	86-89
recognized	O	90-100
as	O	101-103
a	O	104-105
very	O	106-110
large	O	111-116
family	O	117-123
present	O	124-131
throughout	O	132-142
the	O	143-146
genomes	O	147-154
of	O	155-157
plants	O	158-164
and	O	165-168
metazoans	O	169-178
. 	O	178-180

These	O	0-5
small	O	6-11
transcripts	O	12-23
modulate	O	24-32
protein	O	33-40
expression	O	41-51
by	O	52-54
binding	O	55-62
to	O	63-65
complementary	O	66-79
or	O	80-82
partially	O	83-92
complementary	O	93-106
target	O	107-113
protein	O	114-121
-	O	121-122
coding	O	122-128
mRNAs	O	129-134
and	O	135-138
targeting	O	139-148
them	O	149-153
for	O	154-157
degradation	O	158-169
or	O	170-172
translational	O	173-186
inhibition	O	187-197
. 	O	197-199

2	O	0-1
.	O	1-2
The	O	3-6
discovery	O	7-16
of	O	17-19
miRNAs	O	20-26
has	O	27-30
revolutionized	O	31-45
our	O	46-49
understanding	O	50-63
of	O	64-66
the	O	67-70
mechanisms	O	71-81
that	O	82-86
regulate	O	87-95
gene	O	96-100
expression	O	101-111
,	O	111-112
with	O	113-117
the	O	118-121
addition	O	122-130
of	O	131-133
an	O	134-136
entirely	O	137-145
novel	O	146-151
level	O	152-157
of	O	158-160
regulatory	O	161-171
control	O	172-179
. 	O	179-181

3	O	0-1
.	O	1-2
One	O	3-6
of	O	7-9
the	O	10-13
most	O	14-18
active	O	19-25
fields	O	26-32
of	O	33-35
miRNA	O	36-41
research	O	42-50
is	O	51-53
miRNA	O	54-59
regulation	O	60-70
of	O	71-73
apoptosis	O	74-83
,	O	83-84
a	O	85-86
programmed	O	87-97
cell	O	98-102
death	O	103-108
implicated	O	109-119
in	O	120-122
many	O	123-127
human	O	128-133
diseases	O	134-142
,	O	142-143
such	O	144-148
as	O	149-151
cancer	O	152-158
,	O	158-159
Alzheimer	O	160-169
'	O	169-170
s	O	170-171
disease	O	172-179
,	O	179-180
hypertrophy	O	181-192
and	O	193-196
heart	O	197-202
failure	O	203-210
. 	O	210-212

Indeed	O	0-6
,	O	6-7
aberrant	O	8-16
miRNA	O	17-22
expression	O	23-33
has	O	34-37
been	O	38-42
documented	O	43-53
in	O	54-56
human	O	57-62
disease	O	63-70
as	O	71-73
well	O	74-78
as	O	79-81
in	O	82-84
animal	O	85-91
models	O	92-98
,	O	98-99
with	O	100-104
evidence	O	105-113
for	O	114-117
a	O	118-119
causative	O	120-129
role	O	130-134
in	O	135-137
tumourigenesis	O	138-152
. 	O	152-154

We	O	0-2
now	O	3-6
know	O	7-11
that	O	12-16
miRNAs	O	17-23
play	O	24-28
pivotal	O	29-36
roles	O	37-42
in	O	43-45
diverse	O	46-53
processes	O	54-63
,	O	63-64
such	O	65-69
as	O	70-72
development	O	73-84
and	O	85-88
differentiation	O	89-104
,	O	104-105
control	O	106-113
of	O	114-116
cell	O	117-121
proliferation	O	122-135
and	O	136-139
death	O	140-145
,	O	145-146
stress	O	147-153
response	O	154-162
and	O	163-166
metabolism	O	167-177
. 	O	177-179

Considerable	O	0-12
information	O	13-24
on	O	25-27
miRNAs	O	28-34
has	O	35-38
been	O	39-43
accumulated	O	44-55
in	O	56-58
this	O	59-63
rapidly	O	64-71
evolving	O	72-80
research	O	81-89
field	O	90-95
. 	O	95-97

4	O	0-1
.	O	1-2
The	O	3-6
present	O	7-14
review	O	15-21
provides	O	22-30
a	O	31-32
comprehensive	O	33-46
summary	O	47-54
and	O	55-58
analysis	O	59-67
of	O	68-70
the	O	71-74
currently	O	75-84
available	O	85-94
data	O	95-99
,	O	99-100
focusing	O	101-109
on	O	110-112
the	O	113-116
transcriptional	O	117-132
controls	O	133-141
,	O	141-142
target	O	143-149
genes	O	150-155
and	O	156-159
signalling	O	160-170
pathways	O	171-179
linking	O	180-187
the	O	188-191
apoptosis	O	192-201
-	O	201-202
regulating	O	202-212
miRNAs	O	213-219
and	O	220-223
apoptotic	O	224-233
cell	O	234-238
death	O	239-244
.   	O	244-248

Thus	O	0-4
far	O	5-8
,	O	8-9
nearly	O	10-16
30	O	17-19
of	O	20-22
500	O	23-26
human	O	27-32
miRNAs	O	33-39
have	O	40-44
been	O	45-49
validated	O	50-59
experimentally	O	60-74
to	O	75-77
regulate	O	78-86
apoptosis	O	87-96
;	O	96-97
this	O	98-102
number	O	103-109
is	O	110-112
likely	O	113-119
to	O	120-122
increase	O	123-131
with	O	132-136
future	O	137-143
studies	O	144-151
. 	O	151-153

Additionally	O	0-12
,	O	12-13
several	O	14-21
research	O	22-30
groups	O	31-37
have	O	38-42
established	O	43-54
that	O	55-59
inserting	O	60-69
microRNA	O	70-78
(	O	79-80
miRNA	O	80-85
)	O	85-86
-	O	86-87
targeted	O	87-95
sequences	O	96-105
into	O	106-110
the	O	111-114
adenoviral	O	115-125
genome	O	126-132
can	O	133-136
modulate	O	137-145
adenoviral	O	146-156
protein	O	157-164
expression	O	165-175
to	O	176-178
confer	O	179-185
tissue	O	186-192
and	O	193-196
tumor	O	197-202
selectivity	O	203-214
. 	O	214-216

It	O	0-2
has	O	3-6
been	O	7-11
suggested	O	12-21
that	O	22-26
the	O	27-30
use	O	31-34
of	O	35-37
autophagy	O	38-47
inducers	O	48-56
,	O	56-57
such	O	58-62
as	O	63-65
rapamycin	O	66-75
,	O	75-76
can	O	77-80
enhance	O	81-88
the	O	89-92
oncolytic	O	93-102
potency	O	103-110
of	O	111-113
recombinant	O	114-125
adenoviruses	O	126-138
. 	O	138-140

This	O	0-4
review	O	5-11
discusses	O	12-21
three	O	22-27
aspects	O	28-35
of	O	36-38
the	O	39-42
use	O	43-46
of	O	47-49
oncolytic	O	50-59
adenoviruses	O	60-72
to	O	73-75
treat	O	76-81
cancer	O	82-88
:	O	88-89
(	O	90-91
i	O	91-92
)	O	92-93
the	O	94-97
induction	O	98-107
of	O	108-110
autophagy	O	111-120
and	O	121-124
autophagic	O	125-135
cell	O	136-140
death	O	141-146
during	O	147-153
adenoviral	O	154-164
replication	O	165-176
;	O	176-177
(	O	178-179
ii	O	179-181
)	O	181-182
the	O	183-186
opportunities	O	187-200
and	O	201-204
strategies	O	205-215
involved	O	216-224
in	O	225-227
the	O	228-231
exploitation	O	232-244
of	O	245-247
miRNA	O	248-253
specificity	O	254-265
to	O	266-268
generate	O	269-277
tissue	O	278-284
-	O	284-285
and	O	286-289
tumor	O	290-295
-	O	295-296
selective	O	296-305
oncolytic	O	306-315
viruses	O	316-323
;	O	323-324
and	O	325-328
(	O	329-330
iii	O	330-333
)	O	333-334
the	O	335-338
rationale	O	339-348
for	O	349-352
combining	O	353-362
oncolytic	O	363-372
adenoviruses	O	373-385
with	O	386-390
chemotherapeutic	O	391-407
agents	O	408-414
.   	O	414-418

Furthermore	O	0-11
,	O	11-12
the	O	13-16
capability	O	17-27
of	O	28-30
adenoviruses	O	31-43
to	O	44-46
inhibit	O	47-54
the	O	55-58
expression	O	59-69
of	O	70-72
the	O	73-76
DNA	O	77-80
repair	O	81-87
enzyme	O	88-94
MGMT	O	95-99
and	O	100-103
to	O	104-106
chemosensitize	O	107-121
glioma	O	122-128
cells	O	129-134
to	O	135-137
temozolomide	O	138-150
has	O	151-154
been	O	155-159
demonstrated	O	160-172
. 	O	172-174

In	O	0-2
recent	O	3-9
years	O	10-15
,	O	15-16
oncolytic	O	17-26
viruses	O	27-34
have	O	35-39
been	O	40-44
genetically	O	45-56
engineered	O	57-67
to	O	68-70
target	O	71-77
cancer	O	78-84
cells	O	85-90
selectively	O	91-102
. 	O	102-104

Oncolytic	O	0-9
adenoviruses	O	10-22
for	O	23-26
the	O	27-30
treatment	O	31-40
of	O	41-43
brain	O	44-49
tumors	O	50-56
.  	O	56-59

The	O	0-3
observation	O	4-15
that	O	16-20
cells	O	21-26
infected	O	27-35
with	O	36-40
replication	O	41-52
-	O	52-53
competent	O	53-62
adenoviruses	O	63-75
undergo	O	76-83
autophagy	O	84-93
has	O	94-97
provided	O	98-106
new	O	107-110
options	O	111-118
for	O	119-122
investigating	O	123-136
the	O	137-140
mechanism	O	141-150
of	O	151-153
adenovirus	O	154-164
-	O	164-165
induced	O	165-172
cell	O	173-177
death	O	178-183
. 	O	183-185

Adenovirus	O	0-10
is	O	11-13
one	O	14-17
such	O	18-22
oncolytic	O	23-32
virus	O	33-38
that	O	39-43
is	O	44-46
being	O	47-52
tested	O	53-59
in	O	60-62
clinical	O	63-71
trials	O	72-78
for	O	79-82
the	O	83-86
treatment	O	87-96
of	O	97-99
cancer	O	100-106
. 	O	106-108

BACE1	O	0-5
mRNA	O	6-10
levels	O	11-17
tended	O	18-24
to	O	25-27
increase	O	28-36
as	O	37-39
miR	B	40-43
-	I	43-44
107	I	44-47
levels	O	48-54
decreased	O	55-64
in	O	65-67
the	O	68-71
progression	O	72-83
of	O	84-86
AD	O	87-89
.	O	89-90
Cell	O	91-95
culture	O	96-103
reporter	O	104-112
assays	O	113-119
performed	O	120-129
with	O	130-134
a	O	135-136
subset	O	137-143
of	O	144-146
the	O	147-150
predicted	O	151-160
miR	B	161-164
-	I	164-165
107	I	165-168
binding	O	169-176
sites	O	177-182
indicate	O	183-191
the	O	192-195
presence	O	196-204
of	O	205-207
at	O	208-210
least	O	211-216
one	O	217-220
physiological	O	221-234
miR	B	235-238
-	I	238-239
107	I	239-242
miRNA	O	243-248
recognition	O	249-260
sequence	O	261-269
in	O	270-272
the	O	273-276
3	O	277-278
'	O	278-279
-	O	279-280
UTR	O	280-283
of	O	284-286
BACE1	O	287-292
mRNA	O	293-297
. 	O	297-299

Computational	O	0-13
analysis	O	14-22
predicted	O	23-32
that	O	33-37
the	O	38-41
3	O	42-43
'	O	43-44
-	O	44-45
untranslated	O	45-57
region	O	58-64
(	O	65-66
UTR	O	66-69
)	O	69-70
of	O	71-73
beta	O	74-78
-	O	78-79
site	O	79-83
amyloid	O	84-91
precursor	O	92-101
protein	O	102-109
-	O	109-110
cleaving	O	110-118
enzyme	O	119-125
1	O	126-127
(	O	128-129
BACE1	O	129-134
)	O	134-135
mRNA	O	136-140
is	O	141-143
targeted	O	144-152
multiply	O	153-161
by	O	162-164
miR	B	165-168
-	I	168-169
107	I	169-172
. 	O	172-174

From	O	0-4
the	O	5-8
same	O	9-13
RNA	O	14-17
material	O	18-26
analyzed	O	27-35
on	O	36-38
miRNA	O	39-44
microarrays	O	45-56
,	O	56-57
mRNA	O	58-62
expression	O	63-73
profiling	O	74-83
was	O	84-87
performed	O	88-97
using	O	98-103
Affymetrix	O	104-114
Exon	O	115-119
Array	O	120-125
microarrays	O	126-137
on	O	138-140
nondemented	O	141-152
,	O	152-153
MCI	O	154-157
,	O	157-158
and	O	159-162
AD	O	163-165
patients	O	166-174
. 	O	174-176

Among	O	0-5
the	O	6-9
AD	O	10-12
-	O	12-13
related	O	13-20
miRNA	O	21-26
expression	O	27-37
changes	O	38-45
,	O	45-46
miR	B	47-50
-	I	50-51
107	I	51-54
was	O	55-58
exceptional	O	59-70
because	O	71-78
miR	B	79-82
-	I	82-83
107	I	83-86
levels	O	87-93
decreased	O	94-103
significantly	O	104-117
even	O	118-122
in	O	123-125
patients	O	126-134
with	O	135-139
the	O	140-143
earliest	O	144-152
stages	O	153-159
of	O	160-162
pathology	O	163-172
. 	O	172-174

In	O	0-2
situ	O	3-7
hybridization	O	8-21
with	O	22-26
cross	O	27-32
-	O	32-33
comparison	O	33-43
to	O	44-46
neuropathology	O	47-61
demonstrated	O	62-74
that	O	75-79
particular	O	80-90
cerebral	O	91-99
cortical	O	100-108
laminas	O	109-116
involved	O	117-125
by	O	126-128
AD	O	129-131
pathology	O	132-141
exhibit	O	142-149
diminished	O	150-160
neuronal	O	161-169
miR	B	170-173
-	I	173-174
107	I	174-177
expression	O	178-188
. 	O	188-190

We	O	0-2
used	O	3-7
miRNA	O	8-13
expression	O	14-24
microarrays	O	25-36
on	O	37-39
RNA	O	40-43
extracted	O	44-53
from	O	54-58
human	O	59-64
brain	O	65-70
tissue	O	71-77
from	O	78-82
the	O	83-86
University	O	87-97
of	O	98-100
Kentucky	O	101-109
Alzheimer	O	110-119
'	O	119-120
s	O	120-121
Disease	O	122-129
Center	O	130-136
Brain	O	137-142
Bank	O	143-147
with	O	148-152
near	O	153-157
-	O	157-158
optimal	O	158-165
clinicopathological	O	166-185
correlation	O	186-197
. 	O	197-199

Cases	O	0-5
were	O	6-10
separated	O	11-20
into	O	21-25
four	O	26-30
groups	O	31-37
:	O	37-38
elderly	O	39-46
nondemented	O	47-58
with	O	59-63
negligible	O	64-74
AD	O	75-77
-	O	77-78
type	O	78-82
pathology	O	83-92
,	O	92-93
nondemented	O	94-105
with	O	106-110
incipient	O	111-120
AD	O	121-123
pathology	O	124-133
,	O	133-134
mild	O	135-139
cognitive	O	140-149
impairment	O	150-160
(	O	161-162
MCI	O	162-165
)	O	165-166
with	O	167-171
moderate	O	172-180
AD	O	181-183
pathology	O	184-193
,	O	193-194
and	O	195-198
AD	O	199-201
. 	O	201-203

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
regulatory	O	29-39
RNAs	O	40-44
that	O	45-49
participate	O	50-61
in	O	62-64
posttranscriptional	O	65-84
gene	O	85-89
regulation	O	90-100
in	O	101-103
a	O	104-105
sequence	O	106-114
-	O	114-115
specific	O	115-123
manner	O	124-130
. 	O	130-132

However	O	0-7
,	O	7-8
little	O	9-15
is	O	16-18
understood	O	19-29
about	O	30-35
the	O	36-39
role	O	40-44
(	O	44-45
s	O	45-46
)	O	46-47
of	O	48-50
miRNAs	O	51-57
in	O	58-60
Alzheimer	O	61-70
'	O	70-71
s	O	71-72
disease	O	73-80
(	O	81-82
AD	O	82-84
)	O	84-85
. 	O	85-87

Together	O	0-8
,	O	8-9
the	O	10-13
coordinated	O	14-25
application	O	26-37
of	O	38-40
miRNA	O	41-46
profiling	O	47-56
,	O	56-57
Affymetrix	O	58-68
microarrays	O	69-80
,	O	80-81
new	O	82-85
bioinformatics	O	86-100
predictions	O	101-112
,	O	112-113
in	O	114-116
situ	O	117-121
hybridization	O	122-135
,	O	135-136
and	O	137-140
biochemical	O	141-152
validation	O	153-163
indicate	O	164-172
that	O	173-177
miR	B	178-181
-	I	181-182
107	I	182-185
may	O	186-189
be	O	190-192
involved	O	193-201
in	O	202-204
accelerated	O	205-216
disease	O	217-224
progression	O	225-236
through	O	237-244
regulation	O	245-255
of	O	256-258
BACE1	O	259-264
.   	O	264-268

The	O	0-3
expression	O	4-14
of	O	15-17
microRNA	O	18-26
miR	B	27-30
-	I	30-31
107	I	31-34
decreases	O	35-44
early	O	45-50
in	O	51-53
Alzheimer	O	54-63
'	O	63-64
s	O	64-65
disease	O	66-73
and	O	74-77
may	O	78-81
accelerate	O	82-92
disease	O	93-100
progression	O	101-112
through	O	113-120
regulation	O	121-131
of	O	132-134
beta	O	135-139
-	O	139-140
site	O	140-144
amyloid	O	145-152
precursor	O	153-162
protein	O	163-170
-	O	170-171
cleaving	O	171-179
enzyme	O	180-186
1	O	187-188
.  	O	188-191

This	O	0-4
opportunistic	O	5-18
mycosis	O	19-26
infection	O	27-36
presented	O	37-46
with	O	47-51
clinically	O	52-62
totally	O	63-70
nonspecific	O	71-82
signs	O	83-88
and	O	89-92
symptoms	O	93-101
of	O	102-104
CNS	O	105-108
affection	O	109-118
. 	O	118-120

Therefore	O	0-9
,	O	9-10
we	O	11-13
suspected	O	14-23
affection	O	24-33
of	O	34-36
CNS	O	37-40
with	O	41-45
SLE	O	46-49
. 	O	49-51

Even	O	0-4
though	O	5-11
all	O	12-15
diagnostic	O	16-26
procedures	O	27-37
were	O	38-42
made	O	43-47
on	O	48-50
time	O	51-55
and	O	56-59
that	O	60-64
adequate	O	65-73
antifungal	O	74-84
and	O	85-88
supportive	O	89-99
agents	O	100-106
were	O	107-111
applied	O	112-119
very	O	120-124
early	O	125-130
after	O	131-136
the	O	137-140
infection	O	141-150
onset	O	151-156
,	O	156-157
the	O	158-161
outcome	O	162-169
was	O	170-173
fatal	O	174-179
. 	O	179-181

Because	O	0-7
of	O	8-10
infective	O	11-20
diathesis	O	21-30
in	O	31-33
patients	O	34-42
with	O	43-47
SLE	O	48-51
,	O	51-52
which	O	53-58
present	O	59-66
with	O	67-71
common	O	72-78
and	O	79-82
opportunistic	O	83-96
infections	O	97-107
,	O	107-108
and	O	109-112
due	O	113-116
to	O	117-119
high	O	120-124
mortality	O	125-134
rates	O	135-140
caused	O	141-147
by	O	148-150
these	O	151-156
infections	O	157-167
,	O	167-168
we	O	169-171
have	O	172-176
tried	O	177-182
to	O	183-185
emphasise	O	186-195
the	O	196-199
importance	O	200-210
of	O	211-213
taking	O	214-220
adequate	O	221-229
specimens	O	230-239
early	O	240-245
after	O	246-251
infection	O	252-261
outcome	O	262-269
for	O	270-273
these	O	274-279
rare	O	280-284
infective	O	285-294
agents	O	295-301
like	O	302-306
C	O	307-308
.	O	308-309
neophormans	O	310-321
. 	O	321-323

It	O	0-2
was	O	3-6
meningitis	O	7-17
caused	O	18-24
by	O	25-27
C	O	28-29
.	O	29-30
neoformans	O	31-41
. 	O	41-43

Reports	O	0-7
from	O	8-12
Europe	O	13-19
are	O	20-23
very	O	24-28
rare	O	29-33
,	O	33-34
and	O	35-38
this	O	39-43
case	O	44-48
is	O	49-51
the	O	52-55
one	O	56-59
of	O	60-62
that	O	63-67
kind	O	68-72
in	O	73-75
Croatia	O	76-83
.   	O	83-87

In	O	0-2
recent	O	3-9
medical	O	10-17
literature	O	18-28
are	O	29-32
dominant	O	33-41
cases	O	42-47
reported	O	48-56
in	O	57-59
Asia	O	60-64
. 	O	64-66

Systemic	O	0-8
erythematosus	O	9-22
lupus	O	23-28
(	O	29-30
SLE	O	30-33
)	O	33-34
is	O	35-37
a	O	38-39
disease	O	40-47
with	O	48-52
wide	O	53-57
range	O	58-63
of	O	64-66
clinical	O	67-75
manifestations	O	76-90
,	O	90-91
signs	O	92-97
and	O	98-101
symptoms	O	102-110
. 	O	110-112

[	O	0-1
Cryptococcal	O	1-13
meningitis	O	14-24
as	O	25-27
a	O	28-29
diagnostic	O	30-40
problem	O	41-48
in	O	49-51
a	O	52-53
patient	O	54-61
with	O	62-66
SLE	O	67-70
-	O	70-71
-	O	71-72
case	O	72-76
report	O	77-83
]	O	83-84
.  	O	84-87

Very	O	0-4
important	O	5-14
cause	O	15-20
of	O	21-23
death	O	24-29
in	O	30-32
patients	O	33-41
with	O	42-46
SLE	O	47-50
is	O	51-53
infection	O	54-63
. 	O	63-65

Disease	O	0-7
outcome	O	8-15
depends	O	16-23
mostly	O	24-30
on	O	31-33
the	O	34-37
affection	O	38-47
of	O	48-50
kidneys	O	51-58
and	O	59-62
central	O	63-70
nervous	O	71-78
system	O	79-85
by	O	86-88
the	O	89-92
disease	O	93-100
. 	O	100-102

During	O	0-6
one	O	7-10
of	O	11-13
the	O	14-17
disease	O	18-25
flares	O	26-32
the	O	33-36
patient	O	37-44
was	O	45-48
hospitalized	O	49-61
an	O	62-64
opportunistic	O	65-78
infection	O	79-88
developed	O	89-98
. 	O	98-100

As	O	0-2
an	O	3-5
outcome	O	6-13
of	O	14-16
the	O	17-20
combined	O	21-29
effect	O	30-36
of	O	37-39
disease	O	40-47
and	O	48-51
immunosuppressive	O	52-69
agents	O	70-76
used	O	77-81
in	O	82-84
the	O	85-88
treatment	O	89-98
of	O	99-101
the	O	102-105
disease	O	106-113
,	O	113-114
the	O	115-118
patient	O	119-126
had	O	127-130
increased	O	131-140
infective	O	141-150
diathesis	O	151-160
(	O	161-162
repeated	O	162-170
infections	O	171-181
caused	O	182-188
by	O	189-191
S	O	192-193
.	O	193-194
enteritidis	O	195-206
-	O	206-207
-	O	207-208
urinary	O	208-215
infections	O	216-226
and	O	227-230
sepsis	O	231-237
)	O	237-238
. 	O	238-240

In	O	0-2
this	O	3-7
case	O	8-12
report	O	13-19
we	O	20-22
have	O	23-27
presented	O	28-37
a	O	38-39
patient	O	40-47
with	O	48-52
SLE	O	53-56
who	O	57-60
initially	O	61-70
had	O	71-74
severe	O	75-81
renal	O	82-87
affection	O	88-97
,	O	97-98
but	O	99-102
also	O	103-107
complications	O	108-121
of	O	122-124
immunosuppressive	O	125-142
therapy	O	143-150
that	O	151-155
was	O	156-159
administered	O	160-172
. 	O	172-174

Infections	O	0-10
are	O	11-14
very	O	15-19
common	O	20-26
among	O	27-32
these	O	33-38
patients	O	39-47
due	O	48-51
to	O	52-54
aggressive	O	55-65
immunosuppressive	O	66-83
treatment	O	84-93
that	O	94-98
is	O	99-101
needed	O	102-108
for	O	109-112
the	O	113-116
disease	O	117-124
inflammatory	O	125-137
activity	O	138-146
control	O	147-154
. 	O	154-156

Because	O	0-7
of	O	8-10
lupus	O	11-16
nephropathy	O	17-28
,	O	28-29
in	O	30-32
the	O	33-36
early	O	37-42
phase	O	43-48
of	O	49-51
the	O	52-55
disease	O	56-63
we	O	64-66
administered	O	67-79
aggressive	O	80-90
immunosuppressive	O	91-108
therapy	O	109-116
(	O	117-118
combined	O	118-126
parenteral	O	127-137
therapy	O	138-145
of	O	146-148
glucocorticoides	O	149-165
and	O	166-169
cyclophosphamide	O	170-186
)	O	186-187
. 	O	187-189

Even	O	0-4
though	O	5-11
the	O	12-15
disease	O	16-23
was	O	24-27
accidentally	O	28-40
diagnosed	O	41-50
,	O	50-51
it	O	52-54
had	O	55-58
a	O	59-60
severe	O	61-67
clinical	O	68-76
progress	O	77-85
. 	O	85-87

Specifically	O	0-12
,	O	12-13
we	O	14-16
highlight	O	17-26
the	O	27-30
importance	O	31-41
of	O	42-44
unbiased	O	45-53
association	O	54-65
studies	O	66-73
and	O	74-77
follow	O	78-84
-	O	84-85
up	O	85-87
functional	O	88-98
experiments	O	99-110
for	O	111-114
providing	O	115-124
a	O	125-126
clearer	O	127-134
picture	O	135-142
of	O	143-145
the	O	146-149
extent	O	150-156
to	O	157-159
which	O	160-165
microRNA	O	166-174
target	O	175-181
site	O	182-186
variations	O	187-197
are	O	198-201
relevant	O	202-210
in	O	211-213
various	O	214-221
human	O	222-227
diseases	O	228-236
.   	O	236-240

We	O	0-2
therefore	O	3-12
suggest	O	13-20
a	O	21-22
set	O	23-26
of	O	27-29
concrete	O	30-38
recommendations	O	39-54
to	O	55-57
guide	O	58-63
future	O	64-70
investigations	O	71-85
. 	O	85-87

However	O	0-7
,	O	7-8
careful	O	9-16
assessment	O	17-27
of	O	28-30
these	O	31-36
studies	O	37-44
indicates	O	45-54
that	O	55-59
very	O	60-64
few	O	65-68
provide	O	69-76
a	O	77-78
combination	O	79-90
of	O	91-93
rigorous	O	94-102
genetic	O	103-110
and	O	111-114
functional	O	115-125
evidence	O	126-134
. 	O	134-136

Several	O	0-7
studies	O	8-15
have	O	16-20
identified	O	21-31
genetic	O	32-39
variants	O	40-48
in	O	49-51
miRNA	O	52-57
target	O	58-64
sites	O	65-70
that	O	71-75
are	O	76-79
claimed	O	80-87
to	O	88-90
be	O	91-93
associated	O	94-104
with	O	105-109
disorders	O	110-119
ranging	O	120-127
from	O	128-132
Parkinson	O	133-142
'	O	142-143
s	O	143-144
disease	O	145-152
to	O	153-155
cancer	O	156-162
. 	O	162-164

They	O	0-4
have	O	5-9
been	O	10-14
implicated	O	15-25
in	O	26-28
a	O	29-30
broad	O	31-36
range	O	37-42
of	O	43-45
biological	O	46-56
processes	O	57-66
,	O	66-67
and	O	68-71
miRNA	O	72-77
-	O	77-78
related	O	78-85
genetic	O	86-93
alterations	O	94-105
probably	O	106-114
underlie	O	115-123
more	O	124-128
human	O	129-134
diseases	O	135-143
than	O	144-148
currently	O	149-158
appreciated	O	159-170
. 	O	170-172

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
important	O	23-32
regulators	O	33-43
of	O	44-46
eukaryotic	O	47-57
gene	O	58-62
expression	O	63-73
. 	O	73-75

MicroRNA	O	0-8
target	O	9-15
site	O	16-20
polymorphisms	O	21-34
and	O	35-38
human	O	39-44
disease	O	45-52
.  	O	52-55

Human	O	0-5
traumatic	O	6-15
brain	O	16-21
injury	O	22-28
alters	O	29-35
plasma	O	36-42
microRNA	O	43-51
levels	O	52-58
.  	O	58-61

Circulating	O	0-11
microRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
present	O	31-38
in	O	39-41
the	O	42-45
serum	O	46-51
/	O	51-52
plasma	O	52-58
are	O	59-62
characteristically	O	63-81
altered	O	82-89
in	O	90-92
many	O	93-97
pathological	O	98-110
conditions	O	111-121
,	O	121-122
and	O	123-126
have	O	127-131
been	O	132-136
employed	O	137-145
as	O	146-148
diagnostic	O	149-159
markers	O	160-167
for	O	168-171
specific	O	172-180
diseases	O	181-189
. 	O	189-191

We	O	0-2
examined	O	3-11
if	O	12-14
plasma	O	15-21
miRNA	O	22-27
levels	O	28-34
are	O	35-38
altered	O	39-46
in	O	47-49
patients	O	50-58
with	O	59-63
traumatic	O	64-73
brain	O	74-79
injury	O	80-86
(	O	87-88
TBI	O	88-91
)	O	91-92
relative	O	93-101
to	O	102-104
matched	O	105-112
healthy	O	113-120
volunteers	O	121-131
,	O	131-132
and	O	133-136
explored	O	137-145
their	O	146-151
potential	O	152-161
for	O	162-165
use	O	166-169
as	O	170-172
diagnostic	O	173-183
TBI	O	184-187
biomarkers	O	188-198
. 	O	198-200

The	O	0-3
plasma	O	4-10
miRNA	O	11-16
profiles	O	17-25
from	O	26-30
severe	O	31-37
TBI	O	38-41
patients	O	42-50
(	O	51-52
Glasgow	O	52-59
Coma	O	60-64
Scale	O	65-70
[	O	71-72
GCS	O	72-75
]	O	75-76
score	O	77-82
≤8	O	83-85
)	O	85-86
and	O	87-90
age	O	91-94
-	O	94-95
,	O	95-96
gender	O	97-103
-	O	103-104
,	O	104-105
and	O	106-109
race	O	110-114
-	O	114-115
matched	O	115-122
healthy	O	123-130
volunteers	O	131-141
were	O	142-146
compared	O	147-155
by	O	156-158
microarray	O	159-169
analysis	O	170-178
. 	O	178-180

Of	O	0-2
the	O	3-6
108	O	7-10
miRNAs	O	11-17
identified	O	18-28
in	O	29-31
healthy	O	32-39
volunteer	O	40-49
plasma	O	50-56
,	O	56-57
52	O	58-60
were	O	61-65
altered	O	66-73
after	O	74-79
severe	O	80-86
TBI	O	87-90
,	O	90-91
including	O	92-101
33	O	102-104
with	O	105-109
decreased	O	110-119
and	O	120-123
19	O	124-126
with	O	127-131
increased	O	132-141
relative	O	142-150
abundance	O	151-160
. 	O	160-162

An	O	0-2
additional	O	3-13
8	O	14-15
miRNAs	O	16-22
were	O	23-27
detected	O	28-36
only	O	37-41
in	O	42-44
the	O	45-48
TBI	O	49-52
plasma	O	53-59
. 	O	59-61

We	O	0-2
used	O	3-7
quantitative	O	8-20
RT	O	21-23
-	O	23-24
PCR	O	24-27
to	O	28-30
determine	O	31-40
if	O	41-43
plasma	O	44-50
miRNAs	O	51-57
could	O	58-63
identify	O	64-72
TBI	O	73-76
patients	O	77-85
within	O	86-92
the	O	93-96
first	O	97-102
24	O	103-105
h	O	106-107
post	O	108-112
-	O	112-113
injury	O	113-119
. 	O	119-121

Receiver	O	0-8
operating	O	9-18
characteristic	O	19-33
curve	O	34-39
analysis	O	40-48
indicated	O	49-58
that	O	59-63
miR	B	64-67
-	I	67-68
16	I	68-70
,	O	70-71
miR	B	72-75
-	I	75-76
92a	I	76-79
,	O	79-80
and	O	81-84
miR	B	85-88
-	I	88-89
765	I	89-92
were	O	93-97
good	O	98-102
markers	O	103-110
of	O	111-113
severe	O	114-120
TBI	O	121-124
(	O	125-126
0	O	126-127
.	O	127-128
89	O	128-130
,	O	130-131
0	O	132-133
.	O	133-134
82	O	134-136
,	O	136-137
and	O	138-141
0	O	142-143
.	O	143-144
86	O	144-146
AUC	O	147-150
values	O	151-157
,	O	157-158
respectively	O	159-171
)	O	171-172
. 	O	172-174

Multiple	O	0-8
logistic	O	9-17
regression	O	18-28
analysis	O	29-37
revealed	O	38-46
that	O	47-51
combining	O	52-61
these	O	62-67
miRNAs	O	68-74
markedly	O	75-83
increased	O	84-93
diagnostic	O	94-104
accuracy	O	105-113
(	O	114-115
100	O	115-118
%	O	118-119
specificity	O	120-131
and	O	132-135
100	O	136-139
%	O	139-140
sensitivity	O	141-152
)	O	152-153
,	O	153-154
compared	O	155-163
to	O	164-166
either	O	167-173
healthy	O	174-181
volunteers	O	182-192
or	O	193-195
orthopedic	O	196-206
injury	O	207-213
patients	O	214-222
. 	O	222-224

In	O	0-2
mild	O	3-7
TBI	O	8-11
patients	O	12-20
(	O	21-22
GCS	O	22-25
score	O	26-31
>	O	32-33
12	O	34-36
)	O	36-37
,	O	37-38
miR	B	39-42
-	I	42-43
765	I	43-46
levels	O	47-53
were	O	54-58
unchanged	O	59-68
,	O	68-69
while	O	70-75
the	O	76-79
plasma	O	80-86
levels	O	87-93
of	O	94-96
miR	B	97-100
-	I	100-101
92a	I	101-104
and	O	105-108
miR	B	109-112
-	I	112-113
16	I	113-115
were	O	116-120
significantly	O	121-134
increased	O	135-144
within	O	145-151
the	O	152-155
first	O	156-161
24	O	162-164
h	O	165-166
of	O	167-169
injury	O	170-176
compared	O	177-185
to	O	186-188
healthy	O	189-196
volunteers	O	197-207
,	O	207-208
and	O	209-212
had	O	213-216
AUC	O	217-220
values	O	221-227
of	O	228-230
0	O	231-232
.	O	232-233
78	O	233-235
and	O	236-239
0	O	240-241
.	O	241-242
82	O	242-244
,	O	244-245
respectively	O	246-258
. 	O	258-260

Plasma	O	0-6
-	O	6-7
derived	O	7-14
miRNA	O	15-20
biomarkers	O	21-31
,	O	31-32
used	O	33-37
in	O	38-40
combination	O	41-52
with	O	53-57
established	O	58-69
clinical	O	70-78
practices	O	79-88
such	O	89-93
as	O	94-96
imaging	O	97-104
,	O	104-105
neurocognitive	O	106-120
,	O	120-121
and	O	122-125
motor	O	126-131
examinations	O	132-144
,	O	144-145
have	O	146-150
the	O	151-154
potential	O	155-164
to	O	165-167
improve	O	168-175
TBI	O	176-179
patient	O	180-187
classification	O	188-202
and	O	203-206
possibly	O	207-215
management	O	216-226
.   	O	226-230

Our	O	0-3
results	O	4-11
demonstrate	O	12-23
that	O	24-28
circulating	O	29-40
miRNA	O	41-46
levels	O	47-53
are	O	54-57
altered	O	58-65
after	O	66-71
TBI	O	72-75
,	O	75-76
providing	O	77-86
a	O	87-88
rich	O	89-93
new	O	94-97
source	O	98-104
of	O	105-107
potential	O	108-117
molecular	O	118-127
biomarkers	O	128-138
. 	O	138-140

MicroRNA	B	0-8
-	I	8-9
205	I	9-12
inhibits	O	13-21
tumor	O	22-27
cell	O	28-32
migration	O	33-42
through	O	43-50
down	O	51-55
-	O	55-56
regulating	O	56-66
the	O	67-70
expression	O	71-81
of	O	82-84
the	O	85-88
LDL	O	89-92
receptor	O	93-101
-	O	101-102
related	O	102-109
protein	O	110-117
1	O	118-119
.	O	119-120
Low	O	122-125
-	O	125-126
density	O	126-133
lipoprotein	O	134-145
receptor	O	146-154
-	O	154-155
related	O	155-162
protein	O	163-170
1	O	171-172
(	O	173-174
LRP1	O	174-178
)	O	178-179
is	O	180-182
a	O	183-184
multifunctional	O	185-200
endocytic	O	201-210
receptor	O	211-219
that	O	220-224
plays	O	225-230
critical	O	231-239
roles	O	240-245
in	O	246-248
the	O	249-252
pathogenesis	O	253-265
of	O	266-268
several	O	269-276
human	O	277-282
diseases	O	283-291
including	O	292-301
tumor	O	302-307
metastasis	O	308-318
and	O	319-322
Alzheimer	O	323-332
'	O	332-333
s	O	333-334
disease	O	335-342
.  	O	342-344

In	O	0-2
human	O	3-8
cell	O	9-13
lines	O	14-19
,	O	19-20
we	O	21-23
found	O	24-29
that	O	30-34
miR	B	35-38
-	I	38-39
205	I	39-42
down	O	43-47
-	O	47-48
regulates	O	48-57
the	O	58-61
expression	O	62-72
of	O	73-75
LRP1	O	76-80
by	O	81-83
targeting	O	84-93
sequences	O	94-103
in	O	104-106
the	O	107-110
3	O	111-112
'	O	112-113
UTR	O	113-116
of	O	117-119
LRP1	O	120-124
mRNA	O	125-129
. 	O	129-131

However	O	0-7
,	O	7-8
mechanisms	O	9-19
that	O	20-24
regulate	O	25-33
LRP1	O	34-38
expression	O	39-49
under	O	50-55
physiological	O	56-69
and	O	70-73
pathophysiological	O	74-92
conditions	O	93-103
are	O	104-107
not	O	108-111
unclear	O	112-119
. 	O	119-121

The	O	0-3
ectopic	O	4-11
expression	O	12-22
of	O	23-25
miR	B	26-29
-	I	29-30
205	I	30-33
also	O	34-38
significantly	O	39-52
mitigated	O	53-62
migration	O	63-72
of	O	73-75
both	O	76-80
U87	O	81-84
and	O	85-88
SK	O	89-91
-	O	91-92
LU	O	92-94
-	O	94-95
1	O	95-96
cells	O	97-102
. 	O	102-104

This	O	0-4
effect	O	5-11
was	O	12-15
abolished	O	16-25
by	O	26-28
deleting	O	29-37
the	O	38-41
miR	B	42-45
-	I	45-46
205	I	46-49
seed	O	50-54
site	O	55-59
in	O	60-62
the	O	63-66
3	O	67-68
'	O	68-69
UTR	O	69-72
of	O	73-75
LRP1	O	76-80
. 	O	80-82

These	O	0-5
results	O	6-13
,	O	13-14
for	O	15-18
the	O	19-22
first	O	23-28
time	O	29-33
,	O	33-34
demonstrate	O	35-46
that	O	47-51
expression	O	52-62
of	O	63-65
human	O	66-71
LRP1	O	72-76
is	O	77-79
regulated	O	80-89
in	O	90-92
part	O	93-97
by	O	98-100
a	O	101-102
specific	O	103-111
miRNA	O	112-117
,	O	117-118
leading	O	119-126
to	O	127-129
decreased	O	130-139
tumor	O	140-145
cell	O	146-150
migration	O	151-160
.   	O	160-164

In	O	0-2
neurodegenerative	O	3-20
disorders	O	21-30
such	O	31-35
as	O	36-38
Alzheimer	O	39-48
'	O	48-49
s	O	49-50
disease	O	51-58
(	O	59-60
AD	O	60-62
)	O	62-63
,	O	63-64
brain	O	65-70
miRNA	O	71-76
profiles	O	77-85
are	O	86-89
altered	O	90-97
;	O	97-98
thus	O	99-103
miRNA	O	104-109
dysfunction	O	110-121
could	O	122-127
be	O	128-130
both	O	131-135
a	O	136-137
cause	O	138-143
and	O	144-147
a	O	148-149
consequence	O	150-161
of	O	162-164
disease	O	165-172
. 	O	172-174

These	O	0-5
small	O	6-11
non	O	12-15
-	O	15-16
coding	O	16-22
RNA	O	23-26
regulators	O	27-37
are	O	38-41
highly	O	42-48
enriched	O	49-57
in	O	58-60
brain	O	61-66
where	O	67-72
they	O	73-77
play	O	78-82
key	O	83-86
roles	O	87-92
in	O	93-95
neuronal	O	96-104
development	O	105-116
,	O	116-117
plasticity	O	118-128
and	O	129-132
disease	O	133-140
. 	O	140-142

Normal	O	0-6
brain	O	7-12
development	O	13-24
and	O	25-28
function	O	29-37
depends	O	38-45
on	O	46-48
microRNA	O	49-57
(	O	58-59
miRNA	O	59-64
)	O	64-65
networks	O	66-74
to	O	75-77
fine	O	78-82
tune	O	83-87
the	O	88-91
balance	O	92-99
between	O	100-107
the	O	108-111
transcriptome	O	112-125
and	O	126-129
proteome	O	130-138
of	O	139-141
the	O	142-145
cell	O	146-150
. 	O	150-152

Neuronal	O	0-8
microRNA	O	9-17
deregulation	O	18-30
in	O	31-33
response	O	34-42
to	O	43-45
Alzheimer	O	46-55
'	O	55-56
s	O	56-57
disease	O	58-65
amyloid	O	66-73
-	O	73-74
beta	O	74-78
.  	O	78-81

Bioinformatic	O	0-13
analysis	O	14-22
predicts	O	23-31
that	O	32-36
the	O	37-40
deregulated	O	41-52
miRNAs	O	53-59
are	O	60-63
likely	O	64-70
to	O	71-73
affect	O	74-80
target	O	81-87
genes	O	88-93
present	O	94-101
in	O	102-104
prominent	O	105-114
neuronal	O	115-123
pathways	O	124-132
known	O	133-138
to	O	139-141
be	O	142-144
disrupted	O	145-154
in	O	155-157
AD	O	158-160
.	O	160-161
Remarkably	O	162-172
,	O	172-173
we	O	174-176
also	O	177-181
found	O	182-187
that	O	188-192
the	O	193-196
miRNA	O	197-202
deregulation	O	203-215
in	O	216-218
hippocampal	O	219-230
cultures	O	231-239
was	O	240-243
paralleled	O	244-254
in	O	255-257
vivo	O	258-262
by	O	263-265
a	O	266-267
deregulation	O	268-280
in	O	281-283
the	O	284-287
hippocampus	O	288-299
of	O	300-302
Abeta42	O	303-310
-	O	310-311
depositing	O	311-321
APP23	O	322-327
mice	O	328-332
,	O	332-333
at	O	334-336
the	O	337-340
onset	O	341-346
of	O	347-349
Abeta	O	350-355
plaque	O	356-362
formation	O	363-372
. 	O	372-374

Time	O	0-4
-	O	4-5
course	O	5-11
assays	O	12-18
of	O	19-21
neuronal	O	22-30
Abeta	O	31-36
treatments	O	37-47
show	O	48-52
that	O	53-57
Abeta	O	58-63
is	O	64-66
in	O	67-69
fact	O	70-74
a	O	75-76
powerful	O	77-85
regulator	O	86-95
of	O	96-98
miRNA	O	99-104
levels	O	105-111
as	O	112-114
the	O	115-118
response	O	119-127
of	O	128-130
certain	O	131-138
mature	O	139-145
miRNAs	O	146-152
is	O	153-155
extremely	O	156-165
rapid	O	166-171
. 	O	171-173

We	O	0-2
used	O	3-7
sensitive	O	8-17
TaqMan	O	18-24
low	O	25-28
density	O	29-36
miRNA	O	37-42
arrays	O	43-49
(	O	50-51
TLDA	O	51-55
)	O	55-56
on	O	57-59
murine	O	60-66
primary	O	67-74
hippocampal	O	75-86
cultures	O	87-95
to	O	96-98
show	O	99-103
that	O	104-108
about	O	109-114
half	O	115-119
of	O	120-122
all	O	123-126
miRNAs	O	127-133
tested	O	134-140
were	O	141-145
down	O	146-150
-	O	150-151
regulated	O	151-160
in	O	161-163
response	O	164-172
to	O	173-175
Abeta	O	176-181
peptides	O	182-190
. 	O	190-192

Our	O	0-3
study	O	4-9
dissects	O	10-18
the	O	19-22
complexity	O	23-33
of	O	34-36
human	O	37-42
AD	O	43-45
pathology	O	46-55
,	O	55-56
and	O	57-60
addresses	O	61-70
the	O	71-74
hypothesis	O	75-85
that	O	86-90
amyloid	O	91-98
-	O	98-99
beta	O	99-103
(	O	104-105
Abeta	O	105-110
)	O	110-111
itself	O	112-118
,	O	118-119
a	O	120-121
known	O	122-127
causative	O	128-137
factor	O	138-144
of	O	145-147
AD	O	148-150
,	O	150-151
causes	O	152-158
neuronal	O	159-167
miRNA	O	168-173
deregulation	O	174-186
,	O	186-187
which	O	188-193
could	O	194-199
contribute	O	200-210
to	O	211-213
the	O	214-217
pathomechanisms	O	218-233
of	O	234-236
AD	O	237-239
. 	O	239-241

In	O	0-2
addition	O	3-11
,	O	11-12
the	O	13-16
miRNA	O	17-22
deregulation	O	23-35
in	O	36-38
hippocampal	O	39-50
cultures	O	51-59
and	O	60-63
APP23	O	64-69
hippocampus	O	70-81
overlaps	O	82-90
with	O	91-95
those	O	96-101
obtained	O	102-110
in	O	111-113
human	O	114-119
AD	O	120-122
studies	O	123-130
. 	O	130-132

Taken	O	0-5
together	O	6-14
,	O	14-15
our	O	16-19
findings	O	20-28
suggest	O	29-36
that	O	37-41
neuronal	O	42-50
miRNA	O	51-56
deregulation	O	57-69
in	O	70-72
response	O	73-81
to	O	82-84
an	O	85-87
insult	O	88-94
by	O	95-97
Abeta	O	98-103
may	O	104-107
be	O	108-110
an	O	111-113
important	O	114-123
factor	O	124-130
contributing	O	131-143
to	O	144-146
the	O	147-150
cascade	O	151-158
of	O	159-161
events	O	162-168
leading	O	169-176
to	O	177-179
AD	O	180-182
.   	O	182-186

We	O	0-2
report	O	3-9
here	O	10-14
on	O	15-17
a	O	18-19
patient	O	20-27
who	O	28-31
was	O	32-35
treated	O	36-43
for	O	44-47
an	O	48-50
atypical	O	51-59
brain	O	60-65
meningioma	O	66-76
with	O	77-81
multiple	O	82-90
surgeries	O	91-100
and	O	101-104
multiple	O	105-113
sessions	O	114-122
of	O	123-125
stereotactic	O	126-138
radiosurgery	O	139-151
with	O	152-156
good	O	157-161
control	O	162-169
of	O	170-172
his	O	173-176
brain	O	177-182
disease	O	183-190
. 	O	190-192

Thirteen	O	0-8
years	O	9-14
after	O	15-20
diagnosis	O	21-30
,	O	30-31
he	O	32-34
developed	O	35-44
bilateral	O	45-54
large	O	55-60
sacroiliac	O	61-71
and	O	72-75
abdominal	O	76-85
metastases	O	86-96
.   	O	96-100

Extracranial	O	0-12
metastases	O	13-23
from	O	24-28
brain	O	29-34
meningiomas	O	35-46
is	O	47-49
a	O	50-51
rare	O	52-56
,	O	56-57
but	O	58-61
well	O	62-66
-	O	66-67
documented	O	67-77
entity	O	78-84
. 	O	84-86

Metastases	O	0-10
occur	O	11-16
mostly	O	17-23
in	O	24-26
the	O	27-30
lungs	O	31-36
,	O	36-37
pleura	O	38-44
and	O	45-48
liver	O	49-54
,	O	54-55
but	O	56-59
may	O	60-63
also	O	64-68
affect	O	69-75
lymph	O	76-81
nodes	O	82-87
and	O	88-91
bones	O	92-97
. 	O	97-99

Extraneural	O	0-11
metastases	O	12-22
from	O	23-27
cranial	O	28-35
meningioma	O	36-46
:	O	46-47
a	O	48-49
case	O	50-54
report	O	55-61
.  	O	61-64

The	O	0-3
present	O	4-11
review	O	12-18
examines	O	19-27
the	O	28-31
various	O	32-39
miRNAs	O	40-46
that	O	47-51
have	O	52-56
been	O	57-61
identified	O	62-72
as	O	73-75
being	O	76-81
potentially	O	82-93
involved	O	94-102
in	O	103-105
T2D	O	106-109
,	O	109-110
focusing	O	111-119
on	O	120-122
the	O	123-126
insulin	O	127-134
-	O	134-135
sensitive	O	135-144
organs	O	145-151
:	O	151-152
white	O	153-158
adipose	O	159-166
tissue	O	167-173
,	O	173-174
liver	O	175-180
,	O	180-181
skeletal	O	182-190
muscle	O	191-197
and	O	198-201
the	O	202-205
insulin	O	206-213
-	O	213-214
producing	O	214-223
pancreatic	O	224-234
β	O	235-236
-	O	236-237
cells	O	237-242
.   	O	242-246

miRNAs	O	0-6
are	O	7-10
involved	O	11-19
in	O	20-22
a	O	23-24
large	O	25-30
number	O	31-37
of	O	38-40
biological	O	41-51
functions	O	52-61
such	O	62-66
as	O	67-69
development	O	70-81
,	O	81-82
metabolism	O	83-93
,	O	93-94
immunity	O	95-103
and	O	104-107
diseases	O	108-116
such	O	117-121
as	O	122-124
cancer	O	125-131
,	O	131-132
cardiovascular	O	133-147
diseases	O	148-156
and	O	157-160
diabetes	O	161-169
. 	O	169-171

miRNAs	O	0-6
are	O	7-10
small	O	11-16
22	O	17-19
-	O	19-20
25	O	20-22
-	O	22-23
nt	O	23-25
-	O	25-26
long	O	26-30
untranslated	O	31-43
RNAs	O	44-48
that	O	49-53
negatively	O	54-64
regulate	O	65-73
the	O	74-77
translation	O	78-89
of	O	90-92
mRNAs	O	93-98
. 	O	98-100

Although	O	0-8
T2D	O	9-12
seems	O	13-18
to	O	19-21
be	O	22-24
strongly	O	25-33
linked	O	34-40
to	O	41-43
environmental	O	44-57
factors	O	58-65
such	O	66-70
as	O	71-73
nutrition	O	74-83
and	O	84-87
lifestyle	O	88-97
,	O	97-98
studies	O	99-106
have	O	107-111
shown	O	112-117
that	O	118-122
genetic	O	123-130
factors	O	131-138
,	O	138-139
such	O	140-144
as	O	145-147
polymorphisms	O	148-161
associated	O	162-172
with	O	173-177
metabolic	O	178-187
genes	O	188-193
,	O	193-194
imprinting	O	195-205
,	O	205-206
fetal	O	207-212
programming	O	213-224
and	O	225-228
miRNA	O	229-234
(	O	235-236
microRNA	O	236-244
)	O	244-245
expression	O	246-256
,	O	256-257
could	O	258-263
also	O	264-268
contribute	O	269-279
to	O	280-282
the	O	283-286
development	O	287-298
of	O	299-301
this	O	302-306
disease	O	307-314
. 	O	314-316

The	O	0-3
aetiology	O	4-13
and	O	14-17
molecular	O	18-27
mechanisms	O	28-38
of	O	39-41
T2D	O	42-45
are	O	46-49
not	O	50-53
fully	O	54-59
understood	O	60-70
,	O	70-71
but	O	72-75
compelling	O	76-86
evidence	O	87-95
points	O	96-102
to	O	103-105
a	O	106-107
link	O	108-112
between	O	113-120
T2D	O	121-124
,	O	124-125
obesity	O	126-133
,	O	133-134
dyslipidaemia	O	135-148
and	O	149-152
insulin	O	153-160
resistance	O	161-171
. 	O	171-173

Improper	O	0-8
treatment	O	9-18
of	O	19-21
TD2	O	22-25
can	O	26-29
lead	O	30-34
to	O	35-37
severe	O	38-44
complications	O	45-58
such	O	59-63
as	O	64-66
heart	O	67-72
disease	O	73-80
,	O	80-81
stroke	O	82-88
,	O	88-89
kidney	O	90-96
failure	O	97-104
,	O	104-105
blindness	O	106-115
and	O	116-119
nerve	O	120-125
damage	O	126-132
. 	O	132-134

T2D	O	0-3
is	O	4-6
a	O	7-8
progressive	O	9-20
metabolic	O	21-30
disorder	O	31-39
characterized	O	40-53
by	O	54-56
reduced	O	57-64
insulin	O	65-72
sensitivity	O	73-84
,	O	84-85
insulin	O	86-93
resistance	O	94-104
and	O	105-108
pancreatic	O	109-119
β	O	120-121
-	O	121-122
cell	O	122-126
dysfunction	O	127-138
. 	O	138-140

The	O	0-3
involvement	O	4-15
of	O	16-18
microRNAs	O	19-28
in	O	29-31
Type	O	32-36
2	O	37-38
diabetes	O	39-47
.  	O	47-50

T2D	O	0-3
(	O	4-5
Type	O	5-9
2	O	10-11
diabetes	O	12-20
mellitus	O	21-29
)	O	29-30
is	O	31-33
a	O	34-35
major	O	36-41
health	O	42-48
issue	O	49-54
that	O	55-59
has	O	60-63
reached	O	64-71
epidemic	O	72-80
status	O	81-87
worldwide	O	88-97
. 	O	97-99

Isolation	O	0-9
and	O	10-13
characterization	O	14-30
of	O	31-33
a	O	34-35
novel	O	36-41
pituitary	O	42-51
tumor	O	52-57
apoptosis	O	58-67
gene	O	68-72
.  	O	72-75

We	O	0-2
report	O	3-9
the	O	10-13
isolation	O	14-23
of	O	24-26
a	O	27-28
novel	O	29-34
differentially	O	35-49
methylated	O	50-60
chromosome	O	61-71
22	O	72-74
CpG	O	75-78
island	O	79-85
-	O	85-86
associated	O	86-96
gene	O	97-101
(	O	102-103
C22orf3	O	103-110
)	O	110-111
. 	O	111-113

To	O	0-2
determine	O	3-12
mechanisms	O	13-23
for	O	24-27
pituitary	O	28-37
neoplasia	O	38-47
we	O	48-50
used	O	51-55
methylation	O	56-67
-	O	67-68
sensitive	O	68-77
arbitrarily	O	78-89
primed	O	90-96
-	O	96-97
PCR	O	97-100
to	O	101-103
isolate	O	104-111
novel	O	112-117
genes	O	118-123
that	O	124-128
are	O	129-132
differentially	O	133-147
methylated	O	148-158
relative	O	159-167
to	O	168-170
normal	O	171-177
pituitary	O	178-187
. 	O	187-189

Sodium	O	0-6
bisulfite	O	7-16
sequencing	O	17-27
of	O	28-30
individual	O	31-41
adenomas	O	42-50
showed	O	51-57
that	O	58-62
6	O	63-64
of	O	65-67
30	O	68-70
(	O	71-72
20	O	72-74
%	O	74-75
)	O	75-76
that	O	77-81
failed	O	82-88
to	O	89-91
express	O	92-99
pituitary	O	100-109
tumor	O	110-115
apoptosis	O	116-125
gene	O	126-130
(	O	131-132
PTAG	O	132-136
)	O	136-137
were	O	138-142
methylated	O	143-153
;	O	153-154
however	O	155-162
,	O	162-163
genetic	O	164-171
change	O	172-178
as	O	179-181
determined	O	182-192
by	O	193-195
loss	O	196-200
of	O	201-203
heterozygosity	O	204-218
and	O	219-222
sequence	O	223-231
analysis	O	232-240
was	O	241-244
not	O	245-248
apparent	O	249-257
in	O	258-260
the	O	261-264
remaining	O	265-274
tumors	O	275-281
that	O	282-286
failed	O	287-293
to	O	294-296
express	O	297-304
this	O	305-309
gene	O	310-314
. 	O	314-316

Sodium	O	0-6
bisulfite	O	7-16
sequencing	O	17-27
of	O	28-30
pooled	O	31-37
tumor	O	38-43
cohorts	O	44-51
,	O	51-52
used	O	53-57
in	O	58-60
the	O	61-64
isolation	O	65-74
of	O	75-77
this	O	78-82
gene	O	83-87
,	O	87-88
showed	O	89-95
that	O	96-100
only	O	101-105
a	O	106-107
proportion	O	108-118
of	O	119-121
the	O	122-125
adenomas	O	126-134
within	O	135-141
the	O	142-145
pools	O	146-151
were	O	152-156
methylated	O	157-167
;	O	167-168
however	O	169-176
,	O	176-177
expression	O	178-188
analysis	O	189-197
by	O	198-200
quantitative	O	201-213
RT	O	214-216
-	O	216-217
PCR	O	217-220
of	O	221-223
individual	O	224-234
adenoma	O	235-242
irrespective	O	243-255
of	O	256-258
subtype	O	259-266
showed	O	267-273
the	O	274-277
majority	O	278-286
(	O	287-288
30	O	288-290
of	O	291-293
38	O	294-296
;	O	296-297
79	O	298-300
%	O	300-301
)	O	301-302
failed	O	303-309
to	O	310-312
express	O	313-320
this	O	321-325
gene	O	326-330
relative	O	331-339
to	O	340-342
normal	O	343-349
pituitary	O	350-359
. 	O	359-361

Enforced	O	0-8
expression	O	9-19
of	O	20-22
C22orf3	O	23-30
in	O	31-33
AtT20	O	34-39
cells	O	40-45
had	O	46-49
no	O	50-52
measurable	O	53-63
effects	O	64-71
on	O	72-74
cell	O	75-79
proliferation	O	80-93
or	O	94-96
viability	O	97-106
;	O	106-107
however	O	108-115
,	O	115-116
in	O	117-119
response	O	120-128
to	O	129-131
bromocriptine	O	132-145
challenge	O	146-155
(	O	156-157
10	O	157-159
-	O	159-160
40	O	160-162
microm	O	163-169
)	O	169-170
cells	O	171-176
expressing	O	177-187
this	O	188-192
gene	O	193-197
showed	O	198-204
a	O	205-206
significantly	O	207-220
augmented	O	221-230
apoptotic	O	231-240
response	O	241-249
as	O	250-252
determined	O	253-263
by	O	264-266
both	O	267-271
acridine	O	272-280
orange	O	281-287
staining	O	288-296
and	O	297-300
TUNEL	O	301-306
labeling	O	307-315
. 	O	315-317

In	O	0-2
those	O	3-8
cases	O	9-14
where	O	15-20
the	O	21-24
CpG	O	25-28
island	O	29-35
of	O	36-38
these	O	39-44
genes	O	45-50
was	O	51-54
methylated	O	55-65
it	O	66-68
was	O	69-72
invariably	O	73-83
associated	O	84-94
with	O	95-99
loss	O	100-104
of	O	105-107
transcript	O	108-118
expression	O	119-129
. 	O	129-131

In	O	0-2
addition	O	3-11
,	O	11-12
in	O	13-15
time	O	16-20
course	O	21-27
experiments	O	28-39
,	O	39-40
direct	O	41-47
measurement	O	48-59
of	O	60-62
active	O	63-69
caspases	O	70-78
by	O	79-81
fluorochrome	O	82-94
-	O	94-95
labeled	O	95-102
inhibition	O	103-113
of	O	114-116
caspases	O	117-125
,	O	125-126
showed	O	127-133
an	O	134-136
augmented	O	137-146
increase	O	147-155
(	O	156-157
approximately	O	157-170
2	O	171-172
.	O	172-173
4	O	173-174
fold	O	175-179
)	O	179-180
in	O	181-183
active	O	184-190
caspases	O	191-199
in	O	200-202
response	O	203-211
to	O	212-214
bromocriptine	O	215-228
challenge	O	229-238
in	O	239-241
cells	O	242-247
expressing	O	248-258
C22orf3	O	259-266
relative	O	267-275
to	O	276-278
those	O	279-284
harboring	O	285-294
an	O	295-297
empty	O	298-303
vector	O	304-310
control	O	311-318
. 	O	318-320

The	O	0-3
apoptotic	O	4-13
response	O	14-22
to	O	23-25
bromocriptine	O	26-39
challenge	O	40-49
was	O	50-53
inhibited	O	54-63
in	O	64-66
coincubation	O	67-79
experiments	O	80-91
with	O	92-96
the	O	97-100
general	O	101-108
caspase	O	109-116
inhibitor	O	117-126
z	O	127-128
-	O	128-129
VAD	O	129-132
-	O	132-133
fmk	O	133-136
. 	O	136-138

The	O	0-3
pituitary	O	4-13
tumor	O	14-19
derivation	O	20-30
and	O	31-34
its	O	35-38
role	O	39-43
in	O	44-46
apoptosis	O	47-56
of	O	57-59
this	O	60-64
gene	O	65-69
led	O	70-73
us	O	74-76
to	O	77-79
assign	O	80-86
the	O	87-90
acronym	O	91-98
PTAG	O	99-103
to	O	104-106
this	O	107-111
gene	O	112-116
and	O	117-120
its	O	121-124
protein	O	125-132
product	O	133-140
. 	O	140-142

The	O	0-3
ability	O	4-11
of	O	12-14
cells	O	15-20
,	O	20-21
showing	O	22-29
reduced	O	30-37
expression	O	38-48
of	O	49-51
PTAG	O	52-56
,	O	56-57
to	O	58-60
evade	O	61-66
or	O	67-69
show	O	70-74
a	O	75-76
blunted	O	77-84
apoptotic	O	85-94
response	O	95-103
may	O	104-107
underlie	O	108-116
oncogenic	O	117-126
transformation	O	127-141
in	O	142-144
both	O	145-149
the	O	150-153
pituitary	O	154-163
and	O	164-167
other	O	168-173
tumor	O	174-179
types	O	180-185
.   	O	185-189

Loss	O	0-4
of	O	5-7
microRNA	O	8-16
cluster	O	17-24
miR	B	25-28
-	I	28-29
29a	I	29-32
/	I	32-33
b	I	33-34
-	I	34-35
1	I	35-36
in	O	37-39
sporadic	O	40-48
Alzheimer	O	49-58
'	O	58-59
s	O	59-60
disease	O	61-68
correlates	O	69-79
with	O	80-84
increased	O	85-94
BACE1	O	95-100
/	O	100-101
beta	O	101-105
-	O	105-106
secretase	O	106-115
expression	O	116-126
.  	O	126-129

Although	O	0-8
the	O	9-12
role	O	13-17
of	O	18-20
APP	O	21-24
and	O	25-28
PSEN	O	29-33
genes	O	34-39
in	O	40-42
genetic	O	43-50
Alzheimer	O	51-60
'	O	60-61
s	O	61-62
disease	O	63-70
(	O	71-72
AD	O	72-74
)	O	74-75
cases	O	76-81
is	O	82-84
well	O	85-89
established	O	90-101
,	O	101-102
fairly	O	103-109
little	O	110-116
is	O	117-119
known	O	120-125
about	O	126-131
the	O	132-135
molecular	O	136-145
mechanisms	O	146-156
affecting	O	157-166
Abeta	O	167-172
generation	O	173-183
in	O	184-186
sporadic	O	187-195
AD	O	196-198
.	O	198-199
Deficiency	O	200-210
in	O	211-213
Abeta	O	214-219
clearance	O	220-229
is	O	230-232
certainly	O	233-242
a	O	243-244
possibility	O	245-256
,	O	256-257
but	O	258-261
increased	O	262-271
expression	O	272-282
of	O	283-285
proteins	O	286-294
like	O	295-299
APP	O	300-303
or	O	304-306
BACE1	O	307-312
/	O	312-313
beta	O	313-317
-	O	317-318
secretase	O	318-327
may	O	328-331
also	O	332-336
be	O	337-339
associated	O	340-350
with	O	351-355
the	O	356-359
disease	O	360-367
. 	O	367-369

We	O	0-2
therefore	O	3-12
investigated	O	13-25
changes	O	26-33
in	O	34-36
microRNA	O	37-45
(	O	46-47
miRNA	O	47-52
)	O	52-53
expression	O	54-64
profiles	O	65-73
of	O	74-76
sporadic	O	77-85
AD	O	86-88
patients	O	89-97
and	O	98-101
found	O	102-107
that	O	108-112
several	O	113-120
miRNAs	O	121-127
potentially	O	128-139
involved	O	140-148
in	O	149-151
the	O	152-155
regulation	O	156-166
of	O	167-169
APP	O	170-173
and	O	174-177
BACE1	O	178-183
expression	O	184-194
appeared	O	195-203
to	O	204-206
be	O	207-209
decreased	O	210-219
in	O	220-222
diseased	O	223-231
brain	O	232-237
. 	O	237-239

We	O	0-2
show	O	3-7
here	O	8-12
that	O	13-17
miR	B	18-21
-	I	21-22
29a	I	22-25
,	I	25-26
-	I	27-28
29b	I	28-31
-	I	31-32
1	I	32-33
,	I	33-34
and	I	35-38
-	I	39-40
9	I	40-41
can	O	42-45
regulate	O	46-54
BACE1	O	55-60
expression	O	61-71
in	O	72-74
vitro	O	75-80
. 	O	80-82

The	O	0-3
miR	B	4-7
-	I	7-8
29a	I	8-11
/	I	11-12
b	I	12-13
-	I	13-14
1	I	14-15
cluster	O	16-23
was	O	24-27
significantly	O	28-41
(	O	42-43
and	O	43-46
AD	O	47-49
-	O	49-50
dementia	O	50-58
-	O	58-59
specific	O	59-67
)	O	67-68
decreased	O	69-78
in	O	79-81
AD	O	82-84
patients	O	85-93
displaying	O	94-104
abnormally	O	105-115
high	O	116-120
BACE1	O	121-126
protein	O	127-134
. 	O	134-136

Similar	O	0-7
correlations	O	8-20
between	O	21-28
expression	O	29-39
of	O	40-42
this	O	43-47
cluster	O	48-55
and	O	56-59
BACE1	O	60-65
were	O	66-70
found	O	71-76
during	O	77-83
brain	O	84-89
development	O	90-101
and	O	102-105
in	O	106-108
primary	O	109-116
neuronal	O	117-125
cultures	O	126-134
. 	O	134-136

Finally	O	0-7
,	O	7-8
we	O	9-11
provide	O	12-19
evidence	O	20-28
for	O	29-32
a	O	33-34
potential	O	35-44
causal	O	45-51
relationship	O	52-64
between	O	65-72
miR	B	73-76
-	I	76-77
29a	I	77-80
/	I	80-81
b	I	81-82
-	I	82-83
1	I	83-84
expression	O	85-95
and	O	96-99
Abeta	O	100-105
generation	O	106-116
in	O	117-119
a	O	120-121
cell	O	122-126
culture	O	127-134
model	O	135-140
. 	O	140-142

We	O	0-2
propose	O	3-10
that	O	11-15
loss	O	16-20
of	O	21-23
specific	O	24-32
miRNAs	O	33-39
can	O	40-43
contribute	O	44-54
to	O	55-57
increased	O	58-67
BACE1	O	68-73
and	O	74-77
Abeta	O	78-83
levels	O	84-90
in	O	91-93
sporadic	O	94-102
AD	O	103-105
.   	O	105-109

Here	O	0-4
we	O	5-7
expand	O	8-14
the	O	15-18
role	O	19-23
of	O	24-26
GRN	O	27-30
in	O	31-33
FTLD	O	34-38
-	O	38-39
U	O	39-40
and	O	41-44
demonstrate	O	45-56
that	O	57-61
a	O	62-63
common	O	64-70
genetic	O	71-78
variant	O	79-86
(	O	87-88
rs5848	O	88-94
)	O	94-95
,	O	95-96
located	O	97-104
in	O	105-107
the	O	108-111
3	O	112-113
'	O	113-114
-	O	114-115
untranslated	O	115-127
region	O	128-134
(	O	135-136
UTR	O	136-139
)	O	139-140
of	O	141-143
GRN	O	144-147
in	O	148-150
a	O	151-152
binding	O	153-160
-	O	160-161
site	O	161-165
for	O	166-169
miR	B	170-173
-	I	173-174
659	I	174-177
,	O	177-178
is	O	179-181
a	O	182-183
major	O	184-189
susceptibility	O	190-204
factor	O	205-211
for	O	212-215
FTLD	O	216-220
-	O	220-221
U	O	221-222
. 	O	222-224

Loss	O	0-4
-	O	4-5
of	O	5-7
-	O	7-8
function	O	8-16
mutations	O	17-26
in	O	27-29
progranulin	O	30-41
(	O	42-43
GRN	O	43-46
)	O	46-47
cause	O	48-53
ubiquitin	O	54-63
-	O	63-64
and	O	65-68
TAR	O	69-72
DNA	O	73-76
-	O	76-77
binding	O	77-84
protein	O	85-92
43	O	93-95
(	O	96-97
TDP	O	97-100
-	O	100-101
43	O	101-103
)	O	103-104
-	O	104-105
positive	O	105-113
frontotemporal	O	114-128
dementia	O	129-137
(	O	138-139
FTLD	O	139-143
-	O	143-144
U	O	144-145
)	O	145-146
,	O	146-147
a	O	148-149
progressive	O	150-161
neurodegenerative	O	162-179
disease	O	180-187
affecting	O	188-197
approximately	O	198-211
10	O	212-214
%	O	214-215
of	O	216-218
early	O	219-224
-	O	224-225
onset	O	225-230
dementia	O	231-239
patients	O	240-248
. 	O	248-250

Common	O	0-6
variation	O	7-16
in	O	17-19
the	O	20-23
miR	B	24-27
-	I	27-28
659	I	28-31
binding	O	32-39
-	O	39-40
site	O	40-44
of	O	45-47
GRN	O	48-51
is	O	52-54
a	O	55-56
major	O	57-62
risk	O	63-67
factor	O	68-74
for	O	75-78
TDP43	O	79-84
-	O	84-85
positive	O	85-93
frontotemporal	O	94-108
dementia	O	109-117
.  	O	117-120

In	O	0-2
support	O	3-10
of	O	11-13
these	O	14-19
findings	O	20-28
,	O	28-29
the	O	30-33
neuropathology	O	34-48
of	O	49-51
homozygous	O	52-62
rs5848	O	63-69
T	O	70-71
-	O	71-72
allele	O	72-78
carriers	O	79-87
frequently	O	88-98
resembled	O	99-108
the	O	109-112
pathological	O	113-125
FTLD	O	126-130
-	O	130-131
U	O	131-132
subtype	O	133-140
of	O	141-143
GRN	O	144-147
mutation	O	148-156
carriers	O	157-165
. 	O	165-167

A	O	0-1
significant	O	2-13
reduction	O	14-23
in	O	24-26
GRN	O	27-30
protein	O	31-38
was	O	39-42
observed	O	43-51
in	O	52-54
homozygous	O	55-65
T	O	66-67
-	O	67-68
allele	O	68-74
carriers	O	75-83
in	O	84-86
vivo	O	87-91
,	O	91-92
through	O	93-100
biochemical	O	101-112
and	O	113-116
immunohistochemical	O	117-136
methods	O	137-144
,	O	144-145
mimicking	O	146-155
the	O	156-159
effect	O	160-166
of	O	167-169
heterozygous	O	170-182
loss	O	183-187
-	O	187-188
of	O	188-190
-	O	190-191
function	O	191-199
GRN	O	200-203
mutations	O	204-213
. 	O	213-215

We	O	0-2
further	O	3-10
demonstrate	O	11-22
that	O	23-27
miR	B	28-31
-	I	31-32
659	I	32-35
can	O	36-39
regulate	O	40-48
GRN	O	49-52
expression	O	53-63
in	O	64-66
vitro	O	67-72
,	O	72-73
with	O	74-78
miR	B	79-82
-	I	82-83
659	I	83-86
binding	O	87-94
more	O	95-99
efficiently	O	100-111
to	O	112-114
the	O	115-118
high	O	119-123
risk	O	124-128
T	O	129-130
-	O	130-131
allele	O	131-137
of	O	138-140
rs5848	O	141-147
resulting	O	148-157
in	O	158-160
augmented	O	161-170
translational	O	171-184
inhibition	O	185-195
of	O	196-198
GRN	O	199-202
. 	O	202-204

In	O	0-2
a	O	3-4
series	O	5-11
of	O	12-14
pathologically	O	15-29
confirmed	O	30-39
FTLD	O	40-44
-	O	44-45
U	O	45-46
patients	O	47-55
without	O	56-63
GRN	O	64-67
mutations	O	68-77
,	O	77-78
we	O	79-81
show	O	82-86
that	O	87-91
carriers	O	92-100
homozygous	O	101-111
for	O	112-115
the	O	116-119
T	O	120-121
-	O	121-122
allele	O	122-128
of	O	129-131
rs5848	O	132-138
have	O	139-143
a	O	144-145
3	O	146-147
.	O	147-148
2	O	148-149
-	O	149-150
fold	O	150-154
increased	O	155-164
risk	O	165-169
to	O	170-172
develop	O	173-180
FTLD	O	181-185
-	O	185-186
U	O	186-187
compared	O	188-196
with	O	197-201
homozygous	O	202-212
C	O	213-214
-	O	214-215
allele	O	215-221
carriers	O	222-230
(	O	231-232
95	O	232-234
%	O	234-235
CI	O	236-238
:	O	238-239
1	O	240-241
.	O	241-242
50	O	242-244
-	O	244-245
6	O	245-246
.	O	246-247
73	O	247-249
)	O	249-250
. 	O	250-252

Translational	O	0-13
regulation	O	14-24
by	O	25-27
miRNAs	O	28-34
may	O	35-38
represent	O	39-48
a	O	49-50
common	O	51-57
mechanism	O	58-67
underlying	O	68-78
complex	O	79-86
neurodegenerative	O	87-104
disorders	O	105-114
.   	O	114-118

We	O	0-2
suggest	O	3-10
that	O	11-15
the	O	16-19
expression	O	20-30
of	O	31-33
GRN	O	34-37
is	O	38-40
regulated	O	41-50
by	O	51-53
miRNAs	O	54-60
and	O	61-64
that	O	65-69
common	O	70-76
genetic	O	77-84
variability	O	85-96
in	O	97-99
a	O	100-101
miRNA	O	102-107
binding	O	108-115
-	O	115-116
site	O	116-120
can	O	121-124
significantly	O	125-138
increase	O	139-147
the	O	148-151
risk	O	152-156
for	O	157-160
FTLD	O	161-165
-	O	165-166
U	O	166-167
. 	O	167-169

Taken	O	0-5
together	O	6-14
,	O	14-15
our	O	16-19
findings	O	20-28
indicate	O	29-37
that	O	38-42
miR	B	43-46
-	I	46-47
15b	I	47-50
regulates	O	51-60
cell	O	61-65
cycle	O	66-71
progression	O	72-83
in	O	84-86
glioma	O	87-93
cells	O	94-99
by	O	100-102
targeting	O	103-112
cell	O	113-117
cycle	O	118-123
-	O	123-124
related	O	124-131
molecules	O	132-141
.   	O	141-145

Over	O	0-4
-	O	4-5
expression	O	5-15
of	O	16-18
miR	B	19-22
-	I	22-23
15b	I	23-26
resulted	O	27-35
in	O	36-38
cell	O	39-43
cycle	O	44-49
arrest	O	50-56
at	O	57-59
G0	O	60-62
/	O	62-63
G1	O	63-65
phase	O	66-71
while	O	72-77
suppression	O	78-89
of	O	90-92
miR	B	93-96
-	I	96-97
15b	I	97-100
expression	O	101-111
resulted	O	112-120
in	O	121-123
a	O	124-125
decrease	O	126-134
of	O	135-137
cell	O	138-142
populations	O	143-154
in	O	155-157
G0	O	158-160
/	O	160-161
G1	O	161-163
and	O	164-167
a	O	168-169
corresponding	O	170-183
increase	O	184-192
of	O	193-195
cell	O	196-200
populations	O	201-212
in	O	213-215
S	O	216-217
phase	O	218-223
. 	O	223-225

We	O	0-2
further	O	3-10
showed	O	11-17
that	O	18-22
CCNE1	O	23-28
(	O	29-30
encoding	O	30-38
cyclin	O	39-45
E1	O	46-48
)	O	48-49
is	O	50-52
one	O	53-56
of	O	57-59
the	O	60-63
downstream	O	64-74
targets	O	75-82
of	O	83-85
miR	B	86-89
-	I	89-90
15b	I	90-93
. 	O	93-95

We	O	0-2
have	O	3-7
recently	O	8-16
compared	O	17-25
the	O	26-29
miRNA	O	30-35
expression	O	36-46
profiles	O	47-55
between	O	56-63
normal	O	64-70
brain	O	71-76
and	O	77-80
glioma	O	81-87
tissues	O	88-95
from	O	96-100
Chinese	O	101-108
patients	O	109-117
by	O	118-120
miRNA	O	121-126
microarray	O	127-137
and	O	138-141
identified	O	142-152
a	O	153-154
panel	O	155-160
of	O	161-163
differentially	O	164-178
expressed	O	179-188
miRNAs	O	189-195
. 	O	195-197

Here	O	0-4
,	O	4-5
we	O	6-8
studied	O	9-16
the	O	17-20
function	O	21-29
of	O	30-32
one	O	33-36
miRNA	O	37-42
,	O	42-43
miR	B	44-47
-	I	47-48
15b	I	48-51
,	O	51-52
in	O	53-55
glioma	O	56-62
carcinogenesis	O	63-77
and	O	78-81
elucidated	O	82-92
its	O	93-96
downstream	O	97-107
targets	O	108-115
. 	O	115-117

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
non	O	23-26
-	O	26-27
protein	O	27-34
-	O	34-35
coding	O	35-41
RNAs	O	42-46
that	O	47-51
function	O	52-60
as	O	61-63
post	O	64-68
-	O	68-69
transcriptional	O	69-84
gene	O	85-89
regulators	O	90-100
. 	O	100-102

Recent	O	0-6
evidence	O	7-15
has	O	16-19
shown	O	20-25
that	O	26-30
miRNA	O	31-36
plays	O	37-42
a	O	43-44
pivotal	O	45-52
role	O	53-57
in	O	58-60
the	O	61-64
development	O	65-76
of	O	77-79
many	O	80-84
cancers	O	85-92
including	O	93-102
glioma	O	103-109
,	O	109-110
a	O	111-112
lethal	O	113-119
brain	O	120-125
cancer	O	126-132
. 	O	132-134

MicroRNA	B	0-8
-	I	8-9
15b	I	9-12
regulates	O	13-22
cell	O	23-27
cycle	O	28-33
progression	O	34-45
by	O	46-48
targeting	O	49-58
cyclins	O	59-66
in	O	67-69
glioma	O	70-76
cells	O	77-82
.  	O	82-85

It	O	0-2
has	O	3-6
been	O	7-11
recently	O	12-20
demonstrated	O	21-33
that	O	34-38
herpesviruses	O	39-52
encode	O	53-59
miRNAs	O	60-66
to	O	67-69
control	O	70-77
the	O	78-81
post	O	82-86
-	O	86-87
transcriptional	O	87-102
regulation	O	103-113
of	O	114-116
expression	O	117-127
from	O	128-132
their	O	133-138
own	O	139-142
genomes	O	143-150
and	O	151-154
possibly	O	155-163
that	O	164-168
of	O	169-171
their	O	172-177
host	O	178-182
,	O	182-183
thus	O	184-188
adding	O	189-195
an	O	196-198
additional	O	199-209
layer	O	210-215
of	O	216-218
complexity	O	219-229
to	O	230-232
the	O	233-236
physiological	O	237-250
cross	O	251-256
-	O	256-257
talk	O	257-261
between	O	262-269
host	O	270-274
and	O	275-278
pathogen	O	279-287
. 	O	287-289

MicroRNAs	O	0-9
are	O	10-13
small	O	14-19
non	O	20-23
-	O	23-24
coding	O	24-30
RNAs	O	31-35
approximately	O	36-49
22	O	50-52
nt	O	53-55
long	O	56-60
that	O	61-65
modulate	O	66-74
gene	O	75-79
expression	O	80-90
in	O	91-93
animals	O	94-101
and	O	102-105
plants	O	106-112
. 	O	112-114

Co	O	0-2
-	O	2-3
expression	O	3-13
of	O	14-16
host	O	17-21
and	O	22-25
viral	O	26-31
microRNAs	O	32-41
in	O	42-44
porcine	O	45-52
dendritic	O	53-62
cells	O	63-68
infected	O	69-77
by	O	78-80
the	O	81-84
pseudorabies	O	85-97
virus	O	98-103
.  	O	103-106

Almost	O	0-6
95	O	7-9
%	O	9-10
of	O	11-13
reads	O	14-19
mapped	O	20-26
to	O	27-29
the	O	30-33
draft	O	34-39
pig	O	40-43
genome	O	44-50
sequence	O	51-59
and	O	60-63
pig	O	64-67
miRNAs	O	68-74
previously	O	75-85
annotated	O	86-95
in	O	96-98
dedicated	O	99-108
databases	O	109-118
were	O	119-123
detected	O	124-132
by	O	133-135
sequence	O	136-144
alignment	O	145-154
. 	O	154-156

An	O	0-2
average	O	3-10
of	O	11-13
2	O	14-15
million	O	16-23
reads	O	24-29
per	O	30-33
sample	O	34-40
with	O	41-45
a	O	46-47
size	O	48-52
of	O	53-55
21	O	56-58
-	O	58-59
24	O	59-61
nucleotides	O	62-73
was	O	74-77
obtained	O	78-86
from	O	87-91
six	O	92-95
libraries	O	96-105
representing	O	106-118
three	O	119-124
biological	O	125-135
replicates	O	136-146
of	O	147-149
infected	O	150-158
and	O	159-162
mock	O	163-167
-	O	167-168
infected	O	168-176
DCs	O	177-180
. 	O	180-182

A	O	0-1
catalogue	O	2-11
of	O	12-14
porcine	O	15-22
and	O	23-26
viral	O	27-32
miRNAs	O	33-39
,	O	39-40
expressed	O	41-50
eight	O	51-56
hours	O	57-62
post	O	63-67
-	O	67-68
infection	O	68-77
,	O	77-78
was	O	79-82
established	O	83-94
by	O	95-97
deep	O	98-102
sequencing	O	103-113
. 	O	113-115

The	O	0-3
present	O	4-11
study	O	12-17
focussed	O	18-26
on	O	27-29
the	O	30-33
interactions	O	34-46
between	O	47-54
porcine	O	55-62
dendritic	O	63-72
cells	O	73-78
(	O	79-80
DCs	O	80-83
)	O	83-84
and	O	85-88
the	O	89-92
Pseudorabies	O	93-105
virus	O	106-111
(	O	112-113
PRV	O	113-116
)	O	116-117
,	O	117-118
an	O	119-121
alpha	O	122-127
-	O	127-128
herpesvirus	O	128-139
causing	O	140-147
Aujeszky	O	148-156
'	O	156-157
s	O	157-158
disease	O	159-166
in	O	167-169
pigs	O	170-174
. 	O	174-176

In	O	0-2
silico	O	3-9
prediction	O	10-20
allowed	O	21-28
the	O	29-32
identification	O	33-47
of	O	48-50
unknown	O	51-58
porcine	O	59-66
as	O	67-69
well	O	70-74
as	O	75-77
of	O	78-80
five	O	81-85
miRNAs	O	86-92
transcribed	O	93-104
by	O	105-107
the	O	108-111
Large	O	112-117
Latency	O	118-125
Transcript	O	126-136
(	O	137-138
LLT	O	138-141
)	O	141-142
of	O	143-145
PRV	O	146-149
. 	O	149-151

The	O	0-3
gene	O	4-8
target	O	9-15
prediction	O	16-26
of	O	27-29
the	O	30-33
viral	O	34-39
miRNAs	O	40-46
and	O	47-50
the	O	51-54
Ingenuity	O	55-64
Pathway	O	65-72
Analysis	O	73-81
of	O	82-84
differentially	O	85-99
expressed	O	100-109
pig	O	110-113
miRNAs	O	114-120
were	O	121-125
conducted	O	126-135
to	O	136-138
contextualize	O	139-152
the	O	153-156
identified	O	157-167
small	O	168-173
RNA	O	174-177
molecules	O	178-187
and	O	188-191
functionally	O	192-204
characterize	O	205-217
their	O	218-223
involvement	O	224-235
in	O	236-238
the	O	239-242
post	O	243-247
-	O	247-248
transcriptional	O	248-263
regulation	O	264-274
of	O	275-277
gene	O	278-282
expression	O	283-293
. 	O	293-295

The	O	0-3
results	O	4-11
support	O	12-19
a	O	20-21
role	O	22-26
for	O	27-30
PRV	O	31-34
miRNAs	O	35-41
in	O	42-44
the	O	45-48
maintenance	O	49-60
of	O	61-63
the	O	64-67
host	O	68-72
cell	O	73-77
latency	O	78-85
state	O	86-91
through	O	92-99
the	O	100-103
down	O	104-108
-	O	108-109
regulation	O	109-119
of	O	120-122
immediate	O	123-132
-	O	132-133
early	O	133-138
viral	O	139-144
genes	O	145-150
which	O	151-156
is	O	157-159
similar	O	160-167
to	O	168-170
other	O	171-176
herpesviruses	O	177-190
. 	O	190-192

The	O	0-3
differentially	O	4-18
expressed	O	19-28
swine	O	29-34
miRNAs	O	35-41
identified	O	42-52
a	O	53-54
unique	O	55-61
network	O	62-69
of	O	70-72
target	O	73-79
genes	O	80-85
with	O	86-90
highly	O	91-97
significant	O	98-109
functions	O	110-119
in	O	120-122
the	O	123-126
development	O	127-138
and	O	139-142
function	O	143-151
of	O	152-154
the	O	155-158
nervous	O	159-166
system	O	167-173
and	O	174-177
in	O	178-180
infectious	O	181-191
mechanisms	O	192-202
,	O	202-203
suggesting	O	204-214
that	O	215-219
the	O	220-223
modulation	O	224-234
of	O	235-237
both	O	238-242
host	O	243-247
and	O	248-251
viral	O	252-257
miRNAs	O	258-264
is	O	265-267
necessary	O	268-277
for	O	278-281
the	O	282-285
establishment	O	286-299
of	O	300-302
PRV	O	303-306
latency	O	307-314
.   	O	314-318

An	O	0-2
understanding	O	3-16
of	O	17-19
how	O	20-23
microRNAs	O	24-33
influence	O	34-43
the	O	44-47
body	O	48-52
'	O	52-53
s	O	53-54
response	O	55-63
to	O	64-66
certain	O	67-74
drugs	O	75-80
and	O	81-84
how	O	85-88
these	O	89-94
affect	O	95-101
the	O	102-105
expression	O	106-116
of	O	117-119
microRNAs	O	120-129
,	O	129-130
will	O	131-135
be	O	136-138
of	O	139-141
key	O	142-145
importance	O	146-156
in	O	157-159
developing	O	160-170
drugs	O	171-176
with	O	177-181
greater	O	182-189
safety	O	190-196
and	O	197-200
efficacy	O	201-209
.   	O	209-213

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
short	O	23-28
non	O	29-32
-	O	32-33
coding	O	33-39
RNAs	O	40-44
involved	O	45-53
in	O	54-56
post	O	57-61
-	O	61-62
transcriptional	O	62-77
regulation	O	78-88
of	O	89-91
gene	O	92-96
expression	O	97-107
. 	O	107-109

Since	O	0-5
the	O	6-9
discovery	O	10-19
of	O	20-22
the	O	23-26
first	O	27-32
miRNA	O	33-38
gene	O	39-43
lin	B	44-47
-	I	47-48
4	I	48-49
in	O	50-52
C	O	53-54
.	O	54-55
elegans	O	56-63
,	O	63-64
over	O	65-69
500	O	70-73
miRNAs	O	74-80
have	O	81-85
been	O	86-90
identified	O	91-101
in	O	102-104
humans	O	105-111
and	O	112-115
the	O	116-119
list	O	120-124
is	O	125-127
growing	O	128-135
. 	O	135-137

Their	O	0-5
biological	O	6-16
importance	O	17-27
,	O	27-28
initially	O	29-38
demonstrated	O	39-51
in	O	52-54
cancer	O	55-61
,	O	61-62
was	O	63-66
also	O	67-71
more	O	72-76
recently	O	77-85
discovered	O	86-96
in	O	97-99
many	O	100-104
other	O	105-110
pathologies	O	111-122
like	O	123-127
Alzheimer	O	128-137
'	O	137-138
s	O	138-139
disease	O	140-147
,	O	147-148
Parkinson	O	149-158
'	O	158-159
s	O	159-160
disease	O	161-168
,	O	168-169
viral	O	170-175
infections	O	176-186
,	O	186-187
diabetes	O	188-196
,	O	196-197
and	O	198-201
myopathies	O	202-212
. 	O	212-214

In	O	0-2
the	O	3-6
present	O	7-14
review	O	15-21
we	O	22-24
will	O	25-29
summarize	O	30-39
miRNA	O	40-45
profiling	O	46-55
studies	O	56-63
in	O	64-66
human	O	67-72
diseases	O	73-81
and	O	82-85
discuss	O	86-93
the	O	94-97
newly	O	98-103
discovered	O	104-114
link	O	115-119
between	O	120-127
microRNAs	O	128-137
and	O	138-141
drug	O	142-146
response	O	147-155
. 	O	155-157

MicroRNAs	O	0-9
in	O	10-12
diseases	O	13-21
and	O	22-25
drug	O	26-30
response	O	31-39
.  	O	39-42

Role	O	0-4
of	O	5-7
epigenetic	O	8-18
effectors	O	19-28
in	O	29-31
maintenance	O	32-43
of	O	44-46
the	O	47-50
long	O	51-55
-	O	55-56
term	O	56-60
persistent	O	61-71
bystander	O	72-81
effect	O	82-88
in	O	89-91
spleen	O	92-98
in	O	99-101
vivo	O	102-106
.  	O	106-109

These	O	0-5
cancers	O	6-13
are	O	14-17
thought	O	18-25
to	O	26-28
be	O	29-31
linked	O	32-38
to	O	39-41
indirect	O	42-50
radiation	O	51-60
-	O	60-61
induced	O	61-68
bystander	O	69-78
effect	O	79-85
. 	O	85-87

Radiation	O	0-9
therapy	O	10-17
is	O	18-20
a	O	21-22
primary	O	23-30
treatment	O	31-40
modality	O	41-49
for	O	50-53
brain	O	54-59
tumors	O	60-66
,	O	66-67
yet	O	68-71
it	O	72-74
has	O	75-78
been	O	79-83
linked	O	84-90
to	O	91-93
the	O	94-97
increased	O	98-107
incidence	O	108-117
of	O	118-120
secondary	O	121-130
,	O	130-131
post	O	132-136
-	O	136-137
radiation	O	137-146
therapy	O	147-154
cancers	O	155-162
. 	O	162-164

Recent	O	0-6
evidence	O	7-15
suggests	O	16-24
that	O	25-29
bystander	O	30-39
effect	O	40-46
may	O	47-50
be	O	51-53
epigenetic	O	54-64
in	O	65-67
nature	O	68-74
;	O	74-75
however	O	76-83
,	O	83-84
characterization	O	85-101
of	O	102-104
epigenetic	O	105-115
mechanisms	O	116-126
involved	O	127-135
in	O	136-138
bystander	O	139-148
effect	O	149-155
generation	O	156-166
and	O	167-170
its	O	171-174
long	O	175-179
-	O	179-180
term	O	180-184
persistence	O	185-196
has	O	197-200
yet	O	201-204
to	O	205-207
be	O	208-210
defined	O	211-218
. 	O	218-220

Bystander	O	0-9
effect	O	10-16
occurs	O	17-23
when	O	24-28
irradiated	O	29-39
cells	O	40-45
communicate	O	46-57
damage	O	58-64
to	O	65-67
nearby	O	68-74
,	O	74-75
non	O	76-79
-	O	79-80
irradiated	O	80-90
'	O	91-92
bystander	O	92-101
'	O	101-102
cells	O	103-108
,	O	108-109
ultimately	O	110-120
contributing	O	121-133
to	O	134-136
genome	O	137-143
destabilization	O	144-159
in	O	160-162
the	O	163-166
non	O	167-170
-	O	170-171
exposed	O	171-178
cells	O	179-184
. 	O	184-186

We	O	0-2
found	O	3-8
that	O	9-13
localized	O	14-23
cranial	O	24-31
radiation	O	32-41
exposure	O	42-50
led	O	51-54
to	O	55-57
the	O	58-61
induction	O	62-71
of	O	72-74
bystander	O	75-84
effect	O	85-91
in	O	92-94
lead	O	95-99
-	O	99-100
shielded	O	100-108
,	O	108-109
distant	O	110-117
spleen	O	118-124
tissue	O	125-131
. 	O	131-133

To	O	0-2
investigate	O	3-14
the	O	15-18
possibility	O	19-30
that	O	31-35
localized	O	36-45
X	O	46-47
-	O	47-48
ray	O	48-51
irradiation	O	52-63
induces	O	64-71
persistent	O	72-82
bystander	O	83-92
effects	O	93-100
in	O	101-103
distant	O	104-111
tissue	O	112-118
,	O	118-119
we	O	120-122
monitored	O	123-132
the	O	133-136
induction	O	137-146
of	O	147-149
epigenetic	O	150-160
changes	O	161-168
(	O	169-170
i	O	170-171
.	O	171-172
e	O	172-173
.	O	173-174
alterations	O	175-186
in	O	187-189
DNA	O	190-193
methylation	O	194-205
,	O	205-206
histone	O	207-214
methylation	O	215-226
and	O	227-230
microRNA	O	231-239
(	O	240-241
miRNA	O	241-246
)	O	246-247
expression	O	248-258
)	O	258-259
in	O	260-262
the	O	263-266
rat	O	267-270
spleen	O	271-277
tissue	O	278-284
24	O	285-287
h	O	288-289
and	O	290-293
7	O	294-295
months	O	296-302
after	O	303-308
localized	O	309-318
cranial	O	319-326
exposure	O	327-335
to	O	336-338
20	O	339-341
Gy	O	342-344
of	O	345-347
X	O	348-349
-	O	349-350
rays	O	350-354
. 	O	354-356

Further	O	0-7
,	O	7-8
irradiation	O	9-20
significantly	O	21-34
altered	O	35-42
expression	O	43-53
of	O	54-56
miR	B	57-60
-	I	60-61
194	I	61-64
,	O	64-65
a	O	66-67
miRNA	O	68-73
putatively	O	74-84
targeting	O	85-94
both	O	95-99
DNA	O	100-103
methyltransferase	O	104-121
-	O	121-122
3a	O	122-124
and	O	125-128
MeCP2	O	129-134
. 	O	134-136

Specifically	O	0-12
,	O	12-13
this	O	14-18
exposure	O	19-27
caused	O	28-34
the	O	35-38
profound	O	39-47
epigenetic	O	48-58
dysregulation	O	59-72
in	O	73-75
the	O	76-79
bystander	O	80-89
spleen	O	90-96
tissue	O	97-103
that	O	104-108
manifested	O	109-119
as	O	120-122
a	O	123-124
significant	O	125-136
loss	O	137-141
of	O	142-144
global	O	145-151
DNA	O	152-155
methylation	O	156-167
,	O	167-168
alterations	O	169-180
in	O	181-183
methylation	O	184-195
of	O	196-198
long	O	199-203
interspersed	O	204-216
nucleotide	O	217-227
element	O	228-235
-	O	235-236
1	O	236-237
(	O	238-239
LINE	O	239-243
-	O	243-244
1	O	244-245
)	O	245-246
retrotransposable	O	247-264
elements	O	265-273
and	O	274-277
down	O	278-282
-	O	282-283
regulation	O	283-293
of	O	294-296
DNA	O	297-300
methyltransferases	O	301-319
and	O	320-323
methyl	O	324-330
-	O	330-331
binding	O	331-338
protein	O	339-346
methyl	O	347-353
CpG	O	354-357
binding	O	358-365
protein	O	366-373
2	O	374-375
(	O	376-377
MeCP2	O	377-382
)	O	382-383
. 	O	383-385

This	O	0-4
study	O	5-10
is	O	11-13
the	O	14-17
first	O	18-23
to	O	24-26
report	O	27-33
conclusive	O	34-44
evidence	O	45-53
of	O	54-56
the	O	57-60
long	O	61-65
-	O	65-66
term	O	66-70
persistence	O	71-82
of	O	83-85
bystander	O	86-95
effects	O	96-103
in	O	104-106
radiation	O	107-116
carcinogenesis	O	117-131
target	O	132-138
organ	O	139-144
(	O	145-146
spleen	O	146-152
)	O	152-153
upon	O	154-158
localized	O	159-168
distant	O	169-176
exposure	O	177-185
using	O	186-191
the	O	192-195
doses	O	196-201
comparable	O	202-212
with	O	213-217
those	O	218-223
used	O	224-228
for	O	229-232
clinical	O	233-241
brain	O	242-247
tumor	O	248-253
treatments	O	254-264
.   	O	264-268

The	O	0-3
RAKE	O	4-8
assay	O	9-14
is	O	15-17
theoretically	O	18-31
versatile	O	32-41
and	O	42-45
may	O	46-49
be	O	50-52
used	O	53-57
for	O	58-61
other	O	62-67
applications	O	68-80
,	O	80-81
such	O	82-86
as	O	87-89
viral	O	90-95
gene	O	96-100
profiling	O	101-110
.   	O	110-114

Furthermore	O	0-11
,	O	11-12
we	O	13-15
demonstrate	O	16-27
that	O	28-32
miRNAs	O	33-39
can	O	40-43
be	O	44-46
isolated	O	47-55
and	O	56-59
profiled	O	60-68
from	O	69-73
formalin	O	74-82
-	O	82-83
fixed	O	83-88
paraffin	O	89-97
-	O	97-98
embedded	O	98-106
tissue	O	107-113
,	O	113-114
which	O	115-120
opens	O	121-126
up	O	127-129
new	O	130-133
opportunities	O	134-147
for	O	148-151
analyses	O	152-160
of	O	161-163
small	O	164-169
RNAs	O	170-174
from	O	175-179
archival	O	180-188
human	O	189-194
tissue	O	195-201
. 	O	201-203

RAKE	O	0-4
offers	O	5-11
unique	O	12-18
advantages	O	19-29
for	O	30-33
specificity	O	34-45
over	O	46-50
northern	O	51-59
blots	O	60-65
or	O	66-68
other	O	69-74
microarray	O	75-85
-	O	85-86
based	O	86-91
expression	O	92-102
profiling	O	103-112
platforms	O	113-122
. 	O	122-124

We	O	0-2
show	O	3-7
that	O	8-12
the	O	13-16
RAKE	O	17-21
assay	O	22-27
is	O	28-30
sensitive	O	31-40
and	O	41-44
specific	O	45-53
for	O	54-57
miRNAs	O	58-64
and	O	65-68
is	O	69-71
ideally	O	72-79
suited	O	80-86
for	O	87-90
rapid	O	91-96
expression	O	97-107
profiling	O	108-117
of	O	118-120
all	O	121-124
known	O	125-130
miRNAs	O	131-137
. 	O	137-139

We	O	0-2
used	O	3-7
RAKE	O	8-12
to	O	13-15
study	O	16-21
human	O	22-27
cell	O	28-32
lines	O	33-38
and	O	39-42
brain	O	43-48
tumors	O	49-55
. 	O	55-57

The	O	0-3
technique	O	4-13
is	O	14-16
termed	O	17-23
the	O	24-27
RNA	O	28-31
-	O	31-32
primed	O	32-38
,	O	38-39
array	O	40-45
-	O	45-46
based	O	46-51
Klenow	O	52-58
enzyme	O	59-65
(	O	66-67
RAKE	O	67-71
)	O	71-72
assay	O	73-78
,	O	78-79
because	O	80-87
it	O	88-90
involves	O	91-99
on	O	100-102
-	O	102-103
slide	O	103-108
application	O	109-120
of	O	121-123
the	O	124-127
Klenow	O	128-134
fragment	O	135-143
of	O	144-146
DNA	O	147-150
polymerase	O	151-161
I	O	162-163
to	O	164-166
extend	O	167-173
unmodified	O	174-184
miRNAs	O	185-191
hybridized	O	192-202
to	O	203-205
immobilized	O	206-217
DNA	O	218-221
probes	O	222-228
. 	O	228-230

We	O	0-2
describe	O	3-11
a	O	12-13
new	O	14-17
method	O	18-24
for	O	25-28
high	O	29-33
-	O	33-34
throughput	O	34-44
miRNA	O	45-50
detection	O	51-60
. 	O	60-62

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
regulatory	O	29-39
RNAs	O	40-44
that	O	45-49
serve	O	50-55
fundamental	O	56-67
biological	O	68-78
roles	O	79-84
across	O	85-91
eukaryotic	O	92-102
species	O	103-110
. 	O	110-112

Microarray	O	0-10
-	O	10-11
based	O	11-16
,	O	16-17
high	O	18-22
-	O	22-23
throughput	O	23-33
gene	O	34-38
expression	O	39-49
profiling	O	50-59
of	O	60-62
microRNAs	O	63-72
.  	O	72-75

Brain	O	0-5
cells	O	6-11
maintain	O	12-20
distinct	O	21-29
populations	O	30-41
of	O	42-44
miRNAs	O	45-51
that	O	52-56
support	O	57-64
physiologically	O	65-80
normal	O	81-87
patterns	O	88-96
of	O	97-99
expression	O	100-110
,	O	110-111
however	O	112-119
,	O	119-120
certain	O	121-128
miRNA	O	129-134
abundances	O	135-145
are	O	146-149
significantly	O	150-163
altered	O	164-171
in	O	172-174
neurodegenerative	O	175-192
disorders	O	193-202
such	O	203-207
as	O	208-210
Alzheimer	O	211-220
'	O	220-221
s	O	221-222
disease	O	223-230
(	O	231-232
AD	O	232-234
)	O	234-235
. 	O	235-237

Here	O	0-4
we	O	5-7
provide	O	8-15
evidence	O	16-24
in	O	25-27
human	O	28-33
neural	O	34-40
(	O	41-42
HN	O	42-44
)	O	44-45
cells	O	46-51
of	O	52-54
an	O	55-57
aluminum	O	58-66
-	O	66-67
sulfate	O	67-74
-	O	74-75
and	O	76-79
reactive	O	80-88
oxygen	O	89-95
species	O	96-103
(	O	104-105
ROS	O	105-108
)	O	108-109
-	O	109-110
mediated	O	110-118
up	O	119-121
-	O	121-122
regulation	O	122-132
of	O	133-135
an	O	136-138
NF	O	139-141
-	O	141-142
kappaB	O	142-148
-	O	148-149
sensitive	O	149-158
miRNA	B	159-164
-	I	164-165
146a	I	165-169
that	O	170-174
down	O	175-179
-	O	179-180
regulates	O	180-189
the	O	190-193
expression	O	194-204
of	O	205-207
complement	O	208-218
factor	O	219-225
H	O	226-227
(	O	228-229
CFH	O	229-232
)	O	232-233
,	O	233-234
an	O	235-237
important	O	238-247
repressor	O	248-257
of	O	258-260
inflammation	O	261-273
. 	O	273-275

Characterization	O	0-16
of	O	17-19
an	O	20-22
NF	O	23-25
-	O	25-26
kappaB	O	26-32
-	O	32-33
regulated	O	33-42
,	O	42-43
miRNA	B	44-49
-	I	49-50
146a	I	50-54
-	O	54-55
mediated	O	55-63
down	O	64-68
-	O	68-69
regulation	O	69-79
of	O	80-82
complement	O	83-93
factor	O	94-100
H	O	101-102
(	O	103-104
CFH	O	104-107
)	O	107-108
in	O	109-111
metal	O	112-117
-	O	117-118
sulfate	O	118-125
-	O	125-126
stressed	O	126-134
human	O	135-140
brain	O	141-146
cells	O	147-152
.  	O	152-155

Micro	O	0-5
RNAs	O	6-10
(	O	11-12
miRNAs	O	12-18
)	O	18-19
represent	O	20-29
a	O	30-31
family	O	32-38
of	O	39-41
small	O	42-47
ribonucleic	O	48-59
acids	O	60-65
(	O	66-67
RNAs	O	67-71
)	O	71-72
that	O	73-77
are	O	78-81
post	O	82-86
-	O	86-87
transcriptional	O	87-102
regulators	O	103-113
of	O	114-116
messenger	O	117-126
RNA	O	127-130
(	O	131-132
mRNA	O	132-136
)	O	136-137
complexity	O	138-148
. 	O	148-150

An	O	0-2
NF	O	3-5
-	O	5-6
kappaB	O	6-12
-	O	12-13
containing	O	13-23
miRNA	B	24-29
-	I	29-30
146a	I	30-34
-	O	34-35
promoter	O	35-43
-	O	43-44
luciferase	O	44-54
reporter	O	55-63
construct	O	64-73
transfected	O	74-85
into	O	86-90
HN	O	91-93
cells	O	94-99
showed	O	100-106
significant	O	107-118
up	O	119-121
-	O	121-122
regulation	O	122-132
of	O	133-135
miRNA	B	136-141
-	I	141-142
146a	I	142-146
after	O	147-152
aluminum	O	153-161
-	O	161-162
sulfate	O	162-169
treatment	O	170-179
that	O	180-184
corresponded	O	185-197
to	O	198-200
decreased	O	201-210
CFH	O	211-214
gene	O	215-219
expression	O	220-230
. 	O	230-232

These	O	0-5
data	O	6-10
suggest	O	11-18
that	O	19-23
(	O	24-25
1	O	25-26
)	O	26-27
as	O	28-30
in	O	31-33
AD	O	34-36
brain	O	37-42
,	O	42-43
NF	O	44-46
-	O	46-47
kappaB	O	47-53
-	O	53-54
sensitive	O	54-63
,	O	63-64
miRNA	B	65-70
-	I	70-71
146a	I	71-75
-	O	75-76
mediated	O	76-84
,	O	84-85
modulation	O	86-96
of	O	97-99
CFH	O	100-103
gene	O	104-108
expression	O	109-119
may	O	120-123
contribute	O	124-134
to	O	135-137
inflammatory	O	138-150
responses	O	151-160
in	O	161-163
aluminum	O	164-172
-	O	172-173
stressed	O	173-181
HN	O	182-184
cells	O	185-190
,	O	190-191
and	O	192-195
(	O	196-197
2	O	197-198
)	O	198-199
underscores	O	200-211
the	O	212-215
potential	O	216-225
of	O	226-228
nanomolar	O	229-238
aluminum	O	239-247
to	O	248-250
drive	O	251-256
genotoxic	O	257-266
mechanisms	O	267-277
characteristic	O	278-292
of	O	293-295
neurodegenerative	O	296-313
disease	O	314-321
processes	O	322-331
.   	O	331-335

This	O	0-4
NF	O	5-7
-	O	7-8
kappaB	O	8-14
-	O	14-15
miRNA	B	15-20
-	I	20-21
146a	I	21-25
-	O	25-26
CFH	O	26-29
signaling	O	30-39
circuit	O	40-47
is	O	48-50
known	O	51-56
to	O	57-59
be	O	60-62
similarly	O	63-72
affected	O	73-81
by	O	82-84
Abeta42	O	85-92
peptides	O	93-101
and	O	102-105
in	O	106-108
AD	O	109-111
brain	O	112-117
. 	O	117-119

These	O	0-5
aluminum	O	6-14
-	O	14-15
sulfate	O	15-22
-	O	22-23
inducible	O	23-32
events	O	33-39
were	O	40-44
not	O	45-48
observed	O	49-57
in	O	58-60
parallel	O	61-69
experiments	O	70-81
using	O	82-87
iron	O	88-92
-	O	92-93
,	O	93-94
magnesium	O	95-104
-	O	104-105
,	O	105-106
or	O	107-109
zinc	O	110-114
-	O	114-115
sulfate	O	115-122
-	O	122-123
stressed	O	123-131
HN	O	132-134
cells	O	135-140
. 	O	140-142

Extensive	O	0-9
modulation	O	10-20
of	O	21-23
a	O	24-25
set	O	26-29
of	O	30-32
microRNAs	O	33-42
in	O	43-45
primary	O	46-53
glioblastoma	O	54-66
.  	O	66-69

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
short	O	23-28
non	O	29-32
-	O	32-33
coding	O	33-39
RNA	O	40-43
molecules	O	44-53
playing	O	54-61
regulatory	O	62-72
roles	O	73-78
in	O	79-81
animals	O	82-89
and	O	90-93
plants	O	94-100
by	O	101-103
repressing	O	104-114
translation	O	115-126
or	O	127-129
cleaving	O	130-138
RNA	O	139-142
transcripts	O	143-154
. 	O	154-156

The	O	0-3
specific	O	4-12
modulation	O	13-23
of	O	24-26
several	O	27-34
microRNAs	O	35-44
has	O	45-48
been	O	49-53
recently	O	54-62
associated	O	63-73
to	O	74-76
some	O	77-81
forms	O	82-87
of	O	88-90
human	O	91-96
cancer	O	97-103
,	O	103-104
suggesting	O	105-115
that	O	116-120
these	O	121-126
short	O	127-132
molecules	O	133-142
may	O	143-146
represent	O	147-156
a	O	157-158
new	O	159-162
class	O	163-168
of	O	169-171
genes	O	172-177
involved	O	178-186
in	O	187-189
oncogenesis	O	190-201
. 	O	201-203

In	O	0-2
our	O	3-6
study	O	7-12
,	O	12-13
we	O	14-16
examined	O	17-25
by	O	26-28
microarray	O	29-39
the	O	40-43
global	O	44-50
expression	O	51-61
levels	O	62-68
of	O	69-71
245	O	72-75
microRNAs	O	76-85
in	O	86-88
glioblastoma	O	89-101
multiforme	O	102-112
,	O	112-113
the	O	114-117
most	O	118-122
frequent	O	123-131
and	O	132-135
malignant	O	136-145
of	O	146-148
primary	O	149-156
brain	O	157-162
tumors	O	163-169
. 	O	169-171

The	O	0-3
analysis	O	4-12
of	O	13-15
both	O	16-20
glioblastoma	O	21-33
tissues	O	34-41
and	O	42-45
glioblastoma	O	46-58
cell	O	59-63
lines	O	64-69
allowed	O	70-77
us	O	78-80
to	O	81-83
identify	O	84-92
a	O	93-94
group	O	95-100
of	O	101-103
microRNAs	O	104-113
whose	O	114-119
expression	O	120-130
is	O	131-133
significantly	O	134-147
altered	O	148-155
in	O	156-158
this	O	159-163
tumor	O	164-169
. 	O	169-171

The	O	0-3
most	O	4-8
interesting	O	9-20
results	O	21-28
came	O	29-33
from	O	34-38
miR	B	39-42
-	I	42-43
221	I	43-46
,	O	46-47
strongly	O	48-56
up	O	57-59
-	O	59-60
regulated	O	60-69
in	O	70-72
glioblastoma	O	73-85
and	O	86-89
from	O	90-94
a	O	95-96
set	O	97-100
of	O	101-103
brain	O	104-109
-	O	109-110
enriched	O	110-118
miRNAs	O	119-125
,	O	125-126
miR	B	127-130
-	I	130-131
128	I	131-134
,	O	134-135
miR	B	136-139
-	I	139-140
181a	I	140-144
,	O	144-145
miR	B	146-149
-	I	149-150
181b	I	150-154
,	O	154-155
and	O	156-159
miR	B	160-163
-	I	163-164
181c	I	164-168
,	O	168-169
which	O	170-175
are	O	176-179
down	O	180-184
-	O	184-185
regulated	O	185-194
in	O	195-197
glioblastoma	O	198-210
.   	O	210-214

Pharmacologic	O	0-13
and	O	14-17
genetic	O	18-25
inhibition	O	26-36
of	O	37-39
p53	O	40-43
corroborated	O	44-56
the	O	57-60
hypothesis	O	61-71
that	O	72-76
pre	O	77-80
-	O	80-81
miR	B	81-84
-	I	84-85
630	I	85-88
(	O	89-90
but	O	90-93
not	O	94-97
pre	O	98-101
-	O	101-102
miR	B	102-105
-	I	105-106
181a	I	106-110
)	O	110-111
blocks	O	112-118
the	O	119-122
upstream	O	123-131
signaling	O	132-141
pathways	O	142-150
that	O	151-155
are	O	156-159
ignited	O	160-167
by	O	168-170
DNA	O	171-174
damage	O	175-181
and	O	182-185
converge	O	186-194
on	O	195-197
p53	O	198-201
activation	O	202-212
. 	O	212-214

Pre	O	0-3
-	O	3-4
miR	B	4-7
-	I	7-8
630	I	8-11
arrested	O	12-20
A549	O	21-25
cells	O	26-31
in	O	32-34
the	O	35-38
G0	O	39-41
-	O	41-42
G1	O	42-44
phase	O	45-50
of	O	51-53
the	O	54-57
cell	O	58-62
cycle	O	63-68
,	O	68-69
correlating	O	70-81
with	O	82-86
increased	O	87-96
levels	O	97-103
of	O	104-106
the	O	107-110
cell	O	111-115
cycle	O	116-121
inhibitor	O	122-131
p27	O	132-135
(	O	135-136
Kip1	O	136-140
)	O	140-141
as	O	142-144
well	O	145-149
as	O	150-152
with	O	153-157
reduced	O	158-165
proliferation	O	166-179
rates	O	180-185
and	O	186-189
resulting	O	190-199
in	O	200-202
greatly	O	203-210
diminished	O	211-221
sensitivity	O	222-233
of	O	234-236
A549	O	237-241
cells	O	242-247
to	O	248-250
the	O	251-254
late	O	255-259
S	O	260-261
-	O	261-262
G2	O	262-264
-	O	264-265
M	O	265-266
cell	O	267-271
cycle	O	272-277
arrest	O	278-284
mediated	O	285-293
by	O	294-296
CDDP	O	297-301
. 	O	301-303

Altogether	O	0-10
,	O	10-11
these	O	12-17
results	O	18-25
identify	O	26-34
miR	B	35-38
-	I	38-39
181a	I	39-43
and	O	44-47
miR	B	48-51
-	I	51-52
630	I	52-55
as	O	56-58
novel	O	59-64
modulators	O	65-75
of	O	76-78
the	O	79-82
CDDP	O	83-87
response	O	88-96
in	O	97-99
NSCLC	O	100-105
.   	O	105-109

The	O	0-3
corresponding	O	4-17
synthetic	O	18-27
miRNA	O	28-33
precursors	O	34-44
(	O	45-46
pre	O	46-49
-	O	49-50
miRNAs	O	50-56
)	O	56-57
per	O	58-61
se	O	62-64
were	O	65-69
not	O	70-73
lethal	O	74-80
when	O	81-85
transfected	O	86-97
into	O	98-102
A549	O	103-107
cells	O	108-113
yet	O	114-117
affected	O	118-126
cell	O	127-131
death	O	132-137
induction	O	138-147
by	O	148-150
CDDP	O	151-155
,	O	155-156
C2	O	157-159
-	O	159-160
ceramide	O	160-168
,	O	168-169
cadmium	O	170-177
,	O	177-178
etoposide	O	179-188
,	O	188-189
and	O	190-193
mitoxantrone	O	194-206
in	O	207-209
an	O	210-212
inducer	O	213-220
-	O	220-221
specific	O	221-229
fashion	O	230-237
. 	O	237-239

Whereas	O	0-7
synthetic	O	8-17
miRNA	O	18-23
inhibitors	O	24-34
(	O	35-36
anti	O	36-40
-	O	40-41
miRNAs	O	41-47
)	O	47-48
targeting	O	49-58
miR	B	59-62
-	I	62-63
181a	I	63-67
and	O	68-71
miR	B	72-75
-	I	75-76
630	I	76-79
failed	O	80-86
to	O	87-89
modulate	O	90-98
the	O	99-102
response	O	103-111
of	O	112-114
A549	O	115-119
to	O	120-122
CDDP	O	123-127
,	O	127-128
pre	O	129-132
-	O	132-133
miR	B	133-136
-	I	136-137
181a	I	137-141
and	O	142-145
pre	O	146-149
-	O	149-150
miR	B	150-153
-	I	153-154
630	I	154-157
enhanced	O	158-166
and	O	167-170
reduced	O	171-178
CDDP	O	179-183
-	O	183-184
triggered	O	184-193
cell	O	194-198
death	O	199-204
,	O	204-205
respectively	O	206-218
. 	O	218-220

Pre	O	0-3
-	O	3-4
miR	B	4-7
-	I	7-8
181a	I	8-12
and	O	13-16
pre	O	17-20
-	O	20-21
miR	B	21-24
-	I	24-25
630	I	25-28
consistently	O	29-41
modulated	O	42-51
mitochondrial	O	52-65
/	O	65-66
postmitochondrial	O	66-83
steps	O	84-89
of	O	90-92
the	O	93-96
intrinsic	O	97-106
pathway	O	107-114
of	O	115-117
apoptosis	O	118-127
,	O	127-128
including	O	129-138
Bax	O	139-142
oligomerization	O	143-158
,	O	158-159
mitochondrial	O	160-173
transmembrane	O	174-187
potential	O	188-197
dissipation	O	198-209
,	O	209-210
and	O	211-214
the	O	215-218
proteolytic	O	219-230
maturation	O	231-241
of	O	242-244
caspase	O	245-252
-	O	252-253
9	O	253-254
and	O	255-258
caspase	O	259-266
-	O	266-267
3	O	267-268
. 	O	268-270

In	O	0-2
addition	O	3-11
,	O	11-12
pre	O	13-16
-	O	16-17
miR	B	17-20
-	I	20-21
630	I	21-24
blocked	O	25-32
early	O	33-38
manifestations	O	39-53
of	O	54-56
the	O	57-60
DNA	O	61-64
damage	O	65-71
response	O	72-80
,	O	80-81
including	O	82-91
the	O	92-95
phosphorylation	O	96-111
of	O	112-114
the	O	115-118
ataxia	O	119-125
-	O	125-126
telangiectasia	O	126-140
mutated	O	141-148
(	O	149-150
ATM	O	150-153
)	O	153-154
kinase	O	155-161
and	O	162-165
of	O	166-168
two	O	169-172
ATM	O	173-176
substrates	O	177-187
,	O	187-188
histone	O	189-196
H2AX	O	197-201
and	O	202-205
p53	O	206-209
. 	O	209-211

miR	B	0-3
-	I	3-4
181a	I	4-8
and	O	9-12
miR	B	13-16
-	I	16-17
630	I	17-20
regulate	O	21-29
cisplatin	O	30-39
-	O	39-40
induced	O	40-47
cancer	O	48-54
cell	O	55-59
death	O	60-65
.  	O	65-68

MicroRNAs	O	0-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
are	O	18-21
noncoding	O	22-31
RNAs	O	32-36
that	O	37-41
regulate	O	42-50
multiple	O	51-59
cellular	O	60-68
processes	O	69-78
,	O	78-79
including	O	80-89
proliferation	O	90-103
and	O	104-107
apoptosis	O	108-117
. 	O	117-119

We	O	0-2
used	O	3-7
microarray	O	8-18
technology	O	19-29
to	O	30-32
identify	O	33-41
miRNAs	O	42-48
that	O	49-53
were	O	54-58
upregulated	O	59-70
by	O	71-73
non	O	74-77
-	O	77-78
small	O	78-83
cell	O	84-88
lung	O	89-93
cancer	O	94-100
(	O	101-102
NSCLC	O	102-107
)	O	107-108
A549	O	109-113
cells	O	114-119
in	O	120-122
response	O	123-131
to	O	132-134
cisplatin	O	135-144
(	O	145-146
CDDP	O	146-150
)	O	150-151
. 	O	151-153

Here	O	0-4
,	O	4-5
we	O	6-8
discuss	O	9-16
recent	O	17-23
data	O	24-28
that	O	29-33
support	O	34-41
a	O	42-43
view	O	44-48
that	O	49-53
endolysosomal	O	54-67
positioning	O	68-79
of	O	80-82
RNA	O	83-86
might	O	87-92
facilitate	O	93-103
intercellular	O	104-117
transmission	O	118-130
of	O	131-133
RNA	O	134-137
and	O	138-141
host	O	142-146
defence	O	147-154
against	O	155-162
viruses	O	163-170
and	O	171-174
retrotransposons	O	175-191
. 	O	191-193

Positioning	O	0-11
of	O	12-14
RNA	O	15-18
regulatory	O	19-29
mechanisms	O	30-40
on	O	41-43
endolysosomal	O	44-57
membranes	O	58-67
might	O	68-73
permit	O	74-80
rapid	O	81-86
and	O	87-90
localized	O	91-100
control	O	101-108
of	O	109-111
microRNA	O	112-120
(	O	121-122
miRNA	O	122-127
)	O	127-128
gene	O	129-133
regulatory	O	134-144
programs	O	145-153
and	O	154-157
mRNA	O	158-162
translation	O	163-174
in	O	175-177
response	O	178-186
to	O	187-189
environmental	O	190-203
signals	O	204-211
,	O	211-212
such	O	213-217
as	O	218-220
activated	O	221-230
plasma	O	231-237
membrane	O	238-246
receptors	O	247-256
transported	O	257-268
on	O	269-271
endosomes	O	272-281
. 	O	281-283

Finally	O	0-7
,	O	7-8
we	O	9-11
suggest	O	12-19
that	O	20-24
the	O	25-28
pathology	O	29-38
of	O	39-41
several	O	42-49
conditions	O	50-60
,	O	60-61
including	O	62-71
Huntington	O	72-82
'	O	82-83
s	O	83-84
disease	O	85-92
,	O	92-93
might	O	94-99
be	O	100-102
a	O	103-104
consequence	O	105-116
of	O	117-119
the	O	120-123
disruption	O	124-134
of	O	135-137
the	O	138-141
control	O	142-149
of	O	150-152
RNA	O	153-156
via	O	157-160
endolysosomal	O	161-174
membranes	O	175-184
.   	O	184-188

Control	O	0-7
of	O	8-10
RNA	O	11-14
silencing	O	15-24
and	O	25-28
localization	O	29-41
by	O	42-44
endolysosomes	O	45-58
.  	O	58-61

Recent	O	0-6
advances	O	7-15
in	O	16-18
the	O	19-22
cell	O	23-27
biology	O	28-35
of	O	36-38
RNA	O	39-42
silencing	O	43-52
have	O	53-57
unraveled	O	58-67
an	O	68-70
intriguing	O	71-81
association	O	82-93
of	O	94-96
post	O	97-101
-	O	101-102
transcriptionally	O	102-119
regulated	O	120-129
RNA	O	130-133
with	O	134-138
endolysosomal	O	139-152
membranes	O	153-162
in	O	163-165
several	O	166-173
circumstances	O	174-187
of	O	188-190
mRNA	O	191-195
localization	O	196-208
,	O	208-209
microRNA	O	210-218
activity	O	219-227
and	O	228-231
viral	O	232-237
RNA	O	238-241
transport	O	242-251
and	O	252-255
packaging	O	256-265
. 	O	265-267

Endolysosomal	O	0-13
membranes	O	14-23
are	O	24-27
a	O	28-29
nexus	O	30-35
of	O	36-38
communication	O	39-52
and	O	53-56
transport	O	57-66
between	O	67-74
cells	O	75-80
and	O	81-84
their	O	85-90
exterior	O	91-99
environment	O	100-111
for	O	112-115
signaling	O	116-125
receptors	O	126-135
,	O	135-136
pathogens	O	137-146
and	O	147-150
nutrients	O	151-160
. 	O	160-162

A	O	0-1
specific	O	2-10
subset	O	11-17
of	O	18-20
five	O	21-25
miRNAs	O	26-32
revealed	O	33-41
by	O	42-44
in	O	45-47
silico	O	48-54
target	O	55-61
prediction	O	62-72
was	O	73-76
significantly	O	77-90
overexpressed	O	91-104
in	O	105-107
NFA	O	108-111
samples	O	112-119
;	O	119-120
three	O	121-126
miRs	O	127-131
(	O	132-133
miR	B	133-136
-	I	136-137
128a	I	137-141
,	O	141-142
miR	B	143-146
-	I	146-147
155	I	147-150
,	O	150-151
and	O	152-155
miR	B	156-159
-	I	159-160
516a	I	160-164
-	I	164-165
3p	I	165-167
)	O	167-168
targeted	O	169-177
the	O	178-181
3	O	182-183
'	O	183-184
-	O	184-185
untranslated	O	185-197
region	O	198-204
of	O	205-207
the	O	208-211
Wee1	O	212-216
transcript	O	217-227
,	O	227-228
and	O	229-232
exogenous	O	233-242
overexpression	O	243-257
of	O	258-260
these	O	261-266
miRs	O	267-271
inhibited	O	272-281
Wee1	O	282-286
protein	O	287-294
expression	O	295-305
and	O	306-309
HeLa	O	310-314
cell	O	315-319
proliferation	O	320-333
. 	O	333-335

RESULTS	O	0-7
:	O	7-8
Wee1	O	9-13
protein	O	14-21
expression	O	22-32
was	O	33-36
decreased	O	37-46
in	O	47-49
NFAs	O	50-54
and	O	55-58
GH	O	59-61
-	O	61-62
producing	O	62-71
tumors	O	72-78
with	O	79-83
or	O	84-86
without	O	87-94
prolactin	O	95-104
production	O	105-115
,	O	115-116
but	O	117-120
no	O	121-123
change	O	124-130
in	O	131-133
mRNA	O	134-138
expression	O	139-149
was	O	150-153
observed	O	154-162
with	O	163-167
qRT	O	168-171
-	O	171-172
PCR	O	172-175
. 	O	175-177

CONCLUSIONS	O	0-11
:	O	11-12
To	O	13-15
our	O	16-19
knowledge	O	20-29
,	O	29-30
this	O	31-35
is	O	36-38
the	O	39-42
first	O	43-48
report	O	49-55
suggesting	O	56-66
that	O	67-71
regulation	O	72-82
of	O	83-85
Wee1	O	86-90
kinase	O	91-97
by	O	98-100
miRs	O	101-105
may	O	106-109
be	O	110-112
linked	O	113-119
to	O	120-122
pituitary	O	123-132
tumorigenesis	O	133-146
.   	O	146-150

CONTEXT	O	0-7
:	O	7-8
The	O	9-12
tumorigenic	O	13-24
mechanisms	O	25-35
involved	O	36-44
in	O	45-47
pituitary	O	48-57
adenomas	O	58-66
,	O	66-67
especially	O	68-78
of	O	79-81
nonfunctional	O	82-95
pituitary	O	96-105
adenomas	O	106-114
(	O	115-116
NFAs	O	116-120
)	O	120-121
,	O	121-122
remains	O	123-130
unclear	O	131-138
. 	O	138-140

Down	O	0-4
-	O	4-5
regulation	O	5-15
of	O	16-18
Wee1	O	19-23
kinase	O	24-30
by	O	31-33
a	O	34-35
specific	O	36-44
subset	O	45-51
of	O	52-54
microRNA	O	55-63
in	O	64-66
human	O	67-72
sporadic	O	73-81
pituitary	O	82-91
adenomas	O	92-100
.  	O	100-103

OBJECTIVE	O	0-9
:	O	9-10
Our	O	11-14
objective	O	15-24
was	O	25-28
to	O	29-31
examine	O	32-39
the	O	40-43
expression	O	44-54
of	O	55-57
Wee1	O	58-62
in	O	63-65
pituitary	O	66-75
tumors	O	76-82
and	O	83-86
to	O	87-89
identify	O	90-98
microRNAs	O	99-108
(	O	109-110
miRs	O	110-114
)	O	114-115
that	O	116-120
can	O	121-124
regulate	O	125-133
its	O	134-137
expression	O	138-148
. 	O	148-150

Various	O	0-7
cell	O	8-12
cycle	O	13-18
inhibitors	O	19-29
have	O	30-34
been	O	35-39
found	O	40-45
to	O	46-48
be	O	49-51
underexpressed	O	52-66
in	O	67-69
pituitary	O	70-79
tumors	O	80-86
;	O	86-87
however	O	88-95
,	O	95-96
Wee1	O	97-101
kinase	O	102-108
,	O	108-109
a	O	110-111
nuclear	O	112-119
protein	O	120-127
that	O	128-132
delays	O	133-139
mitosis	O	140-147
and	O	148-151
was	O	152-155
recently	O	156-164
recognized	O	165-175
as	O	176-178
a	O	179-180
tumor	O	181-186
suppressor	O	187-197
gene	O	198-202
,	O	202-203
has	O	204-207
not	O	208-211
been	O	212-216
previously	O	217-227
investigated	O	228-240
in	O	241-243
pituitary	O	244-253
tumors	O	254-260
. 	O	260-262

Identification	O	0-14
of	O	15-17
miRs	O	18-22
targeting	O	23-32
the	O	33-36
Wee1	O	37-41
3	O	42-43
'	O	43-44
-	O	44-45
untranslated	O	45-57
region	O	58-64
was	O	65-68
performed	O	69-78
by	O	79-81
miR	O	82-85
array	O	86-91
followed	O	92-100
by	O	101-103
expression	O	104-114
analysis	O	115-123
of	O	124-126
identified	O	127-137
miRs	O	138-142
using	O	143-148
qRT	O	149-152
-	O	152-153
PCR	O	153-156
. 	O	156-158

DESIGN	O	0-6
:	O	6-7
Expression	O	8-18
of	O	19-21
Wee1	O	22-26
was	O	27-30
examined	O	31-39
by	O	40-42
immunohistochemistry	O	43-63
and	O	64-67
quantitative	O	68-80
real	O	81-85
-	O	85-86
time	O	86-90
PCR	O	91-94
(	O	95-96
qRT	O	96-99
-	O	99-100
PCR	O	100-103
)	O	103-104
. 	O	104-106

PATIENTS	O	0-8
:	O	8-9
A	O	10-11
total	O	12-17
of	O	18-20
57	O	21-23
pituitary	O	24-33
tissue	O	34-40
samples	O	41-48
including	O	49-58
27	O	59-61
NFAs	O	62-66
,	O	66-67
15	O	68-70
GH	O	71-73
-	O	73-74
producing	O	74-83
adenomas	O	84-92
with	O	93-97
or	O	98-100
without	O	101-108
prolactin	O	109-118
overproduction	O	119-133
,	O	133-134
and	O	135-138
15	O	139-141
normal	O	142-148
pituitary	O	149-158
glands	O	159-165
were	O	166-170
analyzed	O	171-179
. 	O	179-181

Dual	O	0-4
-	O	4-5
luciferase	O	5-15
assay	O	16-21
and	O	22-25
transient	O	26-35
transfection	O	36-48
of	O	49-51
miRs	O	52-56
into	O	57-61
Hela	O	62-66
cells	O	67-72
followed	O	73-81
by	O	82-84
immunoblot	O	85-95
analysis	O	96-104
of	O	105-107
Wee1	O	108-112
protein	O	113-120
and	O	121-124
cell	O	125-129
proliferation	O	130-143
analysis	O	144-152
were	O	153-157
carried	O	158-165
out	O	166-169
. 	O	169-171

Although	O	0-8
microRNAs	O	9-18
are	O	19-22
being	O	23-28
extensively	O	29-40
studied	O	41-48
for	O	49-52
their	O	53-58
involvement	O	59-70
in	O	71-73
cancer	O	74-80
and	O	81-84
development	O	85-96
,	O	96-97
little	O	98-104
is	O	105-107
known	O	108-113
about	O	114-119
their	O	120-125
roles	O	126-131
in	O	132-134
Alzheimer	O	135-144
'	O	144-145
s	O	145-146
disease	O	147-154
(	O	155-156
AD	O	156-158
)	O	158-159
. 	O	159-161

Joint	O	0-5
genome	O	6-12
-	O	12-13
wide	O	13-17
profiling	O	18-27
of	O	28-30
miRNA	O	31-36
and	O	37-40
mRNA	O	41-45
expression	O	46-56
in	O	57-59
Alzheimer	O	60-69
'	O	69-70
s	O	70-71
disease	O	72-79
cortex	O	80-86
reveals	O	87-94
altered	O	95-102
miRNA	O	103-108
regulation	O	109-119
.  	O	119-122

These	O	0-5
data	O	6-10
provided	O	11-19
the	O	20-23
unique	O	24-30
opportunity	O	31-42
to	O	43-45
study	O	46-51
the	O	52-55
relationship	O	56-68
between	O	69-76
miRNA	O	77-82
and	O	83-86
mRNA	O	87-91
expression	O	92-102
in	O	103-105
normal	O	106-112
and	O	113-116
AD	O	117-119
brains	O	120-126
. 	O	126-128

In	O	0-2
this	O	3-7
study	O	8-13
,	O	13-14
we	O	15-17
used	O	18-22
microarrays	O	23-34
for	O	35-38
the	O	39-42
first	O	43-48
joint	O	49-54
profiling	O	55-64
and	O	65-68
analysis	O	69-77
of	O	78-80
miRNAs	O	81-87
and	O	88-91
mRNAs	O	92-97
expression	O	98-108
in	O	109-111
brain	O	112-117
cortex	O	118-124
from	O	125-129
AD	O	130-132
and	O	133-136
age	O	137-140
-	O	140-141
matched	O	141-148
control	O	149-156
subjects	O	157-165
. 	O	165-167

Comparative	O	0-11
analysis	O	12-20
with	O	21-25
independent	O	26-37
cancer	O	38-44
datasets	O	45-53
showed	O	54-60
that	O	61-65
such	O	66-70
miRNA	O	71-76
-	O	76-77
mRNA	O	77-81
expression	O	82-92
correlations	O	93-105
are	O	106-109
not	O	110-113
static	O	114-120
,	O	120-121
but	O	122-125
rather	O	126-132
context	O	133-140
-	O	140-141
dependent	O	141-150
. 	O	150-152

Using	O	0-5
a	O	6-7
non	O	8-11
-	O	11-12
parametric	O	12-22
analysis	O	23-31
,	O	31-32
we	O	33-35
showed	O	36-42
that	O	43-47
the	O	48-51
levels	O	52-58
of	O	59-61
many	O	62-66
miRNAs	O	67-73
can	O	74-77
be	O	78-80
either	O	81-87
positively	O	88-98
or	O	99-101
negatively	O	102-112
correlated	O	113-123
with	O	124-128
those	O	129-134
of	O	135-137
their	O	138-143
target	O	144-150
mRNAs	O	151-156
. 	O	156-158

Our	O	0-3
results	O	4-11
demonstrate	O	12-23
a	O	24-25
robust	O	26-32
relationship	O	33-45
between	O	46-53
the	O	54-57
levels	O	58-64
of	O	65-67
miRNAs	O	68-74
and	O	75-78
those	O	79-84
of	O	85-87
their	O	88-93
targets	O	94-101
in	O	102-104
the	O	105-108
brain	O	109-114
. 	O	114-116

Subsequently	O	0-12
,	O	12-13
we	O	14-16
identified	O	17-27
a	O	28-29
large	O	30-35
set	O	36-39
of	O	40-42
miRNA	O	43-48
-	O	48-49
mRNA	O	49-53
associations	O	54-66
that	O	67-71
are	O	72-75
changed	O	76-83
in	O	84-86
AD	O	87-89
versus	O	90-96
control	O	97-104
,	O	104-105
highlighting	O	106-118
AD	O	119-121
-	O	121-122
specific	O	122-130
changes	O	131-138
in	O	139-141
the	O	142-145
miRNA	O	146-151
regulatory	O	152-162
system	O	163-169
. 	O	169-171

This	O	0-4
has	O	5-8
implications	O	9-21
in	O	22-24
the	O	25-28
study	O	29-34
of	O	35-37
the	O	38-41
molecular	O	42-51
pathology	O	52-61
of	O	62-64
AD	O	65-67
,	O	67-68
as	O	69-71
well	O	72-76
as	O	77-79
miRNA	O	80-85
biology	O	86-93
in	O	94-96
general	O	97-104
.   	O	104-108

In	O	0-2
this	O	3-7
review	O	8-14
article	O	15-22
,	O	22-23
the	O	24-27
molecular	O	28-37
mechanisms	O	38-48
underlying	O	49-59
the	O	60-63
role	O	64-68
and	O	69-72
function	O	73-81
of	O	82-84
miRNAs	O	85-91
in	O	92-94
the	O	95-98
regulation	O	99-109
of	O	110-112
genes	O	113-118
involved	O	119-127
in	O	128-130
neurological	O	131-143
and	O	144-147
neurodegenerative	O	148-165
diseases	O	166-174
will	O	175-179
be	O	180-182
discussed	O	183-192
,	O	192-193
with	O	194-198
a	O	199-200
focus	O	201-206
on	O	207-209
the	O	210-213
fragile	O	214-221
X	O	222-223
syndrome	O	224-232
,	O	232-233
Alzheimer	O	234-243
'	O	243-244
s	O	244-245
disease	O	246-253
(	O	254-255
AD	O	255-257
)	O	257-258
and	O	259-262
prion	O	263-268
disease	O	269-276
.   	O	276-280

Likely	O	0-6
to	O	7-9
play	O	10-14
a	O	15-16
central	O	17-24
role	O	25-29
in	O	30-32
health	O	33-39
and	O	40-43
disease	O	44-51
,	O	51-52
a	O	53-54
dysfunctional	O	55-68
miRNA	O	69-74
-	O	74-75
based	O	75-80
regulation	O	81-91
of	O	92-94
gene	O	95-99
expression	O	100-110
may	O	111-114
represent	O	115-124
the	O	125-128
main	O	129-133
etiologic	O	134-143
factor	O	144-150
underlying	O	151-161
diseases	O	162-170
affecting	O	171-180
major	O	181-186
organs	O	187-193
,	O	193-194
such	O	195-199
as	O	200-202
the	O	203-206
brain	O	207-212
. 	O	212-214

MicroRNAs	O	0-9
as	O	10-12
a	O	13-14
molecular	O	15-24
basis	O	25-30
for	O	31-34
mental	O	35-41
retardation	O	42-53
,	O	53-54
Alzheimer	O	55-64
'	O	64-65
s	O	65-66
and	O	67-70
prion	O	71-76
diseases	O	77-85
.  	O	85-88

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
,	O	28-29
approximately	O	30-43
21	O	44-46
-	O	46-47
to	O	48-50
23	O	51-53
-	O	53-54
nucleotide	O	54-64
(	O	65-66
nt	O	66-68
)	O	68-69
non	O	70-73
-	O	73-74
coding	O	74-80
RNA	O	81-84
species	O	85-92
that	O	93-97
act	O	98-101
as	O	102-104
key	O	105-108
regulators	O	109-119
of	O	120-122
gene	O	123-127
expression	O	128-138
along	O	139-144
a	O	145-146
central	O	147-154
and	O	155-158
well	O	159-163
-	O	163-164
defined	O	164-171
cellular	O	172-180
process	O	181-188
known	O	189-194
as	O	195-197
RNA	O	198-201
silencing	O	202-211
,	O	211-212
and	O	213-216
involving	O	217-226
the	O	227-230
recognition	O	231-242
and	O	243-246
translational	O	247-260
control	O	261-268
of	O	269-271
specific	O	272-280
messenger	O	281-290
RNA	O	291-294
(	O	295-296
mRNAs	O	296-301
)	O	301-302
. 	O	302-304

Generated	O	0-9
through	O	10-17
the	O	18-21
well	O	22-26
-	O	26-27
orchestrated	O	27-39
and	O	40-43
sequential	O	44-54
processing	O	55-65
of	O	66-68
miRNA	O	69-74
precursor	O	75-84
molecules	O	85-94
,	O	94-95
mature	O	96-102
miRNAs	O	103-109
are	O	110-113
subsequently	O	114-126
incorporated	O	127-139
into	O	140-144
miRNA	O	145-150
-	O	150-151
containing	O	151-161
ribonucleoprotein	O	162-179
effector	O	180-188
complexes	O	189-198
to	O	199-201
regulate	O	202-210
mRNA	O	211-215
translation	O	216-227
through	O	228-235
the	O	236-239
recognition	O	240-251
of	O	252-254
specific	O	255-263
binding	O	264-271
sites	O	272-277
of	O	278-280
imperfect	O	281-290
complementarity	O	291-306
located	O	307-314
mainly	O	315-321
in	O	322-324
the	O	325-328
3	O	329-330
'	O	330-331
untranslated	O	332-344
region	O	345-351
. 	O	351-353

Predicted	O	0-9
to	O	10-12
regulate	O	13-21
up	O	22-24
to	O	25-27
90	O	28-30
%	O	30-31
of	O	32-34
the	O	35-38
genes	O	39-44
in	O	45-47
humans	O	48-54
,	O	54-55
miRNAs	O	56-62
may	O	63-66
thus	O	67-71
control	O	72-79
cellular	O	80-88
processes	O	89-98
in	O	99-101
all	O	102-105
cells	O	106-111
and	O	112-115
tissues	O	116-123
of	O	124-126
the	O	127-130
human	O	131-136
body	O	137-141
. 	O	141-143

Phosphodiesterase	O	0-17
-	O	17-18
4D	O	18-20
knock	O	21-26
-	O	26-27
out	O	27-30
and	O	31-34
RNA	O	35-38
interference	O	39-51
-	O	51-52
mediated	O	52-60
knock	O	61-66
-	O	66-67
down	O	67-71
enhance	O	72-79
memory	O	80-86
and	O	87-90
increase	O	91-99
hippocampal	O	100-111
neurogenesis	O	112-124
via	O	125-128
increased	O	129-138
cAMP	O	139-143
signaling	O	144-153
.  	O	153-156

Phosphodiesterase	O	0-17
-	O	17-18
4	O	18-19
(	O	20-21
PDE4	O	21-25
)	O	25-26
plays	O	27-32
an	O	33-35
important	O	36-45
role	O	46-50
in	O	51-53
mediating	O	54-63
memory	O	64-70
via	O	71-74
the	O	75-78
control	O	79-86
of	O	87-89
intracellular	O	90-103
cAMP	O	104-108
signaling	O	109-118
;	O	118-119
inhibition	O	120-130
of	O	131-133
PDE4	O	134-138
enhances	O	139-147
memory	O	148-154
. 	O	154-156

However	O	0-7
,	O	7-8
development	O	9-20
of	O	21-23
PDE4	O	24-28
inhibitors	O	29-39
as	O	40-42
memory	O	43-49
enhancers	O	50-59
has	O	60-63
been	O	64-68
hampered	O	69-77
by	O	78-80
their	O	81-86
major	O	87-92
side	O	93-97
effect	O	98-104
of	O	105-107
emesis	O	108-114
. 	O	114-116

PDE4	O	0-4
has	O	5-8
four	O	9-13
subtypes	O	14-22
(	O	23-24
PDE4A	O	24-29
-	O	29-30
D	O	30-31
)	O	31-32
consisting	O	33-43
of	O	44-46
25	O	47-49
splice	O	50-56
variants	O	57-65
. 	O	65-67

Mice	O	0-4
deficient	O	5-14
in	O	15-17
PDE4D	O	18-23
displayed	O	24-33
memory	O	34-40
enhancement	O	41-52
in	O	53-55
radial	O	56-62
arm	O	63-66
maze	O	67-71
,	O	71-72
water	O	73-78
maze	O	79-83
,	O	83-84
and	O	85-88
object	O	89-95
recognition	O	96-107
tests	O	108-113
. 	O	113-115

These	O	0-5
effects	O	6-13
were	O	14-18
mimicked	O	19-27
by	O	28-30
repeated	O	31-39
treatment	O	40-49
with	O	50-54
rolipram	O	55-63
in	O	64-66
wild	O	67-71
-	O	71-72
type	O	72-76
mice	O	77-81
. 	O	81-83

In	O	0-2
addition	O	3-11
,	O	11-12
similarly	O	13-22
as	O	23-25
rolipram	O	26-34
-	O	34-35
treated	O	35-42
wild	O	43-47
-	O	47-48
type	O	48-52
mice	O	53-57
,	O	57-58
PDE4D	O	59-64
-	O	64-65
deficient	O	65-74
mice	O	75-79
also	O	80-84
displayed	O	85-94
increased	O	95-104
hippocampal	O	105-116
neurogenesis	O	117-129
and	O	130-133
phosphorylated	O	134-148
cAMP	O	149-153
response	O	154-162
element	O	163-170
-	O	170-171
binding	O	171-178
protein	O	179-186
(	O	187-188
pCREB	O	188-193
)	O	193-194
. 	O	194-196

Furthermore	O	0-11
,	O	11-12
microinfusion	O	13-26
of	O	27-29
lentiviral	O	30-40
vectors	O	41-48
that	O	49-53
contained	O	54-63
microRNAs	O	64-73
(	O	74-75
miRNAs	O	75-81
)	O	81-82
targeting	O	83-92
long	O	93-97
-	O	97-98
form	O	98-102
PDE4D	O	103-108
isoforms	O	109-117
into	O	118-122
bilateral	O	123-132
dentate	O	133-140
gyri	O	141-145
of	O	146-148
the	O	149-152
mouse	O	153-158
hippocampus	O	159-170
downregulated	O	171-184
PDE4D4	O	185-191
and	O	192-195
PDE4D5	O	196-202
,	O	202-203
enhanced	O	204-212
memory	O	213-219
,	O	219-220
and	O	221-224
increased	O	225-234
hippocampal	O	235-246
neurogenesis	O	247-259
and	O	260-263
pCREB	O	264-269
. 	O	269-271

Finally	O	0-7
,	O	7-8
while	O	9-14
rolipram	O	15-23
and	O	24-27
PDE4D	O	28-33
deficiency	O	34-44
shortened	O	45-54
α2	O	55-57
adrenergic	O	58-68
receptor	O	69-77
-	O	77-78
mediated	O	78-86
anesthesia	O	87-97
,	O	97-98
a	O	99-100
surrogate	O	101-110
measure	O	111-118
of	O	119-121
emesis	O	122-128
,	O	128-129
miRNA	O	130-135
-	O	135-136
mediated	O	136-144
PDE4D	O	145-150
knock	O	151-156
-	O	156-157
down	O	157-161
in	O	162-164
the	O	165-168
hippocampus	O	169-180
did	O	181-184
not	O	185-188
. 	O	188-190

The	O	0-3
present	O	4-11
results	O	12-19
suggest	O	20-27
that	O	28-32
PDE4D	O	33-38
,	O	38-39
in	O	40-42
particular	O	43-53
long	O	54-58
-	O	58-59
form	O	59-63
PDE4D	O	64-69
,	O	69-70
plays	O	71-76
a	O	77-78
critical	O	79-87
role	O	88-92
in	O	93-95
the	O	96-99
mediation	O	100-109
of	O	110-112
memory	O	113-119
and	O	120-123
hippocampal	O	124-135
neurogenesis	O	136-148
,	O	148-149
which	O	150-155
are	O	156-159
mediated	O	160-168
by	O	169-171
cAMP	O	172-176
/	O	176-177
CREB	O	177-181
signaling	O	182-191
;	O	191-192
reduced	O	193-200
expression	O	201-211
of	O	212-214
PDE4D	O	215-220
,	O	220-221
or	O	222-224
at	O	225-227
least	O	228-233
PDE4D4	O	234-240
and	O	241-244
PDE4D5	O	245-251
,	O	251-252
in	O	253-255
the	O	256-259
hippocampus	O	260-271
enhances	O	272-280
memory	O	281-287
but	O	288-291
appears	O	292-299
not	O	300-303
to	O	304-306
cause	O	307-312
emesis	O	313-319
. 	O	319-321

These	O	0-5
novel	O	6-11
findings	O	12-20
will	O	21-25
aid	O	26-29
in	O	30-32
the	O	33-36
development	O	37-48
of	O	49-51
PDE4	O	52-56
subtype	O	57-64
-	O	64-65
or	O	66-68
variant	O	69-76
-	O	76-77
selective	O	77-86
inhibitors	O	87-97
for	O	98-101
treatment	O	102-111
of	O	112-114
disorders	O	115-124
involving	O	125-134
impaired	O	135-143
cognition	O	144-153
,	O	153-154
including	O	155-164
Alzheimer	O	165-174
'	O	174-175
s	O	175-176
disease	O	177-184
.   	O	184-188

High	O	0-4
levels	O	5-11
of	O	12-14
high	O	15-19
-	O	19-20
mobility	O	20-28
group	O	29-34
A2	O	35-37
expression	O	38-48
also	O	49-53
significantly	O	54-67
correlated	O	68-78
with	O	79-83
the	O	84-87
proliferation	O	88-101
marker	O	102-108
Ki	O	109-111
-	O	111-112
67	O	112-114
(	O	115-116
P	O	116-117
<	O	117-118
0	O	118-119
.	O	119-120
0001	O	120-124
)	O	124-125
. 	O	125-127

High	O	0-4
levels	O	5-11
of	O	12-14
high	O	15-19
-	O	19-20
mobility	O	20-28
group	O	29-34
A2	O	35-37
expression	O	38-48
were	O	49-53
more	O	54-58
frequently	O	59-69
observed	O	70-78
in	O	79-81
macroadenomas	O	82-95
than	O	96-100
in	O	101-103
microadenomas	O	104-117
(	O	118-119
P	O	119-120
<	O	120-121
0	O	121-122
.	O	122-123
05	O	123-125
)	O	125-126
. 	O	126-128

Overexpression	O	0-14
of	O	15-17
high	O	18-22
-	O	22-23
mobility	O	23-31
group	O	32-37
A2	O	38-40
was	O	41-44
observed	O	45-53
in	O	54-56
39	O	57-59
%	O	59-60
(	O	61-62
38	O	62-64
/	O	64-65
98	O	65-67
)	O	67-68
of	O	69-71
pituitary	O	72-81
adenomas	O	82-90
compared	O	91-99
with	O	100-104
normal	O	105-111
adenohypophysial	O	112-128
tissue	O	129-135
and	O	136-139
was	O	140-143
frequently	O	144-154
found	O	155-160
in	O	161-163
adenomas	O	164-172
including	O	173-182
prolactin	O	183-192
(	O	193-194
PRL	O	194-197
)	O	197-198
,	O	198-199
adrenocorticotrophic	O	200-220
hormone	O	221-228
,	O	228-229
or	O	230-232
follicle	O	233-241
-	O	241-242
stimulating	O	242-253
hormone	O	254-261
/	O	261-262
luteinizing	O	262-273
hormone	O	274-281
and	O	282-285
in	O	286-288
null	O	289-293
cell	O	294-298
adenomas	O	299-307
,	O	307-308
but	O	309-312
relatively	O	313-323
rare	O	324-328
in	O	329-331
growth	O	332-338
hormone	O	339-346
(	O	347-348
GH	O	348-350
)	O	350-351
and	O	352-355
mixed	O	356-361
GH	O	362-364
/	O	364-365
PRL	O	365-368
adenomas	O	369-377
. 	O	377-379

High	O	0-4
-	O	4-5
mobility	O	5-13
group	O	14-19
A2	O	20-22
expression	O	23-33
was	O	34-37
significantly	O	38-51
associated	O	52-62
with	O	63-67
tumor	O	68-73
invasion	O	74-82
(	O	83-84
P	O	84-85
<	O	85-86
0	O	86-87
.	O	87-88
05	O	88-90
)	O	90-91
and	O	92-95
was	O	96-99
significantly	O	100-113
higher	O	114-120
in	O	121-123
grade	O	124-129
IV	O	130-132
than	O	133-137
in	O	138-140
grades	O	141-147
I	O	148-149
,	O	149-150
II	O	151-153
,	O	153-154
and	O	155-158
III	O	159-162
adenomas	O	163-171
(	O	172-173
P	O	173-174
<	O	174-175
0	O	175-176
.	O	176-177
05	O	177-179
)	O	179-180
. 	O	180-182

However	O	0-7
,	O	7-8
no	O	9-11
studies	O	12-19
have	O	20-24
investigated	O	25-37
the	O	38-41
clinical	O	42-50
significance	O	51-63
of	O	64-66
high	O	67-71
-	O	71-72
mobility	O	72-80
group	O	81-86
A2	O	87-89
and	O	90-93
its	O	94-97
relationship	O	98-110
to	O	111-113
the	O	114-117
let	B	118-121
-	I	121-122
7	I	122-123
miRNA	O	124-129
family	O	130-136
in	O	137-139
human	O	140-145
pituitary	O	146-155
adenomas	O	156-164
. 	O	164-166

Using	O	0-5
immunohistochemistry	O	6-26
,	O	26-27
we	O	28-30
analyzed	O	31-39
high	O	40-44
-	O	44-45
mobility	O	45-53
group	O	54-59
A2	O	60-62
expression	O	63-73
with	O	74-78
respect	O	79-86
to	O	87-89
various	O	90-97
clinicopathologic	O	98-115
factors	O	116-123
in	O	124-126
98	O	127-129
pituitary	O	130-139
adenomas	O	140-148
. 	O	148-150

Recent	O	0-6
studies	O	7-14
report	O	15-21
that	O	22-26
high	O	27-31
-	O	31-32
mobility	O	32-40
group	O	41-46
A2	O	47-49
is	O	50-52
negatively	O	53-63
regulated	O	64-73
by	O	74-76
the	O	77-80
let	B	81-84
-	I	84-85
7	I	85-86
microRNAs	O	87-96
(	O	97-98
miRNAs	O	98-104
)	O	104-105
family	O	106-112
in	O	113-115
vitro	O	116-121
. 	O	121-123

The	O	0-3
development	O	4-15
of	O	16-18
pituitary	O	19-28
adenomas	O	29-37
in	O	38-40
high	O	41-45
-	O	45-46
mobility	O	46-54
group	O	55-60
A2	O	61-63
transgenic	O	64-74
mice	O	75-79
showed	O	80-86
that	O	87-91
high	O	92-96
-	O	96-97
mobility	O	97-105
group	O	106-111
A2	O	112-114
may	O	115-118
be	O	119-121
involved	O	122-130
in	O	131-133
pituitary	O	134-143
tumorigenesis	O	144-157
. 	O	157-159

Overexpression	O	0-14
of	O	15-17
HMGA2	O	18-23
relates	O	24-31
to	O	32-34
reduction	O	35-44
of	O	45-47
the	O	48-51
let	B	52-55
-	I	55-56
7	I	56-57
and	O	58-61
its	O	62-65
relationship	O	66-78
to	O	79-81
clinicopathological	O	82-101
features	O	102-110
in	O	111-113
pituitary	O	114-123
adenomas	O	124-132
.  	O	132-135

High	O	0-4
-	O	4-5
mobility	O	5-13
group	O	14-19
A2	O	20-22
is	O	23-25
highly	O	26-32
expressed	O	33-42
during	O	43-49
embryogenesis	O	50-63
and	O	64-67
in	O	68-70
various	O	71-78
benign	O	79-85
and	O	86-89
malignant	O	90-99
tumors	O	100-106
. 	O	106-108

Real	O	0-4
-	O	4-5
time	O	5-9
quantitative	O	10-22
RT	O	23-25
-	O	25-26
PCR	O	26-29
analysis	O	30-38
was	O	39-42
carried	O	43-50
out	O	51-54
to	O	55-57
evaluate	O	58-66
the	O	67-70
expression	O	71-81
of	O	82-84
let	B	85-88
-	I	88-89
7	I	89-90
in	O	91-93
55	O	94-96
pituitary	O	97-106
adenomas	O	107-115
. 	O	115-117

Subsequently	O	0-12
,	O	12-13
decreased	O	14-23
expression	O	24-34
of	O	35-37
let	B	38-41
-	I	41-42
7	I	42-43
was	O	44-47
confirmed	O	48-57
in	O	58-60
23	O	61-63
of	O	64-66
55	O	67-69
(	O	70-71
42	O	71-73
%	O	73-74
)	O	74-75
adenomas	O	76-84
and	O	85-88
was	O	89-92
correlated	O	93-103
with	O	104-108
high	O	109-113
-	O	113-114
grade	O	114-119
tumors	O	120-126
(	O	127-128
P	O	128-129
<	O	129-130
0	O	130-131
.	O	131-132
05	O	132-134
)	O	134-135
. 	O	135-137

An	O	0-2
inverse	O	3-10
correlation	O	11-22
between	O	23-30
let	B	31-34
-	I	34-35
7	I	35-36
and	O	37-40
high	O	41-45
-	O	45-46
mobility	O	46-54
group	O	55-60
A2	O	61-63
expression	O	64-74
was	O	75-78
evident	O	79-86
(	O	87-88
R	O	88-89
=	O	89-90
-	O	90-91
0	O	91-92
.	O	92-93
33	O	93-95
,	O	95-96
P	O	97-98
<	O	98-99
0	O	99-100
.	O	100-101
05	O	101-103
)	O	103-104
. 	O	104-106

These	O	0-5
findings	O	6-14
support	O	15-22
a	O	23-24
causal	O	25-31
link	O	32-36
between	O	37-44
let	B	45-48
-	I	48-49
7	I	49-50
and	O	51-54
high	O	55-59
-	O	59-60
mobility	O	60-68
group	O	69-74
A2	O	75-77
whereby	O	78-85
loss	O	86-90
of	O	91-93
let	B	94-97
-	I	97-98
7	I	98-99
expression	O	100-110
induces	O	111-118
high	O	119-123
-	O	123-124
mobility	O	124-132
group	O	133-138
A2	O	139-141
upregulation	O	142-154
that	O	155-159
represents	O	160-170
an	O	171-173
important	O	174-183
mechanism	O	184-193
in	O	194-196
pituitary	O	197-206
tumorigenesis	O	207-220
and	O	221-224
progression	O	225-236
.   	O	236-240

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
known	O	23-28
to	O	29-31
influence	O	32-41
many	O	42-46
important	O	47-56
cellular	O	57-65
processes	O	66-75
,	O	75-76
including	O	77-86
proliferation	O	87-100
,	O	100-101
apoptosis	O	102-111
,	O	111-112
neurogenesis	O	113-125
,	O	125-126
angiogenesis	O	127-139
,	O	139-140
and	O	141-144
morphogenesis	O	145-158
,	O	158-159
all	O	160-163
processes	O	164-173
that	O	174-178
are	O	179-182
involved	O	183-191
in	O	192-194
TBI	O	195-198
pathophysiology	O	199-214
. 	O	214-216

Multiple	O	0-8
cellular	O	9-17
,	O	17-18
molecular	O	19-28
,	O	28-29
and	O	30-33
biochemical	O	34-45
changes	O	46-53
contribute	O	54-64
to	O	65-67
outcome	O	68-75
after	O	76-81
traumatic	O	82-91
brain	O	92-97
injury	O	98-104
(	O	105-106
TBI	O	106-109
)	O	109-110
. 	O	110-112

In	O	0-2
the	O	3-6
present	O	7-14
study	O	15-20
,	O	20-21
we	O	22-24
used	O	25-29
a	O	30-31
microarray	O	32-42
platform	O	43-51
to	O	52-54
examine	O	55-62
changes	O	63-70
in	O	71-73
the	O	74-77
hippocampal	O	78-89
expression	O	90-100
levels	O	101-107
of	O	108-110
444	O	111-114
verified	O	115-123
rodent	O	124-130
miRNAs	O	131-137
at	O	138-140
3	O	141-142
and	O	143-146
24	O	147-149
hr	O	150-152
after	O	153-158
controlled	O	159-169
cortical	O	170-178
impact	O	179-185
injury	O	186-192
. 	O	192-194

However	O	0-7
,	O	7-8
it	O	9-11
has	O	12-15
not	O	16-19
yet	O	20-23
been	O	24-28
determined	O	29-39
whether	O	40-47
miRNA	O	48-53
expression	O	54-64
is	O	65-67
altered	O	68-75
after	O	76-81
TBI	O	82-85
. 	O	85-87

We	O	0-2
extended	O	3-11
the	O	12-15
microarray	O	16-26
findings	O	27-35
using	O	36-41
quantitative	O	42-54
polymerase	O	55-65
chain	O	66-71
reaction	O	72-80
analysis	O	81-89
for	O	90-93
a	O	94-95
subset	O	96-102
of	O	103-105
the	O	106-109
miRNAs	O	110-116
with	O	117-121
altered	O	122-129
expression	O	130-140
levels	O	141-147
(	O	148-149
miR	B	149-152
-	I	152-153
107	I	153-156
,	I	156-157
-	I	158-159
130a	I	159-163
,	I	163-164
-	I	165-166
223	I	166-169
,	I	169-170
-	I	171-172
292	I	172-175
-	I	175-176
5p	I	176-178
,	I	178-179
-	I	180-181
433	I	181-184
-	I	184-185
3p	I	185-187
,	I	187-188
-	I	189-190
451	I	190-193
,	I	193-194
-	I	195-196
541	I	196-199
,	I	199-200
and	I	201-204
-	I	205-206
711	I	206-209
)	O	209-210
. 	O	210-212

Our	O	0-3
analysis	O	4-12
found	O	13-18
50	O	19-21
miRNAs	O	22-28
exhibited	O	29-38
decreased	O	39-48
expression	O	49-59
levels	O	60-66
and	O	67-70
35	O	71-73
miRNAs	O	74-80
exhibited	O	81-90
increased	O	91-100
expression	O	101-111
levels	O	112-118
in	O	119-121
the	O	122-125
hippocampus	O	126-137
after	O	138-143
injury	O	144-150
. 	O	150-152

Our	O	0-3
results	O	4-11
indicate	O	12-20
that	O	21-25
multiple	O	26-34
protein	O	35-42
targets	O	43-50
and	O	51-54
biological	O	55-65
processes	O	66-75
involved	O	76-84
in	O	85-87
TBI	O	88-91
pathophysiology	O	92-107
may	O	108-111
be	O	112-114
regulated	O	115-124
by	O	125-127
miRNAs	O	128-134
.   	O	134-138

Bioinformatic	O	0-13
analysis	O	14-22
of	O	23-25
the	O	26-29
predicted	O	30-39
targets	O	40-47
for	O	48-51
this	O	52-56
panel	O	57-62
of	O	63-65
miRNAs	O	66-72
revealed	O	73-81
an	O	82-84
overrepresentation	O	85-103
of	O	104-106
proteins	O	107-115
involved	O	116-124
in	O	125-127
several	O	128-135
biological	O	136-146
processes	O	147-156
and	O	157-160
functions	O	161-170
known	O	171-176
to	O	177-179
be	O	180-182
initiated	O	183-192
after	O	193-198
injury	O	199-205
,	O	205-206
including	O	207-216
signal	O	217-223
transduction	O	224-236
,	O	236-237
transcriptional	O	238-253
regulation	O	254-264
,	O	264-265
proliferation	O	266-279
,	O	279-280
and	O	281-284
differentiation	O	285-300
. 	O	300-302

Traumatic	O	0-9
brain	O	10-15
injury	O	16-22
alters	O	23-29
expression	O	30-40
of	O	41-43
hippocampal	O	44-55
microRNAs	O	56-65
:	O	65-66
potential	O	67-76
regulators	O	77-87
of	O	88-90
multiple	O	91-99
pathophysiological	O	100-118
processes	O	119-128
.  	O	128-131

Potent	O	0-6
,	O	6-7
allele	O	8-14
selective	O	15-24
inhibition	O	25-35
of	O	36-38
HTT	O	39-42
by	O	43-45
mismatched	O	46-56
RNAs	O	57-61
provides	O	62-70
a	O	71-72
new	O	73-76
option	O	77-83
for	O	84-87
developing	O	88-98
HD	O	99-101
therapeutics	O	102-114
.   	O	114-118

Switching	O	0-9
the	O	10-13
RNAi	O	14-18
mechanism	O	19-28
toward	O	29-35
that	O	36-40
used	O	41-45
by	O	46-48
miRNAs	O	49-55
by	O	56-58
introducing	O	59-70
one	O	71-74
or	O	75-77
more	O	78-82
mismatched	O	83-93
bases	O	94-99
into	O	100-104
these	O	105-110
duplex	O	111-117
RNAs	O	118-122
leads	O	123-128
to	O	129-131
potent	O	132-138
(	O	139-140
<	O	140-141
10	O	141-143
nM	O	144-146
)	O	146-147
and	O	148-151
highly	O	152-158
selective	O	159-168
(	O	169-170
>	O	170-171
30	O	171-173
-	O	173-174
fold	O	174-178
relative	O	179-187
to	O	188-190
wild	O	191-195
-	O	195-196
type	O	196-200
HTT	O	201-204
)	O	204-205
inhibition	O	206-216
of	O	217-219
mutant	O	220-226
HTT	O	227-230
expression	O	231-241
in	O	242-244
patient	O	245-252
-	O	252-253
derived	O	253-260
cells	O	261-266
. 	O	266-268

We	O	0-2
observe	O	3-10
that	O	11-15
fully	O	16-21
complementary	O	22-35
duplex	O	36-42
RNAs	O	43-47
targeting	O	48-57
the	O	58-61
expanded	O	62-70
CAG	O	71-74
repeat	O	75-81
within	O	82-88
HTT	O	89-92
mRNA	O	93-97
block	O	98-103
expression	O	104-114
of	O	115-117
both	O	118-122
alleles	O	123-130
. 	O	130-132

An	O	0-2
ideal	O	3-8
silencing	O	9-18
agent	O	19-24
would	O	25-30
block	O	31-36
expression	O	37-47
of	O	48-50
mutant	O	51-57
HTT	O	58-61
while	O	62-67
leaving	O	68-75
expression	O	76-86
of	O	87-89
wild	O	90-94
-	O	94-95
type	O	95-99
HTT	O	100-103
intact	O	104-110
. 	O	110-112

Inhibiting	O	0-10
expression	O	11-21
of	O	22-24
huntingtin	O	25-35
(	O	36-37
HTT	O	37-40
)	O	40-41
protein	O	42-49
is	O	50-52
a	O	53-54
promising	O	55-64
strategy	O	65-73
for	O	74-77
treating	O	78-86
Huntington	O	87-97
'	O	97-98
s	O	98-99
disease	O	100-107
(	O	108-109
HD	O	109-111
)	O	111-112
,	O	112-113
but	O	114-117
indiscriminant	O	118-132
inhibition	O	133-143
of	O	144-146
both	O	147-151
wild	O	152-156
-	O	156-157
type	O	157-161
and	O	162-165
mutant	O	166-172
alleles	O	173-180
may	O	181-184
lead	O	185-189
to	O	190-192
toxicity	O	193-201
. 	O	201-203

Allele	O	0-6
-	O	6-7
selective	O	7-16
inhibition	O	17-27
of	O	28-30
huntingtin	O	31-41
expression	O	42-52
by	O	53-55
switching	O	56-65
to	O	66-68
an	O	69-71
miRNA	O	72-77
-	O	77-78
like	O	78-82
RNAi	O	83-87
mechanism	O	88-97
.  	O	97-100

Thus	O	0-4
we	O	5-7
have	O	8-12
identified	O	13-23
a	O	24-25
miRNA	O	26-31
expression	O	32-42
signature	O	43-52
that	O	53-57
can	O	58-61
predict	O	62-69
GBM	O	70-73
patient	O	74-81
survival	O	82-90
. 	O	90-92

Cox	O	0-3
multivariate	O	4-16
analysis	O	17-25
with	O	26-30
patient	O	31-38
age	O	39-42
as	O	43-45
a	O	46-47
covariate	O	48-57
on	O	58-60
the	O	61-64
entire	O	65-71
patient	O	72-79
set	O	80-83
identified	O	84-94
risk	O	95-99
score	O	100-105
based	O	106-111
on	O	112-114
the	O	115-118
10	O	119-121
miRNA	O	122-127
expression	O	128-138
signature	O	139-148
to	O	149-151
be	O	152-154
an	O	155-157
independent	O	158-169
predictor	O	170-179
of	O	180-182
patient	O	183-190
survival	O	191-199
(	O	200-201
HR	O	201-203
=	O	204-205
1	O	206-207
.	O	207-208
120	O	208-211
;	O	211-212
95	O	213-215
%	O	215-216
CI	O	217-219
=	O	220-221
1	O	222-223
.	O	223-224
04	O	224-226
-	O	226-227
1	O	227-228
.	O	228-229
20	O	229-231
;	O	231-232
p	O	233-234
=	O	235-236
0	O	237-238
.	O	238-239
003	O	239-242
)	O	242-243
. 	O	243-245

These	O	0-5
findings	O	6-14
may	O	15-18
have	O	19-23
implications	O	24-36
in	O	37-39
the	O	40-43
understanding	O	44-57
of	O	58-60
gliomagenesis	O	61-74
,	O	74-75
development	O	76-87
of	O	88-90
targeted	O	91-99
therapy	O	100-107
and	O	108-111
selection	O	112-121
of	O	122-124
high	O	125-129
risk	O	130-134
cancer	O	135-141
patients	O	142-150
for	O	151-154
adjuvant	O	155-163
therapy	O	164-171
.   	O	171-175

GBM	O	0-3
patients	O	4-12
with	O	13-17
high	O	18-22
risk	O	23-27
scores	O	28-34
had	O	35-38
overall	O	39-46
poor	O	47-51
survival	O	52-60
compared	O	61-69
to	O	70-72
the	O	73-76
patients	O	77-85
with	O	86-90
low	O	91-94
risk	O	95-99
scores	O	100-106
. 	O	106-108

Overall	O	0-7
survival	O	8-16
among	O	17-22
the	O	23-26
entire	O	27-33
patient	O	34-41
set	O	42-45
was	O	46-49
35	O	50-52
.	O	52-53
0	O	53-54
%	O	54-55
at	O	56-58
2	O	59-60
years	O	61-66
,	O	66-67
21	O	68-70
.	O	70-71
5	O	71-72
%	O	72-73
at	O	74-76
3	O	77-78
years	O	79-84
,	O	84-85
18	O	86-88
.	O	88-89
5	O	89-90
%	O	90-91
at	O	92-94
4	O	95-96
years	O	97-102
and	O	103-106
11	O	107-109
.	O	109-110
8	O	110-111
%	O	111-112
at	O	113-115
5	O	116-117
years	O	118-123
in	O	124-126
the	O	127-130
low	O	131-134
risk	O	135-139
group	O	140-145
,	O	145-146
versus	O	147-153
11	O	154-156
.	O	156-157
0	O	157-158
%	O	158-159
,	O	159-160
5	O	161-162
.	O	162-163
5	O	163-164
%	O	164-165
,	O	165-166
0	O	167-168
.	O	168-169
0	O	169-170
and	O	171-174
0	O	175-176
.	O	176-177
0	O	177-178
%	O	178-179
respectively	O	180-192
in	O	193-195
the	O	196-199
high	O	200-204
risk	O	205-209
group	O	210-215
(	O	216-217
HR	O	217-219
=	O	220-221
2	O	222-223
.	O	223-224
0	O	224-225
;	O	225-226
95	O	227-229
%	O	229-230
CI	O	231-233
=	O	234-235
1	O	236-237
.	O	237-238
4	O	238-239
-	O	239-240
2	O	240-241
.	O	241-242
8	O	242-243
;	O	243-244
p	O	245-246
<	O	246-247
0	O	247-248
.	O	248-249
0001	O	249-253
)	O	253-254
. 	O	254-256

To	O	0-2
identify	O	3-11
a	O	12-13
microRNA	O	14-22
(	O	23-24
miRNA	O	24-29
)	O	29-30
expression	O	31-41
signature	O	42-51
that	O	52-56
can	O	57-60
predict	O	61-68
GBM	O	69-72
patient	O	73-80
survival	O	81-89
,	O	89-90
we	O	91-93
analyzed	O	94-102
the	O	103-106
miRNA	O	107-112
expression	O	113-123
data	O	124-128
of	O	129-131
GBM	O	132-135
patients	O	136-144
(	O	145-146
n	O	146-147
=	O	148-149
222	O	150-153
)	O	153-154
derived	O	155-162
from	O	163-167
The	O	168-171
Cancer	O	172-178
Genome	O	179-185
Atlas	O	186-191
(	O	192-193
TCGA	O	193-197
)	O	197-198
dataset	O	199-206
. 	O	206-208

We	O	0-2
divided	O	3-10
the	O	11-14
patients	O	15-23
randomly	O	24-32
into	O	33-37
training	O	38-46
and	O	47-50
testing	O	51-58
sets	O	59-63
with	O	64-68
equal	O	69-74
number	O	75-81
in	O	82-84
each	O	85-89
group	O	90-95
. 	O	95-97

A	O	0-1
Ten	O	2-5
-	O	5-6
microRNA	O	6-14
Expression	O	15-25
Signature	O	26-35
Predicts	O	36-44
Survival	O	45-53
in	O	54-56
Glioblastoma	O	57-69
.  	O	69-72

Glioblastoma	O	0-12
(	O	13-14
GBM	O	14-17
)	O	17-18
is	O	19-21
the	O	22-25
most	O	26-30
common	O	31-37
and	O	38-41
aggressive	O	42-52
primary	O	53-60
brain	O	61-66
tumor	O	67-72
with	O	73-77
very	O	78-82
poor	O	83-87
patient	O	88-95
median	O	96-102
survival	O	103-111
. 	O	111-113

Of	O	0-2
these	O	3-8
10	O	9-11
miRNAs	O	12-18
,	O	18-19
7	O	20-21
were	O	22-26
found	O	27-32
to	O	33-35
be	O	36-38
risky	O	39-44
miRNAs	O	45-51
and	O	52-55
3	O	56-57
were	O	58-62
found	O	63-68
to	O	69-71
be	O	72-74
protective	O	75-85
. 	O	85-87

This	O	0-4
signature	O	5-14
was	O	15-18
independently	O	19-32
validated	O	33-42
in	O	43-45
the	O	46-49
testing	O	50-57
set	O	58-61
(	O	62-63
HR	O	63-65
=	O	66-67
1	O	68-69
.	O	69-70
7	O	70-71
;	O	71-72
95	O	73-75
%	O	75-76
CI	O	77-79
=	O	80-81
1	O	82-83
.	O	83-84
1	O	84-85
-	O	85-86
2	O	86-87
.	O	87-88
8	O	88-89
;	O	89-90
p	O	91-92
=	O	93-94
0	O	95-96
.	O	96-97
002	O	97-100
)	O	100-101
. 	O	101-103

We	O	0-2
identified	O	3-13
10	O	14-16
significant	O	17-28
miRNAs	O	29-35
using	O	36-41
Cox	O	42-45
regression	O	46-56
analysis	O	57-65
on	O	66-68
the	O	69-72
training	O	73-81
set	O	82-85
and	O	86-89
formulated	O	90-100
a	O	101-102
risk	O	103-107
score	O	108-113
based	O	114-119
on	O	120-122
the	O	123-126
expression	O	127-137
signature	O	138-147
of	O	148-150
these	O	151-156
miRNAs	O	157-163
that	O	164-168
segregated	O	169-179
the	O	180-183
patients	O	184-192
into	O	193-197
high	O	198-202
and	O	203-206
low	O	207-210
risk	O	211-215
groups	O	216-222
with	O	223-227
significantly	O	228-241
different	O	242-251
survival	O	252-260
times	O	261-266
(	O	267-268
hazard	O	268-274
ratio	O	275-280
[	O	281-282
HR	O	282-284
]	O	284-285
=	O	286-287
2	O	288-289
.	O	289-290
4	O	290-291
;	O	291-292
95	O	293-295
%	O	295-296
CI	O	297-299
=	O	300-301
1	O	302-303
.	O	303-304
4	O	304-305
-	O	305-306
3	O	306-307
.	O	307-308
8	O	308-309
;	O	309-310
p	O	311-312
<	O	312-313
0	O	313-314
.	O	314-315
0001	O	315-319
)	O	319-320
. 	O	320-322

Microarray	O	0-10
analysis	O	11-19
showed	O	20-26
differential	O	27-39
expression	O	40-50
of	O	51-53
multiple	O	54-62
miRNAs	O	63-69
in	O	70-72
HIVE	O	73-77
compared	O	78-86
to	O	87-89
control	O	90-97
brains	O	98-104
. 	O	104-106

Target	O	0-6
prediction	O	7-17
and	O	18-21
gene	O	22-26
ontology	O	27-35
enrichment	O	36-46
analysis	O	47-55
disclosed	O	56-65
targeting	O	66-75
of	O	76-78
several	O	79-86
gene	O	87-91
families	O	92-100
/	O	100-101
biological	O	101-111
processes	O	112-121
by	O	122-124
differentially	O	125-139
expressed	O	140-149
miRNAs	O	150-156
(	O	157-158
DEMs	O	158-162
)	O	162-163
,	O	163-164
with	O	165-169
cell	O	170-174
death	O	175-180
-	O	180-181
related	O	181-188
genes	O	189-194
,	O	194-195
including	O	196-205
caspase	O	206-213
-	O	213-214
6	O	214-215
,	O	215-216
showing	O	217-224
a	O	225-226
bias	O	227-231
toward	O	232-238
down	O	239-243
-	O	243-244
regulated	O	244-253
DEMs	O	254-258
. 	O	258-260

Consistent	O	0-10
with	O	11-15
the	O	16-19
miRNA	O	20-25
data	O	26-30
,	O	30-31
HIVE	O	32-36
brains	O	37-43
exhibited	O	44-53
higher	O	54-60
levels	O	61-67
of	O	68-70
caspase	O	71-78
-	O	78-79
6	O	79-80
transcripts	O	81-92
compared	O	93-101
with	O	102-106
control	O	107-114
patients	O	115-123
. 	O	123-125

Immunohistochemical	O	0-19
analysis	O	20-28
showed	O	29-35
localization	O	36-48
of	O	49-51
the	O	52-55
cleaved	O	56-63
form	O	64-68
of	O	69-71
caspase	O	72-79
-	O	79-80
6	O	80-81
in	O	82-84
astrocytes	O	85-95
in	O	96-98
HIVE	O	99-103
brain	O	104-109
sections	O	110-118
. 	O	118-120

Exposure	O	0-8
of	O	9-11
cultured	O	12-20
human	O	21-26
primary	O	27-34
astrocytes	O	35-45
to	O	46-48
HIV	O	49-52
viral	O	53-58
protein	O	59-66
R	O	67-68
(	O	69-70
Vpr	O	70-73
)	O	73-74
induced	O	75-82
p53	O	83-86
up	O	87-89
-	O	89-90
regulation	O	90-100
,	O	100-101
loss	O	102-106
of	O	107-109
mitochondrial	O	110-123
membrane	O	124-132
potential	O	133-142
,	O	142-143
and	O	144-147
caspase	O	148-155
-	O	155-156
6	O	156-157
activation	O	158-168
followed	O	169-177
by	O	178-180
cell	O	181-185
injury	O	186-192
. 	O	192-194

Transgenic	O	0-10
mice	O	11-15
,	O	15-16
expressing	O	17-27
Vpr	O	28-31
in	O	32-34
microglial	O	35-45
cells	O	46-51
,	O	51-52
demonstrated	O	53-65
astrocyte	O	66-75
apoptosis	O	76-85
in	O	86-88
brain	O	89-94
,	O	94-95
which	O	96-101
was	O	102-105
associated	O	106-116
with	O	117-121
caspase	O	122-129
-	O	129-130
6	O	130-131
activation	O	132-142
and	O	143-146
neurobehavioral	O	147-162
abnormalities	O	163-176
. 	O	176-178

Overall	O	0-7
,	O	7-8
these	O	9-14
data	O	15-19
point	O	20-25
to	O	26-28
previously	O	29-39
unrecognized	O	40-52
alterations	O	53-64
in	O	65-67
miRNA	O	68-73
profile	O	74-81
in	O	82-84
the	O	85-88
brain	O	89-94
during	O	95-101
HIV	O	102-105
infection	O	106-115
,	O	115-116
which	O	117-122
contribute	O	123-133
to	O	134-136
cell	O	137-141
death	O	142-147
through	O	148-155
dysregulation	O	156-169
of	O	170-172
cell	O	173-177
death	O	178-183
machinery	O	184-193
.   	O	193-197

MicroRNA	O	0-8
profiling	O	9-18
reveals	O	19-26
new	O	27-30
aspects	O	31-38
of	O	39-41
HIV	O	42-45
neurodegeneration	O	46-63
:	O	63-64
caspase	O	65-72
-	O	72-73
6	O	73-74
regulates	O	75-84
astrocyte	O	85-94
survival	O	95-103
.  	O	103-106

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNA	O	39-42
molecules	O	43-52
,	O	52-53
which	O	54-59
are	O	60-63
known	O	64-69
to	O	70-72
regulate	O	73-81
gene	O	82-86
expression	O	87-97
in	O	98-100
physiological	O	101-114
and	O	115-118
pathological	O	119-131
conditions	O	132-142
. 	O	142-144

miRNA	O	0-5
profiling	O	6-15
was	O	16-19
performed	O	20-29
using	O	30-35
brain	O	36-41
tissue	O	42-48
from	O	49-53
patients	O	54-62
with	O	63-67
HIV	O	68-71
encephalitis	O	72-84
(	O	85-86
HIVE	O	86-90
)	O	90-91
,	O	91-92
a	O	93-94
neuroinflammatory	O	95-112
/	O	112-113
degenerative	O	113-125
disorder	O	126-134
caused	O	135-141
by	O	142-144
HIV	O	145-148
infection	O	149-158
of	O	159-161
the	O	162-165
brain	O	166-171
. 	O	171-173

The	O	0-3
method	O	4-10
by	O	11-13
which	O	14-19
MSCs	O	20-24
could	O	25-30
be	O	31-33
applied	O	34-41
for	O	42-45
future	O	46-52
therapies	O	53-62
might	O	63-68
require	O	69-76
trans	O	77-82
-	O	82-83
disciplinary	O	83-95
approaches	O	96-106
for	O	107-110
personalized	O	111-123
treatments	O	124-134
.   	O	134-138

Implantation	O	0-12
of	O	13-15
adult	O	16-21
human	O	22-27
mesenchymal	O	28-39
stem	O	40-44
cells	O	45-50
(	O	51-52
MSCs	O	52-56
)	O	56-57
to	O	58-60
treat	O	61-66
neural	O	67-73
disorders	O	74-83
shows	O	84-89
promise	O	90-97
. 	O	97-99

Depending	O	0-9
on	O	10-12
their	O	13-18
microenvironment	O	19-35
,	O	35-36
MSCs	O	37-41
could	O	42-47
potentially	O	48-59
be	O	60-62
used	O	63-67
for	O	68-71
the	O	72-75
repair	O	76-82
and	O	83-86
/	O	86-87
or	O	87-89
replacement	O	90-101
of	O	102-104
neurons	O	105-112
in	O	113-115
traumatic	O	116-125
brain	O	126-131
injury	O	132-138
or	O	139-141
the	O	142-145
treatment	O	146-155
of	O	156-158
Parkinson	O	159-168
'	O	168-169
s	O	169-170
disease	O	171-178
. 	O	178-180

This	O	0-4
cross	O	5-10
-	O	10-11
disciplinary	O	11-23
review	O	24-30
incorporates	O	31-43
aspects	O	44-51
of	O	52-54
neuroscience	O	55-67
,	O	67-68
stem	O	69-73
cell	O	74-78
biology	O	79-86
,	O	86-87
cancer	O	88-94
biology	O	95-102
and	O	103-106
immunology	O	107-117
to	O	118-120
discuss	O	121-128
interactions	O	129-141
between	O	142-149
inflammatory	O	150-162
mediators	O	163-172
and	O	173-176
MSCs	O	177-181
. 	O	181-183

We	O	0-2
first	O	3-8
discuss	O	9-16
the	O	17-20
role	O	21-25
of	O	26-28
microRNAs	O	29-38
(	O	39-40
miRNAs	O	40-46
)	O	46-47
in	O	48-50
neurological	O	51-63
development	O	64-75
. 	O	75-77

Neurogenesis	O	0-12
:	O	12-13
role	O	14-18
for	O	19-22
microRNAs	O	23-32
and	O	33-36
mesenchymal	O	37-48
stem	O	49-53
cells	O	54-59
in	O	60-62
pathological	O	63-75
states	O	76-82
.  	O	82-85

Exploring	O	0-9
the	O	10-13
predisposition	O	14-28
of	O	29-31
MSCs	O	32-36
to	O	37-39
oncogenesis	O	40-51
is	O	52-54
critical	O	55-63
for	O	64-67
translational	O	68-81
science	O	82-89
since	O	90-95
the	O	96-99
implementation	O	100-114
of	O	115-117
safeguarding	O	118-130
measures	O	131-139
prior	O	140-145
to	O	146-148
therapy	O	149-156
can	O	157-160
lead	O	161-165
to	O	166-168
the	O	169-172
successful	O	173-183
delivery	O	184-192
of	O	193-195
stem	O	196-200
cells	O	201-206
to	O	207-209
patients	O	210-218
. 	O	218-220

The	O	0-3
administration	O	4-18
of	O	19-21
effective	O	22-31
and	O	32-35
safe	O	36-40
MSC	O	41-44
therapy	O	45-52
must	O	53-57
acknowledge	O	58-69
immune	O	70-76
mediators	O	77-86
that	O	87-91
may	O	92-95
predispose	O	96-106
the	O	107-110
early	O	111-116
differentiating	O	117-132
MSCs	O	133-137
to	O	138-140
oncogenic	O	141-150
insults	O	151-158
. 	O	158-160

Secondly	O	0-8
,	O	8-9
we	O	10-12
discuss	O	13-20
the	O	21-24
ability	O	25-32
of	O	33-35
MSCs	O	36-40
to	O	41-43
transdifferentiate	O	44-62
into	O	63-67
functional	O	68-78
neurons	O	79-86
,	O	86-87
which	O	88-93
are	O	94-97
regulated	O	98-107
by	O	108-110
miRNAs	O	111-117
,	O	117-118
and	O	119-122
the	O	123-126
implications	O	127-139
of	O	140-142
these	O	143-148
cells	O	149-154
for	O	155-158
the	O	159-162
therapy	O	163-170
of	O	171-173
neuropathological	O	174-191
states	O	192-198
. 	O	198-200

Immune	O	0-6
mediators	O	7-16
could	O	17-22
be	O	23-25
central	O	26-33
to	O	34-36
MSC	O	37-40
responses	O	41-50
within	O	51-57
a	O	58-59
region	O	60-66
of	O	67-69
tissue	O	70-76
injury	O	77-83
and	O	84-87
are	O	88-91
also	O	92-96
discussed	O	97-106
in	O	107-109
detail	O	110-116
. 	O	116-118

Thus	O	0-4
,	O	4-5
we	O	6-8
discuss	O	9-16
a	O	17-18
key	O	19-22
gene	O	23-27
,	O	27-28
RE	O	29-31
-	O	31-32
1	O	32-33
silencing	O	34-43
transcription	O	44-57
factor	O	58-64
(	O	65-66
REST	O	66-70
)	O	70-71
,	O	71-72
based	O	73-78
on	O	79-81
its	O	82-85
dual	O	86-90
role	O	91-95
in	O	96-98
neurogenesis	O	99-111
and	O	112-115
cancer	O	116-122
development	O	123-134
. 	O	134-136

Language	O	0-8
brain	O	9-14
dominance	O	15-24
in	O	25-27
patients	O	28-36
with	O	37-41
refractory	O	42-52
temporal	O	53-61
lobe	O	62-66
epilepsy	O	67-75
:	O	75-76
a	O	77-78
comparative	O	79-90
study	O	91-96
between	O	97-104
functional	O	105-115
magnetic	O	116-124
resonance	O	125-134
imaging	O	135-142
and	O	143-146
dichotic	O	147-155
listening	O	156-165
test	O	166-170
.  	O	170-173

PURPOSE	O	0-7
:	O	7-8
To	O	9-11
identify	O	12-20
brain	O	21-26
dominance	O	27-36
for	O	37-40
language	O	41-49
functions	O	50-59
with	O	60-64
DLT	O	65-68
and	O	69-72
correlate	O	73-82
these	O	83-88
results	O	89-96
with	O	97-101
those	O	102-107
obtained	O	108-116
from	O	117-121
fMRI	O	122-126
in	O	127-129
patients	O	130-138
suffering	O	139-148
from	O	149-153
intractable	O	154-165
temporal	O	166-174
lobe	O	175-179
epilepsy	O	180-188
. 	O	188-190

METHOD	O	0-6
:	O	6-7
This	O	8-12
study	O	13-18
reports	O	19-26
on	O	27-29
13	O	30-32
patients	O	33-41
who	O	42-45
underwent	O	46-55
pre	O	56-59
-	O	59-60
surgical	O	60-68
epileptic	O	69-78
evaluation	O	79-89
between	O	90-97
April	O	98-103
and	O	104-107
October	O	108-115
2004	O	116-120
at	O	121-123
the	O	124-127
Epilepsy	O	128-136
Surgery	O	137-144
Program	O	145-152
,	O	152-153
Hospital	O	154-162
Sao	O	163-166
Lucas	O	167-172
,	O	172-173
PUCRS	O	174-179
. 	O	179-181

In	O	0-2
DLT	O	3-6
,	O	6-7
dominance	O	8-17
was	O	18-21
assessed	O	22-30
through	O	31-38
a	O	39-40
consonant	O	41-50
-	O	50-51
vowel	O	51-56
task	O	57-61
,	O	61-62
whereas	O	63-70
in	O	71-73
fMRI	O	74-78
patients	O	79-87
performed	O	88-97
a	O	98-99
verb	O	100-104
generation	O	105-115
task	O	116-120
. 	O	120-122

These	O	0-5
findings	O	6-14
indicate	O	15-23
that	O	24-28
DLT	O	29-32
(	O	33-34
a	O	34-35
non	O	36-39
-	O	39-40
invasive	O	40-48
procedure	O	49-58
)	O	58-59
could	O	60-65
be	O	66-68
a	O	69-70
useful	O	71-77
tool	O	78-82
to	O	83-85
evaluate	O	86-94
language	O	95-103
brain	O	104-109
dominance	O	110-119
in	O	120-122
pre	O	123-126
-	O	126-127
surgical	O	127-135
epileptic	O	136-145
patients	O	146-154
as	O	155-157
it	O	158-160
is	O	161-163
cheaper	O	164-171
to	O	172-174
perform	O	175-182
than	O	183-187
fMRI	O	188-192
.   	O	192-196

CONCLUSION	O	0-10
:	O	10-11
DLT	O	12-15
was	O	16-19
found	O	20-25
to	O	26-28
significantly	O	29-42
correlate	O	43-52
with	O	53-57
fMRI	O	58-62
. 	O	62-64

RESULTS	O	0-7
:	O	7-8
Our	O	9-12
results	O	13-20
identified	O	21-31
a	O	32-33
correlation	O	34-45
between	O	46-53
the	O	54-57
fMRI	O	58-62
lateralization	O	63-77
index	O	78-83
and	O	84-87
the	O	88-91
DLT	O	92-95
ear	O	96-99
predominance	O	100-112
index	O	113-118
and	O	119-122
reply	O	123-128
difference	O	129-139
index	O	140-145
(	O	146-147
r	O	147-148
=	O	148-149
0	O	149-150
.	O	150-151
6	O	151-152
,	O	152-153
p	O	154-155
=	O	155-156
0	O	156-157
.	O	157-158
02	O	158-160
;	O	160-161
Pearson	O	162-169
Correlation	O	170-181
Coefficient	O	182-193
)	O	193-194
,	O	194-195
showing	O	196-203
positive	O	204-212
correlation	O	213-224
between	O	225-232
results	O	233-240
obtained	O	241-249
from	O	250-254
fMRI	O	255-259
and	O	260-263
DLT	O	264-267
. 	O	267-269

Finally	O	0-7
,	O	7-8
a	O	9-10
phylogenetic	O	11-23
analysis	O	24-32
shows	O	33-38
that	O	39-43
ADCK3	O	44-49
belongs	O	50-57
to	O	58-60
the	O	61-64
family	O	65-71
of	O	72-74
atypical	O	75-83
kinases	O	84-91
,	O	91-92
which	O	93-98
includes	O	99-107
phosphoinositide	O	108-124
and	O	125-128
choline	O	129-136
kinases	O	137-144
,	O	144-145
suggesting	O	146-156
that	O	157-161
ADCK3	O	162-167
plays	O	168-173
an	O	174-176
indirect	O	177-185
regulatory	O	186-196
role	O	197-201
in	O	202-204
ubiquinone	O	205-215
biosynthesis	O	216-228
possibly	O	229-237
as	O	238-240
part	O	241-245
of	O	246-248
a	O	249-250
feedback	O	251-259
loop	O	260-264
that	O	265-269
regulates	O	270-279
ATP	O	280-283
production	O	284-294
.   	O	294-298

ADCK3	O	0-5
,	O	5-6
an	O	7-9
ancestral	O	10-19
kinase	O	20-26
,	O	26-27
is	O	28-30
mutated	O	31-38
in	O	39-41
a	O	42-43
form	O	44-48
of	O	49-51
recessive	O	52-61
ataxia	O	62-68
associated	O	69-79
with	O	80-84
coenzyme	O	85-93
Q10	O	94-97
deficiency	O	98-108
.  	O	108-111

Muscle	O	0-6
coenzyme	O	7-15
Q	O	16-17
(	O	17-18
10	O	18-20
)	O	20-21
(	O	22-23
CoQ	O	23-26
(	O	26-27
10	O	27-29
)	O	29-30
or	O	31-33
ubiquinone	O	34-44
)	O	44-45
deficiency	O	46-56
has	O	57-60
been	O	61-65
identified	O	66-76
in	O	77-79
more	O	80-84
than	O	85-89
20	O	90-92
patients	O	93-101
with	O	102-106
presumed	O	107-115
autosomal	O	116-125
-	O	125-126
recessive	O	126-135
ataxia	O	136-142
. 	O	142-144

However	O	0-7
,	O	7-8
mutations	O	9-18
in	O	19-21
genes	O	22-27
required	O	28-36
for	O	37-40
CoQ	O	41-44
(	O	44-45
10	O	45-47
)	O	47-48
biosynthetic	O	49-61
pathway	O	62-69
have	O	70-74
been	O	75-79
identified	O	80-90
only	O	91-95
in	O	96-98
patients	O	99-107
with	O	108-112
infantile	O	113-122
-	O	122-123
onset	O	123-128
multisystemic	O	129-142
diseases	O	143-151
or	O	152-154
isolated	O	155-163
nephropathy	O	164-175
. 	O	175-177

Our	O	0-3
SNP	O	4-7
-	O	7-8
based	O	8-13
genome	O	14-20
-	O	20-21
wide	O	21-25
scan	O	26-30
in	O	31-33
a	O	34-35
large	O	36-41
consanguineous	O	42-56
family	O	57-63
revealed	O	64-72
a	O	73-74
locus	O	75-80
for	O	81-84
autosomal	O	85-94
-	O	94-95
recessive	O	95-104
ataxia	O	105-111
at	O	112-114
chromosome	O	115-125
1q41	O	126-130
. 	O	130-132

The	O	0-3
causative	O	4-13
mutation	O	14-22
is	O	23-25
a	O	26-27
homozygous	O	28-38
splice	O	39-45
-	O	45-46
site	O	46-50
mutation	O	51-59
in	O	60-62
the	O	63-66
aarF	O	67-71
-	O	71-72
domain	O	72-78
-	O	78-79
containing	O	79-89
kinase	O	90-96
3	O	97-98
gene	O	99-103
(	O	104-105
ADCK3	O	105-110
)	O	110-111
. 	O	111-113

Five	O	0-4
additional	O	5-15
mutations	O	16-25
in	O	26-28
ADCK3	O	29-34
were	O	35-39
found	O	40-45
in	O	46-48
three	O	49-54
patients	O	55-63
with	O	64-68
sporadic	O	69-77
ataxia	O	78-84
,	O	84-85
including	O	86-95
one	O	96-99
known	O	100-105
to	O	106-108
have	O	109-113
CoQ	O	114-117
(	O	117-118
10	O	118-120
)	O	120-121
deficiency	O	122-132
in	O	133-135
muscle	O	136-142
. 	O	142-144

All	O	0-3
of	O	4-6
the	O	7-10
patients	O	11-19
have	O	20-24
childhood	O	25-34
-	O	34-35
onset	O	35-40
cerebellar	O	41-51
ataxia	O	52-58
with	O	59-63
slow	O	64-68
progression	O	69-80
,	O	80-81
and	O	82-85
three	O	86-91
of	O	92-94
six	O	95-98
have	O	99-103
mildly	O	104-110
elevated	O	111-119
lactate	O	120-127
levels	O	128-134
. 	O	134-136

ADCK3	O	0-5
is	O	6-8
a	O	9-10
mitochondrial	O	11-24
protein	O	25-32
homologous	O	33-43
to	O	44-46
the	O	47-50
yeast	O	51-56
COQ8	O	57-61
and	O	62-65
the	O	66-69
bacterial	O	70-79
UbiB	O	80-84
proteins	O	85-93
,	O	93-94
which	O	95-100
are	O	101-104
required	O	105-113
for	O	114-117
CoQ	O	118-121
biosynthesis	O	122-134
. 	O	134-136

Three	O	0-5
out	O	6-9
of	O	10-12
four	O	13-17
patients	O	18-26
tested	O	27-33
showed	O	34-40
a	O	41-42
low	O	43-46
endogenous	O	47-57
pool	O	58-62
of	O	63-65
CoQ	O	66-69
(	O	69-70
10	O	70-72
)	O	72-73
in	O	74-76
their	O	77-82
fibroblasts	O	83-94
or	O	95-97
lymphoblasts	O	98-110
,	O	110-111
and	O	112-115
two	O	116-119
out	O	120-123
of	O	124-126
three	O	127-132
patients	O	133-141
showed	O	142-148
impaired	O	149-157
ubiquinone	O	158-168
synthesis	O	169-178
,	O	178-179
strongly	O	180-188
suggesting	O	189-199
that	O	200-204
ADCK3	O	205-210
is	O	211-213
also	O	214-218
involved	O	219-227
in	O	228-230
CoQ	O	231-234
(	O	234-235
10	O	235-237
)	O	237-238
biosynthesis	O	239-251
. 	O	251-253

The	O	0-3
deleterious	O	4-15
nature	O	16-22
of	O	23-25
the	O	26-29
three	O	30-35
identified	O	36-46
missense	O	47-55
changes	O	56-63
was	O	64-67
confirmed	O	68-77
by	O	78-80
the	O	81-84
introduction	O	85-97
of	O	98-100
them	O	101-105
at	O	106-108
the	O	109-112
corresponding	O	113-126
positions	O	127-136
of	O	137-139
the	O	140-143
yeast	O	144-149
COQ8	O	150-154
gene	O	155-159
. 	O	159-161

Our	O	0-3
method	O	4-10
significantly	O	11-24
decreased	O	25-34
the	O	35-38
duration	O	39-47
of	O	48-50
hospital	O	51-59
admission	O	60-69
for	O	70-73
monitoring	O	74-84
and	O	85-88
minimal	O	89-96
complications	O	97-110
occurred	O	111-119
only	O	120-124
in	O	125-127
8	O	128-129
%	O	129-130
of	O	131-133
patients	O	134-142
. 	O	142-144

CONCLUSIONS	O	0-11
:	O	11-12
In	O	13-15
conclusion	O	16-26
,	O	26-27
our	O	28-31
method	O	32-38
for	O	39-42
short	O	43-48
VEEG	O	49-53
monitoring	O	54-64
has	O	65-68
a	O	69-70
high	O	71-75
yield	O	76-81
for	O	82-85
diagnosis	O	86-95
,	O	95-96
minimal	O	97-104
complications	O	105-118
and	O	119-122
is	O	123-125
cost	O	126-130
effective	O	131-140
. 	O	140-142

These	O	0-5
qualities	O	6-15
,	O	15-16
together	O	17-25
with	O	26-30
good	O	31-35
surgery	O	36-43
results	O	44-51
validate	O	52-60
our	O	61-64
method	O	65-71
for	O	72-75
the	O	76-79
investigation	O	80-93
and	O	94-97
treatment	O	98-107
of	O	108-110
refractory	O	111-121
seizure	O	122-129
cases	O	130-135
.   	O	135-139

RESULTS	O	0-7
:	O	7-8
Our	O	9-12
monitoring	O	13-23
answered	O	24-32
the	O	33-36
study	O	37-42
question	O	43-51
in	O	52-54
88	O	55-57
%	O	57-58
of	O	59-61
the	O	62-65
patients	O	66-74
. 	O	74-76

We	O	0-2
prospectively	O	3-16
assessed	O	17-25
the	O	26-29
yield	O	30-35
and	O	36-39
safety	O	40-46
of	O	47-49
the	O	50-53
telemetry	O	54-63
investigation	O	64-77
as	O	78-80
well	O	81-85
as	O	86-88
epilepsy	O	89-97
surgery	O	98-105
outcomes	O	106-114
. 	O	114-116

Our	O	0-3
results	O	4-11
changed	O	12-19
the	O	20-23
management	O	24-34
in	O	35-37
74	O	38-40
%	O	40-41
of	O	42-44
cases	O	45-50
and	O	51-54
potentially	O	55-66
improved	O	67-75
quality	O	76-83
of	O	84-86
life	O	87-91
by	O	92-94
decreasing	O	95-105
the	O	106-109
AEDs	O	110-114
consumption	O	115-126
and	O	127-130
number	O	131-137
of	O	138-140
seizures	O	141-149
per	O	150-153
month	O	154-159
. 	O	159-161

The	O	0-3
question	O	4-12
was	O	13-16
not	O	17-20
answered	O	21-29
in	O	30-32
12	O	33-35
%	O	35-36
of	O	37-39
cases	O	40-45
due	O	46-49
to	O	50-52
the	O	53-56
lack	O	57-61
of	O	62-64
recorded	O	65-73
events	O	74-80
. 	O	80-82

Over	O	0-4
all	O	5-8
,	O	8-9
22	O	10-12
%	O	12-13
received	O	14-22
epilepsy	O	23-31
surgery	O	32-39
and	O	40-43
became	O	44-50
either	O	51-57
seizure	O	58-65
free	O	66-70
or	O	71-73
their	O	74-79
seizures	O	80-88
became	O	89-95
non	O	96-99
-	O	99-100
disabling	O	100-109
. 	O	109-111

Safety	O	0-6
and	O	7-10
yield	O	11-16
of	O	17-19
early	O	20-25
cessation	O	26-35
of	O	36-38
AEDs	O	39-43
in	O	44-46
video	O	47-52
-	O	52-53
EEG	O	53-56
telemetry	O	57-66
and	O	67-70
outcomes	O	71-79
.  	O	79-82

METHODS	O	0-7
:	O	7-8
This	O	9-13
is	O	14-16
a	O	17-18
prospective	O	19-30
study	O	31-36
performed	O	37-46
to	O	47-49
asses	O	50-55
the	O	56-59
safety	O	60-66
and	O	67-70
yield	O	71-76
of	O	77-79
early	O	80-85
discontinuation	O	86-101
of	O	102-104
antiepileptic	O	105-118
drugs	O	119-124
(	O	125-126
AEDs	O	126-130
)	O	130-131
in	O	132-134
the	O	135-138
telemetry	O	139-148
unit	O	149-153
. 	O	153-155

BACKGROUND	O	0-10
:	O	10-11
Video	O	12-17
-	O	17-18
electroencephalography	O	18-40
(	O	41-42
VEEG	O	42-46
)	O	46-47
telemetry	O	48-57
is	O	58-60
the	O	61-64
simultaneous	O	65-77
recording	O	78-87
of	O	88-90
ictal	O	91-96
and	O	97-100
interictal	O	101-111
EEG	O	112-115
pattern	O	116-123
and	O	124-127
paroxysmal	O	128-138
behavior	O	139-147
to	O	148-150
investigate	O	151-162
the	O	163-166
nature	O	167-173
of	O	174-176
paroxysmal	O	177-187
events	O	188-194
. 	O	194-196

In	O	0-2
most	O	3-7
cases	O	8-13
AEDs	O	14-18
(	O	19-20
except	O	20-26
Phenobarbital	O	27-40
)	O	40-41
were	O	42-46
discontinued	O	47-59
in	O	60-62
24h	O	63-66
. 	O	66-68

Over	O	0-4
a	O	5-6
2	O	7-8
.	O	8-9
5	O	9-10
-	O	10-11
year	O	11-15
period	O	16-22
,	O	22-23
50	O	24-26
patients	O	27-35
that	O	36-40
met	O	41-44
the	O	45-48
indications	O	49-60
for	O	61-64
VEEG	O	65-69
monitoring	O	70-80
were	O	81-85
admitted	O	86-94
by	O	95-97
an	O	98-100
epileptologist	O	101-115
to	O	116-118
neuro	O	119-124
-	O	124-125
observation	O	125-136
units	O	137-142
with	O	143-147
continuous	O	148-158
monitoring	O	159-169
,	O	169-170
nursing	O	171-178
coverage	O	179-187
and	O	188-191
EEG	O	192-195
technicians	O	196-207
support	O	208-215
during	O	216-222
working	O	223-230
hours	O	231-236
and	O	237-240
on	O	241-243
-	O	243-244
call	O	244-248
thereafter	O	249-259
. 	O	259-261

The	O	0-3
molecular	O	4-13
mechanisms	O	14-24
that	O	25-29
contribute	O	30-40
to	O	41-43
gliomagenesis	O	44-57
have	O	58-62
become	O	63-69
increasingly	O	70-82
clear	O	83-88
in	O	89-91
recent	O	92-98
years	O	99-104
,	O	104-105
yet	O	106-109
much	O	110-114
remains	O	115-122
to	O	123-125
be	O	126-128
learned	O	129-136
. 	O	136-138

Gliomas	O	0-7
are	O	8-11
the	O	12-15
most	O	16-20
common	O	21-27
form	O	28-32
of	O	33-35
primary	O	36-43
brain	O	44-49
tumors	O	50-56
and	O	57-60
are	O	61-64
associated	O	65-75
with	O	76-80
a	O	81-82
poor	O	83-87
clinical	O	88-96
outcome	O	97-104
. 	O	104-106

microRNAs	O	0-9
in	O	10-12
gliomas	O	13-20
:	O	20-21
small	O	22-27
regulators	O	28-38
of	O	39-41
a	O	42-43
big	O	44-47
problem	O	48-55
.  	O	55-58

This	O	0-4
is	O	5-7
a	O	8-9
rapidly	O	10-17
evolving	O	18-26
field	O	27-32
and	O	33-36
it	O	37-39
is	O	40-42
likely	O	43-49
that	O	50-54
we	O	55-57
have	O	58-62
only	O	63-67
begun	O	68-73
to	O	74-76
appreciate	O	77-87
the	O	88-91
involvement	O	92-103
of	O	104-106
microRNAs	O	107-116
in	O	117-119
relation	O	120-128
to	O	129-131
glioma	O	132-138
formation	O	139-148
,	O	148-149
and	O	150-153
the	O	154-157
therapeutic	O	158-169
potential	O	170-179
of	O	180-182
microRNAs	O	183-192
to	O	193-195
improve	O	196-203
outcome	O	204-211
for	O	212-215
glioma	O	216-222
patients	O	223-231
.   	O	231-235

Here	O	0-4
we	O	5-7
review	O	8-14
the	O	15-18
current	O	19-26
state	O	27-32
of	O	33-35
knowledge	O	36-45
related	O	46-53
to	O	54-56
the	O	57-60
role	O	61-65
of	O	66-68
microRNAs	O	69-78
in	O	79-81
glial	O	82-87
tumor	O	88-93
development	O	94-105
. 	O	105-107

It	O	0-2
is	O	3-5
now	O	6-9
evident	O	10-17
that	O	18-22
microRNAs	O	23-32
regulate	O	33-41
a	O	42-43
wide	O	44-48
variety	O	49-56
of	O	57-59
tumorigenic	O	60-71
processes	O	72-81
including	O	82-91
cellular	O	92-100
proliferation	O	101-114
,	O	114-115
differentiation	O	116-131
,	O	131-132
angiogenesis	O	133-145
,	O	145-146
invasion	O	147-155
,	O	155-156
and	O	157-160
apoptosis	O	161-170
. 	O	170-172

This	O	0-4
is	O	5-7
particularly	O	8-20
true	O	21-25
for	O	26-29
the	O	30-33
role	O	34-38
of	O	39-41
microRNAs	O	42-51
in	O	52-54
gliomagenesis	O	55-68
,	O	68-69
as	O	70-72
an	O	73-75
appreciation	O	76-88
for	O	89-92
the	O	93-96
significance	O	97-109
of	O	110-112
aberrant	O	113-121
miRNA	O	122-127
expression	O	128-138
in	O	139-141
human	O	142-147
cancer	O	148-154
has	O	155-158
only	O	159-163
emerged	O	164-171
in	O	172-174
the	O	175-178
last	O	179-183
5	O	184-185
years	O	186-191
. 	O	191-193

Moreover	O	0-8
,	O	8-9
LPS	O	10-13
stimulation	O	14-25
decreased	O	26-35
expression	O	36-46
of	O	47-49
microRNAs	O	50-59
(	O	60-61
miRNA	O	61-66
)	O	66-67
-	O	67-68
-	O	68-69
miR	B	69-72
-	I	72-73
17	I	73-75
-	I	75-76
5	I	76-77
,	O	77-78
miR	B	79-82
-	I	82-83
20a	I	83-86
,	O	86-87
and	O	88-91
miR	B	92-95
-	I	95-96
93	I	96-98
-	O	98-99
-	O	99-100
which	O	100-105
target	O	106-112
MICA	O	113-117
,	O	117-118
implicating	O	119-130
a	O	131-132
novel	O	133-138
role	O	139-143
for	O	144-147
miRNAs	O	148-154
in	O	155-157
NKG2D	O	158-163
ligand	O	164-170
expression	O	171-181
. 	O	181-183

However	O	0-7
,	O	7-8
it	O	9-11
was	O	12-15
not	O	16-19
sufficient	O	20-30
for	O	31-34
surface	O	35-42
protein	O	43-50
expression	O	51-61
,	O	61-62
which	O	63-68
was	O	69-72
controlled	O	73-83
posttranscriptionally	O	84-105
via	O	106-109
a	O	110-111
separate	O	112-120
pathway	O	121-128
involving	O	129-138
the	O	139-142
ataxia	O	143-149
telangiectasia	O	150-164
mutated	O	165-172
/	O	172-173
ataxia	O	173-179
telangiectasia	O	180-194
and	O	195-198
Rad3	O	199-203
related	O	204-211
kinases	O	212-219
. 	O	219-221

Thus	O	0-4
,	O	4-5
TLR	O	6-9
stimulation	O	10-21
allows	O	22-28
expression	O	29-39
of	O	40-42
NKG2D	O	43-48
ligands	O	49-56
through	O	57-64
multiple	O	65-73
pathways	O	74-82
,	O	82-83
including	O	84-93
downmodulation	O	94-108
of	O	109-111
specific	O	112-120
miRNAs	O	121-127
.   	O	127-131

In	O	0-2
this	O	3-7
paper	O	8-13
,	O	13-14
we	O	15-17
clarify	O	18-25
that	O	26-30
LPS	O	31-34
,	O	34-35
which	O	36-41
ligates	O	42-49
TLR	O	50-53
-	O	53-54
4	O	54-55
,	O	55-56
preferentially	O	57-71
upregulated	O	72-83
MICA	O	84-88
and	O	89-92
not	O	93-96
MICB	O	97-101
;	O	101-102
CL097	O	103-108
,	O	108-109
which	O	110-115
ligates	O	116-123
TLR	O	124-127
-	O	127-128
7	O	128-129
/	O	129-130
8	O	130-131
,	O	131-132
upregulated	O	133-144
both	O	145-149
MICA	O	150-154
and	O	155-158
MICB	O	159-163
;	O	163-164
and	O	165-168
polyinosinic	O	169-181
-	O	181-182
polycytidylic	O	182-195
acid	O	196-200
,	O	200-201
which	O	202-207
ligates	O	208-215
TLR	O	216-219
-	O	219-220
3	O	220-221
,	O	221-222
upregulated	O	223-234
neither	O	235-242
. 	O	242-244

However	O	0-7
,	O	7-8
NKG2D	O	9-14
ligands	O	15-22
can	O	23-26
also	O	27-31
be	O	32-34
induced	O	35-42
on	O	43-45
human	O	46-51
macrophages	O	52-63
by	O	64-66
TLR	O	67-70
stimulation	O	71-82
,	O	82-83
which	O	84-89
has	O	90-93
been	O	94-98
far	O	99-102
less	O	103-107
studied	O	108-115
. 	O	115-117

This	O	0-4
finding	O	5-12
suggests	O	13-21
that	O	22-26
increased	O	27-36
levels	O	37-43
of	O	44-46
MICA	O	47-51
mRNA	O	52-56
following	O	57-66
LPS	O	67-70
stimulation	O	71-82
resulted	O	83-91
from	O	92-96
increased	O	97-106
transcription	O	107-120
. 	O	120-122

To	O	0-2
probe	O	3-8
how	O	9-12
LPS	O	13-16
stimulation	O	17-28
triggers	O	29-37
MICA	O	38-42
expression	O	43-53
,	O	53-54
we	O	55-57
determined	O	58-68
that	O	69-73
the	O	74-77
stability	O	78-87
of	O	88-90
MICA	O	91-95
mRNA	O	96-100
was	O	101-104
much	O	105-109
longer	O	110-116
than	O	117-121
that	O	122-126
of	O	127-129
MICB	O	130-134
mRNA	O	135-139
,	O	139-140
but	O	141-144
neither	O	145-152
was	O	153-156
changed	O	157-164
by	O	165-167
LPS	O	168-171
stimulation	O	172-183
. 	O	183-185

Multiple	O	0-8
mechanisms	O	9-19
downstream	O	20-30
of	O	31-33
TLR	O	34-37
-	O	37-38
4	O	38-39
stimulation	O	40-51
allow	O	52-57
expression	O	58-68
of	O	69-71
NKG2D	O	72-77
ligands	O	78-85
to	O	86-88
facilitate	O	89-99
macrophage	O	100-110
/	O	110-111
NK	O	111-113
cell	O	114-118
crosstalk	O	119-128
.  	O	128-131

This	O	0-4
establishes	O	5-16
recognition	O	17-28
of	O	29-31
"	O	32-33
induced	O	33-40
self	O	41-45
"	O	45-46
as	O	47-49
an	O	50-52
important	O	53-62
strategy	O	63-71
for	O	72-75
surveillance	O	76-88
of	O	89-91
infections	O	92-102
or	O	103-105
tumor	O	106-111
transformation	O	112-126
. 	O	126-128

The	O	0-3
activating	O	4-14
receptor	O	15-23
NKG2D	O	24-29
recognizes	O	30-40
proteins	O	41-49
that	O	50-54
are	O	55-58
not	O	59-62
normally	O	63-71
expressed	O	72-81
at	O	82-84
the	O	85-88
surface	O	89-96
of	O	97-99
most	O	100-104
cells	O	105-110
but	O	111-114
are	O	115-118
expressed	O	119-128
during	O	129-135
a	O	136-137
cellular	O	138-146
"	O	147-148
stress	O	148-154
"	O	154-155
response	O	156-164
(	O	165-166
e	O	166-167
.	O	167-168
g	O	168-169
.	O	169-170
,	O	170-171
upon	O	172-176
induction	O	177-186
of	O	187-189
the	O	190-193
DNA	O	194-197
damage	O	198-204
pathway	O	205-212
)	O	212-213
. 	O	213-215

MicroRNA	O	0-8
in	O	9-11
Situ	O	12-16
Hybridization	O	17-30
in	O	31-33
the	O	34-37
Human	O	38-43
Entorhinal	O	44-54
and	O	55-58
Transentorhinal	O	59-74
Cortex	O	75-81
.  	O	81-84

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
play	O	19-23
key	O	24-27
roles	O	28-33
in	O	34-36
gene	O	37-41
expression	O	42-52
regulation	O	53-63
in	O	64-66
both	O	67-71
healthy	O	72-79
and	O	80-83
disease	O	84-91
brains	O	92-98
. 	O	98-100

To	O	0-2
better	O	3-9
understand	O	10-20
those	O	21-26
roles	O	27-32
,	O	32-33
it	O	34-36
is	O	37-39
necessary	O	40-49
to	O	50-52
characterize	O	53-65
the	O	66-69
miRNAs	O	70-76
that	O	77-81
are	O	82-85
expressed	O	86-95
in	O	96-98
particular	O	99-109
cell	O	110-114
types	O	115-120
under	O	121-126
a	O	127-128
range	O	129-134
of	O	135-137
conditions	O	138-148
. 	O	148-150

In	O	0-2
situ	O	3-7
hybridization	O	8-21
(	O	22-23
ISH	O	23-26
)	O	26-27
can	O	28-31
demonstrate	O	32-43
cell	O	44-48
-	O	48-49
and	O	50-53
lamina	O	54-60
-	O	60-61
specific	O	61-69
patterns	O	70-78
of	O	79-81
miRNA	O	82-87
expression	O	88-98
that	O	99-103
would	O	104-109
be	O	110-112
lost	O	113-117
in	O	118-120
tissue	O	121-127
-	O	127-128
level	O	128-133
expression	O	134-144
profiling	O	145-154
. 	O	154-156

In	O	0-2
the	O	3-6
present	O	7-14
study	O	15-20
,	O	20-21
ISH	O	22-25
was	O	26-29
performed	O	30-39
with	O	40-44
special	O	45-52
focus	O	53-58
on	O	59-61
the	O	62-65
human	O	66-71
entorhinal	O	72-82
cortex	O	83-89
(	O	90-91
EC	O	91-93
)	O	93-94
and	O	95-98
transentorhinal	O	99-114
cortex	O	115-121
(	O	122-123
TEC	O	123-126
)	O	126-127
. 	O	127-129

The	O	0-3
TEC	O	4-7
is	O	8-10
the	O	11-14
area	O	15-19
of	O	20-22
the	O	23-26
cerebral	O	27-35
cortex	O	36-42
that	O	43-47
first	O	48-53
develops	O	54-62
neurofibrillary	O	63-78
tangles	O	79-86
in	O	87-89
Alzheimer	O	90-99
'	O	99-100
s	O	100-101
disease	O	102-109
(	O	110-111
AD	O	111-113
)	O	113-114
. 	O	114-116

However	O	0-7
,	O	7-8
the	O	9-12
reason	O	13-19
for	O	20-23
TEC	O	24-27
'	O	27-28
s	O	28-29
special	O	30-37
vulnerability	O	38-51
to	O	52-54
AD	O	55-57
-	O	57-58
type	O	58-62
pathology	O	63-72
is	O	73-75
unknown	O	76-83
. 	O	83-85

MiRNA	O	0-5
ISH	O	6-9
was	O	10-13
performed	O	14-23
on	O	24-26
three	O	27-32
human	O	33-38
brains	O	39-45
with	O	46-50
well	O	51-55
-	O	55-56
characterized	O	56-69
clinical	O	70-78
and	O	79-82
pathological	O	83-95
parameters	O	96-106
. 	O	106-108

Locked	O	0-6
nucleic	O	7-14
acid	O	15-19
ISH	O	20-23
probes	O	24-30
were	O	31-35
used	O	36-40
referent	O	41-49
to	O	50-52
miR	B	53-56
-	I	56-57
107	I	57-60
,	O	60-61
miR	B	62-65
-	I	65-66
124	I	66-69
,	O	69-70
miR	B	71-74
-	I	74-75
125b	I	75-79
,	O	79-80
and	O	81-84
miR	B	85-88
-	I	88-89
320	I	89-92
. 	O	92-94

In	O	0-2
order	O	3-8
to	O	9-11
correlate	O	12-21
the	O	22-25
ISH	O	26-29
data	O	30-34
with	O	35-39
AD	O	40-42
pathology	O	43-52
,	O	52-53
the	O	54-57
ISH	O	58-61
staining	O	62-70
was	O	71-74
compared	O	75-83
with	O	84-88
near	O	89-93
-	O	93-94
adjacent	O	94-102
slides	O	103-109
processed	O	110-119
using	O	120-125
Thioflavine	O	126-137
stains	O	138-144
. 	O	144-146

MiRNA	O	0-5
ISH	O	6-9
is	O	10-12
among	O	13-18
the	O	19-22
first	O	23-28
methods	O	29-36
to	O	37-39
show	O	40-44
special	O	45-52
staining	O	53-61
characteristics	O	62-77
of	O	78-80
cells	O	81-86
and	O	87-90
laminae	O	91-98
of	O	99-101
the	O	102-105
human	O	106-111
TEC	O	112-115
.   	O	115-119

As	O	0-2
with	O	3-7
other	O	8-13
areas	O	14-19
of	O	20-22
brain	O	23-28
,	O	28-29
the	O	30-33
TEC	O	34-37
and	O	38-41
EC	O	42-44
have	O	45-49
characteristic	O	50-64
miRNA	O	65-70
expression	O	71-81
patterns	O	82-90
. 	O	90-92

Not	O	0-3
all	O	4-7
neurons	O	8-15
or	O	16-18
cortical	O	19-27
lamina	O	28-34
stain	O	35-40
with	O	41-45
equal	O	46-51
intensity	O	52-61
for	O	62-65
individual	O	66-76
miRNAs	O	77-83
. 	O	83-85

Our	O	0-3
in	O	4-6
vitro	O	7-12
results	O	13-20
suggested	O	21-30
that	O	31-35
Aβ42	O	36-40
oligomer	O	41-49
-	O	49-50
induced	O	50-57
miR	B	58-61
-	I	61-62
106b	I	62-66
leads	O	67-72
to	O	73-75
impairment	O	76-86
in	O	87-89
TGF	O	90-93
-	O	93-94
β	O	94-95
signaling	O	96-105
through	O	106-113
TβR	O	114-117
II	O	118-120
,	O	120-121
concomitant	O	122-133
with	O	134-138
retinoic	O	139-147
acid	O	148-152
-	O	152-153
induced	O	153-160
neurodegeneration	O	161-178
in	O	179-181
SH	O	182-184
-	O	184-185
SY5Y	O	185-189
cells	O	190-195
. 	O	195-197

These	O	0-5
results	O	6-13
show	O	14-18
that	O	19-23
TβR	O	24-27
II	O	28-30
is	O	31-33
a	O	34-35
functional	O	36-46
target	O	47-53
of	O	54-56
miR	B	57-60
-	I	60-61
106b	I	61-65
and	O	66-69
that	O	70-74
miR	B	75-78
-	I	78-79
106b	I	79-83
may	O	84-87
influence	O	88-97
TGF	O	98-101
-	O	101-102
β	O	102-103
signaling	O	104-113
,	O	113-114
thereby	O	115-122
contributing	O	123-135
to	O	136-138
the	O	139-142
pathogenesis	O	143-155
of	O	156-158
AD	O	159-161
.   	O	161-165

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
abundantly	O	23-33
expressed	O	34-43
in	O	44-46
the	O	47-50
brain	O	51-56
and	O	57-60
play	O	61-65
an	O	66-68
important	O	69-78
role	O	79-83
in	O	84-86
disorders	O	87-96
of	O	97-99
the	O	100-103
brain	O	104-109
,	O	109-110
including	O	111-120
Alzheimer	O	121-130
'	O	130-131
s	O	131-132
diseases	O	133-141
(	O	142-143
AD	O	143-145
)	O	145-146
. 	O	146-148

miR	B	0-3
-	I	3-4
106b	I	4-8
aberrantly	O	9-19
expressed	O	20-29
in	O	30-32
a	O	33-34
double	O	35-41
transgenic	O	42-52
mouse	O	53-58
model	O	59-64
for	O	65-68
Alzheimer	O	69-78
'	O	78-79
s	O	79-80
disease	O	81-88
targets	O	89-96
TGF	O	97-100
-	O	100-101
β	O	101-102
type	O	103-107
II	O	108-110
receptor	O	111-119
.  	O	119-122

However	O	0-7
,	O	7-8
it	O	9-11
is	O	12-14
unclear	O	15-22
whether	O	23-30
miRNAs	O	31-37
involved	O	38-46
in	O	47-49
AD	O	50-52
pathogenesis	O	53-65
by	O	66-68
regulating	O	69-79
TGF	O	80-83
-	O	83-84
β	O	84-85
signaling	O	86-95
. 	O	95-97

Growing	O	0-7
body	O	8-12
of	O	13-15
evidence	O	16-24
suggests	O	25-33
that	O	34-38
the	O	39-42
TGF	O	43-46
-	O	46-47
β	O	47-48
signaling	O	49-58
pathway	O	59-66
plays	O	67-72
a	O	73-74
key	O	75-78
role	O	79-83
in	O	84-86
the	O	87-90
pathogenesis	O	91-103
of	O	104-106
AD	O	107-109
. 	O	109-111

Sequence	O	0-8
analysis	O	9-17
revealed	O	18-26
two	O	27-30
putative	O	31-39
binding	O	40-47
sites	O	48-53
for	O	54-57
miR	B	58-61
-	I	61-62
106b	I	62-66
in	O	67-69
the	O	70-73
3	O	74-75
'	O	75-76
UTR	O	77-80
of	O	81-83
the	O	84-87
TβR	O	88-91
II	O	92-94
mRNA	O	95-99
. 	O	99-101

Here	O	0-4
we	O	5-7
found	O	8-13
that	O	14-18
miR	B	19-22
-	I	22-23
106b	I	23-27
and	O	28-31
TGF	O	32-35
-	O	35-36
β	O	36-37
type	O	38-42
II	O	43-45
receptor	O	46-54
(	O	55-56
TβR	O	56-59
II	O	60-62
)	O	62-63
were	O	64-68
aberrantly	O	69-79
expressed	O	80-89
in	O	90-92
APPswe	O	93-99
/	O	99-100
PS∆E9	O	100-105
mice	O	106-110
(	O	111-112
a	O	112-113
double	O	114-120
transgenic	O	121-131
mouse	O	132-137
model	O	138-143
for	O	144-147
AD	O	148-150
)	O	150-151
. 	O	151-153

After	O	0-5
induced	O	6-13
neurodifferentiation	O	14-34
with	O	35-39
all	O	40-43
-	O	43-44
trans	O	44-49
retinoic	O	50-58
acid	O	59-63
,	O	63-64
we	O	65-67
observed	O	68-76
significant	O	77-88
neurodegeneration	O	89-106
in	O	107-109
SH	O	110-112
-	O	112-113
SY5Y	O	113-117
cells	O	118-123
stably	O	124-130
transfected	O	131-142
with	O	143-147
miR	B	148-151
-	I	151-152
106b	I	152-156
. 	O	156-158

Our	O	0-3
results	O	4-11
showed	O	12-18
that	O	19-23
the	O	24-27
expression	O	28-38
of	O	39-41
miR	B	42-45
-	I	45-46
106b	I	46-50
was	O	51-54
inversely	O	55-64
correlated	O	65-75
with	O	76-80
TβR	O	81-84
II	O	85-87
protein	O	88-95
levels	O	96-102
and	O	103-106
miR	B	107-110
-	I	110-111
106b	I	111-115
can	O	116-119
directly	O	120-128
inhibit	O	129-136
the	O	137-140
TβR	O	141-144
II	O	145-147
translation	O	148-159
in	O	160-162
vitro	O	163-168
. 	O	168-170

Exposure	O	0-8
of	O	9-11
SH	O	12-14
-	O	14-15
SY5Y	O	15-19
cells	O	20-25
to	O	26-28
Aβ42	O	29-33
oligomers	O	34-43
led	O	44-47
to	O	48-50
the	O	51-54
expression	O	55-65
of	O	66-68
miR	B	69-72
-	I	72-73
106b	I	73-77
was	O	78-81
first	O	82-87
increased	O	88-97
and	O	98-101
then	O	102-106
decreased	O	107-116
and	O	117-120
TβR	O	121-124
II	O	125-127
levels	O	128-134
reduced	O	135-142
. 	O	142-144

Western	O	0-7
blot	O	8-12
analysis	O	13-21
revealed	O	22-30
unchanged	O	31-40
total	O	41-46
Smad2	O	47-52
/	O	52-53
3	O	53-54
protein	O	55-62
levels	O	63-69
,	O	69-70
but	O	71-74
reduced	O	75-82
phospho	O	83-90
-	O	90-91
Smad2	O	91-96
/	O	96-97
3	O	97-98
(	O	99-100
p	O	100-101
-	O	101-102
Smad2	O	102-107
/	O	107-108
3	O	108-109
)	O	109-110
and	O	111-114
increased	O	115-124
Smad6	O	125-130
/	O	130-131
7	O	131-132
protein	O	133-140
levels	O	141-147
in	O	148-150
the	O	151-154
miR	B	155-158
-	I	158-159
106b	I	159-163
stably	O	164-170
transfected	O	171-182
cell	O	183-187
line	O	188-192
. 	O	192-194

Nuclear	O	0-7
factor	O	8-14
TDP	O	15-18
-	O	18-19
43	O	19-21
can	O	22-25
affect	O	26-32
selected	O	33-41
microRNA	O	42-50
levels	O	51-57
.  	O	57-60

TDP	O	0-3
-	O	3-4
43	O	4-6
has	O	7-10
recently	O	11-19
been	O	20-24
described	O	25-34
as	O	35-37
the	O	38-41
major	O	42-47
component	O	48-57
of	O	58-60
the	O	61-64
inclusions	O	65-75
found	O	76-81
in	O	82-84
the	O	85-88
brain	O	89-94
of	O	95-97
patients	O	98-106
with	O	107-111
a	O	112-113
variety	O	114-121
of	O	122-124
neurodegenerative	O	125-142
diseases	O	143-151
,	O	151-152
such	O	153-157
as	O	158-160
frontotemporal	O	161-175
lobar	O	176-181
degeneration	O	182-194
and	O	195-198
amyotrophic	O	199-210
lateral	O	211-218
sclerosis	O	219-228
. 	O	228-230

Apart	O	0-5
from	O	6-10
its	O	11-14
involvement	O	15-26
in	O	27-29
transcription	O	30-43
,	O	43-44
splicing	O	45-53
and	O	54-57
mRNA	O	58-62
stability	O	63-72
,	O	72-73
TDP	O	74-77
-	O	77-78
43	O	78-80
has	O	81-84
also	O	85-89
been	O	90-94
described	O	95-104
as	O	105-107
a	O	108-109
Drosha	O	110-116
-	O	116-117
associated	O	117-127
protein	O	128-135
. 	O	135-137

TDP	O	0-3
-	O	3-4
43	O	4-6
is	O	7-9
a	O	10-11
ubiquitous	O	12-22
protein	O	23-30
whose	O	31-36
specific	O	37-45
functions	O	46-55
are	O	56-59
probably	O	60-68
crucial	O	69-76
to	O	77-79
establishing	O	80-92
its	O	93-96
pathogenic	O	97-107
role	O	108-112
. 	O	112-114

Here	O	0-4
we	O	5-7
report	O	8-14
for	O	15-18
the	O	19-22
first	O	23-28
time	O	29-33
which	O	34-39
changes	O	40-47
occur	O	48-53
in	O	54-56
the	O	57-60
total	O	61-66
miRNA	O	67-72
population	O	73-83
following	O	84-93
TDP	O	94-97
-	O	97-98
43	O	98-100
knockdown	O	101-110
in	O	111-113
culture	O	114-121
cells	O	122-127
. 	O	127-129

However	O	0-7
,	O	7-8
our	O	9-12
knowledge	O	13-22
of	O	23-25
the	O	26-29
role	O	30-34
of	O	35-37
TDP	O	38-41
-	O	41-42
43	O	42-44
in	O	45-47
the	O	48-51
microRNA	O	52-60
(	O	61-62
miRNA	O	62-67
)	O	67-68
synthesis	O	69-78
pathway	O	79-86
is	O	87-89
limited	O	90-97
to	O	98-100
the	O	101-104
association	O	105-116
mentioned	O	117-126
above	O	127-132
. 	O	132-134

Interestingly	O	0-13
,	O	13-14
both	O	15-19
miRNAs	O	20-26
are	O	27-30
capable	O	31-38
of	O	39-41
binding	O	42-49
directly	O	50-58
to	O	59-61
TDP	O	62-65
-	O	65-66
43	O	66-68
in	O	69-71
different	O	72-81
positions	O	82-91
:	O	91-92
within	O	93-99
the	O	100-103
miRNA	O	104-109
sequence	O	110-118
itself	O	119-125
(	O	126-127
let	B	127-130
-	I	130-131
7b	I	131-133
)	O	133-134
or	O	135-137
in	O	138-140
the	O	141-144
hairpin	O	145-152
precursor	O	153-162
(	O	163-164
miR	B	164-167
-	I	167-168
663	I	168-171
)	O	171-172
. 	O	172-174

In	O	0-2
particular	O	3-13
,	O	13-14
we	O	15-17
have	O	18-22
observed	O	23-31
that	O	32-36
let	B	37-40
-	I	40-41
7b	I	41-43
and	O	44-47
miR	B	48-51
-	I	51-52
663	I	52-55
expression	O	56-66
levels	O	67-73
are	O	74-77
down	O	78-82
-	O	82-83
and	O	84-87
upregulated	O	88-99
,	O	99-100
respectively	O	101-113
. 	O	113-115

Using	O	0-5
microarray	O	6-16
data	O	17-21
and	O	22-25
real	O	26-30
-	O	30-31
time	O	31-35
PCR	O	36-39
we	O	40-42
have	O	43-47
also	O	48-52
identified	O	53-63
several	O	64-71
candidate	O	72-81
transcripts	O	82-93
whose	O	94-99
expression	O	100-110
levels	O	111-117
are	O	118-121
selectively	O	122-133
affected	O	134-142
by	O	143-145
these	O	146-151
TDP	O	152-155
-	O	155-156
43	O	156-158
-	O	158-159
miRNA	O	159-164
interactions	O	165-177
.   	O	177-181

Altered	O	0-7
microRNA	O	8-16
expression	O	17-27
following	O	28-37
traumatic	O	38-47
spinal	O	48-54
cord	O	55-59
injury	O	60-66
.  	O	66-69

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
a	O	23-24
novel	O	25-30
class	O	31-36
of	O	37-39
small	O	40-45
non	O	46-49
-	O	49-50
coding	O	50-56
RNAs	O	57-61
that	O	62-66
negatively	O	67-77
regulate	O	78-86
gene	O	87-91
expression	O	92-102
at	O	103-105
the	O	106-109
posttranscriptional	O	110-129
level	O	130-135
by	O	136-138
binding	O	139-146
to	O	147-149
the	O	150-153
3	O	154-155
'	O	155-156
untranslated	O	157-169
region	O	170-176
of	O	177-179
target	O	180-186
mRNAs	O	187-192
leading	O	193-200
to	O	201-203
their	O	204-209
translational	O	210-223
inhibition	O	224-234
or	O	235-237
sometimes	O	238-247
degradation	O	248-259
. 	O	259-261

We	O	0-2
uncovered	O	3-12
a	O	13-14
previously	O	15-25
unknown	O	26-33
alteration	O	34-44
in	O	45-47
temporal	O	48-56
expression	O	57-67
of	O	68-70
a	O	71-72
large	O	73-78
set	O	79-82
of	O	83-85
miRNAs	O	86-92
following	O	93-102
a	O	103-104
contusive	O	105-114
spinal	O	115-121
cord	O	122-126
injury	O	127-133
(	O	134-135
SCI	O	135-138
)	O	138-139
in	O	140-142
adult	O	143-148
rats	O	149-153
using	O	154-159
microarray	O	160-170
analysis	O	171-179
. 	O	179-181

These	O	0-5
altered	O	6-13
miRNAs	O	14-20
can	O	21-24
be	O	25-27
classified	O	28-38
into	O	39-43
3	O	44-45
categories	O	46-56
:	O	56-57
(	O	58-59
1	O	59-60
)	O	60-61
up	O	62-64
-	O	64-65
regulation	O	65-75
,	O	75-76
(	O	77-78
2	O	78-79
)	O	79-80
down	O	81-85
-	O	85-86
regulation	O	86-96
and	O	97-100
(	O	101-102
3	O	102-103
)	O	103-104
an	O	105-107
early	O	108-113
up	O	114-116
-	O	116-117
regulation	O	117-127
at	O	128-130
4	O	131-132
h	O	133-134
followed	O	135-143
by	O	144-146
down	O	147-151
-	O	151-152
regulation	O	152-162
at	O	163-165
1	O	166-167
and	O	168-171
7	O	172-173
days	O	174-178
post	O	179-183
-	O	183-184
SCI	O	184-187
. 	O	187-189

The	O	0-3
bioinformatics	O	4-18
analysis	O	19-27
indicates	O	28-37
that	O	38-42
the	O	43-46
potential	O	47-56
targets	O	57-64
for	O	65-68
miRNAs	O	69-75
altered	O	76-83
after	O	84-89
SCI	O	90-93
include	O	94-101
genes	O	102-107
encoding	O	108-116
components	O	117-127
that	O	128-132
are	O	133-136
involved	O	137-145
in	O	146-148
the	O	149-152
inflammation	O	153-165
,	O	165-166
oxidation	O	167-176
,	O	176-177
and	O	178-181
apoptosis	O	182-191
that	O	192-196
are	O	197-200
known	O	201-206
to	O	207-209
play	O	210-214
important	O	215-224
roles	O	225-230
in	O	231-233
the	O	234-237
pathogenesis	O	238-250
of	O	251-253
SCI	O	254-257
. 	O	257-259

These	O	0-5
findings	O	6-14
suggest	O	15-22
that	O	23-27
abnormal	O	28-36
expression	O	37-47
of	O	48-50
miRNAs	O	51-57
may	O	58-61
contribute	O	62-72
to	O	73-75
the	O	76-79
pathogenesis	O	80-92
of	O	93-95
SCI	O	96-99
and	O	100-103
are	O	104-107
potential	O	108-117
targets	O	118-125
for	O	126-129
therapeutic	O	130-141
interventions	O	142-155
following	O	156-165
SCI	O	166-169
.   	O	169-173

Demyelinating	O	0-13
process	O	14-21
may	O	22-25
be	O	26-28
the	O	29-32
feature	O	33-40
of	O	41-43
nervous	O	44-51
impairment	O	52-62
in	O	63-65
systemic	O	66-74
lupus	O	75-80
erythematosus	O	81-94
,	O	94-95
Behcet	O	96-102
'	O	102-103
s	O	103-104
disease	O	105-112
(	O	113-114
BD	O	114-116
)	O	116-117
,	O	117-118
Sjoegren	O	119-127
'	O	127-128
s	O	128-129
syndrome	O	130-138
(	O	139-140
SS	O	140-142
)	O	142-143
,	O	143-144
systemic	O	145-153
sclerosis	O	154-163
(	O	164-165
SSc	O	165-168
)	O	168-169
or	O	170-172
very	O	173-177
rarely	O	178-184
other	O	185-190
systemic	O	191-199
autoimmune	O	200-210
diseases	O	211-219
. 	O	219-221

An	O	0-2
acute	O	3-8
isolated	O	9-17
neurological	O	18-30
syndrome	O	31-39
,	O	39-40
as	O	41-43
the	O	44-47
most	O	48-52
common	O	53-59
symptom	O	60-67
of	O	68-70
MS	O	71-73
can	O	74-77
sometimes	O	78-87
be	O	88-90
the	O	91-94
only	O	95-99
feature	O	100-107
or	O	108-110
even	O	111-115
first	O	116-121
manifestation	O	122-135
of	O	136-138
nervous	O	139-146
impairment	O	147-157
in	O	158-160
connective	O	161-171
tissue	O	172-178
disease	O	179-186
,	O	186-187
hence	O	188-193
presenting	O	194-204
the	O	205-208
diagnostic	O	209-219
problem	O	220-227
. 	O	227-229

Although	O	0-8
the	O	9-12
white	O	13-18
matter	O	19-25
abnormalities	O	26-39
seen	O	40-44
by	O	45-47
magnetic	O	48-56
resonance	O	57-66
imaging	O	67-74
may	O	75-78
be	O	79-81
similar	O	82-89
in	O	90-92
non	O	93-96
-	O	96-97
MS	O	97-99
autoimmune	O	100-110
demyelination	O	111-124
and	O	125-128
MS	O	129-131
,	O	131-132
it	O	133-135
is	O	136-138
the	O	139-142
most	O	143-147
important	O	148-157
diagnostic	O	158-168
tool	O	169-173
in	O	174-176
the	O	177-180
differential	O	181-193
diagnosis	O	194-203
of	O	204-206
the	O	207-210
mentioned	O	211-220
conditions	O	221-231
. 	O	231-233

Investigating	O	0-13
the	O	14-17
presence	O	18-26
of	O	27-29
various	O	30-37
autoantibodies	O	38-52
potentially	O	53-64
involved	O	65-73
in	O	74-76
the	O	77-80
pathogenesis	O	81-93
of	O	94-96
demyelinating	O	97-110
lesions	O	111-118
as	O	119-121
well	O	122-126
as	O	127-129
cerebrospinal	O	130-143
fluid	O	144-149
(	O	150-151
CSF	O	151-154
)	O	154-155
analysis	O	156-164
can	O	165-168
be	O	169-171
helpful	O	172-179
.   	O	179-183

Non	O	0-3
-	O	3-4
MS	O	4-6
autoimmune	O	7-17
demyelination	O	18-31
.  	O	31-34

Connective	O	0-10
tissue	O	11-17
diseases	O	18-26
can	O	27-30
be	O	31-33
characterised	O	34-47
by	O	48-50
central	O	51-58
nervous	O	59-66
system	O	67-73
(	O	74-75
CNS	O	75-78
)	O	78-79
involvement	O	80-91
,	O	91-92
in	O	93-95
some	O	96-100
patients	O	101-109
manifested	O	110-120
by	O	121-123
demyelination	O	124-137
areas	O	138-143
in	O	144-146
the	O	147-150
white	O	151-156
matter	O	157-163
of	O	164-166
the	O	167-170
brain	O	171-176
and	O	177-180
spinal	O	181-187
cord	O	188-192
,	O	192-193
which	O	194-199
are	O	200-203
difficult	O	204-213
to	O	214-216
differentiate	O	217-230
from	O	231-235
multiple	O	236-244
sclerosis	O	245-254
(	O	255-256
MS	O	256-258
)	O	258-259
and	O	260-263
other	O	264-269
demyelinating	O	270-283
processes	O	284-293
,	O	293-294
such	O	295-299
as	O	300-302
transverse	O	303-313
myelitis	O	314-322
and	O	323-326
optic	O	327-332
neuritis	O	333-341
. 	O	341-343

Targeting	O	0-9
miRNAs	O	10-16
in	O	17-19
Alzheimer	O	20-29
'	O	29-30
s	O	30-31
disease	O	32-39
.     	O	39-45

CONCLUSIONS	O	0-11
:	O	11-12
These	O	13-18
results	O	19-26
demonstrate	O	27-38
that	O	39-43
tissue	O	44-50
-	O	50-51
specific	O	51-59
miRNAs	O	60-66
may	O	67-70
serve	O	71-76
as	O	77-79
diagnostically	O	80-94
sensitive	O	95-104
plasma	O	105-111
biomarkers	O	112-122
of	O	123-125
tissue	O	126-132
injury	O	133-139
.   	O	139-143

The	O	0-3
miR	B	4-7
-	I	7-8
124	I	8-11
concentration	O	12-25
increased	O	26-35
in	O	36-38
the	O	39-42
plasma	O	43-49
of	O	50-52
rats	O	53-57
8	O	58-59
h	O	60-61
after	O	62-67
surgery	O	68-75
to	O	76-78
produce	O	79-86
brain	O	87-92
injury	O	93-99
and	O	100-103
peaked	O	104-110
at	O	111-113
24	O	114-116
h	O	117-118
,	O	118-119
while	O	120-125
the	O	126-129
miR	B	130-133
-	I	133-134
122	I	134-137
and	O	138-141
miR	B	142-145
-	I	145-146
133a	I	146-150
concentrations	O	151-165
remained	O	166-174
at	O	175-177
baseline	O	178-186
values	O	187-193
. 	O	193-195

Furthermore	O	0-11
,	O	11-12
miR	B	13-16
-	I	16-17
122	I	17-20
exhibited	O	21-30
a	O	31-32
diagnostic	O	33-43
sensitivity	O	44-55
superior	O	56-64
to	O	65-67
that	O	68-72
of	O	73-75
ALT	O	76-79
when	O	80-84
the	O	85-88
results	O	89-96
were	O	97-101
correlated	O	102-112
to	O	113-115
the	O	116-119
liver	O	120-125
histopathologic	O	126-141
results	O	142-149
. 	O	149-151

Plasma	O	0-6
MicroRNAs	O	7-16
as	O	17-19
sensitive	O	20-29
and	O	30-33
specific	O	34-42
biomarkers	O	43-53
of	O	54-56
tissue	O	57-63
injury	O	64-70
.  	O	70-73

BACKGROUND	O	0-10
:	O	10-11
MicroRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
are	O	31-34
endogenous	O	35-45
,	O	45-46
small	O	47-52
noncoding	O	53-62
RNAs	O	63-67
. 	O	67-69

Because	O	0-7
of	O	8-10
their	O	11-16
size	O	17-21
,	O	21-22
abundance	O	23-32
,	O	32-33
tissue	O	34-40
specificity	O	41-52
,	O	52-53
and	O	54-57
relative	O	58-66
stability	O	67-76
in	O	77-79
plasma	O	80-86
,	O	86-87
miRNAs	O	88-94
hold	O	95-99
promise	O	100-107
as	O	108-110
unique	O	111-117
accessible	O	118-128
biomarkers	O	129-139
to	O	140-142
monitor	O	143-150
tissue	O	151-157
injury	O	158-164
. 	O	164-166

METHODS	O	0-7
:	O	7-8
We	O	9-11
investigated	O	12-24
the	O	25-28
use	O	29-32
of	O	33-35
liver	O	36-41
-	O	41-42
,	O	42-43
muscle	O	44-50
-	O	50-51
and	O	52-55
brain	O	56-61
-	O	61-62
specific	O	62-70
miRNAs	O	71-77
as	O	78-80
circulating	O	81-92
biomarkers	O	93-103
of	O	104-106
tissue	O	107-113
injury	O	114-120
. 	O	120-122

We	O	0-2
used	O	3-7
a	O	8-9
highly	O	10-16
sensitive	O	17-26
quantitative	O	27-39
PCR	O	40-43
assay	O	44-49
to	O	50-52
measure	O	53-60
specific	O	61-69
miRNAs	O	70-76
(	O	77-78
miR	B	78-81
-	I	81-82
122	I	82-85
,	O	85-86
miR	B	87-90
-	I	90-91
133a	I	91-95
,	O	95-96
and	O	97-100
miR	B	101-104
-	I	104-105
124	I	105-108
)	O	108-109
in	O	110-112
plasma	O	113-119
samples	O	120-127
from	O	128-132
rats	O	133-137
treated	O	138-145
with	O	146-150
liver	O	151-156
or	O	157-159
muscle	O	160-166
toxicants	O	167-176
and	O	177-180
from	O	181-185
a	O	186-187
rat	O	188-191
surgical	O	192-200
model	O	201-206
of	O	207-209
stroke	O	210-216
. 	O	216-218

RESULTS	O	0-7
:	O	7-8
We	O	9-11
observed	O	12-20
increases	O	21-30
in	O	31-33
plasma	O	34-40
concentrations	O	41-55
of	O	56-58
miR	B	59-62
-	I	62-63
122	I	63-66
,	O	66-67
miR	B	68-71
-	I	71-72
133a	I	72-76
,	O	76-77
and	O	78-81
miR	B	82-85
-	I	85-86
124	I	86-89
corresponding	O	90-103
to	O	104-106
injuries	O	107-115
in	O	116-118
liver	O	119-124
,	O	124-125
muscle	O	126-132
,	O	132-133
and	O	134-137
brain	O	138-143
,	O	143-144
respectively	O	145-157
. 	O	157-159

miR	B	0-3
-	I	3-4
122	I	4-7
and	O	8-11
miR	B	12-15
-	I	15-16
133a	I	16-20
illustrated	O	21-32
specificity	O	33-44
for	O	45-48
liver	O	49-54
and	O	55-58
muscle	O	59-65
toxicity	O	66-74
,	O	74-75
respectively	O	76-88
,	O	88-89
because	O	90-97
they	O	98-102
were	O	103-107
not	O	108-111
detectable	O	112-122
in	O	123-125
the	O	126-129
plasma	O	130-136
of	O	137-139
animals	O	140-147
with	O	148-152
toxicity	O	153-161
to	O	162-164
the	O	165-168
other	O	169-174
organ	O	175-180
. 	O	180-182

This	O	0-4
result	O	5-11
contrasted	O	12-22
with	O	23-27
the	O	28-31
results	O	32-39
for	O	40-43
alanine	O	44-51
aminotransferase	O	52-68
(	O	69-70
ALT	O	70-73
)	O	73-74
and	O	75-78
aspartate	O	79-88
aminotransferase	O	89-105
,	O	105-106
which	O	107-112
were	O	113-117
both	O	118-122
increased	O	123-132
with	O	133-137
either	O	138-144
organ	O	145-150
toxicity	O	151-159
. 	O	159-161

Atrial	O	0-6
fibrillation	O	7-19
(	O	20-21
AF	O	21-23
)	O	23-24
is	O	25-27
an	O	28-30
emerging	O	31-39
clinical	O	40-48
problem	O	49-56
with	O	57-61
multifaceted	O	62-74
issues	O	75-81
:	O	81-82
current	O	83-90
and	O	91-94
expected	O	95-103
prevalence	O	104-114
,	O	114-115
significant	O	116-127
morbidity	O	128-137
,	O	137-138
potentially	O	139-150
fatal	O	151-156
outcome	O	157-164
(	O	165-166
e	O	166-167
.	O	167-168
g	O	168-169
.	O	169-170
,	O	170-171
stroke	O	172-178
)	O	178-179
and	O	180-183
gaps	O	184-188
in	O	189-191
therapeutic	O	192-203
approaches	O	204-214
. 	O	214-216

Targeting	O	0-9
the	O	10-13
arrhythmogenic	O	14-28
substrate	O	29-38
in	O	39-41
atrial	O	42-48
fibrillation	O	49-61
:	O	61-62
focus	O	63-68
on	O	69-71
structural	O	72-82
remodeling	O	83-93
.  	O	93-96

Although	O	0-8
a	O	9-10
number	O	11-17
of	O	18-20
drugs	O	21-26
have	O	27-31
just	O	32-36
come	O	37-41
out	O	42-45
of	O	46-48
the	O	49-52
pipeline	O	53-61
with	O	62-66
promising	O	67-76
results	O	77-84
(	O	85-86
e	O	86-87
.	O	87-88
g	O	88-89
.	O	89-90
,	O	90-91
dronedarone	O	92-103
)	O	103-104
,	O	104-105
the	O	106-109
question	O	110-118
arises	O	119-125
whether	O	126-133
channel	O	134-141
-	O	141-142
targeted	O	142-150
drugs	O	151-156
represent	O	157-166
the	O	167-170
only	O	171-175
viable	O	176-182
approach	O	183-191
. 	O	191-193

Current	O	0-7
anti	O	8-12
-	O	12-13
arrhythmic	O	13-23
strategies	O	24-34
not	O	35-38
only	O	39-43
fail	O	44-48
to	O	49-51
guarantee	O	52-61
effective	O	62-71
rhythm	O	72-78
control	O	79-86
,	O	86-87
but	O	88-91
also	O	92-96
cause	O	97-102
"	O	103-104
on	O	104-106
target	O	107-113
"	O	113-114
(	O	115-116
i	O	116-117
.	O	117-118
e	O	118-119
.	O	119-120
,	O	120-121
pro	O	122-125
-	O	125-126
arrhythmia	O	126-136
,	O	136-137
namely	O	138-144
torsade	O	145-152
de	O	153-155
pointes	O	156-163
)	O	163-164
and	O	165-168
"	O	169-170
off	O	170-173
target	O	174-180
"	O	180-181
(	O	182-183
i	O	183-184
.	O	184-185
e	O	185-186
.	O	186-187
,	O	187-188
extra	O	189-194
-	O	194-195
cardiac	O	195-202
toxicities	O	203-213
)	O	213-214
side	O	215-219
effects	O	220-227
. 	O	227-229

Fascinating	O	0-11
and	O	12-15
innovative	O	16-26
strategies	O	27-37
have	O	38-42
been	O	43-47
proposed	O	48-56
(	O	57-58
e	O	58-59
.	O	59-60
g	O	60-61
.	O	61-62
,	O	62-63
miRNAs	O	64-70
modulation	O	71-81
)	O	81-82
,	O	82-83
but	O	84-87
the	O	88-91
actual	O	92-98
benefit	O	99-106
is	O	107-109
debated	O	110-117
. 	O	117-119

This	O	0-4
review	O	5-11
will	O	12-16
provide	O	17-24
mechanistic	O	25-36
insights	O	37-45
into	O	46-50
structural	O	51-61
remodeling	O	62-72
and	O	73-76
highlight	O	77-86
emerging	O	87-95
upstream	O	96-104
strategies	O	105-115
in	O	116-118
AF	O	119-121
management	O	122-132
.   	O	132-136

A	O	0-1
body	O	2-6
of	O	7-9
evidence	O	10-18
has	O	19-22
emerged	O	23-30
supporting	O	31-41
structural	O	42-52
remodeling	O	53-63
as	O	64-66
the	O	67-70
main	O	71-75
arrhythmogenic	O	76-90
substrate	O	91-100
perpetuating	O	101-113
AF	O	114-116
.	O	116-117
Fibrosis	O	118-126
,	O	126-127
inflammation	O	128-140
and	O	141-144
oxidative	O	145-154
stress	O	155-161
appear	O	162-168
strongly	O	169-177
interconnected	O	178-192
in	O	193-195
the	O	196-199
pathogenesis	O	200-212
of	O	213-215
remodeling	O	216-226
-	O	226-227
induced	O	227-234
abnormalities	O	235-248
. 	O	248-250

Moreover	O	0-8
,	O	8-9
insights	O	10-18
into	O	19-23
extracellular	O	24-37
matrix	O	38-44
network	O	45-52
strongly	O	53-61
suggested	O	62-71
an	O	72-74
active	O	75-81
cross	O	82-87
-	O	87-88
talk	O	88-92
within	O	93-99
the	O	100-103
cardiac	O	104-111
microenvironment	O	112-128
,	O	128-129
which	O	130-135
should	O	136-142
be	O	143-145
further	O	146-153
investigated	O	154-166
as	O	167-169
promising	O	170-179
"	O	180-181
anti	O	181-185
-	O	185-186
remodeling	O	186-196
"	O	196-197
approach	O	198-206
. 	O	206-208

Therefore	O	0-9
,	O	9-10
pharmacological	O	11-26
modulation	O	27-37
of	O	38-40
non	O	41-44
-	O	44-45
ionic	O	45-50
targets	O	51-58
(	O	59-60
the	O	60-63
so	O	64-66
called	O	67-73
"	O	74-75
upstream	O	75-83
"	O	83-84
therapy	O	85-92
)	O	92-93
has	O	94-97
gained	O	98-104
interest	O	105-113
as	O	114-116
a	O	117-118
preventive	O	119-129
strategy	O	130-138
in	O	139-141
AF	O	142-144
. 	O	144-146

At	O	0-2
the	O	3-6
present	O	7-14
state	O	15-20
of	O	21-23
knowledge	O	24-33
,	O	33-34
renin	O	35-40
-	O	40-41
angiotensin	O	41-52
-	O	52-53
aldosterone	O	53-64
system	O	65-71
blockers	O	72-80
and	O	81-84
statins	O	85-92
offer	O	93-98
evidence	O	99-107
for	O	108-111
potential	O	112-121
clinical	O	122-130
exploitation	O	131-143
,	O	143-144
while	O	145-150
several	O	151-158
remodeling	O	159-169
-	O	169-170
targeted	O	170-178
therapies	O	179-188
have	O	189-193
been	O	194-198
tested	O	199-205
only	O	206-210
experimentally	O	211-225
or	O	226-228
failed	O	229-235
when	O	236-240
studied	O	241-248
for	O	249-252
human	O	253-258
validation	O	259-269
. 	O	269-271

Epigenetics	O	0-11
are	O	12-15
defined	O	16-23
,	O	23-24
in	O	25-27
broad	O	28-33
-	O	33-34
terms	O	34-39
,	O	39-40
as	O	41-43
alterations	O	44-55
in	O	56-58
gene	O	59-63
expression	O	64-74
without	O	75-82
changes	O	83-90
in	O	91-93
DNA	O	94-97
sequence	O	98-106
. 	O	106-108

Epigenetic	O	0-10
changes	O	11-18
in	O	19-21
gliomas	O	22-29
.  	O	29-32

In	O	0-2
this	O	3-7
review	O	8-14
,	O	14-15
we	O	16-18
will	O	19-23
first	O	24-29
describe	O	30-38
briefly	O	39-46
histone	O	47-54
modifications	O	55-68
,	O	68-69
DNA	O	70-73
methylation	O	74-85
and	O	86-89
miRNAs	O	90-96
and	O	97-100
the	O	101-104
functions	O	105-114
of	O	115-117
these	O	118-123
epigenetic	O	124-134
marks	O	135-140
during	O	141-147
different	O	148-157
cellular	O	158-166
processes	O	167-176
involving	O	177-186
DNA	O	187-190
metabolism	O	191-201
. 	O	201-203

While	O	0-5
histone	O	6-13
modifications	O	14-27
and	O	28-31
DNA	O	32-35
methylation	O	36-47
are	O	48-51
two	O	52-55
classical	O	56-65
means	O	66-71
to	O	72-74
regulate	O	75-83
gene	O	84-88
expression	O	89-99
,	O	99-100
miRNA	O	101-106
has	O	107-110
also	O	111-115
recently	O	116-124
been	O	125-129
documented	O	130-140
to	O	141-143
govern	O	144-150
gene	O	151-155
expression	O	156-166
in	O	167-169
normal	O	170-176
as	O	177-179
well	O	180-184
as	O	185-187
cancer	O	188-194
cells	O	195-200
. 	O	200-202

We	O	0-2
expect	O	3-9
that	O	10-14
novel	O	15-20
therapies	O	21-30
will	O	31-35
be	O	36-38
developed	O	39-48
to	O	49-51
counter	O	52-59
epigenetic	O	60-70
changes	O	71-78
in	O	79-81
this	O	82-86
deadly	O	87-93
disease	O	94-101
.   	O	101-105

We	O	0-2
will	O	3-7
then	O	8-12
highlight	O	13-22
some	O	23-27
epigenetic	O	28-38
changes	O	39-46
in	O	47-49
glioblastomas	O	50-63
,	O	63-64
a	O	65-66
malignant	O	67-76
form	O	77-81
of	O	82-84
brain	O	85-90
tumor	O	91-96
,	O	96-97
and	O	98-101
potential	O	102-111
application	O	112-123
of	O	124-126
epigenetic	O	127-137
means	O	138-143
for	O	144-147
diagnosis	O	148-157
,	O	157-158
prognosis	O	159-168
,	O	168-169
and	O	170-173
treatment	O	174-183
of	O	184-186
gliomas	O	187-194
. 	O	194-196

Interpretation	O	0-14
and	O	15-18
applicability	O	19-32
of	O	33-35
microRNA	O	36-44
data	O	45-49
to	O	50-52
the	O	53-56
context	O	57-64
of	O	65-67
Alzheimer	O	68-77
'	O	77-78
s	O	78-79
and	O	80-83
age	O	84-87
-	O	87-88
related	O	88-95
diseases	O	96-104
.  	O	104-107

Generated	O	0-9
by	O	10-12
the	O	13-16
ribonuclease	O	17-29
III	O	30-33
Dicer	O	34-39
,	O	39-40
microRNAs	O	41-50
(	O	51-52
miRNAs	O	52-58
)	O	58-59
are	O	60-63
predicted	O	64-73
to	O	74-76
regulate	O	77-85
up	O	86-88
to	O	89-91
90	O	92-94
%	O	94-95
of	O	96-98
the	O	99-102
genes	O	103-108
in	O	109-111
humans	O	112-118
,	O	118-119
suggesting	O	120-130
that	O	131-135
they	O	136-140
may	O	141-144
control	O	145-152
every	O	153-158
cellular	O	159-167
processes	O	168-177
in	O	178-180
all	O	181-184
cells	O	185-190
and	O	191-194
tissues	O	195-202
of	O	203-205
the	O	206-209
human	O	210-215
body	O	216-220
! 	O	220-222

Likely	O	0-6
to	O	7-9
play	O	10-14
a	O	15-16
central	O	17-24
role	O	25-29
in	O	30-32
health	O	33-39
and	O	40-43
disease	O	44-51
,	O	51-52
a	O	53-54
dysfunctional	O	55-68
miRNA	O	69-74
-	O	74-75
based	O	75-80
regulation	O	81-91
of	O	92-94
gene	O	95-99
expression	O	100-110
may	O	111-114
represent	O	115-124
the	O	125-128
main	O	129-133
etiologic	O	134-143
factor	O	144-150
underlying	O	151-161
age	O	162-165
-	O	165-166
related	O	166-173
diseases	O	174-182
affecting	O	183-192
major	O	193-198
organs	O	199-205
,	O	205-206
such	O	207-211
as	O	212-214
the	O	215-218
brain	O	219-224
. 	O	224-226

Here	O	0-4
,	O	4-5
we	O	6-8
discuss	O	9-16
some	O	17-21
of	O	22-24
the	O	25-28
limitations	O	29-40
associated	O	41-51
to	O	52-54
the	O	55-58
interpretation	O	59-73
and	O	74-77
applicability	O	78-91
of	O	92-94
miRNA	O	95-100
data	O	101-105
,	O	105-106
based	O	107-112
on	O	113-115
our	O	116-119
recent	O	120-126
study	O	127-132
on	O	133-135
the	O	136-139
etiology	O	140-148
of	O	149-151
Alzheimer	O	152-161
'	O	161-162
s	O	162-163
disease	O	164-171
(	O	172-173
AD	O	173-175
)	O	175-176
. 	O	176-178

Using	O	0-5
transiently	O	6-17
transfected	O	18-29
murine	O	30-36
neuronal	O	37-45
N2a	O	46-49
cells	O	50-55
in	O	56-58
culture	O	59-66
,	O	66-67
in	O	68-70
parallel	O	71-79
to	O	80-82
a	O	83-84
mouse	O	85-90
model	O	91-96
of	O	97-99
AD	O	100-102
,	O	102-103
we	O	104-106
were	O	107-111
able	O	112-116
to	O	117-119
demonstrate	O	120-131
a	O	132-133
role	O	134-138
for	O	139-142
two	O	143-146
miRNAs	O	147-153
(	O	154-155
miR	B	155-158
-	I	158-159
298	I	159-162
and	O	163-166
miR	B	167-170
-	I	170-171
328	I	171-174
)	O	174-175
in	O	176-178
the	O	179-182
regulation	O	183-193
of	O	194-196
beta	O	197-201
-	O	201-202
amyloid	O	202-209
(	O	210-211
Abeta	O	211-216
)	O	216-217
precursor	O	218-227
protein	O	228-235
(	O	236-237
APP	O	237-240
)	O	240-241
-	O	241-242
converting	O	242-252
enzyme	O	253-259
(	O	260-261
BACE	O	261-265
)	O	265-266
messenger	O	267-276
RNA	O	277-280
(	O	281-282
mRNA	O	282-286
)	O	286-287
translation	O	288-299
,	O	299-300
thereby	O	301-308
providing	O	309-318
key	O	319-322
insights	O	323-331
into	O	332-336
the	O	337-340
molecular	O	341-350
basis	O	351-356
underlying	O	357-367
BACE	O	368-372
deregulation	O	373-385
in	O	386-388
AD	O	389-391
. 	O	391-393

However	O	0-7
,	O	7-8
whether	O	9-16
miRNA	O	17-22
data	O	23-27
can	O	28-31
be	O	32-34
extrapolated	O	35-47
and	O	48-51
transposed	O	52-62
to	O	63-65
the	O	66-69
human	O	70-75
context	O	76-83
of	O	84-86
age	O	87-90
-	O	90-91
related	O	91-98
diseases	O	99-107
,	O	107-108
such	O	109-113
as	O	114-116
AD	O	117-119
,	O	119-120
not	O	121-124
only	O	125-129
requires	O	130-138
caution	O	139-146
,	O	146-147
but	O	148-151
also	O	152-156
warrants	O	157-165
several	O	166-173
considerations	O	174-188
.   	O	188-192

Levels	O	0-6
of	O	7-9
protein	O	10-17
expression	O	18-28
of	O	29-31
endothelial	O	32-43
NO	O	44-46
synthase	O	47-55
(	O	56-57
eNOS	O	57-61
)	O	61-62
,	O	62-63
caveolin	O	64-72
-	O	72-73
1	O	73-74
,	O	74-75
and	O	76-79
calmodulin	O	80-90
were	O	91-95
assessed	O	96-104
in	O	105-107
carotid	O	108-115
arteries	O	116-124
using	O	125-130
Western	O	131-138
analysis	O	139-147
. 	O	147-149

Plasma	O	0-6
NO	O	7-9
levels	O	10-16
were	O	17-21
doubled	O	22-29
by	O	30-32
daidzein	O	33-41
or	O	42-44
17beta	O	45-51
-	O	51-52
estradiol	O	52-61
. 	O	61-63

NO	O	0-2
production	O	3-13
and	O	14-17
endothelium	O	18-29
-	O	29-30
dependent	O	30-39
contraction	O	40-51
in	O	52-54
response	O	55-63
to	O	64-66
the	O	67-70
NOS	O	71-74
inhibitor	O	75-84
NG	O	85-87
-	O	87-88
nitro	O	88-93
-	O	93-94
L	O	94-95
-	O	95-96
arginine	O	96-104
(	O	105-106
L	O	106-107
-	O	107-108
NNA	O	108-111
;	O	111-112
100	O	113-116
microM	O	117-123
)	O	123-124
was	O	125-128
enhanced	O	129-137
by	O	138-140
50	O	141-143
to	O	144-146
100	O	147-150
%	O	150-151
in	O	152-154
carotid	O	155-162
arteries	O	163-171
from	O	172-176
rats	O	177-181
treated	O	182-189
with	O	190-194
daidzein	O	195-203
or	O	204-206
17beta	O	207-213
-	O	213-214
estradiol	O	214-223
. 	O	223-225

Acetylcholine	O	0-13
-	O	13-14
induced	O	14-21
relaxation	O	22-32
was	O	33-36
selectively	O	37-48
enhanced	O	49-57
in	O	58-60
carotid	O	61-68
arteries	O	69-77
from	O	78-82
rats	O	83-87
treated	O	88-95
with	O	96-100
daidzein	O	101-109
. 	O	109-111

The	O	0-3
use	O	4-7
of	O	8-10
estrogen	O	11-19
for	O	20-23
protection	O	24-34
against	O	35-42
vascular	O	43-51
dysfunction	O	52-63
is	O	64-66
limited	O	67-74
due	O	75-78
to	O	79-81
its	O	82-85
effects	O	86-93
on	O	94-96
the	O	97-100
reproductive	O	101-113
system	O	114-120
,	O	120-121
particularly	O	122-134
in	O	135-137
males	O	138-143
. 	O	143-145

We	O	0-2
postulated	O	3-13
that	O	14-18
daidzein	O	19-27
,	O	27-28
an	O	29-31
isoflavone	O	32-42
with	O	43-47
estrogen	O	48-56
-	O	56-57
like	O	57-61
effects	O	62-69
on	O	70-72
the	O	73-76
systemic	O	77-85
vasculature	O	86-97
but	O	98-101
not	O	102-105
the	O	106-109
reproductive	O	110-122
system	O	123-129
,	O	129-130
might	O	131-136
enhance	O	137-144
nitric	O	145-151
oxide	O	152-157
(	O	158-159
NO	O	159-161
)	O	161-162
-	O	162-163
mediated	O	163-171
cerebral	O	172-180
vasodilatation	O	181-195
. 	O	195-197

Male	O	0-4
rats	O	5-9
were	O	10-14
administered	O	15-27
vehicle	O	28-35
,	O	35-36
17beta	O	37-43
-	O	43-44
estradiol	O	44-53
(	O	54-55
0	O	55-56
.	O	56-57
1	O	57-58
mg	O	59-61
/	O	61-62
kg	O	62-64
s	O	65-66
.	O	66-67
c	O	67-68
.	O	68-69
)	O	69-70
,	O	70-71
or	O	72-74
daidzein	O	75-83
(	O	84-85
0	O	85-86
.	O	86-87
2	O	87-88
mg	O	89-91
/	O	91-92
kg	O	92-94
s	O	95-96
.	O	96-97
c	O	97-98
.	O	98-99
)	O	99-100
daily	O	101-106
for	O	107-110
7	O	111-112
days	O	113-117
. 	O	117-119

Basal	O	0-5
and	O	6-9
acetylcholine	O	10-23
-	O	23-24
stimulated	O	24-34
NO	O	35-37
release	O	38-45
was	O	46-49
assessed	O	50-58
in	O	59-61
vitro	O	62-67
via	O	68-71
carotid	O	72-79
arterial	O	80-88
rings	O	89-94
or	O	95-97
in	O	98-100
vivo	O	101-105
by	O	106-108
measuring	O	109-118
changes	O	119-126
in	O	127-129
basilar	O	130-137
artery	O	138-144
diameter	O	145-153
. 	O	153-155

Similarly	O	0-9
,	O	9-10
constrictor	O	11-22
responses	O	23-32
of	O	33-35
the	O	36-39
basilar	O	40-47
artery	O	48-54
to	O	55-57
L	O	58-59
-	O	59-60
NNA	O	60-63
in	O	64-66
vivo	O	67-71
were	O	72-76
selectively	O	77-88
augmented	O	89-98
by	O	99-101
approximately	O	102-115
100	O	116-119
%	O	119-120
by	O	121-123
17beta	O	124-130
-	O	130-131
estradiol	O	131-140
treatment	O	141-150
and	O	151-154
tended	O	155-161
to	O	162-164
be	O	165-167
approximately	O	168-181
50	O	182-184
%	O	184-185
greater	O	186-193
in	O	194-196
daidzein	O	197-205
-	O	205-206
treated	O	206-213
rats	O	214-218
. 	O	218-220

Effect	O	0-6
of	O	7-9
short	O	10-15
-	O	15-16
term	O	16-20
phytoestrogen	O	21-34
treatment	O	35-44
in	O	45-47
male	O	48-52
rats	O	53-57
on	O	58-60
nitric	O	61-67
oxide	O	68-73
-	O	73-74
mediated	O	74-82
responses	O	83-92
of	O	93-95
carotid	O	96-103
and	O	104-107
cerebral	O	108-116
arteries	O	117-125
:	O	125-126
comparison	O	127-137
with	O	138-142
17beta	O	143-149
-	O	149-150
estradiol	O	150-159
.  	O	159-162

These	O	0-5
data	O	6-10
suggest	O	11-18
that	O	19-23
short	O	24-29
-	O	29-30
term	O	30-34
administration	O	35-49
of	O	50-52
daidzein	O	53-61
or	O	62-64
17beta	O	65-71
-	O	71-72
estradiol	O	72-81
modulates	O	82-91
cerebral	O	92-100
artery	O	101-107
reactivity	O	108-118
in	O	119-121
males	O	122-127
by	O	128-130
enhancing	O	131-140
synthesis	O	141-150
and	O	151-154
release	O	155-162
of	O	163-165
endothelium	O	166-177
-	O	177-178
derived	O	178-185
NO	O	186-188
.	O	188-189
Isoflavone	O	190-200
therapy	O	201-208
may	O	209-212
therefore	O	213-222
be	O	223-225
a	O	226-227
feasible	O	228-236
approach	O	237-245
to	O	246-248
protect	O	249-256
against	O	257-264
cerebrovascular	O	265-280
disease	O	281-288
and	O	289-292
stroke	O	293-299
.   	O	299-303

Expression	O	0-10
of	O	11-13
caveolin	O	14-22
-	O	22-23
1	O	23-24
was	O	25-28
decreased	O	29-38
,	O	38-39
and	O	40-43
calmodulin	O	44-54
was	O	55-58
increased	O	59-68
,	O	68-69
in	O	70-72
vessels	O	73-80
from	O	81-85
daidzein	O	86-94
-	O	94-95
or	O	96-98
17beta	O	99-105
-	O	105-106
estradiol	O	106-115
-	O	115-116
treated	O	116-123
rats	O	124-128
. 	O	128-130

eNOS	O	0-4
expression	O	5-15
was	O	16-19
unaffected	O	20-30
by	O	31-33
the	O	34-37
treatments	O	38-48
. 	O	48-50

Human	O	0-5
brains	O	6-12
retain	O	13-19
discrete	O	20-28
populations	O	29-40
of	O	41-43
micro	O	44-49
RNA	O	50-53
(	O	54-55
miRNA	O	55-60
)	O	60-61
species	O	62-69
that	O	70-74
support	O	75-82
homeostatic	O	83-94
brain	O	95-100
gene	O	101-105
expression	O	106-116
functions	O	117-126
;	O	126-127
however	O	128-135
,	O	135-136
specific	O	137-145
miRNA	O	146-151
abundance	O	152-161
is	O	162-164
significantly	O	165-178
altered	O	179-186
in	O	187-189
neurological	O	190-202
disorders	O	203-212
such	O	213-217
as	O	218-220
Alzheimer	O	221-230
disease	O	231-238
(	O	239-240
AD	O	240-242
)	O	242-243
when	O	244-248
compared	O	249-257
with	O	258-262
age	O	263-266
-	O	266-267
matched	O	267-274
controls	O	275-283
. 	O	283-285

An	O	0-2
NF	O	3-5
-	O	5-6
kappaB	O	6-12
-	O	12-13
sensitive	O	13-22
micro	B	23-28
RNA	I	29-32
-	I	32-33
146a	I	33-37
-	O	37-38
mediated	O	38-46
inflammatory	O	47-59
circuit	O	60-67
in	O	68-70
Alzheimer	O	71-80
disease	O	81-88
and	O	89-92
in	O	93-95
stressed	O	96-104
human	O	105-110
brain	O	111-116
cells	O	117-122
.  	O	122-125

Up	O	0-2
-	O	2-3
regulation	O	3-13
of	O	14-16
miRNA	B	17-22
-	I	22-23
146a	I	23-27
coupled	O	28-35
to	O	36-38
down	O	39-43
-	O	43-44
regulation	O	44-54
of	O	55-57
CFH	O	58-61
was	O	62-65
observed	O	66-74
in	O	75-77
AD	O	78-80
brain	O	81-86
and	O	87-90
in	O	91-93
interleukin	O	94-105
-	O	105-106
1beta	O	106-111
,	O	111-112
Abeta42	O	113-120
,	O	120-121
and	O	122-125
/	O	125-126
or	O	126-128
oxidatively	O	129-140
stressed	O	141-149
human	O	150-155
neural	O	156-162
(	O	163-164
HN	O	164-166
)	O	166-167
cells	O	168-173
in	O	174-176
primary	O	177-184
culture	O	185-192
. 	O	192-194

Here	O	0-4
we	O	5-7
provide	O	8-15
evidence	O	16-24
in	O	25-27
AD	O	28-30
brains	O	31-37
of	O	38-40
a	O	41-42
specific	O	43-51
up	O	52-54
-	O	54-55
regulation	O	55-65
of	O	66-68
an	O	69-71
NF	O	72-74
-	O	74-75
kappaB	O	75-81
-	O	81-82
sensitive	O	82-91
miRNA	B	92-97
-	I	97-98
146a	I	98-102
highly	O	103-109
complementary	O	110-123
to	O	124-126
the	O	127-130
3	O	131-132
'	O	132-133
-	O	133-134
untranslated	O	134-146
region	O	147-153
of	O	154-156
complement	O	157-167
factor	O	168-174
H	O	175-176
(	O	177-178
CFH	O	178-181
)	O	181-182
,	O	182-183
an	O	184-186
important	O	187-196
repressor	O	197-206
of	O	207-209
the	O	210-213
inflammatory	O	214-226
response	O	227-235
of	O	236-238
the	O	239-242
brain	O	243-248
. 	O	248-250

Treatment	O	0-9
of	O	10-12
stressed	O	13-21
HN	O	22-24
cells	O	25-30
with	O	31-35
the	O	36-39
NF	O	40-42
-	O	42-43
kappaB	O	43-49
inhibitor	O	50-59
pyrollidine	O	60-71
dithiocarbamate	O	72-87
or	O	88-90
the	O	91-94
resveratrol	O	95-106
analog	O	107-113
CAY10512	O	114-122
abrogated	O	123-132
this	O	133-137
response	O	138-146
. 	O	146-148

Transfection	O	0-12
of	O	13-15
HN	O	16-18
cells	O	19-24
using	O	25-30
an	O	31-33
NF	O	34-36
-	O	36-37
kappaB	O	37-43
-	O	43-44
containing	O	44-54
pre	O	55-58
-	O	58-59
miRNA	B	59-64
-	I	64-65
146a	I	65-69
promoter	O	70-78
-	O	78-79
luciferase	O	79-89
reporter	O	90-98
construct	O	99-108
in	O	109-111
stressed	O	112-120
HN	O	121-123
cells	O	124-129
showed	O	130-136
significant	O	137-148
up	O	149-151
-	O	151-152
regulation	O	152-162
of	O	163-165
luciferase	O	166-176
activity	O	177-185
that	O	186-190
paralleled	O	191-201
decreases	O	202-211
in	O	212-214
CFH	O	215-218
gene	O	219-223
expression	O	224-234
. 	O	234-236

Incubation	O	0-10
of	O	11-13
an	O	14-16
antisense	O	17-26
oligonucleotide	O	27-42
to	O	43-45
miRNA	O	46-51
-	O	51-52
146a	O	52-56
(	O	57-58
anti	O	58-62
-	O	62-63
miRNA	O	63-68
-	O	68-69
146a	O	69-73
;	O	73-74
AM	O	75-77
-	O	77-78
146a	O	78-82
)	O	82-83
was	O	84-87
found	O	88-93
to	O	94-96
restore	O	97-104
CFH	O	105-108
expression	O	109-119
levels	O	120-126
. 	O	126-128

These	O	0-5
data	O	6-10
indicate	O	11-19
that	O	20-24
NF	O	25-27
-	O	27-28
kappaB	O	28-34
-	O	34-35
sensitive	O	35-44
miRNA	B	45-50
-	I	50-51
146a	I	51-55
-	O	55-56
mediated	O	56-64
modulation	O	65-75
of	O	76-78
CFH	O	79-82
gene	O	83-87
expression	O	88-98
may	O	99-102
in	O	103-105
part	O	106-110
regulate	O	111-119
an	O	120-122
inflammatory	O	123-135
response	O	136-144
in	O	145-147
AD	O	148-150
brain	O	151-156
and	O	157-160
in	O	161-163
stressed	O	164-172
HN	O	173-175
cell	O	176-180
models	O	181-187
of	O	188-190
AD	O	191-193
and	O	194-197
illustrate	O	198-208
the	O	209-212
potential	O	213-222
for	O	223-226
anti	O	227-231
-	O	231-232
miRNAs	O	232-238
as	O	239-241
an	O	242-244
effective	O	245-254
therapeutic	O	255-266
strategy	O	267-275
against	O	276-283
pathogenic	O	284-294
inflammatory	O	295-307
signaling	O	308-317
.   	O	317-321

Meanwhile	O	0-9
,	O	9-10
3NP	O	11-14
rats	O	15-19
showed	O	20-26
dynamic	O	27-34
changes	O	35-42
in	O	43-45
the	O	46-49
miRNA	O	50-55
profiles	O	56-64
during	O	65-71
disease	O	72-79
development	O	80-91
and	O	92-95
a	O	96-97
few	O	98-101
miRNAs	O	102-108
with	O	109-113
altered	O	114-121
expression	O	122-132
. 	O	132-134

In	O	0-2
10	O	3-5
-	O	5-6
week	O	6-10
-	O	10-11
old	O	11-14
R6	O	15-17
/	O	17-18
2	O	18-19
mice	O	20-24
,	O	24-25
downregulation	O	26-40
was	O	41-44
dominant	O	45-53
in	O	54-56
the	O	57-60
miRNA	O	61-66
expressions	O	67-78
and	O	79-82
the	O	83-86
level	O	87-92
of	O	93-95
Drosha	O	96-102
decreased	O	103-112
concomitantly	O	113-126
. 	O	126-128

Nine	O	0-4
miRNAs	O	5-11
(	O	12-13
miR	B	13-16
-	I	16-17
22	I	17-19
,	O	19-20
miR	B	21-24
-	I	24-25
29c	I	25-28
,	O	28-29
miR	B	30-33
-	I	33-34
128	I	34-37
,	O	37-38
miR	B	39-42
-	I	42-43
132	I	43-46
,	O	46-47
miR	B	48-51
-	I	51-52
138	I	52-55
,	O	55-56
miR	B	57-60
-	I	60-61
218	I	61-64
,	O	64-65
miR	B	66-69
-	I	69-70
222	I	70-73
,	O	73-74
miR	B	75-78
-	I	78-79
344	I	79-82
,	O	82-83
and	O	84-87
miR	B	88-91
-	I	91-92
674	I	92-95
*	O	95-96
)	O	96-97
were	O	98-102
commonly	O	103-111
down	O	112-116
-	O	116-117
regulated	O	117-126
in	O	127-129
both	O	130-134
the	O	135-138
12	O	139-141
-	O	141-142
month	O	142-147
-	O	147-148
old	O	148-151
YAC128	O	152-158
and	O	159-162
10	O	163-165
-	O	165-166
week	O	166-170
-	O	170-171
old	O	171-174
R6	O	175-177
/	O	177-178
2	O	178-179
mice	O	180-184
. 	O	184-186

Concomitantly	O	0-13
,	O	13-14
the	O	15-18
expressions	O	19-30
of	O	31-33
Drosha	O	34-40
-	O	40-41
DGCR8	O	41-46
,	O	46-47
Exportin	O	48-56
-	O	56-57
5	O	57-58
,	O	58-59
and	O	60-63
Dcp1	O	64-68
were	O	69-73
increased	O	74-83
at	O	84-86
5months	O	87-94
,	O	94-95
and	O	96-99
the	O	100-103
expression	O	104-114
of	O	115-117
Dicer	O	118-123
was	O	124-127
decreased	O	128-137
at	O	138-140
12	O	141-143
months	O	144-150
. 	O	150-152

YAC128	O	0-6
mice	O	7-11
showed	O	12-18
upregulation	O	19-31
-	O	31-32
dominant	O	32-40
miRNA	O	41-46
expressions	O	47-58
at	O	59-61
5	O	62-63
months	O	64-70
and	O	71-74
downregulation	O	75-89
-	O	89-90
dominant	O	90-98
expressions	O	99-110
at	O	111-113
12	O	114-116
months	O	117-123
. 	O	123-125

After	O	0-5
characterizing	O	6-20
the	O	21-24
phenotypes	O	25-35
by	O	36-38
behavioral	O	39-49
tests	O	50-55
and	O	56-59
histological	O	60-72
analyses	O	73-81
,	O	81-82
we	O	83-85
profiled	O	86-94
striatal	O	95-103
miRNAs	O	104-110
using	O	111-116
a	O	117-118
miRNA	O	119-124
microarray	O	125-135
and	O	136-139
we	O	140-142
measured	O	143-151
the	O	152-155
key	O	156-159
molecules	O	160-169
involved	O	170-178
in	O	179-181
miRNA	O	182-187
biogenesis	O	188-198
and	O	199-202
function	O	203-211
. 	O	211-213

Here	O	0-4
,	O	4-5
we	O	6-8
analyzed	O	9-17
the	O	18-21
miRNA	O	22-27
expression	O	28-38
and	O	39-42
miRNA	O	43-48
regulators	O	49-59
in	O	60-62
two	O	63-66
transgenic	O	67-77
models	O	78-84
of	O	85-87
HD	O	88-90
,	O	90-91
YAC128	O	92-98
and	O	99-102
R6	O	103-105
/	O	105-106
2	O	106-107
mice	O	108-112
,	O	112-113
and	O	114-117
in	O	118-120
a	O	121-122
3	O	123-124
-	O	124-125
nitropropionic	O	125-139
acid	O	140-144
(	O	145-146
3NP	O	146-149
)	O	149-150
-	O	150-151
induced	O	151-158
striatal	O	159-167
degeneration	O	168-180
rat	O	181-184
model	O	185-190
. 	O	190-192

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
short	O	23-28
RNA	O	29-32
molecules	O	33-42
regulating	O	43-53
gene	O	54-58
expression	O	59-69
,	O	69-70
and	O	71-74
are	O	75-78
implicated	O	79-89
in	O	90-92
a	O	93-94
variety	O	95-102
of	O	103-105
diseases	O	106-114
including	O	115-124
HD	O	125-127
.	O	127-128
However	O	129-136
,	O	136-137
the	O	138-141
profiles	O	142-150
and	O	151-154
regulation	O	155-165
of	O	166-168
miRNAs	O	169-175
in	O	176-178
HD	O	179-181
are	O	182-185
not	O	186-189
fully	O	190-195
understood	O	196-206
. 	O	206-208

Huntington	O	0-10
'	O	10-11
s	O	11-12
disease	O	13-20
(	O	21-22
HD	O	22-24
)	O	24-25
is	O	26-28
a	O	29-30
genetic	O	31-38
neurodegenerative	O	39-56
disease	O	57-64
caused	O	65-71
by	O	72-74
abnormal	O	75-83
CAG	O	84-87
expansion	O	88-97
. 	O	97-99

Altered	O	0-7
microRNA	O	8-16
regulation	O	17-27
in	O	28-30
Huntington	O	31-41
'	O	41-42
s	O	42-43
disease	O	44-51
models	O	52-58
.  	O	58-61

This	O	0-4
information	O	5-16
should	O	17-23
aid	O	24-27
in	O	28-30
future	O	31-37
studies	O	38-45
on	O	46-48
therapeutic	O	49-60
application	O	61-72
of	O	73-75
miRNAs	O	76-82
in	O	83-85
HD	O	86-88
.   	O	88-92

Our	O	0-3
results	O	4-11
show	O	12-16
that	O	17-21
transgenic	O	22-32
HD	O	33-35
mice	O	36-40
have	O	41-45
abnormal	O	46-54
miRNA	O	55-60
biogenesis	O	61-71
. 	O	71-73

The	O	0-3
prevalence	O	4-14
of	O	15-17
neurodegenerative	O	18-35
disorders	O	36-45
is	O	46-48
rising	O	49-55
steadily	O	56-64
as	O	65-67
human	O	68-73
life	O	74-78
expectancy	O	79-89
increases	O	90-99
. 	O	99-101

However	O	0-7
,	O	7-8
limited	O	9-16
knowledge	O	17-26
of	O	27-29
the	O	30-33
molecular	O	34-43
basis	O	44-49
of	O	50-52
disease	O	53-60
pathogenesis	O	61-73
is	O	74-76
a	O	77-78
major	O	79-84
hurdle	O	85-91
in	O	92-94
the	O	95-98
identification	O	99-113
of	O	114-116
drug	O	117-121
targets	O	122-129
and	O	130-133
development	O	134-145
of	O	146-148
therapeutic	O	149-160
strategies	O	161-171
for	O	172-175
these	O	176-181
largely	O	182-189
incurable	O	190-199
disorders	O	200-209
. 	O	209-211

MicroRNAs	O	0-9
:	O	9-10
novel	O	11-16
therapeutic	O	17-28
targets	O	29-36
in	O	37-39
neurodegenerative	O	40-57
diseases	O	58-66
.  	O	66-69

Our	O	0-3
bioinformatic	O	4-17
analysis	O	18-26
suggests	O	27-35
novel	O	36-41
miRNA	O	42-47
-	O	47-48
target	O	48-54
interactions	O	55-67
that	O	68-72
could	O	73-78
potentially	O	79-90
influence	O	91-100
neurodegeneration	O	101-118
. 	O	118-120

The	O	0-3
recent	O	4-10
development	O	11-22
of	O	23-25
molecules	O	26-35
that	O	36-40
alter	O	41-46
miRNA	O	47-52
expression	O	53-63
promises	O	64-72
valuable	O	73-81
tools	O	82-87
that	O	88-92
will	O	93-97
enhance	O	98-105
the	O	106-109
therapeutic	O	110-121
potential	O	122-131
of	O	132-134
miRNAs	O	135-141
.   	O	141-145

Recently	O	0-8
,	O	8-9
differential	O	10-22
expression	O	23-33
of	O	34-36
endogenous	O	37-47
regulatory	O	48-58
small	O	59-64
RNAs	O	65-69
,	O	69-70
known	O	71-76
as	O	77-79
'	O	80-81
microRNAs	O	81-90
'	O	90-91
(	O	92-93
miRNAs	O	93-99
)	O	99-100
,	O	100-101
in	O	102-104
patients	O	105-113
of	O	114-116
Alzheimer	O	117-126
'	O	126-127
s	O	127-128
disease	O	129-136
,	O	136-137
Parkinson	O	138-147
'	O	147-148
s	O	148-149
disease	O	150-157
and	O	158-161
models	O	162-168
of	O	169-171
ataxia	O	172-178
suggest	O	179-186
that	O	187-191
they	O	192-196
might	O	197-202
have	O	203-207
key	O	208-211
regulatory	O	212-222
roles	O	223-228
in	O	229-231
neurodegeneration	O	232-249
. 	O	249-251

miRNAs	O	0-6
that	O	7-11
can	O	12-15
target	O	16-22
known	O	23-28
mediators	O	29-38
of	O	39-41
neurodegeneration	O	42-59
offer	O	60-65
potential	O	66-75
therapeutic	O	76-87
targets	O	88-95
. 	O	95-97

To	O	0-2
our	O	3-6
knowledge	O	7-16
,	O	16-17
this	O	18-22
is	O	23-25
the	O	26-29
first	O	30-35
report	O	36-42
of	O	43-45
miRNA	O	46-51
profiles	O	52-60
in	O	61-63
A	O	64-65
.	O	65-66
cantonensis	O	67-78
,	O	78-79
which	O	80-85
may	O	86-89
represent	O	90-99
a	O	100-101
new	O	102-105
platform	O	106-114
for	O	115-118
studying	O	119-127
regulation	O	128-138
of	O	139-141
genes	O	142-147
and	O	148-151
their	O	152-157
networks	O	158-166
in	O	167-169
A	O	170-171
.	O	171-172
cantonensis	O	173-184
.   	O	184-188

Nucleotide	O	0-10
bias	O	11-15
analysis	O	16-24
showed	O	25-31
that	O	32-36
uracil	O	37-43
was	O	44-47
the	O	48-51
prominent	O	52-61
nucleotide	O	62-72
,	O	72-73
particularly	O	74-86
at	O	87-89
positions	O	90-99
of	O	100-102
1	O	103-104
,	O	104-105
10	O	106-108
,	O	108-109
14	O	110-112
,	O	112-113
17	O	114-116
and	O	117-120
22	O	121-123
,	O	123-124
approximately	O	125-138
at	O	139-141
the	O	142-145
beginning	O	146-155
,	O	155-156
middle	O	157-163
and	O	164-167
the	O	168-171
end	O	172-175
of	O	176-178
the	O	179-182
conserved	O	183-192
miRNAs	O	193-199
. 	O	199-201

No	O	0-2
new	O	3-6
miRNA	O	7-12
sequence	O	13-21
was	O	22-25
found	O	26-31
. 	O	31-33

A	O	0-1
total	O	2-7
of	O	8-10
8861	O	11-15
,	O	15-16
260	O	16-19
and	O	20-23
10	O	24-26
,	O	26-27
957	O	27-30
,	O	30-31
957	O	31-34
high	O	35-39
quality	O	40-47
reads	O	48-53
with	O	54-58
20	O	59-61
and	O	62-65
23	O	66-68
conserved	O	69-78
miRNAs	O	79-85
were	O	86-90
obtained	O	91-99
in	O	100-102
females	O	103-110
and	O	111-114
males	O	115-120
,	O	120-121
respectively	O	122-134
. 	O	134-136

The	O	0-3
objective	O	4-13
of	O	14-16
this	O	17-21
study	O	22-27
was	O	28-31
to	O	32-34
determine	O	35-44
and	O	45-48
characterize	O	49-61
miRNAs	O	62-68
of	O	69-71
female	O	72-78
and	O	79-82
male	O	83-87
adults	O	88-94
of	O	95-97
A	O	98-99
.	O	99-100
cantonensis	O	101-112
by	O	113-115
Solexa	O	116-122
deep	O	123-127
sequencing	O	128-138
. 	O	138-140

They	O	0-4
have	O	5-9
been	O	10-14
identified	O	15-25
in	O	26-28
a	O	29-30
diverse	O	31-38
range	O	39-44
of	O	45-47
organisms	O	48-57
. 	O	57-59

microRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
endogenous	O	23-33
small	O	34-39
non	O	40-43
-	O	43-44
coding	O	44-50
RNAs	O	51-55
that	O	56-60
play	O	61-65
crucial	O	66-73
roles	O	74-79
in	O	80-82
gene	O	83-87
expression	O	88-98
regulation	O	99-109
,	O	109-110
cellular	O	111-119
function	O	120-128
and	O	129-132
defense	O	133-140
,	O	140-141
homeostasis	O	142-153
and	O	154-157
pathogenesis	O	158-170
. 	O	170-172

Angiostrongylus	O	0-15
cantonensis	O	16-27
causes	O	28-34
eosinophilic	O	35-47
meningitis	O	48-58
and	O	59-62
eosinophilic	O	63-75
pleocytosis	O	76-87
in	O	88-90
humans	O	91-97
and	O	98-101
is	O	102-104
of	O	105-107
significant	O	108-119
socio	O	120-125
-	O	125-126
economic	O	126-134
importance	O	135-145
globally	O	146-154
. 	O	154-156

Angiostrongylus	O	0-15
cantonensis	O	16-27
:	O	27-28
Identification	O	29-43
and	O	44-47
characterization	O	48-64
of	O	65-67
microRNAs	O	68-77
in	O	78-80
male	O	81-85
and	O	86-89
female	O	90-96
adults	O	97-103
.  	O	103-106

The	O	0-3
miR	B	4-7
-	I	7-8
146a	I	8-12
expression	O	13-23
was	O	24-27
confirmed	O	28-37
to	O	38-40
be	O	41-43
present	O	44-51
in	O	52-54
reactive	O	55-63
astrocytes	O	64-74
. 	O	74-76

In	O	0-2
human	O	3-8
TLE	O	9-12
with	O	13-17
hippocampal	O	18-29
sclerosis	O	30-39
,	O	39-40
increased	O	41-50
astroglial	O	51-61
expression	O	62-72
of	O	73-75
miR	B	76-79
-	I	79-80
146a	I	80-84
was	O	85-88
observed	O	89-97
mainly	O	98-104
in	O	105-107
regions	O	108-115
where	O	116-121
neuronal	O	122-130
cell	O	131-135
loss	O	136-140
and	O	141-144
reactive	O	145-153
gliosis	O	154-161
occurred	O	162-170
. 	O	170-172

The	O	0-3
increased	O	4-13
and	O	14-17
persistent	O	18-28
expression	O	29-39
of	O	40-42
miR	B	43-46
-	I	46-47
146a	I	47-51
in	O	52-54
reactive	O	55-63
astrocytes	O	64-74
supports	O	75-83
the	O	84-87
possible	O	88-96
involvement	O	97-108
of	O	109-111
miRNAs	O	112-118
in	O	119-121
the	O	122-125
modulation	O	126-136
of	O	137-139
the	O	140-143
astroglial	O	144-154
inflammatory	O	155-167
response	O	168-176
occurring	O	177-186
in	O	187-189
TLE	O	190-193
and	O	194-197
provides	O	198-206
a	O	207-208
target	O	209-215
for	O	216-219
future	O	220-226
studies	O	227-234
aimed	O	235-240
at	O	241-243
developing	O	244-254
strategies	O	255-265
against	O	266-273
pro	O	274-277
-	O	277-278
epileptogenic	O	278-291
inflammatory	O	292-304
signalling	O	305-315
.   	O	315-319

Increasing	O	0-10
evidence	O	11-19
supports	O	20-28
the	O	29-32
involvement	O	33-44
of	O	45-47
inflammatory	O	48-60
and	O	61-64
immune	O	65-71
processes	O	72-81
in	O	82-84
temporal	O	85-93
lobe	O	94-98
epilepsy	O	99-107
(	O	108-109
TLE	O	109-112
)	O	112-113
. 	O	113-115

Expression	O	0-10
pattern	O	11-18
of	O	19-21
miR	B	22-25
-	I	25-26
146a	I	26-30
,	O	30-31
an	O	32-34
inflammation	O	35-47
-	O	47-48
associated	O	48-58
microRNA	O	59-67
,	O	67-68
in	O	69-71
experimental	O	72-84
and	O	85-88
human	O	89-94
temporal	O	95-103
lobe	O	104-108
epilepsy	O	109-117
.  	O	117-120

We	O	0-2
investigated	O	3-15
the	O	16-19
expression	O	20-30
and	O	31-34
cellular	O	35-43
distribution	O	44-56
of	O	57-59
miRNA	B	60-65
-	I	65-66
146a	I	66-70
(	O	71-72
miR	B	72-75
-	I	75-76
146a	I	76-80
)	O	80-81
in	O	82-84
a	O	85-86
rat	O	87-90
model	O	91-96
of	O	97-99
TLE	O	100-103
as	O	104-106
well	O	107-111
as	O	112-114
in	O	115-117
human	O	118-123
TLE	O	124-127
. 	O	127-129

MicroRNAs	O	0-9
(	O	10-11
miRNA	O	11-16
)	O	16-17
represent	O	18-27
small	O	28-33
regulatory	O	34-44
RNA	O	45-48
molecules	O	49-58
that	O	59-63
have	O	64-68
been	O	69-73
shown	O	74-79
to	O	80-82
act	O	83-86
as	O	87-89
negative	O	90-98
regulators	O	99-109
of	O	110-112
gene	O	113-117
expression	O	118-128
controlling	O	129-140
different	O	141-150
biological	O	151-161
processes	O	162-171
,	O	171-172
including	O	173-182
immune	O	183-189
-	O	189-190
system	O	190-196
homeostasis	O	197-208
and	O	209-212
function	O	213-221
. 	O	221-223

Prominent	O	0-9
upregulation	O	10-22
of	O	23-25
miR	B	26-29
-	I	29-30
146a	I	30-34
activation	O	35-45
was	O	46-49
evident	O	50-57
at	O	58-60
1	O	61-62
week	O	63-67
after	O	68-73
SE	O	74-76
and	O	77-80
persisted	O	81-90
in	O	91-93
the	O	94-97
chronic	O	98-105
phase	O	106-111
. 	O	111-113

miR	B	0-3
-	I	3-4
146a	I	4-8
analysis	O	9-17
in	O	18-20
rat	O	21-24
hippocampus	O	25-36
was	O	37-40
performed	O	41-50
by	O	51-53
polymerase	O	54-64
chain	O	65-70
reaction	O	71-79
and	O	80-83
immunocytochemistry	O	84-103
at	O	104-106
1	O	107-108
week	O	109-113
and	O	114-117
3	O	118-119
-	O	119-120
4	O	120-121
months	O	122-128
after	O	129-134
induction	O	135-144
of	O	145-147
status	O	148-154
epilepticus	O	155-166
(	O	167-168
SE	O	168-170
)	O	170-171
. 	O	171-173

However	O	0-7
,	O	7-8
none	O	9-13
of	O	14-16
these	O	17-22
individuals	O	23-34
reported	O	35-43
here	O	44-48
have	O	49-53
epilepsy	O	54-62
,	O	62-63
although	O	64-72
two	O	73-76
have	O	77-81
an	O	82-84
abnormal	O	85-93
EEG	O	94-97
. 	O	97-99

CONCLUSIONS	O	0-11
:	O	11-12
The	O	13-16
phenotype	O	17-26
of	O	27-29
chromosome	O	30-40
15q13	O	41-46
.	O	46-47
2q13	O	47-51
.	O	51-52
3	O	52-53
BP4	O	54-57
-	O	57-58
BP5	O	58-61
microdeletion	O	62-75
/	O	75-76
duplication	O	76-87
syndrome	O	88-96
may	O	97-100
include	O	101-108
features	O	109-117
of	O	118-120
autism	O	121-127
spectrum	O	128-136
disorder	O	137-145
,	O	145-146
a	O	147-148
variety	O	149-156
of	O	157-159
neuropsychiatric	O	160-176
disorders	O	177-186
,	O	186-187
and	O	188-191
cognitive	O	192-201
impairment	O	202-212
. 	O	212-214

Recognition	O	0-11
of	O	12-14
this	O	15-19
broader	O	20-27
phenotype	O	28-37
has	O	38-41
implications	O	42-54
for	O	55-58
clinical	O	59-67
diagnostic	O	68-78
testing	O	79-86
and	O	87-90
efforts	O	91-98
to	O	99-101
understand	O	102-112
the	O	113-116
underlying	O	117-127
aetiology	O	128-137
of	O	138-140
this	O	141-145
syndrome	O	146-154
.   	O	154-158

PATIENTS	O	0-8
:	O	8-9
DNA	O	10-13
samples	O	14-21
from	O	22-26
1445	O	27-31
unrelated	O	32-41
patients	O	42-50
submitted	O	51-60
consecutively	O	61-74
for	O	75-78
clinical	O	79-87
array	O	88-93
comparative	O	94-105
genomic	O	106-113
hybridisation	O	114-127
(	O	128-129
CGH	O	129-132
)	O	132-133
testing	O	134-141
at	O	142-144
Children	O	145-153
'	O	153-154
s	O	154-155
Hospital	O	156-164
Boston	O	165-171
and	O	172-175
DNA	O	176-179
samples	O	180-187
from	O	188-192
1441	O	193-197
individuals	O	198-209
with	O	210-214
autism	O	215-221
from	O	222-226
751	O	227-230
families	O	231-239
in	O	240-242
the	O	243-246
Autism	O	247-253
Genetic	O	254-261
Resource	O	262-270
Exchange	O	271-279
(	O	280-281
AGRE	O	281-285
)	O	285-286
repository	O	287-297
. 	O	297-299

RESULTS	O	0-7
:	O	7-8
We	O	9-11
report	O	12-18
the	O	19-22
clinical	O	23-31
features	O	32-40
of	O	41-43
five	O	44-48
patients	O	49-57
with	O	58-62
a	O	63-64
BP4	O	65-68
-	O	68-69
BP5	O	69-72
deletion	O	73-81
,	O	81-82
three	O	83-88
with	O	89-93
a	O	94-95
BP4	O	96-99
-	O	99-100
BP5	O	100-103
duplication	O	104-115
,	O	115-116
and	O	117-120
two	O	121-124
with	O	125-129
an	O	130-132
overlapping	O	133-144
but	O	145-148
smaller	O	149-156
duplication	O	157-168
identified	O	169-179
by	O	180-182
whole	O	183-188
genome	O	189-195
high	O	196-200
resolution	O	201-211
oligonucleotide	O	212-227
array	O	228-233
CGH	O	234-237
. 	O	237-239

Microdeletion	O	0-13
/	O	13-14
duplication	O	14-25
at	O	26-28
15q13	O	29-34
.	O	34-35
2q13	O	35-39
.	O	39-40
3	O	40-41
among	O	42-47
individuals	O	48-59
with	O	60-64
features	O	65-73
of	O	74-76
autism	O	77-83
and	O	84-87
other	O	88-93
neuropsychiatric	O	94-110
disorders	O	111-120
.  	O	120-123

BACKGROUND	O	0-10
:	O	10-11
Segmental	O	12-21
duplications	O	22-34
at	O	35-37
breakpoints	O	38-49
(	O	50-51
BP4	O	51-54
-	O	54-55
BP5	O	55-58
)	O	58-59
of	O	60-62
chromosome	O	63-73
15q13	O	74-79
.	O	79-80
2q13	O	80-84
.	O	84-85
3	O	85-86
mediate	O	87-94
a	O	95-96
recurrent	O	97-106
genomic	O	107-114
imbalance	O	115-124
syndrome	O	125-133
associated	O	134-144
with	O	145-149
mental	O	150-156
retardation	O	157-168
,	O	168-169
epilepsy	O	170-178
,	O	178-179
and	O	180-183
/	O	183-184
or	O	184-186
electroencephalogram	O	187-207
(	O	208-209
EEG	O	209-212
)	O	212-213
abnormalities	O	214-227
. 	O	227-229

BP4	O	0-3
-	O	3-4
BP5	O	4-7
covers	O	8-14
approximately	O	15-28
1	O	29-30
.	O	30-31
5	O	31-32
Mb	O	33-35
(	O	36-37
chr15	O	37-42
:	O	42-43
28	O	43-45
.	O	45-46
719	O	46-49
-	O	49-50
30	O	50-52
.	O	52-53
298	O	53-56
Mb	O	57-59
)	O	59-60
and	O	61-64
includes	O	65-73
six	O	74-77
reference	O	78-87
genes	O	88-93
and	O	94-97
1	O	98-99
miRNA	O	100-105
gene	O	106-110
,	O	110-111
while	O	112-117
the	O	118-121
smaller	O	122-129
duplications	O	130-142
cover	O	143-148
approximately	O	149-162
500	O	163-166
kb	O	167-169
(	O	170-171
chr15	O	171-176
:	O	176-177
28	O	177-179
.	O	179-180
902	O	180-183
-	O	183-184
29	O	184-186
.	O	186-187
404	O	187-190
Mb	O	191-193
)	O	193-194
and	O	195-198
contain	O	199-206
three	O	207-212
reference	O	213-222
genes	O	223-228
and	O	229-232
one	O	233-236
miRNA	O	237-242
gene	O	243-247
. 	O	247-249

Cognitive	O	0-9
impairment	O	10-20
varied	O	21-27
from	O	28-32
moderate	O	33-41
mental	O	42-48
retardation	O	49-60
to	O	61-63
normal	O	64-70
IQ	O	71-73
with	O	74-78
learning	O	79-87
disability	O	88-98
. 	O	98-100

These	O	0-5
BP4	O	6-9
-	O	9-10
BP5	O	10-13
deletion	O	14-22
cases	O	23-28
exhibit	O	29-36
minor	O	37-42
dysmorphic	O	43-53
features	O	54-62
,	O	62-63
significant	O	64-75
expressive	O	76-86
language	O	87-95
deficits	O	96-104
,	O	104-105
and	O	106-109
a	O	110-111
spectrum	O	112-120
of	O	121-123
neuropsychiatric	O	124-140
impairments	O	141-152
that	O	153-157
include	O	158-165
autism	O	166-172
spectrum	O	173-181
disorder	O	182-190
,	O	190-191
attention	O	192-201
deficit	O	202-209
hyperactivity	O	210-223
disorder	O	224-232
,	O	232-233
anxiety	O	234-241
disorder	O	242-250
,	O	250-251
and	O	252-255
mood	O	256-260
disorder	O	261-269
. 	O	269-271

The	O	0-3
BP4	O	4-7
-	O	7-8
BP5	O	8-11
deletion	O	12-20
and	O	21-24
duplication	O	25-36
events	O	37-43
span	O	44-48
CHRNA7	O	49-55
,	O	55-56
a	O	57-58
candidate	O	59-68
gene	O	69-73
for	O	74-77
seizures	O	78-86
. 	O	86-88

The	O	0-3
KIAA0226	O	4-12
gene	O	13-17
encodes	O	18-25
a	O	26-27
protein	O	28-35
that	O	36-40
we	O	41-43
named	O	44-49
rundataxin	O	50-60
,	O	60-61
with	O	62-66
two	O	67-70
conserved	O	71-80
domains	O	81-88
:	O	88-89
an	O	90-92
N	O	93-94
-	O	94-95
terminal	O	95-103
RUN	O	104-107
domain	O	108-114
and	O	115-118
a	O	119-120
C	O	121-122
-	O	122-123
terminal	O	123-131
domain	O	132-138
containing	O	139-149
a	O	150-151
diacylglycerol	O	152-166
binding	O	167-174
-	O	174-175
like	O	175-179
motif	O	180-185
. 	O	185-187

Mutation	O	0-8
screening	O	9-18
of	O	19-21
all	O	22-25
coding	O	26-32
sequences	O	33-42
revealed	O	43-51
a	O	52-53
single	O	54-60
nucleotide	O	61-71
deletion	O	72-80
,	O	80-81
2927delC	O	82-90
,	O	90-91
in	O	92-94
exon	O	95-99
19	O	100-102
of	O	103-105
the	O	106-109
KIAA0226	O	110-118
gene	O	119-123
,	O	123-124
which	O	125-130
results	O	131-138
in	O	139-141
a	O	142-143
frame	O	144-149
shift	O	150-155
of	O	156-158
the	O	159-162
C	O	163-164
-	O	164-165
terminal	O	165-173
domain	O	174-180
(	O	181-182
p	O	182-183
.	O	183-184
Ala943ValfsX146	O	184-199
)	O	199-200
. 	O	200-202

The	O	0-3
rundataxin	O	4-14
pathway	O	15-22
appears	O	23-30
therefore	O	31-40
distinct	O	41-49
from	O	50-54
the	O	55-58
ataxia	O	59-65
pathways	O	66-74
involving	O	75-84
deficiency	O	85-95
in	O	96-98
mitochondrial	O	99-112
or	O	113-115
nuclear	O	116-123
proteins	O	124-132
and	O	133-136
broadens	O	137-145
the	O	146-149
range	O	150-155
of	O	156-158
mechanisms	O	159-169
leading	O	170-177
to	O	178-180
recessive	O	181-190
ataxias	O	191-198
.   	O	198-202

The	O	0-3
closest	O	4-11
paralogue	O	12-21
of	O	22-24
rundataxin	O	25-35
,	O	35-36
the	O	37-40
plekstrin	O	41-50
homology	O	51-59
domain	O	60-66
family	O	67-73
member	O	74-80
M1	O	81-83
,	O	83-84
has	O	85-88
been	O	89-93
shown	O	94-99
to	O	100-102
colocalize	O	103-113
with	O	114-118
Rab7	O	119-123
,	O	123-124
a	O	125-126
small	O	127-132
GTPase	O	133-139
associated	O	140-150
with	O	151-155
late	O	156-160
endosomes	O	161-170
/	O	170-171
lysosomes	O	171-180
,	O	180-181
suggesting	O	182-192
that	O	193-197
rundataxin	O	198-208
may	O	209-212
also	O	213-217
be	O	218-220
associated	O	221-231
with	O	232-236
vesicular	O	237-246
trafficking	O	247-258
and	O	259-262
signalling	O	263-273
pathways	O	274-282
through	O	283-290
its	O	291-294
RUN	O	295-298
and	O	299-302
diacylglycerol	O	303-317
binding	O	318-325
-	O	325-326
like	O	326-330
domains	O	331-338
. 	O	338-340

The	O	0-3
three	O	4-9
patients	O	10-18
presented	O	19-28
with	O	29-33
childhood	O	34-43
onset	O	44-49
gait	O	50-54
and	O	55-58
limb	O	59-63
ataxia	O	64-70
,	O	70-71
dysarthria	O	72-82
and	O	83-86
had	O	87-90
limited	O	91-98
walking	O	99-106
without	O	107-114
aid	O	115-118
into	O	119-123
their	O	124-129
teenage	O	130-137
years	O	138-143
. 	O	143-145

We	O	0-2
have	O	3-7
identified	O	8-18
a	O	19-20
novel	O	21-26
form	O	27-31
of	O	32-34
recessive	O	35-44
ataxia	O	45-51
that	O	52-56
segregates	O	57-67
in	O	68-70
three	O	71-76
children	O	77-85
of	O	86-88
a	O	89-90
large	O	91-96
consanguineous	O	97-111
Saudi	O	112-117
Arabian	O	118-125
family	O	126-132
. 	O	132-134

Linkage	O	0-7
studies	O	8-15
allowed	O	16-23
us	O	24-26
to	O	27-29
identify	O	30-38
a	O	39-40
single	O	41-47
locus	O	48-53
that	O	54-58
segregated	O	59-69
with	O	70-74
the	O	75-78
disease	O	79-86
on	O	87-89
chromosome	O	90-100
3q28	O	101-105
-	O	105-106
qter	O	106-110
. 	O	110-112

Two	O	0-3
patients	O	4-12
developed	O	13-22
epilepsy	O	23-31
at	O	32-34
7	O	35-36
months	O	37-43
without	O	44-51
relapse	O	52-59
after	O	60-65
treatment	O	66-75
,	O	75-76
and	O	77-80
mental	O	81-87
retardation	O	88-99
. 	O	99-101

Rundataxin	O	0-10
,	O	10-11
a	O	12-13
novel	O	14-19
protein	O	20-27
with	O	28-32
RUN	O	33-36
and	O	37-40
diacylglycerol	O	41-55
binding	O	56-63
domains	O	64-71
,	O	71-72
is	O	73-75
mutant	O	76-82
in	O	83-85
a	O	86-87
new	O	88-91
recessive	O	92-101
ataxia	O	102-108
.  	O	108-111

These	O	0-5
tumors	O	6-12
arise	O	13-18
in	O	19-21
the	O	22-25
cerebellum	O	26-36
and	O	37-40
may	O	41-44
attribute	O	45-54
their	O	55-60
origins	O	61-68
to	O	69-71
deregulated	O	72-83
proliferation	O	84-97
of	O	98-100
neural	O	101-107
progenitor	O	108-118
cells	O	119-124
during	O	125-131
development	O	132-143
. 	O	143-145

However	O	0-7
,	O	7-8
only	O	9-13
a	O	14-15
few	O	16-19
studies	O	20-27
to	O	28-30
date	O	31-35
have	O	36-40
focused	O	41-48
on	O	49-51
the	O	52-55
role	O	56-60
of	O	61-63
miRNAs	O	64-70
in	O	71-73
medulloblastoma	O	74-89
,	O	89-90
the	O	91-94
most	O	95-99
common	O	100-106
malignant	O	107-116
pediatric	O	117-126
brain	O	127-132
tumor	O	133-138
. 	O	138-140

MiRNA	O	0-5
expression	O	6-16
profiling	O	17-26
of	O	27-29
both	O	30-34
mouse	O	35-40
and	O	41-44
human	O	45-50
medulloblastomas	O	51-67
has	O	68-71
led	O	72-75
to	O	76-78
the	O	79-82
identification	O	83-97
of	O	98-100
signatures	O	101-111
correlating	O	112-123
with	O	124-128
the	O	129-132
molecular	O	133-142
subgroups	O	143-152
of	O	153-155
medulloblastoma	O	156-171
,	O	171-172
tumor	O	173-178
diagnosis	O	179-188
and	O	189-192
response	O	193-201
to	O	202-204
treatment	O	205-214
,	O	214-215
as	O	216-218
well	O	219-223
as	O	224-226
novel	O	227-232
targets	O	233-240
of	O	241-243
potential	O	244-253
clinical	O	254-262
relevance	O	263-272
. 	O	272-274

Understanding	O	0-13
the	O	14-17
interplay	O	18-27
between	O	28-35
normal	O	36-42
brain	O	43-48
development	O	49-60
and	O	61-64
medulloblastoma	O	65-80
pathogenesis	O	81-93
is	O	94-96
necessary	O	97-106
in	O	107-109
order	O	110-115
for	O	116-119
more	O	120-124
efficient	O	125-134
,	O	134-135
less	O	136-140
toxic	O	141-146
targeted	O	147-155
therapies	O	156-165
to	O	166-168
be	O	169-171
developed	O	172-181
and	O	182-185
implemented	O	186-197
. 	O	197-199

Normal	O	0-6
and	O	7-10
oncogenic	O	11-20
roles	O	21-26
for	O	27-30
microRNAs	O	31-40
in	O	41-43
the	O	44-47
developing	O	48-58
brain	O	59-64
.  	O	64-67

Emerging	O	0-8
evidence	O	9-17
indicates	O	18-27
that	O	28-32
miRNAs	O	33-39
are	O	40-43
key	O	44-47
players	O	48-55
in	O	56-58
mammalian	O	59-68
development	O	69-80
that	O	81-85
,	O	85-86
when	O	87-91
altered	O	92-99
,	O	99-100
contribute	O	101-111
to	O	112-114
tumorigenesis	O	115-128
. 	O	128-130

MicroRNAS	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
endogenous	O	29-39
non	O	40-43
-	O	43-44
coding	O	44-50
RNAs	O	51-55
that	O	56-60
play	O	61-65
important	O	66-75
roles	O	76-81
in	O	82-84
many	O	85-89
different	O	90-99
biological	O	100-110
processes	O	111-120
including	O	121-130
proliferation	O	131-144
,	O	144-145
differentiation	O	146-161
and	O	162-165
apoptosis	O	166-175
through	O	176-183
silencing	O	184-193
of	O	194-196
target	O	197-203
genes	O	204-209
. 	O	209-211

This	O	0-4
review	O	5-11
summarizes	O	12-22
the	O	23-26
recent	O	27-33
miRNA	O	34-39
literature	O	40-50
in	O	51-53
both	O	54-58
medulloblastoma	O	59-74
and	O	75-78
normal	O	79-85
brain	O	86-91
development	O	92-103
.   	O	103-107

A	O	0-1
miRNA	O	2-7
signature	O	8-17
of	O	18-20
prion	O	21-26
induced	O	27-34
neurodegeneration	O	35-52
.  	O	52-55

Compelling	O	0-10
evidence	O	11-19
links	O	20-25
miRNAs	O	26-32
to	O	33-35
the	O	36-39
control	O	40-47
of	O	48-50
neuronal	O	51-59
development	O	60-71
and	O	72-75
differentiation	O	76-91
,	O	91-92
however	O	93-100
,	O	100-101
little	O	102-108
is	O	109-111
known	O	112-117
about	O	118-123
their	O	124-129
role	O	130-134
in	O	135-137
neurodegeneration	O	138-155
. 	O	155-157

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
,	O	28-29
non	O	30-33
-	O	33-34
coding	O	34-40
RNA	O	41-44
molecules	O	45-54
which	O	55-60
are	O	61-64
emerging	O	65-73
as	O	74-76
key	O	77-80
regulators	O	81-91
of	O	92-94
numerous	O	95-103
cellular	O	104-112
processes	O	113-122
. 	O	122-124

We	O	0-2
determined	O	3-13
15	O	14-16
miRNAs	O	17-23
were	O	24-28
de	O	29-31
-	O	31-32
regulated	O	32-41
during	O	42-48
the	O	49-52
disease	O	53-60
processes	O	61-70
;	O	70-71
miR	B	72-75
-	I	75-76
342	I	76-79
-	I	79-80
3p	I	80-82
,	O	82-83
miR	B	84-87
-	I	87-88
320	I	88-91
,	O	91-92
let	B	93-96
-	I	96-97
7b	I	97-99
,	O	99-100
miR	B	101-104
-	I	104-105
328	I	105-108
,	O	108-109
miR	B	110-113
-	I	113-114
128	I	114-117
,	O	117-118
miR	B	119-122
-	I	122-123
139	I	123-126
-	I	126-127
5p	I	127-129
and	O	130-133
miR	B	134-137
-	I	137-138
146a	I	138-142
were	O	143-147
over	O	148-152
2	O	153-154
.	O	154-155
5	O	155-156
fold	O	157-161
up	O	162-164
-	O	164-165
regulated	O	165-174
and	O	175-178
miR	B	179-182
-	I	182-183
338	I	183-186
-	I	186-187
3p	I	187-189
and	O	190-193
miR	B	194-197
-	I	197-198
337	I	198-201
-	I	201-202
3p	I	202-204
over	O	205-209
2	O	210-211
.	O	211-212
5	O	212-213
fold	O	214-218
down	O	219-223
-	O	223-224
regulated	O	224-233
. 	O	233-235

We	O	0-2
used	O	3-7
microarrays	O	8-19
and	O	20-23
RT	O	24-26
-	O	26-27
PCR	O	27-30
to	O	31-33
profile	O	34-41
miRNA	O	42-47
expression	O	48-58
changes	O	59-66
in	O	67-69
the	O	70-73
brains	O	74-80
of	O	81-83
mice	O	84-88
infected	O	89-97
with	O	98-102
mouse	O	103-108
-	O	108-109
adapted	O	109-116
scrapie	O	117-124
. 	O	124-126

De	O	0-2
-	O	2-3
regulation	O	3-13
of	O	14-16
a	O	17-18
unique	O	19-25
subset	O	26-32
of	O	33-35
miRNAs	O	36-42
suggests	O	43-51
a	O	52-53
conserved	O	54-63
,	O	63-64
disease	O	65-72
-	O	72-73
specific	O	73-81
pattern	O	82-89
of	O	90-92
differentially	O	93-107
expressed	O	108-117
miRNAs	O	118-124
is	O	125-127
associated	O	128-138
with	O	139-143
prion	O	144-149
-	O	149-150
induced	O	150-157
neurodegeneration	O	158-175
. 	O	175-177

Only	O	0-4
one	O	5-8
of	O	9-11
these	O	12-17
miRNAs	O	18-24
,	O	24-25
miR	B	26-29
-	I	29-30
128	I	30-33
,	O	33-34
has	O	35-38
previously	O	39-49
been	O	50-54
shown	O	55-60
to	O	61-63
be	O	64-66
de	O	67-69
-	O	69-70
regulated	O	70-79
in	O	80-82
neurodegenerative	O	83-100
disease	O	101-108
. 	O	108-110

Computational	O	0-13
analysis	O	14-22
predicted	O	23-32
numerous	O	33-41
potential	O	42-51
gene	O	52-56
targets	O	57-64
of	O	65-67
these	O	68-73
miRNAs	O	74-80
,	O	80-81
including	O	82-91
119	O	92-95
genes	O	96-101
previously	O	102-112
determined	O	113-123
to	O	124-126
be	O	127-129
also	O	130-134
de	O	135-137
-	O	137-138
regulated	O	138-147
in	O	148-150
mouse	O	151-156
scrapie	O	157-164
. 	O	164-166

We	O	0-2
used	O	3-7
a	O	8-9
co	O	10-12
-	O	12-13
ordinated	O	13-22
approach	O	23-31
to	O	32-34
integrate	O	35-44
miRNA	O	45-50
and	O	51-54
mRNA	O	55-59
profiling	O	60-69
,	O	69-70
bioinformatic	O	71-84
predictions	O	85-96
and	O	97-100
biochemical	O	101-112
validation	O	113-123
to	O	124-126
determine	O	127-136
miRNA	O	137-142
regulated	O	143-152
processes	O	153-162
and	O	163-166
genes	O	167-172
potentially	O	173-184
involved	O	185-193
in	O	194-196
disease	O	197-204
progression	O	205-216
. 	O	216-218

In	O	0-2
particular	O	3-13
,	O	13-14
a	O	15-16
correlation	O	17-28
between	O	29-36
miRNA	O	37-42
expression	O	43-53
and	O	54-57
putative	O	58-66
gene	O	67-71
targets	O	72-79
involved	O	80-88
in	O	89-91
intracellular	O	92-105
protein	O	106-113
-	O	113-114
degradation	O	114-125
pathways	O	126-134
and	O	135-138
signaling	O	139-148
pathways	O	149-157
related	O	158-165
to	O	166-168
cell	O	169-173
death	O	174-179
,	O	179-180
synapse	O	181-188
function	O	189-197
and	O	198-201
neurogenesis	O	202-214
was	O	215-218
identified	O	219-229
.   	O	229-233

Type	O	0-4
III	O	5-8
RNase	O	9-14
Dicer	O	15-20
is	O	21-23
responsible	O	24-35
for	O	36-39
the	O	40-43
maturation	O	44-54
and	O	55-58
function	O	59-67
of	O	68-70
microRNA	O	71-79
(	O	80-81
miRNA	O	81-86
)	O	86-87
molecules	O	88-97
in	O	98-100
the	O	101-104
cell	O	105-109
. 	O	109-111

Genetic	O	0-7
ablation	O	8-16
of	O	17-19
Dicer	O	20-25
in	O	26-28
adult	O	29-34
forebrain	O	35-44
neurons	O	45-52
results	O	53-60
in	O	61-63
abnormal	O	64-72
tau	O	73-76
hyperphosphorylation	O	77-97
and	O	98-101
neurodegeneration	O	102-119
.  	O	119-122

Although	O	0-8
neuronal	O	9-17
loss	O	18-22
is	O	23-25
observed	O	26-34
in	O	35-37
the	O	38-41
hippocampus	O	42-53
,	O	53-54
cellular	O	55-63
shrinkage	O	64-73
is	O	74-76
predominant	O	77-88
in	O	89-91
the	O	92-95
cortex	O	96-102
. 	O	102-104

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
the	O	18-21
absence	O	22-29
of	O	30-32
Dicer	O	33-38
in	O	39-41
the	O	42-45
adult	O	46-51
forebrain	O	52-61
is	O	62-64
accompanied	O	65-76
by	O	77-79
a	O	80-81
mixed	O	82-87
neurodegenerative	O	88-105
phenotype	O	106-115
. 	O	115-117

However	O	0-7
,	O	7-8
the	O	9-12
underlying	O	13-23
mechanisms	O	24-34
involved	O	35-43
in	O	44-46
neuronal	O	47-55
death	O	56-61
,	O	61-62
particularly	O	63-75
in	O	76-78
the	O	79-82
adult	O	83-88
brain	O	89-94
,	O	94-95
remain	O	96-102
poorly	O	103-109
defined	O	110-117
. 	O	117-119

It	O	0-2
is	O	3-5
now	O	6-9
well	O	10-14
-	O	14-15
documented	O	15-25
that	O	26-30
Dicer	O	31-36
and	O	37-40
the	O	41-44
fine	O	45-49
-	O	49-50
tuning	O	50-56
of	O	57-59
the	O	60-63
miRNA	O	64-69
gene	O	70-74
network	O	75-82
are	O	83-86
important	O	87-96
for	O	97-100
neuronal	O	101-109
integrity	O	110-119
. 	O	119-121

We	O	0-2
further	O	3-10
demonstrate	O	11-22
that	O	23-27
miRNAs	O	28-34
belonging	O	35-44
to	O	45-47
the	O	48-51
miR	B	52-55
-	I	55-56
15	I	56-58
family	O	59-65
are	O	66-69
potent	O	70-76
regulators	O	77-87
of	O	88-90
ERK1	O	91-95
expression	O	96-106
in	O	107-109
mouse	O	110-115
neuronal	O	116-124
cells	O	125-130
and	O	131-134
co	O	135-137
-	O	137-138
expressed	O	138-147
with	O	148-152
ERK1	O	153-157
/	O	157-158
2	O	158-159
in	O	160-162
vivo	O	163-167
. 	O	167-169

Finally	O	0-7
,	O	7-8
we	O	9-11
show	O	12-16
that	O	17-21
miR	B	22-25
-	I	25-26
15a	I	26-29
is	O	30-32
specifically	O	33-45
downregulated	O	46-59
in	O	60-62
Alzheimer	O	63-72
'	O	72-73
s	O	73-74
disease	O	75-82
brain	O	83-88
. 	O	88-90

Interestingly	O	0-13
,	O	13-14
neuronal	O	15-23
degeneration	O	24-36
coincides	O	37-46
with	O	47-51
the	O	52-55
hyperphosphorylation	O	56-76
of	O	77-79
endogenous	O	80-90
tau	O	91-94
at	O	95-97
several	O	98-105
epitopes	O	106-114
previously	O	115-125
associated	O	126-136
with	O	137-141
neurofibrillary	O	142-157
pathology	O	158-167
. 	O	167-169

Transcriptome	O	0-13
analysis	O	14-22
of	O	23-25
enzymes	O	26-33
involved	O	34-42
in	O	43-45
tau	O	46-49
phosphorylation	O	50-65
identified	O	66-76
ERK1	O	77-81
as	O	82-84
one	O	85-88
of	O	89-91
the	O	92-95
candidate	O	96-105
kinases	O	106-113
responsible	O	114-125
for	O	126-129
this	O	130-134
event	O	135-140
in	O	141-143
vivo	O	144-148
. 	O	148-150

In	O	0-2
summary	O	3-10
,	O	10-11
these	O	12-17
results	O	18-25
support	O	26-33
the	O	34-37
hypothesis	O	38-48
that	O	49-53
changes	O	54-61
in	O	62-64
the	O	65-68
miRNA	O	69-74
network	O	75-82
may	O	83-86
contribute	O	87-97
to	O	98-100
a	O	101-102
neurodegenerative	O	103-120
phenotype	O	121-130
by	O	131-133
affecting	O	134-143
tau	O	144-147
phosphorylation	O	148-163
.   	O	163-167

MiR	B	0-3
-	I	3-4
21	I	4-6
can	O	7-10
be	O	11-13
induced	O	14-21
in	O	22-24
neurons	O	25-32
by	O	33-35
prolonged	O	36-45
N	O	46-47
-	O	47-48
methyl	O	48-54
-	O	54-55
D	O	55-56
-	O	56-57
aspartic	O	57-65
acid	O	66-70
receptor	O	71-79
stimulation	O	80-91
,	O	91-92
an	O	93-95
excitotoxic	O	96-107
process	O	108-115
active	O	116-122
in	O	123-125
HIV	O	126-129
and	O	130-133
other	O	134-139
neurodegenerative	O	140-157
diseases	O	158-166
. 	O	166-168

Introduction	O	0-12
of	O	13-15
miR	B	16-19
-	I	19-20
21	I	20-22
into	O	23-27
human	O	28-33
neurons	O	34-41
leads	O	42-47
to	O	48-50
pathological	O	51-63
functional	O	64-74
defects	O	75-82
. 	O	82-84

Furthermore	O	0-11
,	O	11-12
we	O	13-15
show	O	16-20
that	O	21-25
miR	B	26-29
-	I	29-30
21	I	30-32
specifically	O	33-45
targets	O	46-53
the	O	54-57
mRNA	O	58-62
of	O	63-65
myocyte	O	66-73
enhancer	O	74-82
factor	O	83-89
2C	O	90-92
(	O	93-94
MEF2C	O	94-99
)	O	99-100
,	O	100-101
a	O	102-103
transcription	O	104-117
factor	O	118-124
crucial	O	125-132
for	O	133-136
neuronal	O	137-145
function	O	146-154
,	O	154-155
and	O	156-159
reduces	O	160-167
its	O	168-171
expression	O	172-182
. 	O	182-184

MEF2C	O	0-5
is	O	6-8
dramatically	O	9-21
downregulated	O	22-35
in	O	36-38
neurons	O	39-46
of	O	47-49
HIV	O	50-53
-	O	53-54
associated	O	54-64
dementia	O	65-73
patients	O	74-82
as	O	83-85
well	O	86-90
as	O	91-93
monkeys	O	94-101
with	O	102-106
SIVE	O	107-111
. 	O	111-113

Together	O	0-8
,	O	8-9
this	O	10-14
study	O	15-20
elucidates	O	21-31
a	O	32-33
novel	O	34-39
role	O	40-44
for	O	45-48
miR	B	49-52
-	I	52-53
21	I	53-55
in	O	56-58
the	O	59-62
brain	O	63-68
,	O	68-69
not	O	70-73
only	O	74-78
as	O	79-81
a	O	82-83
potential	O	84-93
signature	O	94-103
of	O	104-106
neurological	O	107-119
disease	O	120-127
but	O	128-131
also	O	132-136
as	O	137-139
a	O	140-141
crucial	O	142-149
effector	O	150-158
of	O	159-161
HIV	O	162-165
induced	O	166-173
neuronal	O	174-182
dysfunction	O	183-194
and	O	195-198
neurodegeneration	O	199-216
.   	O	216-220

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
play	O	19-23
important	O	24-33
roles	O	34-39
in	O	40-42
regulating	O	43-53
a	O	54-55
plethora	O	56-64
of	O	65-67
physiological	O	68-81
and	O	82-85
pathophysiogical	O	86-102
processes	O	103-112
including	O	113-122
neurodegeneration	O	123-140
. 	O	140-142

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
dysregulates	O	12-24
the	O	25-28
expression	O	29-39
of	O	40-42
MEF2C	O	43-48
in	O	49-51
neurons	O	52-59
in	O	60-62
monkey	O	63-69
and	O	70-73
human	O	74-79
SIV	O	80-83
/	O	83-84
HIV	O	84-87
neurological	O	88-100
disease	O	101-108
.  	O	108-111

In	O	0-2
situ	O	3-7
hybridization	O	8-21
of	O	22-24
the	O	25-28
diseased	O	29-37
brain	O	38-43
sections	O	44-52
revealed	O	53-61
induction	O	62-71
of	O	72-74
miR	B	75-78
-	I	78-79
21	I	79-81
in	O	82-84
neurons	O	85-92
. 	O	92-94

In	O	0-2
both	O	3-7
HIV	O	8-11
associated	O	12-22
dementia	O	23-31
in	O	32-34
humans	O	35-41
and	O	42-45
its	O	46-49
monkey	O	50-56
model	O	57-62
SIV	O	63-66
encephalitis	O	67-79
we	O	80-82
find	O	83-87
miR	B	88-91
-	I	91-92
21	I	92-94
,	O	94-95
a	O	96-97
miRNA	O	98-103
largely	O	104-111
known	O	112-117
for	O	118-121
its	O	122-125
link	O	126-130
to	O	131-133
oncogenesis	O	134-145
,	O	145-146
to	O	147-149
be	O	150-152
significantly	O	153-166
upregulated	O	167-178
in	O	179-181
the	O	182-185
brain	O	186-191
. 	O	191-193

However	O	0-7
,	O	7-8
by	O	9-11
examining	O	12-21
pairs	O	22-27
in	O	28-30
which	O	31-36
the	O	37-40
significance	O	41-53
of	O	54-56
the	O	57-60
correlation	O	61-72
coefficients	O	73-85
is	O	86-88
modestly	O	89-97
relaxed	O	98-105
,	O	105-106
negative	O	107-115
correlations	O	116-128
do	O	129-131
tend	O	132-136
to	O	137-139
predict	O	140-147
targets	O	148-155
and	O	156-159
positive	O	160-168
correlations	O	169-181
tend	O	182-186
to	O	187-189
predict	O	190-197
physically	O	198-208
proximate	O	209-218
pairs	O	219-224
. 	O	224-226

A	O	0-1
subset	O	2-8
of	O	9-11
high	O	12-16
correlation	O	17-28
pairs	O	29-34
were	O	35-39
experimentally	O	40-54
validated	O	55-64
by	O	65-67
over	O	68-72
-	O	72-73
expressing	O	73-83
or	O	84-86
suppressing	O	87-98
a	O	99-100
miRNA	O	101-106
and	O	107-110
measuring	O	111-120
the	O	121-124
correlated	O	125-135
mRNAs	O	136-141
. 	O	141-143

Most	O	0-4
of	O	5-7
these	O	8-13
highest	O	14-21
correlation	O	22-33
pairs	O	34-39
do	O	40-42
not	O	43-46
contain	O	47-54
sufficiently	O	55-67
complementary	O	68-81
sequences	O	82-91
to	O	92-94
predict	O	95-102
a	O	103-104
target	O	105-111
relationship	O	112-124
;	O	124-125
nor	O	126-129
do	O	130-132
they	O	133-137
lie	O	138-141
in	O	142-144
physical	O	145-153
proximity	O	154-163
to	O	164-166
each	O	167-171
other	O	172-177
. 	O	177-179

From	O	0-4
these	O	5-10
data	O	11-15
sets	O	16-20
,	O	20-21
we	O	22-24
inferred	O	25-33
and	O	34-37
validated	O	38-47
a	O	48-49
tumor	O	50-55
suppression	O	56-67
pathway	O	68-75
linked	O	76-82
to	O	83-85
miR	B	86-89
-	I	89-90
181c	I	90-94
.   	O	94-98

CONCLUSIONS	O	0-11
/	O	11-12
SIGNIFICANCE	O	12-24
:	O	24-25
Sufficient	O	26-36
information	O	37-48
exists	O	49-55
within	O	56-62
a	O	63-64
set	O	65-68
of	O	69-71
tumor	O	72-77
samples	O	78-85
to	O	86-88
detect	O	89-95
endogenous	O	96-106
correlations	O	107-119
between	O	120-127
miRNA	O	128-133
and	O	134-137
mRNA	O	138-142
levels	O	143-149
. 	O	149-151

Based	O	0-5
on	O	6-8
the	O	9-12
validations	O	13-24
the	O	25-28
causal	O	29-35
arrow	O	36-41
for	O	42-45
these	O	46-51
correlations	O	52-64
is	O	65-67
likely	O	68-74
to	O	75-77
be	O	78-80
directed	O	81-89
from	O	90-94
the	O	95-98
miRNAs	O	99-105
to	O	106-108
the	O	109-112
mRNAs	O	113-118
. 	O	118-120

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
RNA	O	32-35
was	O	36-39
extracted	O	40-49
from	O	50-54
12	O	55-57
human	O	58-63
primary	O	64-71
brain	O	72-77
tumor	O	78-83
biopsies	O	84-92
. 	O	92-94

These	O	0-5
samples	O	6-13
were	O	14-18
used	O	19-23
to	O	24-26
determine	O	27-36
genome	O	37-43
-	O	43-44
wide	O	44-48
mRNA	O	49-53
expression	O	54-64
levels	O	65-71
by	O	72-74
microarray	O	75-85
analysis	O	86-94
and	O	95-98
a	O	99-100
miRNA	O	101-106
profile	O	107-114
by	O	115-117
real	O	118-122
-	O	122-123
time	O	123-127
reverse	O	128-135
transcription	O	136-149
PCR	O	150-153
. 	O	153-155

Correlation	O	0-11
coefficients	O	12-24
were	O	25-29
determined	O	30-40
for	O	41-44
all	O	45-48
possible	O	49-57
mRNA	O	58-62
-	O	62-63
miRNA	O	63-68
pairs	O	69-74
and	O	75-78
the	O	79-82
distribution	O	83-95
of	O	96-98
these	O	99-104
correlations	O	105-117
compared	O	118-126
to	O	127-129
the	O	130-133
random	O	134-140
distribution	O	141-153
. 	O	153-155

An	O	0-2
excess	O	3-9
of	O	10-12
high	O	13-17
positive	O	18-26
and	O	27-30
negative	O	31-39
correlation	O	40-51
pairs	O	52-57
were	O	58-62
observed	O	63-71
at	O	72-74
the	O	75-78
tails	O	79-84
of	O	85-87
these	O	88-93
distributions	O	94-107
. 	O	107-109

BACKGROUND	O	0-10
:	O	10-11
microRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
are	O	31-34
approximately	O	35-48
21	O	49-51
nucleotide	O	52-62
non	O	63-66
-	O	66-67
coding	O	67-73
transcripts	O	74-85
capable	O	86-93
of	O	94-96
regulating	O	97-107
gene	O	108-112
expression	O	113-123
. 	O	123-125

Detection	O	0-9
of	O	10-12
a	O	13-14
microRNA	O	15-23
signal	O	24-30
in	O	31-33
an	O	34-36
in	O	37-39
vivo	O	40-44
expression	O	45-55
set	O	56-59
of	O	60-62
mRNAs	O	63-68
.  	O	68-71

As	O	0-2
a	O	3-4
result	O	5-11
,	O	11-12
translation	O	13-24
of	O	25-27
the	O	28-31
target	O	32-38
mRNA	O	39-43
is	O	44-46
inhibited	O	47-56
and	O	57-60
the	O	61-64
mRNA	O	65-69
may	O	70-73
be	O	74-76
destabilized	O	77-89
. 	O	89-91

The	O	0-3
most	O	4-8
widely	O	9-15
studied	O	16-23
mechanism	O	24-33
of	O	34-36
regulation	O	37-47
involves	O	48-56
binding	O	57-64
of	O	65-67
a	O	68-69
miRNA	O	70-75
to	O	76-78
the	O	79-82
target	O	83-89
mRNA	O	90-94
. 	O	94-96

We	O	0-2
asked	O	3-8
whether	O	9-16
endogenous	O	17-27
fluctuations	O	28-40
in	O	41-43
a	O	44-45
set	O	46-49
of	O	50-52
mRNA	O	53-57
and	O	58-61
miRNA	O	62-67
profiles	O	68-76
contain	O	77-84
correlated	O	85-95
changes	O	96-103
that	O	104-108
are	O	109-112
statistically	O	113-126
distinguishable	O	127-142
from	O	143-147
the	O	148-151
many	O	152-156
other	O	157-162
fluctuations	O	163-175
in	O	176-178
the	O	179-182
data	O	183-187
set	O	188-191
. 	O	191-193

The	O	0-3
inhibitory	O	4-14
effects	O	15-22
of	O	23-25
miRNAs	O	26-32
have	O	33-37
been	O	38-42
linked	O	43-49
to	O	50-52
diverse	O	53-60
cellular	O	61-69
processes	O	70-79
including	O	80-89
malignant	O	90-99
proliferation	O	100-113
,	O	113-114
apoptosis	O	115-124
,	O	124-125
development	O	126-137
,	O	137-138
differentiation	O	139-154
,	O	154-155
and	O	156-159
metabolic	O	160-169
processes	O	170-179
. 	O	179-181

A	O	0-1
novel	O	2-7
microRNA	O	8-16
and	O	17-20
transcription	O	21-34
factor	O	35-41
mediated	O	42-50
regulatory	O	51-61
network	O	62-69
in	O	70-72
schizophrenia	O	73-86
.  	O	86-89

Previous	O	0-8
studies	O	9-16
have	O	17-21
suggested	O	22-31
that	O	32-36
changes	O	37-44
in	O	45-47
gene	O	48-52
expression	O	53-63
may	O	64-67
play	O	68-72
an	O	73-75
important	O	76-85
role	O	86-90
in	O	91-93
the	O	94-97
etiology	O	98-106
of	O	107-109
schizophrenia	O	110-123
,	O	123-124
and	O	125-128
that	O	129-133
microRNAs	O	134-143
(	O	144-145
miRNAs	O	145-151
)	O	151-152
and	O	153-156
transcription	O	157-170
factors	O	171-178
(	O	179-180
TFs	O	180-183
)	O	183-184
are	O	185-188
primary	O	189-196
regulators	O	197-207
of	O	208-210
this	O	211-215
gene	O	216-220
expression	O	221-231
. 	O	231-233

BACKGROUND	O	0-10
:	O	10-11
Schizophrenia	O	12-25
is	O	26-28
a	O	29-30
complex	O	31-38
brain	O	39-44
disorder	O	45-53
with	O	54-58
molecular	O	59-68
mechanisms	O	69-79
that	O	80-84
have	O	85-89
yet	O	90-93
to	O	94-96
be	O	97-99
elucidated	O	100-110
. 	O	110-112

We	O	0-2
hypothesized	O	3-15
that	O	16-20
miRNAs	O	21-27
and	O	28-31
TFs	O	32-35
might	O	36-41
play	O	42-46
combinatory	O	47-58
regulatory	O	59-69
roles	O	70-75
for	O	76-79
schizophrenia	O	80-93
genes	O	94-99
and	O	100-103
,	O	103-104
thus	O	105-109
,	O	109-110
explored	O	111-119
miRNA	O	120-125
-	O	125-126
TF	O	126-128
regulatory	O	129-139
networks	O	140-148
in	O	149-151
schizophrenia	O	152-165
. 	O	165-167

So	O	0-2
far	O	3-6
,	O	6-7
several	O	8-15
miRNA	O	16-21
-	O	21-22
TF	O	22-24
mediated	O	25-33
regulatory	O	34-44
modules	O	45-52
have	O	53-57
been	O	58-62
verified	O	63-71
. 	O	71-73

Our	O	0-3
evaluation	O	4-14
revealed	O	15-23
that	O	24-28
these	O	29-34
observed	O	35-43
FFLs	O	44-48
were	O	49-53
significantly	O	54-67
enriched	O	68-76
in	O	77-79
schizophrenia	O	80-93
genes	O	94-99
. 	O	99-101

RESULTS	O	0-7
:	O	7-8
We	O	9-11
identified	O	12-22
32	O	23-25
feed	O	26-30
-	O	30-31
forward	O	31-38
loops	O	39-44
(	O	45-46
FFLs	O	46-50
)	O	50-51
among	O	52-57
our	O	58-61
compiled	O	62-70
schizophrenia	O	71-84
-	O	84-85
related	O	85-92
miRNAs	O	93-99
,	O	99-100
TFs	O	101-104
and	O	105-108
genes	O	109-114
. 	O	114-116

By	O	0-2
converging	O	3-13
the	O	14-17
FFLs	O	18-22
and	O	23-26
mutual	O	27-33
feedback	O	34-42
loops	O	43-48
,	O	48-49
we	O	50-52
constructed	O	53-64
a	O	65-66
novel	O	67-72
miRNA	O	73-78
-	O	78-79
TF	O	79-81
regulatory	O	82-92
network	O	93-100
for	O	101-104
schizophrenia	O	105-118
. 	O	118-120

Our	O	0-3
analysis	O	4-12
revealed	O	13-21
EGR3	O	22-26
and	O	27-30
hsa	B	31-34
-	I	34-35
miR	I	35-38
-	I	38-39
195	I	39-42
were	O	43-47
core	O	48-52
regulators	O	53-63
in	O	64-66
this	O	67-71
regulatory	O	72-82
network	O	83-90
. 	O	90-92

We	O	0-2
next	O	3-7
proposed	O	8-16
a	O	17-18
model	O	19-24
highlighting	O	25-37
EGR3	O	38-42
and	O	43-46
miRNAs	O	47-53
involved	O	54-62
in	O	63-65
signaling	O	66-75
pathways	O	76-84
and	O	85-88
regulatory	O	89-99
networks	O	100-108
in	O	109-111
the	O	112-115
nervous	O	116-123
system	O	124-130
. 	O	130-132

It	O	0-2
represents	O	3-13
the	O	14-17
first	O	18-23
investigation	O	24-37
of	O	38-40
a	O	41-42
miRNA	O	43-48
-	O	48-49
TF	O	49-51
regulatory	O	52-62
network	O	63-70
for	O	71-74
a	O	75-76
complex	O	77-84
disease	O	85-92
,	O	92-93
as	O	94-96
demonstrated	O	97-109
in	O	110-112
schizophrenia	O	113-126
.   	O	126-130

CONCLUSIONS	O	0-11
:	O	11-12
This	O	13-17
study	O	18-23
provides	O	24-32
many	O	33-37
insights	O	38-46
on	O	47-49
the	O	50-53
regulatory	O	54-64
mechanisms	O	65-75
of	O	76-78
genes	O	79-84
involved	O	85-93
in	O	94-96
schizophrenia	O	97-110
. 	O	110-112

Finally	O	0-7
,	O	7-8
we	O	9-11
suggested	O	12-21
several	O	22-29
single	O	30-36
nucleotide	O	37-47
polymorphisms	O	48-61
(	O	62-63
SNPs	O	63-67
)	O	67-68
located	O	69-76
on	O	77-79
miRNAs	O	80-86
,	O	86-87
their	O	88-93
target	O	94-100
sites	O	101-106
,	O	106-107
and	O	108-111
TFBSs	O	112-117
,	O	117-118
which	O	119-124
may	O	125-128
have	O	129-133
an	O	134-136
effect	O	137-143
in	O	144-146
schizophrenia	O	147-160
gene	O	161-165
regulation	O	166-176
. 	O	176-178

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
In	O	32-34
a	O	35-36
screening	O	37-46
of	O	47-49
MB	O	50-52
cell	O	53-57
lines	O	58-63
,	O	63-64
the	O	65-68
miRNA	O	69-74
miR	B	75-78
-	I	78-79
199b	I	79-83
-	I	83-84
5p	I	84-86
was	O	87-90
seen	O	91-95
to	O	96-98
be	O	99-101
a	O	102-103
regulator	O	104-113
of	O	114-116
the	O	117-120
Notch	O	121-126
pathway	O	127-134
through	O	135-142
its	O	143-146
targeting	O	147-156
of	O	157-159
the	O	160-163
transcription	O	164-177
factor	O	178-184
HES1	O	185-189
.	O	189-190
Down	O	191-195
-	O	195-196
regulation	O	196-206
of	O	207-209
HES1	O	210-214
expression	O	215-225
by	O	226-228
miR	B	229-232
-	I	232-233
199b	I	233-237
-	I	237-238
5p	I	238-240
negatively	O	241-251
regulates	O	252-261
the	O	262-265
proliferation	O	266-279
rate	O	280-284
and	O	285-288
anchorage	O	289-298
-	O	298-299
independent	O	299-310
growth	O	311-317
of	O	318-320
MB	O	321-323
cells	O	324-329
. 	O	329-331

MiR	B	0-3
-	I	3-4
199b	I	4-8
-	I	8-9
5p	I	9-11
over	O	12-16
-	O	16-17
expression	O	17-27
blocks	O	28-34
expression	O	35-45
of	O	46-48
several	O	49-56
cancer	O	57-63
stem	O	64-68
-	O	68-69
cell	O	69-73
genes	O	74-79
,	O	79-80
impairs	O	81-88
the	O	89-92
engrafting	O	93-103
potential	O	104-113
of	O	114-116
MB	O	117-119
cells	O	120-125
in	O	126-128
the	O	129-132
cerebellum	O	133-143
of	O	144-146
athymic	O	147-154
/	O	154-155
nude	O	155-159
mice	O	160-164
,	O	164-165
and	O	166-169
of	O	170-172
particular	O	173-183
interest	O	184-192
,	O	192-193
decreases	O	194-203
the	O	204-207
MB	O	208-210
stem	O	211-215
-	O	215-216
cell	O	216-220
-	O	220-221
like	O	221-225
(	O	226-227
CD133	O	227-232
+	O	232-233
)	O	233-234
subpopulation	O	235-248
of	O	249-251
cells	O	252-257
. 	O	257-259

In	O	0-2
our	O	3-6
analysis	O	7-15
of	O	16-18
61	O	19-21
patients	O	22-30
with	O	31-35
MB	O	36-38
,	O	38-39
the	O	40-43
expression	O	44-54
of	O	55-57
miR	B	58-61
-	I	61-62
199b	I	62-66
-	I	66-67
5p	I	67-69
in	O	70-72
the	O	73-76
non	O	77-80
-	O	80-81
metastatic	O	81-91
cases	O	92-97
was	O	98-101
significantly	O	102-115
higher	O	116-122
than	O	123-127
in	O	128-130
the	O	131-134
metastatic	O	135-145
cases	O	146-151
(	O	152-153
P	O	153-154
=	O	155-156
0	O	157-158
.	O	158-159
001	O	159-162
)	O	162-163
. 	O	163-165

Correlation	O	0-11
with	O	12-16
survival	O	17-25
for	O	26-29
these	O	30-35
patients	O	36-44
with	O	45-49
high	O	50-54
levels	O	55-61
of	O	62-64
miR	B	65-68
-	I	68-69
199b	I	69-73
expression	O	74-84
showed	O	85-91
a	O	92-93
positive	O	94-102
trend	O	103-108
to	O	109-111
better	O	112-118
overall	O	119-126
survival	O	127-135
than	O	136-140
for	O	141-144
the	O	145-148
low	O	149-152
-	O	152-153
expressing	O	153-163
patients	O	164-172
. 	O	172-174

Here	O	0-4
we	O	5-7
have	O	8-12
investigated	O	13-25
medulloblastoma	O	26-41
tumors	O	42-48
(	O	49-50
MBs	O	50-53
)	O	53-54
,	O	54-55
which	O	56-61
arise	O	62-67
from	O	68-72
an	O	73-75
early	O	76-81
impairment	O	82-92
of	O	93-95
developmental	O	96-109
processes	O	110-119
in	O	120-122
the	O	123-126
cerebellum	O	127-137
,	O	137-138
where	O	139-144
Notch	O	145-150
signaling	O	151-160
is	O	161-163
involved	O	164-172
in	O	173-175
many	O	176-180
cell	O	181-185
-	O	185-186
fate	O	186-190
-	O	190-191
determining	O	191-202
stages	O	203-209
. 	O	209-211

MBs	O	0-3
occur	O	4-9
bimodally	O	10-19
,	O	19-20
with	O	21-25
the	O	26-29
peak	O	30-34
incidence	O	35-44
seen	O	45-49
between	O	50-57
3	O	58-59
-	O	59-60
4	O	60-61
years	O	62-67
and	O	68-71
8	O	72-73
-	O	73-74
9	O	74-75
years	O	76-81
of	O	82-84
age	O	85-88
,	O	88-89
although	O	90-98
it	O	99-101
can	O	102-105
also	O	106-110
occur	O	111-116
in	O	117-119
adults	O	120-126
. 	O	126-128

Notch	O	0-5
regulates	O	6-15
a	O	16-17
subset	O	18-24
of	O	25-27
the	O	28-31
MB	O	32-34
cells	O	35-40
that	O	41-45
have	O	46-50
stem	O	51-55
-	O	55-56
cell	O	56-60
-	O	60-61
like	O	61-65
properties	O	66-76
and	O	77-80
can	O	81-84
promote	O	85-92
tumor	O	93-98
growth	O	99-105
. 	O	105-107

On	O	0-2
the	O	3-6
basis	O	7-12
of	O	13-15
this	O	16-20
evidence	O	21-29
,	O	29-30
we	O	31-33
hypothesized	O	34-46
that	O	47-51
miRNAs	O	52-58
targeting	O	59-68
the	O	69-72
Notch	O	73-78
pathway	O	79-86
can	O	87-90
regulated	O	91-100
these	O	101-106
phenomena	O	107-116
,	O	116-117
and	O	118-121
can	O	122-125
be	O	126-128
used	O	129-133
in	O	134-136
anti	O	137-141
-	O	141-142
cancer	O	142-148
therapies	O	149-158
. 	O	158-160

BACKGROUND	O	0-10
:	O	10-11
Through	O	12-19
negative	O	20-28
regulation	O	29-39
of	O	40-42
gene	O	43-47
expression	O	48-58
,	O	58-59
microRNAs	O	60-69
(	O	70-71
miRNAs	O	71-77
)	O	77-78
can	O	79-82
function	O	83-91
in	O	92-94
cancers	O	95-102
as	O	103-105
oncosuppressors	O	106-121
,	O	121-122
and	O	123-126
they	O	127-131
can	O	132-135
show	O	136-140
altered	O	141-148
expression	O	149-159
in	O	160-162
various	O	163-170
tumor	O	171-176
types	O	177-182
. 	O	182-184

MicroRNA	B	0-8
-	I	8-9
199b	I	9-13
-	I	13-14
5p	I	14-16
impairs	O	17-24
cancer	O	25-31
stem	O	32-36
cells	O	37-42
through	O	43-50
negative	O	51-59
regulation	O	60-70
of	O	71-73
HES1	O	74-78
in	O	79-81
medulloblastoma	O	82-97
.  	O	97-100

To	O	0-2
date	O	3-7
,	O	7-8
this	O	9-13
is	O	14-16
the	O	17-20
first	O	21-26
report	O	27-33
that	O	34-38
expression	O	39-49
of	O	50-52
a	O	53-54
miRNA	O	55-60
can	O	61-64
deplete	O	65-72
the	O	73-76
tumor	O	77-82
stem	O	83-87
cells	O	88-93
,	O	93-94
indicating	O	95-105
an	O	106-108
interesting	O	109-120
therapeutic	O	121-132
approach	O	133-141
for	O	142-145
the	O	146-149
targeting	O	150-159
of	O	160-162
these	O	163-168
cells	O	169-174
in	O	175-177
brain	O	178-183
tumors	O	184-190
.   	O	190-194

CONCLUSIONS	O	0-11
/	O	11-12
SIGNIFICANCE	O	12-24
:	O	24-25
Despite	O	26-33
advances	O	34-42
in	O	43-45
our	O	46-49
understanding	O	50-63
of	O	64-66
the	O	67-70
pathogenesis	O	71-83
of	O	84-86
MB	O	87-89
,	O	89-90
one	O	91-94
-	O	94-95
third	O	95-100
of	O	101-103
these	O	104-109
patients	O	110-118
remain	O	119-125
incurable	O	126-135
and	O	136-139
current	O	140-147
treatments	O	148-158
can	O	159-162
significantly	O	163-176
damage	O	177-183
long	O	184-188
-	O	188-189
term	O	189-193
survivors	O	194-203
. 	O	203-205

Infection	O	0-9
with	O	10-14
MB	O	15-17
cells	O	18-23
in	O	24-26
an	O	27-29
induced	O	30-37
xenograft	O	38-47
model	O	48-53
in	O	54-56
the	O	57-60
mouse	O	61-66
cerebellum	O	67-77
and	O	78-81
the	O	82-85
use	O	86-89
of	O	90-92
an	O	93-95
adenovirus	O	96-106
carrying	O	107-115
miR	B	116-119
-	I	119-120
199b	I	120-124
-	I	124-125
5p	I	125-127
indicate	O	128-136
a	O	137-138
clinical	O	139-147
benefit	O	148-155
through	O	156-163
this	O	164-168
negative	O	169-177
influence	O	178-187
of	O	188-190
miR	B	191-194
-	I	194-195
199b	I	195-199
-	I	199-200
5p	I	200-202
on	O	203-205
tumor	O	206-211
growth	O	212-218
and	O	219-222
on	O	223-225
the	O	226-229
subset	O	230-236
of	O	237-239
MB	O	240-242
stem	O	243-247
-	O	247-248
cell	O	248-252
-	O	252-253
like	O	253-257
cells	O	258-263
,	O	263-264
providing	O	265-274
further	O	275-282
proof	O	283-288
of	O	289-291
concept	O	292-299
. 	O	299-301

We	O	0-2
further	O	3-10
show	O	11-15
that	O	16-20
in	O	21-23
a	O	24-25
xenograft	O	26-35
model	O	36-41
,	O	41-42
MB	O	43-45
tumor	O	46-51
burden	O	52-58
can	O	59-62
be	O	63-65
reduced	O	66-73
,	O	73-74
indicating	O	75-85
the	O	86-89
use	O	90-93
of	O	94-96
miR199b	B	97-104
-	I	104-105
5p	I	105-107
as	O	108-110
an	O	111-113
adjuvant	O	114-122
therapy	O	123-130
after	O	131-136
surgery	O	137-144
,	O	144-145
in	O	146-148
combination	O	149-160
with	O	161-165
radiation	O	166-175
and	O	176-179
chemotherapy	O	180-192
,	O	192-193
for	O	194-197
the	O	198-201
improvement	O	202-213
of	O	214-216
anti	O	217-221
-	O	221-222
cancer	O	222-228
MB	O	229-231
therapies	O	232-241
and	O	242-245
patient	O	246-253
quality	O	254-261
of	O	262-264
life	O	265-269
. 	O	269-271

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
miR	B	18-21
-	I	21-22
199b	I	22-26
-	I	26-27
5p	I	27-29
expression	O	30-40
correlates	O	41-51
with	O	52-56
metastasis	O	57-67
spread	O	68-74
,	O	74-75
identifying	O	76-87
a	O	88-89
new	O	90-93
molecular	O	94-103
marker	O	104-110
for	O	111-114
a	O	115-116
poor	O	117-121
-	O	121-122
risk	O	122-126
class	O	127-132
in	O	133-135
patients	O	136-144
with	O	145-149
MB	O	150-152
. 	O	152-154

These	O	0-5
data	O	6-10
showing	O	11-18
the	O	19-22
down	O	23-27
-	O	27-28
regulation	O	28-38
of	O	39-41
miR	B	42-45
-	I	45-46
199b	I	46-50
-	I	50-51
5p	I	51-53
in	O	54-56
metastatic	O	57-67
MBs	O	68-71
suggest	O	72-79
a	O	80-81
potential	O	82-91
silencing	O	92-101
mechanism	O	102-111
through	O	112-119
epigenetic	O	120-130
or	O	131-133
genetic	O	134-141
alterations	O	142-153
. 	O	153-155

Furthermore	O	0-11
,	O	11-12
two	O	13-16
cell	O	17-21
lines	O	22-27
(	O	28-29
Med8a	O	29-34
and	O	35-38
UW228	O	39-44
)	O	44-45
showed	O	46-52
significant	O	53-64
up	O	65-67
-	O	67-68
regulation	O	68-78
of	O	79-81
miR	B	82-85
-	I	85-86
199b	I	86-90
-	I	90-91
5p	I	91-93
upon	O	94-98
treatment	O	99-108
. 	O	108-110

Upon	O	0-4
induction	O	5-14
of	O	15-17
de	O	18-20
-	O	20-21
methylation	O	21-32
using	O	33-38
5	O	39-40
-	O	40-41
aza	O	41-44
-	O	44-45
deoxycytidine	O	45-58
,	O	58-59
lower	O	60-65
miR	B	66-69
-	I	69-70
199b	I	70-74
-	I	74-75
5p	I	75-77
expression	O	78-88
was	O	89-92
seen	O	93-97
in	O	98-100
a	O	101-102
panel	O	103-108
of	O	109-111
MB	O	112-114
cell	O	115-119
lines	O	120-125
,	O	125-126
supported	O	127-136
an	O	137-139
epigenetic	O	140-150
mechanism	O	151-160
of	O	161-163
regulation	O	164-174
. 	O	174-176

Many	O	0-4
tools	O	5-10
have	O	11-15
been	O	16-20
developed	O	21-30
to	O	31-33
help	O	34-38
describe	O	39-47
the	O	48-51
repertoire	O	52-62
of	O	63-65
miRNAs	O	66-72
present	O	73-80
at	O	81-83
the	O	84-87
tissue	O	88-94
level	O	95-100
in	O	101-103
a	O	104-105
given	O	106-111
sample	O	112-118
. 	O	118-120

To	O	0-2
understand	O	3-13
how	O	14-17
miRNAs	O	18-24
contribute	O	25-35
to	O	36-38
normal	O	39-45
biologic	O	46-54
functions	O	55-64
and	O	65-68
disease	O	69-76
states	O	77-83
,	O	83-84
it	O	85-87
is	O	88-90
critical	O	91-99
to	O	100-102
understand	O	103-113
the	O	114-117
miRNAs	O	118-124
that	O	125-129
are	O	130-133
expressed	O	134-143
in	O	144-146
particular	O	147-157
cell	O	158-162
types	O	163-168
under	O	169-174
a	O	175-176
range	O	177-182
of	O	183-185
conditions	O	186-196
. 	O	196-198

Such	O	0-4
knowledge	O	5-14
is	O	15-17
especially	O	18-28
important	O	29-38
in	O	39-41
the	O	42-45
nervous	O	46-53
system	O	54-60
with	O	61-65
its	O	66-69
many	O	70-74
cell	O	75-79
types	O	80-85
,	O	85-86
microscopic	O	87-98
heterogeneity	O	99-112
with	O	113-117
regard	O	118-124
to	O	125-127
functionally	O	128-140
distinct	O	141-149
cell	O	150-154
groups	O	155-161
,	O	161-162
and	O	163-166
extreme	O	167-174
geometrical	O	175-186
complexity	O	187-197
in	O	198-200
cellular	O	201-209
shapes	O	210-216
. 	O	216-218

However	O	0-7
,	O	7-8
tissue	O	9-15
level	O	16-21
miRNA	O	22-27
profiling	O	28-37
is	O	38-40
inadequate	O	41-51
to	O	52-54
pinpoint	O	55-63
the	O	64-67
cellular	O	68-76
and	O	77-80
sub	O	81-84
-	O	84-85
cellular	O	85-93
distribution	O	94-106
of	O	107-109
individual	O	110-120
miRNAs	O	121-127
. 	O	127-129

In	O	0-2
situ	O	3-7
hybridization	O	8-21
is	O	22-24
a	O	25-26
necessary	O	27-36
experimental	O	37-49
complement	O	50-60
to	O	61-63
microRNA	O	64-72
(	O	73-74
miRNA	O	74-79
)	O	79-80
expression	O	81-91
profiling	O	92-101
in	O	102-104
the	O	105-108
human	O	109-114
brain	O	115-120
.  	O	120-123

However	O	0-7
,	O	7-8
much	O	9-13
remains	O	14-21
to	O	22-24
be	O	25-27
learned	O	28-35
in	O	36-38
this	O	39-43
fast	O	44-48
-	O	48-49
paced	O	49-54
field	O	55-60
. 	O	60-62

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
play	O	19-23
fundamental	O	24-35
roles	O	36-41
in	O	42-44
human	O	45-50
brain	O	51-56
neurochemistry	O	57-71
. 	O	71-73

Thus	O	0-4
,	O	4-5
in	O	6-8
situ	O	9-13
hybridization	O	14-27
is	O	28-30
an	O	31-33
important	O	34-43
experimental	O	44-56
complement	O	57-67
to	O	68-70
tissue	O	71-77
level	O	78-83
miRNA	O	84-89
expression	O	90-100
profiling	O	101-110
. 	O	110-112

We	O	0-2
have	O	3-7
found	O	8-13
that	O	14-18
in	O	19-21
situ	O	22-26
hybridization	O	27-40
shows	O	41-46
important	O	47-56
cerebral	O	57-65
cortical	O	66-74
lamina	O	75-81
-	O	81-82
specific	O	82-90
patterns	O	91-99
of	O	100-102
miRNA	O	103-108
expression	O	109-119
that	O	120-124
would	O	125-130
be	O	131-133
lost	O	134-138
on	O	139-141
most	O	142-146
tissue	O	147-153
level	O	154-159
expression	O	160-170
studies	O	171-178
,	O	178-179
and	O	180-183
these	O	184-189
lamina	O	190-196
-	O	196-197
specific	O	197-205
patterns	O	206-214
can	O	215-218
be	O	219-221
directly	O	222-230
relevant	O	231-239
to	O	240-242
human	O	243-248
brain	O	249-254
disease	O	255-262
. 	O	262-264

Technical	O	0-9
and	O	10-13
theoretical	O	14-25
aspects	O	26-33
of	O	34-36
this	O	37-41
important	O	42-51
technique	O	52-61
are	O	62-65
described	O	66-75
,	O	75-76
especially	O	77-87
those	O	88-93
pertinent	O	94-103
to	O	104-106
studying	O	107-115
the	O	116-119
human	O	120-125
brain	O	126-131
.   	O	131-135

However	O	0-7
,	O	7-8
we	O	9-11
report	O	12-18
the	O	19-22
experience	O	23-33
of	O	34-36
a	O	37-38
patient	O	39-46
who	O	47-50
inadvertently	O	51-64
received	O	65-73
live	O	74-78
polio	O	79-84
vaccine	O	85-92
whilst	O	93-99
receiving	O	100-109
anti	O	110-114
-	O	114-115
TNF	O	115-118
therapy	O	119-126
. 	O	126-128

International	O	0-13
guidelines	O	14-24
state	O	25-30
that	O	31-35
live	O	36-40
vaccines	O	41-49
are	O	50-53
contraindicated	O	54-69
in	O	70-72
patients	O	73-81
on	O	82-84
anti	O	85-89
-	O	89-90
TNF	O	90-93
therapy	O	94-101
. 	O	101-103

Live	O	0-4
polio	O	5-10
vaccine	O	11-18
exposure	O	19-27
while	O	28-33
receiving	O	34-43
anti	O	44-48
-	O	48-49
TNF	O	49-52
therapy	O	53-60
for	O	61-64
reactive	O	65-73
arthritis	O	74-83
.  	O	83-86

Patients	O	0-8
should	O	9-15
be	O	16-18
counseled	O	19-28
regarding	O	29-38
the	O	39-42
risks	O	43-48
of	O	49-51
live	O	52-56
vaccines	O	57-65
prior	O	66-71
to	O	72-74
treatment	O	75-84
with	O	85-89
anti	O	90-94
-	O	94-95
TNF	O	95-98
therapy	O	99-106
.   	O	106-110

However	O	0-7
,	O	7-8
if	O	9-11
we	O	12-14
consider	O	15-23
adult	O	24-29
patients	O	30-38
with	O	39-43
rheumatic	O	44-53
diseases	O	54-62
to	O	63-65
have	O	66-70
altered	O	71-78
immunocompetence	O	79-95
,	O	95-96
it	O	97-99
is	O	100-102
recommended	O	103-114
that	O	115-119
they	O	120-124
receive	O	125-132
the	O	133-136
usual	O	137-142
inactivated	O	143-154
vaccines	O	155-163
according	O	164-173
to	O	174-176
standard	O	177-185
schedules	O	186-195
,	O	195-196
and	O	197-200
live	O	201-205
vaccines	O	206-214
should	O	215-221
be	O	222-224
avoided	O	225-232
in	O	233-235
those	O	236-241
who	O	242-245
are	O	246-249
treated	O	250-257
with	O	258-262
more	O	263-267
potent	O	268-274
forms	O	275-280
of	O	281-283
immune	O	284-290
suppression	O	291-302
. 	O	302-304

No	O	0-2
clear	O	3-8
guidelines	O	9-19
are	O	20-23
available	O	24-33
for	O	34-37
all	O	38-41
vaccines	O	42-50
in	O	51-53
patients	O	54-62
with	O	63-67
specific	O	68-76
rheumatic	O	77-86
diseases	O	87-95
. 	O	95-97

Patient	O	0-7
did	O	8-11
not	O	12-15
suffer	O	16-22
from	O	23-27
any	O	28-31
infectious	O	32-42
sequel	O	43-49
as	O	50-52
a	O	53-54
result	O	55-61
. 	O	61-63

Thus	O	0-4
we	O	5-7
have	O	8-12
identified	O	13-23
the	O	24-27
miRNA	O	28-33
expression	O	34-44
signature	O	45-54
for	O	55-58
malignant	O	59-68
astrocytoma	O	69-80
,	O	80-81
in	O	82-84
particular	O	85-95
glioblastoma	O	96-108
,	O	108-109
and	O	110-113
showed	O	114-120
the	O	121-124
miRNA	O	125-130
involvement	O	131-142
and	O	143-146
their	O	147-152
importance	O	153-163
in	O	164-166
astrocytoma	O	167-178
development	O	179-190
.   	O	190-194

Inhibition	O	0-10
of	O	11-13
two	O	14-17
glioblastoma	O	18-30
-	O	30-31
upregulated	O	31-42
miRNAs	O	43-49
(	O	50-51
miR	B	51-54
-	I	54-55
21	I	55-57
and	O	58-61
miR	B	62-65
-	I	65-66
23a	I	66-69
)	O	69-70
and	O	71-74
exogenous	O	75-84
overexpression	O	85-99
of	O	100-102
two	O	103-106
glioblastoma	O	107-119
-	O	119-120
downregulated	O	120-133
miRNAs	O	134-140
(	O	141-142
miR	B	142-145
-	I	145-146
218	I	146-149
and	O	150-153
miR	B	154-157
-	I	157-158
219	I	158-161
-	I	161-162
5p	I	162-164
)	O	164-165
resulted	O	166-174
in	O	175-177
reduced	O	178-185
soft	O	186-190
agar	O	191-195
colony	O	196-202
formation	O	203-212
but	O	213-216
showed	O	217-223
varying	O	224-231
effects	O	232-239
on	O	240-242
cell	O	243-247
proliferation	O	248-261
and	O	262-265
chemosensitivity	O	266-282
. 	O	282-284

Among	O	0-5
them	O	6-10
,	O	10-11
glioblastoma	O	12-24
is	O	25-27
the	O	28-31
most	O	32-36
common	O	37-43
primary	O	44-51
brain	O	52-57
tumor	O	58-63
with	O	64-68
dismal	O	69-75
responses	O	76-85
to	O	86-88
all	O	89-92
therapeutic	O	93-104
modalities	O	105-115
. 	O	115-117

Malignant	O	0-9
astrocytoma	O	10-21
includes	O	22-30
anaplastic	O	31-41
astrocytoma	O	42-53
(	O	54-55
grade	O	55-60
III	O	61-64
)	O	64-65
and	O	66-69
glioblastoma	O	70-82
(	O	83-84
grade	O	84-89
IV	O	90-92
)	O	92-93
. 	O	93-95

Genome	O	0-6
-	O	6-7
wide	O	7-11
expression	O	12-22
profiling	O	23-32
identifies	O	33-43
deregulated	O	44-55
miRNAs	O	56-62
in	O	63-65
malignant	O	66-75
astrocytoma	O	76-87
.  	O	87-90

The	O	0-3
differential	O	4-16
expression	O	17-27
pattern	O	28-35
of	O	36-38
nine	O	39-43
miRNAs	O	44-50
was	O	51-54
further	O	55-62
validated	O	63-72
by	O	73-75
real	O	76-80
-	O	80-81
time	O	81-85
RT	O	86-88
-	O	88-89
PCR	O	89-92
on	O	93-95
an	O	96-98
independent	O	99-110
set	O	111-114
of	O	115-117
malignant	O	118-127
astrocytomas	O	128-140
(	O	141-142
n	O	142-143
=	O	143-144
72	O	144-146
)	O	146-147
and	O	148-151
normal	O	152-158
samples	O	159-166
(	O	167-168
n	O	168-169
=	O	169-170
7	O	170-171
)	O	171-172
. 	O	172-174

More	O	0-4
importantly	O	5-16
,	O	16-17
we	O	18-20
identified	O	21-31
a	O	32-33
most	O	34-38
discriminatory	O	39-53
23	O	54-56
-	O	56-57
miRNA	O	57-62
expression	O	63-73
signature	O	74-83
,	O	83-84
by	O	85-87
using	O	88-93
PAM	O	94-97
,	O	97-98
which	O	99-104
precisely	O	105-114
distinguished	O	115-128
glioblastoma	O	129-141
from	O	142-146
anaplastic	O	147-157
astrocytoma	O	158-169
with	O	170-174
an	O	175-177
accuracy	O	178-186
of	O	187-189
95	O	190-192
%	O	192-193
. 	O	193-195

We	O	0-2
identified	O	3-13
several	O	14-21
differentially	O	22-36
regulated	O	37-46
miRNAs	O	47-53
between	O	54-61
these	O	62-67
groups	O	68-74
,	O	74-75
which	O	76-81
could	O	82-87
differentiate	O	88-101
glioma	O	102-108
grades	O	109-115
and	O	116-119
normal	O	120-126
brain	O	127-132
as	O	133-135
recognized	O	136-146
by	O	147-149
PCA	O	150-153
. 	O	153-155

We	O	0-2
performed	O	3-12
a	O	13-14
large	O	15-20
-	O	20-21
scale	O	21-26
,	O	26-27
genome	O	28-34
-	O	34-35
wide	O	35-39
microRNA	O	40-48
(	O	49-50
miRNA	O	50-55
)	O	55-56
(	O	57-58
n	O	58-59
=	O	59-60
756	O	60-63
)	O	63-64
expression	O	65-75
profiling	O	76-85
of	O	86-88
26	O	89-91
glioblastoma	O	92-104
,	O	104-105
13	O	106-108
anaplastic	O	109-119
astrocytoma	O	120-131
and	O	132-135
7	O	136-137
normal	O	138-144
brain	O	145-150
samples	O	151-158
with	O	159-163
an	O	164-166
aim	O	167-170
to	O	171-173
find	O	174-178
deregulated	O	179-190
miRNA	O	191-196
in	O	197-199
malignant	O	200-209
astrocytoma	O	210-221
. 	O	221-223

Our	O	0-3
findings	O	4-12
suggest	O	13-20
a	O	21-22
functional	O	23-33
collaboration	O	34-47
between	O	48-55
the	O	56-59
miR	B	60-63
-	I	63-64
17	I	64-66
approximately	O	67-80
92	O	81-83
cluster	O	84-91
and	O	92-95
the	O	96-99
SHH	O	100-103
signaling	O	104-113
pathway	O	114-121
in	O	122-124
the	O	125-128
development	O	129-140
of	O	141-143
MBs	O	144-147
in	O	148-150
mouse	O	151-156
and	O	157-160
man	O	161-164
.   	O	164-168

Analysis	O	0-8
of	O	9-11
human	O	12-17
MBs	O	18-21
demonstrated	O	22-34
that	O	35-39
3	O	40-41
miR	B	42-45
-	I	45-46
17	I	46-48
approximately	O	49-62
92	O	63-65
cluster	O	66-73
miRNAs	O	74-80
(	O	81-82
miR	B	82-85
-	I	85-86
92	I	86-88
,	O	88-89
miR	B	90-93
-	I	93-94
19a	I	94-97
,	O	97-98
and	O	99-102
miR	B	103-106
-	I	106-107
20	I	107-109
)	O	109-110
were	O	111-115
also	O	116-120
overexpressed	O	121-134
in	O	135-137
human	O	138-143
MBs	O	144-147
with	O	148-152
a	O	153-154
constitutively	O	155-169
activated	O	170-179
Sonic	O	180-185
Hedgehog	O	186-194
(	O	195-196
SHH	O	196-199
)	O	199-200
signaling	O	201-210
pathway	O	211-218
,	O	218-219
but	O	220-223
not	O	224-227
in	O	228-230
other	O	231-236
forms	O	237-242
of	O	243-245
the	O	246-249
disease	O	250-257
. 	O	257-259

To	O	0-2
test	O	3-7
whether	O	8-15
the	O	16-19
miR	B	20-23
-	I	23-24
17	I	24-26
approximately	O	27-40
92	O	41-43
cluster	O	44-51
could	O	52-57
promote	O	58-65
MB	O	66-68
formation	O	69-78
,	O	78-79
we	O	80-82
enforced	O	83-91
expression	O	92-102
of	O	103-105
these	O	106-111
miRNAs	O	112-118
in	O	119-121
GNPs	O	122-126
isolated	O	127-135
from	O	136-140
cerebella	O	141-150
of	O	151-153
postnatal	O	154-163
(	O	164-165
P	O	165-166
)	O	166-167
day	O	168-171
P6	O	172-174
Ink4c	O	175-180
-	O	180-181
/	O	181-182
-	O	182-183
;	O	183-184
Ptch1	O	185-190
+	O	190-191
/	O	191-192
-	O	192-193
mice	O	194-198
. 	O	198-200

These	O	0-5
,	O	5-6
but	O	7-10
not	O	11-14
similarly	O	15-24
engineered	O	25-35
cells	O	36-41
from	O	42-46
Ink4c	O	47-52
-	O	52-53
/	O	53-54
-	O	54-55
;	O	55-56
p53	O	57-60
-	O	60-61
/	O	61-62
-	O	62-63
mice	O	64-68
,	O	68-69
formed	O	70-76
MBs	O	77-80
in	O	81-83
orthotopic	O	84-94
transplants	O	95-106
with	O	107-111
complete	O	112-120
penetrance	O	121-131
. 	O	131-133

Interestingly	O	0-13
,	O	13-14
orthotopic	O	15-25
mouse	O	26-31
tumors	O	32-38
ectopically	O	39-50
expressing	O	51-61
miR	B	62-65
-	I	65-66
17	I	66-68
approximately	O	69-82
92	O	83-85
lost	O	86-90
expression	O	91-101
of	O	102-104
the	O	105-108
wild	O	109-113
-	O	113-114
type	O	114-118
Ptch1	O	119-124
allele	O	125-131
. 	O	131-133

Some	O	0-4
are	O	5-8
thought	O	9-16
to	O	17-19
originate	O	20-29
from	O	30-34
cerebellar	O	35-45
granule	O	46-53
neuron	O	54-60
progenitors	O	61-72
(	O	73-74
GNPs	O	74-78
)	O	78-79
that	O	80-84
fail	O	85-89
to	O	90-92
undergo	O	93-100
normal	O	101-107
cell	O	108-112
cycle	O	113-118
exit	O	119-123
and	O	124-127
differentiation	O	128-143
. 	O	143-145

Because	O	0-7
microRNAs	O	8-17
regulate	O	18-26
numerous	O	27-35
aspects	O	36-43
of	O	44-46
cellular	O	47-55
physiology	O	56-66
and	O	67-70
development	O	71-82
,	O	82-83
we	O	84-86
reasoned	O	87-95
that	O	96-100
alterations	O	101-112
in	O	113-115
miRNA	O	116-121
expression	O	122-132
might	O	133-138
contribute	O	139-149
to	O	150-152
MB	O	153-155
.	O	155-156
We	O	157-159
tested	O	160-166
this	O	167-171
hypothesis	O	172-182
using	O	183-188
2	O	189-190
spontaneous	O	191-202
mouse	O	203-208
MB	O	209-211
models	O	212-218
with	O	219-223
specific	O	224-232
initiating	O	233-243
mutations	O	244-253
,	O	253-254
Ink4c	O	255-260
-	O	260-261
/	O	261-262
-	O	262-263
;	O	263-264
Ptch1	O	265-270
+	O	270-271
/	O	271-272
-	O	272-273
and	O	274-277
Ink4c	O	278-283
-	O	283-284
/	O	284-285
-	O	285-286
;	O	286-287
p53	O	288-291
-	O	291-292
/	O	292-293
-	O	293-294
. 	O	294-296

We	O	0-2
found	O	3-8
that	O	9-13
26	O	14-16
miRNAs	O	17-23
showed	O	24-30
increased	O	31-40
expression	O	41-51
and	O	52-55
24	O	56-58
miRNAs	O	59-65
showed	O	66-72
decreased	O	73-82
expression	O	83-93
in	O	94-96
proliferating	O	97-110
mouse	O	111-116
GNPs	O	117-121
and	O	122-125
MBs	O	126-129
relative	O	130-138
to	O	139-141
mature	O	142-148
mouse	O	149-154
cerebellum	O	155-165
,	O	165-166
regardless	O	167-177
of	O	178-180
genotype	O	181-189
. 	O	189-191

Among	O	0-5
the	O	6-9
26	O	10-12
overexpressed	O	13-26
miRNAs	O	27-33
,	O	33-34
9	O	35-36
were	O	37-41
encoded	O	42-49
by	O	50-52
the	O	53-56
miR	B	57-60
-	I	60-61
17	I	61-63
approximately	O	64-77
92	O	78-80
cluster	O	81-88
family	O	89-95
,	O	95-96
a	O	97-98
group	O	99-104
of	O	105-107
microRNAs	O	108-117
implicated	O	118-128
as	O	129-131
oncogenes	O	132-141
in	O	142-144
several	O	145-152
tumor	O	153-158
types	O	159-164
. 	O	164-166

The	O	0-3
miR	B	4-7
-	I	7-8
17	I	8-10
~	I	10-11
92	I	11-13
cluster	O	14-21
collaborates	O	22-34
with	O	35-39
the	O	40-43
Sonic	O	44-49
Hedgehog	O	50-58
pathway	O	59-66
in	O	67-69
medulloblastoma	O	70-85
.  	O	85-88

Medulloblastomas	O	0-16
(	O	17-18
MBs	O	18-21
)	O	21-22
are	O	23-26
the	O	27-30
most	O	31-35
common	O	36-42
brain	O	43-48
tumors	O	49-55
in	O	56-58
children	O	59-67
. 	O	67-69

Autosomal	O	0-9
-	O	9-10
recessive	O	10-19
cerebellar	O	20-30
ataxias	O	31-38
comprise	O	39-47
a	O	48-49
clinically	O	50-60
and	O	61-64
genetically	O	65-76
heterogeneous	O	77-90
group	O	91-96
of	O	97-99
neurodegenerative	O	100-117
disorders	O	118-127
. 	O	127-129

In	O	0-2
contrast	O	3-11
to	O	12-14
their	O	15-20
dominant	O	21-29
counterparts	O	30-42
,	O	42-43
unraveling	O	44-54
the	O	55-58
molecular	O	59-68
background	O	69-79
of	O	80-82
these	O	83-88
ataxias	O	89-96
has	O	97-100
proven	O	101-107
to	O	108-110
be	O	111-113
more	O	114-118
complicated	O	119-130
and	O	131-134
the	O	135-138
currently	O	139-148
known	O	149-154
mutations	O	155-164
provide	O	165-172
incomplete	O	173-183
coverage	O	184-192
for	O	193-196
genotyping	O	197-207
of	O	208-210
patients	O	211-219
. 	O	219-221

By	O	0-2
combining	O	3-12
SNP	O	13-16
array	O	17-22
-	O	22-23
based	O	23-28
linkage	O	29-36
analysis	O	37-45
and	O	46-49
targeted	O	50-58
resequencing	O	59-71
of	O	72-74
relevant	O	75-83
sequences	O	84-93
in	O	94-96
the	O	97-100
linkage	O	101-108
interval	O	109-117
with	O	118-122
the	O	123-126
use	O	127-130
of	O	131-133
next	O	134-138
-	O	138-139
generation	O	139-149
sequencing	O	150-160
technology	O	161-171
,	O	171-172
we	O	173-175
identified	O	176-186
a	O	187-188
mutation	O	189-197
in	O	198-200
a	O	201-202
gene	O	203-207
and	O	208-211
have	O	212-216
shown	O	217-222
its	O	223-226
association	O	227-238
with	O	239-243
autosomal	O	244-253
-	O	253-254
recessive	O	254-263
cerebellar	O	264-274
ataxia	O	275-281
. 	O	281-283

In	O	0-2
a	O	3-4
Dutch	O	5-10
consanguineous	O	11-25
family	O	26-32
with	O	33-37
three	O	38-43
affected	O	44-52
siblings	O	53-61
a	O	62-63
homozygous	O	64-74
12	O	75-77
.	O	77-78
5	O	78-79
Mb	O	80-82
region	O	83-89
on	O	90-92
chromosome	O	93-103
3	O	104-105
was	O	106-109
targeted	O	110-118
by	O	119-121
array	O	122-127
-	O	127-128
based	O	128-133
sequence	O	134-142
capture	O	143-150
. 	O	150-152

Targeted	O	0-8
next	O	9-13
-	O	13-14
generation	O	14-24
sequencing	O	25-35
of	O	36-38
a	O	39-40
12	O	41-43
.	O	43-44
5	O	44-45
Mb	O	46-48
homozygous	O	49-59
region	O	60-66
reveals	O	67-74
ANO10	O	75-80
mutations	O	81-90
in	O	91-93
patients	O	94-102
with	O	103-107
autosomal	O	108-117
-	O	117-118
recessive	O	118-127
cerebellar	O	128-138
ataxia	O	139-145
.  	O	145-148

The	O	0-3
analysis	O	4-12
of	O	13-15
ANO10	O	16-21
by	O	22-24
Sanger	O	25-31
sequencing	O	32-42
revealed	O	43-51
three	O	52-57
additional	O	58-68
mutations	O	69-78
:	O	78-79
a	O	80-81
homozygous	O	82-92
mutation	O	93-101
(	O	102-103
c	O	103-104
.	O	104-105
1150	O	105-109
_	O	109-110
1151del	O	110-117
[	O	118-119
p	O	119-120
.	O	120-121
Leu384fs	O	121-129
]	O	129-130
)	O	130-131
in	O	132-134
a	O	135-136
Serbian	O	137-144
family	O	145-151
and	O	152-155
a	O	156-157
compound	O	158-166
-	O	166-167
heterozygous	O	167-179
splice	O	180-186
-	O	186-187
site	O	187-191
mutation	O	192-200
(	O	201-202
c	O	202-203
.	O	203-204
1476	O	204-208
+	O	208-209
1G	O	209-211
>	O	211-212
T	O	212-213
)	O	213-214
and	O	215-218
a	O	219-220
frameshift	O	221-231
mutation	O	232-240
(	O	241-242
c	O	242-243
.	O	243-244
1604del	O	244-251
[	O	252-253
p	O	253-254
.	O	254-255
Leu535X	O	255-262
]	O	262-263
)	O	263-264
in	O	265-267
a	O	268-269
French	O	270-276
family	O	277-283
. 	O	283-285

This	O	0-4
illustrates	O	5-16
the	O	17-20
power	O	21-26
of	O	27-29
using	O	30-35
initial	O	36-43
homozygosity	O	44-56
mapping	O	57-64
with	O	65-69
next	O	70-74
-	O	74-75
generation	O	75-85
sequencing	O	86-96
technology	O	97-107
to	O	108-110
identify	O	111-119
genes	O	120-125
involved	O	126-134
in	O	135-137
autosomal	O	138-147
-	O	147-148
recessive	O	148-157
diseases	O	158-166
. 	O	166-168

Prioritization	O	0-14
of	O	15-17
all	O	18-21
detected	O	22-30
sequence	O	31-39
variants	O	40-48
led	O	49-52
to	O	53-55
four	O	56-60
candidate	O	61-70
genes	O	71-76
,	O	76-77
one	O	78-81
of	O	82-84
which	O	85-90
contained	O	91-100
a	O	101-102
variant	O	103-110
with	O	111-115
a	O	116-117
high	O	118-122
base	O	123-127
pair	O	128-132
conservation	O	133-145
score	O	146-151
(	O	152-153
phyloP	O	153-159
score	O	160-165
:	O	165-166
5	O	167-168
.	O	168-169
26	O	169-171
)	O	171-172
. 	O	172-174

This	O	0-4
variant	O	5-12
was	O	13-16
a	O	17-18
leucine	O	19-26
-	O	26-27
to	O	27-29
-	O	29-30
arginine	O	30-38
substitution	O	39-51
in	O	52-54
the	O	55-58
DUF	O	59-62
590	O	63-66
domain	O	67-73
of	O	74-76
a	O	77-78
16K	O	79-82
transmembrane	O	83-96
protein	O	97-104
,	O	104-105
a	O	106-107
putative	O	108-116
calcium	O	117-124
-	O	124-125
activated	O	125-134
chloride	O	135-143
channel	O	144-151
encoded	O	152-159
by	O	160-162
anoctamin	O	163-172
10	O	173-175
(	O	176-177
ANO10	O	177-182
)	O	182-183
. 	O	183-185

Moreover	O	0-8
,	O	8-9
identifying	O	10-21
a	O	22-23
putative	O	24-32
calcium	O	33-40
-	O	40-41
dependent	O	41-50
chloride	O	51-59
channel	O	60-67
involved	O	68-76
in	O	77-79
cerebellar	O	80-90
ataxia	O	91-97
adds	O	98-102
another	O	103-110
pathway	O	111-118
to	O	119-121
the	O	122-125
list	O	126-130
of	O	131-133
pathophysiological	O	134-152
mechanisms	O	153-163
that	O	164-168
may	O	169-172
cause	O	173-178
cerebellar	O	179-189
ataxia	O	190-196
.   	O	196-200

Since	O	0-5
over	O	6-10
-	O	10-11
expression	O	11-21
of	O	22-24
human	O	25-30
SNCA	O	31-35
(	O	36-37
hSNCA	O	37-42
)	O	42-43
leads	O	44-49
to	O	50-52
death	O	53-58
of	O	59-61
dopaminergic	O	62-74
(	O	75-76
DA	O	76-78
)	O	78-79
neurons	O	80-87
in	O	88-90
human	O	91-96
,	O	96-97
rodent	O	98-104
and	O	105-108
fly	O	109-112
brain	O	113-118
,	O	118-119
hSNCA	O	120-125
gene	O	126-130
silencing	O	131-140
may	O	141-144
reduce	O	145-151
levels	O	152-158
of	O	159-161
toxic	O	162-167
forms	O	168-173
of	O	174-176
SNCA	O	177-181
and	O	182-185
ameliorate	O	186-196
degeneration	O	197-209
of	O	210-212
DA	O	213-215
neurons	O	216-223
in	O	224-226
PD	O	227-229
. 	O	229-231

Alpha	O	0-5
-	O	5-6
synuclein	O	6-15
(	O	16-17
SNCA	O	17-21
)	O	21-22
,	O	22-23
an	O	24-26
abundantly	O	27-37
expressed	O	38-47
presynaptic	O	48-59
protein	O	60-67
,	O	67-68
is	O	69-71
implicated	O	72-82
in	O	83-85
Parkinson	O	86-95
'	O	95-96
s	O	96-97
disease	O	98-105
(	O	106-107
PD	O	107-109
)	O	109-110
. 	O	110-112

A	O	0-1
microRNA	O	2-10
embedded	O	11-19
AAV	O	20-23
alpha	O	24-29
-	O	29-30
synuclein	O	30-39
gene	O	40-44
silencing	O	45-54
vector	O	55-61
for	O	62-65
dopaminergic	O	66-78
neurons	O	79-86
.  	O	86-89

Our	O	0-3
in	O	4-6
vitro	O	7-12
data	O	13-17
suggest	O	18-25
that	O	26-30
this	O	31-35
miRNA	O	36-41
-	O	41-42
embedded	O	42-50
silencing	O	51-60
vector	O	61-67
may	O	68-71
be	O	72-74
ideal	O	75-80
for	O	81-84
chronic	O	85-92
in	O	93-95
vivo	O	96-100
SNCA	O	101-105
gene	O	106-110
silencing	O	111-120
in	O	121-123
DA	O	124-126
neurons	O	127-134
.   	O	134-138

However	O	0-7
,	O	7-8
the	O	9-12
mir30	B	13-18
embedded	O	19-27
vector	O	28-34
was	O	35-38
significantly	O	39-52
less	O	53-57
toxic	O	58-63
to	O	64-66
both	O	67-71
PC12	O	72-76
and	O	77-80
SH	O	81-83
-	O	83-84
SY5Y	O	84-88
cells	O	89-94
. 	O	94-96

In	O	0-2
DA	O	3-5
PC12	O	6-10
cells	O	11-16
,	O	16-17
neither	O	18-25
vector	O	26-32
decreased	O	33-42
expression	O	43-53
of	O	54-56
rat	O	57-60
SNCA	O	61-65
,	O	65-66
tyrosine	O	67-75
hydroxylase	O	76-87
(	O	88-89
TH	O	89-91
)	O	91-92
,	O	92-93
dopamine	O	94-102
transporter	O	103-114
(	O	115-116
DAT	O	116-119
)	O	119-120
or	O	121-123
the	O	124-127
vesicular	O	128-137
monoamine	O	138-147
transporter	O	148-159
(	O	160-161
VMAT	O	161-165
)	O	165-166
. 	O	166-168

Both	O	0-4
vectors	O	5-12
silenced	O	13-21
hSNCA	O	22-27
to	O	28-30
the	O	31-34
same	O	35-39
extent	O	40-46
in	O	47-49
293T	O	50-54
cells	O	55-60
transfected	O	61-72
with	O	73-77
hSNCA	O	78-83
. 	O	83-85

The	O	0-3
same	O	4-8
hSNCA	O	9-14
silencing	O	15-24
sequence	O	25-33
(	O	34-35
shRNA	O	35-40
)	O	40-41
was	O	42-45
used	O	46-50
in	O	51-53
both	O	54-58
vectors	O	59-66
,	O	66-67
but	O	68-71
in	O	72-74
one	O	75-78
vector	O	79-85
,	O	85-86
the	O	87-90
shRNA	O	91-96
was	O	97-100
embedded	O	101-109
in	O	110-112
a	O	113-114
microRNA	O	115-123
backbone	O	124-132
and	O	133-136
driven	O	137-143
by	O	144-146
a	O	147-148
pol	O	149-152
II	O	153-155
promoter	O	156-164
,	O	164-165
and	O	166-169
in	O	170-172
the	O	173-176
other	O	177-182
the	O	183-186
shRNA	O	187-192
was	O	193-196
not	O	197-200
embedded	O	201-209
in	O	210-212
a	O	213-214
microRNA	O	215-223
and	O	224-227
was	O	228-231
driven	O	232-238
by	O	239-241
a	O	242-243
pol	O	244-247
III	O	248-251
promoter	O	252-260
. 	O	260-262

To	O	0-2
begin	O	3-8
to	O	9-11
develop	O	12-19
a	O	20-21
gene	O	22-26
therapy	O	27-34
for	O	35-38
PD	O	39-41
based	O	42-47
on	O	48-50
hSNCA	O	51-56
gene	O	57-61
silencing	O	62-71
,	O	71-72
two	O	73-76
AAV	O	77-80
gene	O	81-85
silencing	O	86-95
vectors	O	96-103
were	O	104-108
designed	O	109-117
,	O	117-118
and	O	119-122
tested	O	123-129
for	O	130-133
efficiency	O	134-144
and	O	145-148
specificity	O	149-160
of	O	161-163
silencing	O	164-173
,	O	173-174
as	O	175-177
well	O	178-182
as	O	183-185
toxicity	O	186-194
in	O	195-197
vitro	O	198-203
. 	O	203-205

Taken	O	0-5
together	O	6-14
,	O	14-15
induction	O	16-25
of	O	26-28
microRNA	O	29-37
expression	O	38-48
in	O	49-51
BMC	O	52-55
may	O	56-59
contribute	O	60-70
to	O	71-73
the	O	74-77
aberrant	O	78-86
systemic	O	87-95
decline	O	96-103
in	O	104-106
mRNA	O	107-111
levels	O	112-118
in	O	119-121
sporadic	O	122-130
AD	O	131-133
.   	O	133-137

MicroRNA	O	0-8
expression	O	9-19
in	O	20-22
Alzheimer	O	23-32
blood	O	33-38
mononuclear	O	39-50
cells	O	51-56
.  	O	56-59

Various	O	0-7
coding	O	8-14
genes	O	15-20
representing	O	21-33
multiple	O	34-42
functional	O	43-53
categories	O	54-64
are	O	65-68
downregulated	O	69-82
in	O	83-85
blood	O	86-91
mononuclear	O	92-103
cells	O	104-109
(	O	110-111
BMC	O	111-114
)	O	114-115
of	O	116-118
patients	O	119-127
with	O	128-132
sporadic	O	133-141
Alzheimer	O	142-151
disease	O	152-159
(	O	160-161
AD	O	161-163
)	O	163-164
. 	O	164-166

Noncoding	O	0-9
microRNAs	O	10-19
(	O	20-21
miRNA	O	21-26
)	O	26-27
regulate	O	28-36
gene	O	37-41
expression	O	42-52
by	O	53-55
degrading	O	56-65
messages	O	66-74
or	O	75-77
inhibiting	O	78-88
translation	O	89-100
. 	O	100-102

Using	O	0-5
BMC	O	6-9
as	O	10-12
a	O	13-14
paradigm	O	15-23
for	O	24-27
the	O	28-31
study	O	32-37
of	O	38-40
systemic	O	41-49
alterations	O	50-61
in	O	62-64
AD	O	65-67
,	O	67-68
we	O	69-71
investigated	O	72-84
whether	O	85-92
peripheral	O	93-103
miRNA	O	104-109
expression	O	110-120
is	O	121-123
altered	O	124-131
in	O	132-134
this	O	135-139
condition	O	140-149
. 	O	149-151

MicroRNA	O	0-8
levels	O	9-15
were	O	16-20
assessed	O	21-29
using	O	30-35
the	O	36-39
microRNA	O	40-48
microarray	O	49-59
(	O	60-61
MMChip	O	61-67
)	O	67-68
containing	O	69-79
462	O	80-83
human	O	84-89
miRNA	O	90-95
,	O	95-96
and	O	97-100
the	O	101-104
results	O	105-112
validated	O	113-122
by	O	123-125
real	O	126-130
time	O	131-135
PCR	O	136-139
. 	O	139-141

Sixteen	O	0-7
AD	O	8-10
patients	O	11-19
and	O	20-23
sixteen	O	24-31
normal	O	32-38
elderly	O	39-46
controls	O	47-55
(	O	56-57
NEC	O	57-60
)	O	60-61
were	O	62-66
matched	O	67-74
for	O	75-78
ethnicity	O	79-88
,	O	88-89
age	O	90-93
,	O	93-94
gender	O	95-101
and	O	102-105
education	O	106-115
. 	O	115-117

The	O	0-3
expression	O	4-14
of	O	15-17
several	O	18-25
BMC	O	26-29
miRNAs	O	30-36
was	O	37-40
found	O	41-46
to	O	47-49
increase	O	50-58
in	O	59-61
AD	O	62-64
relative	O	65-73
to	O	74-76
NEC	O	77-80
levels	O	81-87
,	O	87-88
and	O	89-92
may	O	93-96
differ	O	97-103
between	O	104-111
AD	O	112-114
subjects	O	115-123
bearing	O	124-131
one	O	132-135
or	O	136-138
two	O	139-142
APOE4	O	143-148
alleles	O	149-156
. 	O	156-158

As	O	0-2
compared	O	3-11
to	O	12-14
NEC	O	15-18
,	O	18-19
miRNAs	O	20-26
significantly	O	27-40
upregulated	O	41-52
in	O	53-55
AD	O	56-58
subjects	O	59-67
and	O	68-71
confirmed	O	72-81
by	O	82-84
qPCR	O	85-89
were	O	90-94
miR	B	95-98
-	I	98-99
34a	I	99-102
and	I	103-106
181b	I	107-111
. 	O	111-113

Predicted	O	0-9
target	O	10-16
genes	O	17-22
downregulated	O	23-36
in	O	37-39
Alzheimer	O	40-49
BMC	O	50-53
that	O	54-58
correlated	O	59-69
with	O	70-74
the	O	75-78
upregulated	O	79-90
miRNAs	O	91-97
were	O	98-102
largely	O	103-110
represented	O	111-122
in	O	123-125
the	O	126-129
functional	O	130-140
categories	O	141-151
of	O	152-154
Transcription	O	155-168
/	O	168-169
Translation	O	169-180
and	O	181-184
Synaptic	O	185-193
Activity	O	194-202
. 	O	202-204

Several	O	0-7
miRNAs	O	8-14
targeting	O	15-24
the	O	25-28
same	O	29-33
genes	O	34-39
were	O	40-44
within	O	45-51
the	O	52-55
functional	O	56-66
category	O	67-75
of	O	76-78
Injury	O	79-85
response	O	86-94
/	O	94-95
Redox	O	95-100
homeostasis	O	101-112
. 	O	112-114

Despite	O	0-7
the	O	8-11
small	O	12-17
sample	O	18-24
available	O	25-34
,	O	34-35
we	O	36-38
can	O	39-42
show	O	43-47
that	O	48-52
this	O	53-57
approach	O	58-66
permits	O	67-74
identification	O	75-89
of	O	90-92
meaningful	O	93-103
structures	O	104-114
,	O	114-115
in	O	116-118
particular	O	119-129
two	O	130-133
polycistronic	O	134-147
miRNA	O	148-153
genes	O	154-159
related	O	160-167
to	O	168-170
transcriptional	O	171-186
activity	O	187-195
and	O	196-199
likely	O	200-206
to	O	207-209
be	O	210-212
relevant	O	213-221
in	O	222-224
the	O	225-228
discrimination	O	229-243
between	O	244-251
gliosarcomas	O	252-264
and	O	265-268
other	O	269-274
brain	O	275-280
tumors	O	281-287
. 	O	287-289

Our	O	0-3
intention	O	4-13
is	O	14-16
to	O	17-19
identify	O	20-28
structures	O	29-39
that	O	40-44
contain	O	45-52
information	O	53-64
from	O	65-69
both	O	70-74
mRNAs	O	75-80
and	O	81-84
miRNAs	O	85-91
,	O	91-92
and	O	93-96
that	O	97-101
can	O	102-105
explain	O	106-113
the	O	114-117
complexity	O	118-128
of	O	129-131
the	O	132-135
data	O	136-140
. 	O	140-142

RESULTS	O	0-7
:	O	7-8
We	O	9-11
use	O	12-15
Factor	O	16-22
Analysis	O	23-31
coupled	O	32-39
with	O	40-44
pre	O	45-48
-	O	48-49
established	O	49-60
knowledge	O	61-70
as	O	71-73
a	O	74-75
theoretical	O	76-87
base	O	88-92
to	O	93-95
achieve	O	96-103
this	O	104-108
goal	O	109-113
. 	O	113-115

We	O	0-2
analyzed	O	3-11
one	O	12-15
of	O	16-18
the	O	19-22
(	O	23-24
currently	O	24-33
)	O	33-34
few	O	35-38
datasets	O	39-47
that	O	48-52
provide	O	53-60
both	O	61-65
transcriptional	O	66-81
and	O	82-85
post	O	86-90
-	O	90-91
transcriptional	O	91-106
data	O	107-111
of	O	112-114
the	O	115-118
same	O	119-123
samples	O	124-131
to	O	132-134
investigate	O	135-146
the	O	147-150
possibility	O	151-162
to	O	163-165
extract	O	166-173
more	O	174-178
information	O	179-190
,	O	190-191
using	O	192-197
a	O	198-199
joint	O	200-205
analysis	O	206-214
approach	O	215-223
. 	O	223-225

CONCLUSIONS	O	0-11
:	O	11-12
This	O	13-17
suggests	O	18-26
the	O	27-30
need	O	31-35
to	O	36-38
develop	O	39-46
methodologies	O	47-60
to	O	61-63
simultaneously	O	64-78
mine	O	79-83
information	O	84-95
from	O	96-100
different	O	101-110
levels	O	111-117
of	O	118-120
biological	O	121-131
organization	O	132-144
,	O	144-145
rather	O	146-152
than	O	153-157
linking	O	158-165
separate	O	166-174
analyses	O	175-183
performed	O	184-193
in	O	194-196
parallel	O	197-205
.   	O	205-209

However	O	0-7
,	O	7-8
to	O	9-11
date	O	12-16
,	O	16-17
most	O	18-22
computational	O	23-36
and	O	37-40
algorithmic	O	41-52
efforts	O	53-60
have	O	61-65
been	O	66-70
directed	O	71-79
at	O	80-82
mining	O	83-89
data	O	90-94
from	O	95-99
each	O	100-104
of	O	105-107
these	O	108-113
molecular	O	114-123
levels	O	124-130
(	O	131-132
genomic	O	132-139
,	O	139-140
transcriptional	O	141-156
,	O	156-157
etc	O	158-161
.	O	161-162
)	O	162-163
separately	O	164-174
. 	O	174-176

In	O	0-2
view	O	3-7
of	O	8-10
the	O	11-14
rapid	O	15-20
advances	O	21-29
in	O	30-32
technology	O	33-43
(	O	44-45
new	O	45-48
generation	O	49-59
sequencing	O	60-70
,	O	70-71
high	O	72-76
-	O	76-77
throughput	O	77-87
proteomics	O	88-98
)	O	98-99
it	O	100-102
is	O	103-105
important	O	106-115
to	O	116-118
address	O	119-126
the	O	127-130
problem	O	131-138
of	O	139-141
analyzing	O	142-151
these	O	152-157
data	O	158-162
as	O	163-165
a	O	166-167
whole	O	168-173
,	O	173-174
i	O	175-176
.	O	176-177
e	O	177-178
.	O	178-179
preserving	O	180-190
the	O	191-194
emergent	O	195-203
properties	O	204-214
that	O	215-219
appear	O	220-226
in	O	227-229
the	O	230-233
cellular	O	234-242
system	O	243-249
when	O	250-254
all	O	255-258
molecular	O	259-268
levels	O	269-275
are	O	276-279
interacting	O	280-291
. 	O	291-293

Joint	O	0-5
analysis	O	6-14
of	O	15-17
transcriptional	O	18-33
and	O	34-37
post	O	38-42
-	O	42-43
transcriptional	O	44-59
brain	O	60-65
tumor	O	66-71
data	O	72-76
:	O	76-77
searching	O	78-87
for	O	88-91
emergent	O	92-100
properties	O	101-111
of	O	112-114
cellular	O	115-123
systems	O	124-131
.  	O	131-134

UNLABELLED	O	0-10
:	O	10-11
ABSTRACT	O	12-20
:	O	20-21
BACKGROUND	O	22-32
:	O	32-33
Advances	O	34-42
in	O	43-45
biotechnology	O	46-59
offer	O	60-65
a	O	66-67
fast	O	68-72
growing	O	73-80
variety	O	81-88
of	O	89-91
high	O	92-96
-	O	96-97
throughput	O	97-107
data	O	108-112
for	O	113-116
screening	O	117-126
molecular	O	127-136
activities	O	137-147
of	O	148-150
genomic	O	151-158
,	O	158-159
transcriptional	O	160-175
,	O	175-176
post	O	177-181
-	O	181-182
transcriptional	O	182-197
and	O	198-201
translational	O	202-215
observations	O	216-228
. 	O	228-230

To	O	0-2
investigate	O	3-14
noncoding	O	15-24
tiny	O	25-29
microRNA	O	30-38
mediated	O	39-47
gene	O	48-52
regulation	O	53-63
,	O	63-64
miRanda	O	65-72
(	O	73-74
version	O	74-81
1	O	82-83
.	O	83-84
0b	O	84-86
)	O	86-87
was	O	88-91
used	O	92-96
to	O	97-99
predict	O	100-107
human	O	108-113
miRNA	O	114-119
target	O	120-126
sites	O	127-132
on	O	133-135
selected	O	136-144
29	O	145-147
genes	O	148-153
related	O	154-161
to	O	162-164
PD	O	165-167
.	O	167-168
To	O	169-171
verify	O	172-178
output	O	179-185
generated	O	186-195
from	O	196-200
miRanda	O	201-208
,	O	208-209
a	O	210-211
similar	O	212-219
analysis	O	220-228
was	O	229-232
performed	O	233-242
only	O	243-247
for	O	248-251
microRNA	O	252-260
target	O	261-267
sites	O	268-273
in	O	274-276
3	O	277-278
'	O	278-279
UTR	O	279-282
using	O	283-288
TargetScan	O	289-299
(	O	300-301
version	O	301-308
5	O	309-310
.	O	310-311
1	O	311-312
)	O	312-313
. 	O	313-315

Data	O	0-4
extracted	O	5-14
by	O	15-17
miRanda	O	18-25
elucidates	O	26-36
the	O	37-40
mode	O	41-45
of	O	46-48
microRNA	O	49-57
action	O	58-64
based	O	65-70
on	O	71-73
the	O	74-77
location	O	78-86
of	O	87-89
target	O	90-96
sites	O	97-102
in	O	103-105
the	O	106-109
Parkinson	O	110-119
genes	O	120-125
. 	O	125-127

Sites	O	0-5
prone	O	6-11
to	O	12-14
action	O	15-21
of	O	22-24
multiple	O	25-33
miRNAs	O	34-40
were	O	41-45
identified	O	46-56
as	O	57-59
"	O	60-61
hot	O	61-64
spots	O	65-70
.	O	70-71
" 	O	71-73

Important	O	0-9
properties	O	10-20
of	O	21-23
each	O	24-28
miRNA	O	29-34
including	O	35-44
multiplicity	O	45-57
and	O	58-61
cooperativity	O	62-75
appear	O	76-82
to	O	83-85
contribute	O	86-96
towards	O	97-104
a	O	105-106
complex	O	107-114
interplay	O	115-124
between	O	125-132
miRNAs	O	133-139
and	O	140-143
their	O	144-149
targets	O	150-157
. 	O	157-159

Two	O	0-3
sets	O	4-8
of	O	9-11
predicted	O	12-21
results	O	22-29
were	O	30-34
explored	O	35-43
for	O	44-47
the	O	48-51
occurrence	O	52-62
of	O	63-65
target	O	66-72
sites	O	73-78
of	O	79-81
112	O	82-85
miRNAs	O	86-92
expressed	O	93-102
in	O	103-105
midbrain	O	106-114
. 	O	114-116

Overall	O	0-7
,	O	7-8
convergence	O	9-20
of	O	21-23
results	O	24-31
predicted	O	32-41
by	O	42-44
two	O	45-48
algorithms	O	49-59
revealed	O	60-68
that	O	69-73
48	O	74-76
target	O	77-83
sites	O	84-89
for	O	90-93
midbrain	O	94-102
-	O	102-103
specific	O	103-111
miRNA	O	112-117
occur	O	118-123
in	O	124-126
close	O	127-132
proximity	O	133-142
in	O	143-145
9	O	146-147
genes	O	148-153
. 	O	153-155

This	O	0-4
study	O	5-10
will	O	11-15
pave	O	16-20
a	O	21-22
way	O	23-26
for	O	27-30
selection	O	31-40
of	O	41-43
potential	O	44-53
miRNA	O	54-59
candidates	O	60-70
for	O	71-74
Parkinson	O	75-84
'	O	84-85
s	O	85-86
disease	O	87-94
-	O	94-95
related	O	95-102
genes	O	103-108
for	O	109-112
quick	O	113-118
therapeutic	O	119-130
applications	O	131-143
and	O	144-147
diagnosis	O	148-157
.   	O	157-161

Parkinson	O	0-9
'	O	9-10
s	O	10-11
disease	O	12-19
(	O	20-21
PD	O	21-23
)	O	23-24
is	O	25-27
a	O	28-29
complex	O	30-37
multigenic	O	38-48
neurodisorder	O	49-62
frequently	O	63-73
occurring	O	74-83
in	O	84-86
elderly	O	87-94
persons	O	95-102
. 	O	102-104

Interaction	O	0-11
map	O	12-15
and	O	16-19
selection	O	20-29
of	O	30-32
microRNA	O	33-41
targets	O	42-49
in	O	50-52
Parkinson	O	53-62
'	O	62-63
s	O	63-64
disease	O	65-72
-	O	72-73
related	O	73-80
genes	O	81-86
.  	O	86-89

These	O	0-5
studies	O	6-13
suggest	O	14-21
that	O	22-26
miRNAs	O	27-33
may	O	34-37
be	O	38-40
important	O	41-50
for	O	51-54
neuronal	O	55-63
survival	O	64-72
in	O	73-75
the	O	76-79
context	O	80-87
of	O	88-90
human	O	91-96
neurodegenerative	O	97-114
disease	O	115-122
. 	O	122-124

These	O	0-5
studies	O	6-13
provide	O	14-21
the	O	22-25
foundation	O	26-36
to	O	37-39
define	O	40-46
the	O	47-50
miRNAs	O	51-57
involved	O	58-66
in	O	67-69
neurodegenerative	O	70-87
disease	O	88-95
,	O	95-96
and	O	97-100
the	O	101-104
biological	O	105-115
pathways	O	116-124
affected	O	125-133
.   	O	133-137

These	O	0-5
studies	O	6-13
showed	O	14-20
that	O	21-25
upregulation	O	26-38
of	O	39-41
ban	O	42-45
mitigates	O	46-55
degeneration	O	56-68
induced	O	69-76
by	O	77-79
the	O	80-83
pathogenic	O	84-94
polyglutamine	O	95-108
(	O	109-110
polyQ	O	110-115
)	O	115-116
protein	O	117-124
Ataxin	O	125-131
-	O	131-132
3	O	132-133
,	O	133-134
which	O	135-140
is	O	141-143
mutated	O	144-151
in	O	152-154
the	O	155-158
human	O	159-164
polyglutamine	O	165-178
disease	O	179-186
spinocerebellar	O	187-202
ataxia	O	203-209
type	O	210-214
3	O	215-216
(	O	217-218
SCA3	O	218-222
)	O	222-223
. 	O	223-225

To	O	0-2
address	O	3-10
the	O	11-14
broader	O	15-22
role	O	23-27
for	O	28-31
miRNAs	O	32-38
in	O	39-41
neuroprotection	O	42-57
,	O	57-58
we	O	59-61
also	O	62-66
showed	O	67-73
that	O	74-78
loss	O	79-83
of	O	84-86
all	O	87-90
miRNAs	O	91-97
,	O	97-98
by	O	99-101
dicer	O	102-107
mutation	O	108-116
,	O	116-117
dramatically	O	118-130
enhances	O	131-139
pathogenic	O	140-150
polyQ	O	151-156
protein	O	157-164
toxicity	O	165-173
in	O	174-176
flies	O	177-182
and	O	183-186
in	O	187-189
human	O	190-195
HeLa	O	196-200
cells	O	201-206
. 	O	206-208

A	O	0-1
new	O	2-5
role	O	6-10
for	O	11-14
microRNA	O	15-23
pathways	O	24-32
:	O	32-33
modulation	O	34-44
of	O	45-47
degeneration	O	48-60
induced	O	61-68
by	O	69-71
pathogenic	O	72-82
human	O	83-88
disease	O	89-96
proteins	O	97-105
.  	O	105-108

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
RNAs	O	39-43
that	O	44-48
regulate	O	49-57
the	O	58-61
expression	O	62-72
of	O	73-75
target	O	76-82
transcript	O	83-93
mRNAs	O	94-99
. 	O	99-101

Many	O	0-4
miRNAs	O	5-11
have	O	12-16
been	O	17-21
defined	O	22-29
,	O	29-30
however	O	31-38
their	O	39-44
roles	O	45-50
and	O	51-54
the	O	55-58
processes	O	59-68
influenced	O	69-79
by	O	80-82
miRNA	O	83-88
pathways	O	89-97
are	O	98-101
still	O	102-107
being	O	108-113
elucidated	O	114-124
. 	O	124-126

A	O	0-1
role	O	2-6
for	O	7-10
miRNAs	O	11-17
in	O	18-20
development	O	21-32
and	O	33-36
cancer	O	37-43
has	O	44-47
been	O	48-52
described	O	53-62
. 	O	62-64

We	O	0-2
recently	O	3-11
isolated	O	12-20
the	O	21-24
miRNA	O	25-30
bantam	O	31-37
(	O	38-39
ban	O	39-42
)	O	42-43
in	O	44-46
a	O	47-48
genetic	O	49-56
screen	O	57-63
for	O	64-67
modulators	O	68-78
of	O	79-81
pathogenicity	O	82-95
of	O	96-98
a	O	99-100
human	O	101-106
neurodegenerative	O	107-124
disease	O	125-132
model	O	133-138
in	O	139-141
Drosophila	O	142-152
. 	O	152-154

CONCLUSIONS	O	0-11
/	O	11-12
SIGNIFICANCE	O	12-24
:	O	24-25
We	O	26-28
provide	O	29-36
a	O	37-38
list	O	39-43
of	O	44-46
ten	O	47-50
miRNA	O	51-56
loci	O	57-61
potentially	O	62-73
involved	O	74-82
in	O	83-85
the	O	86-89
development	O	90-101
of	O	102-104
blood	O	105-110
cancer	O	111-117
or	O	118-120
brain	O	121-126
tumors	O	127-133
. 	O	133-135

There	O	0-5
is	O	6-8
independent	O	9-20
experimental	O	21-33
support	O	34-41
from	O	42-46
other	O	47-52
studies	O	53-60
for	O	61-64
the	O	65-68
involvement	O	69-80
of	O	81-83
miRNAs	O	84-90
from	O	91-95
at	O	96-98
least	O	99-104
three	O	105-110
CIS	O	111-114
-	O	114-115
associated	O	115-125
miRNA	O	126-131
loci	O	132-136
in	O	137-139
cancer	O	140-146
development	O	147-158
.   	O	158-162

CIS	O	0-3
-	O	3-4
associated	O	4-14
miRNAs	O	15-21
on	O	22-24
average	O	25-32
are	O	33-36
more	O	37-41
conserved	O	42-51
in	O	52-54
vertebrates	O	55-66
than	O	67-71
miRNAs	O	72-78
associated	O	79-89
with	O	90-94
non	O	95-98
-	O	98-99
CIS	O	99-102
inserts	O	103-110
and	O	111-114
their	O	115-120
human	O	121-126
homologs	O	127-135
are	O	136-139
also	O	140-144
located	O	145-152
in	O	153-155
regions	O	156-163
perturbed	O	164-173
in	O	174-176
cancer	O	177-183
. 	O	183-185

In	O	0-2
addition	O	3-11
we	O	12-14
show	O	15-19
that	O	20-24
miRNA	O	25-30
genes	O	31-36
are	O	37-40
enriched	O	41-49
around	O	50-56
promoter	O	57-65
and	O	66-69
/	O	69-70
or	O	70-72
terminator	O	73-83
regions	O	84-91
of	O	92-94
RefSeq	O	95-101
genes	O	102-107
in	O	108-110
both	O	111-115
mouse	O	116-121
and	O	122-125
human	O	126-131
. 	O	131-133

Ten	O	0-3
CIS	O	4-7
-	O	7-8
associated	O	8-18
miRNA	O	19-24
loci	O	25-29
containing	O	30-40
22	O	41-43
miRNAs	O	44-50
are	O	51-54
located	O	55-62
within	O	63-69
10	O	70-72
kb	O	73-75
of	O	76-78
known	O	79-84
CIS	O	85-88
insertions	O	89-99
. 	O	99-101

Only	O	0-4
one	O	5-8
CIS	O	9-12
-	O	12-13
associated	O	13-23
miRNA	O	24-29
locus	O	30-35
overlaps	O	36-44
a	O	45-46
RefSeq	O	47-53
protein	O	54-61
-	O	61-62
coding	O	62-68
gene	O	69-73
and	O	74-77
six	O	78-81
loci	O	82-86
are	O	87-90
located	O	91-98
more	O	99-103
than	O	104-108
10	O	109-111
kb	O	112-114
from	O	115-119
any	O	120-123
RefSeq	O	124-130
gene	O	131-135
. 	O	135-137

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
Using	O	32-37
a	O	38-39
public	O	40-46
database	O	47-55
of	O	56-58
mapped	O	59-65
retroviral	O	66-76
insertion	O	77-86
sites	O	87-92
from	O	93-97
various	O	98-105
mouse	O	106-111
models	O	112-118
of	O	119-121
cancer	O	122-128
we	O	129-131
demonstrate	O	132-143
that	O	144-148
MLV	O	149-152
-	O	152-153
derived	O	153-160
retroviral	O	161-171
inserts	O	172-179
are	O	180-183
enriched	O	184-192
in	O	193-195
close	O	196-201
proximity	O	202-211
to	O	212-214
mouse	O	215-220
miRNA	O	221-226
loci	O	227-231
. 	O	231-233

Clustered	O	0-9
inserts	O	10-17
from	O	18-22
cancer	O	23-29
-	O	29-30
associated	O	30-40
regions	O	41-48
(	O	49-50
Common	O	50-56
Integration	O	57-68
Sites	O	69-74
,	O	74-75
CIS	O	76-79
)	O	79-80
have	O	81-85
a	O	86-87
higher	O	88-94
association	O	95-106
with	O	107-111
miRNAs	O	112-118
than	O	119-123
non	O	124-127
-	O	127-128
clustered	O	128-137
inserts	O	138-145
. 	O	145-147

BACKGROUND	O	0-10
:	O	10-11
MicroRNAs	O	12-21
(	O	22-23
miRNAs	O	23-29
)	O	29-30
are	O	31-34
short	O	35-40
non	O	41-44
-	O	44-45
coding	O	45-51
RNAs	O	52-56
that	O	57-61
regulate	O	62-70
differentiation	O	71-86
and	O	87-90
development	O	91-102
in	O	103-105
many	O	106-110
organisms	O	111-120
and	O	121-124
play	O	125-129
an	O	130-132
important	O	133-142
role	O	143-147
in	O	148-150
cancer	O	151-157
. 	O	157-159

Orthologous	O	0-11
microRNA	O	12-20
genes	O	21-26
are	O	27-30
located	O	31-38
in	O	39-41
cancer	O	42-48
-	O	48-49
associated	O	49-59
genomic	O	60-67
regions	O	68-75
in	O	76-78
human	O	79-84
and	O	85-88
mouse	O	89-94
.  	O	94-97

MicroRNA	O	0-8
expression	O	9-19
in	O	20-22
ACTH	O	23-27
-	O	27-28
producing	O	28-37
pituitary	O	38-47
tumors	O	48-54
:	O	54-55
up	O	56-58
-	O	58-59
regulation	O	59-69
of	O	70-72
microRNA	B	73-81
-	I	81-82
122	I	82-85
and	I	86-89
-	I	90-91
493	I	91-94
in	O	95-97
pituitary	O	98-107
carcinomas	O	108-118
.  	O	118-121

Real	O	0-4
-	O	4-5
time	O	5-9
RT	O	10-12
-	O	12-13
PCR	O	13-16
and	O	17-20
in	O	21-23
situ	O	24-28
hybridization	O	29-42
were	O	43-47
used	O	48-52
to	O	53-55
confirm	O	56-63
and	O	64-67
independently	O	68-81
validate	O	82-90
miRNAs	O	91-97
that	O	98-102
were	O	103-107
significantly	O	108-121
up	O	122-124
-	O	124-125
regulated	O	125-134
or	O	135-137
down	O	138-142
-	O	142-143
regulated	O	143-152
between	O	153-160
the	O	161-164
pituitary	O	165-174
tissues	O	175-182
. 	O	182-184

We	O	0-2
used	O	3-7
miRNA	O	8-13
profiling	O	14-23
with	O	24-28
1	O	29-30
,	O	30-31
145	O	31-34
probes	O	35-41
to	O	42-44
study	O	45-50
miRNA	O	51-56
expression	O	57-67
in	O	68-70
normal	O	71-77
anterior	O	78-86
pituitary	O	87-96
(	O	97-98
6	O	98-99
cases	O	100-105
)	O	105-106
,	O	106-107
adrenocorticotropin	O	108-127
(	O	128-129
ACTH	O	129-133
)	O	133-134
-	O	134-135
producing	O	135-144
adenomas	O	145-153
(	O	154-155
8	O	155-156
cases	O	157-162
)	O	162-163
,	O	163-164
and	O	165-168
ACTH	O	169-173
-	O	173-174
producing	O	174-183
pituitary	O	184-193
carcinomas	O	194-204
(	O	205-206
two	O	206-209
cases	O	210-215
)	O	215-216
. 	O	216-218

The	O	0-3
expression	O	4-14
of	O	15-17
miRNAs	O	18-24
in	O	25-27
pituitary	O	28-37
carcinomas	O	38-48
has	O	49-52
not	O	53-56
been	O	57-61
previously	O	62-72
examined	O	73-81
. 	O	81-83

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
involved	O	23-31
in	O	32-34
cell	O	35-39
proliferation	O	40-53
,	O	53-54
differentiation	O	55-70
,	O	70-71
and	O	72-75
apoptosis	O	76-85
,	O	85-86
and	O	87-90
can	O	91-94
function	O	95-103
as	O	104-106
tumor	O	107-112
suppressor	O	113-123
genes	O	124-129
or	O	130-132
oncogenes	O	133-142
. 	O	142-144

MiRNA	B	0-5
-	I	5-6
493	I	6-9
was	O	10-13
also	O	14-18
up	O	19-21
-	O	21-22
regulated	O	22-31
in	O	32-34
carcinomas	O	35-45
compared	O	46-54
to	O	55-57
ACTH	O	58-62
adenomas	O	63-71
. 	O	71-73

Analysis	O	0-8
of	O	9-11
genes	O	12-17
that	O	18-22
miRNA	B	23-28
-	I	28-29
493	I	29-32
interacts	O	33-42
with	O	43-47
included	O	48-56
LGALS3	O	57-63
and	O	64-67
RUNX2	O	68-73
(	O	74-75
http	O	76-80
:	O	80-81
/	O	81-82
/	O	82-83
microrna	O	83-91
.	O	91-92
sanger	O	92-98
.	O	98-99
ac	O	99-101
.	O	101-102
uk	O	102-104
)	O	105-106
both	O	107-111
of	O	112-114
which	O	115-120
have	O	121-125
been	O	126-130
shown	O	131-136
to	O	137-139
have	O	140-144
roles	O	145-150
in	O	151-153
pituitary	O	154-163
tumor	O	164-169
cell	O	170-174
growth	O	175-181
. 	O	181-183

There	O	0-5
were	O	6-10
more	O	11-15
miRNAs	O	16-22
up	O	23-25
-	O	25-26
(	O	27-28
188	O	28-31
)	O	31-32
or	O	33-35
down	O	36-40
-	O	40-41
regulated	O	41-50
(	O	51-52
160	O	52-55
)	O	55-56
between	O	57-64
adenomas	O	65-73
and	O	74-77
normal	O	78-84
pituitaries	O	85-96
compared	O	97-105
to	O	106-108
carcinomas	O	109-119
and	O	120-123
normal	O	124-130
pituitaries	O	131-142
(	O	143-144
92	O	144-146
up	O	147-149
-	O	149-150
and	O	151-154
91	O	155-157
down	O	158-162
-	O	162-163
regulated	O	163-172
)	O	172-173
or	O	174-176
between	O	177-184
carcinomas	O	185-195
and	O	196-199
adenomas	O	200-208
(	O	209-210
46	O	210-212
up	O	213-215
-	O	215-216
and	O	217-220
52	O	221-223
down	O	224-228
-	O	228-229
regulated	O	229-238
)	O	238-239
. 	O	239-241

Both	O	0-4
real	O	5-9
-	O	9-10
time	O	10-14
RT	O	15-17
-	O	17-18
PCR	O	18-21
and	O	22-25
in	O	26-28
situ	O	29-33
hybridization	O	34-47
showed	O	48-54
significant	O	55-66
up	O	67-69
-	O	69-70
regulation	O	70-80
of	O	81-83
miRNA	B	84-89
-	I	89-90
122	I	90-93
between	O	94-101
pituitary	O	102-111
carcinomas	O	112-122
and	O	123-126
adenomas	O	127-135
. 	O	135-137

These	O	0-5
results	O	6-13
provide	O	14-21
information	O	22-33
about	O	34-39
marker	O	40-46
miRNAs	O	47-53
that	O	54-58
may	O	59-62
lead	O	63-67
to	O	68-70
further	O	71-78
insights	O	79-87
into	O	88-92
the	O	93-96
regulation	O	97-107
of	O	108-110
pituitary	O	111-120
tumor	O	121-126
growth	O	127-133
and	O	134-137
development	O	138-149
.   	O	149-153

METHODS	O	0-7
:	O	7-8
Surgical	O	9-17
outcome	O	18-25
data	O	26-30
were	O	31-35
prospectively	O	36-49
collected	O	50-59
for	O	60-63
2	O	64-65
to	O	66-68
11	O	69-71
years	O	72-77
in	O	78-80
161	O	81-84
consecutive	O	85-96
patients	O	97-105
with	O	106-110
MTLE	O	111-115
/	O	115-116
HS	O	117-119
.	O	119-120
Eighty	O	121-127
patients	O	128-136
underwent	O	137-146
an	O	147-149
ATL	O	150-153
and	O	154-157
81	O	158-160
an	O	161-163
SA	O	164-166
.	O	166-167
Seizure	O	168-175
control	O	176-183
achieved	O	184-192
with	O	193-197
each	O	198-202
technique	O	203-212
was	O	213-216
compared	O	217-225
using	O	226-231
the	O	232-235
Engel	O	236-241
classification	O	242-256
scheme	O	257-263
. 	O	263-265

Postoperative	O	0-13
memory	O	14-20
testing	O	21-28
was	O	29-32
performed	O	33-42
in	O	43-45
86	O	46-48
patients	O	49-57
(	O	58-59
53	O	59-61
%	O	61-62
)	O	62-63
. 	O	63-65

At	O	0-2
the	O	3-6
last	O	7-11
follow	O	12-18
up	O	19-21
,	O	21-22
72	O	23-25
%	O	25-26
of	O	27-29
the	O	30-33
patients	O	34-42
who	O	43-46
had	O	47-50
undergone	O	51-60
an	O	61-63
ATL	O	64-67
(	O	68-69
mean	O	69-73
follow	O	74-80
up	O	81-83
6	O	84-85
.	O	85-86
7	O	86-87
years	O	88-93
)	O	93-94
and	O	95-98
71	O	99-101
%	O	101-102
of	O	103-105
those	O	106-111
who	O	112-115
had	O	116-119
undergone	O	120-129
an	O	130-132
SA	O	133-135
(	O	136-137
mean	O	137-141
follow	O	142-148
up	O	149-151
4	O	152-153
.	O	153-154
5	O	154-155
years	O	156-161
)	O	161-162
were	O	163-167
seizure	O	168-175
free	O	176-180
(	O	181-182
Engle	O	182-187
Class	O	188-193
IA	O	194-196
)	O	196-197
. 	O	197-199

Estimated	O	0-9
survival	O	10-18
in	O	19-21
patients	O	22-30
in	O	31-33
Engel	O	34-39
Classes	O	40-47
I	O	48-49
,	O	49-50
IA	O	51-53
,	O	53-54
and	O	55-58
I	O	59-60
and	O	61-64
II	O	65-67
combined	O	68-76
did	O	77-80
not	O	81-84
differ	O	85-91
between	O	92-99
the	O	100-103
two	O	104-107
surgical	O	108-116
techniques	O	117-127
. 	O	127-129

Preoperatively	O	0-14
,	O	14-15
58	O	16-18
%	O	18-19
of	O	20-22
the	O	23-26
patients	O	27-35
had	O	36-39
verbal	O	40-46
memory	O	47-53
scores	O	54-60
one	O	61-64
standard	O	65-73
deviation	O	74-83
(	O	84-85
SD	O	85-87
)	O	87-88
below	O	89-94
the	O	95-98
normal	O	99-105
mean	O	106-110
. 	O	110-112

One	O	0-3
third	O	4-9
of	O	10-12
the	O	13-16
patients	O	17-25
with	O	26-30
preoperative	O	31-43
scores	O	44-50
in	O	51-53
the	O	54-57
normal	O	58-64
range	O	65-70
worsened	O	71-79
after	O	80-85
surgery	O	86-93
,	O	93-94
although	O	95-103
this	O	104-108
outcome	O	109-116
was	O	117-120
not	O	121-124
related	O	125-132
to	O	133-135
the	O	136-139
surgical	O	140-148
technique	O	149-158
. 	O	158-160

In	O	0-2
contrast	O	3-11
,	O	11-12
one	O	13-16
third	O	17-22
of	O	23-25
those	O	26-31
whose	O	32-37
preoperative	O	38-50
scores	O	51-57
were	O	58-62
less	O	63-67
than	O	68-72
-	O	73-74
1	O	74-75
SD	O	76-78
experienced	O	79-90
improvement	O	91-102
after	O	103-108
surgery	O	109-116
. 	O	116-118

Nine	O	0-4
(	O	5-6
18	O	6-8
%	O	8-9
)	O	9-10
of	O	11-13
the	O	14-17
50	O	18-20
patients	O	21-29
whose	O	30-35
left	O	36-40
side	O	41-45
had	O	46-49
been	O	50-54
surgically	O	55-65
treated	O	66-73
improved	O	74-82
their	O	83-88
verbal	O	89-95
memory	O	96-102
scores	O	103-109
by	O	110-112
more	O	113-117
than	O	118-122
one	O	123-126
SD	O	127-129
.	O	129-130
Seven	O	131-136
(	O	137-138
78	O	138-140
%	O	140-141
)	O	141-142
of	O	143-145
these	O	146-151
nine	O	152-156
underwent	O	157-166
an	O	167-169
SA	O	170-172
(	O	173-174
p	O	174-175
=	O	176-177
0	O	178-179
.	O	179-180
05	O	180-182
)	O	182-183
. 	O	183-185

OBJECT	O	0-6
:	O	6-7
The	O	8-11
aim	O	12-15
of	O	16-18
this	O	19-23
study	O	24-29
was	O	30-33
to	O	34-36
compare	O	37-44
seizure	O	45-52
and	O	53-56
memory	O	57-63
outcome	O	64-71
in	O	72-74
patients	O	75-83
with	O	84-88
medically	O	89-98
refractory	O	99-109
mesial	O	110-116
temporal	O	117-125
lobe	O	126-130
epilepsy	O	131-139
due	O	140-143
to	O	144-146
hippocampal	O	147-158
sclerosis	O	159-168
(	O	169-170
MTLE	O	170-174
/	O	174-175
HS	O	175-177
)	O	177-178
treated	O	179-186
using	O	187-192
an	O	193-195
anterior	O	196-204
temporal	O	205-213
lobectomy	O	214-223
(	O	224-225
ATL	O	225-228
)	O	228-229
or	O	230-232
a	O	233-234
selective	O	235-244
amygdalohippocampectomy	O	245-268
(	O	269-270
SA	O	270-272
)	O	272-273
. 	O	273-275

Seizure	O	0-7
and	O	8-11
memory	O	12-18
outcome	O	19-26
following	O	27-36
temporal	O	37-45
lobe	O	46-50
surgery	O	51-58
:	O	58-59
selective	O	60-69
compared	O	70-78
with	O	79-83
nonselective	O	84-96
approaches	O	97-107
for	O	108-111
hippocampal	O	112-123
sclerosis	O	124-133
.  	O	133-136

Preliminary	O	0-11
data	O	12-16
suggest	O	17-24
that	O	25-29
postoperative	O	30-43
verbal	O	44-50
memory	O	51-57
scores	O	58-64
may	O	65-68
improve	O	69-76
in	O	77-79
patients	O	80-88
who	O	89-92
undergo	O	93-100
selective	O	101-110
resection	O	111-120
of	O	121-123
a	O	124-125
sclerotic	O	126-135
hippocampus	O	136-147
in	O	148-150
the	O	151-154
dominant	O	155-163
temporal	O	164-172
lobe	O	173-177
.   	O	177-181

CONCLUSIONS	O	0-11
:	O	11-12
Both	O	13-17
ATL	O	18-21
and	O	22-25
SA	O	26-28
can	O	29-32
lead	O	33-37
to	O	38-40
similar	O	41-48
favorable	O	49-58
seizure	O	59-66
control	O	67-74
in	O	75-77
patients	O	78-86
with	O	87-91
MTLE	O	92-96
/	O	96-97
HS	O	97-99
. 	O	99-101

Paired	O	0-6
Student	O	7-14
'	O	14-15
s	O	15-16
"	O	17-18
t	O	18-19
"	O	19-20
test	O	21-25
was	O	26-29
applied	O	30-37
to	O	38-40
the	O	41-44
scores	O	45-51
and	O	52-55
no	O	56-58
significant	O	59-70
difference	O	71-81
was	O	82-85
found	O	86-91
(	O	92-93
p	O	93-94
=	O	95-96
0	O	97-98
.	O	98-99
315	O	99-102
)	O	102-103
. 	O	103-105

In	O	0-2
the	O	3-6
postoperative	O	7-20
period	O	21-27
the	O	28-31
mean	O	32-36
MMSE	O	37-41
score	O	42-47
was	O	48-51
28	O	52-54
.	O	54-55
40	O	55-57
(	O	58-59
SD	O	59-61
,	O	61-62
1	O	63-64
.	O	64-65
46	O	65-67
)	O	67-68
. 	O	68-70

METHOD	O	0-6
:	O	6-7
A	O	8-9
consecutive	O	10-21
series	O	22-28
of	O	29-31
40	O	32-34
patients	O	35-43
who	O	44-47
underwent	O	48-57
microsurgical	O	58-71
clipping	O	72-80
for	O	81-84
UIA	O	85-88
were	O	89-93
studied	O	94-101
. 	O	101-103

The	O	0-3
cognitive	O	4-13
assessment	O	14-24
(	O	25-26
Mini	O	26-30
Mental	O	31-37
State	O	38-43
Examination	O	44-55
,	O	55-56
MMSE	O	57-61
)	O	61-62
was	O	63-66
performed	O	67-76
immediately	O	77-88
before	O	89-95
and	O	96-99
at	O	100-102
least	O	103-108
one	O	109-112
month	O	113-118
after	O	119-124
surgery	O	125-132
. 	O	132-134

Paired	O	0-6
Student	O	7-14
'	O	14-15
s	O	15-16
"	O	17-18
t	O	18-19
"	O	19-20
test	O	21-25
and	O	26-29
analysis	O	30-38
of	O	39-41
variance	O	42-50
(	O	51-52
ANOVA	O	52-57
)	O	57-58
were	O	59-63
used	O	64-68
for	O	69-72
statistical	O	73-84
purposes	O	85-93
. 	O	93-95

RESULTS	O	0-7
:	O	7-8
The	O	9-12
mean	O	13-17
MMSE	O	18-22
score	O	23-28
in	O	29-31
the	O	32-35
preoperative	O	36-48
analysis	O	49-57
was	O	58-61
28	O	62-64
.	O	64-65
12	O	65-67
(	O	68-69
SD	O	69-71
,	O	71-72
1	O	73-74
.	O	74-75
34	O	75-77
)	O	77-78
. 	O	78-80

Microsurgical	O	0-13
clipping	O	14-22
in	O	23-25
forty	O	26-31
patients	O	32-40
with	O	41-45
unruptured	O	46-56
anterior	O	57-65
cerebral	O	66-74
circulation	O	75-86
aneurysms	O	87-96
:	O	96-97
an	O	98-100
investigation	O	101-114
into	O	115-119
cognitive	O	120-129
outcome	O	130-137
.  	O	137-140

OBJECTIVE	O	0-9
:	O	9-10
It	O	11-13
is	O	14-16
a	O	17-18
consensus	O	19-28
that	O	29-33
most	O	34-38
unruptured	O	39-49
intracranial	O	50-62
aneurysms	O	63-72
(	O	73-74
UIA	O	74-77
)	O	77-78
can	O	79-82
be	O	83-85
treated	O	86-93
with	O	94-98
acceptably	O	99-109
low	O	110-113
morbidity	O	114-123
. 	O	123-125

However	O	0-7
,	O	7-8
some	O	9-13
studies	O	14-21
recently	O	22-30
reported	O	31-39
postoperative	O	40-53
cognitive	O	54-63
impairment	O	64-74
,	O	74-75
suggesting	O	76-86
that	O	87-91
it	O	92-94
could	O	95-100
be	O	101-103
attributable	O	104-116
to	O	117-119
surgical	O	120-128
damage	O	129-135
. 	O	135-137

Our	O	0-3
goal	O	4-8
is	O	9-11
to	O	12-14
evaluate	O	15-23
cognitive	O	24-33
function	O	34-42
before	O	43-49
and	O	50-53
after	O	54-59
microsurgical	O	60-73
clipping	O	74-82
in	O	83-85
patients	O	86-94
with	O	95-99
UIA	O	100-103
. 	O	103-105

ANOVA	O	0-5
did	O	6-9
not	O	10-13
find	O	14-18
independent	O	19-30
associations	O	31-43
between	O	44-51
MMSE	O	52-56
scores	O	57-63
and	O	64-67
age	O	68-71
,	O	71-72
hypertension	O	73-85
,	O	85-86
smoking	O	87-94
,	O	94-95
dyslipidemia	O	96-108
,	O	108-109
education	O	110-119
,	O	119-120
aneurysm	O	121-129
location	O	130-138
,	O	138-139
number	O	140-146
,	O	146-147
laterality	O	148-158
or	O	159-161
size	O	162-166
. 	O	166-168

CONCLUSION	O	0-10
:	O	10-11
The	O	12-15
present	O	16-23
study	O	24-29
suggests	O	30-38
that	O	39-43
microsurgical	O	44-57
clipping	O	58-66
for	O	67-70
UIA	O	71-74
does	O	75-79
not	O	80-83
result	O	84-90
in	O	91-93
major	O	94-99
cognitive	O	100-109
dysfunction	O	110-121
as	O	122-124
determined	O	125-135
by	O	136-138
the	O	139-142
MMSE	O	143-147
.   	O	147-151

MicroRNA	O	0-8
miR	B	9-12
-	I	12-13
133b	I	13-17
is	O	18-20
essential	O	21-30
for	O	31-34
functional	O	35-45
recovery	O	46-54
after	O	55-60
spinal	O	61-67
cord	O	68-72
injury	O	73-79
in	O	80-82
adult	O	83-88
zebrafish	O	89-98
.  	O	98-101

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
play	O	19-23
important	O	24-33
roles	O	34-39
during	O	40-46
development	O	47-58
and	O	59-62
also	O	63-67
in	O	68-70
adult	O	71-76
organisms	O	77-86
by	O	87-89
regulating	O	90-100
the	O	101-104
expression	O	105-115
of	O	116-118
multiple	O	119-127
target	O	128-134
genes	O	135-140
. 	O	140-142

Here	O	0-4
,	O	4-5
we	O	6-8
studied	O	9-16
the	O	17-20
function	O	21-29
of	O	30-32
miR	B	33-36
-	I	36-37
133b	I	37-41
during	O	42-48
zebrafish	O	49-58
spinal	O	59-65
cord	O	66-70
regeneration	O	71-83
and	O	84-87
show	O	88-92
upregulation	O	93-105
of	O	106-108
miR	B	109-112
-	I	112-113
133b	I	113-117
expression	O	118-128
in	O	129-131
regenerating	O	132-144
neurons	O	145-152
of	O	153-155
the	O	156-159
brainstem	O	160-169
after	O	170-175
transection	O	176-187
of	O	188-190
the	O	191-194
spinal	O	195-201
cord	O	202-206
. 	O	206-208

miR	B	0-3
-	I	3-4
133b	I	4-8
has	O	9-12
been	O	13-17
shown	O	18-23
to	O	24-26
promote	O	27-34
tissue	O	35-41
regeneration	O	42-54
in	O	55-57
other	O	58-63
tissue	O	64-70
,	O	70-71
but	O	72-75
its	O	76-79
ability	O	80-87
to	O	88-90
do	O	91-93
so	O	94-96
in	O	97-99
the	O	100-103
nervous	O	104-111
system	O	112-118
has	O	119-122
yet	O	123-126
to	O	127-129
be	O	130-132
tested	O	133-139
. 	O	139-141

Inhibition	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
133b	I	18-22
expression	O	23-33
by	O	34-36
antisense	O	37-46
morpholino	O	47-57
(	O	58-59
MO	O	59-61
)	O	61-62
application	O	63-74
resulted	O	75-83
in	O	84-86
impaired	O	87-95
locomotor	O	96-105
recovery	O	106-114
and	O	115-118
reduced	O	119-126
regeneration	O	127-139
of	O	140-142
axons	O	143-148
from	O	149-153
neurons	O	154-161
in	O	162-164
the	O	165-168
nucleus	O	169-176
of	O	177-179
the	O	180-183
medial	O	184-190
longitudinal	O	191-203
fascicle	O	204-212
,	O	212-213
superior	O	214-222
reticular	O	223-232
formation	O	233-242
and	O	243-246
intermediate	O	247-259
reticular	O	260-269
formation	O	270-279
. 	O	279-281

miR	B	0-3
-	I	3-4
133b	I	4-8
targets	O	9-16
the	O	17-20
small	O	21-26
GTPase	O	27-33
RhoA	O	34-38
,	O	38-39
which	O	40-45
is	O	46-48
an	O	49-51
inhibitor	O	52-61
of	O	62-64
axonal	O	65-71
growth	O	72-78
,	O	78-79
as	O	80-82
well	O	83-87
as	O	88-90
other	O	91-96
neurite	O	97-104
outgrowth	O	105-114
-	O	114-115
related	O	115-122
molecules	O	123-132
. 	O	132-134

Our	O	0-3
results	O	4-11
indicate	O	12-20
that	O	21-25
miR	B	26-29
-	I	29-30
133b	I	30-34
is	O	35-37
an	O	38-40
important	O	41-50
determinant	O	51-62
in	O	63-65
spinal	O	66-72
cord	O	73-77
regeneration	O	78-90
of	O	91-93
adult	O	94-99
zebrafish	O	100-109
through	O	110-117
reduction	O	118-127
in	O	128-130
RhoA	O	131-135
protein	O	136-143
levels	O	144-150
by	O	151-153
direct	O	154-160
interaction	O	161-172
with	O	173-177
its	O	178-181
mRNA	O	182-186
. 	O	186-188

While	O	0-5
RhoA	O	6-10
has	O	11-14
been	O	15-19
studied	O	20-27
as	O	28-30
a	O	31-32
therapeutic	O	33-44
target	O	45-51
in	O	52-54
spinal	O	55-61
cord	O	62-66
injury	O	67-73
,	O	73-74
this	O	75-79
is	O	80-82
the	O	83-86
first	O	87-92
demonstration	O	93-106
of	O	107-109
endogenous	O	110-120
regulation	O	121-131
of	O	132-134
RhoA	O	135-139
by	O	140-142
a	O	143-144
microRNA	O	145-153
that	O	154-158
is	O	159-161
required	O	162-170
for	O	171-174
spinal	O	175-181
cord	O	182-186
regeneration	O	187-199
in	O	200-202
zebrafish	O	203-212
. 	O	212-214

The	O	0-3
ability	O	4-11
of	O	12-14
miR	B	15-18
-	I	18-19
133b	I	19-23
to	O	24-26
suppress	O	27-35
molecules	O	36-45
that	O	46-50
inhibit	O	51-58
axon	O	59-63
regrowth	O	64-72
may	O	73-76
underlie	O	77-85
the	O	86-89
capacity	O	90-98
for	O	99-102
adult	O	103-108
zebrafish	O	109-118
to	O	119-121
recover	O	122-129
locomotor	O	130-139
function	O	140-148
after	O	149-154
spinal	O	155-161
cord	O	162-166
injury	O	167-173
.   	O	173-177

These	O	0-5
findings	O	6-14
further	O	15-22
support	O	23-30
the	O	31-34
idea	O	35-39
that	O	40-44
iron	O	45-49
-	O	49-50
and	O	51-54
aluminum	O	55-63
-	O	63-64
sulfates	O	64-72
induce	O	73-79
genotoxicity	O	80-92
via	O	93-96
a	O	97-98
ROS	O	99-102
-	O	102-103
mediated	O	103-111
up	O	112-114
-	O	114-115
regulation	O	115-125
of	O	126-128
specific	O	129-137
regulatory	O	138-148
elements	O	149-157
and	O	158-161
pathogenic	O	162-172
genes	O	173-178
that	O	179-183
redirect	O	184-192
brain	O	193-198
cell	O	199-203
fate	O	204-208
towards	O	209-216
progressive	O	217-228
dysfunction	O	229-240
and	O	241-244
apoptotic	O	245-254
cell	O	255-259
death	O	260-265
.   	O	265-269

Notably	O	0-7
,	O	7-8
these	O	9-14
same	O	15-19
miRNAs	O	20-26
are	O	27-30
up	O	31-33
-	O	33-34
regulated	O	34-43
in	O	44-46
AD	O	47-49
brain	O	50-55
. 	O	55-57

The	O	0-3
main	O	4-8
finding	O	9-16
was	O	17-20
that	O	21-25
these	O	26-31
ROS	O	32-35
-	O	35-36
generating	O	36-46
neurotoxic	O	47-57
metal	O	58-63
sulfates	O	64-72
also	O	73-77
up	O	78-80
-	O	80-81
regulate	O	81-89
a	O	90-91
specific	O	92-100
set	O	101-104
of	O	105-107
miRNAs	O	108-114
that	O	115-119
includes	O	120-128
miR	B	129-132
-	I	132-133
9	I	133-134
,	O	134-135
miR	B	136-139
-	I	139-140
125b	I	140-144
and	O	145-148
miR	B	149-152
-	I	152-153
128	I	153-156
. 	O	156-158

In	O	0-2
this	O	3-7
study	O	8-13
we	O	14-16
have	O	17-21
extended	O	22-30
our	O	31-34
investigations	O	35-49
to	O	50-52
analyze	O	53-60
the	O	61-64
expression	O	65-75
of	O	76-78
micro	O	79-84
RNA	O	85-88
(	O	89-90
miRNA	O	90-95
)	O	95-96
populations	O	97-108
in	O	109-111
iron	O	112-116
-	O	116-117
and	O	118-121
aluminum	O	122-130
-	O	130-131
sulfate	O	131-138
treated	O	139-146
human	O	147-152
neural	O	153-159
cells	O	160-165
in	O	166-168
primary	O	169-176
culture	O	177-184
. 	O	184-186

Notably	O	0-7
,	O	7-8
iron	O	9-13
-	O	13-14
and	O	15-18
aluminum	O	19-27
-	O	27-28
sulfate	O	28-35
induce	O	36-42
genes	O	43-48
in	O	49-51
cultured	O	52-60
human	O	61-66
brain	O	67-72
cells	O	73-78
that	O	79-83
exhibit	O	84-91
expression	O	92-102
patterns	O	103-111
similar	O	112-119
to	O	120-122
those	O	123-128
observed	O	129-137
to	O	138-140
be	O	141-143
up	O	144-146
-	O	146-147
regulated	O	147-156
in	O	157-159
moderate	O	160-168
-	O	168-169
to	O	170-172
late	O	173-177
-	O	177-178
stage	O	178-183
Alzheimer	O	184-193
'	O	193-194
s	O	194-195
disease	O	196-203
(	O	204-205
AD	O	205-207
)	O	207-208
. 	O	208-210

Previous	O	0-8
studies	O	9-16
have	O	17-21
shown	O	22-27
that	O	28-32
following	O	33-42
ROS	O	43-46
induction	O	47-56
,	O	56-57
a	O	58-59
family	O	60-66
of	O	67-69
pathogenic	O	70-80
brain	O	81-86
genes	O	87-92
that	O	93-97
promote	O	98-105
inflammatory	O	106-118
signalling	O	119-129
,	O	129-130
cellular	O	131-139
apoptosis	O	140-149
and	O	150-153
brain	O	154-159
cell	O	160-164
death	O	165-170
is	O	171-173
significantly	O	174-187
over	O	188-192
-	O	192-193
expressed	O	193-202
. 	O	202-204

Iron	O	0-4
-	O	4-5
and	O	6-9
aluminum	O	10-18
-	O	18-19
sulfate	O	19-26
together	O	27-35
,	O	35-36
at	O	37-39
nanomolar	O	40-49
concentrations	O	50-64
,	O	64-65
trigger	O	66-73
the	O	74-77
production	O	78-88
of	O	89-91
reactive	O	92-100
oxygen	O	101-107
species	O	108-115
(	O	116-117
ROS	O	117-120
)	O	120-121
in	O	122-124
cultures	O	125-133
of	O	134-136
human	O	137-142
brain	O	143-148
cells	O	149-154
. 	O	154-156

Induction	O	0-9
of	O	10-12
specific	O	13-21
micro	O	22-27
RNA	O	28-31
(	O	32-33
miRNA	O	33-38
)	O	38-39
species	O	40-47
by	O	48-50
ROS	O	51-54
-	O	54-55
generating	O	55-65
metal	O	66-71
sulfates	O	72-80
in	O	81-83
primary	O	84-91
human	O	92-97
brain	O	98-103
cells	O	104-109
.  	O	109-112

As	O	0-2
a	O	3-4
genetically	O	5-16
complex	O	17-24
disease	O	25-32
,	O	32-33
dysregulation	O	34-47
of	O	48-50
miRNA	O	51-56
expression	O	57-67
might	O	68-73
be	O	74-76
a	O	77-78
feature	O	79-86
of	O	87-89
autism	O	90-96
spectrum	O	97-105
disorders	O	106-115
(	O	116-117
ASDs	O	117-121
)	O	121-122
. 	O	122-124

Using	O	0-5
multiplex	O	6-15
quantitative	O	16-28
polymerase	O	29-39
chain	O	40-45
reaction	O	46-54
(	O	55-56
PCR	O	56-59
)	O	59-60
,	O	60-61
we	O	62-64
compared	O	65-73
the	O	74-77
expression	O	78-88
of	O	89-91
466	O	92-95
human	O	96-101
miRNAs	O	102-108
from	O	109-113
postmortem	O	114-124
cerebellar	O	125-135
cortex	O	136-142
tissue	O	143-149
of	O	150-152
individuals	O	153-164
with	O	165-169
ASD	O	170-173
(	O	174-175
n	O	175-176
=	O	177-178
13	O	179-181
)	O	181-182
and	O	183-186
a	O	187-188
control	O	189-196
set	O	197-200
of	O	201-203
non	O	204-207
-	O	207-208
autistic	O	208-216
cerebellar	O	217-227
samples	O	228-235
(	O	236-237
n	O	237-238
=	O	239-240
13	O	241-243
)	O	243-244
. 	O	244-246

microRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
approximately	O	23-36
21	O	37-39
nt	O	40-42
transcripts	O	43-54
capable	O	55-62
of	O	63-65
regulating	O	66-76
the	O	77-80
expression	O	81-91
of	O	92-94
many	O	95-99
mRNAs	O	100-105
and	O	106-109
are	O	110-113
abundant	O	114-122
in	O	123-125
the	O	126-129
brain	O	130-135
. 	O	135-137

miRNAs	O	0-6
have	O	7-11
a	O	12-13
role	O	14-18
in	O	19-21
several	O	22-29
complex	O	30-37
diseases	O	38-46
including	O	47-56
cancer	O	57-63
as	O	64-66
well	O	67-71
as	O	72-74
some	O	75-79
neurological	O	80-92
diseases	O	93-101
such	O	102-106
as	O	107-109
Tourette	O	110-118
'	O	118-119
s	O	119-120
syndrome	O	121-129
and	O	130-133
Fragile	O	134-141
x	O	142-143
syndrome	O	144-152
. 	O	152-154

To	O	0-2
validate	O	3-11
the	O	12-15
finding	O	16-23
,	O	23-24
we	O	25-27
reversed	O	28-36
the	O	37-40
analysis	O	41-49
and	O	50-53
compared	O	54-62
each	O	63-67
non	O	68-71
-	O	71-72
autism	O	72-78
control	O	79-86
to	O	87-89
a	O	90-91
single	O	92-98
mean	O	99-103
value	O	104-109
for	O	110-113
each	O	114-118
miRNA	O	119-124
across	O	125-131
all	O	132-135
autism	O	136-142
cases	O	143-148
. 	O	148-150

In	O	0-2
this	O	3-7
analysis	O	8-16
,	O	16-17
the	O	18-21
number	O	22-28
of	O	29-31
dysregulated	O	32-44
miRNAs	O	45-51
fell	O	52-56
from	O	57-61
28	O	62-64
to	O	65-67
9	O	68-69
miRNAs	O	70-76
. 	O	76-78

While	O	0-5
most	O	6-10
miRNAs	O	11-17
levels	O	18-24
showed	O	25-31
little	O	32-38
variation	O	39-48
across	O	49-55
all	O	56-59
samples	O	60-67
suggesting	O	68-78
that	O	79-83
autism	O	84-90
does	O	91-95
not	O	96-99
induce	O	100-106
global	O	107-113
dysfunction	O	114-125
of	O	126-128
miRNA	O	129-134
expression	O	135-145
,	O	145-146
some	O	147-151
miRNAs	O	152-158
among	O	159-164
the	O	165-168
autistic	O	169-177
samples	O	178-185
were	O	186-190
expressed	O	191-200
at	O	201-203
significantly	O	204-217
different	O	218-227
levels	O	228-234
compared	O	235-243
to	O	244-246
the	O	247-250
mean	O	251-255
control	O	256-263
value	O	264-269
. 	O	269-271

Twenty	O	0-6
-	O	6-7
eight	O	7-12
miRNAs	O	13-19
were	O	20-24
expressed	O	25-34
at	O	35-37
significantly	O	38-51
different	O	52-61
levels	O	62-68
compared	O	69-77
to	O	78-80
the	O	81-84
non	O	85-88
-	O	88-89
autism	O	89-95
control	O	96-103
set	O	104-107
in	O	108-110
at	O	111-113
least	O	114-119
one	O	120-123
of	O	124-126
the	O	127-130
autism	O	131-137
samples	O	138-145
. 	O	145-147

Among	O	0-5
the	O	6-9
predicted	O	10-19
targets	O	20-27
of	O	28-30
dysregulated	O	31-43
miRNAs	O	44-50
are	O	51-54
genes	O	55-60
that	O	61-65
are	O	66-69
known	O	70-75
genetic	O	76-83
causes	O	84-90
of	O	91-93
autism	O	94-100
such	O	101-105
Neurexin	O	106-114
and	O	115-118
SHANK3	O	119-125
. 	O	125-127

Heterogeneous	O	0-13
dysregulation	O	14-27
of	O	28-30
microRNAs	O	31-40
across	O	41-47
the	O	48-51
autism	O	52-58
spectrum	O	59-67
.  	O	67-70

This	O	0-4
study	O	5-10
finds	O	11-16
that	O	17-21
altered	O	22-29
miRNA	O	30-35
expression	O	36-46
levels	O	47-53
are	O	54-57
observed	O	58-66
in	O	67-69
postmortem	O	70-80
cerebellar	O	81-91
cortex	O	92-98
from	O	99-103
autism	O	104-110
patients	O	111-119
,	O	119-120
a	O	121-122
finding	O	123-130
which	O	131-136
suggests	O	137-145
that	O	146-150
dysregulation	O	151-164
of	O	165-167
miRNAs	O	168-174
may	O	175-178
contribute	O	179-189
to	O	190-192
autism	O	193-199
spectrum	O	200-208
phenotype	O	209-218
.   	O	218-222

A	O	0-1
tight	O	2-7
correlation	O	8-19
between	O	20-27
these	O	28-33
miRNAs	O	34-40
and	O	41-44
APP	O	45-48
was	O	49-52
found	O	53-58
during	O	59-65
brain	O	66-71
development	O	72-83
and	O	84-87
in	O	88-90
differentiating	O	91-106
neurons	O	107-114
. 	O	114-116

We	O	0-2
thus	O	3-7
identify	O	8-16
miRNAs	O	17-23
as	O	24-26
novel	O	27-32
endogenous	O	33-43
regulators	O	44-54
of	O	55-57
APP	O	58-61
expression	O	62-72
,	O	72-73
suggesting	O	74-84
that	O	85-89
variations	O	90-100
in	O	101-103
miRNA	O	104-109
expression	O	110-120
could	O	121-126
contribute	O	127-137
to	O	138-140
changes	O	141-148
in	O	149-151
APP	O	152-155
expression	O	156-166
in	O	167-169
the	O	170-173
brain	O	174-179
during	O	180-186
development	O	187-198
and	O	199-202
disease	O	203-210
. 	O	210-212

This	O	0-4
possibility	O	5-16
is	O	17-19
further	O	20-27
corroborated	O	28-40
by	O	41-43
the	O	44-47
observation	O	48-59
that	O	60-64
a	O	65-66
statistically	O	67-80
significant	O	81-92
decrease	O	93-101
in	O	102-104
miR	B	105-108
-	I	108-109
106b	I	109-113
expression	O	114-124
was	O	125-128
found	O	129-134
in	O	135-137
sporadic	O	138-146
AD	O	147-149
patients	O	150-158
.   	O	158-162

MicroRNA	O	0-8
regulation	O	9-19
of	O	20-22
Alzheimer	O	23-32
'	O	32-33
s	O	33-34
Amyloid	O	35-42
precursor	O	43-52
protein	O	53-60
expression	O	61-71
.  	O	71-74

Gene	O	0-4
dosage	O	5-11
effects	O	12-19
of	O	20-22
Amyloid	O	23-30
precursor	O	31-40
protein	O	41-48
(	O	49-50
APP	O	50-53
)	O	53-54
can	O	55-58
cause	O	59-64
familial	O	65-73
AD	O	74-76
.	O	76-77
Recent	O	78-84
evidence	O	85-93
suggest	O	94-101
that	O	102-106
microRNA	O	107-115
(	O	116-117
miRNA	O	117-122
)	O	122-123
pathways	O	124-132
,	O	132-133
implicated	O	134-144
in	O	145-147
gene	O	148-152
transcriptional	O	153-168
control	O	169-176
,	O	176-177
could	O	178-183
be	O	184-186
involved	O	187-195
in	O	196-198
the	O	199-202
development	O	203-214
of	O	215-217
sporadic	O	218-226
Alzheimer	O	227-236
'	O	236-237
s	O	237-238
disease	O	239-246
(	O	247-248
AD	O	248-250
)	O	250-251
. 	O	251-253

We	O	0-2
therefore	O	3-12
investigated	O	13-25
whether	O	26-33
miRNAs	O	34-40
could	O	41-46
participate	O	47-58
in	O	59-61
the	O	62-65
regulation	O	66-76
of	O	77-79
APP	O	80-83
gene	O	84-88
expression	O	89-99
. 	O	99-101

We	O	0-2
show	O	3-7
that	O	8-12
miRNAs	O	13-19
belonging	O	20-29
to	O	30-32
the	O	33-36
miR	B	37-40
-	I	40-41
20a	I	41-44
family	O	45-51
(	O	52-53
that	O	53-57
is	O	58-60
,	O	60-61
miR	B	62-65
-	I	65-66
20a	I	66-69
,	O	69-70
miR	B	71-74
-	I	74-75
17	I	75-77
-	I	77-78
5p	I	78-80
and	O	81-84
miR	B	85-88
-	I	88-89
106b	I	89-93
)	O	93-94
could	O	95-100
regulate	O	101-109
APP	O	110-113
expression	O	114-124
in	O	125-127
vitro	O	128-133
and	O	134-137
at	O	138-140
the	O	141-144
endogenous	O	145-155
level	O	156-161
in	O	162-164
neuronal	O	165-173
cell	O	174-178
lines	O	179-184
. 	O	184-186

These	O	0-5
data	O	6-10
suggest	O	11-18
a	O	19-20
role	O	21-25
for	O	26-29
HSV	O	30-33
-	O	33-34
1	O	34-35
-	O	35-36
induced	O	36-43
miRNA	B	44-49
-	I	49-50
146a	I	50-54
in	O	55-57
the	O	58-61
evasion	O	62-69
of	O	70-72
HSV	O	73-76
-	O	76-77
1	O	77-78
from	O	79-83
the	O	84-87
complement	O	88-98
system	O	99-105
,	O	105-106
and	O	107-110
the	O	111-114
activation	O	115-125
of	O	126-128
key	O	129-132
elements	O	133-141
of	O	142-144
the	O	145-148
arachidonic	O	149-160
acid	O	161-165
cascade	O	166-173
known	O	174-179
to	O	180-182
contribute	O	183-193
to	O	194-196
Alzheimer	O	197-206
-	O	206-207
type	O	207-211
neuropathological	O	212-229
change	O	230-236
.   	O	236-240

A	O	0-1
known	O	2-7
miRNA	B	8-13
-	I	13-14
146a	I	14-18
target	O	19-25
in	O	26-28
the	O	29-32
brain	O	33-38
,	O	38-39
complement	O	40-50
factor	O	51-57
H	O	58-59
,	O	59-60
was	O	61-64
downregulated	O	65-78
. 	O	78-80

Expression	O	0-10
of	O	11-13
cytoplasmic	O	14-25
phospholipase	O	26-39
A2	O	40-42
,	O	42-43
the	O	44-47
inducible	O	48-57
prostaglandin	O	58-71
synthase	O	72-80
cyclooxygenase	O	81-95
-	O	95-96
2	O	96-97
,	O	97-98
and	O	99-102
the	O	103-106
neuroinflammatory	O	107-124
cytokine	O	125-133
interleukin	O	134-145
-	O	145-146
1beta	O	146-151
were	O	152-156
each	O	157-161
upregulated	O	162-173
. 	O	173-175

We	O	0-2
report	O	3-9
that	O	10-14
infection	O	15-24
of	O	25-27
human	O	28-33
primary	O	34-41
neural	O	42-48
cells	O	49-54
with	O	55-59
a	O	60-61
high	O	62-66
phenotypic	O	67-77
reactivator	O	78-89
HSV	O	90-93
-	O	93-94
1	O	94-95
(	O	96-97
17syn	O	97-102
+	O	102-103
)	O	103-104
induces	O	105-112
upregulation	O	113-125
of	O	126-128
a	O	129-130
brain	O	131-136
-	O	136-137
enriched	O	137-145
microRNA	B	146-154
(	I	155-156
miRNA	I	156-161
)	I	161-162
-	I	162-163
146a	I	163-167
that	O	168-172
is	O	173-175
associated	O	176-186
with	O	187-191
proinflammatory	O	192-207
signaling	O	208-217
in	O	218-220
stressed	O	221-229
brain	O	230-235
cells	O	236-241
and	O	242-245
Alzheimer	O	246-255
'	O	255-256
s	O	256-257
disease	O	258-265
. 	O	265-267

Herpes	O	0-6
simplex	O	7-14
virus	O	15-20
type	O	21-25
-	O	25-26
1	O	26-27
(	O	28-29
HSV	O	29-32
-	O	32-33
1	O	33-34
)	O	34-35
infection	O	36-45
of	O	46-48
human	O	49-54
brain	O	55-60
cells	O	61-66
induces	O	67-74
changes	O	75-82
in	O	83-85
gene	O	86-90
expression	O	91-101
favorable	O	102-111
to	O	112-114
the	O	115-118
propagation	O	119-130
of	O	131-133
the	O	134-137
infecting	O	138-147
agent	O	148-153
and	O	154-157
detrimental	O	158-169
to	O	170-172
the	O	173-176
function	O	177-185
of	O	186-188
the	O	189-192
host	O	193-197
cells	O	198-203
. 	O	203-205

HSV	O	0-3
-	O	3-4
1	O	4-5
infection	O	6-15
of	O	16-18
human	O	19-24
brain	O	25-30
cells	O	31-36
induces	O	37-44
miRNA	B	45-50
-	I	50-51
146a	I	51-55
and	O	56-59
Alzheimer	O	60-69
-	O	69-70
type	O	70-74
inflammatory	O	75-87
signaling	O	88-97
.  	O	97-100

We	O	0-2
concluded	O	3-12
that	O	13-17
patients	O	18-26
with	O	27-31
partial	O	32-39
recurrent	O	40-49
seizures	O	50-58
of	O	59-61
temporal	O	62-70
origin	O	71-77
have	O	78-82
poor	O	83-87
subjective	O	88-98
sleep	O	99-104
quality	O	105-112
that	O	113-117
improves	O	118-126
significantly	O	127-140
after	O	141-146
epilepsy	O	147-155
surgery	O	156-163
.   	O	163-167

ESS	O	0-3
and	O	4-7
PSQI	O	8-12
scores	O	13-19
were	O	20-24
also	O	25-29
analyzed	O	30-38
by	O	39-41
gender	O	42-48
,	O	48-49
antiepileptic	O	50-63
drug	O	64-68
class	O	69-74
,	O	74-75
age	O	76-79
,	O	79-80
and	O	81-84
seizure	O	85-92
frequency	O	93-102
,	O	102-103
with	O	104-108
no	O	109-111
significant	O	112-123
differences	O	124-135
. 	O	135-137

Global	O	0-6
PSQI	O	7-11
was	O	12-15
high	O	16-20
(	O	21-22
mean	O	22-26
=	O	26-27
5	O	27-28
.	O	28-29
65	O	29-31
SD	O	32-34
=	O	34-35
3	O	35-36
.	O	36-37
71	O	37-39
)	O	39-40
before	O	41-47
the	O	48-51
surgical	O	52-60
procedure	O	61-70
(	O	71-72
P	O	72-73
<	O	73-74
0	O	74-75
.	O	75-76
001	O	76-79
)	O	79-80
. 	O	80-82

Two	O	0-3
questionnaires	O	4-18
were	O	19-23
used	O	24-28
to	O	29-31
assess	O	32-38
daytime	O	39-46
sleepiness	O	47-57
(	O	58-59
Epworth	O	59-66
Sleepiness	O	67-77
Scale	O	78-83
[	O	84-85
ESS	O	85-88
]	O	88-89
)	O	89-90
and	O	91-94
sleep	O	95-100
quality	O	101-108
(	O	109-110
Pittsburgh	O	110-120
Sleep	O	121-126
Quality	O	127-134
Index	O	135-140
[	O	141-142
PSQI	O	142-146
]	O	146-147
)	O	147-148
. 	O	148-150

PSQI	O	0-4
evaluation	O	5-15
revealed	O	16-24
higher	O	25-31
and	O	32-35
statistically	O	36-49
significant	O	50-61
scores	O	62-68
in	O	69-71
three	O	72-77
components	O	78-88
as	O	89-91
well	O	92-96
as	O	97-99
in	O	100-102
the	O	103-106
global	O	107-113
score	O	114-119
,	O	119-120
when	O	121-125
analyzed	O	126-134
by	O	135-137
predominance	O	138-150
of	O	151-153
daytime	O	154-161
or	O	162-164
nocturnal	O	165-174
seizures	O	175-183
. 	O	183-185

Evaluation	O	0-10
of	O	11-13
sleep	O	14-19
quality	O	20-27
in	O	28-30
patients	O	31-39
with	O	40-44
refractory	O	45-55
seizures	O	56-64
who	O	65-68
undergo	O	69-76
epilepsy	O	77-85
surgery	O	86-93
.  	O	93-96

The	O	0-3
aim	O	4-7
of	O	8-10
the	O	11-14
study	O	15-20
was	O	21-24
to	O	25-27
evaluate	O	28-36
excessive	O	37-46
daytime	O	47-54
sleepiness	O	55-65
and	O	66-69
subjective	O	70-80
sleep	O	81-86
quality	O	87-94
in	O	95-97
patients	O	98-106
who	O	107-110
undergo	O	111-118
epilepsy	O	119-127
surgery	O	128-135
for	O	136-139
treatment	O	140-149
of	O	150-152
refractory	O	153-163
partial	O	164-171
seizures	O	172-180
. 	O	180-182

Forty	O	0-5
-	O	5-6
eight	O	6-11
patients	O	12-20
were	O	21-25
enrolled	O	26-34
in	O	35-37
this	O	38-42
research	O	43-51
study	O	52-57
. 	O	57-59

All	O	0-3
of	O	4-6
them	O	7-11
were	O	12-16
evaluated	O	17-26
2	O	27-28
days	O	29-33
before	O	34-40
and	O	41-44
3	O	45-46
months	O	47-53
after	O	54-59
the	O	60-63
surgery	O	64-71
. 	O	71-73

Here	O	0-4
,	O	4-5
we	O	6-8
investigated	O	9-21
the	O	22-25
possibility	O	26-37
that	O	38-42
IFN	O	43-46
-	O	46-47
beta	O	47-51
may	O	52-55
induce	O	56-62
or	O	63-65
downregulate	O	66-78
cellular	O	79-87
microRNAs	O	88-97
(	O	98-99
miRNA	O	99-104
)	O	104-105
in	O	106-108
human	O	109-114
neoplasms	O	115-124
and	O	125-128
thereby	O	129-136
use	O	137-140
the	O	141-144
RNA	O	145-148
interference	O	149-161
system	O	162-168
to	O	169-171
show	O	172-176
antitumor	O	177-186
effects	O	187-194
. 	O	194-196

Because	O	0-7
of	O	8-10
its	O	11-14
known	O	15-20
connection	O	21-31
to	O	32-34
glioma	O	35-41
biology	O	42-49
,	O	49-50
we	O	51-53
focused	O	54-61
on	O	62-64
miR	B	65-68
-	I	68-69
21	I	69-71
among	O	72-77
seven	O	78-83
miRNAs	O	84-90
influenced	O	91-101
by	O	102-104
IFN	O	105-108
-	O	108-109
beta	O	109-113
. 	O	113-115

The	O	0-3
modulation	O	4-14
of	O	15-17
microRNAs	O	18-27
by	O	28-30
type	O	31-35
I	O	36-37
IFN	O	38-41
through	O	42-49
the	O	50-53
activation	O	54-64
of	O	65-67
signal	O	68-74
transducers	O	75-86
and	O	87-90
activators	O	91-101
of	O	102-104
transcription	O	105-118
3	O	119-120
in	O	121-123
human	O	124-129
glioma	O	130-136
.  	O	136-139

Type	O	0-4
I	O	5-6
IFNs	O	7-11
are	O	12-15
involved	O	16-24
in	O	25-27
double	O	28-34
-	O	34-35
stranded	O	35-43
RNA	O	44-47
responses	O	48-57
. 	O	57-59

The	O	0-3
levels	O	4-10
of	O	11-13
primary	O	14-21
miR	B	22-25
-	I	25-26
21	I	26-28
gene	O	29-33
transcripts	O	34-45
,	O	45-46
precursor	O	47-56
miR	B	57-60
-	I	60-61
21	I	61-63
,	O	63-64
and	O	65-68
mature	O	69-75
miR	B	76-79
-	I	79-80
21	I	80-82
decreased	O	83-92
6	O	93-94
hours	O	95-100
after	O	101-106
the	O	107-110
addition	O	111-119
of	O	120-122
IFN	O	123-126
-	O	126-127
beta	O	127-131
,	O	131-132
indicating	O	133-143
that	O	144-148
the	O	149-152
reduction	O	153-162
in	O	163-165
miR	B	166-169
-	I	169-170
21	I	170-172
levels	O	173-179
was	O	180-183
due	O	184-187
to	O	188-190
transcriptional	O	191-206
suppression	O	207-218
. 	O	218-220

We	O	0-2
did	O	3-6
reporter	O	7-15
assays	O	16-22
to	O	23-25
elucidate	O	26-35
the	O	36-39
IFN	O	40-43
-	O	43-44
beta	O	44-48
-	O	48-49
mediated	O	49-57
suppression	O	58-69
of	O	70-72
miR	B	73-76
-	I	76-77
21	I	77-79
;	O	79-80
the	O	81-84
addition	O	85-93
of	O	94-96
signal	O	97-103
transducers	O	104-115
and	O	116-119
activators	O	120-130
of	O	131-133
transcription	O	134-147
3	O	148-149
(	O	150-151
STAT3	O	151-156
)	O	156-157
-	O	157-158
expressing	O	158-168
vectors	O	169-176
induced	O	177-184
the	O	185-188
IFN	O	189-192
-	O	192-193
beta	O	193-197
-	O	197-198
mediated	O	198-206
suppression	O	207-218
of	O	219-221
miR	B	222-225
-	I	225-226
21	I	226-228
,	O	228-229
whereas	O	230-237
STAT3	O	238-243
-	O	243-244
inhibiting	O	244-254
agents	O	255-261
inhibited	O	262-271
the	O	272-275
miR	B	276-279
-	I	279-280
21	I	280-282
suppression	O	283-294
. 	O	294-296

We	O	0-2
analyzed	O	3-11
the	O	12-15
effect	O	16-22
of	O	23-25
IFN	O	26-29
-	O	29-30
beta	O	30-34
treatment	O	35-44
on	O	45-47
miR	B	48-51
-	I	51-52
21	I	52-54
expression	O	55-65
in	O	66-68
glioma	O	69-75
cells	O	76-81
and	O	82-85
intracranial	O	86-98
glioma	O	99-105
xenografts	O	106-116
. 	O	116-118

IFN	O	0-3
-	O	3-4
beta	O	4-8
treatment	O	9-18
reduced	O	19-26
miR	B	27-30
-	I	30-31
21	I	31-33
expression	O	34-44
in	O	45-47
glioma	O	48-54
cells	O	55-60
markedly	O	61-69
,	O	69-70
and	O	71-74
IFN	O	75-78
-	O	78-79
beta	O	79-83
administration	O	84-98
suppressed	O	99-109
the	O	110-113
growth	O	114-120
of	O	121-123
glioma	O	124-130
-	O	130-131
initiating	O	131-141
cell	O	142-146
-	O	146-147
derived	O	147-154
intracranial	O	155-167
tumors	O	168-174
. 	O	174-176

Thus	O	0-4
,	O	4-5
the	O	6-9
results	O	10-17
of	O	18-20
our	O	21-24
study	O	25-30
show	O	31-35
that	O	36-40
the	O	41-44
downregulation	O	45-59
of	O	60-62
miR	B	63-66
-	I	66-67
21	I	67-69
contributes	O	70-81
to	O	82-84
the	O	85-88
antitumor	O	89-98
effects	O	99-106
of	O	107-109
IFN	O	110-113
-	O	113-114
beta	O	114-118
and	O	119-122
that	O	123-127
miR	B	128-131
-	I	131-132
21	I	132-134
expression	O	135-145
is	O	146-148
negatively	O	149-159
regulated	O	160-169
by	O	170-172
STAT3	O	173-178
activation	O	179-189
. 	O	189-191

These	O	0-5
results	O	6-13
highlight	O	14-23
the	O	24-27
importance	O	28-38
of	O	39-41
understanding	O	42-55
the	O	56-59
transcriptional	O	60-75
regulation	O	76-86
of	O	87-89
the	O	90-93
miRNAs	O	94-100
involved	O	101-109
in	O	110-112
oncogenesis	O	113-124
.   	O	124-128

This	O	0-4
study	O	5-10
reveals	O	11-18
the	O	19-22
occurrence	O	23-33
of	O	34-36
novel	O	37-42
mechanisms	O	43-53
of	O	54-56
HIF	O	57-60
regulation	O	61-71
,	O	71-72
which	O	73-78
might	O	79-84
contribute	O	85-95
to	O	96-98
developing	O	99-109
novel	O	110-115
strategies	O	116-126
for	O	127-130
therapeutic	O	131-142
intervention	O	143-155
of	O	156-158
HIF	O	159-162
-	O	162-163
related	O	163-170
pathologies	O	171-182
,	O	182-183
including	O	184-193
heart	O	194-199
attack	O	200-206
,	O	206-207
cancer	O	208-214
,	O	214-215
and	O	216-219
stroke	O	220-226
.   	O	226-230

One	O	0-3
remarkable	O	4-14
hit	O	15-18
was	O	19-22
the	O	23-26
argonaute	O	27-36
1	O	37-38
(	O	39-40
ago1	O	40-44
)	O	44-45
gene	O	46-50
,	O	50-51
a	O	52-53
central	O	54-61
element	O	62-69
of	O	70-72
the	O	73-76
microRNA	O	77-85
(	O	86-87
miRNA	O	87-92
)	O	92-93
translational	O	94-107
silencing	O	108-117
machinery	O	118-127
. 	O	127-129

Further	O	0-7
studies	O	8-15
confirmed	O	16-25
the	O	26-29
physiological	O	30-43
role	O	44-48
of	O	49-51
the	O	52-55
miRNA	O	56-61
machinery	O	62-71
in	O	72-74
HIF	O	75-78
-	O	78-79
dependent	O	79-88
transcription	O	89-102
. 	O	102-104

After	O	0-5
3	O	6-7
rounds	O	8-14
of	O	15-17
selection	O	18-27
,	O	27-28
30	O	29-31
genes	O	32-37
emerged	O	38-45
as	O	46-48
critical	O	49-57
HIF	O	58-61
regulators	O	62-72
in	O	73-75
hypoxia	O	76-83
,	O	83-84
most	O	85-89
of	O	90-92
which	O	93-98
had	O	99-102
not	O	103-106
been	O	107-111
previously	O	112-122
associated	O	123-133
with	O	134-138
HIF	O	139-142
biology	O	143-150
. 	O	150-152

The	O	0-3
list	O	4-8
of	O	9-11
genes	O	12-17
includes	O	18-26
components	O	27-37
of	O	38-40
chromatin	O	41-50
remodeling	O	51-61
complexes	O	62-71
,	O	71-72
transcription	O	73-86
elongation	O	87-97
factors	O	98-105
,	O	105-106
and	O	107-110
translational	O	111-124
regulators	O	125-135
. 	O	135-137

Molecular	O	0-9
mechanisms	O	10-20
that	O	21-25
mediate	O	26-33
oxygen	O	34-40
-	O	40-41
dependent	O	41-50
HIF	O	51-54
regulation	O	55-65
operate	O	66-73
at	O	74-76
the	O	77-80
level	O	81-86
of	O	87-89
the	O	90-93
alpha	O	94-99
subunit	O	100-107
,	O	107-108
controlling	O	109-120
protein	O	121-128
stability	O	129-138
,	O	138-139
subcellular	O	140-151
localization	O	152-164
,	O	164-165
and	O	166-169
transcriptional	O	170-185
coactivator	O	186-197
recruitment	O	198-209
. 	O	209-211

We	O	0-2
have	O	3-7
conducted	O	8-17
an	O	18-20
unbiased	O	21-29
genome	O	30-36
-	O	36-37
wide	O	37-41
RNA	O	42-45
interference	O	46-58
(	O	59-60
RNAi	O	60-64
)	O	64-65
screen	O	66-72
in	O	73-75
Drosophila	O	76-86
cells	O	87-92
aimed	O	93-98
to	O	99-101
the	O	102-105
identification	O	106-120
of	O	121-123
genes	O	124-129
required	O	130-138
for	O	139-142
HIF	O	143-146
activity	O	147-155
. 	O	155-157

Drosophila	O	0-10
genome	O	11-17
-	O	17-18
wide	O	18-22
RNAi	O	23-27
screen	O	28-34
identifies	O	35-45
multiple	O	46-54
regulators	O	55-65
of	O	66-68
HIF	O	69-72
-	O	72-73
dependent	O	73-82
transcription	O	83-96
in	O	97-99
hypoxia	O	100-107
.  	O	107-110

Hypoxia	O	0-7
-	O	7-8
inducible	O	8-17
factors	O	18-25
(	O	26-27
HIFs	O	27-31
)	O	31-32
are	O	33-36
a	O	37-38
family	O	39-45
of	O	46-48
evolutionary	O	49-61
conserved	O	62-71
alpha	O	72-77
-	O	77-78
beta	O	78-82
heterodimeric	O	83-96
transcription	O	97-110
factors	O	111-118
that	O	119-123
induce	O	124-130
a	O	131-132
wide	O	133-137
range	O	138-143
of	O	144-146
genes	O	147-152
in	O	153-155
response	O	156-164
to	O	165-167
low	O	168-171
oxygen	O	172-178
tension	O	179-186
. 	O	186-188

In	O	0-2
a	O	3-4
well	O	5-9
-	O	9-10
characterized	O	10-23
Belgian	O	24-31
group	O	32-37
of	O	38-40
358	O	41-44
AD	O	45-47
patients	O	48-56
and	O	57-60
462	O	61-64
controls	O	65-73
,	O	73-74
we	O	75-77
examined	O	78-86
whether	O	87-94
genetic	O	95-102
variability	O	103-114
in	O	115-117
microRNA	O	118-126
(	O	127-128
miRNA	O	128-133
)	O	133-134
binding	O	135-142
sites	O	143-148
of	O	149-151
APP	O	152-155
and	O	156-159
BACE1	O	160-165
or	O	166-168
in	O	169-171
associated	O	172-182
miRNAs	O	183-189
influenced	O	190-200
risk	O	201-205
for	O	206-209
AD	O	210-212
.	O	212-213
Direct	O	214-220
sequencing	O	221-231
identified	O	232-242
six	O	243-246
variants	O	247-255
in	O	256-258
the	O	259-262
3	O	263-264
'	O	264-265
untranslated	O	266-278
region	O	279-285
(	O	286-287
UTR	O	287-290
)	O	290-291
of	O	292-294
APP	O	295-298
and	O	299-302
29	O	303-305
variants	O	306-314
in	O	315-317
the	O	318-321
3	O	322-323
'	O	323-324
UTR	O	325-328
of	O	329-331
BACE1	O	332-337
,	O	337-338
of	O	339-341
which	O	342-347
few	O	348-351
variants	O	352-360
were	O	361-365
restricted	O	366-376
to	O	377-379
patients	O	380-388
:	O	388-389
in	O	390-392
APP	O	393-396
;	O	396-397
4	O	398-399
variants	O	400-408
in	O	409-411
6	O	412-413
patients	O	414-422
(	O	423-424
approximately	O	425-438
2	O	439-440
%	O	440-441
)	O	441-442
and	O	443-446
in	O	447-449
BACE1	O	450-455
;	O	455-456
7	O	457-458
variants	O	459-467
in	O	468-470
11	O	471-473
patients	O	474-482
(	O	483-484
approximately	O	485-498
3	O	499-500
.	O	500-501
5	O	501-502
%	O	502-503
)	O	503-504
. 	O	504-506

Expression	O	0-10
levels	O	11-17
of	O	18-20
the	O	21-24
amyloid	O	25-32
precursor	O	33-42
protein	O	43-50
(	O	51-52
APP	O	52-55
)	O	55-56
and	O	57-60
beta	O	61-65
-	O	65-66
site	O	66-70
amyloid	O	71-78
(	O	79-80
Abeta	O	80-85
)	O	85-86
cleaving	O	87-95
enzyme	O	96-102
1	O	103-104
(	O	105-106
BACE1	O	106-111
)	O	111-112
have	O	113-117
been	O	118-122
implicated	O	123-133
in	O	134-136
Alzheimer	O	137-146
disease	O	147-154
(	O	155-156
AD	O	156-158
)	O	158-159
progression	O	160-171
. 	O	171-173

APP	O	0-3
and	O	4-7
BACE1	O	8-13
miRNA	O	14-19
genetic	O	20-27
variability	O	28-39
has	O	40-43
no	O	44-46
major	O	47-52
role	O	53-57
in	O	58-60
risk	O	61-65
for	O	66-69
Alzheimer	O	70-79
disease	O	80-87
.  	O	87-90

Further	O	0-7
genetic	O	8-15
screening	O	16-25
of	O	26-28
the	O	29-32
miR	B	33-36
-	I	36-37
29	I	37-39
cluster	O	40-47
encoding	O	48-56
the	O	57-60
miR	B	61-64
-	I	64-65
29a	I	65-68
/	I	68-69
b	I	69-70
-	I	70-71
1	I	71-72
genes	O	73-78
showed	O	79-85
10	O	86-88
variants	O	89-97
in	O	98-100
close	O	101-106
proximity	O	107-116
of	O	117-119
this	O	120-124
cluster	O	125-132
. 	O	132-134

Association	O	0-11
studies	O	12-19
using	O	20-25
all	O	26-29
common	O	30-36
variants	O	37-45
detected	O	46-54
in	O	55-57
the	O	58-61
3	O	62-63
'	O	63-64
UTR	O	65-68
of	O	69-71
BACE1	O	72-77
and	O	78-81
the	O	82-85
miR	B	86-89
-	I	89-90
29	I	90-92
gene	O	93-97
cluster	O	98-105
did	O	106-109
not	O	110-113
identify	O	114-122
an	O	123-125
association	O	126-137
with	O	138-142
AD	O	143-145
risk	O	146-150
. 	O	150-152

However	O	0-7
,	O	7-8
we	O	9-11
did	O	12-15
observe	O	16-23
statistical	O	24-35
interaction	O	36-47
between	O	48-55
rs535860	O	56-64
(	O	65-66
BACE1	O	66-71
3	O	72-73
'	O	73-74
UTR	O	75-78
)	O	78-79
and	O	80-83
rs34772568	O	84-94
(	O	95-96
near	O	96-100
miR29a	B	101-107
;	O	107-108
odds	O	109-113
ratio	O	114-119
[	O	120-121
OR	O	121-123
]	O	123-124
(	O	124-125
interaction	O	125-136
)	O	136-137
,	O	137-138
0	O	139-140
.	O	140-141
4	O	141-142
;	O	142-143
95	O	144-146
%	O	146-147
confidence	O	148-158
interval	O	159-167
[	O	168-169
CI	O	169-171
]	O	171-172
,	O	172-173
0	O	174-175
.	O	175-176
17	O	176-178
-	O	178-179
0	O	179-180
.	O	180-181
96	O	181-183
;	O	183-184
P	O	185-186
=	O	186-187
0	O	187-188
.	O	188-189
033	O	189-192
)	O	192-193
. 	O	193-195

While	O	0-5
the	O	6-9
exact	O	10-15
role	O	16-20
of	O	21-23
the	O	24-27
patient	O	28-35
-	O	35-36
specific	O	36-44
miRNA	O	45-50
variants	O	51-59
within	O	60-66
the	O	67-70
3	O	71-72
'	O	72-73
UTR	O	74-77
region	O	78-84
of	O	85-87
APP	O	88-91
and	O	92-95
BACE1	O	96-101
demands	O	102-109
further	O	110-117
analyses	O	118-126
,	O	126-127
this	O	128-132
study	O	133-138
does	O	139-143
not	O	144-147
support	O	148-155
a	O	156-157
major	O	158-163
contribution	O	164-176
of	O	177-179
miRNA	O	180-185
genetic	O	186-193
variability	O	194-205
to	O	206-208
AD	O	209-211
pathogenesis	O	212-224
.   	O	224-228

Differential	O	0-12
regulation	O	13-23
of	O	24-26
interleukin	O	27-38
-	O	38-39
1	O	39-40
receptor	O	41-49
-	O	49-50
associated	O	50-60
kinase	O	61-67
-	O	67-68
1	O	68-69
(	O	70-71
IRAK	O	71-75
-	O	75-76
1	O	76-77
)	O	77-78
and	O	79-82
IRAK	O	83-87
-	O	87-88
2	O	88-89
by	O	90-92
microRNA	B	93-101
-	I	101-102
146a	I	102-106
and	O	107-110
NF	O	111-113
-	O	113-114
kappaB	O	114-120
in	O	121-123
stressed	O	124-132
human	O	133-138
astroglial	O	139-149
cells	O	150-155
and	O	156-159
in	O	160-162
Alzheimer	O	163-172
disease	O	173-180
.  	O	180-183

Specific	O	0-8
microRNAs	O	9-18
(	O	19-20
miRNAs	O	20-26
)	O	26-27
,	O	27-28
small	O	29-34
non	O	35-38
-	O	38-39
coding	O	39-45
RNAs	O	46-50
that	O	51-55
support	O	56-63
homeostatic	O	64-75
gene	O	76-80
expression	O	81-91
,	O	91-92
are	O	93-96
significantly	O	97-110
altered	O	111-118
in	O	119-121
abundance	O	122-131
in	O	132-134
human	O	135-140
neurological	O	141-153
disorders	O	154-163
. 	O	163-165

In	O	0-2
monocytes	O	3-12
,	O	12-13
increased	O	14-23
expression	O	24-34
of	O	35-37
an	O	38-40
NF	O	41-43
-	O	43-44
κB	O	44-46
-	O	46-47
regulated	O	47-56
miRNA	B	57-62
-	I	62-63
146a	I	63-67
down	O	68-72
-	O	72-73
regulates	O	73-82
expression	O	83-93
of	O	94-96
the	O	97-100
interleukin	O	101-112
-	O	112-113
1	O	113-114
receptor	O	115-123
-	O	123-124
associated	O	124-134
kinase	O	135-141
-	O	141-142
1	O	142-143
(	O	144-145
IRAK	O	145-149
-	O	149-150
1	O	150-151
)	O	151-152
,	O	152-153
an	O	154-156
essential	O	157-166
component	O	167-176
of	O	177-179
Toll	O	180-184
-	O	184-185
like	O	185-189
/	O	189-190
IL	O	190-192
-	O	192-193
1	O	193-194
receptor	O	195-203
signaling	O	204-213
. 	O	213-215

Here	O	0-4
we	O	5-7
extend	O	8-14
those	O	15-20
observations	O	21-33
to	O	34-36
the	O	37-40
hippocampus	O	41-52
and	O	53-56
neocortex	O	57-66
of	O	67-69
Alzheimer	O	70-79
disease	O	80-87
(	O	88-89
AD	O	89-91
)	O	91-92
brain	O	93-98
and	O	99-102
to	O	103-105
stressed	O	106-114
human	O	115-120
astroglial	O	121-131
(	O	132-133
HAG	O	133-136
)	O	136-137
cells	O	138-143
in	O	144-146
primary	O	147-154
culture	O	155-162
. 	O	162-164

In	O	0-2
66	O	3-5
control	O	6-13
and	O	14-17
AD	O	18-20
samples	O	21-28
we	O	29-31
note	O	32-36
a	O	37-38
significant	O	39-50
up	O	51-53
-	O	53-54
regulation	O	54-64
of	O	65-67
miRNA	B	68-73
-	I	73-74
146a	I	74-78
coupled	O	79-86
to	O	87-89
down	O	90-94
-	O	94-95
regulation	O	95-105
of	O	106-108
IRAK	O	109-113
-	O	113-114
1	O	114-115
and	O	116-119
a	O	120-121
compensatory	O	122-134
up	O	135-137
-	O	137-138
regulation	O	138-148
of	O	149-151
IRAK	O	152-156
-	O	156-157
2	O	157-158
. 	O	158-160

Using	O	0-5
miRNA	B	6-11
-	I	11-12
146a	I	12-16
-	O	16-17
,	O	17-18
IRAK	O	19-23
-	O	23-24
1	O	24-25
-	O	25-26
,	O	26-27
or	O	28-30
IRAK	O	31-35
-	O	35-36
2	O	36-37
promoter	O	38-46
-	O	46-47
luciferase	O	47-57
reporter	O	58-66
constructs	O	67-77
,	O	77-78
we	O	79-81
observe	O	82-89
decreases	O	90-99
in	O	100-102
IRAK	O	103-107
-	O	107-108
1	O	108-109
and	O	110-113
increases	O	114-123
in	O	124-126
miRNA	B	127-132
-	I	132-133
146a	I	133-137
and	O	138-141
IRAK	O	142-146
-	O	146-147
2	O	147-148
expression	O	149-159
in	O	160-162
interleukin	O	163-174
-	O	174-175
1β	O	175-177
(	O	178-179
IL	O	179-181
-	O	181-182
1β	O	182-184
)	O	184-185
and	O	186-189
amyloid	O	190-197
-	O	197-198
β	O	198-199
-	O	199-200
42	O	200-202
(	O	203-204
Aβ42	O	204-208
)	O	208-209
peptide	O	210-217
-	O	217-218
stressed	O	218-226
HAG	O	227-230
cells	O	231-236
. 	O	236-238

NF	O	0-2
-	O	2-3
κB	O	3-5
-	O	5-6
mediated	O	6-14
transcriptional	O	15-30
control	O	31-38
of	O	39-41
human	O	42-47
IRAK	O	48-52
-	O	52-53
2	O	53-54
was	O	55-58
localized	O	59-68
to	O	69-71
between	O	72-79
-	O	80-81
119	O	81-84
and	O	85-88
+	O	89-90
12	O	90-92
bp	O	93-95
of	O	96-98
the	O	99-102
immediate	O	103-112
IRAK	O	113-117
-	O	117-118
2	O	118-119
promoter	O	120-128
. 	O	128-130

The	O	0-3
NF	O	4-6
-	O	6-7
κB	O	7-9
inhibitors	O	10-20
curcumin	O	21-29
,	O	29-30
pyrrolidine	O	31-42
dithiocarbamate	O	43-58
or	O	59-61
CAY10512	O	62-70
abrogated	O	71-80
both	O	81-85
IRAK	O	86-90
-	O	90-91
2	O	91-92
and	O	93-96
miRNA	B	97-102
-	I	102-103
146a	I	103-107
expression	O	108-118
,	O	118-119
whereas	O	120-127
IRAK	O	128-132
-	O	132-133
1	O	133-134
was	O	135-138
up	O	139-141
-	O	141-142
regulated	O	142-151
. 	O	151-153

Incubation	O	0-10
of	O	11-13
a	O	14-15
protected	O	16-25
antisense	O	26-35
miRNA	O	36-41
-	O	41-42
146a	O	42-46
was	O	47-50
found	O	51-56
to	O	57-59
inhibit	O	60-67
miRNA	B	68-73
-	I	73-74
146a	I	74-78
and	O	79-82
restore	O	83-90
IRAK	O	91-95
-	O	95-96
1	O	96-97
,	O	97-98
whereas	O	99-106
IRAK	O	107-111
-	O	111-112
2	O	112-113
remained	O	114-122
unaffected	O	123-133
. 	O	133-135

These	O	0-5
data	O	6-10
suggest	O	11-18
a	O	19-20
significantly	O	21-34
independent	O	35-46
regulation	O	47-57
of	O	58-60
IRAK	O	61-65
-	O	65-66
1	O	66-67
and	O	68-71
IRAK	O	72-76
-	O	76-77
2	O	77-78
in	O	79-81
AD	O	82-84
and	O	85-88
in	O	89-91
IL	O	92-94
-	O	94-95
1β	O	95-97
+	O	97-98
Aβ42	O	98-102
peptide	O	103-110
-	O	110-111
stressed	O	111-119
HAG	O	120-123
cells	O	124-129
and	O	130-133
that	O	134-138
an	O	139-141
inducible	O	142-151
,	O	151-152
NF	O	153-155
-	O	155-156
κB	O	156-158
-	O	158-159
sensitive	O	159-168
,	O	168-169
miRNA	B	170-175
-	I	175-176
146a	I	176-180
-	O	180-181
mediated	O	181-189
down	O	190-194
-	O	194-195
regulation	O	195-205
of	O	206-208
IRAK	O	209-213
-	O	213-214
1	O	214-215
coupled	O	216-223
to	O	224-226
an	O	227-229
NF	O	230-232
-	O	232-233
κB	O	233-235
-	O	235-236
induced	O	236-243
up	O	244-246
-	O	246-247
regulation	O	247-257
of	O	258-260
IRAK	O	261-265
-	O	265-266
2	O	266-267
expression	O	268-278
drives	O	279-285
an	O	286-288
extensively	O	289-300
sustained	O	301-310
inflammatory	O	311-323
response	O	324-332
. 	O	332-334

The	O	0-3
combinatorial	O	4-17
use	O	18-21
of	O	22-24
NF	O	25-27
-	O	27-28
κB	O	28-30
inhibitors	O	31-41
with	O	42-46
miRNA	B	47-52
-	I	52-53
146a	I	53-57
or	O	58-60
antisense	O	61-70
miRNA	O	71-76
-	O	76-77
146a	O	77-81
may	O	82-85
have	O	86-90
potential	O	91-100
as	O	101-103
a	O	104-105
bi	O	106-108
-	O	108-109
pronged	O	109-116
therapeutic	O	117-128
strategy	O	129-137
directed	O	138-146
against	O	147-154
IRAK	O	155-159
-	O	159-160
2	O	160-161
-	O	161-162
driven	O	162-168
pathogenic	O	169-179
signaling	O	180-189
.   	O	189-193

The	O	0-3
interactive	O	4-15
signaling	O	16-25
of	O	26-28
NF	O	29-31
-	O	31-32
κB	O	32-34
and	O	35-38
miRNA	B	39-44
-	I	44-45
146a	I	45-49
further	O	50-57
illustrate	O	58-68
interplay	O	69-78
between	O	79-86
inducible	O	87-96
transcription	O	97-110
factors	O	111-118
and	O	119-122
pro	O	123-126
-	O	126-127
inflammatory	O	127-139
miRNAs	O	140-146
that	O	147-151
regulate	O	152-160
brain	O	161-166
IRAK	O	167-171
expression	O	172-182
. 	O	182-184

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
short	O	23-28
noncoding	O	29-38
regulatory	O	39-49
RNA	O	50-53
molecules	O	54-63
that	O	64-68
modulate	O	69-77
protein	O	78-85
expression	O	86-96
by	O	97-99
inhibiting	O	100-110
mRNA	O	111-115
translation	O	116-127
or	O	128-130
promoting	O	131-140
mRNA	O	141-145
degradation	O	146-157
. 	O	157-159

miR	B	0-3
-	I	3-4
34a	I	4-7
,	O	7-8
a	O	9-10
microRNA	O	11-19
up	O	20-22
-	O	22-23
regulated	O	23-32
in	O	33-35
a	O	36-37
double	O	38-44
transgenic	O	45-55
mouse	O	56-61
model	O	62-67
of	O	68-70
Alzheimer	O	71-80
'	O	80-81
s	O	81-82
disease	O	83-90
,	O	90-91
inhibits	O	92-100
bcl2	O	101-105
translation	O	106-117
.  	O	117-120

During	O	0-6
a	O	7-8
research	O	9-17
for	O	18-21
miRNAs	O	22-28
that	O	29-33
are	O	34-37
differentially	O	38-52
expressed	O	53-62
in	O	63-65
cerebral	O	66-74
cortex	O	75-81
of	O	82-84
APPswe	O	85-91
/	O	91-92
PSDeltaE9	O	92-101
mice	O	102-106
(	O	107-108
a	O	108-109
model	O	110-115
for	O	116-119
Alzheimer	O	120-129
'	O	129-130
s	O	130-131
disease	O	132-139
)	O	139-140
and	O	141-144
age	O	145-148
-	O	148-149
matched	O	149-156
controls	O	157-165
,	O	165-166
one	O	167-170
candidate	O	171-180
miRNA	O	181-186
that	O	187-191
is	O	192-194
relatively	O	195-205
highly	O	206-212
expressed	O	213-222
,	O	222-223
miR	B	224-227
-	I	227-228
34a	I	228-231
,	O	231-232
was	O	233-236
studied	O	237-244
further	O	245-252
because	O	253-260
sequence	O	261-269
analysis	O	270-278
suggested	O	279-288
a	O	289-290
likely	O	291-297
interaction	O	298-309
with	O	310-314
the	O	315-318
3	O	319-320
'	O	320-321
-	O	321-322
untranslated	O	322-334
region	O	335-341
of	O	342-344
bcl2	O	345-349
mRNA	O	350-354
. 	O	354-356

However	O	0-7
,	O	7-8
little	O	9-15
is	O	16-18
understood	O	19-29
about	O	30-35
the	O	36-39
roles	O	40-45
of	O	46-48
miRNAs	O	49-55
in	O	56-58
Alzheimer	O	59-68
'	O	68-69
s	O	69-70
disease	O	71-78
. 	O	78-80

No	O	0-2
effect	O	3-9
on	O	10-12
bcl2	O	13-17
mRNA	O	18-22
level	O	23-28
was	O	29-32
observed	O	33-41
. 	O	41-43

We	O	0-2
show	O	3-7
that	O	8-12
the	O	13-16
expression	O	17-27
of	O	28-30
miR	B	31-34
-	I	34-35
34a	I	35-38
is	O	39-41
inversely	O	42-51
correlated	O	52-62
with	O	63-67
the	O	68-71
protein	O	72-79
level	O	80-85
of	O	86-88
bcl2	O	89-93
in	O	94-96
APPswe	O	97-103
/	O	103-104
PSDeltaE9	O	104-113
mice	O	114-118
and	O	119-122
age	O	123-126
-	O	126-127
matched	O	127-134
controls	O	135-143
,	O	143-144
and	O	145-148
miR	B	149-152
-	I	152-153
34a	I	153-156
expression	O	157-167
directly	O	168-176
inhibits	O	177-185
bcl2	O	186-190
translation	O	191-202
in	O	203-205
SH	O	206-208
-	O	208-209
SY5Y	O	209-213
cells	O	214-219
. 	O	219-221

Consistently	O	0-12
,	O	12-13
miR	B	14-17
-	I	17-18
34a	I	18-21
knockdown	O	22-31
through	O	32-39
antisense	O	40-49
LNA	O	50-53
oligonucleotides	O	54-70
increased	O	71-80
the	O	81-84
level	O	85-90
of	O	91-93
bcl2	O	94-98
protein	O	99-106
in	O	107-109
SH	O	110-112
-	O	112-113
SY5Y	O	113-117
cells	O	118-123
,	O	123-124
which	O	125-130
was	O	131-134
accompanied	O	135-146
by	O	147-149
a	O	150-151
decrease	O	152-160
of	O	161-163
active	O	164-170
caspase	O	171-178
-	O	178-179
3	O	179-180
. 	O	180-182

Western	O	0-7
blot	O	8-12
analysis	O	13-21
of	O	22-24
active	O	25-31
caspase	O	32-39
-	O	39-40
3	O	40-41
showed	O	42-48
higher	O	49-55
levels	O	56-62
in	O	63-65
APPswe	O	66-72
/	O	72-73
PSDeltaE9	O	73-82
mice	O	83-87
and	O	88-91
stable	O	92-98
transfecant	O	99-110
cell	O	111-115
line	O	116-120
of	O	121-123
miR	B	124-127
-	I	127-128
34a	I	128-131
than	O	132-136
in	O	137-139
controls	O	140-148
. 	O	148-150

These	O	0-5
findings	O	6-14
suggested	O	15-24
that	O	25-29
bcl2	O	30-34
is	O	35-37
an	O	38-40
important	O	41-50
functional	O	51-61
target	O	62-68
for	O	69-72
miR	B	73-76
-	I	76-77
34a	I	77-80
,	O	80-81
and	O	82-85
the	O	86-89
abnormal	O	90-98
expression	O	99-109
of	O	110-112
miR	B	113-116
-	I	116-117
34a	I	117-120
may	O	121-124
contribute	O	125-135
to	O	136-138
the	O	139-142
pathogenesis	O	143-155
of	O	156-158
Alzheimer	O	159-168
'	O	168-169
s	O	169-170
disease	O	171-178
,	O	178-179
at	O	180-182
least	O	183-188
in	O	189-191
part	O	192-196
by	O	197-199
affecting	O	200-209
the	O	210-213
expression	O	214-224
of	O	225-227
bcl2	O	228-232
.   	O	232-236

Therein	O	0-7
lies	O	8-12
the	O	13-16
therapeutic	O	17-28
potential	O	29-38
of	O	39-41
miRNA	O	42-47
,	O	47-48
as	O	49-51
it	O	52-54
may	O	55-58
now	O	59-62
be	O	63-65
possible	O	66-74
to	O	75-77
induce	O	78-84
or	O	85-87
inhibit	O	88-95
RNAi	O	96-100
in	O	101-103
a	O	104-105
given	O	106-111
diseased	O	112-120
cell	O	121-125
population	O	126-136
by	O	137-139
controlling	O	140-151
the	O	152-155
cells	O	156-161
'	O	161-162
miRNA	O	163-168
expression	O	169-179
profile	O	180-187
. 	O	187-189

This	O	0-4
review	O	5-11
outlines	O	12-20
the	O	21-24
potential	O	25-34
of	O	35-37
miRNA	O	38-43
as	O	44-46
a	O	47-48
therapeutic	O	49-60
strategy	O	61-69
against	O	70-77
high	O	78-82
-	O	82-83
grade	O	83-88
gliomas	O	89-96
,	O	96-97
and	O	98-101
also	O	102-106
the	O	107-110
technological	O	111-124
hurdles	O	125-132
that	O	133-137
need	O	138-142
to	O	143-145
be	O	146-148
addressed	O	149-158
before	O	159-165
this	O	166-170
promising	O	171-180
technique	O	181-190
can	O	191-194
be	O	195-197
administered	O	198-210
in	O	211-213
a	O	214-215
clinical	O	216-224
setting	O	225-232
.   	O	232-236

Thus	O	0-4
,	O	4-5
miRNA	O	6-11
can	O	12-15
be	O	16-18
considered	O	19-29
the	O	30-33
cells	O	34-39
'	O	39-40
answer	O	41-47
to	O	48-50
siRNA	O	51-56
. 	O	56-58

Discovered	O	0-10
over	O	11-15
a	O	16-17
decade	O	18-24
ago	O	25-28
,	O	28-29
miRNA	O	30-35
is	O	36-38
fast	O	39-43
becoming	O	44-52
recognized	O	53-63
as	O	64-66
crucial	O	67-74
in	O	75-77
regulating	O	78-88
gene	O	89-93
expression	O	94-104
in	O	105-107
cancers	O	108-115
. 	O	115-117

Malignant	O	0-9
brain	O	10-15
tumors	O	16-22
,	O	22-23
including	O	24-33
high	O	34-38
-	O	38-39
grade	O	39-44
gliomas	O	45-52
,	O	52-53
are	O	54-57
among	O	58-63
the	O	64-67
most	O	68-72
lethal	O	73-79
of	O	80-82
all	O	83-86
cancers	O	87-94
. 	O	94-96

MicroRNA	O	0-8
and	O	9-12
brain	O	13-18
tumors	O	19-25
:	O	25-26
a	O	27-28
cause	O	29-34
and	O	35-38
a	O	39-40
cure	O	41-45
?  	O	45-48

MicroRNA	O	0-8
(	O	9-10
miRNA	O	10-15
)	O	15-16
,	O	16-17
an	O	18-20
endogenously	O	21-33
expressed	O	34-43
form	O	44-48
of	O	49-51
siRNA	O	52-57
,	O	57-58
not	O	59-62
only	O	63-67
presents	O	68-76
an	O	77-79
alternate	O	80-89
method	O	90-96
to	O	97-99
induce	O	100-106
RNAi	O	107-111
in	O	112-114
a	O	115-116
given	O	117-122
diseased	O	123-131
tissue	O	132-138
or	O	139-141
organ	O	142-147
,	O	147-148
but	O	149-152
also	O	153-157
exposes	O	158-165
a	O	166-167
unique	O	168-174
set	O	175-178
of	O	179-181
diagnostic	O	182-192
markers	O	193-200
that	O	201-205
can	O	206-209
be	O	210-212
used	O	213-217
to	O	218-220
identify	O	221-229
,	O	229-230
and	O	231-234
then	O	235-239
differentiate	O	240-253
between	O	254-261
tumor	O	262-267
grades	O	268-274
. 	O	274-276

However	O	0-7
,	O	7-8
practical	O	9-18
difficulties	O	19-31
in	O	32-34
tissue	O	35-41
-	O	41-42
or	O	43-45
organ	O	46-51
-	O	51-52
specific	O	52-60
targeting	O	61-70
of	O	71-73
therapeutic	O	74-85
quantities	O	86-96
of	O	97-99
siRNA	O	100-105
still	O	106-111
preclude	O	112-120
its	O	121-124
applicability	O	125-138
in	O	139-141
a	O	142-143
clinical	O	144-152
setting	O	153-160
. 	O	160-162

With	O	0-4
the	O	5-8
discovery	O	9-18
of	O	19-21
RNA	O	22-25
interference	O	26-38
(	O	39-40
RNAi	O	40-44
)	O	44-45
for	O	46-49
target	O	50-56
-	O	56-57
specific	O	57-65
gene	O	66-70
silencing	O	71-80
via	O	81-84
small	O	85-90
interfering	O	91-102
RNA	O	103-106
(	O	107-108
siRNA	O	108-113
)	O	113-114
,	O	114-115
a	O	116-117
novel	O	118-123
method	O	124-130
to	O	131-133
target	O	134-140
malignant	O	141-150
gliomas	O	151-158
has	O	159-162
been	O	163-167
exposed	O	168-175
,	O	175-176
an	O	177-179
endeavor	O	180-188
that	O	189-193
is	O	194-196
aggressively	O	197-209
being	O	210-215
carried	O	216-223
out	O	224-227
in	O	228-230
numerous	O	231-239
laboratories	O	240-252
. 	O	252-254

Despite	O	0-7
considerable	O	8-20
advances	O	21-29
,	O	29-30
including	O	31-40
multi	O	41-46
-	O	46-47
modal	O	47-52
treatments	O	53-63
with	O	64-68
surgery	O	69-76
,	O	76-77
radiotherapy	O	78-90
,	O	90-91
and	O	92-95
chemotherapy	O	96-108
,	O	108-109
the	O	110-113
overall	O	114-121
prognosis	O	122-131
remains	O	132-139
dismal	O	140-146
for	O	147-150
patients	O	151-159
diagnosed	O	160-169
with	O	170-174
these	O	175-180
tumors	O	181-187
. 	O	187-189

The	O	0-3
relative	O	4-12
expression	O	13-23
of	O	24-26
miRNAs	O	27-33
was	O	34-37
measured	O	38-46
by	O	47-49
real	O	50-54
-	O	54-55
time	O	55-59
PCR	O	60-63
using	O	64-69
RNU44	O	70-75
and	O	76-79
RNU49	O	80-85
as	O	86-88
endogenous	O	89-99
controls	O	100-108
. 	O	108-110

Relative	O	0-8
quantification	O	9-23
of	O	24-26
miRNA	O	27-32
expression	O	33-43
was	O	44-47
calculated	O	48-58
using	O	59-64
the	O	65-68
2	O	69-70
(	O	70-71
-	O	71-72
DeltaDeltaCt	O	72-84
)	O	84-85
method	O	86-92
. 	O	92-94

Objective	O	0-9
:	O	9-10
The	O	11-14
aim	O	15-18
of	O	19-21
the	O	22-25
study	O	26-31
was	O	32-35
to	O	36-38
analyze	O	39-46
the	O	47-50
differential	O	51-63
expression	O	64-74
of	O	75-77
let	B	78-81
-	I	81-82
7a	I	82-84
,	O	84-85
miR	B	86-89
-	I	89-90
15a	I	90-93
,	O	93-94
miR	B	95-98
-	I	98-99
16	I	99-101
,	O	101-102
miR	B	103-106
-	I	106-107
21	I	107-109
,	O	109-110
miR	B	111-114
-	I	114-115
141	I	115-118
,	O	118-119
miR	B	120-123
-	I	123-124
143	I	124-127
,	O	127-128
miR	B	129-132
-	I	132-133
145	I	133-136
,	O	136-137
and	O	138-141
miR	B	142-145
-	I	145-146
150	I	146-149
in	O	150-152
corticotropinomas	O	153-170
and	O	171-174
normal	O	175-181
pituitary	O	182-191
tissue	O	192-198
and	O	199-202
verify	O	203-209
whether	O	210-217
their	O	218-223
profile	O	224-231
of	O	232-234
expression	O	235-245
correlates	O	246-256
with	O	257-261
tumor	O	262-267
size	O	268-272
or	O	273-275
remission	O	276-285
after	O	286-291
treatment	O	292-301
. 	O	301-303

MATERIAL	O	0-8
AND	O	9-12
METHODS	O	13-20
:	O	20-21
ACTH	O	22-26
-	O	26-27
secreting	O	27-36
pituitary	O	37-46
tumor	O	47-52
samples	O	53-60
were	O	61-65
obtained	O	66-74
during	O	75-81
transphenoidal	O	82-96
surgery	O	97-104
from	O	105-109
patients	O	110-118
with	O	119-123
Cushing	O	124-131
disease	O	132-139
and	O	140-143
normal	O	144-150
pituitary	O	151-160
tissues	O	161-168
from	O	169-173
autopsies	O	174-183
. 	O	183-185

CONCLUSION	O	0-10
:	O	10-11
Our	O	12-15
results	O	16-23
support	O	24-31
the	O	32-35
possibility	O	36-47
that	O	48-52
altered	O	53-60
miRNA	O	61-66
expression	O	67-77
profile	O	78-85
might	O	86-91
be	O	92-94
involved	O	95-103
in	O	104-106
corticotrophic	O	107-121
tumorigenesis	O	122-135
. 	O	135-137

RESULTS	O	0-7
:	O	7-8
We	O	9-11
found	O	12-17
underexpression	O	18-33
of	O	34-36
miR	B	37-40
-	I	40-41
145	I	41-44
(	O	45-46
2	O	46-47
.	O	47-48
0	O	48-49
-	O	49-50
fold	O	50-54
;	O	54-55
P	O	56-57
=	O	58-59
0	O	60-61
.	O	61-62
04	O	62-64
)	O	64-65
,	O	65-66
miR	B	67-70
-	I	70-71
21	I	71-73
(	O	74-75
2	O	75-76
.	O	76-77
4	O	77-78
-	O	78-79
fold	O	79-83
;	O	83-84
P	O	85-86
=	O	87-88
0	O	89-90
.	O	90-91
004	O	91-94
)	O	94-95
,	O	95-96
miR	B	97-100
-	I	100-101
141	I	101-104
(	O	105-106
2	O	106-107
.	O	107-108
6	O	108-109
-	O	109-110
fold	O	110-114
;	O	114-115
P	O	116-117
=	O	118-119
0	O	120-121
.	O	121-122
02	O	122-124
)	O	124-125
,	O	125-126
let	B	127-130
-	I	130-131
7a	I	131-133
(	O	134-135
3	O	135-136
.	O	136-137
3	O	137-138
-	O	138-139
fold	O	139-143
;	O	143-144
P	O	145-146
=	O	147-148
0	O	149-150
.	O	150-151
003	O	151-154
)	O	154-155
,	O	155-156
miR	B	157-160
-	I	160-161
150	I	161-164
(	O	165-166
3	O	166-167
.	O	167-168
8	O	168-169
-	O	169-170
fold	O	170-174
;	O	174-175
P	O	176-177
=	O	178-179
0	O	180-181
.	O	181-182
04	O	182-184
)	O	184-185
,	O	185-186
miR	B	187-190
-	I	190-191
15a	I	191-194
(	O	195-196
4	O	196-197
.	O	197-198
5	O	198-199
-	O	199-200
fold	O	200-204
;	O	204-205
P	O	206-207
=	O	208-209
0	O	210-211
.	O	211-212
03	O	212-214
)	O	214-215
,	O	215-216
miR	B	217-220
-	I	220-221
16	I	221-223
(	O	224-225
5	O	225-226
.	O	226-227
0	O	227-228
-	O	228-229
fold	O	229-233
;	O	233-234
P	O	235-236
=	O	237-238
0	O	239-240
.	O	240-241
004	O	241-244
)	O	244-245
,	O	245-246
and	O	247-250
miR	B	251-254
-	I	254-255
143	I	255-258
(	O	259-260
6	O	260-261
.	O	261-262
4	O	262-263
-	O	263-264
fold	O	264-268
;	O	268-269
P	O	270-271
=	O	272-273
0	O	274-275
.	O	275-276
004	O	276-279
)	O	279-280
in	O	281-283
ACTH	O	284-288
-	O	288-289
secreting	O	289-298
pituitary	O	299-308
tumors	O	309-315
when	O	316-320
compared	O	321-329
to	O	330-332
normal	O	333-339
pituitary	O	340-349
tissues	O	350-357
. 	O	357-359

There	O	0-5
were	O	6-10
no	O	11-13
differences	O	14-25
between	O	26-33
miRNA	O	34-39
expression	O	40-50
and	O	51-54
tumor	O	55-60
size	O	61-65
as	O	66-68
well	O	69-73
as	O	74-76
miRNA	O	77-82
expression	O	83-93
and	O	94-97
ratio	O	98-103
of	O	104-106
remission	O	107-116
after	O	117-122
surgery	O	123-130
,	O	130-131
except	O	132-138
in	O	139-141
patients	O	142-150
presenting	O	151-161
lower	O	162-167
miR	B	168-171
-	I	171-172
141	I	172-175
expression	O	176-186
who	O	187-190
showed	O	191-197
a	O	198-199
better	O	200-206
chance	O	207-213
of	O	214-216
remission	O	217-226
. 	O	226-228

MicroRNAs	O	0-9
differentially	O	10-24
expressed	O	25-34
in	O	35-37
ACTH	O	38-42
-	O	42-43
secreting	O	43-52
pituitary	O	53-62
tumors	O	63-69
.  	O	69-72

More	O	0-4
than	O	5-9
50	O	10-12
%	O	12-13
of	O	14-16
miRNA	O	17-22
genes	O	23-28
are	O	29-32
located	O	33-40
in	O	41-43
cancer	O	44-50
-	O	50-51
associated	O	51-61
genomic	O	62-69
regions	O	70-77
or	O	78-80
in	O	81-83
fragile	O	84-91
sites	O	92-97
of	O	98-100
the	O	101-104
genome	O	105-111
. 	O	111-113

CONTEXT	O	0-7
:	O	7-8
MicroRNAs	O	9-18
(	O	19-20
miRNAs	O	20-26
)	O	26-27
are	O	28-31
small	O	32-37
noncoding	O	38-47
RNAs	O	48-52
,	O	52-53
functioning	O	54-65
as	O	66-68
antisense	O	69-78
regulators	O	79-89
of	O	90-92
gene	O	93-97
expression	O	98-108
by	O	109-111
targeting	O	112-121
mRNA	O	122-126
and	O	127-130
contributing	O	131-143
to	O	144-146
cancer	O	147-153
development	O	154-165
and	O	166-169
progression	O	170-181
. 	O	181-183

However	O	0-7
,	O	7-8
the	O	9-12
lack	O	13-17
of	O	18-20
knowledge	O	21-30
about	O	31-36
miRNA	O	37-42
target	O	43-49
genes	O	50-55
postpones	O	56-65
full	O	66-70
understanding	O	71-84
of	O	85-87
the	O	88-91
biological	O	92-102
functions	O	103-112
of	O	113-115
down	O	116-120
-	O	120-121
regulated	O	121-130
or	O	131-133
up	O	134-136
-	O	136-137
regulated	O	137-146
miRNAs	O	147-153
in	O	154-156
corticotropinomas	O	157-174
.   	O	174-178

Brain	O	0-5
and	O	6-9
blood	O	10-15
microRNA	O	16-24
expression	O	25-35
profiling	O	36-45
of	O	46-48
ischemic	O	49-57
stroke	O	58-64
,	O	64-65
intracerebral	O	66-79
hemorrhage	O	80-90
,	O	90-91
and	O	92-95
kainate	O	96-103
seizures	O	104-112
.  	O	112-115

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
regulate	O	19-27
gene	O	28-32
expression	O	33-43
and	O	44-47
have	O	48-52
a	O	53-54
critical	O	55-63
role	O	64-68
in	O	69-71
many	O	72-76
biologic	O	77-85
and	O	86-89
pathologic	O	90-100
processes	O	101-110
. 	O	110-112

The	O	0-3
results	O	4-11
show	O	12-16
the	O	17-20
possible	O	21-29
use	O	30-33
of	O	34-36
blood	O	37-42
miRNAs	O	43-49
as	O	50-52
biomarkers	O	53-63
for	O	64-67
brain	O	68-73
injury	O	74-80
;	O	80-81
that	O	82-86
selected	O	87-95
blood	O	96-101
miRNAs	O	102-108
may	O	109-112
correlate	O	113-122
with	O	123-127
miRNA	O	128-133
changes	O	134-141
in	O	142-144
the	O	145-148
brain	O	149-154
;	O	154-155
and	O	156-159
that	O	160-164
many	O	165-169
of	O	170-172
the	O	173-176
mRNAs	O	177-182
,	O	182-183
previously	O	184-194
shown	O	195-200
to	O	201-203
be	O	204-206
regulated	O	207-216
in	O	217-219
brain	O	220-225
and	O	226-229
blood	O	230-235
after	O	236-241
brain	O	242-247
injury	O	248-254
,	O	254-255
are	O	256-259
likely	O	260-266
accounted	O	267-276
for	O	277-280
by	O	281-283
changes	O	284-291
in	O	292-294
miRNA	O	295-300
expression	O	301-311
.   	O	311-315

A	O	0-1
few	O	2-5
miRNAs	O	6-12
(	O	13-14
e	O	14-15
.	O	15-16
g	O	16-17
.	O	17-18
,	O	18-19
miR	B	20-23
-	I	23-24
298	I	24-27
,	O	27-28
miR	B	29-32
-	I	32-33
155	I	33-36
,	O	36-37
and	O	38-41
miR	B	42-45
-	I	45-46
362	I	46-49
-	I	49-50
3p	I	50-52
)	O	52-53
were	O	54-58
upregulated	O	59-70
or	O	71-73
downregulated	O	74-87
more	O	88-92
than	O	93-97
twofold	O	98-105
in	O	106-108
both	O	109-113
brain	O	114-119
and	O	120-123
blood	O	124-129
after	O	130-135
several	O	136-143
different	O	144-153
injuries	O	154-162
. 	O	162-164

Many	O	0-4
miRNAs	O	5-11
changed	O	12-19
more	O	20-24
than	O	25-29
1	O	30-31
.	O	31-32
5	O	32-33
-	O	33-34
fold	O	34-38
in	O	39-41
brain	O	42-47
and	O	48-51
blood	O	52-57
after	O	58-63
each	O	64-68
experimental	O	69-81
manipulation	O	82-94
,	O	94-95
and	O	96-99
several	O	100-107
miRNAs	O	108-114
were	O	115-119
upregulated	O	120-131
or	O	132-134
downregulated	O	135-148
in	O	149-151
both	O	152-156
brain	O	157-162
and	O	163-166
blood	O	167-172
after	O	173-178
a	O	179-180
given	O	181-186
injury	O	187-193
. 	O	193-195

MicroRNA	O	0-8
response	O	9-17
profiles	O	18-26
were	O	27-31
different	O	32-41
for	O	42-45
each	O	46-50
condition	O	51-60
. 	O	60-62

Brain	O	0-5
and	O	6-9
whole	O	10-15
-	O	15-16
blood	O	16-21
miRNA	O	22-27
expression	O	28-38
profiles	O	39-47
were	O	48-52
assessed	O	53-61
24	O	62-64
h	O	65-66
later	O	67-72
using	O	73-78
TaqMan	O	79-85
rodent	O	86-92
miRNA	O	93-98
arrays	O	99-105
. 	O	105-107

Adult	O	0-5
,	O	5-6
untouched	O	7-16
,	O	16-17
control	O	18-25
rats	O	26-30
were	O	31-35
compared	O	36-44
with	O	45-49
rats	O	50-54
with	O	55-59
sham	O	60-64
surgeries	O	65-74
,	O	74-75
ischemic	O	76-84
strokes	O	85-92
,	O	92-93
brain	O	94-99
hemorrhage	O	100-110
(	O	111-112
lysed	O	112-117
blood	O	118-123
,	O	123-124
fresh	O	125-130
blood	O	131-136
,	O	136-137
or	O	138-140
thrombin	O	141-149
)	O	149-150
,	O	150-151
and	O	152-155
kainate	O	156-163
-	O	163-164
induced	O	164-171
seizures	O	172-180
. 	O	180-182

We	O	0-2
hypothesized	O	3-15
that	O	16-20
miRNA	O	21-26
expression	O	27-37
profiles	O	38-46
in	O	47-49
injured	O	50-57
brain	O	58-63
(	O	64-65
hippocampus	O	65-76
)	O	76-77
would	O	78-83
show	O	84-88
common	O	89-95
as	O	96-98
well	O	99-103
as	O	104-106
unique	O	107-113
profiles	O	114-122
when	O	123-127
compared	O	128-136
with	O	137-141
those	O	142-147
of	O	148-150
blood	O	151-156
. 	O	156-158

A	O	0-1
MicroRNA	O	2-10
feedback	O	11-19
circuit	O	20-27
in	O	28-30
midbrain	O	31-39
dopamine	O	40-48
neurons	O	49-56
.  	O	56-59

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
evolutionarily	O	23-37
conserved	O	38-47
,	O	47-48
18	O	49-51
-	O	51-52
to	O	53-55
25	O	56-58
-	O	58-59
nucleotide	O	59-69
,	O	69-70
non	O	71-74
-	O	74-75
protein	O	75-82
coding	O	83-89
transcripts	O	90-101
that	O	102-106
posttranscriptionally	O	107-128
regulate	O	129-137
gene	O	138-142
expression	O	143-153
during	O	154-160
development	O	161-172
. 	O	172-174

miRNAs	O	0-6
also	O	7-11
occur	O	12-17
in	O	18-20
postmitotic	O	21-32
cells	O	33-38
,	O	38-39
such	O	40-44
as	O	45-47
neurons	O	48-55
in	O	56-58
the	O	59-62
mammalian	O	63-72
central	O	73-80
nervous	O	81-88
system	O	89-95
,	O	95-96
but	O	97-100
their	O	101-106
function	O	107-115
is	O	116-118
less	O	119-123
well	O	124-128
characterized	O	129-142
. 	O	142-144

We	O	0-2
investigated	O	3-15
the	O	16-19
role	O	20-24
of	O	25-27
miRNAs	O	28-34
in	O	35-37
mammalian	O	38-47
midbrain	O	48-56
dopaminergic	O	57-69
neurons	O	70-77
(	O	78-79
DNs	O	79-82
)	O	82-83
. 	O	83-85

We	O	0-2
identified	O	3-13
a	O	14-15
miRNA	O	16-21
,	O	21-22
miR	B	23-26
-	I	26-27
133b	I	27-31
,	O	31-32
that	O	33-37
is	O	38-40
specifically	O	41-53
expressed	O	54-63
in	O	64-66
midbrain	O	67-75
DNs	O	76-79
and	O	80-83
is	O	84-86
deficient	O	87-96
in	O	97-99
midbrain	O	100-108
tissue	O	109-115
from	O	116-120
patients	O	121-129
with	O	130-134
Parkinson	O	135-144
'	O	144-145
s	O	145-146
disease	O	147-154
. 	O	154-156

miR	B	0-3
-	I	3-4
133b	I	4-8
regulates	O	9-18
the	O	19-22
maturation	O	23-33
and	O	34-37
function	O	38-46
of	O	47-49
midbrain	O	50-58
DNs	O	59-62
within	O	63-69
a	O	70-71
negative	O	72-80
feedback	O	81-89
circuit	O	90-97
that	O	98-102
includes	O	103-111
the	O	112-115
paired	O	116-122
-	O	122-123
like	O	123-127
homeodomain	O	128-139
transcription	O	140-153
factor	O	154-160
Pitx3	O	161-166
. 	O	166-168

We	O	0-2
propose	O	3-10
a	O	11-12
role	O	13-17
for	O	18-21
this	O	22-26
feedback	O	27-35
circuit	O	36-43
in	O	44-46
the	O	47-50
fine	O	51-55
-	O	55-56
tuning	O	56-62
of	O	63-65
dopaminergic	O	66-78
behaviors	O	79-88
such	O	89-93
as	O	94-96
locomotion	O	97-107
.   	O	107-111

Our	O	0-3
results	O	4-11
implicate	O	12-21
deregulated	O	22-33
synthesis	O	34-43
of	O	44-46
E2F1	O	47-51
/	O	51-52
DP	O	52-54
caused	O	55-61
by	O	62-64
the	O	65-68
miRNA	O	69-74
pathway	O	75-82
impairment	O	83-93
as	O	94-96
a	O	97-98
key	O	99-102
event	O	103-108
in	O	109-111
LRRK2	O	112-117
pathogenesis	O	118-130
and	O	131-134
suggest	O	135-142
novel	O	143-148
miRNA	O	149-154
-	O	154-155
based	O	155-160
therapeutic	O	161-172
strategies	O	173-183
.   	O	183-187

Further	O	0-7
,	O	7-8
pathogenic	O	9-19
LRRK2	O	20-25
promoted	O	26-34
the	O	35-38
association	O	39-50
of	O	51-53
phospho	O	54-61
-	O	61-62
4E	O	62-64
-	O	64-65
BP1	O	65-68
with	O	69-73
hAgo2	O	74-79
. 	O	79-81

The	O	0-3
molecular	O	4-13
mechanism	O	14-23
of	O	24-26
LRRK2	O	27-32
action	O	33-39
is	O	40-42
not	O	43-46
known	O	47-52
. 	O	52-54

Here	O	0-4
we	O	5-7
show	O	8-12
that	O	13-17
LRRK2	O	18-23
interacts	O	24-33
with	O	34-38
the	O	39-42
microRNA	O	43-51
(	O	52-53
miRNA	O	53-58
)	O	58-59
pathway	O	60-67
to	O	68-70
regulate	O	71-79
protein	O	80-87
synthesis	O	88-97
. 	O	97-99

Drosophila	O	0-10
e2f1	O	11-15
and	O	16-19
dp	O	20-22
messenger	O	23-32
RNAs	O	33-37
are	O	38-41
translationally	O	42-57
repressed	O	58-67
by	O	68-70
let	B	71-74
-	I	74-75
7	I	75-76
and	O	77-80
miR	B	81-84
-	I	84-85
184	I	85-88
*	O	88-89
,	O	89-90
respectively	O	91-103
. 	O	103-105

Pathogenic	O	0-10
LRRK2	O	11-16
antagonizes	O	17-28
these	O	29-34
miRNAs	O	35-41
,	O	41-42
leading	O	43-50
to	O	51-53
the	O	54-57
overproduction	O	58-72
of	O	73-75
E2F1	O	76-80
/	O	80-81
DP	O	81-83
,	O	83-84
previously	O	85-95
implicated	O	96-106
in	O	107-109
cell	O	110-114
cycle	O	115-120
and	O	121-124
survival	O	125-133
control	O	134-141
and	O	142-145
shown	O	146-151
here	O	152-156
to	O	157-159
be	O	160-162
critical	O	163-171
for	O	172-175
LRRK2	O	176-181
pathogenesis	O	182-194
. 	O	194-196

Genetic	O	0-7
deletion	O	8-16
of	O	17-19
let	B	20-23
-	I	23-24
7	I	24-25
,	O	25-26
antagomir	O	27-36
-	O	36-37
mediated	O	37-45
blockage	O	46-54
of	O	55-57
let	B	58-61
-	I	61-62
7	I	62-63
and	O	64-67
miR	B	68-71
-	I	71-72
184	I	72-75
*	O	75-76
action	O	77-83
,	O	83-84
transgenic	O	85-95
expression	O	96-106
of	O	107-109
dp	O	110-112
target	O	113-119
protector	O	120-129
,	O	129-130
or	O	131-133
replacement	O	134-145
of	O	146-148
endogenous	O	149-159
dp	O	160-162
with	O	163-167
a	O	168-169
dp	O	170-172
transgene	O	173-182
non	O	183-186
-	O	186-187
responsive	O	187-197
to	O	198-200
let	B	201-204
-	I	204-205
7	I	205-206
each	O	207-211
had	O	212-215
toxic	O	216-221
effects	O	222-229
similar	O	230-237
to	O	238-240
those	O	241-246
of	O	247-249
pathogenic	O	250-260
LRRK2	O	261-266
. 	O	266-268

Conversely	O	0-10
,	O	10-11
increasing	O	12-22
the	O	23-26
level	O	27-32
of	O	33-35
let	B	36-39
-	I	39-40
7	I	40-41
or	O	42-44
miR	B	45-48
-	I	48-49
184	I	49-52
*	O	52-53
attenuated	O	54-64
pathogenic	O	65-75
LRRK2	O	76-81
effects	O	82-89
. 	O	89-91

LRRK2	O	0-5
associated	O	6-16
with	O	17-21
Drosophila	O	22-32
Argonaute	O	33-42
-	O	42-43
1	O	43-44
(	O	45-46
dAgo1	O	46-51
)	O	51-52
or	O	53-55
human	O	56-61
Argonaute	O	62-71
-	O	71-72
2	O	72-73
(	O	74-75
hAgo2	O	75-80
)	O	80-81
of	O	82-84
the	O	85-88
RNA	O	89-92
-	O	92-93
induced	O	93-100
silencing	O	101-110
complex	O	111-118
(	O	119-120
RISC	O	120-124
)	O	124-125
. 	O	125-127

In	O	0-2
aged	O	3-7
fly	O	8-11
brain	O	12-17
,	O	17-18
dAgo1	O	19-24
protein	O	25-32
level	O	33-38
was	O	39-42
negatively	O	43-53
regulated	O	54-63
by	O	64-66
LRRK2	O	67-72
. 	O	72-74

Pathogenic	O	0-10
LRRK2	O	11-16
negatively	O	17-27
regulates	O	28-37
microRNA	O	38-46
-	O	46-47
mediated	O	47-55
translational	O	56-69
repression	O	70-80
.  	O	80-83

Gain	O	0-4
-	O	4-5
of	O	5-7
-	O	7-8
function	O	8-16
mutations	O	17-26
in	O	27-29
leucine	O	30-37
-	O	37-38
rich	O	38-42
repeat	O	43-49
kinase	O	50-56
2	O	57-58
(	O	59-60
LRRK2	O	60-65
)	O	65-66
cause	O	67-72
familial	O	73-81
as	O	82-84
well	O	85-89
as	O	90-92
sporadic	O	93-101
Parkinson	O	102-111
'	O	111-112
s	O	112-113
disease	O	114-121
characterized	O	122-135
by	O	136-138
age	O	139-142
-	O	142-143
dependent	O	143-152
degeneration	O	153-165
of	O	166-168
dopaminergic	O	169-181
neurons	O	182-189
. 	O	189-191

The	O	0-3
predicted	O	4-13
targets	O	14-21
of	O	22-24
these	O	25-30
miRNAs	O	31-37
include	O	38-45
those	O	46-51
with	O	52-56
known	O	57-62
or	O	63-65
suspected	O	66-75
roles	O	76-81
in	O	82-84
oligodendrocyte	O	85-100
development	O	101-112
and	O	113-116
myelination	O	117-128
including	O	129-138
C11Orf9	O	139-146
,	O	146-147
CLDN11	O	148-154
,	O	154-155
MYTL1	O	156-161
,	O	161-162
MBOP	O	163-167
,	O	167-168
MPZL2	O	169-174
,	O	174-175
and	O	176-179
DDR1	O	180-184
. 	O	184-186

CONCLUSIONS	O	0-11
/	O	11-12
SIGNIFICANCE	O	12-24
:	O	24-25
We	O	26-28
demonstrate	O	29-40
miRNA	O	41-46
profiles	O	47-55
during	O	56-62
distinct	O	63-71
stages	O	72-78
in	O	79-81
oligodendroglial	O	82-98
differentiation	O	99-114
that	O	115-119
may	O	120-123
provide	O	124-131
key	O	132-135
markers	O	136-143
of	O	144-146
OL	O	147-149
maturation	O	150-160
. 	O	160-162

Principal	O	0-9
component	O	10-19
analysis	O	20-28
revealed	O	29-37
four	O	38-42
main	O	43-47
clusters	O	48-56
of	O	57-59
miRNA	O	60-65
expression	O	66-76
corresponding	O	77-90
to	O	91-93
early	O	94-99
,	O	99-100
mid	O	101-104
,	O	104-105
and	O	106-109
late	O	110-114
progenitors	O	115-126
,	O	126-127
and	O	128-131
mature	O	132-138
OLs	O	139-142
.	O	142-143
These	O	144-149
results	O	150-157
were	O	158-162
supported	O	163-172
by	O	173-175
correlation	O	176-187
analyses	O	188-196
between	O	197-204
adjacent	O	205-213
stages	O	214-220
. 	O	220-222

Interestingly	O	0-13
,	O	13-14
the	O	15-18
highest	O	19-26
differentially	O	27-41
-	O	41-42
expressed	O	42-51
miRNAs	O	52-58
demonstrated	O	59-71
a	O	72-73
similar	O	74-81
pattern	O	82-89
of	O	90-92
expression	O	93-103
throughout	O	104-114
all	O	115-118
stages	O	119-125
of	O	126-128
differentiation	O	129-144
,	O	144-145
suggesting	O	146-156
that	O	157-161
they	O	162-166
potentially	O	167-178
regulate	O	179-187
a	O	188-189
common	O	190-196
target	O	197-203
or	O	204-206
set	O	207-210
of	O	211-213
targets	O	214-221
in	O	222-224
this	O	225-229
process	O	230-237
. 	O	237-239

Our	O	0-3
results	O	4-11
reveal	O	12-18
pronounced	O	19-29
trends	O	30-36
in	O	37-39
miRNA	O	40-45
expression	O	46-56
and	O	57-60
their	O	61-66
potential	O	67-76
mRNA	O	77-81
target	O	82-88
interactions	O	89-101
that	O	102-106
could	O	107-112
provide	O	113-120
valuable	O	121-129
insight	O	130-137
into	O	138-142
the	O	143-146
molecular	O	147-156
mechanisms	O	157-167
of	O	168-170
differentiation	O	171-186
.   	O	186-190

A	O	0-1
comparison	O	2-12
of	O	13-15
miRNAs	O	16-22
from	O	23-27
our	O	28-31
cultured	O	32-40
OLs	O	41-44
and	O	45-48
OL	O	49-51
progenitors	O	52-63
showed	O	64-70
significant	O	71-82
similarities	O	83-95
with	O	96-100
published	O	101-110
results	O	111-118
from	O	119-123
equivalent	O	124-134
cells	O	135-140
found	O	141-146
in	O	147-149
the	O	150-153
rat	O	154-157
and	O	158-161
mouse	O	162-167
central	O	168-175
nervous	O	176-183
system	O	184-190
. 	O	190-192

MicroRNA	O	0-8
expression	O	9-19
profiling	O	20-29
of	O	30-32
oligodendrocyte	O	33-48
differentiation	O	49-64
from	O	65-69
human	O	70-75
embryonic	O	76-85
stem	O	86-90
cells	O	91-96
.  	O	96-99

However	O	0-7
,	O	7-8
the	O	9-12
molecular	O	13-22
mechanisms	O	23-33
controlling	O	34-45
OL	O	46-48
differentiation	O	49-64
are	O	65-68
largely	O	69-76
unknown	O	77-84
. 	O	84-86

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
considered	O	23-33
the	O	34-37
"	O	38-39
micromanagers	O	39-52
"	O	52-53
of	O	54-56
gene	O	57-61
expression	O	62-72
with	O	73-77
suggestive	O	78-88
roles	O	89-94
in	O	95-97
cellular	O	98-106
differentiation	O	107-122
and	O	123-126
maintenance	O	127-138
. 	O	138-140

BACKGROUND	O	0-10
:	O	10-11
Cells	O	12-17
of	O	18-20
the	O	21-24
oligodendrocyte	O	25-40
(	O	41-42
OL	O	42-44
)	O	44-45
lineage	O	46-53
play	O	54-58
a	O	59-60
vital	O	61-66
role	O	67-71
in	O	72-74
the	O	75-78
production	O	79-89
and	O	90-93
maintenance	O	94-105
of	O	106-108
myelin	O	109-115
,	O	115-116
a	O	117-118
multilamellar	O	119-132
membrane	O	133-141
which	O	142-147
allows	O	148-154
for	O	155-158
saltatory	O	159-168
conduction	O	169-179
along	O	180-185
axons	O	186-191
. 	O	191-193

These	O	0-5
cells	O	6-11
may	O	12-15
provide	O	16-23
immense	O	24-31
therapeutic	O	32-43
potential	O	44-53
for	O	54-57
lost	O	58-62
sensory	O	63-70
and	O	71-74
motor	O	75-80
function	O	81-89
in	O	90-92
demyelinating	O	93-106
conditions	O	107-117
,	O	117-118
such	O	119-123
as	O	124-126
spinal	O	127-133
cord	O	134-138
injury	O	139-145
,	O	145-146
multiple	O	147-155
sclerosis	O	156-165
,	O	165-166
and	O	167-170
transverse	O	171-181
myelitis	O	182-190
. 	O	190-192

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
We	O	32-34
isolated	O	35-43
cells	O	44-49
from	O	50-54
8	O	55-56
stages	O	57-63
of	O	64-66
OL	O	67-69
differentiation	O	70-85
. 	O	85-87

Total	O	0-5
RNA	O	6-9
was	O	10-13
subjected	O	14-23
to	O	24-26
miRNA	O	27-32
profiling	O	33-42
and	O	43-46
validations	O	47-58
preformed	O	59-68
using	O	69-74
real	O	75-79
-	O	79-80
time	O	80-84
qRT	O	85-88
-	O	88-89
PCR	O	89-92
. 	O	92-94

Although	O	0-8
unique	O	9-15
patterns	O	16-24
of	O	25-27
miRNA	O	28-33
expression	O	34-44
in	O	45-47
various	O	48-55
cell	O	56-60
lineages	O	61-69
have	O	70-74
been	O	75-79
characterized	O	80-93
,	O	93-94
this	O	95-99
is	O	100-102
the	O	103-106
first	O	107-112
report	O	113-119
documenting	O	120-131
their	O	132-137
expression	O	138-148
during	O	149-155
oligodendrocyte	O	156-171
maturation	O	172-182
from	O	183-187
human	O	188-193
embryonic	O	194-203
stem	O	204-208
(	O	209-210
hES	O	210-213
)	O	213-214
cells	O	215-220
. 	O	220-222

Here	O	0-4
,	O	4-5
we	O	6-8
performed	O	9-18
a	O	19-20
global	O	21-27
miRNA	O	28-33
analysis	O	34-42
to	O	43-45
reveal	O	46-52
and	O	53-56
identify	O	57-65
characteristic	O	66-80
patterns	O	81-89
in	O	90-92
the	O	93-96
multiple	O	97-105
stages	O	106-112
leading	O	113-120
to	O	121-123
OL	O	124-126
maturation	O	127-137
from	O	138-142
hES	O	143-146
cells	O	147-152
including	O	153-162
those	O	163-168
targeting	O	169-178
factors	O	179-186
involved	O	187-195
in	O	196-198
myelin	O	199-205
production	O	206-216
. 	O	216-218

Recent	O	0-6
evidence	O	7-15
indicates	O	16-25
that	O	26-30
miRNAs	O	31-37
can	O	38-41
function	O	42-50
both	O	51-55
as	O	56-58
tumor	O	59-64
suppressors	O	65-76
and	O	77-80
as	O	81-83
oncogenes	O	84-93
. 	O	93-95

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
small	O	23-28
noncoding	O	29-38
regulatory	O	39-49
RNAs	O	50-54
that	O	55-59
reduce	O	60-66
stability	O	67-76
and	O	77-80
/	O	80-81
or	O	81-83
translation	O	84-95
of	O	96-98
fully	O	99-104
or	O	105-107
partially	O	108-117
sequence	O	118-126
-	O	126-127
complementary	O	127-140
target	O	141-147
mRNAs	O	148-153
. 	O	153-155

Expression	O	0-10
of	O	11-13
miR	B	14-17
-	I	17-18
21	I	18-20
,	I	20-21
221	I	22-25
,	I	25-26
128a	I	27-31
,	I	31-32
128b	I	33-37
,	I	37-38
128c	I	39-43
,	I	43-44
181a	I	45-49
,	I	49-50
181b	I	51-55
,	I	55-56
181c	I	57-61
was	O	62-65
studied	O	66-73
using	O	74-79
real	O	80-84
-	O	84-85
time	O	85-89
quantitative	O	90-102
reverse	O	103-110
transcriptase	O	111-124
polymerase	O	125-135
chain	O	136-141
reaction	O	142-150
and	O	151-154
northern	O	155-163
blotting	O	164-172
for	O	173-176
human	O	177-182
astrocytic	O	183-193
tumors	O	194-200
with	O	201-205
different	O	206-215
grade	O	216-221
of	O	222-224
malignancy	O	225-235
. 	O	235-237

It	O	0-2
has	O	3-6
been	O	7-11
demonstrated	O	12-24
that	O	25-29
in	O	30-32
glioblastoma	O	33-45
multiforme	O	46-56
miR	B	57-60
-	I	60-61
21	I	61-63
and	I	64-67
221	I	68-71
are	O	72-75
upregulated	O	76-87
whereas	O	88-95
miR	B	96-99
-	I	99-100
128	I	100-103
and	I	104-107
181	I	108-111
are	O	112-115
downregulated	O	116-129
. 	O	129-131

miRNA	B	0-5
-	I	5-6
21	I	6-8
was	O	9-12
hyperexpressed	O	13-27
in	O	28-30
all	O	31-34
tumor	O	35-40
samples	O	41-48
whereas	O	49-56
higher	O	57-63
levels	O	64-70
of	O	71-73
miRNA	B	74-79
-	I	79-80
221	I	80-83
were	O	84-88
found	O	89-94
in	O	95-97
high	O	98-102
-	O	102-103
grade	O	103-108
gliomas	O	109-116
. 	O	116-118

miR	B	0-3
-	I	3-4
21	I	4-6
and	I	7-10
221	I	11-14
were	O	15-19
overexpressed	O	20-33
in	O	34-36
glioma	O	37-43
samples	O	44-51
,	O	51-52
whereas	O	53-60
miRNA	B	61-66
181b	I	67-71
was	O	72-75
downregulated	O	76-89
compared	O	90-98
with	O	99-103
normal	O	104-110
brain	O	111-116
tissue	O	117-123
. 	O	123-125

The	O	0-3
different	O	4-13
expression	O	14-24
pattern	O	25-32
observed	O	33-41
in	O	42-44
tumors	O	45-51
at	O	52-54
different	O	55-64
stages	O	65-71
of	O	72-74
malignancy	O	75-85
is	O	86-88
probably	O	89-97
dependent	O	98-107
on	O	108-110
the	O	111-114
cell	O	115-119
-	O	119-120
specific	O	120-128
repertoire	O	129-139
of	O	140-142
target	O	143-149
genes	O	150-155
of	O	156-158
tumors	O	159-165
sharing	O	166-173
different	O	174-183
molecular	O	184-193
pathways	O	194-202
activity	O	203-211
and	O	212-215
suggests	O	216-224
miRNAs	O	225-231
may	O	232-235
have	O	236-240
also	O	241-245
a	O	246-247
place	O	248-253
in	O	254-256
diagnosis	O	257-266
and	O	267-270
staging	O	271-278
of	O	279-281
brain	O	282-287
tumors	O	288-294
.   	O	294-298

This	O	0-4
study	O	5-10
is	O	11-13
the	O	14-17
first	O	18-23
analysis	O	24-32
of	O	33-35
miRNAs	O	36-42
in	O	43-45
astrocytic	O	46-56
tumor	O	57-62
at	O	63-65
different	O	66-75
stages	O	76-82
of	O	83-85
malignancy	O	86-96
. 	O	96-98

miR	B	0-3
-	I	3-4
21	I	4-6
and	I	7-10
221	I	11-14
upregulation	O	15-27
and	O	28-31
miR	B	32-35
-	I	35-36
181b	I	36-40
downregulation	O	41-55
in	O	56-58
human	O	59-64
grade	O	65-70
II	O	71-73
-	O	73-74
IV	O	74-76
astrocytic	O	77-87
tumors	O	88-94
.  	O	94-97

Not	O	0-3
surprisingly	O	4-16
,	O	16-17
deregulation	O	18-30
of	O	31-33
REST	O	34-38
and	O	39-42
ncRNAs	O	43-49
are	O	50-53
both	O	54-58
implicated	O	59-69
in	O	70-72
the	O	73-76
molecular	O	77-86
pathophysiology	O	87-102
underlying	O	103-113
diverse	O	114-121
disorders	O	122-131
that	O	132-136
range	O	137-142
from	O	143-147
brain	O	148-153
cancer	O	154-160
and	O	161-164
stroke	O	165-171
to	O	172-174
neurodevelopmental	O	175-193
and	O	194-197
neurodegenerative	O	198-215
diseases	O	216-224
. 	O	224-226

This	O	0-4
review	O	5-11
summarizes	O	12-22
emerging	O	23-31
aspects	O	32-39
of	O	40-42
the	O	43-46
complex	O	47-54
mechanistic	O	55-66
relationships	O	67-80
between	O	81-88
these	O	89-94
intricately	O	95-106
interlaced	O	107-117
control	O	118-125
systems	O	126-133
for	O	134-137
neural	O	138-144
gene	O	145-149
expression	O	150-160
and	O	161-164
function	O	165-173
.   	O	173-177

REST	O	0-4
and	O	5-8
its	O	9-12
primary	O	13-20
cofactor	O	21-29
,	O	29-30
CoREST	O	31-37
,	O	37-38
dynamically	O	39-50
recruit	O	51-58
highly	O	59-65
malleable	O	66-75
macromolecular	O	76-90
complexes	O	91-100
to	O	101-103
widely	O	104-110
distributed	O	111-122
genomic	O	123-130
regulatory	O	131-141
sequences	O	142-151
,	O	151-152
including	O	153-162
the	O	163-166
repressor	O	167-176
element	O	177-184
-	O	184-185
1	O	185-186
/	O	186-187
neuron	O	187-193
restrictive	O	194-205
silencer	O	206-214
element	O	215-222
(	O	223-224
RE1	O	224-227
/	O	227-228
NRSE	O	228-232
)	O	232-233
. 	O	233-235

Through	O	0-7
epigenetic	O	8-18
mechanisms	O	19-29
,	O	29-30
such	O	31-35
as	O	36-38
site	O	39-43
-	O	43-44
specific	O	44-52
targeting	O	53-62
and	O	63-66
higher	O	67-73
-	O	73-74
order	O	74-79
chromatin	O	80-89
remodeling	O	90-100
,	O	100-101
REST	O	102-106
and	O	107-110
CoREST	O	111-117
can	O	118-121
mediate	O	122-129
cell	O	130-134
type	O	135-139
-	O	139-140
and	O	141-144
developmental	O	145-158
stage	O	159-164
-	O	164-165
specific	O	165-173
gene	O	174-178
repression	O	179-189
,	O	189-190
gene	O	191-195
activation	O	196-206
,	O	206-207
and	O	208-211
long	O	212-216
-	O	216-217
term	O	217-221
gene	O	222-226
silencing	O	227-236
for	O	237-240
protein	O	241-248
-	O	248-249
coding	O	249-255
genes	O	256-261
and	O	262-265
for	O	266-269
several	O	270-277
classes	O	278-285
of	O	286-288
ncRNAs	O	289-295
(	O	296-297
e	O	297-298
.	O	298-299
g	O	299-300
.	O	300-301
microRNAs	O	302-311
[	O	312-313
miRNAs	O	313-319
]	O	319-320
and	O	321-324
long	O	325-329
ncRNAs	O	330-336
)	O	336-337
. 	O	337-339

In	O	0-2
turn	O	3-7
,	O	7-8
these	O	9-14
ncRNAs	O	15-21
have	O	22-26
similarly	O	27-36
been	O	37-41
implicated	O	42-52
in	O	53-55
the	O	56-59
regulation	O	60-70
of	O	71-73
chromatin	O	74-83
architecture	O	84-96
and	O	97-100
dynamics	O	101-109
,	O	109-110
transcription	O	111-124
,	O	124-125
post	O	126-130
-	O	130-131
transcriptional	O	131-146
processing	O	147-157
,	O	157-158
and	O	159-162
RNA	O	163-166
editing	O	167-174
and	O	175-178
trafficking	O	179-190
. 	O	190-192

In	O	0-2
addition	O	3-11
,	O	11-12
REST	O	13-17
and	O	18-21
CoREST	O	22-28
expression	O	29-39
and	O	40-43
function	O	44-52
are	O	53-56
tightly	O	57-64
regulated	O	65-74
by	O	75-77
context	O	78-85
-	O	85-86
specific	O	86-94
transcriptional	O	95-110
and	O	111-114
post	O	115-119
-	O	119-120
transcriptional	O	120-135
mechanisms	O	136-146
including	O	147-156
bidirectional	O	157-170
feedback	O	171-179
loops	O	180-185
with	O	186-190
various	O	191-198
ncRNAs	O	199-205
. 	O	205-207

Regulation	O	0-10
of	O	11-13
non	O	14-17
-	O	17-18
coding	O	18-24
RNA	O	25-28
networks	O	29-37
in	O	38-40
the	O	41-44
nervous	O	45-52
system	O	53-59
-	O	59-60
-	O	60-61
what	O	61-65
'	O	65-66
s	O	66-67
the	O	68-71
REST	O	72-76
of	O	77-79
the	O	80-83
story	O	84-89
?  	O	89-92

The	O	0-3
repressor	O	4-13
element	O	14-21
-	O	21-22
1	O	22-23
silencing	O	24-33
transcription	O	34-47
factor	O	48-54
/	O	54-55
neuron	O	55-61
-	O	61-62
restrictive	O	62-73
silencing	O	74-83
factor	O	84-90
(	O	91-92
REST	O	92-96
/	O	96-97
NRSF	O	97-101
)	O	101-102
and	O	103-106
non	O	107-110
-	O	110-111
coding	O	111-117
RNAs	O	118-122
(	O	123-124
ncRNAs	O	124-130
)	O	130-131
are	O	132-135
emerging	O	136-144
as	O	145-147
key	O	148-151
regulators	O	152-162
that	O	163-167
seem	O	168-172
to	O	173-175
orchestrate	O	176-187
almost	O	188-194
every	O	195-200
aspect	O	201-207
of	O	208-210
nervous	O	211-218
system	O	219-225
development	O	226-237
,	O	237-238
homeostasis	O	239-250
,	O	250-251
and	O	252-255
plasticity	O	256-266
. 	O	266-268

Recent	O	0-6
advances	O	7-15
are	O	16-19
now	O	20-23
providing	O	24-33
novel	O	34-39
insights	O	40-48
into	O	49-53
the	O	54-57
mechanisms	O	58-68
that	O	69-73
underlie	O	74-82
how	O	83-86
cellular	O	87-95
complexity	O	96-106
,	O	106-107
diversity	O	108-117
,	O	117-118
and	O	119-122
connectivity	O	123-135
are	O	136-139
encoded	O	140-147
within	O	148-154
the	O	155-158
genome	O	159-165
. 	O	165-167

The	O	0-3
miRNAs	O	4-10
in	O	11-13
a	O	14-15
whole	O	16-21
cell	O	22-26
regulate	O	27-35
greater	O	36-43
than	O	44-48
30	O	49-51
%	O	51-52
of	O	53-55
all	O	56-59
protein	O	60-67
-	O	67-68
coding	O	68-74
genes	O	75-80
. 	O	80-82

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
are	O	19-22
a	O	23-24
group	O	25-30
of	O	31-33
small	O	34-39
noncoding	O	40-49
RNAs	O	50-54
that	O	55-59
regulate	O	60-68
translational	O	69-82
repression	O	83-93
of	O	94-96
multiple	O	97-105
target	O	106-112
mRNAs	O	113-118
. 	O	118-120

MicroRNAs	O	0-9
and	O	10-13
their	O	14-19
therapeutic	O	20-31
potential	O	32-41
for	O	42-45
human	O	46-51
diseases	O	52-60
:	O	60-61
aberrant	O	62-70
microRNA	O	71-79
expression	O	80-90
in	O	91-93
Alzheimer	O	94-103
'	O	103-104
s	O	104-105
disease	O	106-113
brains	O	114-120
.  	O	120-123

This	O	0-4
review	O	5-11
will	O	12-16
briefly	O	17-24
summarize	O	25-34
recent	O	35-41
studies	O	42-49
that	O	50-54
focus	O	55-60
attention	O	61-70
on	O	71-73
aberrant	O	74-82
miRNA	O	83-88
expression	O	89-99
in	O	100-102
Alzheimer	O	103-112
'	O	112-113
s	O	113-114
disease	O	115-122
brains	O	123-129
.   	O	129-133

However	O	0-7
,	O	7-8
at	O	9-11
present	O	12-19
,	O	19-20
the	O	21-24
pathological	O	25-37
implications	O	38-50
of	O	51-53
deregulated	O	54-65
miRNA	O	66-71
expression	O	72-82
in	O	83-85
neurodegenerative	O	86-103
diseases	O	104-112
remain	O	113-119
largely	O	120-127
unknown	O	128-135
. 	O	135-137

They	O	0-4
play	O	5-9
a	O	10-11
key	O	12-15
role	O	16-20
in	O	21-23
neuronal	O	24-32
development	O	33-44
,	O	44-45
differentiation	O	46-61
,	O	61-62
and	O	63-66
synaptic	O	67-75
plasticity	O	76-86
. 	O	86-88

The	O	0-3
vast	O	4-8
majority	O	9-17
of	O	18-20
presently	O	21-30
identified	O	31-41
miRNAs	O	42-48
are	O	49-52
expressed	O	53-62
in	O	63-65
the	O	66-69
brain	O	70-75
in	O	76-78
a	O	79-80
spatially	O	81-90
and	O	91-94
temporally	O	95-105
controlled	O	106-116
manner	O	117-123
. 	O	123-125

Our	O	0-3
studies	O	4-11
suggest	O	12-19
that	O	20-24
ban	O	25-28
functions	O	29-38
downstream	O	39-49
of	O	50-52
toxicity	O	53-61
of	O	62-64
the	O	65-68
SCA3	O	69-73
protein	O	74-81
,	O	81-82
to	O	83-85
prevent	O	86-93
degeneration	O	94-106
. 	O	106-108

These	O	0-5
findings	O	6-14
indicate	O	15-23
that	O	24-28
miRNA	O	29-34
pathways	O	35-43
dramatically	O	44-56
modulate	O	57-65
polyQ	O	66-71
-	O	71-72
and	O	73-76
tau	O	77-80
-	O	80-81
induced	O	81-88
neurodegeneration	O	89-106
,	O	106-107
providing	O	108-117
the	O	118-121
foundation	O	122-132
for	O	133-136
new	O	137-140
insight	O	141-148
into	O	149-153
therapeutics	O	154-166
.   	O	166-170

To	O	0-2
address	O	3-10
whether	O	11-18
miRNA	O	19-24
pathways	O	25-33
play	O	34-38
a	O	39-40
role	O	41-45
in	O	46-48
neurodegeneration	O	49-66
,	O	66-67
we	O	68-70
tested	O	71-77
whether	O	78-85
genes	O	86-91
critical	O	92-100
for	O	101-104
miRNA	O	105-110
processing	O	111-121
modulated	O	122-131
toxicity	O	132-140
induced	O	141-148
by	O	149-151
the	O	152-155
spinocerebellar	O	156-171
ataxia	O	172-178
type	O	179-183
3	O	184-185
(	O	186-187
SCA3	O	187-191
)	O	191-192
protein	O	193-200
. 	O	200-202

MicroRNAs	O	0-9
(	O	10-11
miRNAs	O	11-17
)	O	17-18
have	O	19-23
been	O	24-28
shown	O	29-34
to	O	35-37
modulate	O	38-46
programmed	O	47-57
cell	O	58-62
death	O	63-68
during	O	69-75
development	O	76-87
. 	O	87-89

In	O	0-2
parallel	O	3-11
genetic	O	12-19
screens	O	20-27
,	O	27-28
we	O	29-31
identified	O	32-42
the	O	43-46
miRNA	O	47-52
bantam	O	53-59
(	O	60-61
ban	O	61-64
)	O	64-65
as	O	66-68
a	O	69-70
potent	O	71-77
modulator	O	78-87
of	O	88-90
both	O	91-95
polyQ	O	96-101
and	O	102-105
tau	O	106-109
toxicity	O	110-118
in	O	119-121
flies	O	122-127
. 	O	127-129

These	O	0-5
studies	O	6-13
revealed	O	14-22
a	O	23-24
striking	O	25-33
enhancement	O	34-45
of	O	46-48
polyQ	O	49-54
toxicity	O	55-63
upon	O	64-68
reduction	O	69-78
of	O	79-81
miRNA	O	82-87
processing	O	88-98
in	O	99-101
Drosophila	O	102-112
and	O	113-116
human	O	117-122
cells	O	123-128
. 	O	128-130

MicroRNA	O	0-8
pathways	O	9-17
modulate	O	18-26
polyglutamine	O	27-40
-	O	40-41
induced	O	41-48
neurodegeneration	O	49-66
.  	O	66-69

Polyglutamine	O	0-13
(	O	14-15
polyQ	O	15-20
)	O	20-21
expansion	O	22-31
confers	O	32-39
dominant	O	40-48
toxicity	O	49-57
,	O	57-58
resulting	O	59-68
in	O	69-71
neuronal	O	72-80
degeneration	O	81-93
. 	O	93-95

Nine	O	0-4
human	O	5-10
neurodegenerative	O	11-28
diseases	O	29-37
are	O	38-41
due	O	42-45
to	O	46-48
expansion	O	49-58
of	O	59-61
a	O	62-63
CAG	O	64-67
repeat	O	68-74
-	O	74-75
encoding	O	76-84
glutamine	O	85-94
within	O	95-101
the	O	102-105
open	O	106-110
reading	O	111-118
frame	O	119-124
of	O	125-127
the	O	128-131
respective	O	132-142
genes	O	143-148
. 	O	148-150

Western	O	0-7
blot	O	8-12
was	O	13-16
applied	O	17-24
to	O	25-27
analyze	O	28-35
the	O	36-39
expression	O	40-50
of	O	51-53
eiF4E3	O	54-60
in	O	61-63
both	O	64-68
experimental	O	69-81
group	O	82-87
and	O	88-91
control	O	92-99
group	O	100-105
. 	O	105-107

RESULT	O	0-6
:	O	6-7
EiF4E3	O	8-14
was	O	15-18
the	O	19-22
most	O	23-27
likely	O	28-34
potential	O	35-44
targeting	O	45-54
protein	O	55-62
of	O	63-65
microRNA	B	66-74
-	I	74-75
338	I	75-78
. 	O	78-80

The	O	0-3
potential	O	4-13
targeting	O	14-23
proteins	O	24-32
were	O	33-37
then	O	38-42
selected	O	43-51
according	O	52-61
to	O	62-64
their	O	65-70
secondary	O	71-80
structures	O	81-91
using	O	92-97
RNA	O	98-101
structure	O	102-111
4	O	112-113
.	O	113-114
6	O	114-115
software	O	116-124
and	O	125-128
their	O	129-134
involvement	O	135-146
in	O	147-149
cerebral	O	150-158
ischemia	O	159-167
and	O	168-171
reperfusion	O	172-183
injury	O	184-190
was	O	191-194
studied	O	195-202
. 	O	202-204

Dual	O	0-4
-	O	4-5
luciferase	O	5-15
reporter	O	16-24
assay	O	25-30
was	O	31-34
used	O	35-39
to	O	40-42
testify	O	43-50
whether	O	51-58
microRNA	B	59-67
-	I	67-68
338	I	68-71
can	O	72-75
recognize	O	76-85
the	O	86-89
3	O	90-91
'	O	91-92
UTR	O	92-95
of	O	96-98
target	O	99-105
protein	O	106-113
. 	O	113-115

OBJECTIVE	O	0-9
:	O	9-10
To	O	11-13
analyze	O	14-21
the	O	22-25
interaction	O	26-37
between	O	38-45
the	O	46-49
microRNA	B	50-58
-	I	58-59
338	I	59-62
and	O	63-66
its	O	67-70
targeting	O	71-80
proteins	O	81-89
during	O	90-96
the	O	97-100
cerebral	O	101-109
ischemia	O	110-118
and	O	119-122
reperfusion	O	123-134
injury	O	135-141
. 	O	141-143

METHODS	O	0-7
:	O	7-8
TargetScan	O	9-19
was	O	20-23
used	O	24-28
to	O	29-31
predict	O	32-39
the	O	40-43
targets	O	44-51
of	O	52-54
microRNA	B	55-63
-	I	63-64
338	I	64-67
. 	O	67-69

[	O	0-1
Interaction	O	1-12
of	O	13-15
microRNA	B	16-24
-	I	24-25
338	I	25-28
and	O	29-32
its	O	33-36
potential	O	37-46
targeting	O	47-56
protein	O	57-64
eiF4E3	O	65-71
]	O	71-72
.  	O	72-75

However	O	0-7
,	O	7-8
there	O	9-14
was	O	15-18
no	O	19-21
significant	O	22-33
difference	O	34-44
in	O	45-47
the	O	48-51
expression	O	52-62
of	O	63-65
eiF4E3	O	66-72
between	O	73-80
these	O	81-86
two	O	87-90
groups	O	91-97
. 	O	97-99

The	O	0-3
secondary	O	4-13
structure	O	14-23
of	O	24-26
local	O	27-32
region	O	33-39
of	O	40-42
eiF4E3	O	43-49
recognizing	O	50-61
microRNA	B	62-70
-	I	70-71
338	I	71-74
was	O	75-78
conservative	O	79-91
. 	O	91-93

The	O	0-3
ratio	O	4-9
of	O	10-12
firefly	O	13-20
to	O	21-23
renilla	O	24-31
luciferase	O	32-42
activity	O	43-51
in	O	52-54
the	O	55-58
experimental	O	59-71
group	O	72-77
was	O	78-81
much	O	82-86
higher	O	87-93
than	O	94-98
that	O	99-103
of	O	104-106
control	O	107-114
group	O	115-120
. 	O	120-122

CONCLUSION	O	0-10
:	O	10-11
MicroRNA	B	12-20
-	I	20-21
338	I	21-24
can	O	25-28
recognize	O	29-38
the	O	39-42
3	O	43-44
'	O	44-45
UTR	O	45-48
of	O	49-51
eiF4E3	O	52-58
while	O	59-64
it	O	65-67
has	O	68-71
no	O	72-74
significant	O	75-86
effect	O	87-93
on	O	94-96
the	O	97-100
expression	O	101-111
of	O	112-114
eiF4E3	O	115-121
. 	O	121-123

The	O	0-3
post	O	4-8
-	O	8-9
target	O	9-15
-	O	15-16
recognizing	O	16-27
regulation	O	28-38
for	O	39-42
miRNA	O	43-48
do	O	49-51
exist	O	52-57
and	O	58-61
this	O	62-66
mechanism	O	67-76
is	O	77-79
possibly	O	80-88
related	O	89-96
to	O	97-99
the	O	100-103
tertiary	O	104-112
structure	O	113-122
of	O	123-125
target	O	126-132
mRNA	O	133-137
.   	O	137-141

We	O	0-2
conclude	O	3-11
that	O	12-16
lentiviral	O	17-27
expression	O	28-38
of	O	39-41
anti	O	42-46
-	O	46-47
ADK	O	47-50
miRNA	O	51-56
constitutes	O	57-68
a	O	69-70
versatile	O	71-80
tool	O	81-85
to	O	86-88
generate	O	89-97
therapeutically	O	98-113
effective	O	114-123
adenosine	O	124-133
releasing	O	134-143
hMSCs	O	144-149
,	O	149-150
thus	O	151-155
representing	O	156-168
a	O	169-170
model	O	171-176
system	O	177-183
to	O	184-186
generate	O	187-195
patient	O	196-203
identical	O	204-213
autologous	O	214-224
adult	O	225-230
stem	O	231-235
cell	O	236-240
grafts	O	241-247
.   	O	247-251

While	O	0-5
mice	O	6-10
with	O	11-15
control	O	16-23
implants	O	24-32
expressing	O	33-43
a	O	44-45
scrambled	O	46-55
miRNA	O	56-61
sequence	O	62-70
or	O	71-73
sham	O	74-78
treated	O	79-86
control	O	87-94
animals	O	95-102
were	O	103-107
characterized	O	108-121
by	O	122-124
KA	O	125-127
-	O	127-128
induced	O	128-135
status	O	136-142
epilepticus	O	143-154
and	O	155-158
subsequent	O	159-169
CA3	O	170-173
neuronal	O	174-182
cell	O	183-187
loss	O	188-192
,	O	192-193
animals	O	194-201
with	O	202-206
therapeutic	O	207-218
ADK	O	219-222
knockdown	O	223-232
implants	O	233-241
displayed	O	242-251
a	O	252-253
35	O	254-256
%	O	256-257
reduction	O	258-267
in	O	268-270
seizure	O	271-278
duration	O	279-287
and	O	288-291
65	O	292-294
%	O	294-295
reduction	O	296-305
in	O	306-308
CA3	O	309-312
neuronal	O	313-321
cell	O	322-326
loss	O	327-331
,	O	331-332
when	O	333-337
analyzed	O	338-346
24	O	347-349
h	O	350-351
after	O	352-357
KA	O	358-360
-	O	360-361
injection	O	361-370
. 	O	370-372

hMSCs	O	0-5
with	O	6-10
a	O	11-12
knockdown	O	13-22
of	O	23-25
ADK	O	26-29
or	O	30-32
cells	O	33-38
expressing	O	39-49
a	O	50-51
scrambled	O	52-61
control	O	62-69
sequence	O	70-78
were	O	79-83
transplanted	O	84-96
into	O	97-101
hippocampi	O	102-112
of	O	113-115
mice	O	116-120
1	O	121-122
week	O	123-127
prior	O	128-133
to	O	134-136
the	O	137-140
intraamygdaloid	O	141-156
injection	O	157-166
of	O	167-169
kainic	O	170-176
acid	O	177-181
(	O	182-183
KA	O	183-185
)	O	185-186
. 	O	186-188

Following	O	0-9
lentiviral	O	10-20
transduction	O	21-33
of	O	34-36
hMSCs	O	37-42
with	O	43-47
anti	O	48-52
-	O	52-53
ADK	O	53-56
miRNA	O	57-62
expression	O	63-73
cassettes	O	74-83
we	O	84-86
demonstrate	O	87-98
up	O	99-101
to	O	102-104
80	O	105-107
%	O	107-108
downregulation	O	109-123
of	O	124-126
ADK	O	127-130
and	O	131-134
a	O	135-136
concentration	O	137-150
of	O	151-153
8	O	154-155
.	O	155-156
5	O	156-157
ng	O	158-160
adenosine	O	161-170
per	O	171-174
ml	O	175-177
of	O	178-180
medium	O	181-187
after	O	188-193
incubating	O	194-204
10	O	205-207
(	O	207-208
5	O	208-209
)	O	209-210
cells	O	211-216
for	O	217-220
8	O	221-222
h	O	223-224
. 	O	224-226

Here	O	0-4
we	O	5-7
describe	O	8-16
a	O	17-18
novel	O	19-24
approach	O	25-33
based	O	34-39
on	O	40-42
lentiviral	O	43-53
RNAi	O	54-58
mediated	O	59-67
downregulation	O	68-82
of	O	83-85
adenosine	O	86-95
kinase	O	96-102
(	O	103-104
ADK	O	104-107
)	O	107-108
,	O	108-109
the	O	110-113
major	O	114-119
adenosine	O	120-129
-	O	129-130
removing	O	130-138
enzyme	O	139-145
,	O	145-146
in	O	147-149
human	O	150-155
mesenchymal	O	156-167
stem	O	168-172
cells	O	173-178
(	O	179-180
hMSCs	O	180-185
)	O	185-186
,	O	186-187
which	O	188-193
would	O	194-199
be	O	200-202
compatible	O	203-213
with	O	214-218
autologous	O	219-229
cell	O	230-234
grafting	O	235-243
in	O	244-246
patients	O	247-255
. 	O	255-257

Autologous	O	0-10
patient	O	11-18
-	O	18-19
derived	O	19-26
adenosine	O	27-36
-	O	36-37
releasing	O	37-46
cell	O	47-51
implants	O	52-60
would	O	61-66
constitute	O	67-77
a	O	78-79
major	O	80-85
therapeutic	O	86-97
advance	O	98-105
to	O	106-108
avoid	O	109-114
both	O	115-119
xenotransplantation	O	120-139
and	O	140-143
immunosuppression	O	144-161
. 	O	161-163

However	O	0-7
,	O	7-8
hitherto	O	9-17
used	O	18-22
therapeutic	O	23-34
cells	O	35-40
were	O	41-45
derived	O	46-53
from	O	54-58
rodents	O	59-66
and	O	67-70
thus	O	71-75
not	O	76-79
suitable	O	80-88
for	O	89-92
clinical	O	93-101
applications	O	102-114
. 	O	114-116

Cell	O	0-4
therapies	O	5-14
based	O	15-20
on	O	21-23
focal	O	24-29
delivery	O	30-38
of	O	39-41
the	O	42-45
inhibitory	O	46-56
neuromodulator	O	57-71
adenosine	O	72-81
were	O	82-86
previously	O	87-97
shown	O	98-103
to	O	104-106
provide	O	107-114
potent	O	115-121
seizure	O	122-129
suppression	O	130-141
in	O	142-144
animal	O	145-151
models	O	152-158
of	O	159-161
epilepsy	O	162-170
. 	O	170-172

Lentiviral	O	0-10
RNAi	O	11-15
-	O	15-16
induced	O	16-23
downregulation	O	24-38
of	O	39-41
adenosine	O	42-51
kinase	O	52-58
in	O	59-61
human	O	62-67
mesenchymal	O	68-79
stem	O	80-84
cell	O	85-89
grafts	O	90-96
:	O	96-97
a	O	98-99
novel	O	100-105
perspective	O	106-117
for	O	118-121
seizure	O	122-129
control	O	130-137
.  	O	137-140

The	O	0-3
PTEN	O	4-8
-	O	8-9
regulating	O	9-19
microRNA	O	20-28
miR	B	29-32
-	I	32-33
26a	I	33-36
is	O	37-39
amplified	O	40-49
in	O	50-52
high	O	53-57
-	O	57-58
grade	O	58-63
glioma	O	64-70
and	O	71-74
facilitates	O	75-86
gliomagenesis	O	87-100
in	O	101-103
vivo	O	104-108
.  	O	108-111

Activated	O	0-9
oncogenic	O	10-19
signaling	O	20-29
is	O	30-32
central	O	33-40
to	O	41-43
the	O	44-47
development	O	48-59
of	O	60-62
nearly	O	63-69
all	O	70-73
forms	O	74-79
of	O	80-82
cancer	O	83-89
,	O	89-90
including	O	91-100
the	O	101-104
most	O	105-109
common	O	110-116
class	O	117-122
of	O	123-125
primary	O	126-133
brain	O	134-139
tumor	O	140-145
,	O	145-146
glioma	O	147-153
. 	O	153-155

Research	O	0-8
over	O	9-13
the	O	14-17
last	O	18-22
two	O	23-26
decades	O	27-34
has	O	35-38
revealed	O	39-47
the	O	48-51
particular	O	52-62
importance	O	63-73
of	O	74-76
the	O	77-80
Akt	O	81-84
pathway	O	85-92
,	O	92-93
and	O	94-97
its	O	98-101
molecular	O	102-111
antagonist	O	112-122
PTEN	O	123-127
(	O	128-129
phosphatase	O	129-140
and	O	141-144
tensin	O	145-151
homolog	O	152-159
)	O	159-160
,	O	160-161
in	O	162-164
the	O	165-168
process	O	169-176
of	O	177-179
gliomagenesis	O	180-193
. 	O	193-195

Recent	O	0-6
studies	O	7-14
have	O	15-19
also	O	20-24
demonstrated	O	25-37
that	O	38-42
microRNAs	O	43-52
(	O	53-54
miRNAs	O	54-60
)	O	60-61
may	O	62-65
be	O	66-68
responsible	O	69-80
for	O	81-84
the	O	85-88
modulation	O	89-99
of	O	100-102
cancer	O	103-109
-	O	109-110
implicated	O	110-120
genes	O	121-126
in	O	127-129
tumors	O	130-136
. 	O	136-138

Here	O	0-4
we	O	5-7
report	O	8-14
the	O	15-18
identification	O	19-33
miR	B	34-37
-	I	37-38
26a	I	38-41
as	O	42-44
a	O	45-46
direct	O	47-53
regulator	O	54-63
of	O	64-66
PTEN	O	67-71
expression	O	72-82
. 	O	82-84

We	O	0-2
also	O	3-7
show	O	8-12
that	O	13-17
miR	B	18-21
-	I	21-22
26a	I	22-25
is	O	26-28
frequently	O	29-39
amplified	O	40-49
at	O	50-52
the	O	53-56
DNA	O	57-60
level	O	61-66
in	O	67-69
human	O	70-75
glioma	O	76-82
,	O	82-83
most	O	84-88
often	O	89-94
in	O	95-97
association	O	98-109
with	O	110-114
monoallelic	O	115-126
PTEN	O	127-131
loss	O	132-136
. 	O	136-138

Finally	O	0-7
,	O	7-8
we	O	9-11
demonstrate	O	12-23
that	O	24-28
miR	B	29-32
-	I	32-33
26a	I	33-36
-	O	36-37
mediated	O	37-45
PTEN	O	46-50
repression	O	51-61
in	O	62-64
a	O	65-66
murine	O	67-73
glioma	O	74-80
model	O	81-86
both	O	87-91
enhances	O	92-100
de	O	101-103
novo	O	104-108
tumor	O	109-114
formation	O	115-124
and	O	125-128
precludes	O	129-138
loss	O	139-143
of	O	144-146
heterozygosity	O	147-161
and	O	162-165
the	O	166-169
PTEN	O	170-174
locus	O	175-180
. 	O	180-182

Our	O	0-3
results	O	4-11
document	O	12-20
a	O	21-22
new	O	23-26
epigenetic	O	27-37
mechanism	O	38-47
for	O	48-51
PTEN	O	52-56
regulation	O	57-67
in	O	68-70
glioma	O	71-77
and	O	78-81
further	O	82-89
highlight	O	90-99
dysregulation	O	100-113
of	O	114-116
Akt	O	117-120
signaling	O	121-130
as	O	131-133
crucial	O	134-141
to	O	142-144
the	O	145-148
development	O	149-160
of	O	161-163
these	O	164-169
tumors	O	170-176
.   	O	176-180

The	O	0-3
research	O	4-12
was	O	13-16
divided	O	17-24
into	O	25-29
two	O	30-33
studies	O	34-41
:	O	41-42
the	O	43-46
first	O	47-52
one	O	53-56
the	O	57-60
test	O	61-65
was	O	66-69
adapted	O	70-77
,	O	77-78
and	O	79-82
in	O	83-85
order	O	86-91
to	O	92-94
check	O	95-100
its	O	101-104
capacity	O	105-113
to	O	114-116
investigate	O	117-128
the	O	129-132
deficits	O	133-141
of	O	142-144
SOM	O	145-148
,	O	148-149
it	O	150-152
has	O	153-156
applied	O	157-164
in	O	165-167
groups	O	168-174
of	O	175-177
10	O	178-180
(	O	181-182
ten	O	182-185
)	O	185-186
subjects	O	187-195
,	O	195-196
one	O	197-200
group	O	201-206
with	O	207-211
patients	O	212-220
that	O	221-225
have	O	226-230
Alzheimer	O	231-240
disease	O	241-248
and	O	249-252
the	O	253-256
other	O	257-262
one	O	263-266
with	O	267-271
healthy	O	272-279
elderly	O	280-287
(	O	288-289
p	O	289-290
<	O	290-291
0	O	291-292
.	O	292-293
001	O	293-296
)	O	296-297
. 	O	297-299

This	O	0-4
study	O	5-10
had	O	11-14
the	O	15-18
purpose	O	19-26
to	O	27-29
adapt	O	30-35
a	O	36-37
test	O	38-42
based	O	43-48
in	O	49-51
these	O	52-57
experiments	O	58-69
in	O	70-72
order	O	73-78
to	O	79-81
check	O	82-87
the	O	88-91
performance	O	92-103
of	O	104-106
SOM	O	107-110
and	O	111-114
the	O	115-118
participation	O	119-132
of	O	133-135
hippocampus	O	136-147
into	O	148-152
SOM	O	153-156
in	O	157-159
patients	O	160-168
with	O	169-173
mesial	O	174-180
temporal	O	181-189
sclerosis	O	190-199
(	O	200-201
MTS	O	201-204
)	O	204-205
. 	O	205-207

Experimental	O	0-12
studies	O	13-20
have	O	21-25
identified	O	26-36
pyramidal	O	37-46
cells	O	47-52
in	O	53-55
hippocampus	O	56-67
in	O	68-70
rats	O	71-75
with	O	76-80
participation	O	81-94
in	O	95-97
the	O	98-101
spatial	O	102-109
orientation	O	110-121
memory	O	122-128
(	O	129-130
SOM	O	130-133
)	O	133-134
,	O	134-135
which	O	136-141
are	O	142-145
named	O	146-151
location	O	152-160
cells	O	161-166
. 	O	166-168

[	O	0-1
Spatial	O	1-8
orientation	O	9-20
memory	O	21-27
:	O	27-28
evaluation	O	29-39
in	O	40-42
patents	O	43-50
with	O	51-55
Alzheimer	O	56-65
disease	O	66-73
and	O	74-77
temporal	O	78-86
lobe	O	87-91
epilepsy	O	92-100
]	O	100-101
.  	O	101-104

The	O	0-3
second	O	4-10
study	O	11-16
has	O	17-20
evaluated	O	21-30
the	O	31-34
participation	O	35-48
of	O	49-51
hippocampus	O	52-63
into	O	64-68
SOM	O	69-72
in	O	73-75
43	O	76-78
patients	O	79-87
(	O	88-89
23	O	89-91
with	O	92-96
mesial	O	97-103
temporal	O	104-112
sclerosis	O	113-122
(	O	123-124
MTS	O	124-127
)	O	127-128
and	O	129-132
20	O	133-135
submitted	O	136-145
to	O	146-148
selective	O	149-158
amygdala	O	159-167
hippocampectomy	O	168-183
(	O	184-185
SAH	O	185-188
)	O	188-189
)	O	189-190
and	O	191-194
23	O	195-197
healthy	O	198-205
volunteers	O	206-216
with	O	217-221
p	O	222-223
<	O	223-224
0	O	224-225
,	O	225-226
05	O	226-228
between	O	229-236
MTS	O	237-240
and	O	241-244
SAH	O	245-248
and	O	249-252
between	O	253-260
controlled	O	261-271
and	O	272-275
SAH	O	276-279
. 	O	279-281

It	O	0-2
was	O	3-6
shown	O	7-12
that	O	13-17
the	O	18-21
test	O	22-26
of	O	27-29
SOM	O	30-33
is	O	34-36
suitable	O	37-45
to	O	46-48
evaluate	O	49-57
deficits	O	58-66
,	O	66-67
but	O	68-71
it	O	72-74
seems	O	75-80
the	O	81-84
SOM	O	85-88
is	O	89-91
not	O	92-95
a	O	96-97
specific	O	98-106
function	O	107-115
of	O	116-118
human	O	119-124
hippocampus	O	125-136
.   	O	136-140

Potential	O	0-9
role	O	10-14
of	O	15-17
miRNAs	O	18-24
and	O	25-28
their	O	29-34
inhibitors	O	35-45
in	O	46-48
glioma	O	49-55
treatment	O	56-65
.  	O	65-68

Recent	O	0-6
years	O	7-12
have	O	13-17
seen	O	18-22
an	O	23-25
intense	O	26-33
period	O	34-40
of	O	41-43
research	O	44-52
on	O	53-55
the	O	56-59
functions	O	60-69
of	O	70-72
miRNAs	O	73-79
,	O	79-80
recently	O	81-89
discovered	O	90-100
key	O	101-104
regulators	O	105-115
of	O	116-118
gene	O	119-123
expression	O	124-134
that	O	135-139
act	O	140-143
through	O	144-151
suppression	O	152-163
of	O	164-166
translation	O	167-178
of	O	179-181
target	O	182-188
mRNAs	O	189-194
. 	O	194-196

Several	O	0-7
hundred	O	8-15
miRNAs	O	16-22
have	O	23-27
been	O	28-32
identified	O	33-43
in	O	44-46
humans	O	47-53
,	O	53-54
and	O	55-58
these	O	59-64
show	O	65-69
characteristic	O	70-84
expression	O	85-95
patterns	O	96-104
,	O	104-105
depending	O	106-115
on	O	116-118
tissue	O	119-125
type	O	126-130
,	O	130-131
cell	O	132-136
type	O	137-141
or	O	142-144
environmental	O	145-158
stimuli	O	159-166
. 	O	166-168

Like	O	0-4
other	O	5-10
types	O	11-16
of	O	17-19
cancer	O	20-26
,	O	26-27
the	O	28-31
brain	O	32-37
tumor	O	38-43
glioblastoma	O	44-56
shows	O	57-62
a	O	63-64
distinct	O	65-73
miRNA	O	74-79
expression	O	80-90
signature	O	91-100
,	O	100-101
and	O	102-105
a	O	106-107
number	O	108-114
of	O	115-117
recent	O	118-124
studies	O	125-132
have	O	133-137
linked	O	138-144
these	O	145-150
miRNA	O	151-156
alterations	O	157-168
to	O	169-171
key	O	172-175
hallmarks	O	176-185
of	O	186-188
glioblastoma	O	189-201
including	O	202-211
proliferation	O	212-225
,	O	225-226
survival	O	227-235
,	O	235-236
invasion	O	237-245
,	O	245-246
angiogenesis	O	247-259
and	O	260-263
stem	O	264-268
cell	O	269-273
-	O	273-274
like	O	274-278
behavior	O	279-287
. 	O	287-289

These	O	0-5
studies	O	6-13
have	O	14-18
opened	O	19-25
the	O	26-29
door	O	30-34
to	O	35-37
the	O	38-41
possibility	O	42-53
of	O	54-56
utilizing	O	57-66
miRNAs	O	67-73
or	O	74-76
miRNA	O	77-82
antagonists	O	83-94
as	O	95-97
therapeutic	O	98-109
agents	O	110-116
for	O	117-120
the	O	121-124
treatment	O	125-134
of	O	135-137
brain	O	138-143
tumors	O	144-150
.   	O	150-154

pHUSH	O	0-5
:	O	5-6
a	O	7-8
single	O	9-15
vector	O	16-22
system	O	23-29
for	O	30-33
conditional	O	34-45
gene	O	46-50
expression	O	51-61
.  	O	61-64

RESULTS	O	0-7
:	O	7-8
Both	O	9-13
Pol	O	14-17
II	O	18-20
and	O	21-24
Pol	O	25-28
III	O	29-32
promoters	O	33-42
have	O	43-47
been	O	48-52
successfully	O	53-65
combined	O	66-74
with	O	75-79
a	O	80-81
second	O	82-88
expression	O	89-99
cassette	O	100-108
containing	O	109-119
a	O	120-121
codon	O	122-127
-	O	127-128
optimized	O	128-137
tetracycline	O	138-150
repressor	O	151-160
and	O	161-164
selectable	O	165-175
marker	O	176-182
. 	O	182-184

We	O	0-2
have	O	3-7
therefore	O	8-17
developed	O	18-27
pHUSH	O	28-33
,	O	33-34
an	O	35-37
inducible	O	38-47
expression	O	48-58
system	O	59-65
that	O	66-70
allows	O	71-77
regulated	O	78-87
expression	O	88-98
of	O	99-101
shRNA	O	102-107
,	O	107-108
miRNA	O	109-114
or	O	115-117
cDNA	O	118-122
cassettes	O	123-132
on	O	133-135
a	O	136-137
single	O	138-144
viral	O	145-150
vector	O	151-157
. 	O	157-159

However	O	0-7
,	O	7-8
most	O	9-13
systems	O	14-21
require	O	22-29
multiple	O	30-38
plasmids	O	39-47
that	O	48-52
must	O	53-57
be	O	58-60
independently	O	61-74
engineered	O	75-85
into	O	86-90
the	O	91-94
target	O	95-101
system	O	102-108
,	O	108-109
resulting	O	110-119
in	O	120-122
experimental	O	123-135
delay	O	136-141
and	O	142-145
an	O	146-148
increased	O	149-158
potential	O	159-168
for	O	169-172
selection	O	173-182
of	O	183-185
a	O	186-187
cell	O	188-192
subpopulation	O	193-206
that	O	207-211
differs	O	212-219
significantly	O	220-233
from	O	234-238
the	O	239-242
parental	O	243-251
line	O	252-256
. 	O	256-258

BACKGROUND	O	0-10
:	O	10-11
Conditional	O	12-23
expression	O	24-34
vectors	O	35-42
have	O	43-47
become	O	48-54
a	O	55-56
valuable	O	57-65
research	O	66-74
tool	O	75-79
to	O	80-82
avoid	O	83-88
artefacts	O	89-98
that	O	99-103
may	O	104-107
result	O	108-114
from	O	115-119
traditional	O	120-131
gene	O	132-136
expression	O	137-147
studies	O	148-155
. 	O	155-157

These	O	0-5
studies	O	6-13
demonstrate	O	14-25
the	O	26-29
broad	O	30-35
application	O	36-47
potential	O	48-57
of	O	58-60
pHUSH	O	61-66
for	O	67-70
conditional	O	71-82
genetic	O	83-90
engineering	O	91-102
in	O	103-105
mammalian	O	106-115
cells	O	116-121
.   	O	121-125

CONCLUSION	O	0-10
:	O	10-11
We	O	12-14
have	O	15-19
successfully	O	20-32
developed	O	33-42
and	O	43-46
employed	O	47-55
a	O	56-57
single	O	58-64
vector	O	65-71
system	O	72-78
that	O	79-83
enables	O	84-91
Doxycycline	O	92-103
regulated	O	104-113
RNAi	O	114-118
or	O	119-121
transgene	O	122-131
expression	O	132-142
in	O	143-145
a	O	146-147
variety	O	148-155
of	O	156-158
in	O	159-161
vitro	O	162-167
and	O	168-171
in	O	172-174
vivo	O	175-179
model	O	180-185
systems	O	186-193
. 	O	193-195

We	O	0-2
provide	O	3-10
examples	O	11-19
of	O	20-22
how	O	23-26
pHUSH	O	27-32
has	O	33-36
been	O	37-41
successfully	O	42-54
employed	O	55-63
to	O	64-66
study	O	67-72
the	O	73-76
function	O	77-85
of	O	86-88
target	O	89-95
genes	O	96-101
in	O	102-104
a	O	105-106
number	O	107-113
of	O	114-116
cell	O	117-121
types	O	122-127
within	O	128-134
in	O	135-137
vitro	O	138-143
and	O	144-147
in	O	148-150
vivo	O	151-155
assays	O	156-162
,	O	162-163
including	O	164-173
conditional	O	174-185
gene	O	186-190
knockdown	O	191-200
in	O	201-203
a	O	204-205
murine	O	206-212
model	O	213-218
of	O	219-221
brain	O	222-227
cancer	O	228-234
. 	O	234-236

SIGNIFICANCE	O	0-12
:	O	12-13
Our	O	14-17
results	O	18-25
show	O	26-30
for	O	31-34
the	O	35-38
first	O	39-44
time	O	45-49
that	O	50-54
the	O	55-58
R337H	O	59-64
TP53	O	65-69
mutation	O	70-78
is	O	79-81
responsible	O	82-93
for	O	94-97
63	O	98-100
%	O	100-101
of	O	102-104
the	O	105-108
CPC	O	109-112
cases	O	113-118
in	O	119-121
children	O	122-130
,	O	130-131
suggesting	O	132-142
a	O	143-144
higher	O	145-151
incidence	O	152-161
of	O	162-164
CPC	O	165-168
in	O	169-171
southern	O	172-180
Brazil	O	181-187
.   	O	187-191

Family	O	0-6
history	O	7-14
of	O	15-17
cancer	O	18-24
(	O	25-26
with	O	26-30
2	O	31-32
or	O	33-35
more	O	36-40
cancer	O	41-47
cases	O	48-53
)	O	53-54
was	O	55-58
exclusively	O	59-70
identified	O	71-81
on	O	82-84
the	O	85-88
parental	O	89-97
side	O	98-102
segregating	O	103-114
the	O	115-118
R337H	O	119-124
mutation	O	125-133
,	O	133-134
and	O	135-138
50	O	139-141
%	O	141-142
(	O	143-144
7	O	144-145
/	O	145-146
14	O	146-148
)	O	148-149
of	O	150-152
them	O	153-157
were	O	158-162
compatible	O	163-173
with	O	174-178
Li	O	179-181
-	O	181-182
Fraumeni	O	182-190
-	O	190-191
like	O	191-195
syndrome	O	196-204
. 	O	204-206

Cure	O	0-4
(	O	5-6
>	O	6-7
5	O	7-8
years	O	9-14
survival	O	15-23
free	O	24-28
of	O	29-31
disease	O	32-39
)	O	39-40
was	O	41-44
observed	O	45-53
in	O	54-56
18	O	57-59
.	O	59-60
1	O	60-61
%	O	61-62
of	O	63-65
the	O	66-69
CPC	O	70-73
cases	O	74-79
with	O	80-84
the	O	85-88
R337H	O	89-94
mutation	O	95-103
(	O	104-105
2	O	105-106
/	O	106-107
11	O	107-109
)	O	109-110
,	O	110-111
71	O	112-114
.	O	114-115
4	O	115-116
%	O	116-117
of	O	118-120
the	O	121-124
Pp	O	125-127
(	O	128-129
5	O	129-130
/	O	130-131
7	O	131-132
)	O	132-133
,	O	133-134
and	O	135-138
25	O	139-141
%	O	141-142
of	O	143-145
CPC	O	146-149
cases	O	150-155
negative	O	156-164
for	O	165-168
the	O	169-172
R337H	O	173-178
mutation	O	179-187
(	O	188-189
2	O	189-190
/	O	190-191
8	O	191-192
)	O	192-193
. 	O	193-195

All	O	0-3
Pp	O	4-6
cases	O	7-12
(	O	13-14
7	O	14-15
/	O	15-16
7	O	16-17
,	O	17-18
100	O	19-22
%	O	22-23
)	O	23-24
were	O	25-29
negative	O	30-38
for	O	39-42
R337H	O	43-48
. 	O	48-50

We	O	0-2
found	O	3-8
63	O	9-11
.	O	11-12
3	O	12-13
%	O	13-14
(	O	15-16
14	O	16-18
/	O	18-19
22	O	19-21
)	O	21-22
of	O	23-25
the	O	26-29
CPC	O	30-33
patients	O	34-42
positive	O	43-51
for	O	52-55
the	O	56-59
germline	O	60-68
R337H	O	69-74
mutation	O	75-83
;	O	83-84
CPC	O	85-88
samples	O	89-96
were	O	97-101
either	O	102-108
heterozygous	O	109-121
(	O	122-123
n	O	123-124
=	O	125-126
7	O	127-128
)	O	128-129
,	O	129-130
lost	O	131-135
only	O	136-140
the	O	141-144
wild	O	145-149
-	O	149-150
type	O	150-154
(	O	155-156
n	O	156-157
=	O	158-159
4	O	160-161
)	O	161-162
,	O	162-163
or	O	164-166
only	O	167-171
the	O	172-175
R337H	O	176-181
copy	O	182-186
(	O	187-188
n	O	188-189
=	O	190-191
2	O	192-193
)	O	193-194
. 	O	194-196

One	O	0-3
CPC	O	4-7
sample	O	8-14
was	O	15-18
not	O	19-22
available	O	23-32
. 	O	32-34

The	O	0-3
patients	O	4-12
,	O	12-13
all	O	14-17
parents	O	18-25
,	O	25-26
and	O	27-30
some	O	31-35
relatives	O	36-45
submitted	O	46-55
samples	O	56-63
for	O	64-67
blood	O	68-73
DNA	O	74-77
analysis	O	78-86
. 	O	86-88

In	O	0-2
addition	O	3-11
,	O	11-12
we	O	13-15
have	O	16-20
also	O	21-25
examined	O	26-34
the	O	35-38
presence	O	39-47
of	O	48-50
the	O	51-54
mutation	O	55-63
in	O	64-66
DNA	O	67-70
from	O	71-75
paraffin	O	76-84
-	O	84-85
embedded	O	85-93
tumor	O	94-99
samples	O	100-107
to	O	108-110
evaluate	O	111-119
loss	O	120-124
of	O	125-127
heterozygosity	O	128-142
. 	O	142-144

BACKGROUND	O	0-10
:	O	10-11
Choroid	O	12-19
plexus	O	20-26
carcinomas	O	27-37
(	O	38-39
CPC	O	39-42
)	O	42-43
are	O	44-47
rare	O	48-52
tumors	O	53-59
predominantly	O	60-73
found	O	74-79
in	O	80-82
children	O	83-91
. 	O	91-93

Increased	O	0-9
incidence	O	10-19
of	O	20-22
choroid	O	23-30
plexus	O	31-37
carcinoma	O	38-47
due	O	48-51
to	O	52-54
the	O	55-58
germline	O	59-67
TP53	O	68-72
R337H	O	73-78
mutation	O	79-87
in	O	88-90
southern	O	91-99
Brazil	O	100-106
.  	O	106-109

Blood	O	0-5
and	O	6-9
/	O	9-10
or	O	10-12
tumor	O	13-18
DNA	O	19-22
was	O	23-26
extracted	O	27-36
and	O	37-40
analyzed	O	41-49
using	O	50-55
PCR	O	56-59
-	O	59-60
RFLP	O	60-64
and	O	65-68
results	O	69-76
were	O	77-81
confirmed	O	82-91
by	O	92-94
sequencing	O	95-105
240	O	106-109
bp	O	110-112
of	O	113-115
the	O	116-119
TP53	O	120-124
exon	O	125-129
10	O	130-132
. 	O	132-134

Surgical	O	0-8
resection	O	9-18
was	O	19-22
possible	O	23-31
in	O	32-34
28	O	35-37
children	O	38-46
. 	O	46-48

METHODOLOGY	O	0-11
/	O	11-12
PRINCIPAL	O	12-21
FINDINGS	O	22-30
:	O	30-31
The	O	32-35
present	O	36-43
series	O	44-50
included	O	51-59
29	O	60-62
patients	O	63-71
that	O	72-76
were	O	77-81
admitted	O	82-90
to	O	91-93
the	O	94-97
same	O	98-102
institution	O	103-114
from	O	115-119
1992	O	120-124
to	O	125-127
2010	O	128-132
,	O	132-133
including	O	134-143
22	O	144-146
children	O	147-155
with	O	156-160
CPC	O	161-164
(	O	165-166
0	O	166-167
.	O	167-168
08	O	168-170
-	O	170-171
13	O	171-173
.	O	173-174
6	O	174-175
years	O	176-181
of	O	182-184
age	O	185-188
at	O	189-191
diagnosis	O	192-201
)	O	201-202
and	O	203-206
7	O	207-208
children	O	209-217
with	O	218-222
papilloma	O	223-232
of	O	233-235
the	O	236-239
choroid	O	240-247
plexus	O	248-254
(	O	255-256
Pp	O	256-258
;	O	258-259
0	O	260-261
.	O	261-262
5	O	262-263
-	O	263-264
9	O	264-265
.	O	265-266
8	O	266-267
years	O	268-273
of	O	274-276
age	O	277-280
)	O	280-281
. 	O	281-283

Given	O	0-5
the	O	6-9
high	O	10-14
frequency	O	15-24
of	O	25-27
the	O	28-31
germline	O	32-40
R337H	O	41-46
mutation	O	47-55
in	O	56-58
the	O	59-62
TP53	O	63-67
gene	O	68-72
in	O	73-75
southern	O	76-84
Brazil	O	85-91
,	O	91-92
we	O	93-95
have	O	96-100
evaluated	O	101-110
the	O	111-114
frequency	O	115-124
of	O	125-127
the	O	128-131
R337H	O	132-137
mutation	O	138-146
in	O	147-149
families	O	150-158
with	O	159-163
CPC	O	164-167
in	O	168-170
children	O	171-179
. 	O	179-181

Here	O	0-4
,	O	4-5
we	O	6-8
present	O	9-16
an	O	17-19
overview	O	20-28
of	O	29-31
the	O	32-35
current	O	36-43
progress	O	44-52
in	O	53-55
miRNA	O	56-61
research	O	62-70
related	O	71-78
to	O	79-81
CNS	O	82-85
disorders	O	86-95
and	O	96-99
also	O	100-104
highlight	O	105-114
the	O	115-118
utility	O	119-126
of	O	127-129
LNA	O	130-133
(	O	134-135
locked	O	135-141
nucleic	O	142-149
acid	O	150-154
)	O	154-155
-	O	155-156
modified	O	156-164
oligonucleotides	O	165-181
in	O	182-184
the	O	185-188
detection	O	189-198
and	O	199-202
modulation	O	203-213
of	O	214-216
miRNA	O	217-222
activity	O	223-231
.   	O	231-235

Recent	O	0-6
studies	O	7-14
have	O	15-19
identified	O	20-30
a	O	31-32
molecular	O	33-42
and	O	43-46
ultimately	O	47-57
pathogenic	O	58-68
role	O	69-73
for	O	74-77
a	O	78-79
subset	O	80-86
of	O	87-89
miRNAs	O	90-96
in	O	97-99
Alzheimer	O	100-109
'	O	109-110
s	O	110-111
disease	O	112-119
and	O	120-123
schizophrenia	O	124-137
,	O	137-138
including	O	139-148
the	O	149-152
characterization	O	153-169
of	O	170-172
their	O	173-178
downstream	O	179-189
CNS	O	190-193
mRNA	O	194-198
targets	O	199-206
,	O	206-207
such	O	208-212
as	O	213-215
beta	O	216-220
-	O	220-221
secretase	O	221-230
(	O	231-232
BACE1	O	232-237
)	O	237-238
and	O	239-242
calmodulin	O	243-253
-	O	253-254
dependent	O	254-263
protein	O	264-271
kinase	O	272-278
II	O	279-281
(	O	282-283
CaMKII	O	283-289
)	O	289-290
. 	O	290-292

The	O	0-3
intricate	O	4-13
molecular	O	14-23
networks	O	24-32
mediated	O	33-41
by	O	42-44
an	O	45-47
miRNA	O	48-53
form	O	54-58
a	O	59-60
robust	O	61-67
mechanism	O	68-77
for	O	78-81
rapid	O	82-87
and	O	88-91
potent	O	92-98
responses	O	99-108
to	O	109-111
cellular	O	112-120
events	O	121-127
throughout	O	128-138
the	O	139-142
development	O	143-154
of	O	155-157
the	O	158-161
human	O	162-167
brain	O	168-173
. 	O	173-175

Disruption	O	0-10
of	O	11-13
miRNA	O	14-19
-	O	19-20
based	O	20-25
post	O	26-30
-	O	30-31
transcriptional	O	31-46
regulation	O	47-57
has	O	58-61
been	O	62-66
implicated	O	67-77
in	O	78-80
a	O	81-82
range	O	83-88
of	O	89-91
CNS	O	92-95
disorders	O	96-105
as	O	106-108
one	O	109-112
miRNA	O	113-118
is	O	119-121
predicted	O	122-131
to	O	132-134
impact	O	135-141
the	O	142-145
expression	O	146-156
of	O	157-159
numerous	O	160-168
downstream	O	169-179
mRNA	O	180-184
targets	O	185-192
. 	O	192-194

Hundreds	O	0-8
of	O	9-11
non	O	12-15
-	O	15-16
coding	O	16-22
regulatory	O	23-33
RNA	O	34-37
molecules	O	38-47
called	O	48-54
microRNAs	O	55-64
(	O	65-66
miRNAs	O	66-72
)	O	72-73
have	O	74-78
been	O	79-83
identified	O	84-94
in	O	95-97
the	O	98-101
mammalian	O	102-111
central	O	112-119
nervous	O	120-127
system	O	128-134
(	O	135-136
CNS	O	136-139
)	O	139-140
and	O	141-144
are	O	145-148
reported	O	149-157
to	O	158-160
mediate	O	161-168
pivotal	O	169-176
roles	O	177-182
in	O	183-185
many	O	186-190
aspects	O	191-198
of	O	199-201
neuronal	O	202-210
functions	O	211-220
. 	O	220-222

In	O	0-2
recent	O	3-9
years	O	10-15
,	O	15-16
there	O	17-22
has	O	23-26
been	O	27-31
a	O	32-33
shift	O	34-39
in	O	40-42
the	O	43-46
conventional	O	47-59
paradigms	O	60-69
for	O	70-73
transcriptional	O	74-89
and	O	90-93
translational	O	94-107
regulation	O	108-118
as	O	119-121
extensive	O	122-131
sequencing	O	132-142
efforts	O	143-150
have	O	151-155
yielded	O	156-163
new	O	164-167
insights	O	168-176
into	O	177-181
the	O	182-185
landscape	O	186-195
of	O	196-198
the	O	199-202
human	O	203-208
genome	O	209-215
and	O	216-219
transcriptome	O	220-233
. 	O	233-235

microRNAs	O	0-9
in	O	10-12
CNS	O	13-16
disorders	O	17-26
.  	O	26-29

